0000950170-22-001769.txt : 20220223 0000950170-22-001769.hdr.sgml : 20220223 20220223160139 ACCESSION NUMBER: 0000950170-22-001769 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 85 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220223 DATE AS OF CHANGE: 20220223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Outset Medical, Inc. CENTRAL INDEX KEY: 0001484612 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 200514392 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39513 FILM NUMBER: 22663371 BUSINESS ADDRESS: STREET 1: 3052 ORCHARD DRIVE CITY: SAN JOSE STATE: CA ZIP: 95134 BUSINESS PHONE: 669-231-8200 MAIL ADDRESS: STREET 1: 3052 ORCHARD DRIVE CITY: SAN JOSE STATE: CA ZIP: 95134 FORMER COMPANY: FORMER CONFORMED NAME: Home Dialysis Plus, Ltd. DATE OF NAME CHANGE: 20100219 10-K 1 om-20211231.htm 10-K 10-K
12 MonthsFYP2Y10001484612false--12-310.12658212 Months0001484612us-gaap:RestrictedStockUnitsRSUMember2020-12-310001484612us-gaap:ConstructionInProgressMember2021-12-310001484612om:WarrantsToPurchaseCommonStockMember2021-01-012021-12-310001484612us-gaap:DomesticCountryMember2021-12-310001484612us-gaap:ProductMember2019-01-012019-12-310001484612om:TwoThousandTwentyEquityIncentivePlanMember2021-01-012021-12-310001484612om:SharesAvailableForFutureGrantUnderTwoThousandAndTwentyPlanMember2021-12-310001484612us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001484612srt:MaximumMember2021-01-012021-12-310001484612om:CustomerFourMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2021-01-012021-12-310001484612country:CA2019-09-012019-09-300001484612om:StockOptionsToPurchaseCommonStockMember2020-01-012020-12-310001484612us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001484612us-gaap:DomesticCountryMembersrt:MaximumMember2021-01-012021-12-310001484612us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberom:CustomerOneMember2020-01-012020-12-3100014846122020-09-082020-09-0800014846122022-02-160001484612om:ConsolesProductMember2019-01-012019-12-310001484612us-gaap:CustomerConcentrationRiskMemberom:CustomerOneMemberus-gaap:AccountsReceivableMember2020-01-012020-12-310001484612us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001484612us-gaap:FurnitureAndFixturesMember2020-12-3100014846122019-01-012019-12-310001484612srt:MaximumMember2019-01-012019-12-310001484612us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001484612om:EmployeeStockOptionExcludingMarketAndPerformanceConditionMember2021-12-310001484612us-gaap:AdditionalPaidInCapitalMember2020-12-310001484612us-gaap:PurchaseCommitmentMember2021-12-310001484612us-gaap:CommonStockMember2019-12-310001484612us-gaap:AdditionalPaidInCapitalMember2021-12-310001484612us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001484612us-gaap:RestrictedStockUnitsRSUMember2021-12-310001484612us-gaap:SellingAndMarketingExpenseMember2019-01-012019-12-310001484612us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2020-01-012020-12-310001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001484612us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001484612srt:MinimumMember2021-01-012021-12-310001484612om:FourzeroonekplanMember2022-01-012022-01-010001484612om:StockOptionsOutstandingMember2021-12-310001484612us-gaap:AccountingStandardsUpdate201912Member2021-12-310001484612us-gaap:CommonStockMember2020-01-012020-12-310001484612us-gaap:RetainedEarningsMember2020-01-012020-12-310001484612us-gaap:ConstructionInProgressMember2020-12-310001484612om:TablosUnderOperatingLeasesMember2020-12-310001484612srt:MaximumMemberom:PerformanceStockUnitsMember2021-01-012021-12-310001484612us-gaap:ProductMember2021-01-012021-12-310001484612om:ServiceAndOtherRevenueMember2019-01-012019-12-310001484612us-gaap:DomesticCountryMemberus-gaap:ResearchMember2021-12-310001484612om:SiliconValleyBankTermLoanMember2020-07-020001484612us-gaap:DomesticCountryMember2021-01-012021-12-310001484612om:ConsumablesProductMember2021-01-012021-12-310001484612us-gaap:CommonStockMember2018-12-310001484612om:TwoThousandTwentyEquityIncentivePlanMember2020-07-012020-09-300001484612om:EmployeesSharePurchasePlanMember2021-12-310001484612us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001484612om:ServiceAndOtherRevenueMember2021-01-012021-12-310001484612us-gaap:IPOMember2020-09-150001484612us-gaap:LeaseholdImprovementsMember2020-12-310001484612us-gaap:LeaseholdImprovementsMember2021-12-310001484612srt:MaximumMember2020-01-012020-12-310001484612om:OperatingLeaseArrangementsMemberom:ConsolesProductMember2021-01-012021-12-310001484612om:ConsolesProductMember2021-01-012021-12-310001484612om:EmployeesSharePurchasePlanMember2021-01-012021-12-3100014846122021-12-310001484612us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-310001484612om:PerceptiveTermLoanMember2017-06-300001484612srt:MaximumMember2021-12-310001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001484612us-gaap:ShareBasedCompensationAwardTrancheOneMember2021-01-012021-12-310001484612om:PerformanceStockUnitsOutstandingMember2021-12-310001484612us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001484612us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:EmployeeStockOptionMember2020-01-012020-12-310001484612us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001484612om:OperatingLeaseArrangementsMemberom:ConsolesProductMember2019-01-012019-12-310001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001484612us-gaap:ProductMember2020-01-012020-12-310001484612us-gaap:RetainedEarningsMember2019-12-310001484612om:EmployeesSharePurchasePlanMember2021-01-010001484612om:EmployeesSharePurchasePlanMember2020-07-012020-09-300001484612om:UnderwritersMember2020-09-152020-09-150001484612om:EmployeesSharePurchasePlanMembersrt:MaximumMember2021-01-012021-12-310001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-3100014846122021-06-300001484612us-gaap:StandbyLettersOfCreditMembercountry:CA2021-12-310001484612us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-12-310001484612us-gaap:CostOfSalesMember2019-01-012019-12-310001484612us-gaap:RedeemableConvertiblePreferredStockMember2019-12-310001484612country:MX2020-05-012020-05-310001484612om:SiliconValleyBankTermLoanMember2020-07-022020-07-020001484612us-gaap:SalesRevenueNetMemberom:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-3100014846122021-04-132021-04-130001484612us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-12-3100014846122020-12-310001484612us-gaap:EmployeeStockOptionMember2020-12-310001484612us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001484612om:WarrantsToPurchaseRedeemableConvertiblePreferredStockMember2019-01-012019-12-3100014846122020-09-152020-09-1500014846122021-01-012021-12-310001484612us-gaap:SellingAndMarketingExpenseMember2021-01-012021-12-310001484612us-gaap:CommonStockMember2019-01-012019-12-310001484612srt:MinimumMember2019-01-012019-12-310001484612us-gaap:RetainedEarningsMember2021-12-310001484612us-gaap:RetainedEarningsMember2021-01-012021-12-310001484612us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:EmployeeStockOptionMember2019-01-012019-12-310001484612us-gaap:StateAndLocalJurisdictionMember2021-01-012021-12-310001484612us-gaap:RedeemableConvertiblePreferredStockMember2019-01-012019-12-310001484612us-gaap:PerformanceSharesMember2021-01-012021-12-310001484612us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001484612us-gaap:RedeemableConvertiblePreferredStockMember2020-01-012020-12-310001484612om:EmployeesSharePurchasePlanMember2020-01-012020-12-310001484612srt:MinimumMember2020-01-012020-12-310001484612om:SiliconValleyBankTermLoanMemberus-gaap:PrimeRateMember2020-07-022020-07-020001484612us-gaap:CommonStockMember2020-12-310001484612us-gaap:ForeignCountryMember2021-01-012021-12-310001484612us-gaap:SalesRevenueNetMemberom:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001484612om:StockOptionsToPurchaseCommonStockMember2019-01-012019-12-310001484612us-gaap:StandbyLettersOfCreditMembercountry:MX2021-12-310001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001484612om:PerceptiveTermLoanMember2021-01-012021-12-3100014846122018-12-310001484612us-gaap:AdditionalPaidInCapitalMember2019-12-310001484612us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001484612country:MX2021-12-310001484612us-gaap:ResearchMemberus-gaap:StateAndLocalJurisdictionMember2021-12-310001484612om:PerceptiveTermLoanMember2020-07-312020-07-310001484612om:RestrictedStockUnitsOutstandingMember2021-12-310001484612om:SiliconValleyBankTermLoanMembersrt:MaximumMember2020-07-022020-07-020001484612srt:MinimumMemberus-gaap:StateAndLocalJurisdictionMember2021-01-012021-12-310001484612us-gaap:ComputerEquipmentMember2020-12-310001484612us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:EmployeeStockOptionMember2021-01-012021-12-310001484612us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001484612us-gaap:IPOMember2020-09-152020-09-150001484612om:OperatingLeaseArrangementsMemberom:ConsolesProductMember2020-01-012020-12-3100014846122019-12-310001484612us-gaap:ShortTermInvestmentsMember2021-12-310001484612us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-3100014846122019-09-012019-09-300001484612om:WarrantsToPurchaseCommonStockMember2020-01-012020-12-310001484612om:TablosUnderOperatingLeasesMember2021-12-310001484612om:EmployeesSharePurchasePlanMembersrt:MaximumMember2020-09-300001484612country:MX2020-05-310001484612om:EmployeesSharePurchasePlanMember2020-12-3100014846122021-01-012021-12-3100014846122022-01-012021-12-310001484612us-gaap:EmployeeStockMember2021-01-012021-12-310001484612us-gaap:PerformanceSharesMember2021-12-310001484612us-gaap:DomesticCountryMembersrt:MinimumMember2021-01-012021-12-310001484612om:ConsolesProductMember2020-01-012020-12-310001484612om:ConsumablesProductMember2019-01-012019-12-310001484612om:SiliconValleyBankTermLoanMember2021-01-012021-12-310001484612us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001484612om:EmployeeStockOptionExcludingMarketAndPerformanceConditionMember2021-01-012021-12-310001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001484612us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001484612om:TwoThousandTwentyEquityIncentivePlanMember2020-09-300001484612us-gaap:DomesticCountryMemberus-gaap:ResearchMember2021-01-012021-12-310001484612country:CA2019-09-300001484612om:StockOptionsToPurchaseCommonStockMember2021-01-012021-12-310001484612us-gaap:RetainedEarningsMember2019-01-012019-12-310001484612us-gaap:SellingAndMarketingExpenseMember2020-01-012020-12-310001484612us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-01-012021-12-310001484612us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001484612us-gaap:CommonStockMember2021-12-310001484612om:ConsumablesProductMember2020-01-012020-12-310001484612us-gaap:FairValueMeasurementsRecurringMember2021-12-310001484612us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberom:CustomerOneMember2021-01-012021-12-310001484612country:MX2021-06-300001484612us-gaap:CommonStockMember2021-01-012021-12-310001484612om:WarrantsToPurchaseCommonStockMember2021-12-310001484612us-gaap:PerformanceSharesMember2020-12-3100014846122020-01-012020-12-310001484612om:SiliconValleyBankTermLoanMember2020-01-012020-12-310001484612us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-12-310001484612us-gaap:PerformanceSharesMember2021-01-012021-12-310001484612om:FollowOnPublicOfferingMember2021-04-130001484612us-gaap:RedeemableConvertiblePreferredStockMember2018-12-310001484612om:ServiceAndOtherRevenueMember2020-01-012020-12-310001484612srt:MaximumMemberus-gaap:StateAndLocalJurisdictionMember2021-01-012021-12-310001484612om:SiliconValleyBankTermLoanMembersrt:MinimumMember2020-07-022020-07-020001484612om:FollowOnPublicOfferingMember2021-04-132021-04-130001484612om:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2020-01-012020-12-310001484612us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001484612us-gaap:CostOfSalesMember2021-01-012021-12-310001484612us-gaap:FairValueMeasurementsRecurringMember2020-12-310001484612om:SharesAvailableForFuturePurchaseUnderEsppMember2021-12-310001484612srt:MaximumMemberom:FourzeroonekplanMember2022-01-012022-01-010001484612om:EmployeesSharePurchasePlanMember2020-09-300001484612us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberom:CustomerThreeMember2020-01-012020-12-310001484612us-gaap:MachineryAndEquipmentMember2020-12-310001484612us-gaap:StateAndLocalJurisdictionMember2021-12-310001484612om:PerceptiveTermLoanMember2017-06-302017-06-300001484612om:PerformanceStockUnitsMember2021-12-310001484612om:TwoThousandTwentyEquityIncentivePlanMember2021-01-010001484612us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001484612us-gaap:MachineryAndEquipmentMember2021-12-310001484612us-gaap:RetainedEarningsMember2020-12-310001484612om:UnderwritersMember2021-04-132021-04-130001484612us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001484612srt:MinimumMemberom:PerformanceStockUnitsMember2021-01-012021-12-310001484612om:PerformanceStockUnitsMember2021-01-012021-12-310001484612us-gaap:EmployeeStockMember2020-01-012020-12-310001484612us-gaap:CostOfSalesMember2020-01-012020-12-310001484612us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberom:CustomerOneMember2019-01-012019-12-310001484612om:EmployeesSharePurchasePlanMembersrt:MinimumMember2021-01-012021-12-310001484612us-gaap:ComputerEquipmentMember2021-12-310001484612om:SiliconValleyBankTermLoanMember2021-12-310001484612us-gaap:RetainedEarningsMember2018-12-310001484612us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001484612us-gaap:FurnitureAndFixturesMember2021-12-31om:Segmentxbrli:pureutr:sqftom:Customerxbrli:sharesiso4217:USDxbrli:sharesiso4217:USD

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO

Commission File Number 001-39513

 

Outset Medical, Inc.

(Exact name of Registrant as specified in its Charter)

 

 

Delaware

20-0514392

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

3052 Orchard Dr.

San Jose, California

95134

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (669) 231-8200

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

OM

 

The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesNo

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YesNo

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesNo

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YesNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Aggregate market value of registrant's common stock held by non-affiliates of the registrant, based upon the closing price of a share of the registrant's common stock on June 30, 2021 (the last business day of the registrant's most recently completed second quarter) as reported by Nasdaq Global Market on that date was $1.7 billion.

The number of shares of the registrant’s common stock, par value $0.001 per share, outstanding as of February 16, 2022 was 47,406,856.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s Proxy Statement for its 2022 Annual Meeting of Stockholders, which is to be filed with the Securities and Exchange Commission within 120 days of the registrant’ fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.

 


Table of Contents

 

 

 

Page

PART I

 

 

Item 1.

Business

3

Item 1A.

Risk Factors

31

Item 1B.

Unresolved Staff Comments

72

Item 2.

Properties

73

Item 3.

Legal Proceedings

73

Item 4.

Mine Safety Disclosures

73

 

 

 

PART II

 

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

74

Item 6.

[Reserved]

75

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

76

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

88

Item 8.

Financial Statements and Supplementary Data

89

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

116

Item 9A.

Controls and Procedures

116

Item 9B.

Other Information

117

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

117

 

 

 

PART III

 

 

Item 10.

Directors, Executive Officers and Corporate Governance

118

Item 11.

Executive Compensation

118

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

118

Item 13.

Certain Relationships and Related Transactions, and Director Independence

118

Item 14.

Principal Accounting Fees and Services

118

 

 

 

PART IV

 

 

Item 15.

Exhibits, Financial Statement Schedules

119

Item 16

Form 10-K Summary

119

 

 

 

i


 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K (this Annual Report) contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements include, but are not limited to, statements about:

our future results of operations and financial position, including our expectations and projections regarding our revenues and revenue growth rate, sales into the home market and such sales as a percentage of revenues, cost of revenues, operating expenses (including as a percentage of revenues), gross margin, capital expenditures and our ability to achieve and maintain future profitability;
our business strategy;
plans and objectives of management for future operations;
key factors we believe affect our performance, including our beliefs about the opportunities presented by these factors, our ability to successfully address each of these factors and the anticipated impacts on our business, financial condition and result of operations;
our expectations regarding the market sizes and growth potential for Tablo, including our estimates of annual spending on dialysis and the number of people affected by kidney failure in the United States, and the total addressable market opportunities for Tablo in the acute care and home settings;
our planned expansion within the home dialysis market and our assumptions about the home market, including regarding adoption of Tablo by home dialysis patients and patient retention;
the impact of the ongoing COVID-19 pandemic on our business and results of operations, and on our customers, suppliers and vendors;
our intent to explore opportunities for international expansion;
continued execution of our initiatives designed to reduce the cost of producing and shipping Tablo devices and our ability to achieve projected cost reductions at the levels or within the timeframe we estimate;
our plans to expand our manufacturing capabilities to support our growth including by expanding our manufacturing workforce;
our plans to continue to invest in our research and development efforts to enhance existing products and develop new products;
our plans to invest in continued expansion of our sales and marketing infrastructure; and
our expectations regarding the uses and sufficiency of our capital resources.

The forward-looking statements in this Annual Report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Such risks and uncertainties include those described throughout this Annual Report, including in the sections titled “Risk Factors” under Part I, Item 1A below and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” under Part II, Item 7 below.

The forward-looking statements in this Annual Report are based upon information available to us as of the date of this Annual Report and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These forward-looking statements, like all statements in this Annual Report, speak only as of their date, and except as required by applicable law, we undertake no obligation to update or revise these statements, whether as a result of any new information, future developments or otherwise. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

1


 

Unless the context requires otherwise, all references in this Annual Report to “we,” “us,” “our,” “Outset” and “the “Company” refer to Outset Medical, Inc.

We have proprietary rights to trademarks, trade names and service marks appearing in this Annual Report that are important to our business. Solely for convenience, the trademarks, service marks, logos and trade names referred to in this Annual Report are without the ® and ™ symbols, but such references are not intended to indicate that we will not assert our rights or the rights of the applicable licensors in these trademarks, service marks and trade names. All trademarks, trade names and service marks appearing in this Annual Report are the property of their respective owners.

2


 

PART I

Item 1. Business.

Our Company

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. We believe the Tablo® Hemodialysis System, cleared by the U.S. Food and Drug Administration (FDA) for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. We designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone.

Our technology is designed to elevate the dialysis experience for patients, and help providers overcome traditional care delivery challenges. Our focus on flexibility, ease of use and user experience translates to meaningfully reduced training times and fixed infrastructure requirements. Requiring only an electrical outlet and tap water to operate, Tablo frees patients and providers from the burdensome infrastructure required to operate traditional dialysis machines. The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo to serve as a dialysis clinic on wheels. With a simple-to-use touchscreen interface, two-way wireless data transmission and a proprietary data analytics platform, Tablo is a new holistic approach to dialysis care. Unlike traditional hemodialysis machines, which have limited clinical versatility across care settings, Tablo can be used seamlessly across multiple care settings and a wide range of clinical applications.

Tablo leverages cloud technology, making it possible for providers to monitor devices and treatments remotely, perform patient and population analytics, and automate clinical recordkeeping, while also enabling us to release features and enhancements through over-the-air (OTA) updates. Tablo’s connectedness also allows it to continually stream more than 500,000 device performance data points after every treatment. We use this data, in conjunction with our diagnostic and predictive algorithms, to determine failure types and, in some instances, predict failures before they occur. In effect, this contributes to a reduction in service hours and an increase in device uptime.

We have generated meaningful evidence to demonstrate that providers can realize significant operational efficiencies, including reducing the cost of their dialysis programs by up to 80% in the intensive care unit (ICU). In addition, Tablo has been shown to deliver robust clinical care. In studies and surveys we have conducted, patients have reported clinical and quality of life benefits on Tablo compared to other dialysis machines. We believe Tablo empowers patients, who have traditionally been passive recipients of care, to regain agency and ownership of their treatment. Tablo is currently cleared by the FDA for use in the hospital, clinic or home setting.

Kidney failure can be temporary and occur spontaneously due to an underlying medical condition, as is the case in acute kidney injury (AKI), or can worsen gradually over time, as is the case in chronic kidney disease (CKD), which may result in end stage renal disease (ESRD). Kidney failure is commonly managed with hemodialysis, a procedure by which waste products and excess fluid are directly removed from a patient’s blood using an external dialysis machine. ESRD patients require complex management and the cost burden of administering dialysis is significant. Hemodialysis can be performed in multiple care settings, including the hospital, clinic or the patient’s home. Typically, different types of dialysis machines are used in different care settings and for different clinical needs. Tablo is an enterprise dialysis solution that allows providers to standardize to a single technology platform.

Driving adoption of Tablo in the acute setting has been our primary focus to date. We have invested in growing our economic and clinical evidence, built a veteran sales and clinical support team with significant expertise, and implemented a comprehensive training and customer experience program. Our experience in the acute market has demonstrated Tablo’s clinical flexibility and operational versatility, while also delivering meaningful cost savings to the providers. We plan to continue leveraging our commercial infrastructure to broaden our installed base in the acute care market as well as driving utilization and fleet expansion with our existing customers. While the ongoing COVID-19 pandemic has presented opportunities to demonstrate the real-world benefits of Tablo over traditional machines, we believe these benefits, in addition to the other advantages of Tablo, are continuing to drive customer purchasing decisions.

Tablo is also well suited for home-based dialysis. Tablo was cleared by the FDA for use in an acute or chronic care facility in September 2014. Subsequently, in March 2020, Tablo was cleared by the FDA for patient use in the home. Our ability to reduce training time, patient dropout, and supplies and infrastructure required to deliver dialysis in the home can drive efficiency and economic improvements to the home care model. In our home investigational device exemption (IDE) trial, patients reported specific quality of life improvements compared to their experience on the incumbent home dialysis machine. To penetrate this market successfully, we are focused on refining our home distribution, logistics and support systems to help ensure they are ready for rapid

3


 

scale. We are also working with providers, patients and payors to increase awareness and adoption of transitional care units (TCUs) as a bridge to home based therapy. To demonstrate the cost advantages of Tablo in the home setting, we are continuing to collect additional patient clinical experience and outcomes data.

We completed our initial public offering in September of 2020. Our common stock is listed on the Nasdaq Global Select Market under the symbol “OM.”

Our Market Opportunity

In the United States, dialysis is a large, expensive sector of healthcare that has seen little technology innovation in the last 30 years. We estimate that annual spending on ESRD in the United States is approximately $73 billion, of which an estimated $41 billion is Medicare spending. In 2019, this spending represented 7% of the total Medicare budget despite ESRD patients only representing 1% of the Medicare population. Dialysis is performed in the acute care setting, outpatient dialysis clinics and the patient’s home based on the patient’s condition and preference. As a result of an aging population and the growing incidence of diabetes, hypertension and obesity, based on historical rates of growth, we estimate the ESRD patient population will continue to grow around 3% annually, roughly 30% compounded growth, over the next ten years in the United States, thereby increasing our opportunity in both markets. We believe that any decrease in the size of the ESRD patient population due to COVID-related deaths may be offset by an increase in the population due to COVID-related AKI and delayed diagnosis of advanced stage CKD. As a result, although we cannot predict the full impact of the COVID-19 pandemic on the ESRD patient population with certainty, we do not anticipate that the pandemic will significantly impact the long-term growth rate of the population. We estimate the total annual addressable market opportunity in the United States for Tablo is approximately $2.5 billion in the acute care setting and approximately $8.9 billion in the home setting.

Acute Care

The acute care market includes short-term acute care hospitals, sub-acute long-term acute care hospitals (LTACHs) and skilled nursing facilities (SNFs). As of 2019, there were approximately 4,500 acute care hospitals and approximately 17,000 LTACHs and SNFs facilities in the United States, of which we believe 3,700 hospitals and 1,600 LTACHs and SNFs facilities are included in our acute care addressable market. We expect acute care hospitals to support higher treatment volumes per facility than LTACHs and SNFs and thus represent a greater proportion of the total market opportunity. The cost of managing a dialysis program is high, typically requiring complex equipment, separate infrastructure and specialized staff. We believe the majority of hospitals currently outsource the management of their dialysis programs to a third party, which is costly and may limit their ability to control the quality of patient care. For hospitals that manage their own dialysis programs, we believe that aggressive cost containment measures are motivating administrators to assess technology alternatives in order to lower the overall cost of care.

Home Care

At the end of 2019, there were approximately 570,000 patients in the United States receiving some sort of dialysis in the clinic or home setting. The majority of these patients were treated in dialysis clinics, although a large and growing number of treatments are transitioning to the patient’s home. In 2019, approximately 13% of patients (75,000 individuals), received dialysis treatment at home through peritoneal dialysis or home hemodialysis. From 2009-2019, the home hemodialysis patient population grew 131%, resulting in approximately 12,200 patients on home hemodialysis therapy, and we estimate that there are approximately 13,500 patients on home hemodialysis therapy today. We believe that the dynamics in the non-acute care market will continue to shift towards more home-based treatments as a result of several factors including the recent Executive Order on Advancing American Kidney Health, the expansion of Medicare Advantage to patients with ESRD and increasing commercial payor focus on reducing the total cost of ESRD care. We believe the recent COVID-19 global pandemic will accelerate the need for and adoption of technologies that enable care closer to and within the patient’s home, such as home-based dialysis therapies and telemedicine.

Overview of Kidney Function and Disease

A healthy human kidney removes waste and excess water from the blood on a continuous basis. Without a properly functioning kidney, byproducts and fluids build up in the body, which leads to progressive toxicity, electrolyte imbalance and fluid overload. There are two primary types of kidney disease: CKD and AKI. CKD is the gradual loss of kidney function over many years. CKD is typically irreversible and eventually leads to ESRD, which is the final stage of CKD. AKI is generally shorter in onset and can be reversible or lead to ESRD.

End Stage Renal Disease (ESRD)

ESRD is most often the result of chronic diseases, such as diabetes or high blood pressure, and is diagnosed when a patient’s kidneys no longer have sufficient function to avoid critical buildup of toxins and fluid in the body. If left untreated, ESRD will result

4


 

in death. The prevalence of ESRD in the United States has increased significantly over the last 40 years, driven in part by the growing rates of diabetes, hypertension, obesity and the overall aging of the population. At the end of 2019, there were approximately 810,000 patients with ESRD in the United States, of which, approximately 570,000 were treated with dialysis and the remainder of whom were living with a kidney transplant. The total ESRD figure is approximately 40% higher than the number reported ten years prior. We expect multiple pre-existing conditions and demographic factors such as diabetes, hypertension, obesity and an aging population to drive the prevalence of kidney failure to one million individuals by 2030.

Acute Kidney Injury (AKI)

AKI is the temporary loss of kidney function. AKI frequently occurs as a result of other medical conditions or treatment, including loss of other organ functions, severe infection, drug toxicity or post-surgical trauma. Patients experiencing AKI may require some form of dialysis in order to survive. Based on data from Centers for Medicare and Medicaid Services (CMS), the rate of beneficiaries experiencing a hospitalization complicated by AKI doubled from 2006-2016, with an approximate one third probability of these patients being newly diagnosed with CKD within the following 12 months. We estimate that there are over 450,000 admissions for AKI in the United States each year.

Kidney Disease Treatment Alternatives and Care Settings

Treatment of kidney disease typically depends on the type and stage of the disease. Approximately 20-25% of patients admitted to the ICU with a diagnosis of AKI may require dialysis treatment until their kidneys recover. If they fail to recover, AKI patients may need to remain on dialysis or receive a kidney transplant. For CKD, early stages of kidney disease can be managed with education, lifestyle changes and drug-based therapies. As kidney function continues to deteriorate and progress towards ESRD, the patient must either obtain a kidney transplant or receive dialysis for the rest of their life. Although transplantation is usually the most desirable option, a shortage of available organs and patient risk factors limit the use of this option. In 2019, only approximately 25,000 transplant procedures were performed in the United States compared to a total dialysis patient population of approximately 570,000. As a result, the vast majority of patients rely on dialysis to survive. While early CKD education and management can slow the progression of disease and help with a patient’s transition to dialysis, the Centers for Disease Control estimates that 90% of patients with CKD do not know they have kidney disease.

Additionally, the United States Renal Data Systems 2021 Annual Report indicates approximately 30% of new ESRD patients receive little or no pre-ESRD care at the time of dialysis initiation and “crash” into dialysis, initiating dialysis in an unplanned fashion.

Hemodialysis, the most common form of dialysis treatment, is a process by which waste products and excess fluid are directly removed from a patient’s blood using an external dialysis machine. Blood from the patient is routed to a dialyzer, also known as an artificial kidney, through plastic tubes where toxins are removed by diffusion across the dialyzer’s semipermeable membrane into a dialysate solution usually comprised of purified water and electrolytes. Excess fluid within the blood is removed in the dialyzer by the movement of water from higher pressure (blood) to lower pressure (dialysate). Cleansed blood from the dialyzer is then returned to the patient. A physician’s dialysis prescription can vary significantly depending on the patient’s level of acuity and the care setting. Key elements of a prescription include treatment duration, treatment frequency, blood flow rate, dialysate flow rate, ultrafiltration rate and dialysate electrolyte composition. After treatment, the patient is disconnected from the machine, which is disinfected before the next use.

Dialysis treatments are performed in the acute care setting, outpatient dialysis clinics and the patient’s home. The most common treatment option for ESRD patients, representing approximately 88% of ESRD dialysis patients in the United States, is treatments in a dialysis clinic. Most dialysis clinics are outpatient, freestanding facilities designed to treat on average 18 patients at a time. There are approximately 7,500 clinics in the United States that typically are open six days per week, treating patients on two to three shifts per day. In-clinic treatment typically lasts three to four hours and is usually performed three times per week. Outset’s commercial efforts are focused on the acute and home care settings where we believe Tablo is most needed and offers the most compelling value proposition based on product-market fit, price tolerance and competitive differentiation
.

Acute Care. The acute care market includes the treatment of AKI and ESRD patients in the hospital setting, or in sub-acute care settings such as LTACHs or SNFs. There are generally three subtypes of hemodialysis treatments that are used in the acute care settings. The decision of which treatment option to use is usually driven by the patient’s level of acuity. However, the decision can also be influenced by the availability of the treatment modality and whether the nurses are trained to use the specific type of dialysis machine.

Home. In 2019, approximately 13% of ESRD dialysis patients in the United States were dialyzing at home, with home hemodialysis patients representing 2% and peritoneal dialysis patients representing 11%.The decision on whether the patient stays in

5


 

clinic or moves to home-based dialysis is made by the provider and patient based on several factors, including the patient’s condition and level of independence. Clinics are mandated by CMS to inform patients of all available treatment alternatives, although surveys show that many patients are unaware of their care setting options. In recent years, there has been a growing trend of delivering dialysis closer to the patient as health systems, dialysis clinic providers and payors are recognizing the opportunity to improve the patient outcomes and lower the total cost of care through home dialysis. In an effort toward moving more patients to home dialysis, some health systems and dialysis providers have established TCUs. TCUs are orientated around educating ESRD patients as they transition into ongoing dialysis care with an emphasis on increasing the percentage of patients who select a home dialysis modality. In addition, there are currently approximately 2,200 clinics with specific home dialysis programs. We expect both TCUs and clinic-based home dialysis programs to grow. Regardless of whether ESRD patients are treated at home or remain in a clinic, they remain under the care of a dialysis provider that purchases their dialysis equipment and treatment supplies. Home dialysis patients receive ongoing clinical support from their nephrologist and the clinic’s care team in their home base clinic.

Patients have two modality choices for home therapy—hemodialysis or peritoneal dialysis. The decision between home hemodialysis and peritoneal dialysis is based on several factors, including patient eligibility, the patient’s level of independence and the clinic’s training capacity.

Home Hemodialysis. A treatment using a hemodialysis machine that stays in the patient’s home. Due to the inherent complexity associated with traditional home hemodialysis machines, patients must first undergo several weeks of intensive training from a nurse in their dialysis clinic before beginning to perform treatments in their home. The incumbent home hemodialysis machine requires more frequent dialysis, sometimes up to six times per week, and significant setup and prep time before each treatment. Patients are responsible for manually logging and submitting detailed information about each treatment to their dialysis care team to enable the provider to submit for reimbursement. This manual administrative work adds to patient fatigue and compliance issues.
Peritoneal Dialysis (PD). A self-administered, at-home treatment option that involves infusing sterile dialysate fluid through a surgically implanted catheter into the patient’s abdomen, or peritoneal cavity manually or via a peritoneal dialysis device, known as a cycler. The body’s natural internal lining acts as a semipermeable membrane which can eliminate toxins and remove fluid from the blood. After four to six hours, the dialysate fluid is drained from the patient’s body through the catheter, disposed of and replaced with fresh dialysate. These exchanges are performed four to five times per day. Peritoneal dialysis is clinically limited due to patients with certain pre-existing conditions such as congestive heart failure and obesity. Additionally, peritoneal dialysis is regarded as a “temporary” modality since approximately 80% of patients are on the therapy for less than three years.

Limitations and Challenges of Current Hemodialysis Machines

Hemodialysis is the most common form of dialysis for both AKI and ESRD patients and is used across multiple care settings. Nevertheless, we believe that limitations of traditional hemodialysis machines create significant operational complexities and challenges to administering dialysis, which ultimately contribute to a higher cost of care. These limitations include:

Operational challenges. Traditional hemodialysis machines are technically complex and require extensive training for both specialized staff and patients. Additionally, traditional machines require incremental equipment and separate water treatment rooms, which is not always practical depending on the care setting. These machines lack intuitive software, integrated data analytics and two-way wireless connectivity resulting in manual treatment set-up, documentation, reporting and machine management.
Clinical challenges. Traditional hemodialysis machines are typically used to deliver a single modality of treatment, requiring multiple machines for different types of treatment types across different care settings, therefore reducing clinical versatility.
Financial challenges. Traditional hemodialysis machines are expensive to operate with high fixed investment in infrastructure, significant recurring supply costs and expensive dialysis-specific labor. In the acute care setting, this very often results in specialized in-house teams or outsourcing to a third-party dialysis provider.

Additionally, we believe there are specific challenges in each individual care setting.

Challenges in the Hospital. In general, the cost of delivering dialysis in the hospital is not reimbursed as a standalone service, so the expense of providing dialysis care, whether managed in-house or outsourced to a third party, has a significant impact on hospital operating margins. In 2018, dialysis was performed across roughly 600 diagnosis-related groups, of which 60% of the inpatient stays with dialysis had negative operating margins, including 30% of inpatient stays that lost more than $10,000 per visit.

6


 

Given the complexity of managing dialysis programs with traditional equipment, many hospital administrators choose to outsource their dialysis program, which can be costly and may limit their ability to control patient care quality. The key challenges of delivering dialysis in the hospital include:

Limited clinical versatility of traditional machines. Hospitals require multiple machines for different treatment modalities to care for patients with varying degrees of acuity. Specifically, patients in the ICU require treatment with machines that deliver lower flow rates for longer durations, while stable patients are typically treated outside of the ICU on devices that deliver higher flow rates for shorter durations. Traditional dialysis machines are typically used to deliver a single modality, requiring different machines for different types of treatment types across care settings. This adds cost, complexity and inefficiency.
Specialized, dialysis-specific labor. Traditional dialysis machines are complicated to learn and use, and therefore require specially trained clinical staff who are in short supply or may not always be readily available for patient care. Training a dialysis nurse on a traditional dialysis machine typically takes weeks, limiting hospitals’ ability to flex their resources on-demand and potentially limiting patient access to prompt care.
Specialized infrastructure, equipment, and expensive supplies. Traditional dialysis machines require industrial water treatment rooms or separate mobile water filtration systems to generate the purified water necessary for dialysate production, which adds significant cost and space requirements to a hospital-based dialysis program. For machines that rely on sterile-packed dialysate bags in lieu of a separate water treatment and dialysate production area, the cost of purchasing and storing these supplies can be high.

 

Challenges in the Home. The limited adoption of home hemodialysis is largely a result of suboptimal existing technologies that make it operationally complex and expensive to manage, and consequently an undesirable treatment alternative for providers and patients. We believe the key challenges are:

Challenges for Providers

Time required to train new patients. The most commonly used home hemodialysis machine requires approximately 100 hours of nurse-led training, which translates into several weeks of commitment, unreimbursed expense and can result in a backlog of patients waiting to be trained due to capacity constraints. This time commitment required of patients and their care partners limits the adoption of home hemodialysis.
Low retention of patients. The incumbent home hemodialysis machine requires patients to dialyze frequently, sometimes up to six times per week. This involves cumbersome setup procedures requiring up to eight hours of prep work several times per week, to prepare batches of dialysate ahead of treatment. This is impractical and ultimately contributes to patient burnout. The patient drop-out rate for home hemodialysis on the incumbent machine is up to 45% within the first year.
Manual process of reporting. The incumbent machine requires patients to manually log their treatment regimen for reporting. Additionally, any machine errors impacting a patient’s treatment go unnoticed unless reported by the patient. This lack of visibility impacts compliance and reduces quality of care. Since clinics require proof of treatment in order to receive reimbursement, the lag created by manual reporting delays reimbursement timing to the provider.

Challenges for Patients

Complicated and time-consuming to learn. The incumbent home dialysis machine is technically complex and unintuitive to operate requiring patients to memorize setup procedures and refer to a paper manual for alarm resolution. As noted above, achieving competency requires approximately 100 hours of nurse-led training, which translates into weeks of commitment creating a significant hurdle to adoption.
Cumbersome setup and burdensome treatment frequency. The incumbent home dialysis machine is limited in its ability to sufficiently remove toxins, which as a result typically requires up to six treatments per week. The requirement of increased treatment frequency intensifies the burden placed on the patient, their care partner and clinical staff. In addition, the need for clean treated water requires significant time to batch and prepare dialysate before treatments. While not required prior to every treatment, this process can range from 16 to 24 hours per week and contributes to lower patient retention on the incumbent machine.

7


 

Manual documentation and reporting. Patients are responsible for reporting the details of each treatment, including vital signs, treatment time and ultrafiltration volumes, to their provider manually given the incumbent machine does not offer integrated wireless connectivity capabilities, or through the purchase of additional hardware, which is not reimbursed. This lack of connectivity limits the ability to remotely assess and troubleshoot any issues with the device, which often results in the machine being sent back to the manufacturer and replaced with a new machine, potentially delaying patient treatment.

Our Solution

We have purposefully designed a dialysis solution to address the limitations and challenges faced by using traditional dialysis systems. In doing so, we sought to completely reinvent the traditional concept of dialysis delivery. We believe Tablo represents meaningful technological advancements in dialysis care, a market which has lacked significant innovation for decades.

Tablo vs. Traditional Hemodialysis Machines.

img263710155_0.jpg 

The Tablo Hemodialysis System (Tablo)

Tablo is an FDA-cleared single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. We designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Unlike traditional hemodialysis machines, Tablo can be used seamlessly across multiple care settings and a wide range of clinical applications, all with the benefit of remote system management, monitoring and maintenance through two-way wireless data transmission capabilities.

The Tablo system is comprised of the following components:

Tablo Console. A compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface. Using advanced sensors, the console automates much of treatment setup and management and can automatically self-diagnose for potential machine issues.
Tablo Cartridge. A proprietary, disposable single use pre-strung cartridge that easily clicks into place, minimizing steps, touch points and connections, allowing for set up of treatment supplies in less than 12 minutes. The Tablo cartridge was designed to simplify and streamline treatment setup to minimize the potential for user error.
Tablo Data Ecosystem. With Tablo, we are bringing data to dialysis. Tablo is built to live in a connected setting with cloud-based system monitoring, patient analytics and clinical recordkeeping.

8


 

Benefits of Tablo

We believe that Tablo’s unique features combine to provide a meaningfully differentiated hemodialysis solution, offering the following benefits:

Simplicity. Tablo’s intuitive, simple and appealing touchscreen interface makes it easy to learn and easy to use, guiding users through treatment from start to finish with 3D animations illustrating each step. Embedded sensors simplify the setup and takedown process by providing validation of each step, reducing the chance of user error. During treatment, sensors automatically alert the user of any problems and provide instructions to resolving the issues on the screen. Our proprietary pre-strung cartridge clicks into place and features color-coded, easy-to-follow connections, allowing users to set up the treatment supplies in less than twelve minutes. Tablo’s simplicity can also reduce the training time necessary to operate the machine by roughly two thirds compared to training for traditional machines.
Clinical Flexibility. Tablo can accommodate a wide range of treatment modalities, durations and flow rates, allowing for broad clinical applications. In combination with its compact size and ease-of-use, Tablo’s clinical flexibility enables providers to standardize to a single solution across multiple care settings.
Operational Versatility. Tablo is an all-in-one device with integrated water purification and on-demand dialysate production, eliminating the need for industrial water treatment rooms required to operate traditional hemodialysis machines. Instead, Tablo only needs an electrical outlet and access to tap water. Tablo’s independence from this infrastructure enables bedside dialysis in the acute setting, saving the time and expense of transporting patients elsewhere for dialysis. By eliminating the need for separate infrastructure, Tablo can practically and cost-efficiently provide patients with access to treatment in additional care settings that previously has not been feasible with traditional dialysis machines.
Progressive Intelligence. Tablo’s two-way wireless connectivity and data ecosystem connects providers and patients through a cloud-based integrated data platform which enables real-time treatment monitoring, centralizes and automates treatment documentation, thereby simplifying compliance and record-keeping requirements. It streamlines machine management while allowing for feature enhancements through remote software upgrades.

Tablo’s clinically differentiated features were specifically designed to address the economic and operational challenges faced by stakeholders across multiple care settings. In addition, patients have reported clinical and quality of life benefits on Tablo compared to other dialysis machines.

In the acute care market, we believe Tablo offers the following benefits:

Increasing hospital operating margins by lowering the total cost of dialysis-related supplies, infrastructure and labor by up to 80% in the ICU.
Enabling hospitals to take dialysis back in-house which, including supplies cost reduction, reduces the total cost per treatment by $300 to $500.
Standardizing to a single, easy-to-learn machine that can deliver multiple dialysis modalities and reduce the cost, complexity and training burden of managing multiple different machines.
Allowing dialysis to be delivered anywhere across the hospital without the need for additional specialized equipment, infrastructure or specialized dialysis staff, easing operational workflow and enhancing productivity and staffing flexibility.
Enabling less expensive labor models, for example the insourcing of dialysis service using existing hospital nursing staff and eliminating expensive, fixed dialysis outsourcing contracts.
Automating data documentation and machine management to increase regulatory compliance.

In the home market, we believe Tablo offers the following benefits for clinics and their patients:

9


 

Improving provider home dialysis economics, including reducing home program staffing costs by reducing total training time and providing a novel learning curriculum that is largely patient managed, resulting in increased patient adoption through a shorter, less burdensome training process.
Offering flexible treatment frequency that can be aligned with payor reimbursement policies as medically appropriate, overcoming a key limitation to home adoption.
Reducing the time and nursing resources needed to train new patients and improving remote management and monitoring of home patients, resulting in higher productivity.
Enabling providers to cost efficiently build TCUs in previously inaccessible locations since specialized infrastructure, such as a water treatment facility, is no longer needed.
Enabling remote machine maintenance, troubleshooting and software updating.
Enabling longer retention and higher treatment compliance by giving patients the option of flexible treatment frequency and potentially fewer treatments, as well as less burdensome setup and management.
Improving treatment experience with fewer headaches, increased energy, less cramping, and a quieter more relaxed experience contributing to improved quality of life.
Improving the accessibility and sustainability of home dialysis for patients. We believe Tablo’s compact size, and its ability to operate with a standard electrical outlet, tap water, and less supplies storage, makes it an accessible option for patients regardless of the size of their living space.

Our Product

Tablo

Tablo is a mobile integrated hemodialysis solution for acute and home hemodialysis therapy. We designed Tablo from the inside out to offer a superior experience for patients and providers across multiple care settings. Tablo features an integrated water purification system, the ability to produce dialysate on demand, and an intuitive user interface and two-way wireless connectivity powered by an ecosystem of cloud-connected and intelligent software.

10


 

The Tablo Hemodialysis System.

img263710155_1.jpg 

Tablo is the only dialysis technology with a fully integrated water treatment system that allows for dialysate to be produced on demand in real time using bicarbonate and acid concentrates. The Tablo console requires only a standard electrical outlet and tap water to operate. This eliminates the need for industrial water treatment rooms, separate water purification machines and pre-filled bags of dialysate associated with traditional dialysis machines.

The Tablo cartridge is a single use consumable intended to facilitate extracorporeal blood purification for patients. We engineered our unique, one-push cartridge design to reduce set up and take down time and avoid contamination by minimizing manual connections and user touchpoints. One cartridge is used per treatment, except in the case of extended therapy, where multiple cartridges can be used if needed.

The Tablo cartridge consists of a user-friendly pre-configured blood, saline, and infusion tubing. The Tablo cartridge requires only two connections to operate as compared to other machines that require stringing, hanging, snapping and tapping multiple lines. Our proprietary cartridge clicks into place and features color-coded, easy-to-follow connections. In our home IDE trial, patients were able to set up the Tablo cartridge and dialysate concentrates in less than 12 minutes, on average. With an average prime period of approximately eight minutes, an uninterrupted patient can initiate therapy in as little as around 20 minutes, representing a significant improvement over traditional machines, which can take approximately 45 minutes to set up.

Tablo’s simple setup and intuitive touchscreen interface combined with sensor-based automation are designed to enhance the user experience by accelerating the training process, expediting device set up, and streamlining the treatment process. For example, Tablo includes an integrated blood pressure monitor, and 70 embedded sensors, which enable features such as automated air removal, priming, and blood return which minimize user errors and save time. Tablo’s touchscreen panel guides the user through the treatment with 3D animations and conversational instructions, making Tablo easy to learn and use for both professional and non-professional users. The screen can be used to change or manage treatment parameters, add patient information, enter treatment notes as well as set reminders for future actions.

During treatment, should any issues arise, Tablo’s touchscreen panel guides the user through an explanation for the alarm and provides intuitive resolution instructions. Traditional machines provide no video guidance and generally require users to memorize or

11


 

reference numerical alarm codes from a separate user manual. Post-treatment, Tablo’s touchscreen interface guides the user through treatment takedown.

The Tablo console is compact, self-contained, and mobile. We designed Tablo with the home in mind to look more like a consumer product than a piece of medical equipment in order to increase patient comfort with having it in their living room. The console can be closed completely when not in use, which lowers the intimidation threshold and makes it ideally suited to a home environment. Tablo’s design allows the user to transport the unit easily throughout the hospital or home setting for storage. The console’s 35-inch height was designed to make it easy for patients, especially those with limited mobility, to engage with the touchscreen during treatment to view progress, resolve alarms and adjust functions as needed. For example, a patient can interact with the touchscreen to adjust the flow rate if they feel the onset of cramping.

Tablo Data Ecosystem

Tablo is the first hemodialysis system on the market with FDA clearance for two-way wireless data transmission. Tablo’s connect­edness helps reduce maintenance costs and enables ongoing system improvements. This is all made possible by our growing team of experienced software, data science, and machine learning engineers.

Tablo leverages cloud technology to make it possible for providers to monitor devices and treatments remotely, perform patient and population analytics, and automate clinical recordkeeping. Due to Tablo’s wireless connectivity, we can release new features and enhancements through OTA updates, without requiring hardware changes or interventions from field service engineers (FSEs). We also release user trainings this way, which means that customers can train and upgrade their device on their own schedule. Over the past two years, we have used these OTA updates to add important new features that extend Tablo’s clinical applicability in addition to updates that enhance device uptime by enabling remote diagnostics and support. These OTA updates help Tablo get smarter over time.

Tablo’s connectedness also allows it to continually stream to the cloud over 500,000 device performance data points after every treatment. We use this data, in conjunction with our diagnostic and predictive algorithms, to determine failure types and, in some instances, predict failures before they occur. Equipped with this information, our FSEs can confidently visit sites knowing they have the correct parts and consumables to address the issues reported, and those that are yet to come. In effect, this contributes to a reduction in service hours and an increase in device uptime.

The above functionality is enabled through two key platforms: TabloHub, a customer-facing portal; and TabloDash, an internal data analytics platform.

TabloHub

TabloHub is designed to be a one-stop shop for providers that allows customers to monitor treatments in real-time across their fleet, visualize historical treatment records and statistics, see system disinfection and service records, search documentation, read news about Tablo, and perform various trainings. It is accessible from virtually anywhere, using a phone, tablet, or a web browser.

Through the Tablo application programming interface (API), providers can integrate Tablo with their Electronic Medical Records (EMR) to receive treatment data and flowsheets automatically to reduce manual record keeping, which in turn, helps reduce record-entry errors and auditing risks. Tablo’s two-way wireless transmission delivers data intended to be compliant with the federal Health Insurance Portability and Accountability Act (HIPAA) to the provider without any need for additional equipment. It connects to the cloud using a standard Ethernet or Wi-Fi connection. TabloHub strengthens care, simplifies meeting documentation requirements, and makes system management easy.

TabloDash

TabloDash is a powerful data analytics platform used by Outset team members to analyze diagnostic data produced by connected devices across all fleets, data from our customer relationship management system, and various other sources. Tablo captures more than 500,000 machine performance data points during every treatment, which is then used to fuel data analytics and machine learning algorithms that drive our research and development pipeline.

Through TabloDash, data can be visualized, graphed, aggregated, and queried to answer complex business intelligence questions, and build performance monitoring dashboards. For example, our service team uses TabloDash to analyze field response times, categorize failures by types, diagnose specific device issues, and monitor customer fleet performance.

12


 

The real-time nature of TabloDash allows our FSEs to troubleshoot and adjust a device remotely during a call with a customer and avoid the need to send FSEs to a site unneces­sarily. If it is necessary to dispatch an FSE, we can use TabloDash to help ensure they arrive with the correct parts to complete the repair, and are also able to address any preventive maintenance predicted by our algorithms, all during the same visit.

TabloDash is the linchpin that helps us optimize the cost of service while increasing the quality of service by reducing unnecessary visits, time spent on-site, and device downtime.

Tablo Data Ecosystem

 

Value to Outset

Value to Our Providers

 

Reinforces customer loyalty through access to a functionally rich data ecosystem.
Improves speed and cost efficiency of design and manufacturing.
Increases efficiency through remote real-time system monitoring, diagnostics, and predictive analytics, lowering servicing costs.
Accelerates delivery of new features and improvements to customers through continuous in-field data analytics.

 

Reduces cost and increases compliance by centralizing and automating documentation and all cloud based medical record reporting from treatment flowsheets to machine management.
Increases uptime through machine-learning algorithms that feed continuous software improvements and predictive analytics.
Increases flexibility and efficiency through remote monitoring of patient treatment data.
Reduces administrative time and cost through EMR integration.

Clinical Outcomes and Studies

We have generated significant evidence to demonstrate that Tablo is safe and effective, clinically versatile and produces robust clinical outcomes, both in acute and non-acute settings. Tablo’s evidence base also indicates that its patient centric design, focused on simplicity and ease of use, provides a favorable clinical experience for both patients and providers. We have invested in building a robust Tablo evidence base that captures both patient and provider experience with Tablo.

Research and Development

We invest in research and development efforts that advance our Tablo system with the goal to expand and improve upon our existing product and solutions. Our research and development expenses totaled $36.7 million and $28.9 million for the years ended December 31, 2021 and 2020, respectively.

Our research and development team includes hardware and software engineers with deep expertise in mechanical and electrical engineering, fluidics, embedded software design, and cloud-based data and security architecture. Their collective efforts are applied to three key areas: (1) engineering and cost reduction initiatives that continually enhance device performance and lower our cost of product revenue, (2) expansion of the Tablo data ecosystem to extend economic, operational and clinical benefits to our customers, and (3) advancing our innovation pipeline, which is directed toward broadening Tablo’s value in the home, chronic, and acute environments for patients and providers. We intend to continue investing significant resources to maintain and strengthen our technological competitive advantage in order to deliver a steady stream of inventive solutions that provide clinical and operational simplicity, versatility and efficiency.

Competition

There are a number of dialysis machine manufacturers in the United States, Europe and Asia. Notable competitors in the United States include Fresenius Medical Care AG & Co. KGaA (Fresenius), Baxter International, Inc. (Baxter) and B. Braun. Medical Inc. (B. Braun). In addition, Quanta Dialysis Technologies Ltd’s (Quanta) dialysis system recently received FDA 510(k) clearance for use in acute and/or chronic settings. Of these competitors, Fresenius is the largest, and is vertically integrated, both manufacturing dialysis products and operating dialysis clinics along with providing inpatient dialysis services to hospitals and health systems. Additionally, companies with dialysis machine development programs include Medtronic and CVS. With the exception of Quanta, our competitors are significantly larger than us with greater financial, marketing, sales and personnel resources, greater brand recognition and longer operating histories. We believe our ability to compete effectively will be dependent on our ability to build the commercial

13


 

infrastructure necessary to effectively demonstrate the value of Tablo, maintain and improve product quality and feature functionality, build the infrastructure to support the operating needs of the business and achieve cost reductions.

Acute Care

While historically customers in this market have focused on machine functionality and price, we believe they are increasingly focused on the total cost of patient care, which favors technology that can provide clinical versatility and improve operational efficiency. In the acute care setting, our competitors are Fresenius, Baxter and B. Braun. We compete primarily on the basis that Tablo is designed to drive operational efficiency through ease of use and cost reduction by reducing infrastructure and supplies cost.

Home Care

We believe competition in the home setting is based on a system’s clinical performance, its cost efficiency, its ease of use and patient preference. In the home hemodialysis setting, competitors include Fresenius (through its acquisition of NxStage). We believe through Tablo’s unique advantages it is easier and faster for patients to learn, and simpler for patients to operate at home, which may position us well against existing competitors. We believe these factors will reduce patient burn-out, thereby extending patient retention, increasing home hemodialysis growth and improving associated margin for providers. We do not consider PD to be competitive to our products given the differences in treatment modality, that PD is clinically limited due to patients with certain pre-existing conditions such as congestive heart failure and obesity and that PD is regarded as a “temporary” modality since approximately 80% of patients are on the therapy for less than three years.

Intellectual Property

Our success depends in part on our ability to protect our proprietary technology and intellectual property rights. We rely on a combination of federal, state, common law and international rights, as well as contractual restrictions, to protect our intellectual property.

We seek patent protection for certain of our key innovations, processes and other inventions. We pursue the registration of our trademarks, service marks and domain names in the United States and in certain other locations. We control access to our proprietary technology by entering into confidentiality and invention assignment agreements with our employees and contractors, and confidentiality agreements with third parties. Our intellectual property includes specific algorithms for the Tablo console, including those related to pressure sensors, blood leakage and pump control loops.

Patents

As of December 31, 2021, we had 19 issued U.S. patents, as well as nine pending U.S. patent applications, including 12 patents and patent applications previously exclusively licensed to us from Oregon State University (OSU), which OSU assigned to us upon termination of our license agreement with OSU. We had an aggregate of 40 issued patents in Australia, Canada, China, France, Germany, Hong Kong, Japan, Spain and the United Kingdom, as well as 18 pending patent applications in Japan, the European Patent Office and under the Patent Cooperation Treaty, including 22 patents previously exclusively licensed to us from OSU, which OSU assigned to us upon termination of our license agreement with OSU. Some of our patents and other intellectual property cover aspects of Tablo that enable it to be used by anyone, including the patient, through the automation of functions formerly performed by dialysis center technicians using traditional dialysis systems. Our proprietary data ecosystem provides what we believe is a unique way of connecting providers and patients for real-time treatment monitoring, automated treatment documentation, and simplified compliance and record-keeping.

Our patents expire between October 2025 and November 2041. The term of individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. In the United States, a patent’s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office (USPTO) in examining and granting a patent, or it may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. We cannot be sure that our pending patent applications or future patent applications will result in issued patents or that any patents that have issued or might issue in the future will protect our current or future products, provide us with any competitive advantage or will not be challenged, invalidated, or circumvented.

Various aspects of Tablo, including, without limitation, sensor technology, connectivity, automation, analytics and interface are covered by software, algorithms, processes, trade secret or other proprietary rights. We protect our trade secrets through a variety of measures, including confidentiality agreements and proprietary information agreements with suppliers, employees, consultants and

14


 

others who may have access to our proprietary information. Trade secrets and proprietary information can be difficult to protect, however. While we have confidence in the measures we take to protect and preserve our trade secrets and proprietary information, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets and proprietary information may otherwise become known or be independently discovered by competitors.

There is no active patent litigation involving any of our patents, and we have not received any notices claiming that our activities infringe a third party’s patent.

Manufacturing, Supply Chain and Logistics

We direct the manufacturing and supporting supply chain, distribution and logistics for the Tablo console, the Tablo cartridge and other consumables (electrolyte concentrates and plastic tubing that transports the concentrates into Tablo to enable on-demand dialysate production). We partner with several different contract manufacturers in the assembly and testing of our products and operate under a Quality Management System that has been certified to ISO 13485 Medical Device Quality Management System standard.

Tablo Console

Until early 2021, we exclusively relied on our contract manufacturing partner, Paramit Corporation (Paramit), based in Morgan Hill, California, for the production of the Tablo console. Tablo consoles manufactured by Paramit at their facility in Morgan Hill, California underwent extensive in-process and integrated system testing protocols designed by us. Consoles were then transported to our headquarters in San Jose, California, where our test engineers performed final testing, and then direct-shipped the consoles to our customers. We used a network of short-haul and long-haul freight forwarders optimized for time and cost efficiency.

In order to help ensure a high level of console production capacity through rapid scale, and to help lower our costs, we established a console manufacturing facility in Tijuana, Mexico, enabling us to insource Tablo console manufacturing beginning in early 2021. We are operating in Mexico in collaboration with TACNA Services (TACNA), a well-known outsourced business administration service provider that provides all the back-office and facility infrastructure support, allowing us to focus on our core competencies – design and high-volume manufacturing for reliability and cost reduction. Tablo consoles manufactured in our Mexico facility are tested at the facility using the same integrated system testing protocols designed by us, and then direct-shipped to our distribution centers, using a network of short-haul and long-haul freight forwarders optimized for time and cost efficiency. We terminated our contract with Paramit.

Pursuant to the terms of our manufacturing services agreement with TACNA (the TACNA Agreement), TACNA provides support services in connection with our manufacturing activities in Mexico. Under the TACNA Agreement, TACNA hires employees as requested by us and is responsible for human resource functions including maintenance of employee files and reports. TACNA is also responsible for performing internal statutory accounting and payroll services, as well as payables processing. Additional services that TACNA is obligated to provide under the TACNA Agreement include interfacing with both Mexican and U.S. governmental agencies, preparing import-export documentation, coordinating shipment of equipment, raw materials and finished products, and obtaining necessary permits and licenses required in Mexico. Under the TACNA Agreement, TACNA’s services are generally performed under a pass-through cost model under which costs incurred are approved by us. We are also obligated to pay TACNA fees based on the number of employees under the TACNA Agreement. The TACNA Agreement has an initial three-year term and will continue thereafter until terminated by us or TACNA in accordance with the terms of the TACNA Agreement.

The number of suppliers feeding into Tablo console production is in excess of 250 worldwide. We consider approximately 9% of these suppliers, located in the United States, Europe and China, as critical providers of components such as pumps, motors, valves and PCBA boards. We are undertaking a second source qualification process for the majority of these critical components. Where second sourcing is unavailable or infeasible, we have sought to mitigate supply interruption risks with increased levels of safety stock.

Tablo Cartridge

Until recently, the Tablo cartridge was manufactured exclusively by Infus Medical Co. Ltd. (Infus), a contract manufacturer with two facilities in Thailand. As part of our arrangement, we direct the oversight of the raw materials sourcing, selection and planning while Infus takes receipt of the Tablo cartridge components, and performs assembly, testing and Ethylene Oxide sterilization before shipment. The various components for the Tablo cartridge are manufactured by approximately 50 different suppliers located in various countries including Singapore, Italy and the United States, some of which are single-source suppliers. The Tablo cartridges have shipped primarily via ocean freight, though in times of peak demand or other supply chain constraints, we have shipped by air freight. Our team inspects the product before releasing it for shipment.

15


 

We recently moved production of a majority of Tablo cartridges to a manufacturing site in Tijuana, Mexico in partnership with Providien Medical (Providien). Providien, part of Carlisle Companies Incorporated, offers expertise in high volume disposable assembly services. Through enhanced product design, high capacity tooling and simplified freight and logistics, we expect this site will be able to produce cartridges at a lower cost, increase our supply capacity and help mitigate against global supply chain interruption. Tablo cartridges produced at this new facility undergo sterilization using electronic beam (e-beam) technology, which is an environmentally friendly sterilization method. Following our receipt of 510(k) clearance from the FDA for the new cartridge sterilization method in November 2021, we began manufacturing and commercially distributing Tablo cartridges manufactured at this new facility.

In addition to the Tablo cartridge, each treatment requires a concentrated container of bicarbonate and a concentrated container of acid, and two small plastic straws that draw the appropriate amount of the concentrates into the Tablo console in order to produce dialysate on demand.

Government Regulation

United States Food and Drug Administration

In the United States, our products are subject to regulation by the FDA as medical devices pursuant to the Federal Food Drug and Cosmetic Act (FDCA). The FDA regulates the development, design, non-clinical and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, adverse event reporting, advertising, promotion, marketing and distribution, and import and export of medical devices to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements of the FDCA.

FDA Premarket Clearance and Approval Requirements

Unless an exemption applies, each medical device commercially distributed in the United States requires either FDA clearance of a 510(k) premarket notification, approval of a de novo application, or approval of a premarket approval (PMA). Under the FDCA, medical devices are classified into one of three classes—Class I, Class II or Class III—depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA’s General Controls for medical devices, which include compliance with the applicable portions of the Quality System Regulation (QSR) facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials. Class II devices are subject to the FDA’s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance documents.

While most Class I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of the FDCA requesting permission to commercially distribute the device. The FDA’s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance. Devices deemed by the FDA to pose the greatest risks, such as life sustaining, life supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class III, requiring approval of a PMA. Some pre-amendment devices are unclassified, but are subject to FDA’s premarket notification and clearance process in order to be commercially distributed. Tablo is a Class II device subject to 510(k) clearance.

510(k) Clearance Marketing Pathway

To obtain 510(k) clearance, we must submit to the FDA a premarket notification submission demonstrating that the proposed device is “substantially equivalent” to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to PMA, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was found substantially equivalent through the 510(k) process. The FDA’s 510(k) clearance process usually takes from three to twelve months, but often takes longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. In addition, the FDA collects user fees for certain medical device submissions and annual fees for medical device establishments.

If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If the FDA determines that the device is “not substantially equivalent” to a previously cleared device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the “de novo” process, which

16


 

is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. If a de novo request is granted, the device may be legally marketed and a new classification is established. If the device is classified as Class II, the device may serve as a predicate for future 510(k) submissions. If the device is not approved through de novo review, then it must go through the standard PMA process for Class III devices.

After a device receives 510(k) marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer’s determination. If the FDA disagrees with a manufacturer’s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until 510(k) marketing clearance or PMA approval is obtained. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties.

PMA Approval Pathway

Class III devices require approval of a PMA before they can be marketed, although some pre-amendment Class III devices for which the FDA has not yet required a PMA are cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process. In a PMA application, the manufacturer must demonstrate that the device is safe and effective, and the PMA application must be supported by extensive data, including data from preclinical studies and human clinical trials. The PMA application must also contain a full description of the device and its components, a full description of the methods, facilities, and controls used for manufacturing, and proposed labeling. Following receipt of a PMA application, the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180 days under the FDCA to complete its review of a PMA application, although in practice, the FDA’s review often takes significantly longer, and can take up to several years. An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel’s recommendation. In addition, the FDA will generally conduct a pre-approval inspection of the applicant or its third-party manufacturers’ or suppliers’ manufacturing facility or facilities to ensure compliance with the QSR. PMA devices are also subject to the payment of user fees.

The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA application constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). A PMA may include post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term follow-up data from patients in the clinical study that supported the PMA or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval.

Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness. None of our products are currently marketed pursuant to a PMA.

De novo Classification

Medical device types that the FDA has not previously classified as Class I, II or III are automatically classified into Class III regardless of the level of risk they pose. To market low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, a manufacturer may request a de novo down-classification. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. A medical device may be eligible for de novo classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent or a manufacturer may request

17


 

de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination. The FDA is required to classify the device within 120 calendar days following receipt of the de novo application, although in practice, the FDA’s review may take significantly longer. During the pendency of the FDA’s review, the FDA may issue an additional information letter, which places the de novo request on hold and stops the review clock pending receipt of the additional information requested. In the event the de novo requestor does not provide the requested information within 180 calendar days, the FDA will consider the de novo request to be withdrawn. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject the de novo request for classification if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed. In the event the FDA determines the data and information submitted demonstrate that general controls or general and special controls are adequate to provide reasonable assurance of safety and effectiveness, the FDA will grant the de novo request for classification. When the FDA grants a de novo request for classification, the device is granted marketing authorization and further can serve as a predicate for future devices of that type, through a 510(k) premarket notification.

Breakthrough Device Program

The FDA has implemented a Breakthrough Device Program that is intended to help patients receive more timely access to breakthrough medical technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. A device also must meet one of the following criteria: (i) it represents breakthrough technology; (ii) there is no approved or cleared alternative; (iii) it offers significant advantages over existing cleared or approved devices; or (iv) availability of the device is in the best interest of patients. Under the program, we are eligible to receive priority review and interactive communications from the FDA regarding device development and clinical trial protocols, all the way through to commercialization decisions.

Clinical Trials

Clinical trials are almost always required to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA’s IDE regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a “significant risk,” to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.

In addition, the study must be approved by, and conducted under the oversight of, an Institutional Review Board (IRB) for each clinical site. The IRB is responsible for the initial and continuing review of the IDE study, and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare of human subjects.

During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical study are also subject to FDA regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device, and comply with all

18


 

reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.

Post-market Regulation

After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include:

establishment registration and device listing with the FDA;
QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;
labeling regulations and FDA prohibitions against the promotion of investigational products, or the promotion of ‘‘off-label’’ uses of cleared or approved products;
requirements related to promotional activities;
clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices, or approval of certain modifications to PMA-approved devices;
medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;
correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;
the FDA’s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and
post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.

Our manufacturing processes are required to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file, and complaint files. As a manufacturer, we are subject to periodic scheduled or unscheduled inspections by the FDA. Our failure to maintain compliance with the QSR requirements could result in the shut-down of, or restrictions on, our manufacturing operations and the recall or seizure of our products, which would have a material adverse effect on our business. The discovery of previously unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls.

The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:

untitled letters, warning letters, it has come to our attention letters, fines, injunctions, consent decrees and civil penalties;
unanticipated expenditures to address or defend such actions;
customer notifications or repair, replacement, refunds, recall, detention or seizure of our products;

19


 

operating restrictions, partial suspension or total shutdown of production;
refusing or delaying our requests for regulatory approvals or clearances of new products or modified products;
withdrawing a PMA that has already been granted;
refusal to grant export approval for our products; or
criminal prosecution.

Current FDA Regulatory Status

We currently have regulatory clearances required to market the Tablo Hemodialysis System in the U.S. for use in patients with acute and/or chronic renal failure, with or without ultrafiltration, in an acute or chronic care facility. The Tablo Hemodialysis System is also indicated for use in the home and observed by a trained individual. The Tablo Hemodialysis System is not cleared by the FDA for Continuous Renal Replacement Therapy (CRRT), a subtype of hemodialysis intended to be performed without interruption at lower flow and ultrafiltration rates for hemodynamically unstable patients who may not tolerate higher flow or ultrafiltration rates typically associated with conventional dialysis. Treatments must be administered under a physician’s prescription and observed by a trained individual who is considered competent in the use of the device. The FDA’s authorizations for the Tablo System and Tablo Cartridge have thus far been granted as 510(k) clearances.

While the Tablo Hemodialysis System is indicated for use in the home, the FDA notified us that the Tablo System is subject to a mandatory post-market surveillance order under Section 522 of FDCA. The FDA has required that we conduct a human factors study, as well as conduct a detailed analysis of adverse events and complaints from home users. In response to the 522 order, we submitted a simulated human factors test protocol to the agency which leveraged testing from our validation study that was initiated in 2019. In late 2020, the FDA requested additional information and notified us that we will need to conduct a new human factors study encompassing both summative and real-world data to meet the requirements of the 522 order. We responded to the FDA’s requests for additional information in January 2021 and in March 2021, the FDA approved our 522 study protocol. We have made certain changes over time, including software updates, to the Tablo System, including to accommodate patient use in the home. Although we originally documented these changes in memoranda to file, we have submitted a “catch-up” 510(k) application to the FDA which covers these design changes. Once cleared, this 510(k) will be used as the baseline submission for future 510(k) applications for the Tablo System. Because this also is the version of the Tablo System and software that we plan to use in the human factors study, we intend to initiate the human factors study upon FDA clearance. Once we are able to commence, conduct and complete our study, a final report will be provided to the FDA. Should the FDA decide that use of the Tablo System in the home environment identifies new concerns related to the safety and effectiveness of the product, or if the FDA determines that the requirements of the 522 order are otherwise unmet, we may be required to make changes to our Tablo System for which we may need to submit new marketing authorization applications and obtain clearance.

We continue to seek opportunities for product improvements and feature enhancements, which will, from time to time, require FDA clearance or approval before commercial launch.

Healthcare Fraud and Abuse Laws

Certain U.S. federal healthcare fraud and abuse laws apply by virtue of the fact that our customers will submit claims for our products and services that are reimbursed, in whole or in part, by Medicare, Medicaid, or other federal healthcare programs (as that term is defined at 42 U.S.C. § 1320a- 7b(f)). The principal federal fraud and abuse laws that apply in these circumstances are discussed below.

The U.S. federal Anti-Kickback Statute is a broad criminal statute that prohibits, among other things, the knowing and willful offer, solicitation, receipt, or payment of any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, for the purpose of inducing or rewarding the order, purchase, use or recommendation of items or services that may be paid for, or reimbursed by, in whole or in part, a federal healthcare program, such as Medicare or Medicaid. This includes products, like Tablo, that are not directly reimbursed but are purchased and used in a service paid for by such programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the term “remuneration” has been broadly interpreted to include anything of value. The Affordable Care Act (ACA) healthcare reform legislation specified that any claims submitted as a result of a violation of the federal Anti-Kickback Statute constitute false claims and are subject to enforcement under the federal False Claims Act, which is discussed in more detail below. Government officials have focused recent federal Anti-Kickback Statute enforcement efforts on, among other things, the sales and marketing activities of medical device manufacturers and other healthcare companies, and recently have brought cases against individuals or entities who allegedly offered unlawful

20


 

inducements to potential or existing customers in an attempt to procure their business. Judgments and settlements of these cases by healthcare companies have involved significant fines and, in some instances, criminal pleas and convictions. Conviction under the federal Anti-Kickback Statue results in mandatory exclusion from participation in the federal healthcare programs, meaning that federal healthcare programs will not reimburse (directly or indirectly) for products or services furnished by the excluded entity or individuals. Violators are subject to, among other things, imprisonment and significant criminal fines for each violation under the Anti-Kickback Statute, plus up to three times the remuneration involved and other civil penalties under the False Claims Act, as discussed in more detail below.

Given the breadth of the federal Anti-Kickback Statute, and to allow innocuous or beneficial arrangements that may otherwise implicate the law, there are statutory exceptions and regulatory safe harbors that protect certain arrangements from liability under the law when all elements of an applicable exception or safe harbor are met. However, these exceptions and safe harbors are narrowly drawn, and there is no exception or safe harbor for many common business activities like educational grants or reimbursement support programs. Given that the Anti-Kickback Statute is an intent-based law, the failure of a transaction or arrangement to fit precisely within an exception or safe harbor does not necessarily mean that it is illegal or that prosecution will be pursued.

Conduct and business arrangements that do not fully satisfy all elements of an applicable exception or safe harbor may result in increased scrutiny by government enforcement authorities such as the Department of Health and Human Services (HHS) Office of Inspector General (OIG). If scrutinized, arrangements that implicate the federal Anti- Kickback Statute that do not fall within an exception or safe harbor, are analyzed by the OIG and other enforcement authorities on a case-by-case basis with review based on the totality of the facts and circumstances to assess whether a given arrangement is prohibited by the federal Anti-Kickback Statute.

The federal civil False Claims Act (FCA) imposes civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment of government funds that are false or fraudulent, or knowingly making, using, or causing to be made or used a false record or statement material to an obligation to pay money to the government, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. This statute also permits a private individual acting as a “qui tam whistleblower” to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties for each false claim submitted or statement made. Government enforcement agencies and private whistleblowers have investigated medical device manufacturers for, or asserted liability under, the FCA for a variety of alleged inappropriate promotional and marketing activities, including those involving the provision of free product or other items of value to customers, certain financial arrangements with healthcare providers, the provision of billing, coding, and reimbursement advice, and purported “off-label” promotion of products, among other things.

Another key federal healthcare law is the federal healthcare fraud statute, which was added by HIPAA. The federal healthcare fraud statute imposes liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate them in order to have committed a violation.

The Physician Payments Sunshine Act (Sunshine Act) was enacted by Congress in 2010 as part of the Affordable Care Act and was amended in 2018 by the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act. The Sunshine Act requires us to collect and report annually certain data on payments and other transfers of value we make to U.S.-licensed physicians, teaching hospitals, and, for reporting beginning January 1, 2022, U.S.-licensed physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants, and certified nurse-midwives. Accordingly, we are required to track certain payments and other transfers of value made to these additional covered recipients during the 2021 calendar year. Manufacturers are also required to report ownership and investment interests held by the physicians described above and their immediate family members. The data are sent to CMS for public disclosure on the Open Payments website. Failure to timely report information in accordance with the Sunshine Act may result in significant financial penalties.

In addition to these federal laws, there are often state laws and regulations, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third- party payor, including private insurers; state laws that require medical device companies to comply with the medical device industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and regulations that require drug and device manufacturers to file reports relating to

21


 

pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities. In some states, applicable state anti-kickback laws apply with respect to all payors, including commercial health insurance companies.

Through our compliance efforts, we constantly strive to structure our business operations and relationships with our customers to comply with all applicable legal requirements. However, many of the laws and regulations applicable to us are broad in scope and may be interpreted or applied by prosecutorial, regulatory or judicial authorities or whistleblowers in ways that we cannot predict. Thus, it is possible that governmental entities or other parties could interpret these laws differently or assert non-compliance with respect to one or more of our business operations and relationships. Moreover, the standards of business conduct expected of healthcare companies under these laws and regulations have become more stringent in recent years, even in instances where there has been no change in statutory or regulatory language. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, and/or exclusion from government funded healthcare programs, such as Medicare and Medicaid. In addition, we may become subject to additional oversight and reporting requirements under a corporate integrity agreement as part of a settlement to resolve allegations of non-compliance with these laws (even if we do not admit violations). We may also need to curtail or restructure our operations as a result of being found to violate these laws, having such violations asserted against us, or based on enforcement actions instituted with respect to comparable practices by others. Any of these outcomes could have an adverse effect on our financial condition and ability to conduct our operations.

Privacy and Security

In the course of performing our business we obtain personally identifiable information (PII), including health-related information. Numerous federal and state laws and regulations, including HIPAA, govern the collection, dissemination, security, use and confidentiality of patient-identifiable health information or personal information. Such laws and regulations relating to privacy, data protection, and consumer protection are evolving and subject to potentially differing interpretations. These requirements may be interpreted and applied in a manner that varies from one jurisdiction to another and/or may conflict with other laws or regulations. HIPAA establishes a set of national privacy and security standards for the protection of individually identifiable health information, including protected health information (PHI) for certain covered entities, including healthcare providers that submit certain covered transactions electronically, as well as their ‘‘business associates,’’ which are persons or entities that perform a function or provide certain services for, or on behalf of, a covered entity that involve creating, receiving, maintaining or transmitting PHI. HIPAA also imposes breach reporting obligations on such covered entities and their respective business associates. Penalties for failure to comply with a requirement of HIPAA vary significantly depending on the failure and could include civil monetary or criminal penalties. HIPAA also authorizes state attorneys general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneys’ fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. The Department of Health and Human Services Office for Civil Rights (OCR) has recently increased its enforcement efforts on compliance with HIPAA, including the security regulations (Security Rule), bringing actions against entities which have failed to implement security measures sufficient to reduce risks to electronic protected health information or to conduct an accurate and thorough risk analysis, among other violations. HIPAA enforcement actions may lead to monetary penalties and costly and burdensome corrective action plans. We are also required to report known breaches of PHI consistent with applicable breach reporting requirements set forth in applicable laws and regulations. Finally, on December 10, 2020, OCR issued proposed revisions to the Privacy Rule aimed at reducing regulatory burdens that may exist in discouraging coordination of care, including creating an exception to the minimum necessary standard for healthcare coordination, and other proposals to increase patient access to their health information, among other changes. While a final rule has not yet been issued, if adopted, these proposed changes may require us to update our HIPAA policies and procedures to comply with the new requirements.

In addition, various federal and state legislative and regulatory bodies, or self-regulatory organizations, may expand current laws or regulations, enact new laws or regulations or issue revised rules or guidance regarding privacy, data protection and consumer protection. For instance, the California Consumer Privacy Act (CCPA) became effective on January 1, 2020. The CCPA gives California residents new rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although there are limited exemptions for PHI and the CCPA’s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, the CCPA may increase our compliance costs and potential liability. Additionally, a California ballot initiative, the California Privacy Rights Act (CPRA), passed in November 2020, and the majority of the provisions will take effect on January 1, 2023. The CPRA will impose additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit

22


 

requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may be required. Laws similar to the California laws have passed in Virginia and Colorado, and have been proposed in other states and at the federal level that may ultimately have conflicting requirements that would further complicate compliance. Further, new health information standards, whether implemented pursuant to HIPAA, congressional action or otherwise, could have a significant effect on the manner in which we handle health-related information, and the cost of complying with these standards could be significant. If we do not comply with existing or new laws and regulations related to patient health information, we could be subject to criminal or civil sanctions.

Additionally, the Federal Trade Commission (FTC) and many state attorneys general are interpreting existing federal and state consumer protection laws to impose evolving standards for the online collection, use, dissemination and security of health-related and other personal information. Courts may also adopt the standards for fair information practices promulgated by the FTC, which concern consumer notice, choice, security and access. Consumer protection laws require us to publish statements that describe how we handle personal information and choices individuals may have about the way we handle their personal information. If such information that we publish is considered untrue, we may be subject to government claims of unfair or deceptive trade practices, which could lead to significant liabilities and consequences. Furthermore, according to the FTC, violating consumers’ privacy rights or failing to take appropriate steps to keep consumers’ personal information secure may constitute unfair or deceptive acts or practices in violation of Section 5 of the FTC Act. The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC’s guidance for appropriately securing consumers’ personal information is similar to what is required by the HIPAA Security Rule. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions.

We may also be subject to laws and regulations in foreign countries covering data privacy and other protection of health and employee information that may be more onerous than corresponding U.S. laws. These regulations may require that we obtain individual consent before we collect or process any sensitive personal data, restrict our use or transfer of personal data, impose technical and organizational measures to ensure the security of personal data, add obligations to our data analytics services, and require that we notify regulatory agencies, individuals or the public about any data security breaches. As we expand our international operations, we may be required to expend significant time and resources to put in place additional mechanisms to ensure compliance with multiple robust and evolving data privacy laws as they become applicable to our business.

Our business relies on secure and continuous processing of information and the availability of our Information technology (IT) networks and IT resources, as well as critical IT vendors that support our technology and data processing operations. Security breaches, computer malware and computer hacking attacks have become more prevalent across industries and may occur on our systems or those of our third-party service providers. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication, and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may face increased cybersecurity risks due to our reliance on internet technology and the increased frequency of employees working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. OCR, in partnership with the Healthcare and Public Health Sector Coordinating Council, issued cybersecurity guidelines for healthcare organizations that reflect consensus-based, voluntary practices to cost-effectively reduce cybersecurity risks for organizations of varying sizes. Although these HHS-backed guidelines, entitled “Health Industry Cybersecurity Practices: Managing Threats and Protecting Patients,” are voluntary, they are likely to serve as an important reference point for the healthcare industry, and may cause us to invest additional resources in technology, personnel and programmatic cybersecurity controls as the cybersecurity risks we face continue to evolve.

We regularly monitor, defend against and respond to cyber and other security threats to our networks and other information security incidents. Despite our information security efforts, our facilities, systems, and data, as well as those of our third party service providers, may be vulnerable to privacy and information security incidents such as data breaches, viruses or other malicious code, exploitation of known or unknown vulnerabilities, coordinated attacks, data loss, phishing attacks, ransomware, denial of service attacks, or other security or IT incidents caused by threat actors, technological vulnerabilities or human error. If we, or any of our IT support vendors, fail to comply with laws requiring the protection of sensitive personal information, or fail to safeguard and defend personal information or other critical data assets or IT systems, or if our incident response, containment or mitigation measures are inadequate in the face of a particular data security incident, we may face significant business interruptions, incur reputational damage, and be subject to regulatory enforcement and fines as well as private civil actions. We may be required to expend significant resources in the response, containment, mitigation of cybersecurity incidents as well as in defense against claims that our information security was unreasonable or otherwise violated applicable laws or contractual obligations.

Failure to comply with applicable data protection laws and regulations could result in government enforcement actions (which could include civil and/or criminal penalties), private litigation and/or adverse publicity and could negatively affect our

23


 

operating results and business. Compliance with these laws is difficult, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an increasing and substantial cost in the future.

Reimbursement in the Clinic and Home Settings

We sell our Tablo to dialysis clinics. These clinics, in turn, provide equipment and services to the patient and are reimbursed by Medicare, Medicaid, private insurers, and other third-party payors.

Medicare

In the clinic and home setting, the largest payor of dialysis services is Medicare, and Medicare requires all dialysis patients to be under the care of a dialysis clinic provider, whether they are in the clinic or in the home.

Most patients who require regular dialysis, that is, those with ESRD, have coverage through Medicare Part B, which, effective January 1, 2011, pays dialysis clinics through a prospective, or bundled, payment system. Reimbursement is generally provided on a per treatment basis, and it is the same whether the patient is treated in the clinic or in the home setting. We believe that the current per treatment reimbursement amount received by our customers under Medicare Part B adequately covers the amortization of the cost of capital equipment, and specifically our Tablo console, as well as the per treatment supplies and disposables cost for Tablo, whether it is in the home or the in-clinic setting. Dialysis clinics’ continuing adoption of Tablo, however, will depend on whether the cost of treatments involving Tablo (including the amortized cost of the Tablo console and other capital equipment) will continue to be adequately covered by the reimbursement that the dialysis clinics receive from these third-party payors.

Under the ESRD Prospective Payment System (PPS), CMS generally makes a single bundled payment to the dialysis facility for each dialysis treatment that covers all renal dialysis services, which is broadly defined and includes home dialysis and most drugs. On October 29, 2021, CMS published the final rule for Calendar Year (CY ) 2022, which increased the base reimbursement rate per dialysis treatment to $257.90, an increase of $4.77 over the CY 2021 base rate of $253.13. CMS may adjust the base rate to account for factors that increase the cost of providing dialysis to a certain patient, for example, based on patient factors such as age, body surface area, low body mass index, and certain comorbidities, and based on facility factors like volume and geographic location. With a vast majority of U.S. ESRD patients covered by Medicare, the Medicare reimbursement rate is an important factor in a potential customer’s decision to use the Tablo and limits the fees for which we can sell or rent the Tablo.

Additionally, current CMS rules limit the number of hemodialysis treatments paid for by Medicare Part B to three times a week, unless there is medical justification provided by the dialysis facility based on information from the patient’s physician for additional treatments. Using currently available technology, most patients who receive home dialysis have been prescribed to receive more than three treatments per week. The Tablo system can allow providers to prescribe as few as three home dialysis treatments per week. However, to the extent that providers continue to prescribe more than three home dialysis treatments per week and Medicare contractors determine they will not pay for such additional treatments, adoption of the Tablo system could be adversely impacted. As there is not a uniform national standard for what constitutes medical justification, a clinic’s decision as to how much it is willing to spend on home dialysis equipment and services will be at least partly dependent on the number of weekly treatments prescribed for home dialysis with the Tablo system and, if greater than three, the level of confidence the center has in the predictability of receiving reimbursement from Medicare for additional treatments per week based on submitted claims for medical justification.

Beginning January 1, 2021, more dialysis patients enrolled in coverage under a Medicare Advantage plan when changes from the 21st Century Cures Act went into effect. While Medicare Advantage plans must provide at least the same level of coverage for Medicare beneficiaries as traditional Medicare, reimbursement to dialysis facilities is most often higher than traditional Medicare with a wide range of variability in payment rates to providers. Reimbursement rates depend on each Medicare Advantage plan’s contracts and network agreements with each dialysis facility. In CY 2021, Medicare Advantage plans overall saw a 31% increase in enrollment of ESRD patients, with the most significant increases coming from lower income patients who are dually eligible for Medicare and Medicaid.

The CY 2021 Medicare ESRD PPS final rule, among other things, encourages the development of new and innovative home dialysis machines that would give Medicare beneficiaries more dialysis treatment options in the home and improve their quality of life. Specifically, the final rule includes capital equipment in transitional add-on payment adjustments for new and innovative equipment and supplies (TPNIES). For home dialysis equipment CMS provided a pathway for capital related assets to secure TPNIES (CRA). We applied for and received CRA TPNIES in connection with the Tablo Hemodialysis System use by one patient per one machine in the home, pursuant to which Medicare will pay 65% of the Medicare Administrative Contractor-determined pre-adjusted per treatment amount for two calendar years beginning in CY 2022.

24


 

Medicaid

Many ESRD patients also have Medicaid coverage that is supplemental to Medicare coverage, that is, it helps cover Medicare Part B coinsurance and items and services not covered by Medicare Part B, but some ESRD patients may have Medicaid as their primary coverage. Because Medicaid is a state-administered program, Medicaid reimbursement for dialysis services varies by state.

Private Insurance

Finally, some patients may have coverage through private insurance, for example through a marketplace plan set up under the Affordable Care Act or through an employer or union group health plan. Private insurance reimbursement is generally higher than government reimbursement, but it varies by sponsor and plan.

Reimbursement in the Critical Care Setting

For Medicare patients, both acute kidney failure and fluid overload therapies provided in an in-patient hospital setting are reimbursed under the Medicare Severity Diagnosis Related Group System (MS-DRG). Under this system, reimbursement is determined based on a patient’s diagnoses, demographics, and procedures furnished during the stay, and is intended to cover all of the hospital’s costs of treating the patient. Longer hospitalization stays and higher labor needs, which are typical for patients with acute kidney failure and fluid overload, must be managed for care of these patients to be cost-effective. Similar to dialysis clinics that are reimbursed by Medicare under the ESRD bundled payment methodology, we believe that there is a significant incentive for hospitals to find the most cost-efficient way to treat these patients in order to improve hospital economics for these therapies.

In the in-patient setting under Medicare, dialysis and UF are not directly reimbursed, but rather are paid for out of the in-patient MS-DRG for a patient’s admission. In most cases, AKI or fluid overload requiring dialysis or ultrafiltration will increase the severity of the underlying diagnosis, and therefore could result in higher reimbursement than those cases without dialysis. Given dialysis is a “fixed cost” for providers within the MS-DRG, we believe that there is significant motivation for providers to attempt to reduce costs associated with dialysis in order to improve overall service line profitability.

United States Health Reform

Changes in healthcare policy could increase our costs and subject us to additional legislative and regulatory requirements that may interrupt commercialization of our current and future products, decrease our revenue and adversely impact sales of, and pricing of and reimbursement for, our current and future products. The United States and some foreign jurisdictions are considering or have enacted a number of other legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.

The implementation of the Affordable Care Act in the United States, for example, has changed healthcare financing and delivery by both governmental and private insurers substantially, and affected medical device manufacturers significantly. The Affordable Care Act, among other things, implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Additionally, the Affordable Care Act encouraged expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.

There have been judicial and Congressional challenges to various elements of the Affordable Care Act, as well as efforts to modify certain aspects of the Affordable Care Act. For example, Congress eliminated, starting January 1, 2019, the tax penalty for not complying with the Affordable Care Act’s individual mandate to carry health insurance. The Further Consolidated Appropriations Act of 2020, Pub. L. No. 116-94, signed into law December 20, 2019, fully repealed the Affordable Care Act’s “Cadillac Tax” on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share (repeal effective in 2021), and the medical device excise tax on non-exempt medical devices. The American Rescue Plan of 2021, Pub. L. No. 117-2, enacted on March 11, 2021, temporarily increased premium tax credit assistance for those eligible for subsidies for 2021 and 2022 and removed the 400% federal poverty level limit that otherwise applies for purposes of eligibility to receive premium tax credits. It is unclear efforts to challenge, or modify, or alter the implementation or interpretation of the Affordable Care Act will affect our business, financial condition and results of operations.

25


 

In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, the Budget Control Act of 2011, among other things, resulted in reductions in payments to Medicare providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect into 2031 unless additional Congressional action is taken, with the exception of a temporary suspension of the 2% cut in Medicare payments from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the COVID-19 pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. As long as these cuts remain in effect, they could adversely impact payment for any products we may commercialize in the future. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced CMS payments to several types of providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five years.

Moreover, other legislative and executive actions have encouraged the development of new payment and care models for ESRD patients. For example, an executive order signed in July 2019 directed the Secretary of HHS to develop, among other things, Medicare payment models designed to identify and treat at-risk populations earlier in disease development, and in connection with the executive order, HHS announced a goal of having 80% of new ESRD patients in 2025 either receive dialysis at home or receive a transplant. CMS subsequently published a final rule on September 29, 2020, among other things, to implement the End-Stage Renal Disease Treatment Choices (ETC) Model. The ETC Model is a mandatory payment model that adjusts certain Medicare payments to selected ESRD facilities, nephrologists, and other clinicians managing beneficiaries with ESRD starting January 1, 2021 and continuing through June 30, 2027. Specifically, the ETC Model will adjust ESRD facilities’ treatment base rates under the ESRD Prospective Payment System and managing clinicians’ monthly Medicare capitation payments to incentivize greater use of home dialysis and kidney transplants. CMS is also preparing to implement the Kidney Care Choices Model, a voluntary Medicare payment model with four distinct payment options designed to help providers reduce costs and improve quality of care for patients with late-stage chronic kidney disease and ESRD, to delay the need for dialysis and to encourage kidney transplantation. The first performance year of the Kidney Care Choices Model began on January 1, 2022. Finally, the Chronic Kidney Disease Improvement in Research and Treatment Act was introduced in the U.S. Senate (S. 1971) on June 8, 2021 and in the U.S. House of Representatives (H.R. 4065) on June 23, 2021. The Jack Reynolds Memory Medigap Expansion Act (HR 1676) was introduced in the U.S. House of Representatives on March 9, 2021. If enacted, either bill would guarantee access to Medigap insurance policies to all ESRD Medicare beneficiaries regardless of age. The Chronic Kidney Disease Improvement in Research and Treatment Act would also, among other policy changes, allow patients with ESRD to retain private insurance as their primary payer for an additional 12 months, and require CMS to adjust the ESRD PPS bundled rate when the current rate would not cover the cost of adding a new drug, biologic, or other technology into the bundle after the transitional payment period ends. Changes to the models of patient care, including an increased focus on treatments earlier in disease progression, may adversely affect our customers’ businesses and potentially decrease the demand for our product or result in additional pricing pressures. Further, with home dialysis as a growing trend in the industry and issuance of the executive order and the ETC Model final rule, a failure to implement our expansion into home dialysis could have a material adverse impact on our business.

We believe that there will continue to be proposals and other actions by legislators and other policymakers at both the federal and state levels, and by regulators and third-party payors to reduce costs and/or expand individual healthcare coverage. Changes to federal and state legislatures and executive offices following the November 2020 elections have resulted in and will likely continue to result in further healthcare policy changes. For example, on January 28, 2021, President Biden issued the “Executive Order on Strengthening Medicaid and the Affordable Care Act,” which, among other things revoked certain executive orders of the previous administration, stated that it is the current administration’s policy “to protect and strengthen Medicaid and the ACA and to make high-quality healthcare accessible and affordable for every American,” and directed heads of relevant executive departments and agencies immediately to review agency actions to determine whether any such actions are inconsistent with this policy. Additionally, on July 9, 2021, President Biden issued an executive order to promote competition in the American economy, including in the healthcare sector. Among the provisions in the executive order was a directive to HHS to standardize plan options in the national health insurance marketplaces (i.e., the Exchanges) to facilitate improved comparison shopping for insurance plans. Other actions by the Biden administration, the Congress, state governments, and third-party payors could impact our business in ways that are difficult to predict but that could have a material adverse effect on our business and financial condition. For example, certain of these changes could impose additional limitations on the rates we will be able to charge for our current and future products or the amounts of reimbursement available for our current and future products from governmental agencies or third-party payors. Current and future healthcare reform legislation and policies could also have a material adverse effect on our business and financial condition.

Human Capital Resources

As of December 31, 2021, we had 444 full-time employees, with 48% in our field sales and service teams and 52% in the rest of the company. Our workforce hails from across industries, including technology, medical devices, life sciences and retail management.

26


 

As of December 31, 2021, our manufacturing facility in Tijuana, Mexico had 149 full-time team members on-site across quality, engineering, manufacturing, supply chain, and support functions. TACNA facilitates the hiring of new team members and is responsible for human resource functions and payroll processing.

There are no unions represented within our employee base and no members of our workforce are covered under collective bargaining agreements.

In October 2021, we published our inaugural Environmental, Social, and Governance (ESG) Report (ESG Report) which is available on our website at https://investors.outsetmedical.com/environmental-social-and-governance and includes more detailed information on our human capital programs and initiatives. Nothing contained on or accessible through our website, including our ESG Report or sections thereof, shall be deemed incorporated by reference into this Annual Report.

Talent and Pay Philosophies

We are committed to attracting the best talent we can find, while providing our employees with challenging work in a fast-paced environment. We recruit broadly and welcome diverse candidates. We have a principle that “everyone is a recruiter” and often hold crowd recruiting sessions to identify candidates collectively, and welcome employee referrals.

Our environment is goal-driven, and we believe in paying for outstanding performance and future potential. We offer competitive, market-based salaries, an annual cash bonus program tied to individual and company performance, a broad-based equity incentive compensation program including an employee stock purchase plan, a comprehensive benefits package, team incentives and peer incentives.

Performance Management, Career Development and Engagement

We believe that preparing our employees for growth and development is a key business activity and managers have two key performance conversations a year with their team members. Our year-end conversation, “Yearbook,” is focused on evaluating the success and learnings of the past year. Our mid-year conversation, “Passport,” is focused on skill development and future growth opportunities.

We have a formalized practice around performance development and have numerous avenues for employees to gain experience, exposure and build new skills. For example, we have invested in various training and development opportunities for our employees including programs taught by internal leaders, development sessions led by external speakers, and access to on-demand learning resources.

We strongly believe in growing from within and have numerous avenues for in-role stretch assignments, cross-group short assignments, internal mobility, and promotions. In addition, we conduct employee surveys to monitor employee engagement and identify areas of focus for our human capital management. Information on the results of these surveys is included in our ESG Report.

Diversity, Equity and Inclusion Strategy

We are committed to creating and nurturing an inclusive workplace, where everyone feels respected, valued, and included – not only because it’s the right thing to do, but also because we strongly believe that it’s vital to our success and crucial to fully support the diverse communities we serve. We embrace diversity and equal opportunity in an intentional way. We are committed to building a team that represents a variety of backgrounds, perspectives, and skills. We believe that creating an environment where employees feel comfortable to speak up and share ideas means we all do great work.

In mid-2020, we brought together an engaged group of employees to design our diversity, equity and inclusion strategy. We defined three key areas of focus: 1) raising awareness of racial disparities in kidney care, 2) impactful community outreach with students to advocate for careers in the medical device industry, and 3) providing internal education on bias. We continued to actively pursue these three areas of focus in 2021, and intend to do so moving forward.

Additional information on our diversity, equity and inclusion strategy, including data regarding our U.S. workforce and new hire demographics by gender and ethnicity, are publicly disclosed in our ESG Report.

Employee Health and Safety

At Outset, safety is a priority and is part of everyone’s job. We are committed to providing a safe workplace and we comply with applicable health and safety laws and regulations. We strictly prohibit any violent or threatening behavior on our premises or

27


 

during any work-related activities. Our employees participate in applicable emergency response training and periodic drills to help maintain awareness of security, safety and emergency response protocols.

We determined early in the COVID-19 outbreak that supporting, educating and keeping our workforce safe was paramount. We moved quickly to connect with and help our employees so we could continue our business operations and provide ongoing support for our patient population. Since we qualified as an essential business, we continued to operate our facility in San Jose, California through the shelter-in-place orders, and immediately categorized our workforce based on the essentialness of working onsite. For roles that required employees to be physically onsite, such as our R&D and manufacturing technical staff, we implemented infection control procedures, social distancing protocols, increased sanitization standards, personal protective equipment, and daily temperature checks. When COVID-19 testing became available, we implemented onsite testing in our facilities. We also provided vaccination clinics at each of our facilities to make it convenient for our workforce to receive COVID-19 vaccinations once available. During the third quarter of 2021, we defined a policy requiring our customer-facing and on-site employees to be fully vaccinated by October 2021, subject to religious and medical exemptions. With nearly all our employees now vaccinated, we have begun to move toward more normal operations in accordance with local guidelines, including resuming more on-site activity to increase productive collaboration while continuing to prioritize employee safety. For employees working on-site, we continue to follow masking protocols consistent with evolving health and safety guidelines, facilitate social distancing and practice increased sanitizing standards.

Corporate Information

We were incorporated in the State of Delaware in 2003 under the name Home Dialysis Plus, Ltd. We changed our name to Outset Medical, Inc. in January 2015. Our principal executive offices are located at 3052 Orchard Dr., San Jose, California 95134, and our telephone number is (669) 231-8200.

Available Information

We make our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports, available free of charge at our website as soon as reasonably practicable after they have been filed with the Securities and Exchange Commission (SEC). Our website address is www.outsetmedical.com. Information on our website is not part of this report. The SEC maintains a website that contains the materials we file with the SEC at www.sec.gov.

Information About Our Executive Officers

The following table sets forth information concerning our executive officers and directors as of the date of this Annual Report:

Name

 

Age

 

 

Position(s)

Executive Officers

 

 

 

 

 

 

Leslie Trigg

 

 

51

 

 

President, Chief Executive Officer and Chair of the Board

Nabeel Ahmed

 

 

46

 

 

Chief Financial Officer

John L. Brottem

 

 

48

 

 

General Counsel and Secretary

Stacey Porter

 

 

47

 

 

Chief People Officer

Jean-Olivier Racine

 

 

40

 

 

Chief Technology Officer

Martín Vazquez

 

 

52

 

 

Chief Operating Officer

Steve Williamson

 

 

49

 

 

Chief Commercial Officer

 

28


 

Leslie Trigg

Leslie Trigg has served as our President and Chief Executive Officer and a member of our board of directors since November 2014 and as Chair of our Board since February 2022. Ms. Trigg joined the Company from Warburg Pincus, a private equity firm, where she was an Executive in Residence from March 2012 to March 2014. Prior to that, Ms. Trigg served in several roles at Lutonix (acquired by CR Bard), a medical device company, from January 2010 to February 2012, most recently as Executive Vice President, and as Chief Business Officer of AccessClosure (acquired by Cardinal Health), a medical device company, from September 2006 to June 2009. She also previously held positions with FoxHollow Technologies (acquired by ev3/Covidien), a manufacturer of devices to treat peripheral artery disease, Cytyc, a diagnostic and medical device company, Pro-Duct Health (acquired by Cytyc), a medical device company, and Guidant, a cardiovascular medical device company. Ms. Trigg has served on the board of directors of Adaptive Biotechnologies Corporation, a biotechnology company, since March 2021, and on the board of directors of ARYA Sciences Acquisition Corp IV, a special purpose acquisition company, since March 2021. Ms. Trigg also serves on the board of directors of the Medical Device Manufacturers Association. Ms. Trigg holds a B.S. degree from Northwestern University and an M.B.A. from The Haas School of Business, UC Berkeley.

Nabeel Ahmed

Nabeel Ahmed has served as our Chief Financial Officer since August 2021. Mr. Ahmed joined the Company in May 2020 as Vice President, Controller, was named Vice President, Finance in May 2021, and was appointed as Interim Chief Financial Officer effective July 2021. Prior to joining the Company, Mr. Ahmed served as Vice President, Finance at 8x8, Inc., a communications platform provider, from April 2019 through January 2020, and as Vice President, Finance at Vocera Communications, Inc., a provider of clinical communication and workflow solutions, from December 2014 through April 2019. Prior to that, he held various leadership positions in accounting and finance, including as CFO at Wanderful Media from 2013 to 2014, as well as Vice President, Finance and then CFO at MarketTools, Inc. from 2009 to 2012. Earlier in his career, Mr. Ahmed held various positions of increasing responsibility at Ernst & Young LLP from 1997 to 2004 and at eBay, Inc. from 2004 to 2008. Mr. Ahmed holds a Bachelor of Commerce from Laurentian University and an M.B.A. from The Wharton School, University of Pennsylvania.

John L. Brottem

John L. Brottem has served as our General Counsel and Secretary since May 2020. Prior to joining the Company, Mr. Brottem served in a number of roles at Omnicell, Inc., a leading provider of medication management automation solutions and adherence tools for healthcare systems and pharmacies: as Vice President, Legal and Deputy General Counsel from September 2019 to May 2020; as Vice President, Legal and Associate General Counsel from April 2016 to September 2019; and Senior Director, Legal and Associate General Counsel from November 2011 to April 2016. Prior to Omnicell, Mr. Brottem was Corporate Counsel at Brocade Communications Systems, Inc., a networking solutions company, from January 2009 to November 2011; Corporate Counsel at Foundry Networks, Inc., a networking solutions company, from February 2008 to January 2009; and Associate at Cooley Godward Kronish LLP, an international law firm, from November 2001 to February 2008. Mr. Brottem holds a B.A. from Occidental College and a J.D. from the University of California, Davis, School of Law.

Stacey Porter

Stacey Porter has served as our Chief People Officer since October 2021. Ms. Porter joined the Company in November 2018 as Vice President, People Operations. Prior to joining the Company, Ms. Porter served as Head of Global Talent Development at Intuitive Surgical, Inc., a manufacturer of robotic surgical systems, from October 2012 to November 2018. Prior to that, Ms. Porter held various leadership positions in talent development, including as Director, Global Talent Development at VMware, Inc. from 2011 to 2012, and as Head of Learning and Development at Roche Pharmaceuticals from 2005 to 2009. Ms. Porter holds a B.A. from University of Kentucky and a MSW from University of Louisville.

Jean-Olivier Racine

Jean-Olivier Racine has served as our Chief Technology Officer since June 2021. Mr. Racine joined the Company from Amazon.com, Inc., an electronic commerce and cloud computing company, where he served in a number of roles: as Head of Engineering and Science, AWS Health AI from June 2020 to June 2021, Head of Cloud Services and Alexa, Halo (a health wearable device) from October 2018 to June 2020, as Head of Digital Media Catalog Services, Fire TV from January 2013 to October 2018, and as Fluidity and Performance Lead, Fire Tablet, Launcher and Platform from November 2011 to February 2013. Prior to that, Mr. Racine was a Senior Programmer-Analyst at the Montréal Exchange from January 2011 to November 2011, and a Projects Leader at NexGen Ergonomics, Inc. from January 2008 to January 2011. Mr. Racine holds a B.Eng. degree and a M.Eng. degree from École de Technologie Supérieure.

29


 

Martín Vazquez

Martín Vazquez has served as our Chief Operating Officer since November 2017. Prior to joining the Company, Mr. Vazquez was Vice President of North America Operations and Global Sales and Operations Planning at Abbott Rapid Dx (formerly Alere), a rapid point-of-care diagnostics company, from July 2015 to November 2017. Prior to that, Mr. Vazquez served as Vice President, Manufacturing Management/WW Operations at Becton Dickinson, a medical technology company, from March 2012 to June 2015, and Director Operations Mexico at Smiths Medical, a manufacturer of specialty medical devices, from May 2009 to March 2012. He also previously held positions with Integer Holdings (formerly Greatbatch Medical), a medical device manufacturing company, Alcon Laboratories, a subsidiary of Novartis AG focused on eye care products, Venusa, a medical device manufacturing company, and Ethicon (J&J), a medical device company. Mr. Vazquez holds a B.S. from University of Texas at El Paso and an M.B.A. from The Marshall School of Business, University of Southern California.

Steve Williamson

Steve Williamson has served as our Chief Commercial Officer since November 2020. Prior to joining the Company, Mr. Williamson was Worldwide President, Peripheral Intervention at Becton, Dickinson and Company, a medical technology company, from January 2018 to November 2020, and President, Peripheral Vascular at C.R. Bard (now part of Becton, Dickinson and Company) from August 2012 to December 2017. Prior to that, he was Senior Vice President and General Manager, Gyn Surgical Products from December 2009 to August 2012 and Vice President of Sales and Marketing, Gyn Surgical Products from October 2007 to December 2009 with Hologic, Inc., a medical technology company. Mr. Williamson holds a B.B.A. from University of Massachusetts Amherst and an M.B.A. from Bentley University.

30


 

Item 1A. Risk Factors.

Risk Factors Summary

The following summarizes the principal factors that make an investment in our company speculative or risky, all of which are more fully described in the risk factors section below. This summary should be read in conjunction with the risk factors section and should not be relied upon as an exhaustive summary of the material risks facing our business. The following factors could result in harm to our business, reputation, revenue, financial results, and prospects, among other impacts:

Risks Related to Our Business and Industry

Our history of net losses and expectation that we will continue to incur losses
Our ability to reduce manufacturing costs
Our ability to attain market acceptance for Tablo among providers and patients
Concentration of our revenues in a single product and concentration of a large percentage of our revenues from a limited number of customers
Our ability to expand into the home hemodialysis market
Our reliance on third-party suppliers, including single source suppliers and contract manufacturers, and our ability to overcome manufacturing disruptions, including any supply chain disruptions resulting from the ongoing COVID-19 pandemic
The impact of the ongoing COVID-19 pandemic, natural or man-made disasters and similar events on our business
Our ability to ensure strong product performance and reliability, offer high quality support, and ensure proper training and use of Tablo
Our ability to continue innovating and improving Tablo
Our ability to compete effectively
Our ability to effectively manage privacy, information and data security risks, including our ability to adequately defend against, respond to and manage increasingly sophisticated cyberattacks in an increasingly complex cyber ecosystem
Our ability to manage our growth, including maintaining and growing our sales and marketing organization
Our estimates of the sizes of the markets for Tablo
Our ability to accurately forecast customer demand and manage our inventory
Fluctuations in our operating results
Potential disruptions of service provided by third parties that host our cloud-based ecosystem and information technology systems
Potential litigation, including product liability claims, and the expense and potential unavailability of insurance coverage for any liabilities resulting from Tablo
Our ability to obtain additional capital when needed
Cost containment efforts of our customers, purchasing groups and government organizations

Risks Related to Government Regulation

Our compliance with FDA and other medical device regulations applicable to our products and operations, including our ability to: comply with the post-market surveillance order recently issued by the FDA for Tablo; obtain and maintain necessary FDA regulatory clearance or approvals for Tablo, related products, or any future product modifications or new

31


 

products; comply with ongoing FDA requirements, including related to the manufacturing, marketing and promotion of our products, and the ability of our suppliers to so comply; and manage the risks and expenses associated any clinical trials necessary to support future product submissions to the FDA
Impact of potential changes to reimbursement rates for dialysis treatments or healthcare reform measures
Impact of potential adverse medical events associated with Tablo, product failures or malfunctions, or our failure to report such events to the FDA
Our ability to comply with various laws and regulations regarding healthcare, data privacy and security, and environmental and occupational safety

Risks Related to Our Intellectual Property

Our ability to obtain, maintain, protect and enforce our intellectual property rights, including our patents, copyrights, trademarks and trade secrets

Risks Related to Ownership of Our Common Stock

Fluctuations in the market price of our common stock in response to numerous factors regardless of our operating performance
Influence of principal stockholders and management over matters subject to stockholder approval
Impact of future issuances of securities
Our organizational documents include certain provisions that may make a change of control more difficult, as well as exclusive forum requirements

General Risks

General economic and financial market conditions
Substantial resources associated with operating as a public company, and our ability to maintain effective internal control over financial reporting and disclosure controls and procedures
Our ability to attract and retain key personnel and maintain our corporate culture
Risks associated with potential future acquisitions or investments
Our ability to comply with anti-corruption, anti-bribery, anti-money laundering and similar laws
Our estimates or judgments relating to our critical accounting policies
Expectations relating to ESG factors

The summary risk factors described above should be read together with the text of the full risk factors below and the other information set forth in this Annual Report, including our financial statements and the related notes and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, as well as in other documents that we file with the SEC. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us, or that we currently deem to be immaterial, may also arise and materially impact our business. If any of these risks occur, our business, results of operations and financial condition could be materially and adversely affected and the trading price of our common stock could decline.

 

32


 

Risks Related to our Business and Industry

We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we ever achieve profitability, we may not be able to sustain it.

We have incurred losses since our inception and expect to continue to incur significant net losses for the foreseeable future. We have incurred net losses of $131.9 million, $121.5 million and $68.3 million for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021, we had $372.8 million in cash, cash equivalents, restricted cash and short-term investments, and an accumulated deficit of $626.0 million. Based on our current planned operations, we expect our existing cash, cash equivalents and short-term investments, and cash generated from revenues from our products and services, will be sufficient to meet our anticipated needs for at least the next 12 months from the date of this Annual Report. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.

Our revenue is derived, and we expect it to continue to be derived, primarily from sales of Tablo, its associated consumables and related services. Because of its recent commercial introduction, Tablo currently has limited product and brand recognition. In addition, demand for Tablo may decline or may not increase as quickly as we expect. Our ability to generate revenue from sales of Tablo, associated consumables and related services, or from any products we may develop in the future, may not be sufficient to enable us to transition to profitability and generate positive cash flows.

We expect that our sales and marketing, research and development, regulatory and other expenses will continue to increase as we expand our marketing efforts to increase adoption of Tablo, expand existing relationships with our customers, obtain regulatory clearances or approvals for future product enhancements to Tablo, and conduct clinical trials on Tablo. In addition, we expect our general and administrative expenses to increase due to the additional costs associated with scaling our business operations as well as our status of being a public company, including due to legal, accounting, insurance, exchange listing and SEC compliance, investor relations and other expenses. As a result, we expect to continue to incur operating losses and may never achieve profitability. We will need to generate significant additional revenue in order to achieve and sustain profitability. Even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time. If we do not achieve or sustain profitability, it will be more difficult for us to finance our business and accomplish our strategic objectives, either of which would have a material adverse effect on our business, financial condition and results of operations.

33


 

Our ability to achieve sustainable gross margins depends on the success of our initiatives designed to reduce the cost of manufacturing and producing Tablo devices.

We partner with contract manufacturers in the production of the Tablo cartridge. Until early 2021, we exclusively relied on a contract manufacturer based in California for the production of the Tablo console, which resulted in higher costs associated with labor and component parts. As part of a number of initiatives designed to reduce the cost of producing Tablo devices, we established a new manufacturing facility for the production of Tablo consoles in Tijuana, Mexico which we operate in collaboration with our outsourced business administration service provider, TACNA, enabling us to insource Tablo console manufacturing at this new facility in early 2021. In addition, in the fourth quarter of 2021, we have qualified a second source to increase Tablo cartridge production through a new manufacturing partner in Mexico. Moving Tablo console production to Mexico has lowered our costs of manufacturing and producing consoles, and we anticipate that transitioning cartridge production to our new second source located in Mexico will help mitigate supply chain challenges and reduce the need for costly and capacity-constrained air freight delivery of the cartridges. However, there is no guarantee that we will be able to sustain cost reductions or achieve planned cost reductions from our various cost savings initiatives. For example, we may be unable to sustain the savings associated with our manufacturing facility with TACNA, or the savings we anticipate will result from our second source of Tablo cartridges in Mexico, may not be as significant as projected or realized within the timeframe we currently estimate. There may also be unforeseen occurrences that increase our costs, such as increased prices of the components of Tablo, changes to labor costs, less favorable terms with third party suppliers or contract manufacturing partners, or disruptions to the operations of our contract manufacturers or third party suppliers including as a result of the ongoing COVID-19 pandemic. For example, during the fourth quarter of 2021, supply chain disruptions exacerbated by COVID-19 outbreaks and protocols escalated, and we have faced increased supply constraints, which increased freight costs associated with the transportation of Tablo cartridges. See the risk factor below entitled “We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making us vulnerable to supply problems and price fluctuations.” Our ability to maintain Tablo’s pricing is dependent on our customers’ recognition that the benefits outweigh the higher upfront purchase price. If we are unable to reduce our costs, if cost reductions are less significant or less timely than projected or if we are unable to maintain Tablo’s pricing, we will not be able to achieve sustainable gross margins, which would adversely affect our ability to invest in and grow our business and adversely impact our business, financial condition and results of operations.

The commercial success of Tablo will depend upon attaining significant market acceptance among providers and patients.

Our success will depend, in part, on the acceptance of Tablo as safe, easy to learn, easy to use, clinically flexible, operationally versatile and, with respect to providers, cost effective. We began commercializing Tablo throughout the United States in 2018 and began the process to commercialize Tablo for home-based dialysis in 2020. Our limited commercialization experience makes it difficult to evaluate our current business and predict our future prospects. We cannot predict how quickly, if at all, providers and patients will accept Tablo or, if accepted, how frequently it will be used. These constituents must believe that Tablo offers benefits over traditional machines. The degree of market acceptance of Tablo will depend on a number of factors, including:

whether providers and others in the medical community consider Tablo to be a safe and cost-effective treatment method;
the potential and perceived advantages of Tablo over traditional machines;
the cost of treatment, maintenance and upkeep using Tablo in relation to traditional machines;
the convenience and ease of use of Tablo relative to traditional machines;
the effectiveness of our sales and marketing efforts for Tablo;
our ability to provide incremental data that show the clinical benefits and cost effectiveness of, and operational benefits from, Tablo;
any changes to the availability of coverage and adequate reimbursement for dialysis from payors, including government authorities;
pricing pressure, including from Group Purchasing Organizations (GPOs), seeking to obtain discounts on Tablo based on the collective buying power of the GPO members;
product labeling or product insert requirements by the FDA or other regulatory authorities; and
limitations or warnings contained in the labeling cleared or approved by the FDA or other authorities.

34


 

Additionally, even if Tablo achieves widespread market acceptance, it may not maintain that market acceptance over time if competing products or technologies, which are more cost effective or received more favorably, are introduced. Failure to achieve or maintain market acceptance and/or market share would limit our ability to generate revenue and would have a material adverse effect on our business, financial condition and results of operations.

We currently derive substantially all of our revenue from the sale of Tablo and associated consumables and are therefore highly dependent on Tablo for our success.

We derive substantially all of our revenues from sales of Tablo and its associated consumables, with the remainder of our revenues largely coming from services provided for the support and maintenance of Tablo. Accordingly, our business is exposed to risks that our revenues are concentrated in a single product. As a result, any event that adversely affects Tablo or the market for Tablo and associated consumables could adversely affect our business, financial condition and results of operation.

Our ability to generate revenue from home-based dialysis is subject to certain risks and uncertainties, including around the adoption of Tablo in the home setting.

In March 2020, Tablo was cleared by the FDA for patient use in the home of patients with acute and/or chronic renal failure, with or without ultrafiltration, and we intend to expand within the home market. However, this goal is subject to certain risks, including our ability to attract, retain and manage patients. Our business strategy, including our pricing of Tablo, while informed by our limited history of selling Tablo in the home care setting, continues to be based in part on certain assumptions about the adoption of Tablo by home dialysis patients, as well as patient retention. If these assumptions about the home market are inaccurate and we are unable to increase our share of the home dialysis market by attracting new patients, or retain such market share once achieved, we would need to significantly change certain aspects of our business strategy, including the pricing of the Tablo console, associated consumables and support and maintenance, which could adversely affect our business, financial condition and results of operations.

Our limited experience in the distribution, logistics and service support that relate to the use of Tablo in the home care setting may also negatively impact our ability to generate revenue from home-based dialysis. Currently, the provision of in-clinic and home dialysis is largely dominated by DaVita Inc. (DaVita) and Fresenius, and our expansion within the home dialysis market is dependent on our ability to grow new home programs with health systems and innovative dialysis clinic partners. In addition, patients and their care partners using Tablo for home dialysis may not successfully operate Tablo or may require increased service and support from us. Moreover, given the home dialysis market remains a relatively novel one for us, we also face the risk that we may encounter difficulties whose precise nature or magnitude we cannot accurately predict at this time, but which may have a material adverse effect on our business, financial condition or results of operations.

We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making us vulnerable to supply problems and price fluctuations.

We rely on third-party suppliers, including in some instances single source suppliers, to provide us with certain components of Tablo. The number of suppliers feeding into Tablo console production is in excess of 250 worldwide. We consider approximately 9% of these suppliers, located in the United States, Europe and China, as critical providers of components such as pumps, motors, valves and Printed Circuit Board Assembly (PCBA) boards. While we are undertaking a second source qualification process for the majority of these critical components, we may not ultimately be successful in securing second sourcing for all of them.

In addition, we purchase supplies through purchase orders and do not have long-term supply agreements with, or guaranteed commitments from, our suppliers, including single source suppliers. Moreover, at present, we rely on contract manufacturers for the production of the Tablo cartridge. Many of our suppliers and contract manufacturers are not obligated to perform services or supply products for any specific period, in any specific quantity or at any specific price, except as may be provided in a particular purchase order. We depend on our suppliers and contract manufacturers to provide us and our customers with materials in a timely manner that meet our and their quality, quantity and cost requirements. These suppliers and contract manufacturers may encounter problems during manufacturing for a variety of reasons, including as a result of public health crises such as the ongoing COVID-19 pandemic, labor disputes, work stoppages, damage or interruption from fires, severe weather or other natural disasters, vandalism, terrorism or other political hostilities, any of which could delay or impede their ability to meet our demand. These suppliers and contract manufacturers may cease producing the components we purchase from them or otherwise decide to cease doing business with us. Further, we maintain limited volumes of inventory from most of our suppliers and contract manufacturers. If we inaccurately forecast demand for finished goods, we may be unable to meet customer demand which could harm our competitive position and reputation. Further, if we fail to effectively manage our relationships with our suppliers and contract manufacturers, we may be required to change suppliers or contract manufacturers. While we believe replacement suppliers exist for all materials, components and services necessary to continue manufacturing our Tablo system, establishing additional or replacement suppliers for any of these materials, components or services could be time-consuming and expensive, may result in interruptions in our operations and product delivery,

35


 

may affect the performance specifications of our Tablo system or could require that we modify Tablo’s design. Even if we are able to find replacement suppliers, we will be required to verify that the new supplier maintains facilities, procedures and operations that comply with our quality expectations and applicable regulatory requirements. Any of these events could require that we obtain a new regulatory authority approval before we implement the change, which could result in further delay and which may not be obtained at all. If our third-party suppliers fail to deliver the required commercial quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement suppliers capable of production at a substantially equivalent cost in substantially equivalent volumes and quality on a timely basis, the continued commercialization of our Tablo system, the supply of our products to customers and the development of any future products will be delayed, limited or prevented, which could have material adverse effect on our business, financial condition and results of operations.

For example, the COVID-19 pandemic has disrupted the operations of certain of our third-party suppliers, resulting in increased lead-times, higher component costs and lower allocations for our purchases of some components (including certain critical components) and, in certain cases, requiring us to procure materials from alternative sources or incur higher logistical expenses. We have worked closely with our manufacturing partners and suppliers to enable us to source key components and maintain appropriate inventory levels to meet customer demand, and have not experienced material disruptions in our supply chain to date. However, there is no assurance that we will not experience more significant disruptions in our supply chain in the future, particularly if the operations of our contract manufacturing partners, any of our critical single source component providers, or the facility we operate in Tijuana, Mexico in collaboration with our outsourced business administration service provider, TACNA, are more severely impacted by the pandemic and associated containment measures. If these contract manufacturers or suppliers experience disruptions as a result of the pandemic that impede their ability to meet our demand in a timely manner, we may be unable to find alternative sources of supply, be required to pay higher prices, or fail to meet customer demand, any of which would harm our business.

Additionally, surges and shifts in consumer demand as the economy reopens, further exacerbated by COVID-19 outbreaks and protocols, have strained the global freight network and placed significant stress on air, ocean and ground freight carriers. This has resulted in labor shortages, container and chassis shortages, reduced carrier capacity, carrier delays and longer lead times, shipment receiving and unloading backlogs at many U.S. ports, and escalating freight costs. During the fourth quarter of 2021, these supply chain disruptions escalated, and we are facing increased supply chain constraints, notably with the transportation of Tablo cartridges from our contract manufacturing partner in Southeast Asia. As a result, we have faced, and may continue to face, increased transportation and related costs associated with delivering adequate supply of Tablo treatments to our customers. In the fourth quarter of 2021, we have qualified a second source to increase Tablo cartridge production through a new manufacturing partner in Mexico. While we anticipate that this second source will help mitigate supply chain challenges and reduce the need for costly and capacity-constrained air freight delivery of the cartridges, there is no assurance that we will not continue to face supply chain constraints. Continued escalation of these supply chain disruptions and a sustained rise in freight costs could negatively impact our ability to meet customer demand on a timely basis, result in customer dissatisfaction and adversely impact our operating margins and results of operation.

We may experience manufacturing disruptions, and our transition to manufacturing our Tablo consoles and the majority of Tablo cartridges outside of the United States subjects us to additional risks associated with international manufacturing operations.

We continue to rely on contract manufacturing partners for the production of the Tablo cartridge. If any of our contract manufacturing partners’ facilities were disrupted, by labor disputes, work stoppages, public health crises including the ongoing COVID-19 pandemic, riots, terrorism, vandalism, cyber security attacks, natural disaster or otherwise, it could cause substantial delays in our operations and we may not have a sufficient number of Tablo consoles or Tablo cartridges in inventory to fulfill orders. Further, to the extent we seek to renew or renegotiate our arrangements with any of our contract manufacturing partners, and cannot agree to the terms and conditions of future contract manufacturing arrangements, or if any of our contract manufacturing partners terminate existing agreements with us, our ability to produce and sell Tablo could be delayed until an alternative manufacturing partner or arrangement is identified, a new contract manufacturing agreement is negotiated and new production lines are established.

In addition, we established a new manufacturing facility in Tijuana, Mexico which we operate in collaboration with our outsourced business administration service provider, TACNA, for the production of the Tablo console. Under our arrangement with TACNA, we control the operations, engineering, quality and materials supply functions at the new facility, while TACNA provides manufacturing space, the workforce, utilities, cross-border logistics, local permits and licenses. With the establishment of our new manufacturing facility in Tijuana, Mexico and the transfer of the production of a majority of the Tablo cartridge to a new contract manufacturing partner in Tijuana, Mexico, the manufacturing of the Tablo console and a majority of the Tablo cartridge is currently located in Tijuana, Mexico. We are subject to a number of additional risks associated with operating our Mexico-based manufacturing facility and increased international manufacturing operations generally. We may experience strikes, work stoppages, work slowdowns, high personnel turnover, grievances, complaints, claims of unfair labor practices, other collective bargaining disputes or other labor disputes at our new facility. Our manufacturing operations at the new facility may also suffer disruptions from global or regional public health crises such as the ongoing COVID-19 pandemic, natural disasters, cyber security attacks, vandalism, terrorism or other

36


 

political hostilities. Any such occurrences could negatively impact our ability to produce the Tablo console. We are also subject to a variety of foreign laws and regulations, including trade and labor restrictions and laws relating to importation, exportation and taxation of goods, and U.S. laws and regulations relating to foreign operations, including anti-corruption, anti-bribery and anti-money laundering laws. In addition, because certain of our Mexico-based manufacturing operations incur costs that are denominated in Mexican Pesos (MXN), we are exposed to additional risk of currency fluctuations between the U.S. dollars (USD) and MXN, which could increase our product and labor costs, thus reducing our gross profit. Moreover, while certain members of our management team have some manufacturing experience, as an organization, we do not have any prior experience in this type of manufacturing arrangement, and we could accordingly experience other risks, the nature and magnitude of which we are unable to assess precisely at this time. Furthermore, changes in export or import regulation and other trade barriers and uncertainties may disrupt our Mexico-based manufacturing operations, and may cause us to be unable to meet customers’ demand and adversely impact our results of operations.

A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, including the ongoing COVID-19 pandemic, could adversely affect our business.

If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or worldwide, our business may be adversely affected. For example, the COVID-19 pandemic continues to persist and precautionary measures designed to contain the spread and mitigate the impact of COVID-19, such as travel restrictions, “shelter-in-place” orders, quarantines and business shutdowns, have impacted many of the regions in which we, our customers and our suppliers operate. Moreover, new or more restrictive measures have and may continue to be adopted or reimposed if the pandemic worsens or evolves, including due to new variants of the COVID-19 virus such as the Delta and Omicron variants. Disruptions or potential disruptions to our business from COVID-19 or a future pandemic include the inability of our suppliers to manufacture components and parts and to deliver these to us on a timely basis, or at all; disruptions in our production schedule and ability to manufacture and assemble products; inventory shortages or obsolescence; diversion of or limitations on employee resources that would otherwise be focused on the operations of our business; delays in growing or reductions in our sales organization, including through delays in hiring, lay-offs, furloughs or other losses of sales representatives; business adjustments or disruptions of or to certain third parties, including suppliers and customers; delays to any clinical trials we are conducting or plan to conduct; delays in our ability to timely submit 510(k) notifications or PMAs or PMA supplements, as applicable, and to obtain clearance or approval from the FDA to market our products; and additional government requirements or other incremental mitigation efforts that may further impact our or our suppliers’ capacity to manufacture Tablo.

For example, in response to the COVID-19 pandemic, we made modifications to our normal operations, employing precautionary measures designed to help protect our employees while providing ongoing support for our customers and their patients. Among other measures, we restricted non-essential travel of our employees and asked the majority of our employees to work from home. With nearly all our employees now vaccinated, we have begun to move toward more normal operations in accordance with local guidelines, including resuming more on-site activity to increase productive collaboration while continuing to prioritize employee safety. For employees working on-site, we continue to follow masking protocols consistent with evolving health and safety guidelines, facilitate social distancing and practice increased sanitizing standards. Notwithstanding recent trends that have allowed us to return to more on-site activity, we may experience future disruptions as a result of the ongoing COVID-19 pandemic that could adversely impact the health and availability our workforce, particularly in light of insufficient vaccination of the general population and the emergence of new variants. If significant or critical portions of our workforce are unable to work effectively, or at all, as a result of the COVID-19 pandemic, including because of illness, quarantines, facility closures, ineffective remote work arrangements or technology failures or limitations, our operations would be materially adversely impacted. In addition, to the extent dialysis providers, including outpatient dialysis clinics, reduce demand for our products due to COVID-related patient deaths, our business would be adversely impacted.

Moreover, healthcare providers (including our existing and prospective customers) are facing a nationwide shortage of qualified nurses and other clinical personnel due to long-term trends that have been exacerbated by the COVID-19 pandemic. As competition for these healthcare professionals has intensified, providers are facing increased difficulties attracting and retaining skilled clinical personnel, resulting in increased costs, staffing shortages, and other disruptions. These challenging labor market conditions in the healthcare industry have been heightened by the increased demand for, and demand upon, nurses and other staff resulting from the ongoing pandemic. There is a risk that the increased costs and other disruptions caused by the shortage of dialysis nurses, technicians and other staff could cause existing or prospective customers to delay continued investment in or adoption of new technologies and postpone purchasing decisions. If our customers continue to face prolonged volatility, uncertainty, and staffing shortages, whether due to the pandemic or otherwise, it could ultimately adversely impact our ability to expand existing customer relationships or attract new customers of Tablo, and have a material adverse effect on our revenues, results of operations, and future growth.

How long the pandemic, and measures intended to contain the spread of COVID-19, will continue remains uncertain and depends on ongoing developments, including but not limited to any resurgences of the virus including emerging variant strains, federal, state, and local government actions taken in response, and continued availability, effectiveness and public acceptance of

37


 

COVID-19 vaccines, as well as the extent and duration of the effect on the economy and how quickly and to what extent normal economic and operating conditions can resume. Additionally, the duration and severity of disruptions in the global supply chain, largely driven by high demand as the economy reopens and the ongoing impact of the pandemic, also remain uncertain and depend on various factors, including the effectiveness of recent government actions intended to mitigate these disruptions. As a result, we cannot predict what effect COVID-19, the associated containment measures, and the related supply chain disruptions will ultimately have on our business and result of operations.

While the potential economic impact brought by and the duration of any pandemic, epidemic or outbreak of an infectious disease, including COVID-19, may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, which could result in a reduction in our ability to access capital and delays in payments of outstanding receivables that could adversely affect our liquidity. In addition, a recession or market correction resulting from the spread of an infectious disease, including COVID-19, could materially affect our business. Such economic recession could have a material adverse effect on our long-term business. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this “Risk Factors” section.

We need to ensure strong product performance and reliability to maintain and grow our business.

We need to maintain and continuously improve the performance and reliability of Tablo to achieve our profitability objectives. Poor product performance and reliability could lead to customer dissatisfaction, adversely affect our reputation and revenues, and increase our service and distribution costs and working capital requirements. Software and hardware incorporated into Tablo may contain errors or defects, especially when first introduced and while we have made efforts to test this software and hardware extensively, we cannot assure that the software and hardware, or software and hardware developed in the future, will not experience errors or performance problems. In addition, with our transition to manufacturing Tablo consoles at our facility in Tijuana, Mexico operated in collaboration with TACNA, we are more exposed to risks relating to product quality and reliability until the manufacturing processes mature. Like all transitions of this nature, they could increase our costs in the near-term and accordingly adversely affect our business, financial condition and results of operations.

If we are unable to continue to innovate and improve Tablo, we could lose customers or market share.

Our success will depend on our ability to keep ahead of developments in the dialysis industry. It is critical to our competitiveness that we continue to innovate and make improvements to Tablo’s functionality and efficiency. If we fail to make improvements to Tablo’s functionality over time, our competitors may develop products that offer features and functionality similar or superior to those of Tablo. If we fail to make improvements to Tablo’s efficiency, our competitors may develop products that are more cost effective than Tablo. Our failure to make continuous improvements to Tablo to keep ahead of the products of our competitors could result in the loss of customers or market share that would adversely affect our business, results of operations, and financial condition.

We face competition from many sources, including larger companies and new entrants, and we may be unable to compete successfully.

There are a number of dialysis machine manufacturers in the United States, Europe and Asia. Notable competitors in the United States include Fresenius, Baxter and B. Braun. In addition, Quanta Dialysis Technologies Ltd’s (Quanta) dialysis system received FDA 510(k) clearance for use in acute and/or chronic settings. Of these competitors, Fresenius is the largest and it supplies dialysis products, operates a significant number of dialysis clinics and provides outsourced dialysis services in many hospitals. Fresenius, Baxter and B. Braun all supply machines and supplies in both the acute and home care settings. With the exception of Quanta, all of these organizations are currently significantly larger with greater financial and personnel resources than us, enjoy significantly greater market share than ours and have greater resources than we do. As a consequence, they are able to spend more on product development, marketing, sales and other product initiatives than we can. Additionally, companies with dialysis machine development programs include Medtronic and CVS. Some of our competitors have:

substantially greater name recognition;
broader, deeper or longer-term relations with healthcare professionals, customers and third-party payors;
more established distribution networks;
additional lines of products and the ability to offer rebates or bundle products to offer greater discounts or other incentives to gain a competitive advantage;

38


 

greater experience in conducting research and development, manufacturing, clinical trials, marketing and obtaining regulatory clearance or approval for products; and
greater financial and human resources for product development, sales and marketing and patent litigation.

Our continued success depends on our ability to:

further penetrate the acute care market and drive utilization and fleet expansion among our existing customers in the acute care setting;
successfully expand within the home dialysis market;
maintain and widen our technology lead over competitors by continuing to innovate and deliver new product enhancements on a continuous basis;
cost-effectively manufacture Tablo and its component parts as well as drive down the cost of service; and
increase adoption of Tablo in the chronic outpatient facility setting via transitional care programs within existing dialysis clinics.

In addition, competitors with greater financial resources than ours could acquire other companies to gain enhanced name recognition and market share, as well as new technologies or products that could effectively compete with our existing products, which may cause our revenue to decline and would harm our business.

Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, as well as in acquiring technologies complementary to, or necessary for, Tablo. Because of the complex and technical nature of Tablo and the dynamic market in which we compete, any failure to attract and retain a sufficient number of qualified employees could materially harm our ability to develop and commercialize Tablo, which would have a material adverse effect on our business, financial condition and results of operations.

As we attain greater commercial success, our competitors are likely to develop products that offer features and functionality similar to Tablo. Improvements in existing competitive products or the introduction of new competitive products may make it more difficult for us to compete for sales, particularly if those competitive products demonstrate better reliability, convenience or effectiveness or are offered at lower prices.

More generally, the development of viable medical, pharmacological and technological advances in treating or preventing kidney failure may also limit the opportunity for Tablo and our services. While kidney transplantation is the treatment of choice for most patients with ESRD, it is not currently a viable treatment for most patients. This may change, however, with the development of new medications designed to reduce the incidence of kidney transplant rejection, progress in using kidneys harvested from genetically engineered animals as a source of transplants, and other advances in kidney transplantation.

We may face additional costs, loss of revenue, significant liabilities, harm to our brand, decreased use of our platform and business disruption if there are any security or data privacy breaches or other unauthorized or improper access.

In connection with various facets of our business, we collect and use a variety of personal information as part of the Tablo data ecosystem, such as name, mailing address, email addresses, mobile telephone number, location information, and prescription information. Security breaches, computer malware and computer hacking attacks have become more prevalent across industries and may occur on our systems or those of our third-party service providers, suppliers or other partners. Despite the implementation of security measures, our internal computer systems and those of our third-party service providers, suppliers and other partners are vulnerable to damage from computer viruses, hacking and other means of unauthorized access, denial of service and other attacks, natural disasters, terrorism, war and telecommunication and electrical failures. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Further, as a result of the COVID-19 pandemic, we may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who may continue to work remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. In addition to unauthorized access to or acquisition of personal information, confidential information, intellectual property or other sensitive information, such attacks could include the deployment of harmful malware and ransomware, and may use a variety of methods, including denial-of-service attacks, social engineering and other means, to attain such unauthorized access or acquisition or otherwise affect service reliability and threaten the confidentiality, integrity and availability of information. Any failure to prevent or mitigate security

39


 

breaches or improper access to, or use or disclosure of, our data or consumers’ personal information, including information hosted by third party service providers such as Amazon Web Services (AWS), could result in significant liability under applicable data protection laws, such as state breach notification laws and the HIPAA and its implementing regulations. Such an incident may also cause a material loss of revenue from the potential adverse impact to our reputation and brand, affect our ability to retain or attract new users of Tablo and potentially disrupt our business, as well as require significant expenditure of resources to contain, mitigate and remediate the incident. Because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently or may be designed to remain dormant until a predetermined or other future event and often are not recognized until launched against a target, we and our partners may be unable to anticipate these techniques or to implement adequate preventative measures. Further, we do not have any direct control over the operations of the facilities or technology of AWS or our other cloud and service providers. Our systems, servers and platforms, those of our cloud service providers, and Tablo’s two-way wireless communication system, may be vulnerable to computer viruses or physical or electronic break-ins that our or their security measures may not detect or effectively block, and may be breached due to the actions of outside parties, employee error or misconduct, malfeasance, or a combination of these and, as a result, an unauthorized party may obtain access to our data or the personal information maintained by us or on our behalf. Additionally, outside parties may attempt to fraudulently induce employees to disclose sensitive information in order to gain access to the data and personal information we maintain. Threat actors, including individuals, criminal groups, state sponsored actors or others may be able to circumvent such security measures and misappropriate our confidential or proprietary information, disrupt our operations, corrupt our data, damage our computers or otherwise impair our reputation and business. We may need to expend significant resources and make significant capital investment to protect against security breaches or to mitigate the impact of any such breaches. In addition, to the extent that our cloud and other service providers experience security breaches that result in the unauthorized or improper use of confidential information, employee information or personal information, we may not be indemnified for any losses resulting from such breaches. If we are unable to prevent or mitigate the impact of such security breaches or other cyber events that impact our operations, our ability to attract and retain new customers, patients, and other partners could be harmed, as they may be reluctant to entrust us with their data, and we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business or other adverse consequences.

We may encounter difficulties in managing our growth, which could disrupt our operations.

As of December 31, 2021, we had 444 full-time employees. Over the next several years, we expect to increase significantly the scope of our operations, particularly in the areas of manufacturing and commercial functions, including sales and marketing, as well as in general and administrative functions to support our growth. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational quality and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to manage the expansion of our operations or recruit and train additional qualified personnel in an effective manner. In addition, the physical expansion of our operations, including the establishment of our manufacturing facility in Tijuana, Mexico, may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.

The home hemodialysis market may not expand sufficiently to support our growth prospects.

We believe a significant growth opportunity exists within the home hemodialysis market. However, home hemodialysis therapies to date have not been extensively adopted. We believe that the home hemodialysis market is sufficient to fuel our growth in the near term if we are able to capture sufficient market share; however, there can be no assurance that we will be successful in increasing our market share.

Our long term growth will require us to shift patients’ and the medical community’s understanding and view of home hemodialysis and will require further increases in the number of patients who adopt home hemodialysis from current levels, physicians who are willing to prescribe home hemodialysis, and dialysis centers that are willing to support home hemodialysis growth. Most dialysis centers presently do not have the infrastructure to support a significant home hemodialysis patient population, including the availability of home hemodialysis training nurses, and may not be motivated to invest in home hemodialysis programs. The nationwide shortage of nurses and other clinical personnel that has been exacerbated by the COVID-19 pandemic poses increased challenges for dialysis centers looking to retain or attract the staff necessary to support a home hemodialysis program. We will need to continue to devote significant resources to expanding the home hemodialysis market, but these efforts ultimately may not be successful.

We have significant customer concentration, with a limited number of customers accounting for a substantial portion of our revenues.

For the year ended December 31, 2021, two customers accounted for 30% and 15% of revenues, respectively. There are risks whenever a large percentage of total revenues are concentrated with a limited number of customers. It is not possible for us to predict

40


 

the level of demand for Tablo that will be generated by any of these customers in the future. In addition, revenues from these larger customers may fluctuate from time to time based on these customers’ business needs and customer experience, the timing of which may be affected by market conditions or other factors outside of our control. Furthermore, because our business model consists of an upfront capital purchase by our customers, and relatively lower recurring revenue from future sales of consumables and services, revenues from these larger customers may not represent a substantial portion of our revenues in future periods. These customers could also potentially pressure us to reduce the prices we charge for Tablo, which could have an adverse effect on our margins and financial position and could negatively affect our revenues and results of operations. If any of our largest customers terminates its relationship with us, such termination could negatively affect our revenues and results of operations.

Natural or man-made disasters and other similar events, including the COVID-19 pandemic, may significantly disrupt our business, and negatively impact our business, financial condition and results of operations.

A significant portion of our employee base, operating facilities and infrastructure are centralized in Northern California. Any of our facilities may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, wildfires, floods, nuclear disasters, riots, acts of terrorism or other criminal activities, infectious disease outbreaks or pandemic events, including the ongoing COVID-19 pandemic, power outages and other infrastructure failures, which may render it difficult or impossible for us to operate our business for some period of time. Our facilities would likely be costly to repair or replace, and any such efforts would likely require substantial time. Any disruptions in our operations could adversely affect our business and results of operations and harm our reputation. Moreover, although we have disaster recovery plans, they may prove inadequate. We may not carry sufficient business insurance to compensate for losses that may occur. Any such losses or damages could have a material adverse effect on our business and results of operations. In addition, our facility in Mexico and the facilities of our suppliers and manufacturers may be harmed or rendered inoperable by such natural or man-made disasters, which may cause disruptions, difficulties or otherwise materially and adversely affect our business.

Any failure to offer high-quality product support for Tablo may adversely affect our relationships with providers and negatively impact our reputation among patients and providers, which may adversely affect our business, financial condition, and results of operations.

We operate a multichannel model, including remote and on-site product support to respond to and resolve issues reported to us by providers and nurses on behalf of their patients. In implementing and using Tablo, providers depend on our support to resolve product quality- and performance-related issues in a timely manner. We may be unable to respond quickly enough to accommodate short-term increases in demand for customer support. Increased customer demand for product support could increase costs and adversely affect our business, financial condition and results of operations. Our sales are highly dependent on our reputation and on positive recommendations from our existing patients, care partners and providers. Any failure to maintain high-quality customer support for our products, or a market perception that we do not maintain high-quality customer support for our products, could adversely affect our reputation, our ability to sell Tablo, and in turn our business, results of operations, and financial condition.

The sizes of the markets for Tablo in the acute and home settings have not been established with precision and may be smaller than we estimate and may decline.

Our estimates of the annual total addressable market for Tablo is based on a number of internal and third-party estimates, including, without limitation, the assumed prices at which we can sell Tablo in the acute and home markets. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors.

As a result, our estimates of the annual total addressable market for Tablo in different settings may prove to be incorrect. If the actual number of patients who would benefit from Tablo, the price at which we can sell Tablo, or the total addressable market for Tablo is smaller than we have estimated, it may impair our sales growth and negatively affect our business, financial condition and results of operations.

Our results of operations will be materially harmed if we are unable to accurately forecast customer demand for, and utilization of, Tablo and manage our inventory.

To ensure adequate inventory supply, we must forecast inventory needs and manufacture the Tablo console and the Tablo cartridge based on our estimates of future demand for Tablo. Our ability to accurately forecast demand for Tablo could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for Tablo or for products of our competitors, our failure to accurately forecast customer acceptance of new products, potential disruption in our supply chain from regional or global public health crises including the ongoing

41


 

COVID-19 pandemic, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand for Tablo, our supply chain, manufacturing partners and/or internal manufacturing team may not be able to deliver components and products to meet our requirements, and this could result in damage to our reputation and customer relationships. In addition, if we experience a significant increase in demand, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, which will adversely affect our business, financial condition and results of operations.

Inadequate training of, and improper use of Tablo by, nurses, dialysis technicians, care partners and patients may lead to negative patient outcomes, affect adoption of Tablo and adversely affect our business.

The success of Tablo depends in part on the proper training and use of Tablo by nurses and dialysis technicians in the acute setting or patients and care partners in the home setting. We train nurses and dialysis technicians on the appropriate use of Tablo, as well as how to train other users, including patients and care partners who use Tablo in the home setting, on the appropriate use of Tablo. If nurses and dialysis technicians, including those we train directly and those trained by others, or patients and care partners, who are not trained by us directly, use Tablo inappropriately or incorrectly, or with supplies that are not compatible with Tablo or without adhering to or completing training sessions, patient outcomes may not be consistent with expected results. This may result in adverse events, including reduced treatment efficacy, and may negatively impact the perception of patient benefit and safety and limit adoption of Tablo, which would have a material adverse effect on our business, financial condition and results of operations. In addition, we may face liability for inadequate training and training materials for nurses and other providers who use our products.

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.

Our quarterly and annual results of operation, including our revenue, gross margin, profitability and cash flows, may fluctuate significantly, which makes it difficult for us to predict our future operating results. Accordingly, the results of any one quarter or period should not be relied upon as an indication of future performance. Our quarterly and annual operating results may fluctuate as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business. These fluctuations may occur due to a variety of factors, including, but not limited to:

the level of demand for Tablo, which may vary significantly, our ability to accurately forecast and meet customer demand and the timing of customer orders;
the cost of manufacturing Tablo, which may vary depending on the quantity of production, the terms of our agreements with third- party suppliers and manufacturers, costs of raw materials and components, and any related foreign currency impact;
expenditures that we may incur to acquire, develop or commercialize additional products and technologies;
unanticipated pricing pressures;
the rate at which we grow our sales force and the speed at which newly hired salespeople become effective, and the cost and level of investment therein;
the degree of competition in our industry and any change in the competitive landscape of our industry, including product enhancements or the introduction of new products or technologies by our competitors, or consolidation among our competitors or future partners;
coverage and reimbursement policies with respect to dialysis equipment, and potential future products that compete with Tablo;
the timing and success or failure of clinical trials for Tablo or any enhancements to Tablo we develop, or changes made to competing products;
positive or negative coverage, or public perception, of Tablo or products of our competitors or broader industry trends;

42


 

the impact, if any, that the ongoing COVID-19 pandemic may have on our operations, financial results and the number of patients treated;
the timing and cost of, and level of investment in, research, development, licenses, regulatory approval, commercialization activities, acquisitions and other strategic transactions, or other significant events relating to Tablo, which may change from time to time;
the timing and cost of obtaining and maintaining regulatory approvals or clearances for the current version of Tablo, as well as planned or future improvements or enhancements to Tablo;
pricing and discounts for Tablo or competing products;
legal, accounting and other expenses we may incur as a result of operating as a public company, including costs related to compliance with the Sarbanes-Oxley Act;
future accounting pronouncements or changes in our accounting policies; and
general economic conditions or political instability, including changes in tariff or trade laws and policies.

The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual financial results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Further, our historical results are not necessarily indicative of results expected for any future period, and quarterly results are not necessarily indicative of the results to be expected for the full year or any other period, and accordingly should not be relied upon as indicative of future performance.

This variability and unpredictability could also result in our failure to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, it will negatively affect our business, financial condition and results of operations.

We use Amazon Web Services to support Tablo’s cloud connectivity and any disruption of service could interrupt or delay our ability to receive and deliver critical treatment and reporting information from and to providers and patients.

We currently use AWS to host our cloud-based ecosystem. We also use other cloud service providers in our operations. We do not have direct control over the operations of the facilities of AWS or of our other cloud service providers and these facilities are vulnerable to damage or interruption from earthquakes, hurricanes, floods, fires, cyber security attacks, terrorist attacks, power losses, telecommunications failures and similar events. The occurrence of a natural disaster or an act of terrorism, a decision by AWS or another cloud service provider to close the facilities without adequate notice, or other unanticipated problems could result in lengthy interruptions in, or curtailment of, Tablo’s functionality and our ability to provide software updates or analyze patient and machine data. The facilities also could be subject to break-ins, computer viruses, sabotage, intentional acts of vandalism and other misconduct. The continuing and uninterrupted performance of Tablo is critical to our success. Because our customer-facing software platform is used by providers to gain insight into treatment performance, it is critical that our customer facing software platform be accessible without interruption or degradation of performance or data. Providers and patients may become dissatisfied by any system failure that interrupts our ability to provide the full suite of Tablo capabilities to them. Outages could lead to the triggering of our service level agreements and the issuance of credits to our clients, in which case, we may not be fully indemnified for such losses pursuant to our agreement with AWS or our agreements with our other cloud service providers. We may not be able to easily switch our AWS operations to another cloud provider if there are sustained disruptions or interference with our use of AWS. Repeated or prolonged system failures may reduce the attractiveness of Tablo to providers and patients and result in a decreased demand for Tablo, thereby adversely affecting our business, financial condition and results of operations. Moreover, negative publicity arising from these types of disruptions could damage our reputation and may adversely impact use of Tablo.

AWS and our other cloud service providers are not obligated to renew agreements with us on commercially reasonable terms, or at all. If we are unable to renew our agreements with AWS or our other cloud service providers on commercially reasonable terms, if our agreements with AWS or our other cloud service providers are prematurely terminated, or if in the future we add additional data providers, we may experience costs or downtime in connection with the transfer to, or the addition of, new providers. If these providers were to increase the cost of their services, we may have to increase the price of Tablo or take other measures to offset such cost increases, which could have a material adverse effect on our business, financial condition and results of operations.

43


 

If we experience significant disruptions in our information technology systems, our business may be adversely affected.

We depend on our information technology systems for the efficient functioning of our business, including the manufacture, distribution and maintenance of Tablo, as well as for accounting, data storage, compliance, purchasing and inventory management. We do not have redundant information technology in all aspects of our systems at this time. Our information technology systems may be subject to computer viruses, ransomware or other malware, attacks by computer hackers or malicious insiders, failures during the process of upgrading or replacing software, databases or components thereof, power outages, damage or interruption from fires or other natural disasters, hardware failures, telecommunication failures and user errors, among other malfunctions. We could be subject to an unintentional event that involves a third party gaining unauthorized access to our systems, which could disrupt our operations, corrupt our data or result in release of our confidential information. Technological interruptions or malfunction would disrupt our operations, including our ability to timely ship and track Tablo orders, project inventory requirements, ensure the integrity of our data analytics services, manage our supply chain and otherwise adequately service our customers or disrupt our customers’ ability to use Tablo. In the event we experience significant disruptions, we may be unable to repair our data or systems in an efficient and timely manner. Accordingly, such events may disrupt or reduce the efficiency of our entire operation and have a material adverse effect on our business, financial condition and results of operations. Currently, we carry business interruption coverage to mitigate certain potential losses but this insurance is limited in amount, and we cannot be certain that such potential losses will not exceed our policy limits. We are increasingly dependent on complex information technology to manage our infrastructure. Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance our existing systems. Failure to maintain or protect our information systems and data integrity effectively could have a material adverse effect on our business, financial condition and results of operations.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of Tablo. The expense and potential unavailability of insurance coverage for liabilities resulting from Tablo could harm us and our ability to sell Tablo.

We face an inherent risk of product liability as a result of the marketing and sale of Tablo. For example, we may be sued if Tablo or any of its component parts causes, or is perceived to cause, injury or is found to be otherwise unsuitable during manufacturing, marketing or sale. Any such product liability claim may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. In addition, we may be subject to claims against us even if the apparent injury is due to the actions of others or the pre-existing health conditions of the patient. For example, nurses, dialysis technicians, care partners and patients operate Tablo. If these nurses, dialysis technicians, care partners or patients are not properly trained, are negligent or use Tablo incorrectly, the capabilities of Tablo may be diminished or the patient may suffer critical injury. We may also be subject to claims that are caused by the activities of our suppliers, such as those who provide us with components and sub-assemblies, or manufacturers who produce Tablo consoles and cartridges.

If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or halt the marketing and sale of Tablo. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

decreased demand for Tablo;
harm to our reputation;
initiation of investigations by regulators, which could result in enforcement action against us or our contract manufacturers;
costs to defend the related litigation;
a diversion of management’s time and our resources;
substantial monetary awards to trial participants or patients;
product recalls, withdrawals or labeling, marketing or promotional restrictions;
loss of revenue; and
exhaustion of any available insurance and our capital resources.

44


 

We believe we have adequate product liability insurance, but it may not prove to be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain or obtain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage. The potential inability to obtain sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit the marketing and sale of Tablo. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts, which would have a material adverse effect on our business, financial condition and results of operations. In addition, any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation in the industry, significantly increase our expenses and reduce product sales.

We expect to continue to incur net losses for the next several years and we may require substantial additional capital to finance our planned operations, which may include future equity and debt financings. This additional capital may not be available to us on acceptable terms or at all. Our failure to obtain additional financing when needed on acceptable terms, or at all, could force us to delay, limit, reduce or eliminate our commercialization, sales and marketing efforts, product development programs or other operations.

We may require additional financing to fund working capital and pay our obligations. We may seek to raise any necessary additional capital through a combination of public or private equity offerings or debt financings. There can be no assurance, however, that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us. If adequate funds are not available on acceptable terms when needed, we may be required to significantly reduce operating expenses, which may negatively affect our business, financial condition and results of operations. If we do raise additional capital through public or private equity or convertible debt offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing (including through refinancing our existing debt), we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Additional capital may not be available on reasonable terms, or at all.

Performance issues, service interruptions or price increases by our shipping carriers and warehousing providers could adversely affect our business and harm our reputation and ability to provide our services on a timely basis.

Expedited, reliable shipping and secure warehousing are essential to our operations. We rely heavily on providers of transport services for reliable and secure point-to-point transport of our Tablo system to our customers and for tracking of these shipments, and from time to time require warehousing for our products. Should a carrier encounter delivery performance issues such as loss, damage or destruction of any systems, it would be costly to replace such systems in a timely manner and such occurrences may damage our reputation and lead to decreased demand for our Tablo system and increased cost and expense to our business. In addition, any significant increase in shipping or warehousing rates could adversely affect our operating margins and results of operations. For example, during the fourth quarter of 2021, surges and shifts in consumer demand as the economy reopened, further exacerbated by COVID-19 outbreaks and protocols, strained the global freight network and placed significant stress on air, ocean and freight ground carriers, resulting in increased freight costs associated with our transportation of Tablo cartridges. If freight costs continue to escalate and/or remain high for a sustained period of time, our operating margins and results of operations would be adversely impacted. Similarly, strikes, severe weather, natural disasters or other service interruptions affecting delivery or warehousing services we use would adversely affect our ability to process orders for our Tablo system on a timely basis.

We bear the risk of warranty claims on our Tablo system.

We bear the risk of warranty claims on our Tablo system. We may not be successful in claiming recovery under any warranty or indemnity provided to us by our suppliers or vendors in the event of a successful warranty claim against us by a customer or any recovery from such vendor or supplier may not be adequate. In addition, warranty claims brought by our customers related to third-party components may arise after our ability to bring corresponding warranty claims against such suppliers expires, which could result in costs to us.

Cost-containment efforts of our customers, purchasing groups and governmental organizations could have a material adverse effect on our sales and profitability.

In an effort to reduce costs, many hospitals in the United States have become members of GPOs and Integrated Delivery Networks (IDNs). GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors and then offer these negotiated prices to affiliated hospitals and other members. GPOs and IDNs typically award contracts on a category-by-category basis through a competitive bidding process. Bids are generally solicited from multiple providers with the intention of driving down

45


 

pricing or reducing the number of vendors. Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain new, or maintain existing, contract positions with major GPOs and IDNs. Furthermore, the increasing leverage of organized buying groups may reduce market prices for Tablo, thereby reducing our revenue and margins.

While having a contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract positions can offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to individual purchase orders. Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category, members of the GPO or IDN are generally free to purchase from other suppliers. Furthermore, GPO and IDN contracts typically are terminable without cause by the GPO or IDN upon 60 to 90 days’ notice. Accordingly, the members of such groups may choose to purchase alternative products due to the price or quality offered by other companies, which could result in a decline in our revenue.

If we fail to retain sales and marketing personnel and, as we grow, fail to increase our sales and marketing capabilities or develop broad awareness of Tablo in a cost-effective manner, we may not be able to generate revenue growth.

We have limited experience marketing and selling Tablo. We currently rely on our direct sales force to sell Tablo in the United States, and any failure to maintain and grow our direct sales force will negatively affect our business, financial condition and results of operations. The members of our direct sales force are highly trained and possess substantial technical expertise, which we believe is critical in increasing adoption of Tablo. The members of our U.S. sales force are at-will employees. The loss of these personnel to competitors, or otherwise, will negatively affect our business, financial condition and results of operations. If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical expertise and qualifications, or if we are unable to successfully instill such technical expertise in replacement personnel, it may negatively affect our business, financial condition and results of operations. In addition, our services revenue is dependent in part on our FSEs, and any failure to maintain and grow, or adequately train, our team of FSEs could negatively impact our services revenue.

In order to generate future growth, we plan to continue to expand and leverage our sales and marketing infrastructure to increase the number of customers that adopt Tablo. Identifying and recruiting qualified sales and marketing personnel and training them on Tablo, on applicable federal and state laws and regulations and on our internal policies and procedures requires significant time, expense and attention. It often takes several months or more before a sales representative is fully trained and productive. Our sales force may subject us to higher fixed costs than those of companies with competing techniques or products that utilize independent third parties, which could place us at a competitive disadvantage. It will negatively affect our business, financial condition and results of operations if our efforts to expand and train our sales force do not generate a corresponding increase in revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for Tablo. Any failure to hire, develop and retain talented sales personnel, to achieve desired productivity levels in a reasonable period of time or timely reduce fixed costs, could negatively affect our business, financial condition and results of operations. Our ability to increase our customer base and achieve broader market acceptance of Tablo will depend to a significant extent on our ability to expand our marketing efforts. We plan to dedicate significant resources to our marketing programs. It will negatively affect our business, financial condition and results of operations if our marketing efforts and expenditures do not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of Tablo in a cost-effective manner is critical to achieving broad acceptance of Tablo. Promotion activities may not generate patient or physician awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad adoption of Tablo.

Litigation and other legal proceedings may adversely affect our business.

From time to time we may become involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee claims, tort or contract claims, federal regulatory investigations, securities class action and other legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or investigations in the future, which could have a material adverse effect on our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, undermine our customers’ confidence and reduce long-term demand for Tablo, even if the regulatory or legal action is unfounded or not material to our operations.

46


 

We may seek strategic alliances, joint ventures or collaborations, or enter into licensing or partnership arrangements in the future and may not be successful in doing so, and even if we are, we may not realize the benefits or costs of such relationships.

We may form or seek strategic alliances, create joint ventures or collaborations or enter into licensing or partnership arrangements with third parties that we believe will compliment or augment our sales and marketing efforts with respect to Tablo. We may not be successful in our efforts to establish such collaborations for Tablo. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic alliance or other alternative arrangements for Tablo. We cannot be certain that, following a strategic alliance or similar arrangement, we will achieve the revenue or specific net income that justifies such transaction. In addition, any potential future collaborations may be terminable by our collaborators, and we may not be able to adequately protect our rights under these agreements. Any termination of collaborations we enter into in the future, or delays in entering into new strategic partnership agreements could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.

 

To the extent we enter into foreign markets, we would be subject to additional regulatory burdens and other risks and uncertainties.

While we currently do not market or sell Tablo outside of the United States, to the extent we enter into foreign markets in the future, we would face additional risks and uncertainties. We are not permitted to market or promote Tablo before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for Tablo. To obtain separate regulatory approvals in other countries we may be required to comply with numerous and varying regulatory requirements of such countries regarding the safety and efficacy of Tablo and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product, and we cannot predict success in these jurisdictions. If we obtain approval of Tablo and sell Tablo in foreign markets, we would be subject to additional risks and uncertainties in those markets, including:

foreign currency exchange rate fluctuations and currency controls;
economic weakness, including inflation, or political instability in particular economies and markets;
potentially adverse and/or unexpected tax consequences, including penalties due to the failure of tax planning or due to the challenge by tax authorities on the basis of transfer pricing and liabilities imposed from inconsistent enforcement;
the burden of complying with complex and changing regulatory, tax, accounting and legal requirements, many of which vary between countries;
different medical practices and customs in multiple countries affecting acceptance of medical products in the marketplace;
differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;
tariffs, trade barriers, import or export licensing requirements or other restrictive actions;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
reduced or loss of protection of intellectual property rights in some foreign countries; and
becoming subject to the different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations.

Our ability to utilize our net operating loss carryforwards and research and development credit may be limited.

As of December 31, 2021, we had U.S. federal and state net operating loss (NOL) carryforwards of $409.0 million and $213.7 million, respectively. If not utilized, our U.S. federal NOLs generated in taxable years beginning before 2018 will begin to expire in 2024 and our state NOLs will begin to expire in 2022. Deductibility of U.S. federal NOLs generated in taxable years beginning after 2017 and used in taxable years beginning after 2020 do not expire but are limited to 80% of our taxable income before the deduction of such NOLs. As of December 31, 2021, we also had U.S. federal and state research and development credits of $6.6 million and $5.1 million, respectively. Our U.S. federal research and development credits begin to expire in 2030. State research and development credits do not expire. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code) a corporation that undergoes an ownership change, generally defined as a greater than 50% change by value in its equity ownership over a three-year period, is subject to limitations on its ability to utilize its pre-change net operating losses and its research and development credit carryforwards to offset future taxable income. Our existing NOLs and research and development credit carryforwards may be subject to limitations arising from previous ownership changes, and if we undergo an ownership change, our ability to utilize NOLs

47


 

and research and development credit carryforwards could be further limited by Sections 382 and 383 of the Code. Similar rules may apply under state tax laws. In addition, our ability to deduct net interest expense may be limited if we have insufficient taxable income for the year during which the interest is incurred, and any future carryovers of such disallowed interest would be subject to the limitation rules similar to those applicable to NOLs and other attributes. Future changes in our stock ownership, some of which might be beyond our control, could result in an ownership change under Section 382 of the Code. For these reasons, in the event we experience a change of control, we may not be able to utilize a material portion of the existing NOLs, research and development credit carryforwards or future disallowed interest expense carryovers, even if we attain profitability. Any limitation on using NOLs could adversely impact operating results and result in our retaining less cash after payment of U.S. federal and state income taxes.

The terms of our credit agreement require us to meet certain operating and financial covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.

We entered into a senior secured term loan facility with Silicon Valley Bank (SVB) in July 2020 (the SVB Loan and Security Agreement) which provides for a $30.0 million term loan (the SVB Term Loan). The loan is secured by substantially all of our assets, including all of the capital stock held by us, if any, (subject to a 65% limitation on pledges of capital stock of foreign subsidiaries), subject to certain exceptions (including an exception regarding intellectual property). The SVB Loan and Security Agreement contains a number of restrictive covenants, and the terms may restrict our current and future operations, particularly our ability to respond to certain changes in our business or industry or take future actions. See the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Debt Obligations.”

The SVB Loan and Security Agreement contains customary representations and warranties and affirmative covenants and also contains certain restrictive covenants, including, among others, limitations on: the incurrence of additional debt, liens on property, acquisitions and investments, loans and guarantees, mergers, consolidations, liquidations and dissolutions, asset sales, dividends and other payments in respect of our capital stock, prepayments of certain debt, transactions with affiliates and changes to our type of business, management of the business, control of the business or business locations. The SVB Loan and Security Agreement does not include any financial covenants but does require us to maintain cash collateral in a deposit account at SVB in an amount equal to or greater than the outstanding principal balance of the SVB Term Loan. The SVB Loan and Security Agreement also contains customary events of default. If we fail to comply with such covenants, payments or other terms of the SVB Loan and Security Agreement, our lender could declare an event of default, which would give it the right to declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. In addition, our lender would have the right to proceed against the assets we provided as collateral pursuant to the SVB Loan and Security Agreement. If the debt under SVB Loan and Security Agreement was accelerated, we may not have sufficient cash or be able to sell sufficient assets to repay this debt, which would harm our business and financial condition.

Risks Related to Governmental Regulation

We are subject to a post-market surveillance order issued by the FDA for our Tablo System. If the FDA determines that our Tablo System does not perform as anticipated in the home use setting, or if the FDA identifies new concerns related to the safety and effectiveness of the device, we may need to make changes to or recall or withdraw the Tablo System from the field, which could harm our business.

The FDA has notified us that the Tablo System is subject to a mandatory post-market surveillance order under Section 522 of the FDCA. Section 522 of the FDCA authorizes the FDA to require a manufacturer to conduct post-market surveillance for devices that meet certain criteria. Relevant here, the FDA determined that the Tablo is a device where its failure would be reasonably likely to have serious adverse health consequences, and that it is intended to be a life-sustaining or life-supporting device used outside a device user facility.

The FDA issued this 522 order to address (i) whether there are use-related safety concerns when the Tablo System is used by the new user population in the home environment unsupervised by a trained healthcare professional; (ii) whether the safety profile in this new user population and home environment requires us to provide changes to the device design, labeling, and/or training and, if so, what labeling and training are necessary to support user understanding and adherence to minimize use-related safety concerns, adverse events, or complaints when the Tablo System is used at home; and (iii) what adverse events and complaints are observed when the Tablo System is used at home unsupervised by a trained healthcare professional.

To address these issues, the FDA has required that we conduct a human factors study, as well as conduct a detailed analysis of adverse events and complaints from home users. With respect to the post-market surveillance issues, the FDA has ordered collection of prospective data on use in the home environment to assess adverse events and human factors.

48


 

In March 2021, the FDA approved our 522 study protocol. We subsequently submitted a “catch-up” 510(k) application to the FDA which covers certain design changes, including software updates, we have made over time to the Tablo System, including to accommodate patient use in the home, that we originally documented in memoranda to file. Because this also is the version of the Tablo System and software that we plan to use in the human factors study, we intend to initiate the human factors study upon FDA clearance. Once we are able to commence, conduct and complete our study, a final report will be provided to the FDA. Should the FDA decide that use of the Tablo System in the home environment identifies new concerns related to the safety and effectiveness of the product, does not clear our pending 510(k), or if the FDA determines that the requirements of the 522 order are otherwise unmet, we may be required to make additional changes to our Tablo System for which we may need to submit new marketing authorization applications and obtain clearance, we may be required to conduct additional studies or collect additional information, we may need to withdraw or recall the Tablo System from the market, and may be subject to other enforcement action, which could harm our business.

Changes to the reimbursement rates for dialysis treatments and measures to reduce healthcare costs may adversely impact our business.

Our customers depend upon reimbursement by government and commercial insurance payors for dialysis services using our products. With a vast majority of U.S. patients with ESRD covered by Medicare, the Medicare reimbursement rate is an important factor in a customer’s decision to use Tablo and limits the prices we may charge for our products. For patients with Medicare coverage, virtually all payments for renal dialysis services are currently made under a single bundled payment rate which provides a fixed payment rate to encompass virtually all goods and services provided during the dialysis treatment. The bundled payment rate is also adjusted for certain patient characteristics, a geographic wage index, and other factors. The ESRD PPS is subject to rebasing, which can have a positive financial effect, or a negative one if the government fails to rebase in a manner that adequately addresses the costs borne by dialysis facilities.

Additionally, federal regulations provide for transitional add-on payment adjustments under the Medicare ESRD PPS for certain TPNIES. For home dialysis equipment, CMS provided a pathway for CRA to secure TPNIES. We applied for and received CRA TPNIES in connection with the Tablo Hemodialysis System use by one patient per one machine in the home, pursuant to which Medicare will pay 65% of the Medicare Administrative Contractor-determined pre-adjusted per treatment amount for two calendar years beginning with CY 2022. Though our TPNIES approval may increase provider reimbursement over the short term and positively affect our revenues as a result, such increased reimbursement is temporary and, thus, may not be sufficient to cause healthcare providers to adopt Tablo at rates we expect. Accordingly, we cannot fully assess the impact of the TPNIES approval on our financial performance.

CMS rules limit the number of hemodialysis treatments paid for by Medicare Part B to three times a week, unless there is medical justification provided by the dialysis facility based on information from the patient’s physician for additional treatments. To the extent that over three treatments per week are prescribed for Tablo patients and Medicare contractors determine they will not pay for additional treatments, adoption of the Tablo System could be impaired. As there is not a uniform national standard for what constitutes medical justification, a clinic’s decision as to how much it is willing to spend on home dialysis equipment and services will be at least partly dependent on the number of weekly treatments prescribed for home dialysis, and if greater than three, the level of confidence the center has in the predictability of receiving reimbursement from Medicare for additional treatments per week based on submitted claims for medical justification.

Although most ESRD patients are currently covered by traditional Medicare, beginning January 1, 2021, when changes from the 21st Century Cures Act entered into effect, more dialysis patients were eligible to enroll in Medicare Advantage managed care plans. While Medicare Advantage plans must provide at least the same level of coverage for Medicare beneficiaries as traditional Medicare, reimbursement to dialysis facilities is most often higher than traditional Medicare with a wide range of variability in payment rates to providers. Reimbursement rates depend on each Medicare Advantage plan’s contracts and network agreements with each dialysis facility. In CY 2021, Medicare Advantage plans overall saw a 31% increase in enrollment of ESRD patients, with the most significant increases coming from lower income patients who are dually eligible for Medicare and Medicaid.

Many ESRD patients have Medicaid coverage that is supplemental to Medicare coverage, and some ESRD patients may have Medicaid as their primary coverage. Because Medicaid is a state-administered program, Medicaid reimbursement for dialysis services varies by state. Changes in state Medicaid or other non-Medicare government-based programs or payment rates could have an adverse effect on our customers’ business.

Finally, some patients may have coverage through private insurance, for example through a marketplace plan set up under the Affordable Care Act or through an employer or union group health plan. Private insurance reimbursement is generally higher than government reimbursement, but it varies by sponsor and plan. Commercial payment rates are negotiated between our customers and insurers or other third-party administrators, and commercial payors may also exert downward pressure on payment rates for dialysis services.

49


 

Any reduction in reimbursement rates for dialysis treatments may adversely affect our customers’ businesses and cause them to enact cost reduction measures that may include reducing the scope of their home hemodialysis programs, which could result in reduced demand for our product or additional pricing pressures.

Healthcare reform measures could hinder or prevent the commercial success of Tablo.

In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that may harm our future revenues and profitability and the demand for Tablo. As discussed in the section titled “Business – Government Regulation – United States Health Reform” above, federal and state lawmakers regularly propose and, at times, enact legislation and propose and finalize regulations that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative or regulatory proposals to further reform healthcare or reduce healthcare costs may limit coverage of and/or lower reimbursement for the procedures associated with the use of Tablo. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of Tablo.

By way of example, in the United States, the Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts our industry. The Affordable Care Act contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which impact existing government healthcare programs and have resulted in the development of new programs.

As discussed in the section titled “Business – Government Regulation – United States Health Reform” above, there have been judicial and Congressional challenges to several elements of the Affordable Care Act, as well as efforts by both the executive and legislative branches of the federal government to modify certain aspects of the Affordable Care Act. It is unclear how these and other efforts to challenge or modify, or alter the implementation or interpretation of the Affordable Care Act will affect our business, financial condition and results of operations.

In addition, as discussed in the section titled “Business – Government Regulation – United States Health Reform” above, other legislative and executive actions have encouraged the development of new payment and care models for ESRD patients. Changes to the models of patient care, including an increased focus on treatments earlier in disease progression, may adversely affect our customers’ businesses and potentially decrease the demand for our product or result in additional pricing pressures. Further, with home dialysis as a growing trend in the industry and issuance of the executive order and the ETC Model final rule, a failure to implement our expansion into home dialysis could have a material adverse impact on our business.

The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may harm our ability to set a price that we believe is fair for Tablo, our ability to generate revenue and achieve or maintain profitability, and the availability of capital.

We believe that there will continue to be proposals and other actions by legislators and other policymakers at both the federal and state levels, and by regulators and third-party payors to reduce costs and/or expand individual healthcare coverage. Additionally, as discussed in the section titled “Government Regulation – United States Health Reform” above, changes to federal and state legislatures and executive offices following the November 2020 elections have resulted, and could continue to result, in further healthcare policy changes. We cannot predict what other healthcare policies will ultimately be proposed or implemented at the federal or state level or the effect of any future legislation or regulation in the United States on our business, financial condition and results of operations. Future changes in healthcare policy could increase our costs and subject us to additional legislative and regulatory requirements that may interrupt commercialization of our current and future solutions, decrease our revenue and impact sales of and pricing for our current and future products.

We must comply with anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations.

Our current and future operations are subject to various federal and state healthcare laws and regulations. These laws affect our sales, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with dialysis providers, hospitals, physicians or other potential purchasers or users, including patients, of medical devices and services. They also impose additional administrative and compliance burdens on us. In particular, these laws influence, among other things, how we structure our sales and rental offerings, including discount practices, customer support, education and training programs and physician consulting and other service arrangements. These laws include, but are not limited to, the healthcare fraud and

50


 

abuse laws described in the section titled “Business – Government Regulation – Healthcare Fraud and Abuse Laws” above, and the Federal Food, Drug, and Cosmetic Act, which governs, among other things, the misbranding and adulteration of medical devices.

If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, compliance oversight and reporting requirements and the curtailment or restructuring of our operations. Moreover, any investigation into our practices could cause adverse publicity and require a costly and time-consuming response.

Tablo and our operations are subject to extensive government regulation and oversight in the United States. If we fail to obtain or maintain necessary regulatory approvals for Tablo and related products, or if approvals or clearances for future products are delayed or not issued, it will negatively affect our business, financial condition and results of operations.

Tablo is a medical device subject to extensive regulation in the United States and elsewhere, including by the FDA and its foreign counterparts. Government regulations specific to medical devices are wide ranging and govern, among other things:

product design, development, manufacture, and release;
laboratory and clinical testing, labeling, packaging, storage and distribution;
product safety and efficacy;
premarketing clearance or approval;
service operations;
record keeping;
product marketing, promotion and advertising, sales and distribution;
post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals;
post-market approval studies; and
product import and export.

The FDA classifies medical devices into one of three classes on the basis of the intended use of the device, the risk associated with the use of the device for that indication, as determined by the FDA, and on the controls deemed by the FDA to be necessary to reasonably ensure their safety and effectiveness.

Before a new medical device, or a new intended use of, claim for, or significant modification to an existing device, can be marketed in the United States, a company must first submit an application for and receive either 510(k) clearance pursuant to a premarket notification submitted under Section 510(k) of the FDCA, de-novo classification, or PMA approval from the FDA, unless an exemption applies. The 510(k), de-novo or PMA processes can be expensive, lengthy and unpredictable. The FDA’s 510(k) clearance process usually takes from three to 12 months but can last longer. The process of obtaining a PMA approval is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even longer, from the time the application is filed with the FDA. In addition, a PMA approval generally requires the performance of one or more clinical trials. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the device, which may limit the market for the device.

We have obtained 510(k) clearances to market Tablo for use in patients with acute and/or chronic renal failure, with or without ultrafiltration, in the settings of an acute or chronic care facility and the home. However, Tablo is not cleared by the FDA for CRRT.

51


 

The FDA or other regulators could delay, limit, or deny clearance or approval of a device for many reasons, including:

our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that the Tablo System, or any other future device, and any accessories are substantially equivalent to a legally marketed predicate device or safe or effective for their proposed intended use;
the disagreement of the FDA with the design or implementation of any clinical trials or the interpretation of data from preclinical studies or clinical trials;
serious and unexpected adverse device effects experienced by participants in our clinical trials;
the insufficiency of the data from preclinical studies or clinical trials to support clearance or approval, where required;
our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;
the failure of our manufacturing process or facilities to meet applicable requirements; and
the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval.

The regulations to which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales. The FDA enforces these regulatory requirements through, among other means, periodic unannounced inspections. We do not know whether we will be found compliant in connection with any future regulatory inspections. Moreover, the FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by any such agency, which may include any of the following sanctions:

adverse publicity, warning letters, untitled letters, it has come to our attention letters, fines, injunctions, consent decrees and civil penalties;
repair, replacement, refunds, recall or seizure of Tablo;
operating restrictions, partial suspension or total shutdown of production;
denial of our requests for regulatory clearance or PMA approval of new products or services, new intended uses or modifications to existing products or services;
withdrawal of regulatory clearance or PMA approvals that have already been granted; or
criminal prosecution.

If any of these events were to occur, it would negatively affect our business, financial condition and results of operations.

Our future success depends on our ability to develop, receive regulatory clearance or approval for, and introduce new products that will be accepted by the market in a timely manner. There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of our future products on a timely basis, if at all, and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.

It is important to our business that we build a pipeline of product offerings that address limitations of current dialysis products. As such, our success will depend in part on our ability to develop and introduce new products. However, we may not be able to successfully develop and obtain regulatory clearance or approval for product enhancements, or new products for any number of reasons, including due to the cost associated with certain regulatory approval requirements, or these products may not be accepted by physicians or users.

The success of any new product offering or enhancement to an existing product will depend on a number of factors, including our ability to, among others:

identify and anticipate physician and patient needs properly;

52


 

develop and introduce new products or product enhancements in a timely manner;
avoid infringing upon the intellectual property rights of third parties;
demonstrate, if required, the safety and efficacy of new products with data from clinical studies;
obtain the necessary regulatory clearances or approvals for new products or product enhancements;
comply fully with the FDA and applicable foreign regulations on marketing of new products or modified products; and
provide adequate training to potential users of Tablo.

If we do not develop new products or product enhancements in time to meet market demand or if there is insufficient demand for these products or enhancements, or if our competitors introduce enhanced or new products with functionalities that are superior to ours, our results of operations will suffer.

Some of our future products will require FDA clearance of a 510(k). Other products may require the approval of a PMA. In addition, some of our future products may require clinical trials to support regulatory approval and we may not successfully complete these clinical trials. The FDA may not approve or clear these products for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for 510(k) clearance or PMA approval of new products. Failure to receive clearance or approval for our new products would have an adverse effect on our ability to expand our business.

Modifications to our marketed products may require new 510(k) clearances or approval of PMA supplements, or may require us to cease marketing or recall the modified products until clearances or approvals are obtained.

Modifications to Tablo and associated consumables may require new regulatory approvals or clearances, including 510(k) clearances or approval of PMA supplements, or require us to recall or cease marketing the modified systems until these clearances or approvals are obtained. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance. A manufacturer may determine that a modification could not significantly affect safety or efficacy and does not represent a major change in its intended use, so that no new 510(k) clearance is necessary. However, the FDA can review a manufacturer’s decision and may disagree. The FDA may also on its own initiative determine that a new clearance or approval is required. We have made modifications to Tablo in the past and may make additional modifications in the future that, except for the changes for which we have previously submitted 510(k) clearances, we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing Tablo as modified, which could require us to redesign Tablo and/or seek new marketing authorizations and harm our operating results. In these circumstances, we may also be subject to significant enforcement actions.

If a manufacturer determines that a modification to an FDA-cleared device could significantly affect its safety or effectiveness or would constitute a major change in its intended use, then the manufacturer must file for a new 510(k) clearance or possibly a new PMA or approval of a PMA supplement. Where we determine that modifications to Tablo require a new 510(k) clearance or PMA approval, we may not be able to obtain those additional clearances or approvals for the modifications or additional indications in a timely manner, or at all. Obtaining clearances and approvals can be a time-consuming process, and delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth. For example, we have made certain changes over time, including software updates, to Tablo that we originally documented in memoranda to file, and recently submitted a “catch-up” 510(k) application to the FDA which covers these design changes for patient use in the home. However, if the FDA fails to clear this pending 510(k) application, we may be required to stop marketing and selling Tablo as modified in the home market, which could have a material adverse effect on our reputation, business, financial condition and results of operations.

If we or our suppliers fail to comply with ongoing FDA or other foreign regulatory authority requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.

Even though we have obtained 510(k) clearance for Tablo, it and any other product for which we obtain clearance or approval, and the manufacturing processes, post-market surveillance, post-approval clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight, requirements, and periodic inspections by the FDA and other domestic and foreign regulatory bodies. In particular, we and our suppliers are required to comply with FDA’s QSR and other regulations enforced outside the United States which cover the manufacture of our products and the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of medical devices. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and

53


 

adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, any of the following enforcement actions:

untitled letters, warning letters, it has come to our attention letters, fines, injunctions, consent decrees and civil penalties;
unanticipated expenditures to address or defend such actions
customer notifications for repair, replacement, refunds;
recall, detention or seizure of our products;
operating restrictions or partial suspension or total shutdown of production;
refusing or delaying our requests for 510(k) clearance or PMA approval of new products or modified products;
operating restrictions;
withdrawal of 510(k) clearances on PMA approvals that have already been granted;
refusal to grant export approval for our products; or
criminal prosecution.

If any of these actions were to occur it would harm our reputation and cause our product sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce our products on a timely basis and in the required quantities, if at all.

In addition, we are required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our products. For example, the FDA has issued to us a post-market surveillance order under Section 522 of the FDCA which requires that we conduct a human factors study, as well as conduct a detailed analysis of adverse events and complaints from home users. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.

Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.

We are subject to the FDA’s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. Manufacturers are also expected to maintain certain policies, procedures, and records regarding complaints and medical device reporting. If we fail to comply with our reporting and recordkeeping obligations, the FDA could take action, including warning letters, untitled letters, it has come to our attention letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance or approval, seizure of our products or delay in clearance or approval of future products.

The FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA’s authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions,

54


 

manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future.

Depending on the corrective action we take to redress a product’s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new clearances or approvals for the device before we may market or distribute the corrected device. Seeking such clearances or approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines.

Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, will distract management from operating our business and may harm our reputation and financial results.

Our products must be manufactured in accordance with federal and state regulations, and we could be forced to recall our devices or terminate production if we fail to comply with these regulations.

The methods used in, and the facilities used for, the manufacture of our products must comply with the FDA’s QSR, which is a complex regulatory scheme that covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging, handling, storage, distribution, installation, servicing and shipping of medical devices. Furthermore, we are required to verify that our suppliers maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory requirements. The FDA enforces the QSR through periodic announced or unannounced inspections of medical device manufacturing facilities, which may include the facilities of subcontractors. Our products are also subject to similar state regulations and various laws and regulations of foreign countries governing manufacturing.

Our third-party manufacturers may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our products. In addition, failure to comply with applicable FDA requirements or later discovery of previously unknown problems with our products or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties; suspension or withdrawal of approvals; seizures or recalls of our products; total or partial suspension of production or distribution; administrative or judicially imposed sanctions; the FDA’s refusal to grant pending or future clearances or approvals for our products; clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us, our suppliers, or our employees.

Any of these actions could significantly and negatively affect supply of our products. If any of these events occurs, our reputation could be harmed, we could be exposed to product liability claims and we could lose customers and experience reduced sales and increased costs.

Our products, such as Tablo, may in the future be subject to product recalls that could harm our reputation, business and financial results.

Medical devices can experience performance problems in the field that require review and possible corrective action. The occurrence of component failures, manufacturing errors, software errors, design defects or labeling inadequacies affecting a medical device could lead to a government-mandated or voluntary recall by the device manufacturer, in particular when such deficiencies may endanger health. The FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving Tablo in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. Product recalls may divert management attention and financial resources, expose us to product liability or other claims, harm our reputation with customers and adversely impact our business, financial condition and results of operations.

We may be subject to regulatory or enforcement actions if we engage in improper marketing or promotion of Tablo.

Our educational and promotional activities and training methods must comply with FDA and other applicable laws, including the prohibition of the promotion of a medical device for a use that has not been cleared or approved by the FDA. Use of a device outside of its cleared or approved indications is known as “off-label” use. Physicians may use Tablo off-label in their professional medical judgment, as the FDA does not restrict or regulate a physician’s choice of treatment within the practice of medicine.

55


 

However, if the FDA determines that our educational and promotional activities or training constitutes promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of warning letters, untitled letters, fines, penalties, injunctions, or seizures, any of which could have an adverse impact on our reputation and financial results.

It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our educational and promotional activities or training methods to constitute promotion of an off-label use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged, and adoption of the products could be impaired. Although our policy is to refrain from statements that could be considered off-label promotion of Tablo, the FDA or another regulatory agency could disagree and conclude that we have engaged in off-label promotion. It is also possible that other federal, state or foreign enforcement authorities might take action, including, but not limited to, through a whistleblower action under the FCA, if they consider our business activities constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil or administrative penalties, treble damages, fines, disgorgement, exclusion from participation in government healthcare programs, reporting requirements and compliance oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations. In addition, the off-label use of Tablo may increase the risk of product liability claims. Product liability claims are expensive to defend and could divert our management’s attention, result in substantial damage awards against us, and harm our reputation.

Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of any future products and to manufacture, market and distribute our products after clearance or approval is obtained.

From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our future products under development or impact our ability to modify our currently cleared products on a timely basis. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of planned or future products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.

FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance or approval for, manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional record keeping.

The FDA’s and other regulatory authorities’ policies may change and additional government regulations may be promulgated that could prevent, limit or delay regulatory clearance or approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. For example, the change in administration may impact our business and industry. Namely, the Trump administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA’s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these executive actions will be implemented, or whether they will be rescinded or replaced under the current Biden administration. The policies and priorities of a new administration are unknown and could materially impact the regulation governing our products.

Any change in the laws or regulations that govern the clearance and approval processes relating to our current, planned and future products could make it more difficult and costly to obtain clearance or approval for new products or to produce, market and distribute existing products. Significant delays in receiving clearance or approval or the failure to receive clearance or approval for any new products would have an adverse effect on our ability to expand our business. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing clearance that we may have obtained and we may not achieve or sustain profitability.

56


 

Clinical trials may be necessary to support future product submissions to the FDA. The clinical trial process is lengthy and expensive with uncertain outcomes, and often requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new products and will adversely affect our business, operating results and prospects.

Initiating and completing clinical trials necessary to support any future PMAs, and additional safety and efficacy data beyond that typically required for a 510(k) clearance, for our possible future product candidates, will be time-consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials. The results of preclinical studies and clinical trials of our products conducted to date and ongoing or future studies and trials of our current, planned or future products may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Our interpretation of data and results from our clinical trials do not ensure that we will achieve similar results in future clinical trials. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their products performed satisfactorily in preclinical studies and earlier clinical trials have nonetheless failed to replicate results in later clinical trials. Products in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and earlier clinical trials. Failure can occur at any stage of clinical testing. Our clinical studies may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and non-clinical testing in addition to those we have planned.

The initiation and completion of any of clinical studies may be prevented, delayed, or halted for numerous reasons. We may experience delays in our ongoing clinical trials for a number of reasons, which could adversely affect the costs, timing or successful completion of our clinical trials, including related to the following:

we may be required to submit an IDE application to the FDA, which must become effective prior to commencing certain human clinical trials of medical devices, and the FDA may reject our IDE application and notify us that we may not begin clinical trials;
regulators and other comparable foreign regulatory authorities may disagree as to the design or implementation of our clinical trials;
regulators and/or an IRB, or other reviewing bodies may not authorize us or our investigators to commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site;
we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;
the number of subjects or patients required for clinical trials may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate;
our third-party contractors, including those manufacturing products or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;
we might have to suspend or terminate clinical trials for various reasons, including the withdrawal of approval of an IDE by the FDA based on, for example, a finding that the subjects are being exposed to unacceptable health risks;
we may have to amend clinical trial protocols or conduct additional studies to reflect changes in regulatory requirements or guidance, which we may be required to submit to an IRB and/or regulatory authorities for re-examination;
regulators, IRBs, or other parties may require or recommend that we or our investigators suspend or terminate clinical research for various reasons, including safety signals or noncompliance with regulatory requirements;
the cost of clinical trials may be greater than we anticipate;

57


 

clinical sites may not adhere to the clinical protocol or may drop out of a clinical trial;
we may be unable to recruit a sufficient number of clinical trial sites;
regulators, IRBs, or other reviewing bodies may fail to approve or subsequently find fault with our manufacturing processes or facilities of third-party manufacturers with which we enter into agreement for clinical and commercial supplies, the supply of devices or other materials necessary to conduct clinical trials may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply;
approval policies or regulations of the FDA or applicable foreign regulatory agencies may change in a manner rendering our clinical data insufficient for approval;
our current or future products may have undesirable side effects or other unexpected characteristics; and
impacts of regional or global public health crises including the ongoing COVID-19 pandemic could adversely affect any clinical trials we are conducting or plan to conduct, including delays or difficulties in enrolling or onboarding patients, initiating clinical sites, or obtaining the requisite regulatory approvals, interruption of key clinical trial activities, or supply chain disruptions that delay or make it more difficult or costly to obtain the supplies and materials we need for clinical trials.

Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

Clinical trials must be conducted in accordance with applicable laws and regulations of the FDA and other regulatory authorities’ applicable legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and IRBs at the medical institutions where the clinical trials are conducted. Conducting successful clinical studies will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and able to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our products or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts.

We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice (GCP) requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both. In addition, clinical trials that are conducted in countries outside the United States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA, and different standards of diagnosis, screening and medical care.

Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDA may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays in the approval and attempted commercialization of our products or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical trials, the FDA may not consider our data adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.

58


 

If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as required or expected, we may not be able to obtain regulatory clearance or approval for or commercialize our products.

We may not have the ability to independently conduct our pre-clinical and clinical trials for our future products and we may need to rely on third parties, such as CROs, medical institutions, clinical investigators and contract laboratories to conduct such trials. We would depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with GCP requirements, and other regulatory requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, including achieving full enrollment, including on account of the outbreak of infectious disease, such as the COVID-19 pandemic, or otherwise, we may be affected by increased costs, program delays or both, any resulting data may be unreliable or unusable for regulatory purposes, and we may be subject to enforcement action.

If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our products on a timely basis, if at all, and our business, operating results and prospects may be adversely affected.

The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.

We cannot be certain that the results of our future clinical trials will support our future product claims or that the FDA will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercialize our product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the future product’s profile.

Changes in funding or disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new product applications to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including for 35 days beginning on December 22, 2018, the U.S. government shut down several times and certain regulatory agencies, including the FDA, had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities. On March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials. In May 2020, the FDA announced that it will continue to postpone domestic and foreign routine surveillance inspections due to COVID-19. Beginning in July 2020, the agency has resumed some prioritized domestic inspections deemed to be “mission-critical.” The FDA has published guidance, most recently updated in May 2021, outlining how it determines which inspections are “mission-critical.” While the FDA indicated that it will consider alternative methods for inspections and could exercise discretion on a case-by-case basis to approve products based on a desk review, if a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. In addition, the

59


 

FDA could amend its priorities with respect to inspections at any time, and those changes could have a material effect on our regulatory submissions and on our business.

Our use, disclosure, and other processing of personally identifiable information, including health information, is subject to HIPAA and other federal, state, and data privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our client base, member base and revenue.

Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of PHI and PII. These laws and regulations include HIPAA. HIPAA establishes a set of national privacy and security standards for the protection of PHI (as defined in HIPAA) by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract to provide specified services or perform a function for or on behalf of such covered entities. We are a business associate under HIPAA and we execute business associate agreements with our clients.

HIPAA requires covered entities and business associates, such as us, to develop and maintain policies with respect to the protection, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and imposes certain notification and reporting requirements in the event of a data breach.

Violations of HIPAA may result in significant civil and criminal penalties. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts may award damages, costs and attorneys’ fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. OCR has recently increased its enforcement efforts on compliance with HIPAA, including the security regulations (Security Rule), bringing actions against entities which have failed to implement security measures sufficient to reduce risks to electronic protected health information or to conduct an accurate and thorough risk analysis, among other violations. HIPAA enforcement actions may lead to monetary penalties and costly and burdensome corrective action plans. We are also required to report known breaches of PHI consistent with applicable breach reporting requirements set forth in applicable laws and regulations.

In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities and business associates. With regard to business associates, those audits assess the business associate’s compliance with the HIPAA Privacy and Security Rules. Such audits are conducted randomly and after an entity experiences a breach affecting more than 500 individuals’ data. Undergoing an audit can be costly, can result in fines or onerous obligations, and can damage a business associate’s reputation.

Finally, on December 10, 2020, OCR issued a proposed rule aimed at reducing regulatory burdens that may exist in discouraging coordination of care, including creating an exception to the minimum necessary standard for healthcare coordination, among other changes. While a final rule has not yet been issued, if adopted, these proposed changes may require us to update our HIPAA policies and procedures to comply with the new requirements.

In addition to HIPAA, numerous other federal and state laws and regulations protect the confidentiality, privacy, availability, integrity and security of PHI and other types of PII. Some of these laws and regulations may be preempted by HIPAA with respect to PHI, or may exclude PHI from their scope but impose obligations with regard to PII that is not PHI, and in some cases, can impose additional obligations with regard to PHI. These laws and regulations are often uncertain, contradictory, and subject to changed or differing interpretations, and we expect new laws, rules and regulations regarding privacy, data protection, and information security to be proposed and enacted in the future. For example, the CCPA, became effective on January 1, 2020. The CCPA gives California residents new rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although the law includes limited exceptions, including for PHI maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context, and the CCPA may increase our compliance costs and potential liability. Additionally, our machine learning and data analytics offerings may be subject to laws and evolving regulations regarding the use of artificial intelligence, controlling for data bias, and antidiscrimination.

Other states, including Nevada, Virginia and Colorado, have passed data protection laws, or are considering passing legislation, similar to CCPA. These laws would impose organizational requirements and grant individual rights that are comparable to those established in the CCPA. Additionally, a ballot initiative, the CPRA, passed in November 2020 in California. The CPRA will impose additional data protection obligations on companies doing business in California, including additional consumer rights

60


 

processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes will be required.

Additionally, the FTC and many state attorneys general are interpreting existing federal and state consumer protection laws to impose evolving standards for the online collection, use, dissemination and security of health-related and other personal information. Courts may also adopt the standards for fair information practices promulgated by the FTC, which concern consumer notice, choice, security and access. Consumer protection laws require us to publish statements that describe how we handle personal information and choices individuals may have about the way we handle their personal information. If such information that we publish is considered untrue, we may be subject to government claims of unfair or deceptive trade practices, which could lead to significant liabilities and consequences. Furthermore, according to the FTC, violating consumers’ privacy rights or failing to take appropriate steps to keep consumers’ personal information secure may constitute unfair or deceptive acts or practices in violation of Section 5 of the FTC Act. The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC’s guidance for appropriately securing consumers’ personal information is similar to what is required by the HIPAA Security Rule. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions.

This complex, dynamic legal landscape regarding privacy, data protection, data analytics and information security creates significant compliance issues for us and our clients and potentially exposes us to additional expense, adverse publicity and liability. While we have implemented data privacy and security measures in an effort to comply with applicable laws and regulations relating to privacy and data protection, some PHI and other PII or confidential information is transmitted to us by third parties, who may not implement adequate security and privacy measures, and it is possible that laws, rules and regulations relating to privacy, data protection, or information security may be interpreted and applied in a manner that is inconsistent with our practices or those of third parties who transmit PHI and other PII or confidential information to us. If we or these third parties are found to have violated such laws, rules or regulations, it could result in government-imposed fines, orders requiring that we or these third parties change our or their practices, or criminal charges, which could adversely affect our business. Complying with these various laws and regulations could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business.

We regularly monitor, defend against and respond to attacks to our networks and other information security incidents. Despite our information security efforts, our facilities, systems, and data, as well as those of our third-party service providers, may be vulnerable to privacy and information security incidents such as data breaches, viruses or other malicious code, coordinated attacks, data loss, phishing attacks, ransomware, denial of service attacks, or other security or IT incidents caused by threat actors, technological vulnerabilities or human error. If we, or any of our vendors that support our IT or have access to our data, fail to comply with laws requiring the protection of personal information, or fail to safeguard and defend personal information or other critical data assets or IT systems, we may be subject to regulatory enforcement and fines as well as private civil actions. We may be required to expend significant resources in the response, containment, mitigation of cybersecurity incidents as well as in defense against claims that our information security was unreasonable or otherwise violated applicable laws or contractual obligations.

Our employees, collaborators, independent contractors and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk that our employees, collaborators, independent contractors and consultants may engage in fraudulent or other illegal activity with respect to our business. Misconduct by these persons could include intentional, reckless and/or negligent conduct or unauthorized activity that violates:

FDA requirements, including those laws requiring the reporting of true, complete and accurate information to the FDA authorities;
manufacturing standards;
federal and state healthcare fraud and abuse laws and regulations; or
laws that require the true, complete and accurate reporting of financial information or data.

In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or

61


 

prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve individually identifiable information, including, without limitation, the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any incidents or any other conduct that leads to an employee, contractor, or other agent, or our company, receiving an FDA debarment or exclusion by OIG could result in penalties, a loss of business from third parties, and severe reputational harm.

It is not always possible to identify and deter misconduct by our employees and other agents, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, treble damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, reporting requirements and compliance oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations.

We must comply with environmental and occupational safety laws.

Our research and development programs as well as our manufacturing operations involve the controlled use of hazardous materials. Accordingly, we are subject to federal, state and local laws, as well as the laws of foreign countries, governing the use, handling and disposal of these materials. In the event of an accident or failure to comply with environmental or occupational safety laws, we could be held liable for resulting damages, and any such liability could exceed our insurance coverage and may accordingly adversely affect our business, financial condition or results of operations.

Risks Related to our Intellectual Property

We have to protect our intellectual property.

Our commercial success will depend in part in our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our technology. We rely on patent protection, as well as a combination of copyright, trade secret and trademark laws, to protect our proprietary technology and prevent others from duplicating Tablo. However, these means may afford only limited protection and may not prevent our competitors from duplicating Tablo, prevent our competitors from gaining access to our proprietary information and technology, or permit us to gain or maintain a competitive advantage.

Any of our patents, including those we may license, may be challenged, invalidated, rendered unenforceable or circumvented. We may not prevail if our patents are challenged by competitors or other third parties. The U.S. federal courts or equivalent national courts or patent offices elsewhere may invalidate our patents, find them unenforceable, or narrow their scope. Furthermore, competitors may be able to design around our patents, or obtain patent protection for more effective technologies, designs or methods for treating kidney failure. If these developments were to occur, Tablo may become less competitive and sales of Tablo may decline.

We have filed numerous patent applications seeking protection of products and other inventions originating from our research and development. Our patent applications may not result in issued patents, and any patents that are issued may not provide meaningful protection against competitors or competitive technologies. Further, the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The scope of a patent may also be reinterpreted after issuance. The rights that may be granted under our future issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. If we are unable to obtain and maintain patent protection for our technology, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize products similar or superior to ours, and our competitive position may be adversely affected. It is also possible that we will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them. In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner.

Additionally, while software and other of our proprietary works may be protected under copyright law, we have chosen not to register any copyrights in these works, and instead, primarily rely on protecting our software as a trade secret. In order to bring a copyright infringement lawsuit in the United States, the copyright must be registered. Accordingly, the remedies and damages available to us for unauthorized use of our software may be limited.

62


 

We may be subject to claims challenging the ownership or inventorship of our patents and other intellectual property and, if unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, or to cease the development, manufacture and commercialization of Tablo.

We may be subject to claims that current or former employees, collaborators or other third parties have an interest in our patents, trade secrets or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing Tablo. Litigation may be necessary to defend against these and other claims challenging inventorship of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to Tablo. If we were to lose exclusive ownership of such intellectual property, other owners may be able to license their rights to other third parties, including our competitors. We also may be required to obtain and maintain licenses from third parties, including parties involved in any such disputes. Such licenses may not be available on commercially reasonable terms, or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture and commercialization of Tablo. The loss of exclusivity or the narrowing of our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.

In addition to seeking patent protection for Tablo, we also rely upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain a competitive position. We seek to protect such proprietary information, in part, through confidentiality agreements with our employees, collaborators, contractors, advisors, consultants and other third parties and invention assignment agreements with our employees. We also have agreements with some of our consultants that require them to assign to us any inventions created as a result of their working with us. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses containing invention assignment, to grant us ownership of technologies that are developed through a relationship with employees or third parties.

We cannot guarantee that we have entered into such agreements with each party that has or may have had access to our trade secrets or proprietary information. Additionally, despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor or other third party, our competitive position would be materially and adversely harmed. Furthermore, we expect these trade secrets, know-how and proprietary information to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of personnel from academic to industry scientific positions.

We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known, or be independently discovered by, competitors. To the extent that our employees, consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions, which could have a material adverse effect on our business, financial condition and results of operations.

We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors and third parties may claim an ownership interest in intellectual property we regard as our own.

Many of our employees and consultants were previously employed at or engaged by other medical device, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or

63


 

otherwise, misappropriated the intellectual property or disclosed the alleged trade secrets or other proprietary information, of these former employers or competitors.

Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to Tablo, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers.

An inability to incorporate technologies or features that are important or essential to our product could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from selling Tablo. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product, which could have an adverse effect on our business, financial condition and results of operations.

Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products.

Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In 2011, the Leahy-Smith America Invents Act (Leahy-Smith Act) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation. These also include provisions that switched the United States from a first-to-invent system to a first-to-file system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective in 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and results of operations.

In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.

If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.

Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be violating or infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners and customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement or dilution claims brought by owners of other trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names or other intellectual property may be ineffective, could result in substantial costs and diversion of resources and could adversely affect our business, financial condition and results of operations.

64


 

We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful.

Competitors may infringe our patents, or we may be required to enforce patents issued or licensed to us, to protect our trade secrets or know-how, to defend against claims of infringement of the rights of others or to determine the scope and validity of the proprietary rights of others. In addition, our patents also may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time-consuming and could divert our attention from other functions and responsibilities. In an infringement proceeding, a court may decide that a patent owned by us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover such technology. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, even if our patents are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer’s competition in the market. Adverse determinations in litigation could subject us to significant liabilities to third parties, require us to seek licenses from third parties and prevent us from manufacturing, selling or using the product, any of which could severely harm our business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation.

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our management and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our common stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.

Our use of “open source” software could subject our proprietary software to general release, adversely affect our ability to sell Tablo and subject us to possible litigation.

A portion of the products or technologies licensed, developed and/or distributed by us incorporate so-called “open source” software and we may incorporate open-source software into other products in the future. Such open-source software is generally licensed by its authors or other third parties under open-source licenses. Some open-source licenses contain requirements that we disclose source code for modifications we make to the open-source software and that we license such modifications to third parties at no cost. In some circumstances, distribution of our software in connection with open-source software could require that we disclose and license some or all of our proprietary code in that software, as well as distribute our software that uses particular open-source software at no cost to the user. We monitor our use of open-source software in an effort to avoid uses in a manner that would require us to disclose or grant licenses under our proprietary source code; however, there can be no assurance that such efforts will be successful. Open-source license terms are often ambiguous and such use could inadvertently occur. There is little legal precedent governing the interpretation of many of the terms of these licenses, and the potential impact of these terms on our business may result in unanticipated obligations regarding Tablo and our technologies. Companies that incorporate open-source software into their products have, in the past, faced claims seeking enforcement of open-source license provisions and claims asserting ownership of open-source software incorporated into their product. If an author or other third party that distributes such open-source software were to allege that we had not complied with the conditions of an open-source license, we could incur significant legal costs defending ourselves against such allegations. In the event such claims were successful, we could be subject to significant damages or be enjoined from the distribution of Tablo. In addition, if we combine our proprietary software with open-source software in certain ways, under some open-source licenses, we could be required to release the source code of our proprietary software, which could substantially help our competitors develop products that are similar to or better than ours and otherwise adversely affect our business. These risks could be difficult to eliminate or manage, and, if not addressed, could harm our business, financial condition and results of operations.

65


 

Intellectual property rights do not necessarily address all potential threats.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

others may be able to make products that are similar to Tablo or utilize similar technology but that are not covered by the claims of our patents or that incorporate certain technology in Tablo that is in the public domain;
we, or our future licensors or collaborators, might not have been the first to make the inventions covered by the applicable issued patent or pending patent application that we own now or may own or license in the future;
we, or our future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;
it is possible that our current or future pending patent applications will not lead to issued patents;
issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;
our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
we may not develop additional proprietary technologies that are patentable;
the patents of others may harm our business; and
we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.

We may not be able to protect our intellectual property and proprietary rights throughout the world.

Third parties may attempt to commercialize competitive products or services in foreign countries where we do not have any patents or patent applications and/or where legal recourse may be limited. This may have a significant commercial impact on any foreign business operations.

Filing, prosecuting and defending patents on Tablo in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with Tablo, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to

66


 

enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition and results of operations may be adversely affected.

Risks Related to Ownership of Our Common Stock

The market price of our common stock has been and may continue to be volatile and may decline steeply or suddenly regardless of our operating performance, which could result in substantial losses for holders of our common stock, and we may not be able to meet investor or analyst expectations.

The market price of our common stock has been and may continue to be highly volatile and may continue to fluctuate or decline significantly in response to numerous factors, many of which are beyond our control, including:

actual or anticipated changes in our operating results, and variations between our actual operating results and the expectations of securities analysts, investors and the financial community;
any forward-looking financial or operating information we may provide to the public or securities analysts, any changes in this information or our failure to meet expectations based on this information;
actions of securities analysts who initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow our company or our failure to meet these estimates or the expectations of investors;
additional shares of our common stock being sold into the market by us or our existing stockholders, or the anticipation of such sales;
hedging activities by market participants;
regulatory actions with respect to our products or our competitors’ products;
announcements by us or our competitors of significant products or features, technical innovations, acquisitions, strategic partnerships, joint ventures or capital commitments;
changes in operating performance and stock market valuations of companies in our industry, including our competitors;
price and volume fluctuations in the overall stock market, including as a result of trends in the economy as a whole;
lawsuits threatened or filed against us;
developments in new legislation and pending lawsuits or regulatory actions, including interim or final rulings by judicial or regulatory bodies; and
other events or factors, including those resulting from political conditions, election cycles, war or incidents of terrorism, or responses to these events.

In addition, extreme price and volume fluctuations in the stock markets have affected and continue to affect many life sciences and technology companies’ stock prices. Stock prices often fluctuate in ways unrelated or disproportionate to the companies’ operating performance. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and seriously harm our business.

Moreover, because of these fluctuations, comparing our operating results on a period-to-period basis may not be meaningful. You should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failure to meet the expectations of industry or financial analysts or investors for any period. If our revenues or operating

67


 

results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings forecasts that we may provide.

We do not intend to pay dividends for the foreseeable future and, as a result, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.

We have never declared or paid any cash dividends on our common stock and do not intend to pay any cash dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the development of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. In addition, the terms of the SVB Loan and Security Agreement restrict our ability to pay dividends to limited circumstances. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.

If securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the trading price or trading volume of our common stock could decline.

The trading market for our common stock is influenced in part by the research and reports that securities or industry analysts may publish about us, our business, our market or our competitors. If one or more analysts initiate research with an unfavorable rating or downgrade our common stock, provide a more favorable recommendation about our competitors or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the trading price or trading volume of our common stock to decline.

Our principal stockholders and management own a significant percentage of our stock and are able to exercise significant influence over matters subject to stockholder approval.

As of December 31, 2021, our executive officers, directors and 5% stockholders beneficially owned approximately 52% of the outstanding shares of capital stock. In addition, as of December 31, 2021, our executive officers and directors held options to purchase an aggregate of 2,303,391 shares of our common stock at a weighted-average exercise price of $9.81 per share, and 257,820 restricted stock units, which would give our officers and directors ownership of approximately 5% of our outstanding common stock as of December 31, 2021 if such awards were fully vested and exercised or settled in full (assuming over-achievement of any performance conditions). Therefore, these stockholders have the ability to influence us through this ownership position. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could attempt to delay or prevent a change in control of us, even if such change in control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of us or our assets and might affect the prevailing market price of our common stock due to investors’ perceptions that conflicts of interest may exist or arise. As a result, this concentration of ownership may not be in the best interests of our other stockholders.

Future securities issuances could result in significant dilution to our stockholders and impair the market price of our common stock.

Future issuances of shares of our common stock, or the perception that these sales may occur, could depress the market price of our common stock and result in dilution to existing holders of our common stock. Also, to the extent outstanding options to purchase shares of our common stock are exercised or options, restricted stock units or other stock-based awards are issued or become vested, there will be further dilution. The amount of dilution could be substantial depending upon the size of the issuances or exercises. Furthermore, we may issue additional equity securities that could have rights senior to those of our common stock. As a result, purchasers of our common stock bear the risk that future issuances of debt or equity securities may reduce the value of our common stock and further dilute their ownership interest.

68


 

Delaware law and provisions in our amended and restated certificate of incorporation and bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.

Our amended and restated certificate of incorporation and bylaws contain provisions that could depress the trading price of our common stock by acting to discourage, delay or prevent a change of control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions include the following:

establish a classified board of directors so that not all members of our board of directors are elected at one time;
permit the board of directors to establish the number of directors and fill any vacancies and newly-created directorships;
provide that directors may only be removed for cause and only by the affirmative vote of the holders of at least a majority of the voting power of all then outstanding shares of our capital stock;
require super-majority voting to amend some provisions in our amended and restated certificate of incorporation and bylaws;
authorize the issuance of “blank check” preferred stock that our board of directors could use to implement a stockholder rights plan;
prohibit stockholders from calling special meetings of stockholders;
prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;
provide that the board of directors is expressly authorized to make, alter or repeal our bylaws;
restrict the forum for certain litigation against us to Delaware; and
establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.

Any provision of our amended and restated certificate of incorporation or bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.

Our amended and restated certificate of incorporation designates a state or federal court located within the State of Delaware as the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to choose the judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf under Delaware law, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action arising pursuant to any provision of the Delaware General Corporation Law (DGCL), our amended and restated certificate of incorporation or bylaws, (4) any other action asserting a claim that is governed by the internal affairs doctrine, or (5) any other action asserting an “internal corporate claim,” as defined in Section 115 of the DGCL, shall be the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) in all cases subject to the court having jurisdiction over indispensable parties named as defendants. These exclusive-forum provisions do not apply to claims under the Securities Act or the Exchange Act.

To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.

Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. However, our amended and restated certificate of incorporation contains a federal forum provision which provides that unless the company consents in writing to the

69


 

selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.

Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision. This exclusive forum provision may limit a stockholder’s ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find the exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations.

General Risks

General economic and financial market conditions may exacerbate our business risks.

Global macroeconomic conditions and the world’s financial markets remain susceptible to significant stresses, resulting in reductions in available credit and government spending, economic downturn or stagnation, foreign currency fluctuations and volatility in the valuations of securities generally. Our customers may respond to such economic pressures by reducing or deferring their capital spending or reducing staff. Furthermore, unfavorable changes in foreign exchange rates versus USD could increase our product and labor costs, thus reducing our gross profit.

We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success.

We are highly dependent on our senior management, including our chief executive officer, Leslie Trigg, and other key personnel. Our success will depend on our ability to retain senior management and to attract and retain qualified personnel in the future, including sales and marketing professionals, scientists, clinical specialists, engineers and other highly skilled personnel and to integrate current and additional personnel in all departments. The loss of members of our senior management, sales and marketing professionals, scientists, clinical and regulatory specialists and engineers could result in delays in product development and harm our business. If we are not successful in attracting and retaining highly qualified personnel, it would have a material adverse effect on our business, financial condition and results of operations.

Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued and may continue to issue equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Our employment arrangements with our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We also do not maintain “key man” insurance policies on the lives of these individuals or the lives of any of our other employees.

Operating as a public company requires us to incur substantial costs and requires substantial management attention.

We have incurred and will continue to incur substantial legal, accounting and other expenses as a result of operating as a public company. For example, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the Exchange Act), the applicable requirements of the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act and the rules and regulations of the SEC. Our management and other personnel have needed to divert attention from other business matters to devote substantial time to the reporting and other requirements of being a public company. Until December 31, 2021, we were eligible for reduced reporting and disclosure requirements as an “emerging growth company.” We are no longer an “emerging growth company” and, accordingly, we are required to comply with several supplemental requirements that will necessitate additional resources and management time and expense. The rules and regulations of the Nasdaq Global Select Market also apply to us. As part of these requirements, we have made changes to our corporate governance practices and will need to maintain effective disclosure and financial controls that are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that information required to be disclosed in reports under the Exchange Act is accumulated and communicated to our principal executive and financial officers. Any failure to maintain effective controls could adversely affect the results of periodic management evaluations. Compliance with these requirements has and will continue to increase our legal and financial compliance costs and will continue to make some activities more time-consuming.

70


 

Additionally, being a public company and complying with applicable rules and regulations also makes it more expensive for us to obtain director and officer liability insurance. Given recent developments in the market for such coverage, we expect to incur substantially higher costs to obtain and maintain the same or similar coverage. These factors could also make it more difficult for us to attract and retain qualified executive officers and members of our board of directors.

If our internal control over financial reporting or our disclosure controls and procedures are not effective, we may not be able to accurately report our financial results, prevent fraud or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information.

We recently became a “large accelerated filer” under the Exchange Act, which requires us to comply with the requirements of Section 404 of the Sarbanes-Oxley Act. Section 404 of the Sarbanes-Oxley Act requires that we maintain effective internal control over financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluations, document our controls and perform testing of our key controls over financial reporting to allow management and our independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. We have incurred significant expense and devoted substantial management effort to complying with the requirements of Section 404 of the Sarbanes-Oxley Act, which we expect will continue. We anticipate hiring additional accounting and financial staff with appropriate public company experience and technical accounting knowledge to support future growth. If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act or if we encounter difficulties in the timely and accurate reporting of our financial results, or if we or our independent registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, our investors could lose confidence in our reported financial information, the market price of our stock may decline and we could be subject to lawsuits, sanctions or investigations by regulatory authorities, which would require additional financial and management resources.

Our corporate culture has contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovation, creativity and teamwork fostered by our culture and our business may be harmed.

We believe that our culture has been and will continue to be a critical contributor to our success. We expect to continue to hire aggressively as we expand, and we believe our corporate culture has been crucial in our success and our ability to attract highly skilled personnel. If we do not continue to develop our corporate culture or maintain and preserve our core values as we grow and evolve, we may be unable to foster the innovation, curiosity, creativity, focus on execution, teamwork and the facilitation of critical knowledge transfer and knowledge sharing we believe we need to support our growth. Our anticipated headcount growth and our public company status may result in a change to our corporate culture, which could harm our business.

We may acquire other businesses which could require significant management attention, disrupt our business, dilute stockholder value and adversely affect our results of operations.

As part of our business strategy, we may in the future make acquisitions or investments in complementary companies, products or technologies that we believe fit within our business model and can address the needs of our customers and potential customers. In the future, we may not be able to acquire and integrate other companies, products or technologies in a successful manner. We may not be able to find suitable acquisition candidates, and we may not be able to complete such acquisitions on favorable terms, if at all. In addition, the pursuit of potential acquisitions may divert the attention of management and cause us to incur additional expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. If we do complete acquisitions, we may not ultimately strengthen our competitive position or achieve our goals, including increases in revenue, and any acquisitions we complete could be viewed negatively by our customers, investors and industry analysts.

Future acquisitions may reduce our cash available for operations and other uses and could result in amortization expense related to identifiable assets acquired. We may have to pay cash, incur debt or issue equity securities to pay for any such acquisition, each of which could adversely affect our financial condition or the value of our common stock. The sale or issuance of equity to finance any such acquisitions would result in dilution to our stockholders. The incurrence of indebtedness to finance any such acquisition would result in fixed obligations and could also include covenants or other restrictions that could impede our ability to manage our operations. In addition, our future results of operations may be adversely affected by the dilutive effect of an acquisition, performance earn-outs or contingent bonuses associated with an acquisition. Furthermore, acquisitions may require large, onetime charges and can result in increased debt or contingent liabilities, adverse tax consequences, additional stock-based compensation expenses and the recording and subsequent amortization of amounts related to certain purchased intangible assets, any of which items could negatively affect our future results of operations. We may also incur goodwill impairment charges in the future if we do not realize the expected value of any such acquisitions.

Also, the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize, or such strategic alliance, joint venture or acquisition may be prohibited. In July 2020, we entered into the SVB Loan and Security Agreement which

71


 

also restricts our ability to pursue certain mergers, acquisitions, amalgamations or consolidations that we may believe to be in our best interest. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results.

If we fail to comply with anti-corruption, anti-bribery, anti-money laundering and similar laws, we could suffer severe penalties.

We are subject to the U.S. Foreign Corrupt Practices Act which generally prohibits U.S. companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business and requires companies to maintain accurate books and records and internal controls, including at foreign controlled subsidiaries. We are also subject to requirements under the U.S. Treasury Department’s Office of Foreign Assets Control, U.S. domestic bribery laws and other anti-corruption, anti-bribery and anti-money laundering laws. While we have policies and procedures in place designed to promote compliance with such laws, our employees or other agents may nonetheless engage in prohibited conduct under these laws for which we or our executives might be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have an adverse effect on our business, financial condition and results of operations.

If our estimates or judgments relating to our critical accounting policies prove to be incorrect, our results of operations could be adversely affected.

The preparation of financial statements in conformity with the United States generally accepted accounting principles (U.S. GAAP) and our key metrics require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and amounts reported in our key metrics. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, as provided in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The results of these estimates form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses that are not readily apparent from other sources. Significant assumptions and estimates used in preparing our financial statements include those related to allowance for doubtful accounts, assessment of the useful life and recoverability of long-lived assets, warranty obligations, fair values of stock-based awards, warrants, contingent consideration, and income taxes. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the trading price of our common stock.

Expectations relating to ESG factors may impose additional costs and expose us to new risks.

There is increasing focus from certain investors, customers and other stakeholders concerning corporate responsibility, specifically related to ESG factors. Some investors may use ESG factors to guide their investment strategies and, in some cases, may choose not to invest in us if they believe our policies and actions relating to ESG matters are inadequate. Third party providers of ESG ratings and reports on companies have increased in number to meet growing investor demand for measurement of ESG performance, resulting in varied and in some cases inconsistent standards. In addition, the criteria by which companies’ ESG practices are assessed are evolving, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. Alternatively, if we elect not to or are unable to satisfy such new criteria, some investors may conclude that our policies with respect ESG matters are inadequate. We may face reputational damages in the event that our ESG procedures or standards do not meet the standards set by various constituencies. Furthermore, if our competitors’ ESG performance is perceived to be better than ours, potential or current investors may elect to invest with our competitors instead.

In addition, from time to time, we communicate certain initiatives and goals related to ESG matters. For example, in October 2021, we published our inaugural ESG Report, including updates on our ESG programs, priorities, initiatives, goals and performance. We could fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could fail in fully and accurately reporting our progress on such initiatives and goals. In addition, we could be criticized for the scope of such initiatives or goals or perceived as not acting responsibly in connection with these matters. Our business could be negatively impacted by such matters. If we fail to satisfy the ESG-related expectations of investors, customers and other stakeholders or our initiatives or goals are not executed or achieved as planned, our reputation and financial results could be materially and adversely affected.

Item 1B. Unresolved Staff Comments.

None.

72


 

Item 2. Properties.

In May 2020, we entered into an operating lease agreement for our manufacturing facility in Tijuana, Mexico. This facility includes a main building with 48,437 square feet and a secondary space with 38,750 square feet. The initial term of this lease expires in 2026.

In addition, we lease 40,413 square feet for our corporate headquarters located in San Jose, California under a lease agreement that terminates in 2027. This facility supports research and development and general and administrative activities, as well as complimentary manufacturing and distribution for consoles and service parts.

We believe that these facilities are suitable and sufficient to meet our current and anticipated needs in the near term and that additional space can be obtained on commercially reasonable terms as needed.

From time to time we may become involved in legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition or cash flows.

Item 4. Mine Safety Disclosures.

Not applicable.

73


 

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock has been listed on the Nasdaq Global Select Market under the symbol “OM” since September 15, 2020. Prior to that date, there was no public trading market for our common stock.

 

Holders of Common Stock

As of January 31, 2022, there were 131 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.

Dividend Policy

We have never declared or paid, and do not anticipate declaring or paying in the foreseeable future, any cash dividends on our capital stock. Any future determination as to the declaration and payment of dividends, if any, will be at the discretion of our board of directors, subject to applicable laws and will depend on then existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant.

Stock Performance Graph

The following shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference into any of our other filings under the Exchange Act or the Securities Act of 1933, as amended, except to the extent we specifically incorporate it by reference into such filing.

The following graph compares the cumulative total return on our common stock relative to the cumulative total returns of the NASDAQ Composite Index and the NASDAQ Biotechnology Index for the period from September 15, 2020 (the first day of trading of our common stock) through December 31, 2021. An investment of $100 is assumed to have been made in our common stock and each index at market close on September 15, 2020 and its relative performance is tracked through December 31, 2021. Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The offering price of our common stock in our initial public offering (IPO), which had a closing stock price of $60.68 on September 15, 2020, was $27.00 per share. Note that historic stock price performance is not necessarily indicative of future stock price performance.

74


 

img263710155_2.jpg 

Recent Sales of Unregistered Securities

None.

Issuer Purchases or Equity Securities

None.

Item 6. [Reserved].

75


 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion of our financial condition and results of operations is expected to better allow investors to view the Company from management’s perspective and should be read together with our audited financial statements and related notes and other financial information included elsewhere in this Annual Report. The following discussion contains forward-looking statements that reflect our current plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Annual Report, particularly in the section titled “Risk Factors.” Our historical results are not necessarily indicative of the results that may be expected for any period in the future.

We have elected to omit discussion of the earliest of the three years covered by the audited financial statements presented. Refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, located in our annual report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 22, 2021, for reference to discussion of the year ended December 31, 2019, the earliest of the three fiscal years presented.

Overview

Our technology is designed to elevate the dialysis experience for patients and help providers overcome traditional care delivery challenges. Requiring only an electrical outlet and tap water to operate, the Tablo® Hemodialysis System frees patients and providers from the burdensome infrastructure required to operate traditional dialysis machines. The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo to serve as a dialysis clinic on wheels. With a simple-to-use touchscreen interface, two-way wireless data transmission and a proprietary data analytics platform, Tablo is a new holistic approach to dialysis care. Unlike existing hemodialysis machines, which have limited clinical versatility across care settings, Tablo can be used seamlessly across multiple care settings and a wide range of clinical applications.

Tablo leverages cloud technology, making it possible for providers to monitor devices and treatments remotely, perform patient and population analytics, and automate clinical recordkeeping, while also enabling us to release features and enhancements through OTA updates. Tablo’s connectedness also allows it to continually stream more than 500,000 device performance data points after every treatment. We use this data, in conjunction with our diagnostic and predictive algorithms, to determine failure types and, in some instances, predict failures before they occur. In effect, this contributes to a reduction in service hours and an increase in device uptime.

We have generated meaningful evidence to demonstrate that providers can realize significant operational efficiencies, including reducing the cost of their dialysis programs by up to 80% in the intensive care unit. In addition, Tablo has been shown to deliver robust clinical care. In studies we have conducted, patients have reported experiencing fewer symptoms and better quality sleep while on Tablo. We believe Tablo empowers patients, who have traditionally been passive recipients of care, to regain agency and ownership of their treatment. Tablo is cleared by the FDA for use in the hospital, clinic, or home setting.

Driving adoption of Tablo in the acute care setting has been our primary focus to date. We have invested in growing our economic and clinical evidence, built a veteran sales and clinical support team with significant expertise, and implemented a comprehensive training and customer experience program. Our experience in the acute market has demonstrated Tablo’s clinical flexibility and operational versatility, while also delivering meaningful cost savings to the providers. We plan to continue leveraging our commercial infrastructure to broaden our installed base in the acute care market as well as driving utilization and fleet expansion with our existing customers. While the ongoing COVID-19 pandemic has presented opportunities to demonstrate the real-world benefits of Tablo over traditional machines, we believe these benefits, in addition to the other advantages of Tablo, are continuing to drive customer purchasing decisions.

Tablo is also well suited for home-based dialysis. Our ability to reduce training time, patient dropout, and the supplies and infrastructure required to deliver dialysis in the home can drive efficiency and economic improvements to the home care model. In our home IDE trial, patients reported specific quality of life improvements compared to their experience on the incumbent home dialysis machine. To penetrate this market successfully, we are focused on refining our home distribution, logistics and support systems to help ensure they are ready for rapid scale. We are also working with providers, patients, and payors to increase awareness and adoption of TCUs as a bridge to home-based therapy. To demonstrate the cost advantages of Tablo in the home setting, we are continuing to collect additional patient clinical experience and outcomes data.

We sell our solution through our direct sales organization, which covers most major metropolitan markets in the United States. As of December 31, 2021, our sales organization is comprised of 36 capital sales team members, responsible for generating new customer demand for Tablo, and 82 clinical sales team members, responsible for driving utilization and fleet expansion of Tablo consoles at existing customer sites. In addition, our field service team, comprised of 93 members, provides maintenance services and

76


 

product support to Tablo customers. The same sales organization and field service team drive Tablo penetration in both the acute and home markets. We believe the ability to leverage one team to serve both markets will result in significant productivity and cost optimization as we continue to scale our business.

We generate revenue primarily from the initial sale of Tablo consoles, and recurring sales of per-treatment consumables, including the Tablo cartridge, which generates significant total revenue over the life of the console. We generate additional revenue via annual service contracts and shipping and handling charged to customers. For the years ended December 31, 2021, 2020 and 2019, sales of our consoles accounted for 63%, 66% and 81% of our revenue, respectively, sales of our consumables accounted for 19%, 13% and 10% of our revenue, respectively, and sales of services and other accounted for 18%, 21% and 9% of our revenue, respectively.

Historically, we have financed our operations and capital expenditures primarily through sales of redeemable convertible preferred stock and common stock, revenue from sales, and debt financing. On September 17, 2020, we completed our IPO, in which we sold 10,293,777 shares of common stock (which included 1,342,666 shares that were offered and sold pursuant to the full exercise of the IPO underwriters’ option to purchase additional shares in connection with the IPO) at a price to the public of $27.00 per share. Including the full exercise of the underwriters’ option to purchase additional shares, we received aggregate net proceeds of approximately $254.8 million after deducting offering costs, underwriting discounts and commissions of approximately $23.1 million. Upon the closing of the IPO, all of our outstanding redeemable convertible preferred stock automatically converted into shares of common stock.

On April 13, 2021, we completed a follow-on public offering and sold 2,945,864 shares of our common stock (which included 445,864 shares that were offered and sold pursuant to the full exercise of the underwriters’ option to purchase additional shares) at a price to the public of $53.50 per share. We received aggregate net proceeds of approximately $149.1 million after deducting offering costs, underwriting discounts and commissions of $8.5 million.

Since our inception, we have incurred net losses in each year. For the years ended December 31, 2021, 2020 and 2019, we incurred net losses of $131.9 million, $121.5 million and $68.3 million, respectively. As of December 31, 2021, we had an accumulated deficit of $626.0 million. We expect to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term.

Key Factors Affecting Our Performance

We believe that our financial performance has been and in the foreseeable future will continue to be primarily driven by the following factors. While we believe each of these factors presents significant opportunities for our business, they also pose important challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address the factors below is subject to various risks and uncertainties, including those described in the section titled “Risk Factors.”

Market Acceptance of Tablo in Acute Setting

We plan to further broaden our installed base by continuing to target national and regional IDNs and health systems, and sub-acute LTACH and SNF providers. In addition, we focus on driving utilization and fleet expansion with existing customers by providing an exceptional user experience delivered through our commercial team and a steady release of software enhancements that amplify Tablo’s operational reliability and clinical versatility. Our ability to successfully execute on this strategy, and thereby increase our revenue, will in part drive our results of operations and the growth of our business.

Expansion of Tablo within the Home Setting

We believe a significant growth opportunity exists within the home hemodialysis market. We are partnering with innovative dialysis clinic providers and health systems who are motivated to grow their home hemodialysis population, and who share our vision of creating a seamless and supported transition to the home. We are also investing in market development over the longer term to expand the home hemodialysis market itself. The expansion of the home hemodialysis market and our ability to penetrate this market will be an important factor in driving the future growth of our business.

Gross Margin

We are continuing to execute a well-defined strategy designed to expand gross margins. First, in the first quarter of 2021, we successfully began production at our own console manufacturing facility in Tijuana, Mexico which we operate in collaboration with our outsourced business administration service provider, TACNA. Second, following our receipt of 510(k) clearance from the FDA

77


 

for the new cartridge sterilization method in the fourth quarter of 2021, we have qualified a second source to increase Tablo cartridge production through a new manufacturing partner in Mexico, which we anticipate will result in cost reductions, including lower freight costs. Third, we will continue to drive scale across our console platform to leverage our supply base and help improve our manufacturing efficiency. Fourth, we will continue to utilize our cloud-based data system, as well as enhanced product performance, to help drive down the cost of service. Our ability to grow our business will depend in part on these and other measures to control the costs of our products being successful. Likewise, it will be important that we effectively manage the costs of generating our service revenue.

Impacts of the COVID-19 Pandemic

We believe that the ongoing COVID-19 pandemic has highlighted the limitations of traditional machines and the benefits of Tablo, which drove an increase in demand for Tablo during 2020. We also believe the advantages of Tablo highlighted by the pandemic are now embedded as one of the many factors driving our customers’ purchasing decisions. We did not experience significant demand driven by COVID-19 during 2021 and do not expect to in future periods.

In response to the COVID-19 pandemic, we made modifications to our normal operations, employing precautionary measures designed to help protect our employees while providing ongoing support for our customers and their patients. Among other measures, we restricted non-essential travel of our employees and asked the majority of our employees to work from home. When COVID-19 testing became available, we implemented onsite testing in our facilities. We also provided vaccination clinics at each of our facilities to make it convenient for our workforce to receive COVID-19 vaccinations once available. During the third quarter of 2021, we defined a policy requiring our customer-facing and on-site employees to be fully vaccinated by October 2021, subject to medical and religious exemptions. With nearly all our employees now vaccinated, we have begun to move toward more normal business operations in accordance with local guidelines, including resuming more on-site activity to increase productive collaboration while continuing to prioritize employee safety. For employees working on-site, we continue to follow masking protocols consistent with evolving health and safety guidelines, facilitate social distancing, and practice increased sanitizing standards. Lastly, we have created a business continuity plan and incident management team to respond quickly and effectively to changes in order to offer customers uninterrupted products, services and support while safeguarding the best interest of employees, suppliers and stockholders.

Our business may be impacted by an escalation or a continuation of the COVID-19 pandemic. While the operations at our contract manufacturing partners’ facilities and our outsourced business administration service provider, TACNA, for our facility in Tijuana, Mexico, have not yet experienced significant disruption as a result of the pandemic, the possibility that such disruption may occur remains. Additionally, the COVID-19 pandemic has disrupted the operations of certain of our third-party suppliers, resulting in increased lead-times, higher component costs, and lower allocations for our purchase of some components (including certain critical components) and, in certain cases, requiring us to procure materials from alternative sources or incur higher logistical expenses. We have worked closely with our manufacturing partners and suppliers to enable us to source key components and maintain appropriate inventory levels to meet customer demand, and have not experienced material disruptions in our supply chain to date.

Additionally, surges and shifts in consumer demand as the economy reopens, further exacerbated by COVID-19 outbreaks and protocols, have strained the global freight network and placed significant stress on air, ocean, and ground freight carriers. This has resulted in labor shortages, container and chassis shortages, reduced carrier capacity, carrier delays and longer lead times, shipment receiving and unloading backlogs at many U.S. ports, and escalating freight costs. During the fourth quarter of 2021, these supply chain disruptions escalated, and we are facing increased supply chain constraints, notably with the transportation of Tablo cartridges from our contract manufacturing partner in Southeast Asia. As a result, we have faced, and may continue to face, increased transportation and related costs associated with delivering adequate supply of Tablo treatments to our customers. In the fourth quarter of 2021, we have qualified a second source to increase Tablo cartridge production through a new manufacturing partner in Mexico. While we anticipate that this second source will help mitigate supply chain challenges and reduce the need for costly and capacity-constrained air freight delivery of the cartridges, there is no assurance that we will not continue to face supply chain constraints. Continued escalation of these supply chain disruptions and a sustained rise in freight costs could negatively impact our ability to meet customer demand on a timely basis, result in customer dissatisfaction and adversely impact our operating margins and results of operations.

Moreover, healthcare providers (including our existing and prospective customers) are facing a nationwide shortage of qualified nurses and other clinical personnel due to long-term trends that have been exacerbated by the COVID-19 pandemic. As competition for these healthcare professionals has intensified, and providers are facing increased difficulties attracting and retaining skilled clinical personnel, resulting in increased costs, staffing shortages and other disruptions. These challenging labor market conditions in the healthcare industry have been heightened by the increased demand for, and demand upon, nurses and other staff resulting from the ongoing pandemic. We believe Tablo offers automation and ease-of-use benefits over traditional machines that can enhance our existing and potential customers’ ability to support their patient populations despite staffing shortages. However, there is also a risk that the increased costs and other disruptions caused by the shortage of dialysis nurses, technicians and other staff could

78


 

cause existing or prospective customers delay continued investment in or adoption of new technologies and postpone purchasing decisions. If our customers continue to face prolonged volatility, uncertainty, and staffing shortages, whether due to the pandemic or otherwise, it could ultimately adversely impact our ability to expand existing customer relationships or attract new customers of Tablo, and have a material adverse effect on our revenues, results of operations, and future growth.

How long the pandemic, and measures intended to contain the spread of COVID-19, will continue remains uncertain and depends on ongoing developments, including but not limited to any resurgences of the virus including emerging variant strains such as the Delta and Omicron variants, federal, state, and local government actions taken in response, and continued availability, effectiveness and public acceptance of COVID-19 vaccines. Additionally, the duration and severity of disruptions in the global supply chain, largely driven by high demand as the economy reopens and the ongoing impact of the pandemic, also remain uncertain and depend on various factors, including the effectiveness of recent government actions intended to mitigate these disruptions. As a result, we cannot predict what effect COVID-19, the associated containment measures, and the related supply chain disruptions will ultimately have on our business and results of operations, on our customers, or on our suppliers and vendors, in particular for any of our suppliers and vendors that may not qualify as essential businesses and suffer more significant or lengthier disruptions to their business operations. There is no assurance that we will not experience more significant disruptions in our supply chain in the future, particularly if the operations of our contract manufacturing partners, our critical single-source component providers, or the facility we operate in Tijuana, Mexico in collaboration with TACNA, are more severely impacted by the pandemic and associated containment measures.

Components of Operating Results

Revenue

We generate our revenue primarily from the sale of products and services. In addition, we enter into console operating lease arrangements that contain lease and non-lease components. Revenue related to lease arrangements is allocated to the lease and non-lease elements based on their relative standalone selling price, with the lease component recorded in product revenue and the non-lease component recorded in service and other revenue. Our product and services revenue are generated primarily through direct sales to customers in the United States.

Product Revenue

We generate product revenue from the sale, and to a lesser extent, leasing of our Tablo consoles and the sale of related consumables, including the Tablo cartridges. Our Tablo consoles and consumables are generally sold without the right of return. Revenue is recognized when control of our Tablo consoles is transferred, generally upon shipment, and excludes the value of the initial service agreement, which is recognized as service and other revenue over the term of the initial service agreement. Revenue is recognized net of any sales incentive, rebates and any taxes collected from customers. Leases of Tablo consoles are considered operating leases and recognized as revenue over their lease term. Consumables, including the Tablo cartridges, are recognized primarily upon shipment.

Service and Other Revenue

We generate service revenue primarily from service agreements for our Tablo consoles and other revenue from shipping and handling charged to customers. Under the service agreements, we provide maintenance, repair and training services, connectivity to our cloud infrastructure, including TabloHub, as well as software updates, when and if available, for Tablo consoles. The service agreements are typically entered into for a one-year term. Revenue from the sale of service agreements, including the revenue associated with the first-year service, is recognized ratably over the service period.

Cost of Revenue

Cost of Product Revenue

Cost of product revenue primarily consists of finished goods, inbound freight costs, and manufacturing costs incurred in the production process including personnel and related costs, costs of component materials, manufacturing overhead, and allocated costs including facilities and information technology. We plan to grow our manufacturing workforce as well as expand our manufacturing capabilities to support our growth. In addition, cost of product revenue includes warranty costs and provisions for excess and obsolete inventory. Cost of product revenue in absolute dollars will increase as our sales volume increases.

79


 

Cost of Service and Other Revenue

Cost of service and other revenue primarily consists of personnel and related costs and component costs incurred in connection with our obligations under our service agreements. We plan to invest in personnel to support the expansion of our Tablo fleet while also utilizing our cloud-based data system, as well as enhanced product performance, to lower the cost of service as a percentage of revenue. Cost of service and other revenue in absolute dollars will increase as our sales volume increases.

Gross Profit and Gross Margin

We calculate gross margin as gross profit divided by total revenue. Our gross profit has been and will continue to be, affected by a variety of factors, including market conditions that may impact our pricing; sales mix changes among Tablo consoles, consumables and services; excess and obsolete inventories; our cost structure for manufacturing operations relative to volume; inbound freight costs, and product warranty obligations. We expect our margin to increase over the long term to the extent we are successful in our ability to lower the costs associated with the production of the Tablo console and consumables. We continue to use our design, engineering and manufacturing capabilities to further advance and improve the efficiency of our manufacturing processes, which, if successful, we believe will lower production costs and enable us to increase our gross margin. While we expect gross margin to increase over the long term, we also anticipate it will likely fluctuate from quarter to quarter.

Operating Expenses

Research and Development

Research and development expenses primarily consist of compensation and personnel costs, consulting services, laboratory supplies and materials expenses, and allocated costs including facilities and information technology.

We plan to continue to invest in our research and development efforts, including hiring additional employees, to enhance existing products and develop new products. As a percentage of revenue, we expect research and development expenses to vary over time, depending on the level and timing of the enhancement of the existing products and new product development initiatives.

Sales and Marketing

Sales and marketing expenses primarily consist of compensation and personnel costs, marketing and promotional activities, government affairs, costs of outside consultants, travel and customer services costs, and allocated costs including facilities and information technology. Shipping and handling costs, as well as the associated personnel expenses, are included in sales and marketing expenses.

As we continue to drive the expansion of Tablo, we expect to continue to invest in our sales and support teams, marketing, and shipping and handling costs. As a result, we expect sales and marketing expenses to increase in absolute dollars in future periods. As a percentage of revenue, however, we expect sales and marketing expenses to continue to decrease over the long-term primarily as and to the extent our revenue grows.

General and Administrative

General and administrative expenses primarily consist of compensation and personnel costs, accounting and legal expenses, regulatory fees, general corporate expenses and allocated costs including facilities and information technology.

We expect to incur additional general and administrative expenses due to increased costs for accounting, human resources, legal, insurance and investor relations. We expect to continue our hiring in all these areas in line with the continued growth of our business. We also expect allocated facilities costs to increase in future periods as a result of higher costs associated with the expansion of our operations. As a result of these and other initiatives, we expect general and administrative expenses to vary from period to period and increase in absolute dollars in future periods. However, as a percentage of revenue, we expect general and administrative expenses to decrease over the long-term primarily as, and to the extent, our revenue grows.

We expect our stock-based compensation expense allocated to cost of revenue, research and development expenses, sales and marketing expenses, and general and administrative expenses to increase in absolute dollars due primarily to potential increases in the value of our common stock and as we issue additional stock-based awards under our equity incentive plan and employee stock purchase plan to attract and retain employees.

80


 

Interest Income and Other Income, Net

Interest income and other income, net, primarily consists of interest earned on our cash and cash equivalents and short-term investments.

Interest Expense

Interest expense consists of interest on our debt and amortization of associated debt discount. See Note 7 to the financial statements for further details.

Change in Fair Value of Redeemable Convertible Preferred Stock Warrant Liability

In connection with our prior credit agreements and the Perceptive Term Loan Agreement, we issued warrants to purchase shares of our Series A, Series B and Series C redeemable convertible preferred stock to the respective lenders. We classified these warrants as a liability on our balance sheets that were remeasured to fair value at each reporting date with the corresponding change in fair value recognized in our statements of operations. Upon the completion of our IPO in 2020, the redeemable convertible preferred stock warrant liability was reclassified to additional paid-in capital.

Loss on Extinguishment of Term Loan

Loss on extinguishment of term loan is related to the repayment of the Perceptive Term Loan in July 2020, which included early prepayment and exit fees.

Provision for Income Taxes

Provision for income taxes primarily consists of foreign taxes in Mexico and state taxes in the United States. We have a full valuation allowance for deferred tax assets, including net operating loss carryforwards and tax credits related primarily to research and development.

81


 

Results of Operations

In this section, we discuss the results of our operations for the year ended December 31, 2021 compared to the year ended December 31, 2020.

The following table sets forth, for the years indicated, our results of operations (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Revenue:

 

 

 

 

 

 

 

 

 

Product revenue

 

$

84,312

 

 

$

39,612

 

 

$

13,750

 

Service and other revenue

 

 

18,290

 

 

 

10,323

 

 

 

1,328

 

Total revenue

 

 

102,602

 

 

 

49,935

 

 

 

15,078

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

 

84,639

 

 

 

57,035

 

 

 

27,164

 

Cost of service and other revenue

 

 

10,355

 

 

 

5,937

 

 

 

5,716

 

Total cost of revenue

 

 

94,994

 

 

 

62,972

 

 

 

32,880

 

Gross profit

 

 

7,608

 

 

 

(13,037

)

 

 

(17,802

)

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

 

36,741

 

 

 

28,850

 

 

 

23,327

 

Sales and marketing

 

 

65,070

 

 

 

45,068

 

 

 

20,259

 

General and administrative

 

 

36,316

 

 

 

30,512

 

 

 

8,919

 

Total operating expenses

 

 

138,127

 

 

 

104,430

 

 

 

52,505

 

Loss from operations

 

 

(130,519

)

 

 

(117,467

)

 

 

(70,307

)

Interest income and other income, net

 

 

498

 

 

 

526

 

 

 

2,485

 

Interest expense

 

 

(1,715

)

 

 

(2,891

)

 

 

(4,257

)

Change in fair value of redeemable convertible preferred stock
   warrant liability

 

 

 

 

 

(93

)

 

 

3,800

 

Loss on extinguishment of term loan

 

 

 

 

 

(1,567

)

 

 

 

Loss before provision for income taxes

 

 

(131,736

)

 

 

(121,492

)

 

 

(68,279

)

Provision for income taxes

 

 

199

 

 

 

 

 

 

20

 

Net loss

 

$

(131,935

)

 

$

(121,492

)

 

$

(68,299

)

Revenue

 

 

Years Ended December 31,

 

 

Change

 

(dollars in thousands)

 

2021

 

 

2020

 

 

$

 

 

%

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

$

84,312

 

 

$

39,612

 

 

$

44,700

 

 

 

113

%

Service and other revenue

 

 

18,290

 

 

 

10,323

 

 

 

7,967

 

 

 

77

%

Total revenue

 

$

102,602

 

 

$

49,935

 

 

 

52,667

 

 

 

105

%

Product revenue increased by $44.7 million, or 113%, for the year ended December 31, 2021 as compared to the prior year. The increase was primarily due to a $32.3 million increase in console revenue and a $12.4 million increase in consumables revenue. The increase in consoles revenue was driven by new customer adoption, fleet expansion across existing customer sites, a higher average selling price, and an increase in console leasing revenue. The increase in consumables revenue was driven by the growth in our Tablo installed base.

Service and other revenue increased by $8.0 million, or 77%, for the year ended December 31, 2021 as compared to the prior year. The increase was primarily due to services associated with our larger Tablo installed base, including leased consoles.

82


 

Cost of Revenue, Gross Profit and Gross Margin

 

 

Years Ended December 31,

 

 

Change

 

(dollars in thousands)

 

2021

 

 

2020

 

 

$

 

 

%

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

$

84,639

 

 

$

57,035

 

 

$

27,604

 

 

 

48

%

Cost of service and other revenue

 

 

10,355

 

 

 

5,937

 

 

 

4,418

 

 

 

74

%

Total cost of revenue

 

$

94,994

 

 

$

62,972

 

 

 

32,022

 

 

 

51

%

Gross profit

 

 

7,608

 

 

 

(13,037

)

 

 

20,645

 

 

 

158

%

Gross margin

 

 

7.4

 

%

 

(26.1

)

%

 

 

 

 

 

The total cost of revenue increased by $32.0 million, or 51%, for the year ended December 31, 2021 as compared to the prior year. This increase was primarily due to growth in sales volume. Gross profit increased by $20.6 million, or 158%, for the year ended December 31, 2021 as compared to the prior year. The gross margin percentage improved by 33.5 percentage points for the year ended December 31, 2021 as compared to the prior year. This improvement in gross profit and gross margin was primarily driven by the impact of our cost reduction activities and higher average selling prices.

During the fourth quarter of 2021, supply chain disruptions driven primarily by the ongoing COVID-19 pandemic escalated, and we are facing increased supply chain constraints, most notably with the transportation of the Tablo cartridges from our contract manufacturing partner in Southeast Asia. As a result, we have faced, and may continue to face, increased transportation and related costs associated with delivering adequate supply of Tablo treatments to our customers. In the fourth quarter of 2021, we have qualified a second source to increase Tablo cartridge production through a new manufacturing partner in Mexico. While we anticipate that this second source will help mitigate supply chain challenges and reduce the need for costly and capacity-constrained air freight delivery of the cartridges, there is no assurance that we will not continue to face supply chain constraints. Continued escalation of these supply chain disruptions and a sustained rise in freight costs could negatively impact our gross margin in future periods.

Operating Expenses

 

 

Years Ended December 31,

 

 

Change

 

(dollars in thousands)

 

2021

 

 

2020

 

 

$

 

 

%

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

36,741

 

 

$

28,850

 

 

$

7,891

 

 

 

27

%

Sales and marketing

 

 

65,070

 

 

 

45,068

 

 

 

20,002

 

 

 

44

%

General and administrative

 

 

36,316

 

 

 

30,512

 

 

 

5,804

 

 

 

19

%

Total operating expenses

 

$

138,127

 

 

$

104,430

 

 

 

33,697

 

 

 

32

%

Research and development expenses increased by $7.9 million, or 27%, for the year ended December 31, 2021 as compared to the prior year. The increase was primarily due to a $4.5 million increase in consulting services, a $3.4 million net increase in compensation and personnel costs as a result of increased headcount, which includes a $4.2 million increase in compensation offset by a $0.8 million decrease in stock-based compensation expense due to the one-time cumulative expense related to stock options with performance and market-based vesting conditions in 2020, and a $0.4 million increase in travel expenses. The increases were partially offset by a $0.4 million decrease in supplies and materials.

Sales and marketing expenses increased by $20.0 million, or 44% for the year ended December 31, 2021 as compared to the prior year. The increase was primarily due to a $13.3 million increase in compensation and personnel costs as a result of increased headcount, which includes a $1.5 million increase in stock-based compensation expense, a $2.2 million increase in clinical sales consultant and professional services, a $2.1 million increase in allocated costs for facilities and information technology to support the general expansion of our operations, a $1.7 million increase in travel expenses, and a $0.7 million increase in distribution expenses related to increased sales volume and freight costs.

General and administrative expenses increased by $5.8 million, or 19%, for the year ended December 31, 2021 as compared to the prior year. The increase was primarily due to a $2.5 million increase in insurance costs, a $1.7 million net increase in compensation and personnel costs as a result of increased headcount, which includes a $6.4 million increase in compensation offset by a $4.7 million decrease in stock-based compensation expense due to the one-time cumulative expense related to stock options with performance and market-based vesting conditions in 2020, a $0.7 million increase in professional and consulting services and a $0.8 million increase in allocated costs for facilities and information technology to support the general expansion of our operations.

83


 

Other Income (Expenses), Net

 

 

Years Ended December 31,

 

 

Change

 

(dollars in thousands)

 

2021

 

 

2020

 

 

$

 

 

%

 

Other Income (Expenses), Net:

 

 

 

 

 

 

 

 

 

 

 

 

Interest income and other income, net

 

$

498

 

 

$

526

 

 

$

(28

)

 

 

(5

)%

Interest expense

 

 

(1,715

)

 

 

(2,891

)

 

 

1,176

 

 

 

(41

)%

Change in fair value of redeemable convertible preferred
  stock warrant liability

 

 

 

 

 

(93

)

 

 

93

 

 

*

 

Loss on extinguishment of term loan

 

 

 

 

 

(1,567

)

 

 

1,567

 

 

*

 

Total other expenses, net

 

$

(1,217

)

 

$

(4,025

)

 

 

2,808

 

 

 

(70

)%

* Not meaningful

 

 

 

 

 

 

 

 

 

 

 

 

Interest income and other income, net, for the year ended December 31, 2021 was relatively consistent with the prior year amount.

Interest expense decreased by $1.2 million, or 41%, for the year ended December 31, 2021 as compared to the prior year. The decrease was driven primarily by a lower interest rate under the SVB Term Loan as compared to the rate under the Perceptive Term Loan, which we voluntarily repaid in the prior year.

The change in the fair value of redeemable convertible preferred stock warrant liability was driven by the changes in assumptions used to value the warrant liability. Upon the closing of our IPO in the third quarter of 2020, all shares of our outstanding redeemable convertible preferred stock warrants were either exercised into common stock or automatically converted into warrants to purchase common stock. Accordingly, we have ceased to incur the change in fair value of redeemable convertible preferred stock warrant liability as the entire redeemable convertible preferred stock warrant liability was reclassified to additional paid-in capital.

The loss on extinguishment of term loan of $1.6 million was recognized for the repayment of the Perceptive Term Loan in the prior year, which included early prepayment and exit fees.

Liquidity and Capital Resources

Sources of Liquidity

As of December 31, 2021, the Company had cash, cash equivalents, and short-term investments of $339.5 million, which are available to fund future operations, and restricted cash of $33.3 million.

Since our inception, we have incurred net losses and negative cash flows from operations. To date, we have financed our operations and capital expenditures primarily through sales of redeemable convertible preferred stock and common stock, revenue from sales, debt financings, and proceeds from stock option exercises and employee stock purchases. In September 2020, we completed our IPO for aggregate net proceeds of approximately $254.8 million (inclusive of the full exercise of the underwriters’ option to purchase additional shares), net of offering costs, underwriter discounts and commissions of approximately $23.1 million. In April 2021, we completed a follow-on public offering for aggregate net proceeds of approximately $149.1 million, after deducting offering costs, underwriting discounts and commissions of $8.5 million.

We expect to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while we make investments to support our anticipated growth. We may raise additional capital through the issuance of additional equity financing, debt financings, including through refinancing our existing debt, or other sources. If this financing is not available to us at adequate levels or on acceptable terms, we may need to reevaluate our operating plans. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. We believe that our existing cash, cash equivalents and short-term investments, and cash generated from sales of our products and services, will be sufficient to meet our anticipated needs for at least the next 12 months from the date of this Annual Report.

84


 

Cash Flows Summary

The following table summarizes the cash flows for each of the periods indicated (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Net cash (used in) provided by:

 

 

 

 

 

 

 

 

 

Operating activities

 

$

(130,264

)

 

$

(99,015

)

 

$

(70,292

)

Investing activities

 

 

(142,507

)

 

 

3,947

 

 

 

74,297

 

Financing activities

 

 

160,147

 

 

 

385,682

 

 

 

249

 

Net (decrease) increase in cash, cash equivalents and restricted cash

 

$

(112,624

)

 

$

290,614

 

 

$

4,254

 

Operating Activities

Net cash used in operating activities of $130.3 million for the year ended December 31, 2021 was due to a net loss of $131.9 million and a net cash outflow from the change in our operating assets and liabilities of $25.6 million, partially offset by the primary non-cash adjustments for stock-based compensation expense of $17.4 million, depreciation and amortization of $5.2 million, accretion of discount on investments of $2.0 million, non-cash lease expense of $1.0 million, provision for inventories of $1.0 million, and non-cash interest expense of $0.6 million. The net cash outflow from operating assets and liabilities was primarily due to an increase in inventories due to the timing of inventory purchases including advance purchases of inventory to meet anticipated demand and to mitigate supply chain disruptions, an increase in accounts receivable due to timing of collections, a decrease in accounts payable due to timing of vendor payments and a decrease in operating lease liabilities. The net cash outflow from operating assets and liabilities was partially offset by an increase in accrued payroll and related benefits due to an increase in headcount, an increase in accrued expenses and other current liabilities, an increase in deferred revenue due to the growth of our business, a decrease in prepaid expenses and other assets and an increase in accrued warranty liability.

The net cash used in operating activities of $99.0 million for the year ended December 30, 2020 was due to a net loss of $121.5 million and a net cash outflow from the change in our operating assets and liabilities of $5.8 million, which were partially offset by the primary non-cash adjustments for stock-based compensation expense of $21.4 million, depreciation and amortization of $3.2 million, loss on extinguishment of term loan of $1.6 million, non-cash interest expense of $0.6 million, and non-cash lease expense of $0.6 million, provision for inventories of $0.5 million, and loss on disposal of property and equipment of $0.2 million. The net cash outflow from operating assets and liabilities was primarily due to an increase in inventories due to the timing of inventory purchases including advance purchases of inventory to meet anticipated demand, an increase in prepaid expenses and other assets, an increase in accounts receivable due to timing of collections and a decrease in accrued interest. The net cash outflow from operating assets and liabilities was partially offset by an increase in accrued payroll and related benefits due to an increase in headcount, an increase in accrued expenses and other current liabilities due to the growth of our business, an increase in deferred revenue, an increase in accrued warranty liability, and an increase in accounts payable due to timing of vendor payments.

Investing Activities

Net cash used in investing activities of $142.5 million for the year ended December 31, 2021 was due primarily to purchases of investment securities of $178.4 million and purchases of property and equipment of $3.1 million, partially offset by the sales and maturities of investment securities of $39.0 million.

Net cash provided by investing activities of $3.9 million for the year ended December 31, 2020 was due primarily to the sales and maturities of short-term investments of $45.9 million, partially offset by the purchases of investment securities of $32.9 million and purchases of property and equipment of $9.1 million.

Financing Activities

Net cash provided by financing activities of $160.1 million for the year ended December 31, 2021 was due primarily to the net proceeds of $149.1 million from the issuance of our common stock in our follow-on offering and the proceeds of $11.1 million from employee exercises of stock options and employee stock purchase plan purchases.

Net cash provided by financing activities of $385.7 million for the year ended December 31, 2020 was due primarily to the net proceeds of $254.8 million from the issuance of our common stock in our IPO, net of issuance costs, the net proceeds of $126.8 million from the issuance of our Series E redeemable convertible preferred stock, the net proceeds of $29.6 million from borrowings on the SVB Loan and Security Agreement, proceeds of $4.3 million from the exercise of the Series C redeemable convertible

85


 

preferred stock warrants, and proceeds of $1.2 million from the issuance of common stock from exercises of stock options, partially offset by the cash outflow of $31.0 million in repayment of the Perceptive Term Loan which included early prepayment and exit fees.

Debt Obligations

We entered into the SVB Loan and Security Agreement with SVB in July 2020, which provides for a $30.0 million term loan (the SVB Term Loan). We used the SVB Term Loan proceeds to repay in full all amounts due under the Perceptive Term Loan and cash on hand to pay $1.2 million in early prepayment, accrued interest and exit fees.

The SVB Term Loan matures on November 1, 2025. Payments under the SVB Term Loan are for interest only through May 2023, and then 30 monthly principal and interest payments from June 2023 until maturity. The SVB Term Loan bears interest at a rate per annum equal to the greater of (A) 0.50% above the Prime Rate as reported in the Wall Street Journal then in effect (which shall not be less than zero) and (B) 3.75%.

There is also a final payment equal to 6.75% of the original principal amount of the SVB Term Loan, or approximately $2.0 million, due at maturity (or any earlier date of optional pre-payment or acceleration of principal due to an event of default). We may, at our option, prepay the SVB Term Loan in full, subject to an additional prepayment fee ranging between 1% and 3% of the outstanding principal amount of the SVB Term Loan. The prepayment fee would also be due and payable in the event of an acceleration of the principal amount of the supplemental term loan due to an event of default. The SVB Term Loan is secured by substantially all of our assets, including all of the capital stock held by us, if any (subject to a 65% limitation on pledges of capital stock of foreign subsidiaries), subject to certain exceptions.

In the event of default or change in control, all unpaid principal and all accrued and unpaid interest amounts (if any) become immediately due and payable including the prepayment fee. Events of default include, but are not limited to, a payment default, a material adverse change, and insolvency. The SVB Loan and Security Agreement contains customary representations, warranties, affirmative covenants and also contains certain restrictive covenants, including, among others, limitations on: the incurrence of additional debt, liens on property, acquisitions and investments, loans and guarantees, mergers, consolidations, liquidations and dissolutions, asset sales, dividends and other payments in respect of our capital stock, prepayments of certain debt, transactions with affiliates and changes to our type of business, management of the business, control of the business or business locations. We are also obligated to maintain a restricted cash balance greater or equal to the outstanding principal balance of $30.0 million of the SVB Term Loan.

Critical Accounting Policies and Estimates

Our financial statements have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses incurred during the reporting periods. The estimates are based on historical experience and on various other factors that are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.

While the significant accounting policies are more fully described in Note 2 to our audited financial statements included elsewhere in this Annual Report, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.

Revenue Recognition

We generate our revenue primarily from contracts with customers for the sale of products and services. Each customer contract defines our distinct performance obligations. Revenue is recognized when a performance obligation is satisfied. Revenue from product sales is recognized at a point in time when management has determined that control has transferred to the customer, which is generally when legal title has transferred to the customer. Certain contracts include variable consideration such as rebates, revenue for such contracts is recognized only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Revenue from service contracts is recognized over time as the service is performed, typically evenly over the contract term. Revenue is recognized net of any taxes collected from customers, which are subsequently remitted to governmental authorities.

Our contracts with customers often include multiple performance obligations. For such contracts, we allocate the contracted transaction price to each performance obligation based upon the relative standalone sale prices (SSP). We determine the SSP based

86


 

upon the facts and circumstances of each performance obligation (product or services), which often requires management's judgement. We use an observable price to estimate SSP for items that are sold separately, including customer service agreements. In instances where SSP is not directly observable, such as when we do not sell the product or service separately, we determine the SSP using information that may include market conditions and other observable inputs. We may offer additional goods or services to customers at the inception of customer contracts at prices not at SSP. If such contracts result in a material right, we allocate part of the transaction price to that right and recognize the associated revenue when those future goods and services are transferred to the customer. SSP is assigned based on the estimated value of the material right.

Stock-Based Compensation Expense

Our stock-based compensation expense relates to stock options with a service-based vesting condition, stock options with performance and market-based vesting conditions, stock purchase rights under our Employee Stock Purchase Plan (ESPP), restricted stock units (RSUs) and performance stock units (PSUs). Stock-based compensation expense for our stock-based awards is based on their grant date fair value. We estimate the fair value of stock options with a service condition and stock purchase rights under our ESPP on the grant date using the Black-Scholes option-pricing model. The fair value of these awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur.

The Black-Scholes model considers several variables and assumptions in estimating the fair value of service-based stock options and stock purchase rights under our ESPP. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and expected stock price volatility over the expected term. For all stock options granted, we calculate the expected term using the simplified method for “plain vanilla” stock option awards. We had no publicly available stock price information prior to our IPO and limited available stock price information subsequent to our IPO; therefore, we have used the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled award.

For stock options with performance- and market-based vesting conditions, stock-based compensation expense begins to be recognized over the remaining service period when it is considered probable that the performance vesting condition will be satisfied. Prior to our IPO in September 2020, we had not recognized any stock-based compensation expense as the satisfaction of the performance condition was not considered probable. Upon the closing of our IPO, we recorded a cumulative stock-based compensation expense using the accelerated attribution method as the performance condition was satisfied. Stock-based compensation expense related to these options is not reversed if the achievement of the market-based vesting condition does not occur. The fair value of these stock options is estimated using the Monte Carlo simulation model.

The fair value of RSUs and PSUs with service- or performance-based vesting conditions is based on the market price of our common stock on the date of grant. The determination of the stock-based compensation expense related to PSUs with performance-based vesting conditions to be recognized requires the use of certain estimates and assumptions. At each reporting period, we reassess the probability of the achievement of corporate performance goals to estimate the number of shares to be released. Any increase or decrease in stock-based compensation expense resulting from an adjustment in the estimated shares to be released is treated as accumulative catch-up in the period of adjustment. If any of the assumptions or estimates used change significantly, stock-based compensation expense may differ materially from what we have recorded in the current period. The fair value of PSUs with market-based vesting conditions is estimated using the Monte Carlo simulation model. Stock-based compensation expense related to these PSUs is recognized using the accelerated attribution method and not reversed if the achievement of the market conditions does not occur.

Inventories

Inventory is stated at the lower of cost or net realizable value, with approximate costs determined on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The carrying value of inventories is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods.

Recent Accounting Pronouncements

Refer to Note 2, “Summary of Significant Accounting Policies” in our audited financial statements included in Part II, Item 8 of this Annual Report for a discussion of recent accounting pronouncements that may impact us.

87


 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Risk

Our cash, cash equivalents, restricted cash and short-term investments are held in bank deposits, money market funds, U.S. Treasury and debt securities. Such interest-earning instruments carry a degree of interest rate risk. The goals of our investment policy are liquidity and capital preservation; we do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate exposure. We believe that we do not have any material exposure to changes in the fair value of these assets as a result of changes in interest rates due to the short-term nature of our cash, cash equivalents and short-term investments.

As of December 31, 2021, we had $30.0 million in variable rate debt outstanding. The SVB Term Loan matures on November 1, 2025. Payments under the SVB Term Loan are for interest only through May 2023, and then 30 monthly principal and interest payments from June 2023 until maturity. The SVB Term Loan bears interest at a rate per annum equal to the greater of (A) 0.50% above the Prime Rate as reported in the Wall Street Journal then in effect (which shall not be less than zero) and (B) 3.75%. An immediate 100 basis point change in the prime rate would not have a material impact on our debt-related obligations, financial position or results of operations.

Foreign Currency Exchange Risk

Our expenses are generally denominated in USD. However, as certain of our Mexico-based manufacturing operations incur costs that are denominated in MXN, we are exposed to the risk of currency fluctuations between USD and MXN. To date, foreign currency transaction gains and losses have not been material to our financial statements.

Unfavorable changes in foreign exchange rates versus USD could increase our product costs, thus reducing our gross profit. We have not engaged in the hedging of foreign currency transactions to date, although we may choose to do so in the future. We do not believe that an immediate 10% increase or decrease in the relative value of USD to other currencies would have a material effect on operating results or financial condition.

 

88


 

Item 8. Financial Statements and Supplementary Data.

Outset Medical, Inc.

Index to Financial Statements

 

 

Page

 

 

Report of Independent Registered Public Accounting Firm

90

Balance Sheets

92

Statements of Operations

93

Statements of Comprehensive Loss

94

Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

95

Statements of Cash Flows

96

Notes to Financial Statements

98

 

89


 

Report of Independent Registered Public Accounting Firm

 

 

To the Stockholders and Board of Directors

Outset Medical, Inc.:

Opinions on the Financial Statements and Internal Control Over Financial Reporting

We have audited the accompanying balance sheets of Outset Medical, Inc. (the Company) as of December 31, 2021 and 2020, the related statements of operations, comprehensive loss, redeemable convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the financial statements). We also have audited the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021 based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

Basis for Opinions

The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s financial statements and an opinion on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

90


 

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Identification of performance obligations in certain revenue contracts

As discussed in Note 3 to the financial statements, the Company recorded $102,602 thousand of total revenues for the year ended December 31, 2021, of which $84,312 thousand related to product revenue, and $18,290 thousand related to service and other revenue. As discussed in Note 2 to the financial statements, the Company’s revenue is generated primarily from the sale of its products and services and contracts often include multiple performance obligations. Product revenue consists primarily of sales of the Tablo console and related consumables, including Tablo cartridges, used in treatment delivery. Service and other revenue consists primarily of revenue generated from console service contracts and other revenue from shipping and handling charged to customers. When a contract includes multiple performance obligations, determining whether the products and services are considered distinct performance obligations that should be accounted for separately may require significant judgment by management.

We identified the evaluation of the Company’s identification of performance obligations in certain revenue contracts with customers as a critical audit matter. Evaluating whether the Company’s promises to transfer products or services are distinct performance obligations that should be accounted for separately required subjective auditor judgment due to the varying nature of the underlying promises and the associated contract terms.

The following are the primary procedures we performed to address the critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company’s revenue recognition process, including a control related to the Company’s review of customer contracts for the identification of performance obligations. In addition, for a sample of the Company’s recorded revenue, we evaluated the identification of performance obligations by reading the contract to understand its terms and conditions and considering the nature of the promises within the contract, and whether the promises were distinct from other promised goods and services.

/s/ KPMG LLP

We have served as the Company's auditor since 2011.

San Francisco, California

February 23, 2022

91


 

Outset Medical, Inc.

Balance Sheets

(in thousands, except per share amounts)

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

182,348

 

 

$

294,972

 

Short-term investments

 

 

157,140

 

 

 

19,898

 

Accounts receivable, net

 

 

25,600

 

 

 

6,468

 

Inventories

 

 

39,185

 

 

 

18,384

 

Prepaid expenses and other current assets

 

 

5,529

 

 

 

6,189

 

Total current assets

 

 

409,802

 

 

 

345,911

 

Restricted cash

 

 

33,311

 

 

 

33,311

 

Property and equipment, net

 

 

12,964

 

 

 

14,998

 

Operating lease right-of-use assets

 

 

7,231

 

 

 

8,253

 

Other assets

 

 

156

 

 

 

1,356

 

Total assets

 

$

463,464

 

 

$

403,829

 

Liabilities and stockholders' equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

1,763

 

 

$

4,948

 

Accrued compensation and related benefits

 

 

24,948

 

 

 

16,845

 

Accrued expenses and other current liabilities

 

 

13,789

 

 

 

7,903

 

Accrued warranty liability

 

 

3,704

 

 

 

2,913

 

Deferred revenue, current

 

 

6,340

 

 

 

3,201

 

Operating lease liabilities, current

 

 

1,151

 

 

 

882

 

Total current liabilities

 

 

51,695

 

 

 

36,692

 

Accrued interest, noncurrent

 

 

721

 

 

 

240

 

Deferred revenue, noncurrent

 

 

312

 

 

 

570

 

Operating lease liabilities, noncurrent

 

 

6,893

 

 

 

8,044

 

Term loan, noncurrent

 

 

29,762

 

 

 

29,674

 

Total liabilities

 

 

89,383

 

 

 

75,220

 

Commitments and contingencies (Note 6)

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of December 31, 2021 and 2020

 

 

 

 

 

 

Common stock, $0.001 par value; 300,000 shares authorized as of December 31, 2021 and 2020; 47,241 and 42,722 shares issued and outstanding as of December 31, 2021 and 2020, respectively

 

 

47

 

 

 

43

 

Additional paid-in capital

 

 

1,000,212

 

 

 

822,624

 

Accumulated other comprehensive (loss) income

 

 

(184

)

 

 

1

 

Accumulated deficit

 

 

(625,994

)

 

 

(494,059

)

Total stockholders' equity

 

 

374,081

 

 

 

328,609

 

Total liabilities and stockholders' equity

 

$

463,464

 

 

$

403,829

 

The accompanying notes are an integral part of these financial statements

92


 

Outset Medical, Inc.

Statements of Operations

(in thousands, except per share amounts)

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Revenue:

 

 

 

 

 

 

 

 

 

Product revenue

 

$

84,312

 

 

$

39,612

 

 

$

13,750

 

Service and other revenue

 

 

18,290

 

 

 

10,323

 

 

 

1,328

 

Total revenue

 

 

102,602

 

 

 

49,935

 

 

 

15,078

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

Cost of product revenue

 

 

84,639

 

 

 

57,035

 

 

 

27,164

 

Cost of service and other revenue

 

 

10,355

 

 

 

5,937

 

 

 

5,716

 

Total cost of revenue

 

 

94,994

 

 

 

62,972

 

 

 

32,880

 

Gross profit

 

 

7,608

 

 

 

(13,037

)

 

 

(17,802

)

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

 

36,741

 

 

 

28,850

 

 

 

23,327

 

Sales and marketing

 

 

65,070

 

 

 

45,068

 

 

 

20,259

 

General and administrative

 

 

36,316

 

 

 

30,512

 

 

 

8,919

 

Total operating expenses

 

 

138,127

 

 

 

104,430

 

 

 

52,505

 

Loss from operations

 

 

(130,519

)

 

 

(117,467

)

 

 

(70,307

)

Interest income and other income, net

 

 

498

 

 

 

526

 

 

 

2,485

 

Interest expense

 

 

(1,715

)

 

 

(2,891

)

 

 

(4,257

)

Change in fair value of redeemable convertible preferred stock
   warrant liability

 

 

 

 

 

(93

)

 

 

3,800

 

Loss on extinguishment of term loan

 

 

 

 

 

(1,567

)

 

 

 

Loss before provision for income taxes

 

 

(131,736

)

 

 

(121,492

)

 

 

(68,279

)

Provision for income taxes

 

 

199

 

 

 

 

 

 

20

 

Net loss

 

$

(131,935

)

 

$

(121,492

)

 

$

(68,299

)

 

 

 

 

 

 

 

 

 

 

Net loss attributable to common stockholders, basic and diluted

 

$

(131,935

)

 

$

(79,324

)

 

$

(85,461

)

Net loss per share attributable to common stockholders,
   basic and diluted

 

$

(2.89

)

 

$

(4.85

)

 

$

(99.58

)

Weighted-average shares used in computing net loss per share
   attributable to common stockholders, basic and diluted

 

 

45,589

 

 

 

16,358

 

 

 

858

 

The accompanying notes are an integral part of these financial statements

93


 

Outset Medical, Inc.

Statements of Comprehensive Loss

(in thousands)

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Net loss

 

$

(131,935

)

 

$

(121,492

)

 

$

(68,299

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale securities

 

 

(185

)

 

 

(21

)

 

 

82

 

Comprehensive loss

 

$

(132,120

)

 

$

(121,513

)

 

$

(68,217

)

The accompanying notes are an integral part of these financial statements

94


 

Outset Medical, Inc.

Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(in thousands)

 

 

 

Redeemable Convertible
Preferred Stock

 

 

 

Common Stock

 

 

Additional
Paid-in

 

 

Accumulated
Other
Comprehensive

 

 

Accumulated

 

 

Total
Stockholders’ Equity

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

(Deficit)

 

Balance as of December 31, 2018

 

 

147,214

 

 

 

392,284

 

 

 

 

789

 

 

 

1

 

 

 

 

 

 

(60

)

 

 

(287,891

)

 

 

(287,950

)

Common stock warrant exercises

 

 

 

 

 

 

 

 

 

9

 

 

 

 

 

 

76

 

 

 

 

 

 

 

 

 

76

 

Adjustment to redemption value on redeemable convertible
   preferred stock

 

 

 

 

 

134,760

 

 

 

 

 

 

 

 

 

 

(966

)

 

 

 

 

 

(133,794

)

 

 

(134,760

)

Gain on extinguishment of redeemable convertible preferred stock

 

 

 

 

 

(117,417

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

117,417

 

 

 

117,417

 

Costs to adjust the redemption value on redeemable convertible
  preferred stock

 

 

 

 

 

(181

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock option exercises

 

 

 

 

 

 

 

 

 

124

 

 

 

 

 

 

364

 

 

 

 

 

 

 

 

 

364

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

883

 

 

 

 

 

 

 

 

 

883

 

Unrealized gain on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

82

 

 

 

 

 

 

82

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(68,299

)

 

 

(68,299

)

Balance as of December 31, 2019

 

 

147,214

 

 

 

409,446

 

 

 

 

922

 

 

 

1

 

 

 

357

 

 

 

22

 

 

 

(372,567

)

 

 

(372,187

)

Issuance of Series E redeemable convertible preferred stock,
  net of issuance costs

 

 

57,782

 

 

 

126,758

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of common stock on settlement of accrued dividend

 

 

 

 

 

(41,763

)

 

 

 

4,850

 

 

 

5

 

 

 

41,758

 

 

 

 

 

 

 

 

 

41,763

 

Deemed dividend on settlement of accrued dividend

 

 

 

 

 

(42,530

)

 

 

 

 

 

 

 

 

 

42,530

 

 

 

 

 

 

 

 

 

42,530

 

Adjustment to redemption value on redeemable convertible
  preferred stock

 

 

 

 

 

362

 

 

 

 

 

 

 

 

 

 

(362

)

 

 

 

 

 

 

 

 

(362

)

Issuance of common stock upon net exercises of Series B
  redeemable convertible preferred stock warrants

 

 

 

 

 

 

 

 

 

65

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash exercises of Series C redeemable convertible preferred
  stock warrants

 

 

1,655

 

 

 

4,288

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Conversion of Series A redeemable convertible preferred
  stock warrants to common stock warrants

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,252

 

 

 

 

 

 

 

 

 

1,252

 

Conversion of redeemable convertible preferred stock to common
  stock upon initial public offering

 

 

(206,651

)

 

 

(456,561

)

 

 

 

26,167

 

 

 

26

 

 

 

456,535

 

 

 

 

 

 

 

 

 

456,561

 

Issuance of common stock upon initial public offering,
  net of issuance costs

 

 

 

 

 

 

 

 

 

10,294

 

 

 

10

 

 

 

254,795

 

 

 

 

 

 

 

 

 

254,805

 

Reclassification of redeemable convertible preferred
  stock warrant liability to equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,126

 

 

 

 

 

 

 

 

 

3,126

 

Issuance of common stock for settlement of RSUs

 

 

 

 

 

 

 

 

 

5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock option exercises

 

 

 

 

 

 

 

 

 

419

 

 

 

1

 

 

 

1,194

 

 

 

 

 

 

 

 

 

1,195

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

21,439

 

 

 

 

 

 

 

 

 

21,439

 

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(21

)

 

 

 

 

 

(21

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(121,492

)

 

 

(121,492

)

Balance as of December 31, 2020

 

 

 

 

$

 

 

 

 

42,722

 

 

$

43

 

 

$

822,624

 

 

$

1

 

 

$

(494,059

)

 

$

328,609

 

Issuance of common stock upon follow-on
  public offering, net of issuance costs

 

 

 

 

 

 

 

 

 

2,946

 

 

 

3

 

 

 

149,082

 

 

 

 

 

 

 

 

 

149,085

 

Issuance of common stock through employee stock purchase plan

 

 

 

 

 

 

 

 

 

116

 

 

 

 

 

 

3,434

 

 

 

 

 

 

 

 

 

3,434

 

Issuance of common stock for settlement of RSUs

 

 

 

 

 

 

 

 

 

19

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock option exercises

 

 

 

 

 

 

 

 

 

1,438

 

 

 

1

 

 

 

7,627

 

 

 

 

 

 

 

 

 

7,628

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

17,445

 

 

 

 

 

 

 

 

 

17,445

 

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(185

)

 

 

 

 

 

(185

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(131,935

)

 

 

(131,935

)

Balance as of December 31, 2021

 

 

 

 

$

 

 

 

 

47,241

 

 

$

47

 

 

$

1,000,212

 

 

$

(184

)

 

$

(625,994

)

 

$

374,081

 

 

The accompanying notes are an integral part of these financial statements

95


 

Outset Medical, Inc.

Statements of Cash Flows

(in thousands)

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

Net loss

 

$

(131,935

)

 

$

(121,492

)

 

$

(68,299

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

5,162

 

 

 

3,159

 

 

 

1,484

 

Non-cash lease expense

 

 

1,022

 

 

 

596

 

 

 

451

 

Non-cash interest expense

 

 

569

 

 

 

641

 

 

 

893

 

Accretion (amortization) of discount (premium) on investments, net

 

 

1,972

 

 

 

50

 

 

 

(983

)

Provision for accounts receivable

 

 

5

 

 

 

12

 

 

 

59

 

Provision for inventories

 

 

1,023

 

 

 

534

 

 

 

326

 

Loss on disposal of property and equipment

 

 

76

 

 

 

235

 

 

 

293

 

Stock-based compensation expense

 

 

17,445

 

 

 

21,439

 

 

 

883

 

Change in fair value of redeemable convertible preferred stock warrant liability

 

 

 

 

 

93

 

 

 

(3,800

)

Loss on extinguishment of term loan

 

 

 

 

 

1,567

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(19,137

)

 

 

(2,566

)

 

 

(2,886

)

Inventories

 

 

(22,042

)

 

 

(16,287

)

 

 

(5,020

)

Prepaid expenses and other assets

 

 

1,860

 

 

 

(6,245

)

 

 

(228

)

Accounts payable

 

 

(3,066

)

 

 

737

 

 

 

802

 

Accrued payroll and related benefits

 

 

8,103

 

 

 

9,889

 

 

 

3,119

 

Accrued expenses and other current liabilities

 

 

5,889

 

 

 

4,798

 

 

 

974

 

Accrued warranty liability

 

 

791

 

 

 

1,211

 

 

 

1,410

 

Deferred revenue

 

 

2,881

 

 

 

2,754

 

 

 

735

 

Accrued interest

 

 

 

 

 

(217

)

 

 

 

Operating lease liabilities

 

 

(882

)

 

 

77

 

 

 

(505

)

Net cash used in operating activities

 

 

(130,264

)

 

 

(99,015

)

 

 

(70,292

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(3,108

)

 

 

(9,108

)

 

 

(3,293

)

Purchases of investment securities

 

 

(178,432

)

 

 

(32,884

)

 

 

(91,878

)

Sales and maturities of investment securities

 

 

39,033

 

 

 

45,908

 

 

 

169,468

 

Net cash provided by (used in) investing activities

 

 

(142,507

)

 

 

3,947

 

 

 

74,297

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock upon initial and follow-on
  public offerings, net of issuance costs

 

 

149,085

 

 

 

254,805

 

 

 

 

Proceeds from cash exercise of redeemable convertible preferred stock warrants

 

 

 

 

 

4,288

 

 

 

 

Proceeds from issuance of redeemable convertible preferred stock,
   net of issuance costs

 

 

 

 

 

126,758

 

 

 

 

Proceeds from stock option exercises and employee stock purchase plan purchases

 

 

11,062

 

 

 

1,195

 

 

 

363

 

Proceeds from issuance of term loan, net of issuance costs

 

 

 

 

 

29,630

 

 

 

 

Repayment of term loan and extinguishment costs

 

 

 

 

 

(30,985

)

 

 

 

Repayment of finance lease

 

 

 

 

 

(9

)

 

 

(9

)

Proceeds from exercise of common stock warrant

 

 

 

 

 

 

 

 

76

 

Payment of redeemable convertible preferred stock issuance costs

 

 

 

 

 

 

 

 

(181

)

Net cash provided by financing activities

 

 

160,147

 

 

 

385,682

 

 

 

249

 

Net (decrease) increase in cash, cash equivalents and restricted cash

 

 

(112,624

)

 

 

290,614

 

 

 

4,254

 

Cash, cash equivalents and restricted cash as of beginning of period

 

 

328,283

 

 

 

37,669

 

 

 

33,415

 

Cash, cash equivalents and restricted cash as of end of period

 

$

215,659

 

 

$

328,283

 

 

$

37,669

 

 

 

 

 

 

 

 

 

 

 

Supplemental cash flow disclosures:

 

 

 

 

 

 

 

 

 

Cash paid for income taxes

 

$

83

 

 

$

19

 

 

$

35

 

Cash paid for interest

 

$

1,146

 

 

$

3,270

 

 

$

3,352

 

Cash paid for amounts included in the measurement of operating lease liabilities

 

$

882

 

 

$

 

 

$

505

 

The accompanying notes are an integral part of these financial statements

 

96


 

Outset Medical, Inc.

Statements of Cash Flows

(in thousands)

 

 

 

 

 

 

 

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Supplemental non-cash investing and financing activities:

 

 

 

 

 

 

 

 

 

Capital expenditures included in accounts payable and accrued expenses

 

$

121

 

 

$

323

 

 

$

867

 

Transfer of inventories to property and equipment

 

$

1,410

 

 

$

2,131

 

 

$

3,119

 

Right-of-use assets obtained in exchange for lease liabilities

 

$

 

 

$

8,849

 

 

$

 

Deemed dividend on settlement of accrued dividend

 

$

 

 

$

42,530

 

 

$

 

Adjustment to redemption value on redeemable convertible preferred stock

 

$

 

 

$

362

 

 

$

134,760

 

Conversion of redeemable convertible preferred stock into common stock
  upon initial public offering

 

$

 

 

$

456,561

 

 

$

 

Reclassification of redeemable convertible preferred stock warrant liability
  for conversion of Series A redeemable preferred stock warrants
  into common stock warrants

 

$

 

 

$

1,252

 

 

$

 

Reclassification of redeemable convertible preferred stock warrant liability
  to additional paid-in capital

 

$

 

 

$

3,126

 

 

$

 

Issuance of common stock on settlement of accrued dividend

 

$

 

 

$

41,763

 

 

$

 

Gain on extinguishment of redeemable convertible preferred stock

 

$

 

 

$

 

 

$

117,598

 

Transfer of property and equipment to inventories

 

$

1,192

 

 

$

 

 

$

 

The accompanying notes are an integral part of these financial statements

97


 

Notes to Financial Statements

1. Description of Business

Outset Medical, Inc. is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement designed to transform the dialysis experience for patients and operationally simplify it for providers. Tablo serves as a single enterprise solution designed to be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo to serve as a dialysis clinic on wheels. With a simple-to-use touchscreen interface, two-way wireless data transmission and a proprietary data analytics platform, Tablo is a new holistic approach to dialysis care. The Company’s headquarters are located in San Jose, CA.

The Company’s registration statement on Form S-1 related to its IPO was declared effective by the SEC on September 14, 2020, and the Company’s common stock began trading on the Nasdaq Global Select Market on September 15, 2020. Upon the completion of the IPO, the Company sold 10,294,000 shares of common stock (which included 1,343,000 shares that were sold pursuant to the full exercise of the underwriters’ option to purchase additional shares in connection with the IPO) at a price to the public of $27.00 per share. Including the full exercise of the underwriters’ option to purchase additional shares, the Company received aggregate net proceeds of approximately $254.8 million after deducting offering costs, underwriting discounts and commissions of approximately $23.1 million.

On April 13, 2021, the Company completed a follow-on public offering and sold 2,946,000 shares of common stock (which included 446,000 shares that were offered and sold pursuant to the full exercise of the underwriters’ option to purchase additional shares) at a price to the public of $53.50 per share. The Company received aggregate net proceeds of approximately $149.1 million after deducting offering costs, underwriting discounts and commissions of $8.5 million.

Reverse Stock Split

In September 2020, the Company’s board of directors and shareholders approved a certificate of amendment to the amended and restated certificate of incorporation to effect a reverse split of shares of the Company’s common stock on a 7.9-for-one basis (the Reverse Stock Split) effective as of September 8, 2020. The number of authorized shares and the par values of the common stock and redeemable convertible preferred stock were not adjusted as a result of the Reverse Stock Split. In connection with the Reverse Stock Split, the conversion ratio for the Company’s outstanding redeemable convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. All references to common stock and options to purchase common stock, share data, per share data and related information contained in these financial statements and related notes have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.

Liquidity

Since inception, the Company has incurred net losses and negative cash flows from operations. The Company incurred net losses of $131.9 million, $121.5 million and $68.3 million for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021, the Company had an accumulated deficit of $626.0 million.

As of December 31, 2021, the Company had cash, cash equivalents and short-term investments of $339.5 million, which are available to fund future operations, and restricted cash of $33.3 million. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. Management believes that the Company’s existing cash, cash equivalents and short-term investments, which include the proceeds from the IPO and the follow-on public offering, and cash generated from revenues from its products and services, will be sufficient to meet its anticipated needs for at least the next 12 months from the issuance date of the financial statements.

Basis of Presentation

The financial statements have been prepared in accordance with U.S. GAAP. All share amounts disclosed in the notes to the financial statements are rounded to the nearest thousand except for per share amounts.

98


 

2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, allowance for doubtful accounts, inventory valuation and write-downs, warranty obligations, the fair value of equity awards, the valuation of investments, recoverability of the Company’s net deferred tax assets, and certain accrued expenses. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results may differ from those estimates under different assumptions or conditions and the differences may be material.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, restricted cash, short-term investments and accounts receivable. Substantially all the Company’s cash and cash equivalents, restricted cash, and investments are held at one financial institution in the United States that management believes is of high credit quality. Such investments may, at times, exceed federally insured limits or may not be covered by deposit insurance at all. The Company has not experienced any credit losses on its cash and cash equivalents, restricted cash or short-term investments through December 31, 2021.

For the year ended December 31, 2021, two customers accounted for 30% and 15% of revenues, respectively. For the year ended December 31, 2020, three customers accounted for 22%, 19% and 16% of revenues, respectively. One customer accounted for 11% of revenues for the year ended December 31, 2019. Accounts receivable are unsecured and the Company does not require collateral; however, the Company does assess the collectability of accounts receivable based on a number of factors, including past transaction history with, and the creditworthiness of, the customer. Accordingly, the Company is exposed to credit risk associated with accounts receivable. One customer accounted for 10% of accounts receivable as of December 31, 2021. Two customers accounted for 22% and 16% of accounts receivable, respectively, as of December 31, 2020. To reduce risk, the Company closely monitors the amounts due from its customers and assesses the financial strength of its customers through a variety of methods that include, but are not limited to, engaging directly with customer operations and leadership personnel, visiting customer locations to observe operating activities, and assessing customer longevity and reputation in the marketplace. As a result, the Company believes that its accounts receivable credit risk exposure is limited. A material default in payment or a material reduction in purchases from these or any other large customers could have a material adverse impact on the Company’s financial condition, results of operations, and liquidity.

The Company has a manufacturing facility in Tijuana, Mexico which it operates in collaboration with its outsourced business administration service provider, TACNA, for the production of the Tablo console. The Company is subject to a number of risks associated with operating its Mexico-based manufacturing facility. The manufacturing operations at the facility may suffer disruptions from global or regional public health crises such as the ongoing COVID-19 pandemic, natural disasters, cyber security attacks, vandalism, terrorism or other political hostilities. Any such occurrences could negatively impact the Company’s ability to produce the Tablo console. The Company is also subject to a variety of foreign laws and regulations, including trade and labor restrictions and laws relating to importation, exportation and taxation of goods, and U.S. laws and regulations relating to foreign operations. In addition, because certain of its Mexico-based manufacturing operations incur costs that are denominated in MXN, the Company is exposed to additional risk of currency fluctuations between USD and MXN, which could increase its product and labor costs, thus reducing its gross profit. To date, foreign currency transaction gains and losses have not been material to the Company’s financial statements.

The Company is subject to additional risks and uncertainties due to the COVID-19 pandemic. How long the pandemic, and measures intended to contain the spread of COVID-19, will continue remains uncertain and depends on ongoing developments, including but not limited to any resurgences of the virus including emerging variant strains, federal, state and local government actions taken in response, and continued availability, effectiveness and public acceptance of COVID-19 vaccines, as well as the extent and duration of the effect on the economy and how quickly and to what extent normal economic and operating conditions can resume. Additionally, the duration and severity of disruptions in the global supply chain, largely driven by high demand as the economy reopens and the ongoing impact of the pandemic, also remain uncertain and depend on various factors, including the effectiveness of recent government actions intended to mitigate these disruptions. As a result, the Company cannot predict what effect COVID-19, the associated containment measures and the related supply chain disruptions will ultimately have on its business and result of operations.

While the potential economic impact and duration of the COVID-19 pandemic may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets,

99


 

which could result in a reduction in the Company’s ability to access capital and delays in payments of outstanding receivables that could adversely affect our liquidity. In addition, a recession or market correction resulting from the spread COVID-19 could materially affect the Company's business and financial results. As of the date of issuance of the financial statements, the extent to which the COVID-19 pandemic may materially adversely affect the Company's financial condition, liquidity, or results of operations is uncertain.

Fair Value of Financial Instruments

The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.

The Company classifies financial instruments using a three-tiered fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Management believes that its term loan bears interest at the prevailing market rates for instruments with similar characteristics; accordingly, the carrying value of this instrument approximates its fair value.

Cash Equivalents and Short-Term Investments

The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and are stated at fair value.

The Company primarily holds corporate debt securities, commercial paper, and U.S. Treasury securities, and has the ability, if necessary, to liquidate any of its investments to meet its liquidity needs in the next 12 months, without significant penalty. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term investments on the accompanying balance sheets. Short-term investments have been classified as available-for-sale at the time of purchase. The Company evaluates the appropriate classification of its investments as of each balance sheet date.

The Company’s investment securities are recorded at fair value based on the fair value hierarchy. Money market funds and U.S. Treasury securities are classified within Level 1 of the fair value hierarchy. Other securities are classified within Level 2 of the fair value hierarchy. Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).

A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold.

Accounts Receivable, Net

Accounts receivable are recorded at invoice value, net of any allowance for doubtful accounts. Estimates of the allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of customers and individual customer circumstances. The allowance for doubtful accounts was not significant as of December 31, 2021 and 2020.

Inventories

Inventory is stated at the lower of cost or net realizable value, with approximate costs determined on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The carrying value of inventories is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on the Company’s statements of operations.

100


 

Property and Equipment, Net

Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is generally computed using the straight-line method based on the estimated useful lives of the assets, which is generally two to five years. Certain Tablo consoles under operating leases are depreciated using the accelerated method. Leasehold improvements are amortized using the straight-line method over the shorter of the assets estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to expense as incurred. Significant improvements that substantially enhance the useful life of an asset are capitalized and depreciated. When assets are retired or disposed of, the cost together with related accumulated depreciation is removed from the balance sheet and any resulting gain or loss is reflected in the Company’s statements of operations in the period realized.

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. There were no such impairment losses as of December 31, 2021 and 2020.

Leases

The Company determines if an arrangement is a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term. Operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.

As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. Lease costs for the Company’s operating leases are recognized on a straight-line basis over the reasonably assured lease term. Variable lease payments include lease operating expenses.

The Company has elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.

Accrued Warranty Liability

The Company generally provides a one-year warranty for defective parts and workmanship on its Tablo consoles, commencing upon the transfer of title and risk of loss to the customer. The Company accrues the estimated cost of product warranties when it invoices the customer, based on historical experience and expected results. Should actual product failure rates and material usage costs differ from these estimates, revisions to the estimated warranty liability would be required. The Company periodically assesses the adequacy of its recorded product warranty liabilities and adjusts the balance as required. Warranty expense is recorded as a component of cost of product revenue in the statements of operations.

Contract Liabilities - Deferred Revenue

The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue is recognized subsequent to invoicing. For multi-year service agreements, the Company generally invoices customers annually at the beginning of each annual coverage period. Deferred revenue that will be recognized during the 12 months following the balance sheet date is recorded as the current portion of deferred revenue and the remaining portion is recorded as noncurrent.

Revenue

The Company generates revenue primarily from contracts with customers for the sale of its products and services. Product revenue consists primarily of sales of the Tablo console and related consumables, including Tablo cartridges, used in treatment

101


 

delivery. Service and other revenue consists primarily of revenue generated from consoles service contracts and other revenue from shipping and handling charged to customers.

Each customer contract defines our distinct performance obligations and the associated transaction price for each obligation. Tablo consoles and consumables are generally sold without the right of return. Revenue is recognized when a performance obligation is satisfied. Revenue from product sales is recognized at a point in time when management has determined that control has transferred to the customer, which is generally when legal title has transferred to the customer. Revenue from service contracts is recognized over time as the service is performed, typically evenly over the contract term. Certain contracts include variable consideration such as rebates, revenue for such contracts is recognized only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Revenue is recognized net of any taxes collected from customers, which are subsequently remitted to governmental authorities.

The Company’s contracts with customers often include multiple performance obligations. For such contracts, the Company allocates the contracted transaction price to each performance obligation based upon the relative SSP. The Company determines the SSP based upon the facts and circumstances of each performance obligation (product or services), which often requires management's judgement. The Company uses an observable price to estimate SSP for items that are sold separately, including customer service agreements. In instances where SSP is not directly observable, such as when the Company does not sell the product or service separately, the Company determines the SSP using information that may include market conditions and other observable inputs. The Company may offer additional goods or services to customers at the inception of customer contracts at prices not at SSP. If such contracts result in a material right, the Company allocates part of the transaction price to that right and recognizes the associated revenue when those future goods and services are transferred to the customer. SSP is assigned based on the estimated value of the material right.

Costs associated with product sales include commissions. The Company applies the practical expedient to expense the commissions as incurred as the expected amortization period is one year or less. Commissions are recorded as sales and marketing expenses in the statements of operations.

Operating Lease Arrangements

The Company enters into operating lease arrangements that contain both lease and non-lease elements. The lease element includes Tablo consoles, while non-lease elements include consumables, services and training. Revenue related to such arrangements is allocated to lease and non-lease elements based on their relative SSP. Revenue for the lease element, net of any taxes collected from customers, is recognized on a straight-line basis as product revenue over the lease term, generally three months to one year, in the statements of operations. The costs of the leased Tablo consoles are included in property and equipment, net in the balance sheets and amortized to cost of product revenue.

Shipping and Handling Costs

Shipping and handling charged to customers are recorded as revenue. Shipping and handling costs are expensed as incurred and are included in sales and marketing expenses.

Stock-Based Compensation Expense

Stock-based compensation expense relates to stock options with a service-based vesting condition, stock options with performance and market-based vesting conditions, stock purchase rights under our ESPP, RSUs and PSUs with performance or market-based vesting conditions. Stock-based compensation expense for the Company’s stock-based awards is based on their grant date fair value.

Service-based options granted to an optionee generally vest at a rate of 25% on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining three years. The fair value of stock options with a service condition and stock purchase rights under the ESPP on the grant date is estimated using the Black-Scholes option-pricing model. The fair value of these awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur.

The Black-Scholes model considers several variables and assumptions in estimating the fair value of service-based stock options and stock purchase rights under the ESPP. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and expected stock price volatility over the expected term. For all service-based stock options granted, the Company calculates the expected term using the simplified method for “plain vanilla” stock option awards. The Company had no publicly available stock price information prior to the IPO and limited

102


 

available stock price information subsequent to the IPO; therefore, the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term on the equity settled award.

For stock options with performance- and market-based vesting conditions, stock-based compensation expense begins to be recognized over the remaining service period when it is considered probable that the performance vesting condition will be satisfied. Prior to the IPO in September 2020, the Company had not recognized any stock-based compensation expense as the satisfaction of the performance condition was not considered probable. Upon the closing of the IPO, the Company recorded a cumulative stock-based compensation expense using the accelerated attribution method as the performance condition was satisfied. Stock-based compensation expense related to these options is recognized using the accelerated attribution method as the performance-based vesting condition and not reversed if the achievement of the market condition does not occur. The fair value of these stock options is estimated using the Monte Carlo simulation model.

RSUs with a service-based vesting condition granted to an optionee generally vest at a rate of 25% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining three years. The fair value of RSUs and PSUs with a service- or performance-based vesting condition is based on the market price of the Company’s common stock on the date of grant. The determination of the stock-based compensation expense related to PSUs to be recognized in the Company’s statements of operations requires the use of certain estimates and assumptions. At each reported period, the Company reassesses the probability of the achievement of corporate performance goals to estimate the number of shares to be released. Any increase or decrease in stock-based compensation expense resulting from an adjustment in the estimated shares to be released is treated as accumulative catch-up in the period of adjustment. If any of the assumptions or estimates used change significantly, stock-based compensation expense may differ materially from what the Company has recorded in the current period. The fair value of PSUs with a market-based vesting condition is estimated using the Monte Carlo simulation model. Stock-based compensation expense related to these PSUs is recognized using the accelerated attribution method and not reversed if the achievement of the market conditions does not occur.

Research and Development

The Company expenses all research and development costs as incurred. These expenses include the costs of proprietary research and development efforts, quality engineering, clinical studies and trials and regulatory affairs. Costs primarily consist of compensation and personnel costs, consulting services, supplies and materials expenses, and allocated costs including facilities and information technology.

Advertising Costs

Advertising costs are expensed as incurred. The advertising costs for years ended December 31, 2021, 2020 and 2019 were not significant.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and remeasured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.

The Company utilizes a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.

The Company includes any penalties and interest expense related to income taxes as a component of other expense, net, as necessary.

Net Loss per Share Attributable to Common Stockholders

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive securities.

103


 

Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents of potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, awards under the Company’s equity compensation plan and warrants are considered to be potentially dilutive securities. For periods in which the Company reports net losses, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders because the effects of potentially dilutive securities are antidilutive.

Employee Benefit Plan

The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their eligible compensation on a pre- or post-tax basis. The Company is authorized to make matching contributions but has not made such contributions for the years ended December 31, 2021, 2020 and 2019. Effective January 1, 2022, the Company began to match 100% of each employee’s contributions up to a maximum matching contribution equal to 2% of such employee’s eligible compensation, subject to the terms and limitations of the 401(k) plan and applicable law.

Segment

The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for the purposes of allocating resources and evaluating financial performance. The Company has operated a manufacturing facility in Mexico since 2020. The Company's long-lived tangible assets, net, as well as the Company's operating lease right-of-use assets recognized on the balance sheets, located in Mexico were $6.2 million as of December 31, 2021.

Recently Adopted Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board (FASB) issued ASU No. 2019-12, Income Taxes (Topic 740), which simplifies the accounting for income taxes, primarily by eliminating certain exceptions to ASC 740. The Company early adopted ASU 2019-12 on a modified retrospective basis as of January 1, 2021, which did not have a material impact on its financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (CECL) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its financial statements.

3. Revenue from Contracts with Customers

Disaggregation of Revenue

Revenue by source consisted of the following (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Consoles

 

$

65,133

 

 

$

32,871

 

 

$

12,187

 

Consumables

 

 

19,179

 

 

 

6,742

 

 

 

1,563

 

Total product revenue

 

 

84,312

 

 

 

39,612

 

 

 

13,750

 

Service and other revenue

 

 

18,290

 

 

 

10,323

 

 

 

1,328

 

Total revenue

 

$

102,602

 

 

$

49,935

 

 

$

15,078

 

 

104


 

For the years ended December 31, 2021, 2020 and 2019, $4.7 million, $3.1 million and $0.5 million, respectively, of consoles revenue were from console operating lease arrangements. The remaining operating lease payments of $1.7 million as of December 31, 2021 will be recognized during the year ending December 31, 2022.

Remaining Performance Obligations and Contract Liabilities

As of December 31, 2021, the aggregate amount of the transaction price allocated to the remaining performance obligations related to customer service contracts that are unsatisfied or partially unsatisfied was $6.7 million, which is recorded as deferred revenue on the Company’s balance sheet. Of that amount, $6.3 million will be recognized as revenue during the year ended December 31, 2022, and $0.3 million thereafter.

The contract liabilities consist of deferred revenue which represents payments received in advance of revenue recognition. Revenue under these agreements is recognized over the related service period. During the years ended December 31, 2021, 2020 and 2019, the Company recognized $3.2 million, $0.9 million, and $0.3 million, respectively, of previously deferred revenue.

4. Fair Value Measurements

The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

 

 

 

 

December 31, 2021

 

 

 

Valuation
Hierarchy

 

Amortized
Costs

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

60,844

 

 

$

 

 

$

 

 

$

60,844

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

Level 1

 

 

18,064

 

 

 

 

 

 

(60

)

 

 

18,004

 

Corporate debt

 

Level 2

 

 

124,178

 

 

 

2

 

 

 

(125

)

 

 

124,055

 

Commercial paper

 

Level 2

 

 

15,081

 

 

 

 

 

 

 

 

 

15,081

 

Total cash equivalents and
   short-term investments

 

 

 

$

218,167

 

 

$

2

 

 

$

(185

)

 

$

217,984

 

 

 

 

 

 

December 31, 2020

 

 

 

Valuation
Hierarchy

 

Amortized
Costs

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

56,056

 

 

$

 

 

$

 

 

$

56,056

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

Level 1

 

 

14,999

 

 

 

1

 

 

 

 

 

 

15,000

 

Corporate debt

 

Level 2

 

 

4,898

 

 

 

 

 

 

 

 

 

4,898

 

Total cash equivalents and
   short-term investments

 

 

 

$

75,953

 

 

$

1

 

 

$

 

 

$

75,954

 

As of December 31, 2021, the remaining contractual maturities for short-term investments were as follows (in thousands):

 

 

Aggregate Fair Value

 

Due within one year

 

$

135,766

 

After one but within five years

 

 

21,374

 

Total

 

$

157,140

 

The Company’s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly

105


 

or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources and confirming those securities traded in active markets.

Impairment assessments are made at the individual security level at each reporting period. When the fair value of an available-for-sale security is less than its cost at the balance sheet date, a determination is made as to whether the impairment is other-than-temporary and, if it is other-than-temporary, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date. There were no unrealized losses for securities in an unrealized loss position for more than 12 months as of December 31, 2021. During the years ended December 31, 2021, 2020 and 2019, the Company did not recognize other-than-temporary impairment losses related to its investment securities.

5. Balance Sheet Components

Cash, Cash Equivalents and Restricted Cash

As of December 31, 2021 and 2020, the restricted cash balance of $33.3 million primarily relates to contractual obligations under the SVB Loan and Security Agreement (see Note 7) and collateral for the building leases in San Jose, CA and Tijuana, Mexico (see Note 6). The restricted cash balance of $0.7 million as of December 31, 2019 relates to collateral for building leases.

The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the statements of cash flows (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cash and cash equivalents

 

$

182,348

 

 

$

294,972

 

 

$

36,926

 

Restricted cash

 

 

33,311

 

 

 

33,311

 

 

 

743

 

Total cash, cash equivalents and restricted cash

 

$

215,659

 

 

$

328,283

 

 

$

37,669

 

Inventories

Inventories consist of the following (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Raw materials

 

$

18,114

 

 

$

7,989

 

Work in process

 

 

6,054

 

 

 

6,200

 

Finished goods

 

 

15,017

 

 

 

4,195

 

Total inventories

 

$

39,185

 

 

$

18,384

 

Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Tablos under operating leases

 

 

2,412

 

 

 

5,158

 

Computers and software

 

 

3,777

 

 

 

3,131

 

Furniture and fixtures

 

 

1,494

 

 

 

1,399

 

Machinery and equipment

 

 

7,197

 

 

 

4,496

 

Leasehold improvements

 

 

4,864

 

 

 

4,459

 

Construction in progress

 

 

874

 

 

 

1,343

 

Total property and equipment

 

 

20,618

 

 

 

19,986

 

Less: accumulated depreciation and amortization

 

 

(7,654

)

 

 

(4,988

)

Property and equipment, net

 

 

12,964

 

 

 

14,998

 

Total depreciation and amortization expense for the years ended December 31, 2021, 2020, and 2019 was $5.2 million, $3.2 million, and $1.5 million, respectively.

106


 

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Accrued inventory

 

$

4,808

 

 

$

3,576

 

Accrued research and development expenses

 

 

574

 

 

 

175

 

Accrued professional services

 

 

1,269

 

 

 

2,187

 

Accrued rebate

 

 

3,121

 

 

 

566

 

 Other

 

 

4,017

 

 

 

1,399

 

Total accrued expenses and other current liabilities

 

$

13,789

 

 

$

7,903

 

Accrued Warranty Liability

The change in accrued warranty liability is presented in the following table (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Balance at the beginning of the period

 

$

2,913

 

 

$

1,702

 

Additions charged to cost of product revenue

 

 

7,310

 

 

 

4,858

 

Consumption

 

 

(6,519

)

 

 

(3,647

)

Balance at the end of the period

 

$

3,704

 

 

$

2,913

 

 

6. Commitments and Contingencies

Leases

In September 2019, the Company entered into an operating lease agreement for its new facility and office space in San Jose, CA that commenced in April 2020 and expires in March 2027. This operating lease contains a free rent period and an escalation clause. The landlord provided the Company with a tenant improvement allowance of up to $2.0 million. The Company issued an irrevocable standby letter of credit in the amount of $0.3 million in lieu of a cash security deposit. The letter of credit is fully secured by cash held at the bank in a restricted account.

In May 2020, the Company entered into an operating lease agreement for its manufacturing facility in Tijuana, Mexico that commenced in May 2020 and will expire in August 2026. The Company took initial possession of the building with 48,437 square feet in May 2020 and subsequently took possession of the second space with 38,750 square feet in June 2021. This operating lease contains a free rent period and an escalation clause. The Company issued an irrevocable standby letter of credit in the amount of $3.0 million, in lieu of a cash security deposit. The letter of credit is fully secured by cash held at the bank in a restricted account.

Both leases include renewal options at the election of the Company to renew or extend the lease. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities.

The components of lease costs were as follows (in thousands):

 

 

Years ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Operating lease costs

 

 

1,759

 

 

 

1,070

 

 

 

 

Variable lease costs

 

 

375

 

 

 

233

 

 

 

100

 

Short-term lease costs

 

 

180

 

 

 

371

 

 

 

520

 

Total lease costs

 

$

2,314

 

 

$

1,674

 

 

$

620

 

 

107


 

The weighted-average remaining lease term and discount rate were as follows:

 

 

December 31,

 

 

 

2021

 

 

2020

 

Weighted-average remaining lease term (in years)

 

 

5.3

 

 

 

6.3

 

Weighted-average discount rate

 

8.7%

 

 

8.7%

 

The maturity of the Company’s operating lease liabilities as of December 31, 2021 were as follows (in thousands):

Years Ending December 31:

 

 

 

2022

 

$

1,796

 

2023

 

 

1,856

 

2024

 

 

1,911

 

2025

 

 

1,969

 

Thereafter

 

 

2,523

 

Total lease payments

 

$

10,055

 

Less: imputed interest

 

 

(2,011

)

Present value of operating lease liabilities

 

$

8,044

 

Operating lease liabilities, current

 

$

1,151

 

Operating lease liabilities, noncurrent

 

$

6,893

 

Purchase Commitments

The Company's commitments as of December 31, 2021 include an estimated amount of $68.6 million relating to the Company’s open purchase orders and contractual obligations that occur in the ordinary course of business, including commitments with contract manufacturers and suppliers for which the Company has not received the goods or services, commitments for capital expenditures, consulting activities for which the Company has not received the services, and subscription of software services. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel within a reasonable period, reschedule, and adjust its requirements based on its business needs prior to the delivery of goods or performance of services.

Litigation

From time to time, the Company may become involved in legal proceedings or investigations, which could have an adverse impact on its reputation, business and financial condition and divert the attention of the Company’s management from the operation of the Company’s business. The Company is not presently a party to any legal proceedings that, if determined adversely to the Company, would individually or taken together have a material adverse effect on its business, results of operations, financial condition or cash flows.

Indemnifications

In the ordinary course of business, the Company often includes standard indemnification provisions in its arrangements with its partners, customers and suppliers. Pursuant to these provisions, the Company may be obligated to indemnify such parties for losses or claims suffered or incurred in connection with its service, breach of representations or covenants, intellectual property infringement or other claims made against such parties. These provisions may limit the time within which an indemnification claim can be made. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such indemnification obligations and has not accrued any liabilities related to such obligations in these financial statements.

108


 

7. Term Loans

Term loans consist of the following (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Principal of term loan

 

$

30,000

 

 

$

30,000

 

Unamortized debt discount

 

 

(238

)

 

 

(326

)

Total term loan, noncurrent

 

$

29,762

 

 

$

29,674

 

Perceptive Term Loans

In 2017, the Company entered into a senior, secured, delayed-draw term loan facility (the Perceptive Term Loan Agreement) with Perceptive Credit Holdings, LP, as the administrative agent and the collateral agent, for various related Perceptive group companies to borrow up to $40.0 million (the Perceptive Term Loans). The Perceptive Term Loans bore interest at a rate of 8.55%, plus the greater of the three-month London Inter-bank Offered Rate (LIBOR) and 2.00%.

In July 2020, the Company used the SVB Term Loan (see below) to repay in full all amounts due under the Perceptive Term Loan and cash on hand to pay $1.2 million in early prepayment, accrued interest and exit fees. The repayment of the Perceptive Term Loan was accounted for as a debt extinguishment, which resulted in a loss on extinguishment of $1.6 million recorded in the statements of operations for the year ended December 31, 2020.

SVB Loan and Security Agreement

On July 2, 2020, the Company entered into a senior secured term loan facility with Silicon Valley Bank (SVB) (the SVB Loan and Security Agreement), which provides for a $30.0 million term loan (the SVB Term Loan).

The SVB Term Loan matures on November 1, 2025. Payments under the SVB Term Loan are for interest only through May 2023, and then 30 monthly principal and interest payments from June 2023 until maturity. The SVB Term Loan bears interest at a rate per annum equal to the greater of (A) 0.50% above the Prime Rate as reported in the Wall Street Journal then in effect (which shall not be less than zero) and (B) 3.75% (3.75% as of December 31, 2021). The Company is obligated to maintain a restricted cash balance greater or equal to the outstanding principal balance of $30.0 million of the SVB Term Loan.

There is also a final payment fee equal to 6.75% of the original principal amount of the SVB Term Loan, or approximately $2.0 million, due at maturity (or any earlier date of optional pre-payment or acceleration of principal due to an event of default). Such fee is being accreted to interest expense using the effective interest method with the offset recorded in noncurrent accrued interest. The Company may, at its option, prepay the SVB Term Loan in full, subject to an additional prepayment fee ranging between 1% and 3% of the outstanding principal amount of the SVB Term Loan.

In the event of default or change in control, all unpaid principal and all accrued and unpaid interest amounts (if any) become immediately due and payable including the prepayment fee. Events of default include, but are not limited to, a payment default, a material adverse change, and insolvency. The SVB Term Loan is secured by substantially all of the Company’s assets, including all of the capital stock held by the Company, if any (subject to a 65% limitation on pledges of capital stock of foreign subsidiaries), subject to certain exceptions. The SVB Loan and Security Agreement contains customary representations, warranties, affirmative covenants and also contains certain restrictive covenants.

Debt issuance costs paid directly to SVB and other debt issuance costs amounting to $0.4 million were accounted for as discounts on the SVB Term Loan. These debt discounts, along with the final payment fee, are being amortized over the term of the SVB Term Loan using the effective interest rate method. As of December 31, 2021, the unamortized debt discount was $0.2 million, which is recorded as a direct deduction from the SVB Term Loan on the balance sheets.

109


 

Aggregate annual payments due on the SVB Term Loan as of December 31, 2021 were as follows (in thousands):

Years Ending December 31:

 

 

 

2022

 

$

1,141

 

2023

 

 

8,073

 

2024

 

 

12,667

 

2025

 

 

13,233

 

Total future payments

 

 

35,114

 

Less: amount representing interest

 

 

(3,089

)

Less: final payment

 

 

(2,025

)

Total term loan

 

 

30,000

 

Less: unamortized debt discount

 

 

(238

)

Total term loan, net of debt discount

 

$

29,762

 

 

8. Stockholders’ Equity

The Company has reserved shares of common stock for issuance as of December 31, 2021 as follows (in thousands):

 

 

Shares

 

Warrants to purchase common stock

 

 

63

 

Stock options outstanding

 

 

3,533

 

Restricted stock units outstanding

 

 

563

 

Performance stock units outstanding

 

 

110

 

Shares available for future purchase under ESPP

 

 

999

 

Shares available for future grant under 2020 Plan

 

 

4,415

 

Total reserved shares

 

 

9,683

 

 

9. Equity Incentive Plan

In 2019, the Company terminated the 2010 Stock Incentive Plan (the 2010 Plan) and adopted the 2019 Equity Incentive Plan (the 2019 Plan, and together with 2010 Plan, the Prior Plans) for the purpose of providing incentive and non-statutory stock options to employees, directors and certain non-employees.

In the third quarter of 2020, the Company adopted the 2020 Equity Incentive Plan (the 2020 Plan, and together with the Prior Plans, the Plans), which became effective in connection with the IPO. As a result, the Company may not grant any additional awards under the Prior Plans. The Prior Plans will continue to govern outstanding equity awards previously granted thereunder. The Company has initially reserved 3,665,000 shares of common stock for the issuance of awards under the 2020 Plan. In addition, the number of shares of common stock available under the 2020 Plan automatically increases on the first day of each fiscal year until (and including) the fiscal year ending December 31, 2030, with such annual increase equal to an amount equal to the lesser of (i) 4% of the number of shares of common stock issued and outstanding on December 31 of the immediately preceding calendar year, and (ii) an amount determined by the Company’s board of directors. On January 1, 2021, the number of shares of common stock reserved for the issuance of awards under the 2020 Plan was increased by 1,709,000 shares as a result of the automatic increase pursuant to the 2020 Plan.

Options under the 2020 Plan have a contractual term of 10 years. The exercise price of an option shall not be less than 100% of the fair market value of the shares on the date of grant.

110


 

Stock Options

A summary of the Company’s stock option activity under the Plans is set forth below (in thousands, except exercise price and remaining contractual life data):

 

 

Outstanding
Options

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Terms
(Years)

 

 

Aggregate
Intrinsic
Value

 

Balance as of December 31, 2020

 

 

4,763

 

 

$

6.35

 

 

 

 

 

 

 

Granted

 

 

634

 

 

$

47.91

 

 

 

 

 

 

 

Exercised

 

 

(1,437

)

 

$

5.31

 

 

 

 

 

 

 

Forfeited and expired

 

 

(427

)

 

$

19.58

 

 

 

 

 

 

 

Balance as of December 31, 2021

 

 

3,533

 

 

$

12.63

 

 

 

6.82

 

 

$

119,959

 

Exercisable as of December 31, 2021

 

 

2,453

 

 

$

5.42

 

 

 

6.07

 

 

$

99,853

 

The weighted average grant date fair value of options granted to employees was $24.74, $7.97, and $2.77 per share during the years ended December 31, 2021, 2020 and 2019, respectively. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $61.0 million, $8.2 million, and $0.2 million, respectively. The intrinsic value is the difference between the estimated fair value of the Company’s common stock at the time of exercise and the exercise price of the stock option.

The total fair value of options that vested during the years ended December 31, 2021, 2020 and 2019 was $24.5 million, $3.3 million, and $0.7 million, respectively. As of December 31, 2021, the total unrecognized stock-based compensation expense related to the stock options was $14.0 million, which will be recognized over a weighted-average period of 2.63 years.

Stock Options with Performance and Market Conditions

As of December 31, 2020, the Company had 1,933,000 shares of outstanding stock options with performance- and market-based vesting conditions. The options were scheduled to vest over the requisite service period if the Company achieves both (i) a performance condition tied to a liquidity event, which includes the effectiveness of an IPO, and (ii) certain market conditions, provided the optionee is providing services on the date of the event. As of December 31, 2021, all outstanding options with these conditions were fully vested and related stock-based compensation was recognized in full. For the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense of $4.3 million and $18.5 million, respectively, related to these stock options. No such expense was recorded for the year ended December 31, 2019 as the performance-based vesting condition was not satisfied until the closing of the IPO in September 2020.

The fair value of each stock option grant is estimated on the date of grant using the following assumptions for the periods indicated:

 

 

Years Ended December 31,

 

 

2021

 

2020

 

2019

Expected term (in years)

 

5.95 – 6.08

 

5.06 – 10.00

 

4.97 – 5.05

Expected volatility

 

53.9% – 55.3%

 

52.1% – 62.7%

 

49.3% – 50.9%

Risk-free interest rate

 

0.66% – 1.36%

 

0.35% – 1.54%

 

1.57% – 2.48%

Dividend yield

 

0%

 

0%

 

0%

Restricted Stock

The Company issues RSUs and PSUs, both of which are considered restricted stock. The Company grants restricted stock pursuant to the 2020 Plan and satisfies such grants through the issuance of new shares. RSUs are share awards that, upon vesting, will deliver to the holder shares of our common stock. The PSUs may vest upon the achievement of specified revenue targets (performance-based vesting conditions) or specified market stock prices (market-based vesting conditions) and continued performance of services. Certain PSUs with performance-based vesting conditions vest in a range between 0% and 200% of the units approved based on the performance relative to specified revenue targets.

111


 

Restricted stock activity was as follows (in thousands, except per share amounts):

 

 

Restricted
Stock Units

 

 

Performance
Stock Units

 

 

Weighted-Average
Grant Date Fair
Value Per Share

 

 

 

(RSU)

 

 

(PSU)

 

 

RSU

 

 

PSU

 

Outstanding as of December 31, 2020

 

 

44

 

 

 

25

 

 

$

52.32

 

 

$

52.55

 

Granted

 

 

639

 

 

 

85

 

 

$

47.78

 

 

$

46.22

 

Vested

 

 

(19

)

 

 

 

 

$

51.03

 

 

$

 

Forfeited

 

 

(101

)

 

 

 

 

$

48.04

 

 

$

 

Outstanding as of December 31, 2021

 

 

563

 

 

 

110

 

 

$

47.98

 

 

$

47.65

 

The total grant date fair value of RSUs vested for the years ended December 31, 2021 and 2020 were $1.0 million and $0.2 million, respectively. There were no RSUs granted prior to 2020. As of December 31, 2021, the total unrecognized stock-based compensation expense related to the RSUs was $22.6 million, which will be recognized over a weighted-average period of 3.12 years.

As of December 31, 2021, the total unrecognized stock-based compensation expense related to the PSUs with market-based vesting conditions was $1.3 million, which will be recognized over a weighted-average period of 1.25 years.

Employees Stock Purchase Plan (ESPP)

In the third quarter of 2020, the Company adopted the ESPP. The Company has initially reserved 687,000 shares of common stock for purchase under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP increases automatically on the first day of each fiscal year until (and including) the fiscal year ending December 31, 2030, with such annual increase equal to the lesser of (i) 687,000 shares, (ii) 1% of the number of common stock issued and outstanding on December 31 of the immediately preceding fiscal year, and (iii) an amount determined by the Company’s board of directors. On January 1, 2021, the number of shares of common stock reserved for purchase under the ESPP was increased by 427,000 shares as a result of the automatic increase pursuant to the ESPP.

Subject to any limitations contained therein, the ESPP allows eligible participants to contribute, through payroll deductions, up to 15% of their eligible compensation to purchase the Company’s common stock at a purchase price equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The ESPP generally provides for consecutive 6-month offering periods. Effective beginning with the offering period commencing on March 1, 2022, the ESPP allows eligible participants to purchase shares pursuant to a cashless exercise program, and the duration for each offering period will be a 24-month period consisting of four separate consecutive purchase periods of approximately six months in length. This includes a two-year look-back feature in the ESPP, with a reset feature, which causes the offering period to reset if the fair value of the Company’s common stock on the first day of a new offering period is less than that on the original offering date.

The fair value of the stock purchase rights under the ESPP is estimated using the Black-Scholes option pricing model. The weighted average grant date fair value and assumptions used in estimating the fair value of the stock purchase rights under the ESPP were as follows:

 

 

Years Ended December 31,

 

 

2021

 

2020

Expected term (in years)

 

0.50

 

0.47

Expected volatility

 

41.0% – 43.8%

 

57.0%

Risk-free interest rate

 

0.06% – 0.07%

 

0.12%

Dividend yield

 

0%

 

0%

Grant Date Fair Value

 

$13.25 – $13.95

 

$8.00

During the years ended December 31, 2021 and 2020, 116,000 and zero shares of common stock were purchased pursuant to the ESPP, respectively. As of December 31, 2021, the total unrecognized stock-based compensation expense related to the ESPP was $0.2 million, which will be recognized over a weighted-average period of 0.17 years.

112


 

Stock-based Compensation Expense

The following table sets forth stock-based compensation expense included in the Company’s statements of operations (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cost of revenue

 

$

269

 

 

$

255

 

 

$

5

 

Research and development

 

 

3,809

 

 

 

4,615

 

 

 

328

 

Sales and marketing

 

 

5,897

 

 

 

4,423

 

 

 

172

 

General and administrative

 

 

7,470

 

 

 

12,146

 

 

 

378

 

Total stock-based compensation expense

 

$

17,445

 

 

$

21,439

 

 

$

883

 

 

10. Income Taxes

Loss before provision for income taxes were as follows for the periods indicated (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Domestic

 

$

(128,400

)

 

$

(121,492

)

 

$

(68,299

)

Foreign

 

 

(3,336

)

 

 

 

 

 

 

Loss before provision for income taxes

 

$

(131,736

)

 

$

(121,492

)

 

$

(68,299

)

The provision for income taxes was $0.2 million for the years ended December 31, 2021, which related to foreign income taxes. For years ended December 31, 2020 and 2019, the provision for income taxes were insignificant. The Company has incurred net operating losses for all periods presented. The Company has not reflected any benefit of such net operating loss carryforwards in the financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.

The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:

 

 

Years Ended December 31,

 

 

2021

 

2020

 

2019

Federal statutory income tax rate

 

 

21.0

 

%

 

 

21.0

 

%

 

 

21.0

 

%

State taxes

 

 

1.3

 

 

 

 

3.8

 

 

 

 

7.8

 

 

Change in valuation allowance

 

 

(22.8

)

 

 

 

(23.3

)

 

 

 

(28.5

)

 

Federal and state tax credits

 

 

1.2

 

 

 

 

1.0

 

 

 

 

0.9

 

 

Stock-based compensation expense

 

 

8.1

 

 

 

 

1.2

 

 

 

 

 

 

Non-deductible permanent expenses

 

 

(0.1

)

 

 

 

(0.2

)

 

 

 

(1.2

)

 

Effect of deferred tax adjustment

 

 

(0.7

)

 

 

 

(1.4

)

 

 

 

 

 

Non-deductible compensation

 

 

(8.2

)

 

 

 

(2.1

)

 

 

 

 

 

Effective income tax rate

 

 

(0.2

)

%

 

 

 

%

 

 

 

%

 

113


 

Deferred tax assets and liabilities

Deferred income taxes reflect the net tax effect of temporary differences between amounts recorded for financial reporting purposes and amounts used for tax purposes. The major components of deferred tax assets and liabilities were as follows as of the dates indicated (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

102,094

 

 

$

76,838

 

Tax credits

 

 

11,767

 

 

 

10,039

 

Accrual and reserves

 

 

3,573

 

 

 

2,392

 

Tangible and intangible assets

 

 

20,249

 

 

 

19,090

 

Stock-based compensation expense

 

 

3,566

 

 

 

2,843

 

Lease liabilities

 

 

1,955

 

 

 

1,733

 

Other deferred tax asset

 

 

282

 

 

 

 

Gross deferred tax assets

 

 

143,486

 

 

 

112,935

 

Valuation allowance

 

 

(141,729

)

 

 

(111,061

)

Net deferred tax assets

 

$

1,757

 

 

$

1,874

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax liabilities:

 

 

 

 

 

 

  Right-of-use assets

 

$

(1,757

)

 

$

(1,874

)

  Gross deferred tax liabilities

 

$

(1,757

)

 

$

(1,874

)

Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2021 and 2020 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The valuation allowance increased by $30.7 million, $28.4 million and $23.7 million during the years ended December 31, 2021, 2020 and 2019, respectively.

Net Operating Loss and Tax Credit Carryforwards

As of December 31, 2021, the Company had a net operating loss carryforward for federal income tax purposes of $409.0 million. Federal net operating losses of $281.2 million incurred after 2017 do not expire but usage is limited to 80% of taxable income. The remaining $127.8 million of federal net operating loss carryforward will begin to expire in 2024 and continue to expire through 2037. The Company had a total state net operating loss carryforward of $213.7 million. State net operating losses of $53.2 million do not expire. The remaining state net operating loss carryforward of $160.5 million will begin to expire in 2022 and continue to expire through 2041.

The Company had federal research and development credits of $6.6 million, which will begin to expire in 2030 and state research and development credits of $5.1 million which have no expiration date. These tax credits are subject to the same limitations discussed above.

Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company’s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced. The Company’s deferred tax asset and related valuation allowance would be reduced, as a result. The Company has not performed a Section 382 study to determine the amount of reduction, if any. Unrecognized tax benefits at December 31, 2021 have been recorded as an offset to federal and state research and development credit carryforwards.

114


 

Unrecognized Tax Benefits

A reconciliation of the total unrecognized tax benefits for the periods presented was as follows (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Balance, beginning of year

 

$

1,582

 

 

$

1,020

 

Decrease related to current year positions

 

 

 

 

 

 

Increase related to current year positions

 

 

608

 

 

 

562

 

Balance, end of year

 

$

2,190

 

 

$

1,582

 

The Company does not have any material accrued interest or penalties associated with unrecognized tax benefits. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change within the next twelve months.

The Company files income tax returns in the United States and various states and Mexico. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by federal, state, and foreign authorities for three, four, and five years, respectively, from the date of utilization of any net operating loss or credits.

11. Net Loss per Share Attributable to Common Stockholders

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to common stockholders was as follows (in thousands, except per share amounts):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Numerator:

 

 

 

 

 

 

 

 

 

Net loss

 

$

(131,935

)

 

$

(121,492

)

 

$

(68,299

)

Adjustment to redemption value on redeemable
   convertible preferred stock

 

 

 

 

 

(362

)

 

 

(134,760

)

Deemed dividend on settlement of accrued dividend

 

 

 

 

 

42,530

 

 

 

 

Gain on extinguishment of redeemable convertible preferred stock

 

 

 

 

 

 

 

 

117,598

 

Net loss attributable to common stockholders,
  basic and diluted

 

$

(131,935

)

 

$

(79,324

)

 

$

(85,461

)

Denominator:

 

 

 

 

 

 

 

 

 

Weighted-average shares of common stock,
   basic and diluted

 

 

45,589

 

 

 

16,358

 

 

 

858

 

Net loss per share attributable to common stockholders,
   basic and diluted

 

$

(2.89

)

 

$

(4.85

)

 

$

(99.58

)

The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Stock options to purchase common stock

 

 

3,533

 

 

 

4,763

 

 

 

3,757

 

Warrant to purchase common stock

 

 

63

 

 

 

63

 

 

 

 

Restricted stock units

 

 

581

 

 

 

 

 

 

 

Shares committed under ESPP

 

 

37

 

 

 

52

 

 

 

 

Performance stock units

 

 

17

 

 

 

 

 

 

 

Redeemable convertible preferred stock, on an as-if converted basis

 

 

 

 

 

 

 

 

18,634

 

Warrants to purchase redeemable convertible preferred stock

 

 

 

 

 

 

 

 

599

 

Total

 

 

4,231

 

 

 

4,878

 

 

 

22,990

 

 

115


 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation and supervision of our Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Annual Report. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures are also designed to provide reasonable assurance that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of December 31, 2021.

Management’s Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. The rules define internal control over financial reporting as a process designed by, or under the supervision of, the Company’s Chief Executive Officer and Chief Financial Officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an assessment of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the results of our assessment under the framework in the Internal Control - Integrated Framework (2013), our management concluded that our internal control over financial reporting was effective as of December 31, 2021.

The effectiveness of our internal control over financial reporting as of December 31, 2021 has been audited by an independent registered public accounting firm, as stated in their report, which is included under “Item 8. Financial Statements and Supplementary Data” of this Annual Report.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

116


 

Item 9B. Other Information.

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

None.

117


 

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

The information required by this Item 10 with respect to executive officers may be found under the heading “Information About Our Executive Officers” in Part I, Item 1 of this Annual Report.

We have adopted a code of conduct applicable to our principal executive, financial and accounting officers and all persons performing similar functions. A copy of our code of conduct is available on our principal corporate website at www.outsetmedical.com in the Investors section under “Corporate Governance”. We intend to post any required disclosures regarding an amendment to, or waiver from, a provision of our code of conduct on the same website.

The remaining information required by this Item 10 is incorporated by reference from the sections entitled “Board and Corporate Governance Matters,” “Audit Matters” and “Delinquent Section 16(a) Reports” to be included in our definitive proxy statement to be filed with the Securities and Exchange Commission in connection with our 2022 Annual Meeting of Stockholders within 120 days of our fiscal year ended December 31, 2021 (the Proxy Statement).

Item 11. Executive Compensation.

The information required by this Item 11 will be set forth in the sections entitled “Director Compensation,” “Executive Compensation,” “Compensation Committee Report and “Compensation Committee Interlocks and Insider Participation” to be included in the Proxy Statement and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this Item 12 will be set forth in the section entitled “Security Ownership of Certain Beneficial Owners and Management” and “Equity Plan Information” to be included in the Proxy Statement and is incorporated herein by reference.

The information required by this Item 13 will be set forth in the sections entitled “Certain Relationships and Related Party Transactions” and “Director Independence” to be included in the Proxy Statement and is incorporated herein by reference.

Item 14. Principal Accounting Fees and Services.

Our independent registered public accounting firm is KPMG LLP, San Francisco, CA, Auditor ID: 185.

The information required by this Item 14 will be set forth in the section entitled “Audit Matters” to be included in the Proxy Statement and is incorporated herein by reference.

118


 

PART IV

Item 15. Exhibits, Financial Statement Schedules.

We have filed the following documents as part of this Annual Report:

1.
Financial Statements: The financial statements included in “Index to Financial Statements” in Part II, Item 8 are filed as part of this Annual Report.
2.
Exhibits: The exhibits listed in the accompanying Exhibit Index are filed or incorporated by reference as part of this Annual Report.

Item 16. Form 10-K Summary.

None.

119


 

Exhibit Index

 

 

 

 

 

Incorporation by Reference

Exhibit

Number

 

Description

 

Form

 

File No.

 

Exhibit

 

Filing Date

3.1

 

Form of Amended and Restated Certificate of Incorporation of Outset Medical, Inc.

 

S-1/A

 

333-248225

 

3.1

 

September 9, 2020

3.2

 

Form of Amended and Restated Bylaws of Outset Medical, Inc.

 

S-1/A

 

333-248225

 

3.2

 

September 9, 2020

4.1

 

Form of Common Stock Certificate

 

S-1/A

 

333-248225

 

4.1

 

September 9, 2020

4.2

 

Amended and Restated Registration Rights Agreement

 

S-1

 

333-248225

 

4.2

 

August 21, 2020

4.3

 

Form of Series A Warrant Agreement #1

 

S-1

 

333-248225

 

4.3

 

August 21, 2020

4.4

 

Form of Series A Warrant Agreement #2

 

S-1

 

333-248225

 

4.4

 

August 21, 2020

4.5

 

Description of Outset Medical, Inc.’s Securities Registered Pursuant to Section 12 of the Exchange Act

 

10-K

 

001-39513

 

4.5

 

March 22, 2021

10.1†

 

Form of Indemnification Agreement

 

S-1/A

 

333-248225

 

10.1

 

September 9, 2020

10.2†

 

Outset Medical, Inc. 2010 Equity Incentive Plan and related form agreements

 

S-1

 

333-248225

 

10.2

 

August 21, 2020

10.3†

 

Outset Medical, Inc. 2019 Equity Incentive Plan and related form agreements

 

S-1

 

333-248225

 

10.3

 

August 21, 2020

10.4†

 

Outset Medical, Inc. 2020 Equity Incentive Plan

 

S-1/A

 

333-248225

 

10.4

 

September 9, 2020

10.5†

 

Form of Stock Option Grant Notice and Option Agreement for Outset Medical, Inc. 2020 Equity Incentive Plan

 

10-K

 

001-39513

 

10.5

 

March 22, 2021

10.6†

 

Form of Restricted Stock Unit Award Grant Notice and Award Agreement for Outset Medical, Inc. 2020 Equity Incentive Plan

 

10-K

 

001-39513

 

10.6

 

March 22, 2021

10.7†

 

Form of Restricted Stock Award Grant Notice and Award Agreement for Outset Medical, Inc. 2020 Equity Incentive Plan

 

10-K

 

001-39513

 

10.7

 

March 22, 2021

10.8†

 

Form of Performance Stock Unit Award Grant Notice and Award Agreement for Outset Medical, Inc. 2020 Equity Incentive Plan

 

10-K

 

001-39513

 

10.8

 

March 22, 2021

10.9†*

 

Outset Medical, Inc. 2020 Employee Stock Purchase Plan, as amended and restated

 

 

 

 

 

 

 

 

10.10†

 

Employment Agreement by and between Outset Medical and Leslie Trigg, dated as of February 23, 2015

 

S-1

 

333-248225

 

10.6

 

August 21, 2020

10.11†

 

Form of Amended and Restated Change in Control and Severance Agreement for Chief Executive Officer

 

S-1/A

 

333-248225

 

10.7

 

September 9, 2020

10.12†

 

Form of Amended and Restated Change in Control and Severance Agreement for non-Chief Executive Officer executive officers

 

S-1/A

 

333-248225

 

10.8

 

September 9, 2020

10.13#

 

Lease by and between WH Silicon Valley IV LP and Outset Medical, Inc., dated as of September 19, 2019

 

S-1

 

333-248225

 

10.10

 

August 21, 2020

10.14#

 

Sublease Agreement by and among Inmobiliaria IAMSA, S.A. de C.V. (Sublessor), Baja Fur S.A. de C.V. (Sublessee) and Outset Medical, Inc. (Guarantor), dated as of May 5, 2020

 

S-1

 

333-248225

 

10.11

 

August 21, 2020

10.15#

 

First Amendment Agreement by and among Inmobiliaria IAMSA, S.A. de C.V. (Sublessor), Baja Fur S.A. de C.V. (Sublessee) and Outset Medical, Inc. (Guarantor), dated as of June 26, 2020

 

S-1

 

333-248225

 

10.12

 

August 21, 2020

10.16#

 

Guaranty by and between Inmobiliaria IAMSA, S.A. de C.V. and Outset Medical, Inc dated as of May 6, 2020

 

S-1

 

333-248225

 

10.13

 

August 21, 2020

10.17#

 

Loan and Security Agreement by and between Silicon Valley Bank and Outset Medical, Inc. dated as of July 2, 2020

 

S-1

 

333-248225

 

10.14

 

August 21, 2020

 

120


 

10.18#

 

Manufacturing Services Agreement by and between TACNA Services, Inc. and Outset Medical, Inc. dated as of January 15, 2020

 

S-1

 

333-248225

 

10.17

 

August 21, 2020

10.19#

 

Authorized Reseller Agreement by and between SDV Office Systems, LLC dba SDV Medical and Outset Medical, Inc. dated as of October 14, 2019

 

S-1

 

333-248225

 

10.18

 

August 21, 2020

10.20#

 

Amendment 1 to the Authorized Reseller Agreement by and between SDV Office Systems, LLC dba SDV Medical and Outset Medical, Inc. dated as of March 26, 2020

 

S-1

 

333-248225

 

10.19

 

August 21, 2020

10.21#

 

Amendment 2 to the Authorized Reseller Agreement by and between SDV Office Systems, LLC dba SDV Medical and Outset Medical, Inc. dated as of May 6, 2020

 

S-1

 

333-248225

 

10.20

 

August 21, 2020

10.22#

 

Purchasing Agreement by and between HCA Management Services, L.P. and Outset Medical, Inc. dated as of May 1, 2020

 

S-1

 

333-248225

 

10.21

 

August 21, 2020

10.23#

 

Award/Contract from the Biomedical Advanced Research and Development Authority to Outset Medical, Inc., effective September 30, 2019

 

S-1

 

333-248225

 

10.22

 

August 21, 2020

10.24#

 

Amendment of Solicitation/Modification of Contract from the Biomedical Advanced Research and Development Authority to Outset Medical, Inc., effective May 9, 2020

 

S-1

 

333-248225

 

10.23

 

August 21, 2020

10.25#

 

Solicitation/Contract/Order for Commercial Items from ASPR/SNS to Outset Medical, Inc., effective August 17, 2020

 

S-1/A

 

333-248225

 

10.24

 

September 9, 2020

10.26#

 

Amendment to Solicitation/Modification of Contract from ASPR-BARDA to Outset Medical, Inc., dated November 25, 2020

 

10-K

 

001-39513

 

10.29

 

March 22, 2021

10.27#

 

Supply Agreement by and between Carlisle Interconnect Technologies, Inc. and Outset Medical, Inc., dated January 12, 2021

 

 

10-K

 

001-39513

 

10.30

 

March 22, 2021

23.1*

 

Consent of KPMG LLP, independent registered public accounting firm

 

 

 

 

 

 

 

 

24.1*

 

Power of Attorney (included on the signature page)

 

 

 

 

 

 

 

 

31.1*

 

Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

 

31.2*

 

Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

 

32.1*

 

Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

 

 

 

101.INS*

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

 

 

 

 

 

 

 

101.SCH*

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

 

 

 

 

 

101.CAL*

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

 

 

 

 

 

101.DEF*

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

 

 

 

 

 

101.LAB*

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

 

 

 

 

 

101.PRE*

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

 

 

 

 

 

 

 

 

 

* Filed herewith

† Indicates a management contract or compensatory plan or arrangement.

# Portions of the exhibit have been or will be excluded because it is both not material and is the type of information that the registrant treats as private or confidential.

121


 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

Outset Medical, Inc.

 

 

 

 

Date: February 23, 2022

 

By:

/s/ Leslie Trigg

 

 

 

Leslie Trigg

 

 

 

President and Chief Executive Officer; Chair of the Board

 

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Leslie Trigg and Nabeel Ahmed, and each of them, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

 

/s/ Leslie Trigg

 

President and Chief Executive Officer; Chair of the Board (Principal Executive Officer)

 

February 23, 2022

Leslie Trigg

 

 

 

 

 

 

/s/ Nabeel Ahmed

 

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

 

February 23, 2022

Nabeel Ahmed

 

 

 

 

 

/s/ D. Keith Grossman

 

Lead Independent Director

 

February 23, 2022

D. Keith Grossman

 

 

 

 

 

/s/ Karen Drexler

 

Director

 

February 23, 2022

Karen Drexler

 

 

 

 

 

/s/ Patrick T. Hackett

 

Director

 

February 23, 2022

Patrick T. Hackett

 

 

 

 

 

/s/ Jim Hinrichs

 

Director

 

February 23, 2022

Jim Hinrichs

 

 

 

 

 

 

 

 

 

/s/ Andrea L. Saia

 

Director

 

February 23, 2022

Andrea L. Saia

 

 

 

 

 

 

 

 

 

 

/s/ Catherine Szyman

 

Director

 

February 23, 2022

Catherine Szyman

 

 

 

 

 

122


EX-10.9 2 om-ex10_9.htm EX-10.9 EX-10.9

 

Exhibit 10.9

Outset Medical, Inc.

Employee Stock Purchase Plan

 

Adopted By The Board Of Directors: September 2, 2020

Approved By The Stockholders: September 7, 2020

Termination Date: September 2, 2030

(Amended and Restated, Effective March 1, 2022)
 

1.
Purpose. The purpose of the Outset Medical, Inc. Employee Stock Purchase Plan (this “Plan”) is to provide eligible Employees of the Company and Participating Subsidiaries with a convenient means of acquiring an equity interest in the Company through payroll deductions and other contributions in order to enhance such employees’ sense of participation in the affairs of the Company. This Plan is amended and restated as set forth herein and such amendment and restatement shall apply to Offering Periods beginning on or after March 1, 2022.

This Plan includes two components: (a) a component intended to qualify as an “employee stock purchase plan” under Section 423 of the Code (the “423 Component”), the provisions of which shall be construed so as to extend and limit participation in a uniform and nondiscriminatory manner consistent with the requirements of Section 423 of the Code; and (b) a component that does not qualify as an “employee stock purchase plan” under Section 423 of the Code (the “Non-423 Component”), under which options shall be granted pursuant to rules, procedures or sub-plans adopted by the Committee designed to achieve tax, securities laws or other objectives for eligible Employees, the Company and its Participating Subsidiaries. Except as otherwise provided in this Plan, the Non-423 Component will operate and be administered in the same manner as the 423 Component.

2.
Definitions. As used herein, the terms set forth below have the meanings assigned to them in this Section 2 and shall include the plural as well as the singular.

“1933 Act” means the Securities Act of 1933, as amended.

“1934 Act” means the Securities Exchange Act of 1934, as amended.

“Board” means the Board of Directors of Outset Medical, Inc.

“Business Day” shall mean a day on which NASDAQ is open for trading.

“Brokerage Account” means the account in which the Purchased Shares are held.

“Code” means the Internal Revenue Code of 1986, as amended.

“Committee” means the Compensation Committee of the Board, or the designee of the Compensation Committee.

“Company” means Outset Medical, Inc., a Delaware corporation.

1


 

“Compensation” means base pay, commissions, overtime, and vacation, holiday and sick pay. Compensation does not include: (1) income related to stock option awards, stock grants and other equity incentive awards, (2) expense reimbursements, (3) relocation-related payments, (4) benefit plan payments (including but not limited to short-term disability pay, long-term disability pay, maternity pay, military pay, tuition reimbursement and adoption assistance), (5) accrued but unpaid compensation for a deceased Participant, (6) income from non-cash and fringe benefits, (7) severance payments, (8) annual, quarterly, monthly and other cash bonuses, and (9) other forms of compensation not specifically listed herein.

“Employee” means any individual who is a common law employee of the Company or any other Participating Subsidiary. For purposes of the Plan, the employment relationship shall be treated as continuing intact while the individual is on sick leave or other leave of absence approved by the Company or the Participating Subsidiary, as appropriate, and only to the extent permitted under Section 423 of the Code with respect to the 423 Component. For purposes of the Plan, an individual who performs services for the Company or a Participating Subsidiary pursuant to an agreement (written or oral) that classifies such individual’s relationship with the Company or a Participating Subsidiary as other than a common law employee shall not be considered an “employee” with respect to any period preceding the date on which a court or administrative agency issues a final determination that such individual is an “employee.”

“Enrollment Date” means the first Business Day of each Offering Period.

“Exercise Date” means the last Business Day of each Offering Period (or, if determined by the Committee, the Purchase Period if different from the Offering Period).

“Fair Market Value” on or as of any date means the official closing price for a Share as reported on NASDAQ on the relevant valuation date or, if no official closing price is reported on such date, on the preceding day on which an official closing price is reported on NASDAQ was reported; or, if the Shares are no longer listed on NASDAQ, the closing price for Shares as reported on the official website for such other exchange on which the Shares are listed. Notwithstanding the foregoing, if the first Offering Period commences on the first Business Day on or after the date on which the Securities and Exchange Commission declares the Company’s Registration Statement to be effective, the Fair Market Value for purposes of the Enrollment Date for such first Offering Period shall be the initial price to the public as set forth in the final prospectus included in the Registration Statement.

“Offering Period” means each six-month period or, effective March 1, 2022, each 24-month period, beginning the first Business Day of March and the first Business Day of September or such other period designated by the Committee; provided that in no event shall an Offering Period exceed 27 months, with the commencement of the first Offering Period to be determined by the Committee. Notwithstanding anything herein to the contrary, the Committee may establish an Offering Period with multiple Purchase Periods within such Offering Period.

“Option” means an option granted under this Plan that entitles a Participant to purchase Shares.

“Participant” means an Employee who satisfies the requirements of Sections 3 and 5 of the Plan.

2


 

“Participating Subsidiary” means each Subsidiary other than those that the Committee or the Board has excluded from participation in the Plan.

“Plan” means this Outset Medical, Inc. Employee Stock Purchase Plan, as amended from time to time.

“Purchase Account” means the account used to purchase Shares through the exercise of Options under the Plan.

“Purchase Period” means the period designated by Committee during which payroll deductions and other contributions of the Participants are accumulated under the Plan. A Purchase Period may coincide with an entire Offering Period or there may be multiple Purchase Periods within an Offering Period, as determined by the Committee prior to the commencement of the applicable Offering Period.

“Purchase Price” shall be the lesser of: (i) 85% percent of the Fair Market Value of a Share on the applicable Enrollment Date for an Offering Period and (ii) 85% percent of the Fair Market Value of a Share on the applicable Exercise Date; provided, however, that the Committee may determine a different per share Purchase Price provided that such per share Purchase Price is communicated to Participants prior to the beginning of the Offering Period and provided that in no event shall such per share Purchase Price be less than the lesser of (i) 85% of the Fair Market Value of a Share on the applicable Enrollment Date or (ii) 85% of the Fair Market Value of a Share on the Exercise Date.

“Purchased Shares” means the full Shares issued or delivered pursuant to the exercise of Options under the Plan.

“Registration Statement” means the registration statement on Form S-1 filed with the Securities and Exchange Commission for the initial public offering of the Common Stock.

“Shares” means shares of the common stock of the Company.

“Subsidiary” means an entity, domestic or foreign, of which not less than 50% of the voting equity is held by the Company or a Subsidiary, whether or not such entity now exists or is hereafter organized or acquired by the Company or a Subsidiary; provided such entity is also a “subsidiary” within the meaning of Section 424 of the Code.

“Termination Date” means (i) the date on which a Participant terminates employment or on which the Participant ceases to provide services to the Company or a Subsidiary as an employee or as otherwise required under Section 423 with respect to the 423 Component or (ii) subject to Section 423 of the Code with respect to the 423 Component, the date on which the Participant’s employment is determined to have been terminated for purposes of the Plan by the Committee. The Termination Date specifically does not include any period following that date which the Participant may be eligible for or in receipt of other payments from the Company including in lieu of notice or termination or severance pay or as wrongful dismissal damages.

3


 

3.
Eligibility.
(a)
Only Employees of the Company or a Participating Subsidiary (i) whose customary employment is 20 hours or more per week and (ii) whose customary employment is for five months or more in any calendar year shall be eligible to be granted Options under the Plan and, in no event may a Participant be granted an Option under the Plan following his or her Termination Date.
(b)
Any provisions of the Plan to the contrary notwithstanding, no Employee shall be granted an Option under the 423 Component of the Plan if (i) immediately after the grant, such Employee (or any other person whose stock would be attributed to such Employee pursuant to Section 424(d) of the Code) would own capital stock of the Company and/or hold outstanding Options or options to purchase stock possessing 5% or more of the total combined voting power or value of all classes of stock of the Company or of any of its Subsidiaries or (ii) such Option would permit his or her rights to purchase stock under all employee stock purchase plans (described in Section 423 of the Code) of the Company and its Subsidiaries to accrue at a rate that exceeds $25,000 of the Fair Market Value of such stock (determined at the time each such Option is granted) for each calendar year in which such Option is outstanding at any time. Except as otherwise determined by the Committee prior to the commencement of an Offering Period, no Participant may purchase more than 1,265 Shares during any Offering Period.
4.
Exercise of an Option. Options shall be exercised on behalf of Participants in the Plan every Exercise Date, using (i) payroll deductions that have accumulated in the Participants’ Purchase Accounts during the immediately preceding Purchase Period or that have been retained from a prior Purchase Period pursuant to Section 8 hereof and (ii) additional contributions to the Company made pursuant to the Cashless Participation Program approved by the Committee.
5.
Participation.
(a)
Unless otherwise determined by the Committee prior to the commencement of an Offering Period and in accordance with Section 423 of the Code with respect to the 423 Component, an Employee shall be eligible to participate on the first Enrollment Date that occurs after such Employee’s first date of employment with the Company or a Participating Subsidiary; provided, that such Employee properly completes and submits an election form by the deadline prescribed by the Company.
(b)
An Employee who does not become a Participant on the first Enrollment Date on which he or she is eligible may thereafter become a Participant on any subsequent Enrollment Date by properly completing and submitting an election form by the deadline prescribed by the Company.
(c)
Payroll deductions for a Participant shall commence on the first payroll date following the Enrollment Date and shall end on the last payroll date in the Purchase Period to which such authorization is applicable, unless sooner terminated by the Participant as provided in Section 12 hereof.

 

4


 

6.
Payroll Deductions and Other Contributions.
(a)
A Participant shall elect to have payroll deductions made during a Purchase Period equal to no less than 1% of the Participant’s Compensation up to a maximum of 15% (or such greater amount as the Committee establishes from time to time). The amount of such payroll deductions shall be in whole percentages. All payroll deductions made by a Participant shall be credited to his or her Purchase Account. In addition to such payroll deductions credited to a Participant’s Purchase Account during the Purchase Period, Participants other than executive officers of the Company, within the meaning of the 1934 Act, may elect to purchase Shares pursuant to a cashless participation program approved by the Committee (the “Cashless Participation Program”) by designating an additional amount to be contributed to such Participant’s Purchase Account at the end of such Purchase Period. In addition, notwithstanding any provisions to the contrary in the Plan, the Committee may allow participants to make other contributions under the Plan via cash, check, or other means instead of payroll deductions if payroll deductions are not permitted under applicable local law, and for any Offering Period under the 423 Component, the Committee determines that such other contributions are permissible under Section 423 of the Code.
(b)
Except as otherwise determined by the Committee prior to the commencement of an Offering Period, a Participant may not increase the rate of payroll deductions or other contributions to be made to the Plan during a Purchase Period. A Participant may decrease the rate of payroll deductions during a Purchase Period by properly completing and submitting an election change form in accordance with the procedures prescribed by the Committee and/or any other forms required by the Committee and by following any other procedures as may be established by the Committee, in which case the new rate shall become effective as soon as administratively practicable after the Participant elects such change and shall continue for the remainder of the Offering Period unless changed as described below. Such change in the rate of payroll deductions may be made at any time during a Purchase Period, but not more than one (1) change may be made effective during any Purchase Period, except that a Participant may elect at any time during a Purchase Period, regardless of whether the Participant previously decreased his or her payroll deduction percentage, to reduce his or her contribution percentage to 0% and such change shall become effective as soon as administratively practicable after the Participant elects such change and shall continue for the remainder of the Offering Period unless changed as described below. If a Participant reduces his or her payroll deduction percentage to 0%, then any election to purchase Shares pursuant to the Cashless Participation Program shall automatically terminate. A Participant may change his or her payroll deduction percentage or additional contribution amount under subsection (a) above for any subsequent Purchase Period by properly completing and submitting an election change form in accordance with the procedures prescribed by the Committee. The change in amount shall be effective as of the first Enrollment Date following the date of filing of the election change form. Unless otherwise determined by the Committee prior to the commencement of an Offering Period, a payroll deduction election and additional contribution election will automatically apply to the next Offering Period, unless otherwise cancelled or changed by the Participant prior to the commencement of such Offering Period.

5


 

(c)
Notwithstanding the foregoing, to the extent necessary to comply with Section 423(b)(8) of the Code and Section 3(b) hereof, a Participant’s payroll deduction and additional contribution elections may be decreased to 0% at any time during an Offering Period. Payroll deductions and additional contributions shall recommence at the rate provided in such Participant’s election form at the beginning of the first Offering Period which is scheduled to end in the following calendar year, unless terminated by the Participant as provided in Section 12 hereof.
7.
Grant of Option. On the applicable Enrollment Date, each Participant in an Offering Period shall be granted an Option to purchase on the applicable Exercise Date a number of full Shares determined by dividing such Participant’s payroll deductions and additional contributions accumulated on or before such Exercise Date and retained in the Participant’s Purchase Account as of the applicable Exercise Date by the applicable Purchase Price.
8.
Exercise of Option. A Participant’s Option for the purchase of Shares shall be exercised automatically on the Exercise Date, and the maximum number of Shares subject to the Option shall be purchased for such Participant at the applicable Purchase Price with the accumulated payroll deductions and additional contributions in his or her Purchase Account. If the Fair Market Value of a Share on the first day of the current Offering Period in which a participant is enrolled is higher than the Fair Market Value of a Share on the first day of any subsequent Offering Period, the Company may establish procedures to automatically enroll such participant in the subsequent Offering Period and any funds accumulated in a participant’s account prior to the first day of such subsequent Offering Period will be applied to the purchase of shares on the Exercise Date immediately prior to the first day of such subsequent Offering Period. A participant does not need to file any forms with the Company to be automatically enrolled in the subsequent Offering Period.

No fractional Shares shall be purchased; any payroll deductions and other contributions accumulated in a Participant’s Purchase Account which are not sufficient to purchase a full Share shall be retained in the Purchase Account for the next subsequent Purchase Period, subject to earlier withdrawal by the Participant as provided in Section 12 hereof. All other payroll deductions and other contributions accumulated in a Participant’s Purchase Account and not used to purchase Shares on an Exercise Date shall be distributed to the Participant. During a Participant’s lifetime, a Participant’s Option is exercisable only by him or her. The Company shall satisfy the exercise of all Participants’ Options for the purchase of Shares through (a) the issuance of authorized but unissued Shares, (b) the transfer of treasury Shares, (c) the purchase of Shares on behalf of the applicable Participants on the open market through an independent broker and/or (d) a combination of the foregoing.

6


 

9.
Issuance of Stock. The Shares purchased by each Participant shall be issued in book entry form and shall be considered to be issued and outstanding to such Participant’s credit as of the end of the last day of each Purchase Period. The Committee may permit or require that shares be deposited directly in a Brokerage Account with one or more brokers designated by the Committee or to one or more designated agents of the Company, and the Committee may use electronic or automated methods of share transfer. The Committee may require that Shares be retained with such brokers or agents for a designated period of time and/or may establish other procedures to permit tracking of disqualifying dispositions of such shares, and may also impose a transaction fee with respect to a sale of Shares issued to a Participant’s credit and held by such a broker or agent. The Committee may permit Shares purchased under the Plan to participate in a dividend reinvestment plan or program maintained by the Company, and establish a default method for the payment of dividends.
10.
Approval by Stockholders. Notwithstanding the above, the Plan is expressly made subject to the approval of the stockholders of the Company within 12 months before or after the date the Plan is adopted by the Board. Such stockholder approval shall be obtained in the manner and to the degree required under applicable federal and state law. If the Plan is not so approved by the stockholders within 12 months before or after the date the Plan is adopted by the Board, this Plan shall not come into effect.
11.
Administration.
(a)
Powers and Duties of the Committee. The Plan shall be administered by the Committee. Subject to the provisions of the Plan, Section 423 of the Code and the regulations thereunder with respect to the 423 Component, the Committee shall have the discretionary authority to determine the time and frequency of granting Options, the duration of Offering Periods and Purchase Periods, the terms and conditions of the Options and the number of Shares subject to each Option. The Committee shall also have the discretionary authority to do everything necessary and appropriate to administer the Plan, including, without limitation, interpreting the provisions of the Plan (but any such interpretation shall not be inconsistent with the provisions of Section 423 of the Code with respect to the 423 Component). All actions, decisions and determinations of, and interpretations by the Committee with respect to the Plan shall be final and binding upon all Participants and upon their executors, administrators, personal representatives, heirs and legatees. No member of the Board or the Committee shall be liable for any action, decision, determination or interpretation made in good faith with respect to the Plan or any Option granted hereunder. With respect to the 423 Component, an Offering Period shall be administered so as to ensure that all Participants have the same rights and privileges as provided by Section 423(b)(5) of the Code.
(b)
Administrator. The Company, Board or the Committee may engage the services of one or more brokerage firms or other companies to perform certain ministerial and procedural duties under the Plan including, but not limited to, mailing and receiving notices contemplated under the Plan, determining the number of Purchased Shares for each Participant, maintaining or causing to be maintained the Purchase Account and the Brokerage Account, disbursing funds maintained in the Purchase Account or proceeds from the sale of Shares through the Brokerage Account, and filing with the appropriate tax authorities proper tax returns and forms (including information returns) and providing to each Participant statements as required by law or regulation.

7


 

(c)
Indemnification. Each person who is or shall have been (a) a member of the Board, (b) a member of the Committee, or (c) an officer or employee of the Company to whom authority was delegated in relation to this Plan, shall be indemnified and held harmless by the Company against and from any loss, cost, liability or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action, suit or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under the Plan and against and from any and all amounts paid by him or her in settlement thereof, with the Company’s approval, or paid by him or her in satisfaction of any judgment in any such claim, action, suit or proceeding against him or her; provided, however, that he or she shall give the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf, unless such loss, cost, liability or expense is a result of his or her own willful misconduct or except as expressly provided by statute.

The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such persons may be entitled under the Company’s certificate of incorporation or bylaws, any contract with the Company, as a matter of law, or otherwise, or of any power that the Company may have to indemnify them or hold them harmless.

12.
Withdrawal. A Participant may withdraw from the Plan by properly completing and submitting to the Company a withdrawal form in accordance with the procedures prescribed by the Committee, which must be submitted prior to the date specified by the Committee before the last day of the applicable Offering Period. Upon withdrawal, any payroll deductions credited to the Participant’s Purchase Account prior to the effective date of the Participant’s withdrawal from the Plan will be returned to the Participant. No further payroll deductions or additional contributions for the purchase of Shares will be made during subsequent Offering Periods, unless the Participant properly completes and submits an election form, by the deadline prescribed by the Company. A Participant’s withdrawal from an offering will not have any effect upon his or her eligibility to participate in the Plan or in any similar plan that may hereafter be adopted by the Company.
13.
Termination of Employment. On the Termination Date of a Participant for any reason prior to the applicable Exercise Date, whether voluntary or involuntary, and including termination of employment due to retirement, death or as a result of liquidation, dissolution, sale, merger or a similar event affecting the Company or a Participating Subsidiary, the corresponding payroll deductions credited to his or her Purchase Account will be returned to him or her or, in the case of the Participant’s death, to the person or persons entitled thereto under Section 16, and his or her Option will be automatically terminated.
14.
Interest. No interest shall accrue on the payroll deductions or other contributions of a Participant in the Plan.
15.
Stock.
(a)
The stock subject to Options shall be common stock of the Company as traded on NASDAQ or on such other exchange as the Shares may be listed.

8


 

(b)
Subject to adjustment upon changes in capitalization of the Company as provided in Section 18 hereof, the maximum number of Shares which shall be made available for sale under the Plan shall be 687,218 Shares. In addition, subject to adjustments upon changes in capitalization of the Company as provided in Section 18 hereof, the maximum number of Shares which shall be made available for sale under the Plan shall automatically increase on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2021, and continuing until (and including) the fiscal year ending December 31, 2030, with such annual increase equal to the lesser of (i) 687,218 Shares, (ii) 1% of the number of Shares issued and outstanding on December 31 of the immediately preceding fiscal year, and (iii) an amount determined by the Board. If, on a given Exercise Date, the number of Shares with respect to which Options are to be exercised exceeds the number of Shares then available under the Plan, the Committee shall make a pro rata allocation of the Shares remaining available for purchase in as uniform a manner as shall be practicable and as it shall determine to be equitable.
(c)
A Participant shall have no interest or voting right in Shares covered by his or her Option until such Option has been exercised and the Participant has become a holder of record of Shares acquired pursuant to such exercise.
16.
Designation of Beneficiary. The Committee may permit Participants to designate beneficiaries to receive any Purchased Shares or payroll deductions, if any, in the Participant’s accounts under the Plan in the event of such Participant’s death. Beneficiary designations shall be made in accordance with procedures prescribed by the Committee. If no properly designated beneficiary survives the Participant, the Purchased Shares and payroll deductions, if any, will be distributed to the Participant’s estate.
17.
Assignability of Options. Neither payroll deductions or other contributions credited to a Participant’s Purchase Account nor any rights with regard to the exercise of an Option or to receive Shares under the Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in Section 16 hereof) by the Participant; provided that the Shares acquired pursuant to the terms of the Cashless Participation Program may be pledged and sold pursuant to the terms of the Cashless Participation Program. Any such attempt at assignment, transfer, pledge or other disposition shall be without effect, except that the Company may treat such act as an election to withdraw from an Offering Period in accordance with Section 12 hereof.

9


 

18.
Adjustment of Number of Shares Subject to Options.
(a)
Adjustment. Subject to any required action by the stockholders of the Company, the maximum number of securities available for purchase under the Plan, as well as the price per security and the number of securities covered by each Option under the Plan which has not yet been exercised shall be appropriately adjusted in the event of any a stock split, reverse stock split, stock dividend, combination or reclassification of the common stock of the Company, or any other increase or decrease in the number of Shares effected without receipt of consideration by the Company; provided, however, that conversion of any convertible securities of the Company shall not be deemed to have been “effected without receipt of consideration.” Such adjustment shall be made by the Board or the Committee, whose determination in that respect shall be final, binding and conclusive. If any such adjustment would result in a fractional security being available under the Plan, such fractional security shall be disregarded. Except as expressly provided herein, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of Shares subject to an Option. With respect to the 423 Component, the Options granted pursuant to the Plan shall not be adjusted in a manner that causes the Options to fail to qualify as options issued pursuant to an “employee stock purchase plan” within the meaning of Section 423 of the Code.
(b)
Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company, any Offering Period then in progress will terminate immediately prior to the consummation of such proposed action, unless otherwise provided by the Board, and the Board may either provide for the purchase of Shares as of the date on which such Offering Period terminates or return to each Participant the payroll deductions credited to such Participant’s Purchase Account.
(c)
Merger or Asset Sale. In the event of a proposed sale of all or substantially all of the assets of the Company, or the merger of the Company with or into another corporation, each outstanding Option shall be assumed or an equivalent option substituted by the successor corporation or a parent or subsidiary of the successor corporation, unless the Board determines, in the exercise of its sole discretion, that in lieu of such assumption or substitution to either terminate all outstanding Options and return to each Participant the payroll deductions credited to such Participant’s Purchase Account or to provide for the Offering Period in progress to end on a date prior to the consummation of such sale or merger.
19.
Amendments or Termination of the Plan.
(a)
The Board or the Committee may at any time and for any reason amend, modify, suspend, discontinue or terminate the Plan without notice; provided that no Participant’s existing rights in respect of existing Options are adversely affected thereby. To the extent necessary to comply with Section 423 of the Code (or any other applicable law, regulation or stock exchange rule), the Company shall obtain stockholder approval in such a manner and to such a degree as required.

10


 

(b)
Without stockholder consent and without regard to whether any Participant rights may be considered to have been “adversely affected,” the Board or the Committee shall be entitled to change the Purchase Price, Offering Periods, Purchase Periods, eligibility requirements, limit or increase the frequency and/or number of changes in the amount withheld during a Purchase Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding or other contributions in an amount less than or greater than the amount designated by a Participant in order to adjust for delays or mistakes in the Company’s processing of properly completed withholding elections, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Shares for each Participant properly correspond with amounts withheld from the Participant’s Compensation, and establish such other limitations or procedures as the Board or the Committee determines in its sole discretion advisable which are consistent with the Plan; provided, however, that changes to (i) the Purchase Price, (ii) the Offering Period, (iii) the Purchase Period, (iv) the maximum percentage of Compensation that may be deducted pursuant to Section 6(a) or (v) the maximum number of Shares that may be purchased in a Purchase Period, shall not be effective until communicated to Participants in a reasonable manner, with the determination of such reasonable manner in the sole discretion of the Board or the Committee.
20.
No Other Obligations. The receipt of an Option pursuant to the Plan shall impose no obligation upon the Participant to purchase any Shares covered by such Option. Nor shall the granting of an Option pursuant to the Plan constitute an agreement or an understanding, express or implied, on the part of the Company to employ the Participant for any specified period.
21.
Notices and Communication. Any notice or other form of communication which the Company or a Participant may be required or permitted to give to the other shall be provided through such means as designated by the Committee, including but not limited to any paper or electronic method.
22.
Condition upon Issuance of Shares.
(a)
Shares shall not be issued with respect to an Option unless the exercise of such Option and the issuance and delivery of such Shares pursuant thereto shall comply with all applicable provisions of law, domestic or foreign, including, without limitation, the 1933 Act and the 1934 Act and the rules and regulations promulgated thereunder, and the requirements of any stock exchange upon which the Shares may then be listed, and shall be further subject to the approval of counsel for the Company with respect to such compliance.
(b)
As a condition to the exercise of an Option, the Company may require the person exercising such Option to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required by any of the aforementioned applicable provisions of law.
23.
General Compliance. The Plan will be administered and Options will be exercised in compliance with the 1933 Act, 1934 Act and all other applicable securities laws and Company policies, including without limitation, any insider trading policy of the Company.

11


 

24.
Term of the Plan. The Plan shall become effective upon the earlier to occur of (i) its adoption by the Board and (ii) its approval by the stockholders of the Company (the earlier of such events, the “Effective Date”), and shall continue in effect until the earlier of (A) the termination of the Plan pursuant to Section 19 hereof and (B) the ten-year anniversary of the Effective Date, with no new Offering Periods commencing on or after such ten-year anniversary.
25.
Governing Law. The Plan and all Options granted hereunder shall be construed in accordance with and governed by the laws of the State of Delaware without reference to choice of law principles and subject in all cases to the Code and the regulations thereunder.
26.
Non-U.S. Participants. To the extent permitted under Section 423 of the Code, without the amendment of the Plan, the Company may provide for the participation in the Plan by Employees who are subject to the laws of foreign countries or jurisdictions on such terms and conditions different from those specified in the Plan as may in the judgment of the Company be necessary or desirable to foster and promote achievement of the purposes of the Plan and, in furtherance of such purposes the Company may make such modifications, amendments, procedures, subplans and the like as may be necessary or advisable to comply with provisions of laws of other countries or jurisdictions in which the Company or the Participating Subsidiaries operate or have employees. Each subplan shall constitute a separate “offering” under this Plan in accordance with Treas. Reg. §1.423-2(a) and, to the extent inconsistent with the requirements of Section 423, any such subplan shall be considered part of the Non-423 Component, and rights granted thereunder shall not be required by the terms of the Plan to comply with Section 423 of the Code.
27.
Section 409A. The 423 Component is exempt from the application of Section 409A of the Code, and any ambiguities herein shall be interpreted to so be exempt from Section 409A of the Code. The Non-423 Component is intended to be exempt from the application of Section 409A of the Code under the short-term deferral exception and any ambiguities shall be construed and interpreted in accordance with such intent. In furtherance of the foregoing and notwithstanding any provision in the Plan to the contrary, if the Committee determines that an option granted under the Plan may be subject to Section 409A of the Code or that any provision in the Plan would cause an option under the Plan to be subject to Section 409A, the Committee may amend the terms of the Plan and/or of an outstanding option granted under the Plan, or take such other action the Committee determines is necessary or appropriate, in each case, without the participant’s consent, to exempt any outstanding option or future option that may be granted under the Plan from or to allow any such options to comply with Section 409A of the Code, but only to the extent any such amendments or action by the Committee would not violate Section 409A of the Code. Notwithstanding the foregoing, the Company shall have no liability to a participant or any other party if the option under the Plan that is intended to be exempt from or compliant with Section 409A of the Code is not so exempt or compliant or for any action taken by the Committee with respect thereto.

 

 

12


EX-23.1 3 om-ex23_1.htm EX-23.1 EX-23.1

Exhibit 23.1

 

 

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the registration statement (No. 333‑248903) on Form S-8 of our report dated February 23, 2022, with respect to the financial statements of Outset Medical, Inc. and the effectiveness of internal control over financial reporting.

/s/ KPMG LLP

San Francisco, California
February 23, 2022

 

 


EX-31.1 4 om-ex31_1.htm EX-31.1 EX-31.1

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Leslie Trigg, certify that:

1.
I have reviewed this annual report on Form 10-K of Outset Medical, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 23, 2022

By:

/s/ Leslie Trigg

 

 

Leslie Trigg

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 

 


EX-31.2 5 om-ex31_2.htm EX-31.2 EX-31.2

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Nabeel Ahmed, certify that:

1.
I have reviewed this annual report on Form 10-K of Outset Medical, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 23, 2022

By:

/s/ Nabeel Ahmed

 

 

Nabeel Ahmed

 

 

Chief Financial Officer

 

 

(Principal Financial Officer)

 

 


EX-32.1 6 om-ex32_1.htm EX-32.1 EX-32.1

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Outset Medical, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to her knowledge:

1.
The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations the Company.

 

Date: February 23, 2022

By:

/s/ Leslie Trigg

 

 

Leslie Trigg

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 

Date: February 23, 2022

By:

/s/ Nabeel Ahmed

 

 

Nabeel Ahmed

 

 

Chief Financial Officer

 

 

(Principal Financial Officer)

 

 

 


GRAPHIC 7 img263710155_0.jpg GRAPHIC begin 644 img263710155_0.jpg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ⅅ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𓆋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ɉ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ⅅ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�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�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end GRAPHIC 9 img263710155_2.jpg GRAPHIC begin 644 img263710155_2.jpg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end EX-101.DEF 10 om-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.CAL 11 om-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.SCH 12 om-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Commitments and Contingencies - Maturity of Operating Lease Liabilities (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - Income Taxes - Summary of Components of the Deferred Tax Assets (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - Statement of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Revenue from Contracts with Customers link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Term Loans link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Equity Incentive Plan link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Net Loss Per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Selected Quarterly Information link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Revenue from Contracts with Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Term Loans (Tables) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Equity Incentive Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Selected Quarterly Information (Tables) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Description of Business - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Revenue from Contracts with Customers - Summary of Revenue by Source (Detail) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail) 1 link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis by Level Within Fair Value Hierarchy (Detail) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Fair Value Measurements - Summary of Remaining Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Balance Sheet Components - Summary of cash, cash equivalents and restricted cash (Detail) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Balance Sheet Components - Schedule of Inventories (Detail) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Balance Sheet Components - Summary of Property Plant and Equipment (Detail) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Balance Sheet Components - Accrued Warranty Liability (Detail) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Balance Sheet Components - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Commitment and Contingencies (Additional Information) (Detail) link:presentationLink link:calculationLink link:definitionLink 100490 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Detail) link:presentationLink link:calculationLink link:definitionLink 100500 - Disclosure - Commitments and Contingencies - Schedule of Weighted-average Remaining Lease Term and Discount Rate (Detail) link:presentationLink link:calculationLink link:definitionLink 100510 - Disclosure - Commitments and Contingencies - Maturity of Operating Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 100520 - Disclosure - Term Loans - Schedule of Term Loan (Detail) link:presentationLink link:calculationLink link:definitionLink 100530 - Disclosure - Term Loans - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100540 - Disclosure - Term Loans - Summary of Debt Maturities (Detail) link:presentationLink link:calculationLink link:definitionLink 100550 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink 100560 - Disclosure - Stockholders' Equity - Summary of Reserved Shares of Common Stock on Converted Basis for Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 100570 - Disclosure - Equity Incentive Plans - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100580 - Disclosure - Equity Incentive Plan - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 100590 - Disclosure - Equity Incentive Plan - Schedule of Stock Option Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 100600 - Disclosure - Equity Incentive Plan - Summary of Restricted stock activity (Details) link:presentationLink link:calculationLink link:definitionLink 100610 - Disclosure - Equity Incentive Plan - Schedule of Employees Stock Purchase Plan (ESPP) (Details) link:presentationLink link:calculationLink link:definitionLink 100620 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 100630 - Disclosure - Income Taxes - Loss before Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 100640 - Disclosure - Income Taxes (Additional Information) (Detail) link:presentationLink link:calculationLink link:definitionLink 100650 - Disclosure - Income Taxes - Summary of Effective Tax Rate of the Provision for Income Taxes (Detail) link:presentationLink link:calculationLink link:definitionLink 100660 - Disclosure - Income Taxes - Summary of Components of the Deferred Tax Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 100670 - Disclosure - Income Taxes - Summary of Reconciliation of the Total Unrecognized Tax Benefits (Detail) link:presentationLink link:calculationLink link:definitionLink 100680 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 100690 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 13 om-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 14 om-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Performance Stock Units Outstanding Member. Performance Stock Units Outstanding [Member] Performance Stock Units Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period General vesting period Exercise of warrants for common stock shares Exercise of warrants for common stock shares Common stock warrant exercises (shares) Segment Reporting, Policy [Policy Text Block] Segment Gross Profit Gross profit Gross profit Reclassification of preferred stock warrant liability to additional paid in capital. Reclassification Of Preferred Stock Warrant Liability To Additional Paid In Capital Reclassification of preferred stock warrant liability to additional paid in capital Additions charged to cost of product revenue Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Standard and Extended Product Warranty Accrual, Increase for Warranties Issued, Total Operating Loss Carryforwards, Total Operating Loss Carryforwards Operating loss carryforward Forecast [Member] Forecast Operating loss carryforwards amount expired. Operating Loss Carry forwards Amount Expired Operating loss carryforward expiration beginning Temporary Equity, Shares Authorized Redeemable convertible preferred stock, shares authorized Other debt issuance costs. Other Debt Issuance Costs Other debt issuance costs Auditor Location Auditor Location Right-of-use assets Deferred Tax Liabilities Right Of Use Assets Deferred tax liabilities Right-of-use assets. Series C Redeemable Convertible Preferred Stock Warrants Member. Series C Redeemable Convertible Preferred Stock Warrants [Member] Series C Redeemable Convertible Preferred Stock Warrants Operating Expenses [Abstract] Operating expenses: Temporary Equity, Accretion to Redemption Value, Adjustment Adjustment to redemption value on redeemable convertible preferred stock Asset Class [Domain] Asset Class Operating Income (Loss) Loss from operations Proceeds from stock option exercises and employee stock purchase plan purchases. Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases Proceeds from stock option exercises and employee stock purchase plan purchases Customer two member Customer Two [Member] Customer 2 Inventory, Finished Goods, Gross Finished goods Inventory, Finished Goods, Gross, Total Concentration Risk Type [Domain] Purchase Commitment, Remaining Minimum Amount Committed Non-cancellable purchase commitments within next 12 months Open purchase commitments Percentage Of Employees Deferrals Required To Match Higher Percentage Of Employees Deferrals Required To Match Higher Percentage of employees deferrals required to match higher Entity Emerging Growth Company Entity Emerging Growth Company Investment, Policy [Policy Text Block] Short-Term Investments Income Tax Disclosure [Abstract] Financial Instrument [Axis] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value Per Share, Forfeited Schedule of Cash and Cash Equivalents [Table Text Block] Summary of Cash, Cash Equivalents and Restricted Cash Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares granted of stock options with performance and market-based conditions to employees Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Geographical [Axis] Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Common stock, $0.001 par value; 300,000 shares authorized as of December 31, 2021 and December 31, 2020; 47,018 and 42,722 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively Entity Address, State or Province Entity Address, State or Province Liabilities Total liabilities Disaggregation of Revenue [Table Text Block] Summary of Revenue by Source Inventory, Raw Materials, Gross Raw materials Inventory, Raw Materials, Gross, Total Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Stockholders' Equity, Reverse Stock Split Reverse stock split, description Increase (decrease) in operating lease liabilities. Increase Decrease In Operating Lease Liabilities Operating lease liabilities Class of Stock [Domain] Class of Stock Convertible Preferred Stock, Shares Issued upon Conversion Redeemable convertible preferred stock converted to common stock OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized gain (loss) on available-for-sale securities Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted Weighted-average shares of common stock, basic and diluted Redeemable Convertible Preferred Stock [Member] Redeemable Convertible Preferred Stock Redeemable Convertible Preferred Stock, on an as-if Converted Basis Temporary equity adjustment to redemption value on redeemable convertible preferred stock. Temporary Equity Adjustment To Redemption Value On Redeemable Convertible Preferred Stock Temporary equity, Adjustment to redemption value on redeemable convertible preferred stock Increase (decrease) in accrued warranty liability. Increase Decrease In Accrued Warranty Liability Accrued warranty liability Temporary equity deemed dividend on settlement of accrued dividend. Temporary Equity Deemed Dividend On Settlement Of Accrued Dividend Temporary Equity, Deemed dividend on settlement of accrued dividend General and Administrative Expense [Member] General and Administrative Accrued Employee Benefits, Current Accrued compensation and related benefits Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Term, Exercisable as of December 31, 2021 Restricted Cash, Total Restricted Cash Restricted cash balance Restricted cash Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date ESPP Expiration Date Product [Member] Product Revenue Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current, Total Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Contract with Customer, Liability, Revenue Recognized Revenue recognized Number Of Common Stock Shares Purchased Pursuant To Employee Stock Purchase Plan Number Of Common Stock Shares Purchased Pursuant To Employee Stock Purchase Plan Number of Shares Purchased Other Liabilities, Current Other Other Liabilities, Current, Total City Area Code City Area Code Purchase Commitment [Member] Purchase Commitments Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of Estimated Fair Value of Stock Option Grants Gross deferred tax assets Deferred Tax Assets, Gross Gross deferred tax assets Temporary Equity, Par or Stated Value Per Share Redeemable convertible preferred stock, par value Net deferred tax assets Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance US Treasury Securities [Member] U.S. Treasury securities Revenues [Abstract] Revenue: Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Change in accounting principle, accounting standards update, adopted Operating lease expiration month and year Lessee Operating Lease Expiration Month And Year Operating lease expiration month and year Commitments and Contingencies Commitments and contingencies (Note 6) Non-cash interest expense. Non Cash Interest Expense Non-cash interest expense Proceeds from Sale, Maturity and Collection of Investments Sales and maturities of investment securities Proceeds from Sale, Maturity and Collection of Investments, Total Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share Description of business. Description Of Business [Line Items] Description Of Business [Line Items] Schedule of Product Warranty Liability [Table Text Block] Accrued Warranty Liability Defined Benefit Plan, Plan Assets, Accounting Policy Election, Measurement Date [Policy Text Block] Employee Benefit Plan Stock Issued During Period, Shares, New Issues Issuance of common stock upon initial public offering, net of issuance costs (shares) Stock issued during the period Debt Securities, Available-for-sale Aggregate Fair Value Debt Securities, Available-for-sale, Total Debt Instrument, Basis Spread on Variable Rate Basis spread on variable rate Scenario [Axis] Revenue Benchmark [Member] Revenue Benchmark Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Tenant Improvements Tenant improvement allowance Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock through employee stock purchase plan (shares) Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Denominator: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Change in accounting principle, accounting standards update, immaterial effect Cash equivalents and short-term investments policy text block Cash Equivalents and Short-Term Investments [Policy Text Block] Cash Equivalents and Short-Term Investments Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of redeemable convertible preferred stock to common stock upon initial public offering Income Statement [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Debt Disclosure [Text Block] Term Loan Capital Expenditures Incurred but Not yet Paid Capital expenditures included in accounts payable and accrued expenses Tax Credit Carryforward [Axis] Restricted Stock Units Outstanding Member. Restricted Stock Units Outstanding [Member] Restricted Stock Units Outstanding Capitalized contract cost amortization period description Capitalized Contract Cost Amortization Period Description Capitalized contract cost amortization period description Standard and Extended Product Warranty Accrual, Decrease for Payments Consumption Standard and Extended Product Warranty Accrual, Decrease for Payments, Total Quarterly Financial Information [Text Block] Selected Quarterly Information Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Percentage Of Maximum Number of Common Stock Outstanding Tax Credit Carryforward, Name [Domain] General and Administrative Expense General and administrative General and Administrative Expense, Total Property, Plant and Equipment, Net Property and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Property and equipment, net Contract with Customer, Liability, Current Deferred revenue, current Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Operating leases. Operating Leases [Abstract] Operating leases: Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Stock Units, Forfeited Income tax examination open years for examination Income Tax Examination Open Years For Examination Open year examination Statement of Comprehensive Income [Abstract] Gross deferred tax liabilities Gross deferred tax liabilities Gross deferred tax liabilities Deferred Tax Liabilities, Gross Debt Securities, Available-for-sale, Amortized Cost Amortized Costs Right-of-use assets Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Temporary equity gain on extinguishment of redeemable convertible preferred stock Temporary equity gain on extinguishment of redeemable convertible preferred stock Temporary Equity, Gain on extinguishment of redeemable convertible preferred stock Revenue from operating lease arrangements Revenue from Consoles Operating Lease Arrangements Revenue from Consoles Operating Lease Arrangements Customer Concentration Risk [Member] Customer Concentration Risk Security Exchange Name Security Exchange Name Statistical Measurement [Domain] Statistical Measurement Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Long-Term Debt, Maturity, Year Three 2024 Furniture and Fixtures [Member] Furniture and Fixtures Share-Based Compensation Arrangement By Share-Based Payment Award Offering Period Share-Based Compensation Arrangement By Share-Based Payment Award Offering Period ESPP Offering Period Accounting Standards Update 2019-12 [Member] ASU 2019-12 Subsequent Event Type [Domain] Line of Credit Facility, Maximum Borrowing Capacity Credit facility, maximum borrowing capacity Stockholders' Equity Redeemable convertible preferred stock and stockholders equity deficit text block. Redeemable Convertible Preferred Stock And Stockholders Equity Deficit [Text Block] Debt Disclosure [Abstract] Document Period End Date Document Period End Date Restricted Cash, Noncurrent Restricted cash Income Statement Location [Axis] Income Statement Location Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Inventory, Work in Process, Gross Work in process Investments [Domain] Investments Reclassification Of Redeemable Convertible Preferred Stock Warrant Liability To Additional Paid In Capital Reclassification of redeemable convertible preferred stock warrant liability to additional paid in capital. Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital Common Stock, Shares Authorized Common stock, shares authorized Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Summary of Reconciliation of the Total Unrecognized Tax Benefits Schedule of cash, cash equivalents and restricted cash. Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block] Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash Use of Estimates, Policy [Policy Text Block] Use Of Estimates Operating Lease, Liability, Current Operating lease liabilities, current Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discount on investments, net Temporary Equity Shares Conversion Of Convertible Redeemable Preferred Stock In to Common Stock Temporary Equity Shares Conversion Of Convertible Redeemable Preferred Stock In to Common Stock Temporary equity, Conversion of redeemable convertible preferred stock to common stock upon initial public offering (Shares) Class of Stock [Axis] Class of Stock Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Concentration Risk Benchmark [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive shares excluded from calculation of diluted net loss per share Purchase Commitment, Excluding Long-term Commitment [Axis] Long-Term Debt, Maturity, Year Two 2023 Schedule of Long-term Debt Instruments [Table] Debt Instrument [Table] Lease related assets and liabilities. Lease Related Assets And Liabilities Table TextBlock Summary of Company ROU Assets and Lease Liabilities Vesting [Axis] Vesting Debt Instrument, Maturity Date Loan maturity date Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent, Total Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of Financial Assets Measured at Fair Value On Recurring Basis by Level Within Fair Value Hierarchy Deferred Tax Assets, Net [Abstract] Deferred tax assets: Operating Lease Payments Maturity [Table Text Block] Operating Lease Payments Maturity [Table Text Block] Summary of Maturity of Operating Leases Machinery and Equipment [Member] Machinery and Equipment Schedule of Inventory, Current [Table Text Block] Schedule of Inventories Current Fiscal Year End Date Current Fiscal Year End Date Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) increase in cash, cash equivalents and restricted cash Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Operating Lease, Cost Operating lease costs Grantee Status [Axis] Deferred Tax Assets, Other Lessee, Operating Lease, Existence of Option to Extend [true false] Operating lease existence of option to extend [true false] Disaggregation of Revenue [Table] Disaggregation Of Revenue [Table] Assets [Abstract] Assets Assets: Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Lessee Operating Lease Liability Payments Due After Year Four Thereafter Tabular disclosure of the components of cash and cash equivalents and restricted cash. Schedule Of Cash And Cash Equivalents And Restricted Cash [Table Text Block] Summary of Cash, Cash Equivalents and Restricted Cash Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of redeemable convertible preferred stock to common stock upon initial public offering (shares) Performance Stock Units. Performance Stock Units [Member] Performance Stock Units Business Description and Basis of Presentation [Text Block] Description of Business Registration Payment Arrangement [Line Items] Commitments And Contingencies [Line Items] Lessee, Operating Lease, Liability, to be Paid, Year One 2022 Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Debt Instrument, Name [Domain] Debt Instrument, Name CANADA San Jose, CA Debt Instrument, Face Amount Principal of term loan Total term loan Common Stock, Par or Stated Value Per Share Common stock, par value revenue performance obligation 1 revenue performance obligation 1 Revenue Performance Obligation 1 Revenue from Contract with Customer [Policy Text Block] Revenue Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Summary of Effective Tax Rate of the Provision for Income Taxes Financial Support to Nonconsolidated Legal Entity [Domain] Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Increase related to current year positions State and Local Jurisdiction [Member] State Shares, Outstanding Ending Balance (shares) Beginning Balance (shares) Investments, Debt and Equity Securities [Abstract] Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Research and Development Expense, Policy [Policy Text Block] Research and Development Perceptive Term Loan [Member] Perceptive Term Loan [Member] Perceptive Term Loan Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before provision for income taxes Loss on extinguishment of term loan Document Type Document Type Vesting [Domain] Vesting Gain on extinguishment of redeemable convertible preferred stock Gain on extinguishment of redeemable convertible preferred stock Gain on extinguishment of redeemable convertible preferred stock Domestic Tax Authority [Member] Federal Preferred Stock, Value, Issued Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of December 31, 2021 and December 31, 2020 Operating Lease, Liability, Noncurrent Operating lease liabilities, noncurrent Operating Lease Liability Noncurrent, Total Consumables product. Consumables Product [Member] Consumables Product Assets, Current Total current assets Accounts Receivable, Credit Loss Expense (Reversal) Provision for accounts receivable Net operating loss carryforwards latest expiration year. Net Operating Loss Carry forwards Latest Expiration Year Expiration year Reclassification Of Redeemable Convertible Preferred Stock Warrant Liability For Conversion Of Seriesa Warrants In to Common Stock Warrants Reclassification of redeemable convertible preferred stock warrant liability for conversion of series A warrants into common stock warrants. Reclassification of redeemable convertible preferred stock warrant liability for conversion of Series A redeemable preferred stock warrants into common stock warrants Reclassification of redeemable convertible preferred stock warrant liability for conversion of Series A redeemable preferred stock warrants into common stock warrants Disaggregation of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Share-based Payment Arrangement, Employee [Member] Share-based Payment Arrangement [Policy Text Block] Stock-Based Compensation Expense Schedule Of Contract With Customer Liability [Table Text Block] Schedule Of Contract With Customer Liability [Table Text Block] Schedule of Contract Liabilities Share-based Payment Arrangement, Option [Member] Stock Option Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-Average Remaining Term Income Tax Expense (Benefit) Provision for income taxes Income Tax Expense (Benefit), Total Stock Options Outstanding Member. Stock Options Outstanding [Member] Stock Options Outstanding Service and other revenue. Service And Other Revenue [Member] Service and Other Revenue Increase (Decrease) in Deferred Revenue Deferred revenue Earnings Per Share, Basic and Diluted Net loss per share attributable to common stockholders, basic and diluted Net loss per share attributable to common stockholders, basic and diluted Earnings Per Share, Basic and Diluted, Total Standard Product Warranty, Policy [Policy Text Block] Accrued Warranty Liability Antidilutive Securities [Axis] Antidilutive Securities Temporary equity settlement of accrued dividend. Temporary Equity Settlement Of Accrued Dividends Temporary Equity, Issuance of common stock on settlement of accrued dividend Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Stock Units, Outstanding as of December 31, 2019 Stock Units, Outstanding as of December 31, 2020 Provision for inventories. Provision For Inventories Provision for inventories Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Deferred Tax Assets, Operating Loss Carryforwards, Total Deferred Tax Assets, Operating Loss Carryforwards Net operating loss carryforwards Stock Issued Issuance of common stock on settlement of accrued dividend Warrants issued to purchase common stock price per share. Warrants Issued To Purchase Common Stock Price Per Share Exercise price Temporary equity stock issued during period shares new issues. Temporary Equity Stock Issued During Period Shares New Issues Temporary Equity, Issuance of Series D and Series E redeemable convertible preferred stock, net of issuance costs (shares) Proceeds From Issuance Of Cash Exercise Of Redeemable Convertible Preferred Stock Warrant Proceeds from issuance of cash exercise of redeemable convertible preferred stock warrant. Proceeds from cash exercise of redeemable convertible preferred stock warrants Aggregate cash proceed of redeemable convertible preferred stock warrant Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Cash cash equivalents, restricted cash and short term investments. Cash Cash Equivalents Restricted Cash And Short Term Investments Cash, cash equivalents, restricted cash and short-term investments Class of Warrant or Right [Domain] Plan Name [Axis] Plan Name Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Less: accumulated depreciation and amortization Underwriters. Underwriters [Member] Underwriters Operating Expenses Total operating expenses IPO [Member] IPO Employees share purchase plan. Employees Share Purchase Plan [Member] Employees Share Purchase Plan (ESPP) Lease, Cost Total lease costs Inventory, Net Inventories Total inventories Financial Instruments [Domain] Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Holding Losses Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price, Balance as of December 31, 2020 Weighted-Average Exercise Price, Balance as of December 31, 2021 Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Share Based Compensation Arrangement By Share Based Payment Award Options Estimated Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award Options Estimated Grant Date Fair Value Estimated Grant Date Fair Value Transfer of property and equipment to inventories. Transfer Of Property And Equipment To Inventories Transfer of property and equipment to inventories Lessee, Operating Lease, Liability, Maturity [Table Text Block] Maturity of Operating Lease Liabilities Operating Loss Carryforwards [Table] Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercise price Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Holding Gains Earnings Per Share [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Description Stock options, description Lessee, Operating Lease, Liability, to be Paid, Year Two 2023 Net Income (Loss) Attributable to Parent Net loss Net loss Net loss Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Increase (Decrease) in Prepaid Expenses, Other Prepaid expenses and other assets Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Research and Development Expense [Member] Research and Development Document Fiscal Period Focus Document Fiscal Period Focus Temporary Equity, Stock Issued During Period, Value, New Issues Temporary Equity, Issuance of Series D and Series E redeemable convertible preferred stock, net of issuance costs Concentration Risk Number Of Major Customers Concentration Risk Number Of Major Customers Number of major customers Accounting Policies [Abstract] Accrued research and development expenses. Accrued Research And Development Expenses Accrued research and development expenses Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Entity Address, Address Line One Entity Address, Address Line One Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Total intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding Stock Options Outstanding Options, Balance as of December 31, 2020 Outstanding Options, Balance as of December 31, 2021 Adjustment to redemption value on redeemable convertible preferred stock. Adjustment To Redemption Value On Redeemable Convertible Preferred Stock Adjustment to redemption value on redeemable convertible preferred stock Finance Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Asset-backed Securities [Member] Asset-backed securities Liabilities, Current Total current liabilities Commercial Paper [Member] Commercial paper Entity Address, Postal Zip Code Entity Address, Postal Zip Code Warrants issued to purchase common stock value. Warrants Issued To Purchase Common Stock Value Fair value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Balance as of December 31, 2019 Aggregate Intrinsic Value, Balance as of December 31, 2021 Lessee, Operating Lease, Liability, to be Paid Total lease payments Product and Service [Domain] Product and Service Debt instrument principal payment term after interest only period expires. Debt Instrument Principal Payment Term After Interest Only Period Expires Debt instrument principal repayment period Temporary Equity, Carrying Amount, Attributable to Parent Temporary Equity, Ending Balance Temporary Equity, Beginning Balance Redeemable convertible preferred stock, $0.001 par value; no shares authorized and no shares issued and outstanding as of December 31, 2020; 154,592 shares authorized and 147,214 shares issued and outstanding as of December 31, 2019 Stock options to purchase common stock. Stock Options To Purchase Common Stock [Member] Stock Options to Purchase Common Stock Proceeds from Issuance Initial Public Offering Aggregate net proceeds from IPO Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Debt instrument interest only payments year and month. Debt Instrument Interest Only Payments Year And Month Debt instrument interest only payments end date Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash, cash equivalents and restricted cash as of end of period Cash, cash equivalents and restricted cash as of beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Debt Securities, Available-for-sale, Unrealized Loss Position, Total Debt Securities, Available-for-sale, Unrealized Loss Position Available-for-sale securities in unrealized loss position Equity Components [Axis] Equity Components Proceeds from Issuance of Long-term Debt, Total Proceeds from Issuance of Long-term Debt Proceeds from issuance of term loan, net of issuance costs Lease, Cost [Table Text Block] Schedule of Components of Lease Costs Assets, Current [Abstract] Current assets: Variable Lease, Cost Variable lease costs Entity Registrant Name Entity Registrant Name Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive loss: Cost of Revenue [Abstract] Cost of revenue: Gain (Loss) on Disposition of Property Plant Equipment, Total Gain (Loss) on Disposition of Property Plant Equipment Loss on disposal of property and equipment Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Service-based options vesting period Entity Interactive Data Current Entity Interactive Data Current Net income (loss) attributable to common stockholders, basic and diluted. Net Income Loss Attributable To Common Stockholders Basic And Diluted Net loss attributable to common stockholders, basic and diluted Net loss attributable to common stockholders, basic and diluted Prime Rate [Member] Prime Rate Entity Address, City or Town Entity Address, City or Town Customer [Axis] Accounts Receivable [Member] Accounts Receivable Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total Effective Income Tax Rate Reconciliation, Tax Credit, Percent Federal and state tax credits Unamortized Debt Issuance Expense Less: amount representing interest Less: amount representing interest Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Components Customer three member Customer Three [Member] Customer 3 Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Trading Symbol Trading Symbol Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of Fair Value of Warrants Finance lease. Finance Lease [Abstract] Finance lease: Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest Concentration Risk Type [Axis] Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Summary of Restricted stock activity Inventory, Policy [Policy Text Block] Inventories Two thousand twenty equity incentive plan. Two Thousand Twenty Equity Incentive Plan [Member] 2020 Equity Incentive Plan Foreign Foreign Tax Authority [Member] Capitalized Contract Cost, Amortization Period Capitalized contract cost, amortization period Payment of redeemable convertible preferred stock issuance costs. Payment Of Redeemable Convertible Preferred Stock Issuance Costs Payment of redeemable convertible preferred stock issuance costs Short-term Investments [Member] Short-term investments Local Phone Number Local Phone Number Advertising Expense Advertising costs Stockholders' Equity Attributable to Parent Ending Balance Beginning Balance Total stockholders' equity (deficit) Subsequent Event Type [Axis] Non-cash lease expense. Non Cash Lease Expense Non-cash lease expense Entity Bankruptcy Proceedings, Reporting Current Entity Bankruptcy Proceedings, Reporting Current Quarterly Financial Information [Table Text Block] Schedule of Unaudited Quarterly Financial Information Unrecognized Tax Benefits Balance, beginning of year Balance, end of year Product Warranties Disclosures [Abstract] Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Debt Instrument, Description of Variable Rate Basis Description of variable rate basis Statistical Measurement [Axis] Statistical Measurement Entity Small Business Entity Small Business Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Deferred Tax Assets, Tax Credit Carryforwards, Total Deferred Tax Assets, Tax Credit Carryforwards Tax credits Organization, Consolidation and Presentation of Financial Statements [Abstract] Lessee, Leases [Policy Text Block] Leases Fair Value, Separate Account Investment [Table] Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Forfeited and expired Forfeited and expired Share Price Share price Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Long-term Debt, Excluding Current Maturities Term loan, noncurrent Total term loan, noncurrent Variable Rate [Axis] Variable Rate Summary of Components of the Deferred Tax Assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment for Long-Lived Assets Research Tax Credit Carryforward [Member] Research and Development Selling and Marketing Expense [Member] Sales and Marketing Purchase Commitment, Excluding Long-term Commitment [Domain] Variable Rate [Domain] Variable Rate Property, Plant and Equipment, Useful Life Estimated useful lives of the assets Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Number of common stock issued Defined Contribution Plan, Employer Matching Contribution, Percent of Match Employer matching contribution Stock Issued During Period, Value, Stock Dividend Issuance of common stock on settlement of accrued dividend Accrued expenses and other current liabilities. Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Net Income (Loss) Attributable to Parent [Abstract] Numerator: Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Granted Purchase Commitment, Description Purchase commitment descriptions Registration Payment Arrangement [Table] Sale of Stock [Domain] Sale of Stock Temporary Equity, Shares Issued Redeemable convertible preferred stock, shares issued Equity [Abstract] Revenue from Contract with Customer [Abstract] Land Subject to Ground Leases Area of lease | ft Plan Name [Domain] Plan Name Schedule of weighted-average remaining lease term and discount rate. Schedule Of Weighted Average Remaining Lease Term And Discount Rate Table TextBlock Schedule of Weighted-average Remaining Lease Term and Discount Rate Class of Stock [Line Items] Customer one member Customer One [Member] Customer 1 Long-Term Debt, Maturity, Year One 2022 Income Tax Authority [Axis] Yankee debt securities. Yankee Debt Securities [Member] Yankee debt securities Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Valuation allowance Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State taxes Share-Based Compensation Arrangement By Share-Based Payment Award Initial Offering Date Share-Based Compensation Arrangement By Share-Based Payment Award Initial Offering Date ESPP Initial Offering Date Stock Issued During Period, Value, New Issues Issuance of common stock upon initial public offering, net of issuance costs Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering Conversion of redeemable convertible preferred stock into common stock upon initial public offering. Conversion of redeemable convertible preferred stock into common stock upon initial public offering Conversion of redeemable convertible preferred stock into common stock upon initial public offering Common stock warrants expiration date. Common Stock Warrants Expiration Date Common stock warrants expiration date Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Non-deductible compensation Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent, Total Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent Quarterly Financial Information Disclosure [Abstract] Interest Expense Interest expense Interest Expense, Total Debt Instrument, Unamortized Discount Debt discount on Perceptive Term Loan Unamortized debt discount Debt Instrument, Unamortized Discount, Total Less: unamortized debt discount Proceeds from Warrant Exercises Proceeds from exercise of common stock warrant Stock issued during period shares stock dividend. Stock Issued During Period Shares Stock Dividend Issuance of common stock on settlement of accrued dividend (shares) Share-based Payment Arrangement, Noncash Expense Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense, Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Change in fair value of redeemable convertible preferred stock warrant liability. Change In Fair Value Of Redeemable Convertible Preferred Stock Warrant Liability Change in fair value of redeemable convertible preferred stock warrant liability Change in fair value of redeemable convertible preferred stock warrant liability Exercise of warrants for common stock Exercise of warrants for common stock Common stock warrant exercises Share-based Payment Arrangement, Option, Activity [Table Text Block] Summary of the Stock option activity Long-Lived Tangible Asset [Domain] Inventory Disclosure [Abstract] Warrants to purchase common stock. Warrants To Purchase Common Stock [Member] Warrant to Purchase Common Stock Tablos under operating leases. Tablos Under Operating Leases [Member] Tablos Under Operating Leases Equity Incentive Plan [Table] Equity Incentive Plan [Table] Equity Incentive Plan [Table] Accrued interest, noncurrent. Accrued Interest Noncurrent Accrued interest, noncurrent Warranty period Warranty Period Warranty period Temporary equity costs to adjust redemption value on redeemable convertible preferred stock Temporary equity costs to adjust redemption value on redeemable convertible preferred stock Temporary Equity, Costs to adjust the redemption value on redeemable convertible preferred stock Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable as of December 31, 2021 Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Four Zero One K Plan Member FourZeroOneKPlan [Member] Four zero one k plan [Member] Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Eligible Compensation Percentage to Purchase Common Stock Commitments and Contingencies Disclosure [Abstract] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for lease liabilities Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value Per Share, Vested Assets Total assets Fair Value, Inputs, Level 2 [Member] Level 2 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Stock option exercises (shares) Increase (Decrease) in Employee Related Liabilities Accrued payroll and related benefits Increase (Decrease) in Employee Related Liabilities, Total Statement [Line Items] Statement [Line Items] Liabilities and Equity Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) Class of Warrant or Right [Axis] Property, Plant and Equipment [Abstract] Summary of Loss before provision for income taxes Schedule of Loss before provision for income taxes [Table Text Block] Schedule of Loss before provision for income taxes [Table Text Block] Statement of Cash Flows [Abstract] Accrued expenses and other current liabilities. Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block] Accrued Expenses and Other Current Liabilities Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings Other-than-temporary impairment losses related to investments Additional Paid-in Capital [Member] Additional Paid-in Capital Title of 12(b) Security Title of 12(b) Security Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Equity Incentive Plan [Line Items] Equity Incentive Plan [Line Items] Equity Incentive Plan [Line Items] Shares Available For Future Grant Under Two Thousand And Twenty Plan Member. Shares Available For Future Grant Under Two Thousand And Twenty Plan [Member] Shares Available for Future Grant Under 2020 Plan Employee stock option excluding market and performance condition. Employee Stock Option Excluding Market And Performance Condition [Member] Fair Value, Inputs, Level 3 [Member] Level 3 Debt Instrument [Line Items] Debt Instrument [Line Items] Entity Well-known Seasoned Issuer Operating Loss Carryforwards [Line Items] Income Taxes [Line Items] Standby Letters of Credit [Member] Standby Letters of Credit Award Type [Domain] Award Type Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting rate Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Contractual Term Supplemental Cash Flow Elements [Abstract] Supplemental cash flow disclosures: Property, Plant and Equipment [Table Text Block] Summary of Property Plant and Equipment Fair Value, Inputs, Level 1 [Member] Level 1 Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Total Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Stock-based compensation Schedule of Maturities of Long-term Debt [Table Text Block] Summary of Debt Maturities Lessee, Operating Lease, Liability, to be Paid, Year Four 2025 Lease liabilities Gross deferred tax liabilites Deferred Tax Assets, Net Share based compensation arrangement by share based payment award vesting period month and year. Share Based Compensation Arrangement By Share Based Payment Award Vesting Period Month And Year Award vesting period, month and year Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Effect of deferred tax adjustment Accrued inventory current. Accrued Inventory Current Accrued inventory Restricted Stock [Member] Restricted Stock Nonoperating Income (Expense) Interest income and other income, net Nonoperating Income (Expense), Total Corporate Debt Securities [Member] Corporate debt Contract liabilities deferred revenue policy text block Contract Liabilities Deferred Revenue [Policy Text Block] Contract Liabilities - Deferred Revenue Subsidiary, Sale of Stock [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted Entity Current Reporting Status Entity Current Reporting Status Revenue from Contract with Customer [Text Block] Revenue from Contracts with Customers Investment Type [Axis] Investment Type Revenue, Remaining Performance Obligation, Amount Remaining performance obligations Noncash Investing and Financing Items [Abstract] Supplemental non-cash investing and financing activities: Entity Voluntary Filers Scenario [Domain] Money Market Funds [Member] Money market funds Retirement Plan Name [Axis] Documents Incorporated by Reference [Text Block] Documents Incorporated by Reference Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-Average Grant Date Fair Value Per Share, Granted Lessee, Operating Lease, Option to Extend Operating lease option to extend Performance Shares [Member] Performance Stock Units Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Attributable to Common Stockholders Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Contribution by employees Income Taxes Paid Cash paid for income taxes Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock-based Compensation Expense Computer Equipment [Member] Computers and Software Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock Adjustment to redemption value on redeemable convertible preferred stock AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Financial Support to Nonconsolidated Legal Entity [Axis] Auditor Firm ID Auditor Firm ID Income Statement Location [Domain] Income Statement Location Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Change in Fair Value of Redeemable Convertible Preferred Stock Warrant Liability Lessee operating lease commencement month and year. Lessee Operating Lease Commencement Month And Year Operating lease commencement month and year Share-based Payment Arrangement, Tranche One [Member] First Anniversary Increase (Decrease) in Interest Payable, Net Accrued interest Auditor Name Auditor Name Preferred Stock, Shares Authorized Preferred stock, shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighed-Average Exercise Price, Exercisable as of December 31, 2021 Minimum [Member] Minimum Effective income tax rate reconciliation nondeductible permanent expenses. Effective Income Tax Rate Reconciliation Non deductible Permanent Expense Non-deductible permanent expenses Summary of reserved shares of common stock on converted basis for issuance table text block. Summary Of Reserved Shares Of Common Stock On Converted Basis For Issuance [Table Text Block] Summary of Reserved Shares of Common Stock on Converted Basis for Issuance Cash and Cash Equivalents [Abstract] Measurement Frequency [Domain] Measurement Frequency Stock Issued During Period, Value, Stock Options Exercised Stock option exercises Schedule of Debt [Table Text Block] Schedule of Term Loan Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Total Fair Value of Options Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Stock Units, Granted Document Annual Report Document Annual Report Asset Impairment Charges, Total Asset Impairment Charges Impairment losses Gain on extinguishment of redeemable convertible preferred stock before cost adjustment. Gain On Extinguishment Of Redeemable Convertible Preferred Stock Before Cost Adjustment Gain on extinguishment of redeemable convertible preferred stock Valuation allowance Deferred Tax Assets, Valuation Allowance, Total Deferred Tax Assets, Valuation Allowance Valuation allowance Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Shares Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Shares Temporary Equity, Cash exercises of Series C redeemable convertible preferred stock warrants (shares) Debt Instrument, Payment Terms Description of payment terms Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Debt Instrument [Axis] Debt Instrument Entity Filer Category Entity Filer Category Income Tax, Policy [Policy Text Block] Income Taxes Document Fiscal Year Focus Document Fiscal Year Focus Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Payment for debt prepayment accrued interest and exit fees Payment for debt prepayment accrued interest and exit fees Early prepayment, accrued interest and exit fees Customer four member Customer Four [Member] Customer 4 Construction in Progress [Member] Construction In Progress Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value of Options granted to Employees Grant Date Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Securities in unrealized loss position for more than 12 months Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Summary of significant accounting policies. Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Income Tax Disclosure [Text Block] Income Taxes Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation, Depletion and Amortization, Nonproduction Total depreciation and amortization expense Letters of Credit Outstanding, Amount Letter of credit issued in lieu of a cash security deposit Adjustment of redeemable capital shares to redemption value. Adjustment Of Redeemable Capital Shares To Redemption Value Adjustment to redemption value on redeemable convertible preferred stock Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Stock options, nonvested, number of shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance Entity Ex Transition Period Entity Ex Transition Period Significant Change in Unrecognized Tax Benefits, Nature of Event Change in Unrecognized Tax Benefits Fair Value Disclosures [Abstract] Short-term Lease, Cost Short-term lease costs Maximum [Member] Maximum Cash paid for amounts included in the measurement of operating lease liabilities. Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities Cash paid for amounts included in the measurement of operating lease liabilities Entity Central Index Key Entity Central Index Key Temporary Equity Conversion Of Convertible Redeemable Preferred Stock In to Common Stock Temporary Equity Conversion Of Convertible Redeemable Preferred Stock In to Common Stock Temporary equity, Conversion of redeemable convertible preferred stock to common stock upon initial public offering Fair Value, Separate Account Investment [Line Items] Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents and Restricted Cash Long-Term Debt, Maturity, Year Five 2025 Payables and Accruals [Abstract] Transfer of inventories to property and equipment. Transfer Of Inventories To Property And Equipment Transfer of inventories to property and equipment Series B Redeemable Convertible Preferred Stock Warrants Member. Series B Redeemable Convertible Preferred Stock Warrants [Member] Series B Redeemable Convertible Preferred Stock Warrants Entity Tax Identification Number Entity Tax Identification Number Equity Component [Domain] Equity Component Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Gain (Loss) on Extinguishment of Debt, Total Gain (Loss) on Extinguishment of Debt Loss on extinguishment of term loan Loss on extinguishment of term loan Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment, Net Stockholders' Equity Note, Stock Split, Conversion Ratio Stock split conversion ratio Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Change in valuation allowance Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Debt instrument, final payment amount Finance Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term Income Tax Authority [Domain] Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Estimated weighted average period over which unamortized share-based compensation are expected to be recognize Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Accrual and reserves Deferred Tax Liabilities, Gross [Abstract] Conversion Of Redeemable Convertible Preferred Stock Warrants To Common Stock Warrants Value Conversion Of Redeemable Convertible Preferred Stock Warrants To Common Stock Warrants Value Conversion of Series A redeemable convertible preferred stock warrants to common stock warrants Increase (Decrease) in Accounts Receivable Accounts receivable Change in Accounting Principle, Accounting Standards Update, Adoption Date Change in accounting principle, accounting standards update, adoption date Subsequent Events [Abstract] Operating lease arrangements. Operating Lease Arrangements [Member] Operating Lease Arrangements Leasehold Improvements [Member] Leasehold Improvements Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value Stock Options, New Grant Date Fair Value Concentration Risk, Percentage Concentration of risk, percentage Statement [Table] Statement [Table] Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term (in years) Cash Equivalents [Member] Cash equivalents Entity File Number Entity File Number Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Retained Earnings [Member] Accumulated Deficit Consoles product. Consoles Product [Member] Consoles Product Stock issued during period shares issued on exercise of warrants. Stock Issued During Period Shares Issued On Exercise Of Warrants Common stock issued on exercise of outstanding redeemable convertible preferred stock warrants Description of business. Description Of Business [Table] Description Of Business [Table] Accounting Standards Update [Domain] Accounting Standards Update Accounting Standards Update [Axis] Accounting Standards Update Revenue from Contract with Customer, Excluding Assessed Tax Revenue Revenue from Contract with Customer, Excluding Assessed Tax, Total Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Liabilities, Current [Abstract] Current liabilities: Current: Share-based Payment Arrangement [Text Block] Equity Incentive Plan Subsequent Event [Member] Subsequent Event Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Operating Lease, Liability Present value of operating lease liabilities Present value of operating lease liabilities Common Stock [Member] Common Stock Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross Total property and equipment Total property and equipment Accrued Professional Fees, Current Accrued professional services Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table] Entity Public Float Entity Public Float Cover [Abstract] MEXICO Mexico Shares Available For Future Purchase Under ESPP Member. Shares Available For Future Purchase Under ESPP [Member] Shares Available for Future Purchase Under ESPP Long term debt future minimum payments due Long term debt future minimum payments due Total future payments Total future payments Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Asset Class [Axis] Asset Class Proceeds from Issuance of Redeemable Convertible Preferred Stock Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs Temporary Equity, Shares Outstanding Temporary Equity, Ending Balance (shares) Temporary Equity, Beginning Balance (shares) Redeemable convertible preferred stock, shares outstanding Statement of Stockholders' Equity [Abstract] Property, Plant and Equipment [Table] Number Of Operating Segments Number of Operating Segments Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of common stock for settlement of RSUs (shares) Share-based Payment Arrangement [Abstract] Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Restricted Stock Units (RSUs) [Member] RSU Restricted Stock Units Cash, Cash Equivalents, and Short-term Investments Cash, cash equivalents and short-term investments Cash, Cash Equivalents, and Short-term Investments, Total Long-Lived Tangible Asset [Axis] Silicon valley bank term loan. Silicon Valley Bank Term Loan [Member] SVB Term Loan Document Transition Report Document Transition Report Grantee Status [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Forfeited and Expired Advertising Cost [Policy Text Block] Advertising Costs Research and Development Expense Research and development Research and Development Expense, Total Contract with Customer, Liability, Noncurrent Deferred revenue, noncurrent Debt, Current, Total Debt, Current Less: final payment Less: final payment Cost of Goods and Services Sold Cost of revenue Cost of Goods and Services Sold, Total Share-based Payment Arrangement, Expense Cumulative stock-based compensation Stock-based compensation expense Offering costs, underwriting discounts and commissions expenses. Offering Costs Underwriting Discounts And Commissions Expenses Offering costs, underwriting discounts and commissions expenses Concentration Risk Benchmark [Axis] Warrants to Purchase Redeemable Convertible Preferred Stock Warrants To Purchase Redeemable Convertible Preferred Stock [Member] Warrants to purchase redeemable convertible preferred stock. Statement of Financial Position [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Stock Units, Vested Depreciation, Depletion and Amortization Depreciation and amortization Depreciation, Depletion and Amortization, Total Deferred Tax Assets, Goodwill and Intangible Assets Tangible and intangible assets Tax credit carry forward expiration year. Tax Credit Carry Forward Expiration Year Tax credit carry forward expiration year Product Warranty Accrual, Current Balance at the end of the period Balance at the beginning of the period Accrued warranty liability Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Federal statutory income tax rate Deemed dividend on settlement of accrued dividend. Deemed Dividend On Settlement Of Accrued Dividend Deemed dividend on settlement of accrued dividend Deemed dividend on settlement of accrued dividend Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Selling and Marketing Expense Sales and marketing Selling and Marketing Expense, Total Loss before provision for income taxes Loss before Provision for Income Taxes Loss before Provision for Income Taxes Percentage of limitation on pledges of capital stock of foreign subsidiaries. Percentage Of Limitation On Pledges Of Capital Stock Of Foreign Subsidiaries Percentage of limitation on pledges of capital stock of foreign subsidiaries Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Value Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Value Temporary Equity, Cash exercises of Series C redeemable convertible preferred stock warrants Accounts Receivable [Policy Text Block] Accounts Receivable, Net Payments to Acquire Investments Purchases of investment securities Payments to Acquire Investments, Total Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Exercised Increase (Decrease) in Inventories Inventories Increase (Decrease) in Inventories, Total Long-Term Debt, Maturity, Year Four 2025 Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Repayment Of Term Loan And Extinguishment Costs Repayment of term loan and extinguishment costs. Repayment of term loan and extinguishment costs Lessee, Operating Lease, Liability, to be Paid, Year Three 2024 Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent Stock based compensation Performance based units approved based on performance relative to specified revenue targets. Performance Based Units Approved Based On Performance Relative To Specified Revenue Targets Performance based units approved based on performance relative to specified revenue targets Total reserved shares Common Stock, Capital Shares Reserved for Future Issuance Retirement Plan Name [Domain] Measurement Frequency [Axis] Measurement Frequency Reclassifications of Temporary to Permanent Equity Reclassification of redeemable convertible preferred stock warrant liability to equity Award Type [Axis] Award Type Entity Shell Company Entity Shell Company Liabilities and Equity [Abstract] Labilities, redeemable convertible preferred stock and stockholders' equity (deficit) ICFR Auditor Attestation Flag Debt Instrument, Interest Rate, Effective Percentage Debt interest rate Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock through employee stock purchase plan Stock Issued During Period, Value, Restricted Stock Award, Gross Issuance of common stock for settlement of RSUs Earnings Per Share [Text Block] Net Loss Per Share Attributable to Common Stockholders Remaining operating lease payments recognized in 2022 Operating Lease Arrangements Minimum Lease Payments Due Year Two Operating Lease Arrangements Minimum Lease Payments Due Year Two 2022 Amendment Flag Amendment Flag Series A Redeemable Convertible Preferred Stock Warrants Member. Series A Redeemable Convertible Preferred Stock Warrants [Member] Series A Redeemable Convertible Preferred Stock Warrants Schedule of Stock by Class [Table] Product and Service [Axis] Product and Service Finance Lease, Principal Payments Repayment of finance lease Short-term Investments Short-term investments Short-term Investments, Total Accrued Exchange Fee Rebate, Current Accrued rebate Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted Tax Credit Carryforward, Amount Tax credit carryforward, amount Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unamortized stock-based compensation expense amount Debt instrument prepayment fee percentage. Debt Instrument Prepayment Fee Percentage Debt instrument prepayment fee percentage Long-term Debt Total term loan, net of debt discount Fair Value, Recurring [Member] Fair Value, Recurring Subsequent Events [Text Block] Subsequent Event Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other current liabilities Redeemable convertible preferred stock warrant liability member. Redeemable Convertible Preferred Stock Warrant Liability [Member] Redeemable convertible preferred stock warrant liability Follow-On Public Offering [Member] Follow On Public Offering [Member] Follow-on Public Offering Stock Issued During Period Share Redeemable Convertible Preferred Stock Warrants Stock Issued During Period Share Redeemable Convertible Preferred Stock Warrants Issuance of common stock upon net exercises of Serie B redeemable convertible preferred stock warrants (shares) Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Property, Plant and Equipment [Line Items] Other Assets, Noncurrent Other assets Other Assets, Noncurrent, Total Warrants issued to purchase common stock. Warrants Issued To Purchase Common Stock Warrant to purchase shares Employee Stock Purchase Plan (ESPP) Employee Stock [Member] Shares Committed under ESPP Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Geographical [Domain] Conversion of redeemable convertible preferred stock warrants to common stock warrants shares. Conversion Of Redeemable Convertible Preferred Stock Warrants To Common Stock Warrants Shares Number of redeemable convertible preferred stock warrants converted Customer [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable as of December 31, 2021 Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Percentage of fair market value of common stock Cost of Sales [Member] Cost of Revenue Sale of Stock [Axis] Sale of Stock Fair Value Disclosures [Text Block] Fair Value Measurements Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Total unrecognized stock-based compensation expense Proceeds from Issuance of Common Stock Proceeds from issuance of common stock upon follow-on public offering, net of issuance costs Proceeds from issuance of common stock upon initial and follow-on public offering, net of issuance costs XML 15 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information - USD ($)
$ in Billions
12 Months Ended
Dec. 31, 2021
Feb. 16, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Year Focus 2021    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Entity File Number 001-39513    
Entity Registrant Name Outset Medical, Inc.    
Entity Central Index Key 0001484612    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 20-0514392    
Entity Address, Address Line One 3052 Orchard Dr.    
Entity Address, City or Town San Jose    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 95134    
City Area Code 669    
Local Phone Number 231-8200    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol OM    
Security Exchange Name NASDAQ    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Well-known Seasoned Issuer Yes    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 1.7
ICFR Auditor Attestation Flag false    
Entity Common Stock, Shares Outstanding   47,406,856  
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s Proxy Statement for its 2022 Annual Meeting of Stockholders, which is to be filed with the Securities and Exchange Commission within 120 days of the registrant’ fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.

   
Auditor Name KPMG LLP    
Auditor Firm ID 185    
Auditor Location San Francisco, California    

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end GRAPHIC 8 img263710155_1.jpg GRAPHIC begin 644 img263710155_1.jpg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

XML 16 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 182,348 $ 294,972
Short-term investments 157,140 19,898
Accounts receivable, net 25,600 6,468
Inventories 39,185 18,384
Prepaid expenses and other current assets 5,529 6,189
Total current assets 409,802 345,911
Restricted cash 33,311 33,311
Property and equipment, net 12,964 14,998
Operating lease right-of-use assets 7,231 8,253
Other assets 156 1,356
Total assets 463,464 403,829
Current liabilities:    
Accounts payable 1,763 4,948
Accrued compensation and related benefits 24,948 16,845
Accrued expenses and other current liabilities 13,789 7,903
Accrued warranty liability 3,704 2,913
Deferred revenue, current 6,340 3,201
Operating lease liabilities, current 1,151 882
Total current liabilities 51,695 36,692
Accrued interest, noncurrent 721 240
Deferred revenue, noncurrent 312 570
Operating lease liabilities, noncurrent 6,893 8,044
Term loan, noncurrent 29,762 29,674
Total liabilities 89,383 75,220
Commitments and contingencies (Note 6)
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of December 31, 2021 and December 31, 2020 0 0
Common stock, $0.001 par value; 300,000 shares authorized as of December 31, 2021 and December 31, 2020; 47,018 and 42,722 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively 47 43
Additional paid-in capital 1,000,212 822,624
Accumulated other comprehensive (loss) income (184) 1
Accumulated deficit (625,994) (494,059)
Total stockholders' equity (deficit) 374,081 328,609
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) $ 463,464 $ 403,829
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 47,241,000 42,722,000
Common stock, shares outstanding 47,241,000 42,722,000
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenue:      
Revenue $ 102,602 $ 49,935 $ 15,078
Cost of revenue:      
Cost of revenue 94,994 62,972 32,880
Gross profit 7,608 (13,037) (17,802)
Operating expenses:      
Research and development 36,741 28,850 23,327
Sales and marketing 65,070 45,068 20,259
General and administrative 36,316 30,512 8,919
Total operating expenses 138,127 104,430 52,505
Loss from operations (130,519) (117,467) (70,307)
Interest income and other income, net 498 526 2,485
Interest expense (1,715) (2,891) (4,257)
Change in fair value of redeemable convertible preferred stock warrant liability   (93) 3,800
Loss on extinguishment of term loan   1,567  
Loss before provision for income taxes (131,736) (121,492) (68,279)
Provision for income taxes 199 0 20
Net loss (131,935) (121,492) (68,299)
Net loss attributable to common stockholders, basic and diluted $ (131,935) $ (79,324) $ (85,461)
Net loss per share attributable to common stockholders, basic and diluted $ (2.89) $ (4.85) $ (99.58)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 45,589 16,358 858
Product Revenue      
Revenue:      
Revenue $ 84,312 $ 39,612 $ 13,750
Cost of revenue:      
Cost of revenue 84,639 57,035 27,164
Service and Other Revenue      
Revenue:      
Revenue 18,290 10,323 1,328
Cost of revenue:      
Cost of revenue $ 10,355 $ 5,937 $ 5,716
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Statement of Comprehensive Income [Abstract]      
Net loss $ (131,935) $ (121,492) $ (68,299)
Other comprehensive loss:      
Unrealized gain (loss) on available-for-sale securities (185) (21) 82
Comprehensive loss $ (132,120) $ (121,513) $ (68,217)
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statement of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
shares in Thousands, $ in Thousands
Total
Redeemable Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning Balance at Dec. 31, 2018 $ (287,950)   $ 1   $ (60) $ (287,891)
Beginning Balance (shares) at Dec. 31, 2018     789      
Temporary Equity, Beginning Balance at Dec. 31, 2018   $ 392,284        
Temporary Equity, Beginning Balance (shares) at Dec. 31, 2018   147,214        
Adjustment to redemption value on redeemable convertible preferred stock (134,760) $ 134,760   $ (966)   (133,794)
Common stock warrant exercises 76     76    
Common stock warrant exercises (shares)     9      
Gain on extinguishment of redeemable convertible preferred stock 117,417 (117,417)       117,417
Temporary Equity, Costs to adjust the redemption value on redeemable convertible preferred stock   (181)        
Issuance of common stock on settlement of accrued dividend   $ 41,763        
Stock option exercises 364     364    
Stock option exercises (shares)     124      
Stock-based compensation expense 883     883    
Unrealized gain (loss) on available-for-sale securities 82       82  
Net loss (68,299)         (68,299)
Ending Balance at Dec. 31, 2019 (372,187)   $ 1 357 22 (372,567)
Temporary Equity, Ending Balance (shares) at Dec. 31, 2019   147,214        
Temporary Equity, Ending Balance at Dec. 31, 2019   $ 409,446        
Ending Balance (shares) at Dec. 31, 2019     922      
Issuance of common stock upon net exercises of Serie B redeemable convertible preferred stock warrants (shares)     65      
Temporary Equity, Issuance of Series D and Series E redeemable convertible preferred stock, net of issuance costs   $ 126,758        
Temporary Equity, Issuance of Series D and Series E redeemable convertible preferred stock, net of issuance costs (shares)   57,782        
Adjustment to redemption value on redeemable convertible preferred stock (362) $ 362   (362)    
Issuance of common stock on settlement of accrued dividend   41,763 $ 5 41,758    
Temporary Equity, Issuance of common stock on settlement of accrued dividend   $ 42,530        
Issuance of common stock on settlement of accrued dividend (shares)     4,850      
Deemed dividend on settlement of accrued dividend 42,530     42,530    
Temporary Equity, Cash exercises of Series C redeemable convertible preferred stock warrants $ 4,288          
Temporary Equity, Cash exercises of Series C redeemable convertible preferred stock warrants (shares) 1,655          
Conversion of Series A redeemable convertible preferred stock warrants to common stock warrants $ 1,252     1,252    
Conversion of redeemable convertible preferred stock to common stock upon initial public offering     $ 26      
Temporary equity, Conversion of redeemable convertible preferred stock to common stock upon initial public offering (Shares)   (206,651)        
Temporary equity, Conversion of redeemable convertible preferred stock to common stock upon initial public offering 456,561 $ (456,561)   456,535    
Conversion of redeemable convertible preferred stock to common stock upon initial public offering (shares)     26,167      
Issuance of common stock upon initial public offering, net of issuance costs 254,805   $ 10 254,795    
Issuance of common stock upon initial public offering, net of issuance costs (shares)     10,294      
Reclassification of redeemable convertible preferred stock warrant liability to equity 3,126     3,126    
Issuance of common stock for settlement of RSUs (shares)     5      
Stock option exercises 1,195   $ 1 1,194    
Stock option exercises (shares)     419      
Stock-based compensation expense 21,439     21,439    
Unrealized gain (loss) on available-for-sale securities (21)       (21)  
Net loss (121,492)         (121,492)
Ending Balance at Dec. 31, 2020 328,609   $ 43 822,624 1 (494,059)
Ending Balance (shares) at Dec. 31, 2020     42,722      
Issuance of common stock through employee stock purchase plan     $ 3,434 3,434    
Issuance of common stock through employee stock purchase plan (shares)     116      
Issuance of common stock upon initial public offering, net of issuance costs 149,085   $ 3 149,082    
Issuance of common stock upon initial public offering, net of issuance costs (shares)     2,946      
Issuance of common stock for settlement of RSUs (shares)     19      
Stock option exercises $ 7,628   $ 1 7,627    
Stock option exercises (shares) 1,437   1,438      
Stock-based compensation expense $ 17,445     17,445    
Unrealized gain (loss) on available-for-sale securities (185)       (185)  
Net loss (131,935)         (131,935)
Ending Balance at Dec. 31, 2021 $ 374,081   $ 47 $ 1,000,212 $ (184) $ (625,994)
Ending Balance (shares) at Dec. 31, 2021     47,241      
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:      
Net loss $ (131,935) $ (121,492) $ (68,299)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 5,162 3,159 1,484
Non-cash lease expense 1,022 596 451
Non-cash interest expense 569 641 893
Accretion of discount on investments, net 1,972 50 (983)
Provision for accounts receivable 5 12 59
Provision for inventories 1,023 534 326
Loss on disposal of property and equipment 76 235 293
Stock-based compensation expense 17,445 21,439 883
Change in fair value of redeemable convertible preferred stock warrant liability   93 (3,800)
Loss on extinguishment of term loan   (1,567)  
Changes in operating assets and liabilities:      
Accounts receivable (19,137) (2,566) (2,886)
Inventories (22,042) (16,287) (5,020)
Prepaid expenses and other assets 1,860 (6,245) (228)
Accounts payable (3,066) 737 802
Accrued payroll and related benefits 8,103 9,889 3,119
Accrued expenses and other current liabilities 5,889 4,798 974
Accrued warranty liability 791 1,211 1,410
Deferred revenue 2,881 2,754 735
Accrued interest   (217)  
Operating lease liabilities (882) 77 (505)
Net cash used in operating activities (130,264) (99,015) (70,292)
Cash flows from investing activities:      
Purchases of property and equipment (3,108) (9,108) (3,293)
Purchases of investment securities (178,432) (32,884) (91,878)
Sales and maturities of investment securities 39,033 45,908 169,468
Net cash used in investing activities (142,507) 3,947 74,297
Cash flows from financing activities:      
Proceeds from issuance of common stock upon initial and follow-on public offering, net of issuance costs 149,085 254,805  
Proceeds from cash exercise of redeemable convertible preferred stock warrants   4,288  
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs   126,758  
Proceeds from stock option exercises and employee stock purchase plan purchases 11,062 1,195 363
Proceeds from issuance of term loan, net of issuance costs   29,630  
Repayment of term loan and extinguishment costs   (30,985)  
Repayment of finance lease   (9) (9)
Proceeds from exercise of common stock warrant     76
Payment of redeemable convertible preferred stock issuance costs     (181)
Net cash provided by financing activities 160,147 385,682 249
Net (decrease) increase in cash, cash equivalents and restricted cash (112,624) 290,614 4,254
Cash, cash equivalents and restricted cash as of beginning of period 328,283 37,669 33,415
Cash, cash equivalents and restricted cash as of end of period 215,659 328,283 37,669
Supplemental cash flow disclosures:      
Cash paid for income taxes 83 19 35
Cash paid for interest 1,146 3,270 3,352
Cash paid for amounts included in the measurement of operating lease liabilities 882   505
Supplemental non-cash investing and financing activities:      
Capital expenditures included in accounts payable and accrued expenses 121 323 867
Transfer of inventories to property and equipment 1,410 2,131 3,119
Right-of-use assets obtained in exchange for lease liabilities   8,849  
Deemed dividend on settlement of accrued dividend   42,530  
Adjustment to redemption value on redeemable convertible preferred stock   362 134,760
Conversion of redeemable convertible preferred stock into common stock upon initial public offering   456,561  
Reclassification of redeemable convertible preferred stock warrant liability for conversion of Series A redeemable preferred stock warrants into common stock warrants   1,252  
Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital   3,126  
Issuance of common stock on settlement of accrued dividend   $ 41,763  
Gain on extinguishment of redeemable convertible preferred stock     $ 117,598
Transfer of property and equipment to inventories $ 1,192    
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of Business
12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business

1. Description of Business

Outset Medical, Inc. is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement designed to transform the dialysis experience for patients and operationally simplify it for providers. Tablo serves as a single enterprise solution designed to be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo to serve as a dialysis clinic on wheels. With a simple-to-use touchscreen interface, two-way wireless data transmission and a proprietary data analytics platform, Tablo is a new holistic approach to dialysis care. The Company’s headquarters are located in San Jose, CA.

The Company’s registration statement on Form S-1 related to its IPO was declared effective by the SEC on September 14, 2020, and the Company’s common stock began trading on the Nasdaq Global Select Market on September 15, 2020. Upon the completion of the IPO, the Company sold 10,294,000 shares of common stock (which included 1,343,000 shares that were sold pursuant to the full exercise of the underwriters’ option to purchase additional shares in connection with the IPO) at a price to the public of $27.00 per share. Including the full exercise of the underwriters’ option to purchase additional shares, the Company received aggregate net proceeds of approximately $254.8 million after deducting offering costs, underwriting discounts and commissions of approximately $23.1 million.

On April 13, 2021, the Company completed a follow-on public offering and sold 2,946,000 shares of common stock (which included 446,000 shares that were offered and sold pursuant to the full exercise of the underwriters’ option to purchase additional shares) at a price to the public of $53.50 per share. The Company received aggregate net proceeds of approximately $149.1 million after deducting offering costs, underwriting discounts and commissions of $8.5 million.

Reverse Stock Split

In September 2020, the Company’s board of directors and shareholders approved a certificate of amendment to the amended and restated certificate of incorporation to effect a reverse split of shares of the Company’s common stock on a 7.9-for-one basis (the Reverse Stock Split) effective as of September 8, 2020. The number of authorized shares and the par values of the common stock and redeemable convertible preferred stock were not adjusted as a result of the Reverse Stock Split. In connection with the Reverse Stock Split, the conversion ratio for the Company’s outstanding redeemable convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. All references to common stock and options to purchase common stock, share data, per share data and related information contained in these financial statements and related notes have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.

Liquidity

Since inception, the Company has incurred net losses and negative cash flows from operations. The Company incurred net losses of $131.9 million, $121.5 million and $68.3 million for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021, the Company had an accumulated deficit of $626.0 million.

As of December 31, 2021, the Company had cash, cash equivalents and short-term investments of $339.5 million, which are available to fund future operations, and restricted cash of $33.3 million. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. Management believes that the Company’s existing cash, cash equivalents and short-term investments, which include the proceeds from the IPO and the follow-on public offering, and cash generated from revenues from its products and services, will be sufficient to meet its anticipated needs for at least the next 12 months from the issuance date of the financial statements.

Basis of Presentation

The financial statements have been prepared in accordance with U.S. GAAP. All share amounts disclosed in the notes to the financial statements are rounded to the nearest thousand except for per share amounts.

XML 23 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, allowance for doubtful accounts, inventory valuation and write-downs, warranty obligations, the fair value of equity awards, the valuation of investments, recoverability of the Company’s net deferred tax assets, and certain accrued expenses. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results may differ from those estimates under different assumptions or conditions and the differences may be material.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, restricted cash, short-term investments and accounts receivable. Substantially all the Company’s cash and cash equivalents, restricted cash, and investments are held at one financial institution in the United States that management believes is of high credit quality. Such investments may, at times, exceed federally insured limits or may not be covered by deposit insurance at all. The Company has not experienced any credit losses on its cash and cash equivalents, restricted cash or short-term investments through December 31, 2021.

For the year ended December 31, 2021, two customers accounted for 30% and 15% of revenues, respectively. For the year ended December 31, 2020, three customers accounted for 22%, 19% and 16% of revenues, respectively. One customer accounted for 11% of revenues for the year ended December 31, 2019. Accounts receivable are unsecured and the Company does not require collateral; however, the Company does assess the collectability of accounts receivable based on a number of factors, including past transaction history with, and the creditworthiness of, the customer. Accordingly, the Company is exposed to credit risk associated with accounts receivable. One customer accounted for 10% of accounts receivable as of December 31, 2021. Two customers accounted for 22% and 16% of accounts receivable, respectively, as of December 31, 2020. To reduce risk, the Company closely monitors the amounts due from its customers and assesses the financial strength of its customers through a variety of methods that include, but are not limited to, engaging directly with customer operations and leadership personnel, visiting customer locations to observe operating activities, and assessing customer longevity and reputation in the marketplace. As a result, the Company believes that its accounts receivable credit risk exposure is limited. A material default in payment or a material reduction in purchases from these or any other large customers could have a material adverse impact on the Company’s financial condition, results of operations, and liquidity.

The Company has a manufacturing facility in Tijuana, Mexico which it operates in collaboration with its outsourced business administration service provider, TACNA, for the production of the Tablo console. The Company is subject to a number of risks associated with operating its Mexico-based manufacturing facility. The manufacturing operations at the facility may suffer disruptions from global or regional public health crises such as the ongoing COVID-19 pandemic, natural disasters, cyber security attacks, vandalism, terrorism or other political hostilities. Any such occurrences could negatively impact the Company’s ability to produce the Tablo console. The Company is also subject to a variety of foreign laws and regulations, including trade and labor restrictions and laws relating to importation, exportation and taxation of goods, and U.S. laws and regulations relating to foreign operations. In addition, because certain of its Mexico-based manufacturing operations incur costs that are denominated in MXN, the Company is exposed to additional risk of currency fluctuations between USD and MXN, which could increase its product and labor costs, thus reducing its gross profit. To date, foreign currency transaction gains and losses have not been material to the Company’s financial statements.

The Company is subject to additional risks and uncertainties due to the COVID-19 pandemic. How long the pandemic, and measures intended to contain the spread of COVID-19, will continue remains uncertain and depends on ongoing developments, including but not limited to any resurgences of the virus including emerging variant strains, federal, state and local government actions taken in response, and continued availability, effectiveness and public acceptance of COVID-19 vaccines, as well as the extent and duration of the effect on the economy and how quickly and to what extent normal economic and operating conditions can resume. Additionally, the duration and severity of disruptions in the global supply chain, largely driven by high demand as the economy reopens and the ongoing impact of the pandemic, also remain uncertain and depend on various factors, including the effectiveness of recent government actions intended to mitigate these disruptions. As a result, the Company cannot predict what effect COVID-19, the associated containment measures and the related supply chain disruptions will ultimately have on its business and result of operations.

While the potential economic impact and duration of the COVID-19 pandemic may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets,

which could result in a reduction in the Company’s ability to access capital and delays in payments of outstanding receivables that could adversely affect our liquidity. In addition, a recession or market correction resulting from the spread COVID-19 could materially affect the Company's business and financial results. As of the date of issuance of the financial statements, the extent to which the COVID-19 pandemic may materially adversely affect the Company's financial condition, liquidity, or results of operations is uncertain.

Fair Value of Financial Instruments

The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.

The Company classifies financial instruments using a three-tiered fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Management believes that its term loan bears interest at the prevailing market rates for instruments with similar characteristics; accordingly, the carrying value of this instrument approximates its fair value.

Cash Equivalents and Short-Term Investments

The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and are stated at fair value.

The Company primarily holds corporate debt securities, commercial paper, and U.S. Treasury securities, and has the ability, if necessary, to liquidate any of its investments to meet its liquidity needs in the next 12 months, without significant penalty. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term investments on the accompanying balance sheets. Short-term investments have been classified as available-for-sale at the time of purchase. The Company evaluates the appropriate classification of its investments as of each balance sheet date.

The Company’s investment securities are recorded at fair value based on the fair value hierarchy. Money market funds and U.S. Treasury securities are classified within Level 1 of the fair value hierarchy. Other securities are classified within Level 2 of the fair value hierarchy. Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).

A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold.

Accounts Receivable, Net

Accounts receivable are recorded at invoice value, net of any allowance for doubtful accounts. Estimates of the allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of customers and individual customer circumstances. The allowance for doubtful accounts was not significant as of December 31, 2021 and 2020.

Inventories

Inventory is stated at the lower of cost or net realizable value, with approximate costs determined on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The carrying value of inventories is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on the Company’s statements of operations.

Property and Equipment, Net

Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is generally computed using the straight-line method based on the estimated useful lives of the assets, which is generally two to five years. Certain Tablo consoles under operating leases are depreciated using the accelerated method. Leasehold improvements are amortized using the straight-line method over the shorter of the assets estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to expense as incurred. Significant improvements that substantially enhance the useful life of an asset are capitalized and depreciated. When assets are retired or disposed of, the cost together with related accumulated depreciation is removed from the balance sheet and any resulting gain or loss is reflected in the Company’s statements of operations in the period realized.

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. There were no such impairment losses as of December 31, 2021 and 2020.

Leases

The Company determines if an arrangement is a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term. Operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.

As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. Lease costs for the Company’s operating leases are recognized on a straight-line basis over the reasonably assured lease term. Variable lease payments include lease operating expenses.

The Company has elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.

Accrued Warranty Liability

The Company generally provides a one-year warranty for defective parts and workmanship on its Tablo consoles, commencing upon the transfer of title and risk of loss to the customer. The Company accrues the estimated cost of product warranties when it invoices the customer, based on historical experience and expected results. Should actual product failure rates and material usage costs differ from these estimates, revisions to the estimated warranty liability would be required. The Company periodically assesses the adequacy of its recorded product warranty liabilities and adjusts the balance as required. Warranty expense is recorded as a component of cost of product revenue in the statements of operations.

Contract Liabilities - Deferred Revenue

The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue is recognized subsequent to invoicing. For multi-year service agreements, the Company generally invoices customers annually at the beginning of each annual coverage period. Deferred revenue that will be recognized during the 12 months following the balance sheet date is recorded as the current portion of deferred revenue and the remaining portion is recorded as noncurrent.

Revenue

The Company generates revenue primarily from contracts with customers for the sale of its products and services. Product revenue consists primarily of sales of the Tablo console and related consumables, including Tablo cartridges, used in treatment

delivery. Service and other revenue consists primarily of revenue generated from consoles service contracts and other revenue from shipping and handling charged to customers.

Each customer contract defines our distinct performance obligations and the associated transaction price for each obligation. Tablo consoles and consumables are generally sold without the right of return. Revenue is recognized when a performance obligation is satisfied. Revenue from product sales is recognized at a point in time when management has determined that control has transferred to the customer, which is generally when legal title has transferred to the customer. Revenue from service contracts is recognized over time as the service is performed, typically evenly over the contract term. Certain contracts include variable consideration such as rebates, revenue for such contracts is recognized only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Revenue is recognized net of any taxes collected from customers, which are subsequently remitted to governmental authorities.

The Company’s contracts with customers often include multiple performance obligations. For such contracts, the Company allocates the contracted transaction price to each performance obligation based upon the relative SSP. The Company determines the SSP based upon the facts and circumstances of each performance obligation (product or services), which often requires management's judgement. The Company uses an observable price to estimate SSP for items that are sold separately, including customer service agreements. In instances where SSP is not directly observable, such as when the Company does not sell the product or service separately, the Company determines the SSP using information that may include market conditions and other observable inputs. The Company may offer additional goods or services to customers at the inception of customer contracts at prices not at SSP. If such contracts result in a material right, the Company allocates part of the transaction price to that right and recognizes the associated revenue when those future goods and services are transferred to the customer. SSP is assigned based on the estimated value of the material right.

Costs associated with product sales include commissions. The Company applies the practical expedient to expense the commissions as incurred as the expected amortization period is one year or less. Commissions are recorded as sales and marketing expenses in the statements of operations.

Operating Lease Arrangements

The Company enters into operating lease arrangements that contain both lease and non-lease elements. The lease element includes Tablo consoles, while non-lease elements include consumables, services and training. Revenue related to such arrangements is allocated to lease and non-lease elements based on their relative SSP. Revenue for the lease element, net of any taxes collected from customers, is recognized on a straight-line basis as product revenue over the lease term, generally three months to one year, in the statements of operations. The costs of the leased Tablo consoles are included in property and equipment, net in the balance sheets and amortized to cost of product revenue.

Shipping and Handling Costs

Shipping and handling charged to customers are recorded as revenue. Shipping and handling costs are expensed as incurred and are included in sales and marketing expenses.

Stock-Based Compensation Expense

Stock-based compensation expense relates to stock options with a service-based vesting condition, stock options with performance and market-based vesting conditions, stock purchase rights under our ESPP, RSUs and PSUs with performance or market-based vesting conditions. Stock-based compensation expense for the Company’s stock-based awards is based on their grant date fair value.

Service-based options granted to an optionee generally vest at a rate of 25% on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining three years. The fair value of stock options with a service condition and stock purchase rights under the ESPP on the grant date is estimated using the Black-Scholes option-pricing model. The fair value of these awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur.

The Black-Scholes model considers several variables and assumptions in estimating the fair value of service-based stock options and stock purchase rights under the ESPP. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and expected stock price volatility over the expected term. For all service-based stock options granted, the Company calculates the expected term using the simplified method for “plain vanilla” stock option awards. The Company had no publicly available stock price information prior to the IPO and limited

available stock price information subsequent to the IPO; therefore, the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term on the equity settled award.

For stock options with performance- and market-based vesting conditions, stock-based compensation expense begins to be recognized over the remaining service period when it is considered probable that the performance vesting condition will be satisfied. Prior to the IPO in September 2020, the Company had not recognized any stock-based compensation expense as the satisfaction of the performance condition was not considered probable. Upon the closing of the IPO, the Company recorded a cumulative stock-based compensation expense using the accelerated attribution method as the performance condition was satisfied. Stock-based compensation expense related to these options is recognized using the accelerated attribution method as the performance-based vesting condition and not reversed if the achievement of the market condition does not occur. The fair value of these stock options is estimated using the Monte Carlo simulation model.

RSUs with a service-based vesting condition granted to an optionee generally vest at a rate of 25% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining three years. The fair value of RSUs and PSUs with a service- or performance-based vesting condition is based on the market price of the Company’s common stock on the date of grant. The determination of the stock-based compensation expense related to PSUs to be recognized in the Company’s statements of operations requires the use of certain estimates and assumptions. At each reported period, the Company reassesses the probability of the achievement of corporate performance goals to estimate the number of shares to be released. Any increase or decrease in stock-based compensation expense resulting from an adjustment in the estimated shares to be released is treated as accumulative catch-up in the period of adjustment. If any of the assumptions or estimates used change significantly, stock-based compensation expense may differ materially from what the Company has recorded in the current period. The fair value of PSUs with a market-based vesting condition is estimated using the Monte Carlo simulation model. Stock-based compensation expense related to these PSUs is recognized using the accelerated attribution method and not reversed if the achievement of the market conditions does not occur.

Research and Development

The Company expenses all research and development costs as incurred. These expenses include the costs of proprietary research and development efforts, quality engineering, clinical studies and trials and regulatory affairs. Costs primarily consist of compensation and personnel costs, consulting services, supplies and materials expenses, and allocated costs including facilities and information technology.

Advertising Costs

Advertising costs are expensed as incurred. The advertising costs for years ended December 31, 2021, 2020 and 2019 were not significant.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and remeasured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.

The Company utilizes a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.

The Company includes any penalties and interest expense related to income taxes as a component of other expense, net, as necessary.

Net Loss per Share Attributable to Common Stockholders

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive securities.

Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents of potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, awards under the Company’s equity compensation plan and warrants are considered to be potentially dilutive securities. For periods in which the Company reports net losses, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders because the effects of potentially dilutive securities are antidilutive.

Employee Benefit Plan

The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their eligible compensation on a pre- or post-tax basis. The Company is authorized to make matching contributions but has not made such contributions for the years ended December 31, 2021, 2020 and 2019. Effective January 1, 2022, the Company began to match 100% of each employee’s contributions up to a maximum matching contribution equal to 2% of such employee’s eligible compensation, subject to the terms and limitations of the 401(k) plan and applicable law.

Segment

The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for the purposes of allocating resources and evaluating financial performance. The Company has operated a manufacturing facility in Mexico since 2020. The Company's long-lived tangible assets, net, as well as the Company's operating lease right-of-use assets recognized on the balance sheets, located in Mexico were $6.2 million as of December 31, 2021.

Recently Adopted Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board (FASB) issued ASU No. 2019-12, Income Taxes (Topic 740), which simplifies the accounting for income taxes, primarily by eliminating certain exceptions to ASC 740. The Company early adopted ASU 2019-12 on a modified retrospective basis as of January 1, 2021, which did not have a material impact on its financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (CECL) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its financial statements.

XML 24 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue from Contracts with Customers
12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers

3. Revenue from Contracts with Customers

Disaggregation of Revenue

Revenue by source consisted of the following (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Consoles

 

$

65,133

 

 

$

32,871

 

 

$

12,187

 

Consumables

 

 

19,179

 

 

 

6,742

 

 

 

1,563

 

Total product revenue

 

 

84,312

 

 

 

39,612

 

 

 

13,750

 

Service and other revenue

 

 

18,290

 

 

 

10,323

 

 

 

1,328

 

Total revenue

 

$

102,602

 

 

$

49,935

 

 

$

15,078

 

 

For the years ended December 31, 2021, 2020 and 2019, $4.7 million, $3.1 million and $0.5 million, respectively, of consoles revenue were from console operating lease arrangements. The remaining operating lease payments of $1.7 million as of December 31, 2021 will be recognized during the year ending December 31, 2022.

Remaining Performance Obligations and Contract Liabilities

As of December 31, 2021, the aggregate amount of the transaction price allocated to the remaining performance obligations related to customer service contracts that are unsatisfied or partially unsatisfied was $6.7 million, which is recorded as deferred revenue on the Company’s balance sheet. Of that amount, $6.3 million will be recognized as revenue during the year ended December 31, 2022, and $0.3 million thereafter.

The contract liabilities consist of deferred revenue which represents payments received in advance of revenue recognition. Revenue under these agreements is recognized over the related service period. During the years ended December 31, 2021, 2020 and 2019, the Company recognized $3.2 million, $0.9 million, and $0.3 million, respectively, of previously deferred revenue.

XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements
12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

4. Fair Value Measurements

The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

 

 

 

 

December 31, 2021

 

 

 

Valuation
Hierarchy

 

Amortized
Costs

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

60,844

 

 

$

 

 

$

 

 

$

60,844

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

Level 1

 

 

18,064

 

 

 

 

 

 

(60

)

 

 

18,004

 

Corporate debt

 

Level 2

 

 

124,178

 

 

 

2

 

 

 

(125

)

 

 

124,055

 

Commercial paper

 

Level 2

 

 

15,081

 

 

 

 

 

 

 

 

 

15,081

 

Total cash equivalents and
   short-term investments

 

 

 

$

218,167

 

 

$

2

 

 

$

(185

)

 

$

217,984

 

 

 

 

 

 

December 31, 2020

 

 

 

Valuation
Hierarchy

 

Amortized
Costs

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

56,056

 

 

$

 

 

$

 

 

$

56,056

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

Level 1

 

 

14,999

 

 

 

1

 

 

 

 

 

 

15,000

 

Corporate debt

 

Level 2

 

 

4,898

 

 

 

 

 

 

 

 

 

4,898

 

Total cash equivalents and
   short-term investments

 

 

 

$

75,953

 

 

$

1

 

 

$

 

 

$

75,954

 

As of December 31, 2021, the remaining contractual maturities for short-term investments were as follows (in thousands):

 

 

Aggregate Fair Value

 

Due within one year

 

$

135,766

 

After one but within five years

 

 

21,374

 

Total

 

$

157,140

 

The Company’s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly

or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources and confirming those securities traded in active markets.

Impairment assessments are made at the individual security level at each reporting period. When the fair value of an available-for-sale security is less than its cost at the balance sheet date, a determination is made as to whether the impairment is other-than-temporary and, if it is other-than-temporary, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date. There were no unrealized losses for securities in an unrealized loss position for more than 12 months as of December 31, 2021. During the years ended December 31, 2021, 2020 and 2019, the Company did not recognize other-than-temporary impairment losses related to its investment securities.

XML 26 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components
12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Components

5. Balance Sheet Components

Cash, Cash Equivalents and Restricted Cash

As of December 31, 2021 and 2020, the restricted cash balance of $33.3 million primarily relates to contractual obligations under the SVB Loan and Security Agreement (see Note 7) and collateral for the building leases in San Jose, CA and Tijuana, Mexico (see Note 6). The restricted cash balance of $0.7 million as of December 31, 2019 relates to collateral for building leases.

The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the statements of cash flows (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cash and cash equivalents

 

$

182,348

 

 

$

294,972

 

 

$

36,926

 

Restricted cash

 

 

33,311

 

 

 

33,311

 

 

 

743

 

Total cash, cash equivalents and restricted cash

 

$

215,659

 

 

$

328,283

 

 

$

37,669

 

Inventories

Inventories consist of the following (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Raw materials

 

$

18,114

 

 

$

7,989

 

Work in process

 

 

6,054

 

 

 

6,200

 

Finished goods

 

 

15,017

 

 

 

4,195

 

Total inventories

 

$

39,185

 

 

$

18,384

 

Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Tablos under operating leases

 

 

2,412

 

 

 

5,158

 

Computers and software

 

 

3,777

 

 

 

3,131

 

Furniture and fixtures

 

 

1,494

 

 

 

1,399

 

Machinery and equipment

 

 

7,197

 

 

 

4,496

 

Leasehold improvements

 

 

4,864

 

 

 

4,459

 

Construction in progress

 

 

874

 

 

 

1,343

 

Total property and equipment

 

 

20,618

 

 

 

19,986

 

Less: accumulated depreciation and amortization

 

 

(7,654

)

 

 

(4,988

)

Property and equipment, net

 

 

12,964

 

 

 

14,998

 

Total depreciation and amortization expense for the years ended December 31, 2021, 2020, and 2019 was $5.2 million, $3.2 million, and $1.5 million, respectively.

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Accrued inventory

 

$

4,808

 

 

$

3,576

 

Accrued research and development expenses

 

 

574

 

 

 

175

 

Accrued professional services

 

 

1,269

 

 

 

2,187

 

Accrued rebate

 

 

3,121

 

 

 

566

 

 Other

 

 

4,017

 

 

 

1,399

 

Total accrued expenses and other current liabilities

 

$

13,789

 

 

$

7,903

 

Accrued Warranty Liability

The change in accrued warranty liability is presented in the following table (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Balance at the beginning of the period

 

$

2,913

 

 

$

1,702

 

Additions charged to cost of product revenue

 

 

7,310

 

 

 

4,858

 

Consumption

 

 

(6,519

)

 

 

(3,647

)

Balance at the end of the period

 

$

3,704

 

 

$

2,913

 

XML 27 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

6. Commitments and Contingencies

Leases

In September 2019, the Company entered into an operating lease agreement for its new facility and office space in San Jose, CA that commenced in April 2020 and expires in March 2027. This operating lease contains a free rent period and an escalation clause. The landlord provided the Company with a tenant improvement allowance of up to $2.0 million. The Company issued an irrevocable standby letter of credit in the amount of $0.3 million in lieu of a cash security deposit. The letter of credit is fully secured by cash held at the bank in a restricted account.

In May 2020, the Company entered into an operating lease agreement for its manufacturing facility in Tijuana, Mexico that commenced in May 2020 and will expire in August 2026. The Company took initial possession of the building with 48,437 square feet in May 2020 and subsequently took possession of the second space with 38,750 square feet in June 2021. This operating lease contains a free rent period and an escalation clause. The Company issued an irrevocable standby letter of credit in the amount of $3.0 million, in lieu of a cash security deposit. The letter of credit is fully secured by cash held at the bank in a restricted account.

Both leases include renewal options at the election of the Company to renew or extend the lease. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities.

The components of lease costs were as follows (in thousands):

 

 

Years ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Operating lease costs

 

 

1,759

 

 

 

1,070

 

 

 

 

Variable lease costs

 

 

375

 

 

 

233

 

 

 

100

 

Short-term lease costs

 

 

180

 

 

 

371

 

 

 

520

 

Total lease costs

 

$

2,314

 

 

$

1,674

 

 

$

620

 

 

The weighted-average remaining lease term and discount rate were as follows:

 

 

December 31,

 

 

 

2021

 

 

2020

 

Weighted-average remaining lease term (in years)

 

 

5.3

 

 

 

6.3

 

Weighted-average discount rate

 

8.7%

 

 

8.7%

 

The maturity of the Company’s operating lease liabilities as of December 31, 2021 were as follows (in thousands):

Years Ending December 31:

 

 

 

2022

 

$

1,796

 

2023

 

 

1,856

 

2024

 

 

1,911

 

2025

 

 

1,969

 

Thereafter

 

 

2,523

 

Total lease payments

 

$

10,055

 

Less: imputed interest

 

 

(2,011

)

Present value of operating lease liabilities

 

$

8,044

 

Operating lease liabilities, current

 

$

1,151

 

Operating lease liabilities, noncurrent

 

$

6,893

 

Purchase Commitments

The Company's commitments as of December 31, 2021 include an estimated amount of $68.6 million relating to the Company’s open purchase orders and contractual obligations that occur in the ordinary course of business, including commitments with contract manufacturers and suppliers for which the Company has not received the goods or services, commitments for capital expenditures, consulting activities for which the Company has not received the services, and subscription of software services. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel within a reasonable period, reschedule, and adjust its requirements based on its business needs prior to the delivery of goods or performance of services.

Litigation

From time to time, the Company may become involved in legal proceedings or investigations, which could have an adverse impact on its reputation, business and financial condition and divert the attention of the Company’s management from the operation of the Company’s business. The Company is not presently a party to any legal proceedings that, if determined adversely to the Company, would individually or taken together have a material adverse effect on its business, results of operations, financial condition or cash flows.

Indemnifications

In the ordinary course of business, the Company often includes standard indemnification provisions in its arrangements with its partners, customers and suppliers. Pursuant to these provisions, the Company may be obligated to indemnify such parties for losses or claims suffered or incurred in connection with its service, breach of representations or covenants, intellectual property infringement or other claims made against such parties. These provisions may limit the time within which an indemnification claim can be made. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such indemnification obligations and has not accrued any liabilities related to such obligations in these financial statements.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Term Loans
12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Term Loan

7. Term Loans

Term loans consist of the following (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Principal of term loan

 

$

30,000

 

 

$

30,000

 

Unamortized debt discount

 

 

(238

)

 

 

(326

)

Total term loan, noncurrent

 

$

29,762

 

 

$

29,674

 

Perceptive Term Loans

In 2017, the Company entered into a senior, secured, delayed-draw term loan facility (the Perceptive Term Loan Agreement) with Perceptive Credit Holdings, LP, as the administrative agent and the collateral agent, for various related Perceptive group companies to borrow up to $40.0 million (the Perceptive Term Loans). The Perceptive Term Loans bore interest at a rate of 8.55%, plus the greater of the three-month London Inter-bank Offered Rate (LIBOR) and 2.00%.

In July 2020, the Company used the SVB Term Loan (see below) to repay in full all amounts due under the Perceptive Term Loan and cash on hand to pay $1.2 million in early prepayment, accrued interest and exit fees. The repayment of the Perceptive Term Loan was accounted for as a debt extinguishment, which resulted in a loss on extinguishment of $1.6 million recorded in the statements of operations for the year ended December 31, 2020.

SVB Loan and Security Agreement

On July 2, 2020, the Company entered into a senior secured term loan facility with Silicon Valley Bank (SVB) (the SVB Loan and Security Agreement), which provides for a $30.0 million term loan (the SVB Term Loan).

The SVB Term Loan matures on November 1, 2025. Payments under the SVB Term Loan are for interest only through May 2023, and then 30 monthly principal and interest payments from June 2023 until maturity. The SVB Term Loan bears interest at a rate per annum equal to the greater of (A) 0.50% above the Prime Rate as reported in the Wall Street Journal then in effect (which shall not be less than zero) and (B) 3.75% (3.75% as of December 31, 2021). The Company is obligated to maintain a restricted cash balance greater or equal to the outstanding principal balance of $30.0 million of the SVB Term Loan.

There is also a final payment fee equal to 6.75% of the original principal amount of the SVB Term Loan, or approximately $2.0 million, due at maturity (or any earlier date of optional pre-payment or acceleration of principal due to an event of default). Such fee is being accreted to interest expense using the effective interest method with the offset recorded in noncurrent accrued interest. The Company may, at its option, prepay the SVB Term Loan in full, subject to an additional prepayment fee ranging between 1% and 3% of the outstanding principal amount of the SVB Term Loan.

In the event of default or change in control, all unpaid principal and all accrued and unpaid interest amounts (if any) become immediately due and payable including the prepayment fee. Events of default include, but are not limited to, a payment default, a material adverse change, and insolvency. The SVB Term Loan is secured by substantially all of the Company’s assets, including all of the capital stock held by the Company, if any (subject to a 65% limitation on pledges of capital stock of foreign subsidiaries), subject to certain exceptions. The SVB Loan and Security Agreement contains customary representations, warranties, affirmative covenants and also contains certain restrictive covenants.

Debt issuance costs paid directly to SVB and other debt issuance costs amounting to $0.4 million were accounted for as discounts on the SVB Term Loan. These debt discounts, along with the final payment fee, are being amortized over the term of the SVB Term Loan using the effective interest rate method. As of December 31, 2021, the unamortized debt discount was $0.2 million, which is recorded as a direct deduction from the SVB Term Loan on the balance sheets.

Aggregate annual payments due on the SVB Term Loan as of December 31, 2021 were as follows (in thousands):

Years Ending December 31:

 

 

 

2022

 

$

1,141

 

2023

 

 

8,073

 

2024

 

 

12,667

 

2025

 

 

13,233

 

Total future payments

 

 

35,114

 

Less: amount representing interest

 

 

(3,089

)

Less: final payment

 

 

(2,025

)

Total term loan

 

 

30,000

 

Less: unamortized debt discount

 

 

(238

)

Total term loan, net of debt discount

 

$

29,762

 

XML 29 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity
12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Stockholders' Equity

8. Stockholders’ Equity

The Company has reserved shares of common stock for issuance as of December 31, 2021 as follows (in thousands):

 

 

Shares

 

Warrants to purchase common stock

 

 

63

 

Stock options outstanding

 

 

3,533

 

Restricted stock units outstanding

 

 

563

 

Performance stock units outstanding

 

 

110

 

Shares available for future purchase under ESPP

 

 

999

 

Shares available for future grant under 2020 Plan

 

 

4,415

 

Total reserved shares

 

 

9,683

 

XML 30 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plan
12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Equity Incentive Plan

9. Equity Incentive Plan

In 2019, the Company terminated the 2010 Stock Incentive Plan (the 2010 Plan) and adopted the 2019 Equity Incentive Plan (the 2019 Plan, and together with 2010 Plan, the Prior Plans) for the purpose of providing incentive and non-statutory stock options to employees, directors and certain non-employees.

In the third quarter of 2020, the Company adopted the 2020 Equity Incentive Plan (the 2020 Plan, and together with the Prior Plans, the Plans), which became effective in connection with the IPO. As a result, the Company may not grant any additional awards under the Prior Plans. The Prior Plans will continue to govern outstanding equity awards previously granted thereunder. The Company has initially reserved 3,665,000 shares of common stock for the issuance of awards under the 2020 Plan. In addition, the number of shares of common stock available under the 2020 Plan automatically increases on the first day of each fiscal year until (and including) the fiscal year ending December 31, 2030, with such annual increase equal to an amount equal to the lesser of (i) 4% of the number of shares of common stock issued and outstanding on December 31 of the immediately preceding calendar year, and (ii) an amount determined by the Company’s board of directors. On January 1, 2021, the number of shares of common stock reserved for the issuance of awards under the 2020 Plan was increased by 1,709,000 shares as a result of the automatic increase pursuant to the 2020 Plan.

Options under the 2020 Plan have a contractual term of 10 years. The exercise price of an option shall not be less than 100% of the fair market value of the shares on the date of grant.

Stock Options

A summary of the Company’s stock option activity under the Plans is set forth below (in thousands, except exercise price and remaining contractual life data):

 

 

Outstanding
Options

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Terms
(Years)

 

 

Aggregate
Intrinsic
Value

 

Balance as of December 31, 2020

 

 

4,763

 

 

$

6.35

 

 

 

 

 

 

 

Granted

 

 

634

 

 

$

47.91

 

 

 

 

 

 

 

Exercised

 

 

(1,437

)

 

$

5.31

 

 

 

 

 

 

 

Forfeited and expired

 

 

(427

)

 

$

19.58

 

 

 

 

 

 

 

Balance as of December 31, 2021

 

 

3,533

 

 

$

12.63

 

 

 

6.82

 

 

$

119,959

 

Exercisable as of December 31, 2021

 

 

2,453

 

 

$

5.42

 

 

 

6.07

 

 

$

99,853

 

The weighted average grant date fair value of options granted to employees was $24.74, $7.97, and $2.77 per share during the years ended December 31, 2021, 2020 and 2019, respectively. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was $61.0 million, $8.2 million, and $0.2 million, respectively. The intrinsic value is the difference between the estimated fair value of the Company’s common stock at the time of exercise and the exercise price of the stock option.

The total fair value of options that vested during the years ended December 31, 2021, 2020 and 2019 was $24.5 million, $3.3 million, and $0.7 million, respectively. As of December 31, 2021, the total unrecognized stock-based compensation expense related to the stock options was $14.0 million, which will be recognized over a weighted-average period of 2.63 years.

Stock Options with Performance and Market Conditions

As of December 31, 2020, the Company had 1,933,000 shares of outstanding stock options with performance- and market-based vesting conditions. The options were scheduled to vest over the requisite service period if the Company achieves both (i) a performance condition tied to a liquidity event, which includes the effectiveness of an IPO, and (ii) certain market conditions, provided the optionee is providing services on the date of the event. As of December 31, 2021, all outstanding options with these conditions were fully vested and related stock-based compensation was recognized in full. For the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense of $4.3 million and $18.5 million, respectively, related to these stock options. No such expense was recorded for the year ended December 31, 2019 as the performance-based vesting condition was not satisfied until the closing of the IPO in September 2020.

The fair value of each stock option grant is estimated on the date of grant using the following assumptions for the periods indicated:

 

 

Years Ended December 31,

 

 

2021

 

2020

 

2019

Expected term (in years)

 

5.95 – 6.08

 

5.06 – 10.00

 

4.97 – 5.05

Expected volatility

 

53.9% – 55.3%

 

52.1% – 62.7%

 

49.3% – 50.9%

Risk-free interest rate

 

0.66% – 1.36%

 

0.35% – 1.54%

 

1.57% – 2.48%

Dividend yield

 

0%

 

0%

 

0%

Restricted Stock

The Company issues RSUs and PSUs, both of which are considered restricted stock. The Company grants restricted stock pursuant to the 2020 Plan and satisfies such grants through the issuance of new shares. RSUs are share awards that, upon vesting, will deliver to the holder shares of our common stock. The PSUs may vest upon the achievement of specified revenue targets (performance-based vesting conditions) or specified market stock prices (market-based vesting conditions) and continued performance of services. Certain PSUs with performance-based vesting conditions vest in a range between 0% and 200% of the units approved based on the performance relative to specified revenue targets.

Restricted stock activity was as follows (in thousands, except per share amounts):

 

 

Restricted
Stock Units

 

 

Performance
Stock Units

 

 

Weighted-Average
Grant Date Fair
Value Per Share

 

 

 

(RSU)

 

 

(PSU)

 

 

RSU

 

 

PSU

 

Outstanding as of December 31, 2020

 

 

44

 

 

 

25

 

 

$

52.32

 

 

$

52.55

 

Granted

 

 

639

 

 

 

85

 

 

$

47.78

 

 

$

46.22

 

Vested

 

 

(19

)

 

 

 

 

$

51.03

 

 

$

 

Forfeited

 

 

(101

)

 

 

 

 

$

48.04

 

 

$

 

Outstanding as of December 31, 2021

 

 

563

 

 

 

110

 

 

$

47.98

 

 

$

47.65

 

The total grant date fair value of RSUs vested for the years ended December 31, 2021 and 2020 were $1.0 million and $0.2 million, respectively. There were no RSUs granted prior to 2020. As of December 31, 2021, the total unrecognized stock-based compensation expense related to the RSUs was $22.6 million, which will be recognized over a weighted-average period of 3.12 years.

As of December 31, 2021, the total unrecognized stock-based compensation expense related to the PSUs with market-based vesting conditions was $1.3 million, which will be recognized over a weighted-average period of 1.25 years.

Employees Stock Purchase Plan (ESPP)

In the third quarter of 2020, the Company adopted the ESPP. The Company has initially reserved 687,000 shares of common stock for purchase under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP increases automatically on the first day of each fiscal year until (and including) the fiscal year ending December 31, 2030, with such annual increase equal to the lesser of (i) 687,000 shares, (ii) 1% of the number of common stock issued and outstanding on December 31 of the immediately preceding fiscal year, and (iii) an amount determined by the Company’s board of directors. On January 1, 2021, the number of shares of common stock reserved for purchase under the ESPP was increased by 427,000 shares as a result of the automatic increase pursuant to the ESPP.

Subject to any limitations contained therein, the ESPP allows eligible participants to contribute, through payroll deductions, up to 15% of their eligible compensation to purchase the Company’s common stock at a purchase price equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. The ESPP generally provides for consecutive 6-month offering periods. Effective beginning with the offering period commencing on March 1, 2022, the ESPP allows eligible participants to purchase shares pursuant to a cashless exercise program, and the duration for each offering period will be a 24-month period consisting of four separate consecutive purchase periods of approximately six months in length. This includes a two-year look-back feature in the ESPP, with a reset feature, which causes the offering period to reset if the fair value of the Company’s common stock on the first day of a new offering period is less than that on the original offering date.

The fair value of the stock purchase rights under the ESPP is estimated using the Black-Scholes option pricing model. The weighted average grant date fair value and assumptions used in estimating the fair value of the stock purchase rights under the ESPP were as follows:

 

 

Years Ended December 31,

 

 

2021

 

2020

Expected term (in years)

 

0.50

 

0.47

Expected volatility

 

41.0% – 43.8%

 

57.0%

Risk-free interest rate

 

0.06% – 0.07%

 

0.12%

Dividend yield

 

0%

 

0%

Grant Date Fair Value

 

$13.25 – $13.95

 

$8.00

During the years ended December 31, 2021 and 2020, 116,000 and zero shares of common stock were purchased pursuant to the ESPP, respectively. As of December 31, 2021, the total unrecognized stock-based compensation expense related to the ESPP was $0.2 million, which will be recognized over a weighted-average period of 0.17 years.

Stock-based Compensation Expense

The following table sets forth stock-based compensation expense included in the Company’s statements of operations (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cost of revenue

 

$

269

 

 

$

255

 

 

$

5

 

Research and development

 

 

3,809

 

 

 

4,615

 

 

 

328

 

Sales and marketing

 

 

5,897

 

 

 

4,423

 

 

 

172

 

General and administrative

 

 

7,470

 

 

 

12,146

 

 

 

378

 

Total stock-based compensation expense

 

$

17,445

 

 

$

21,439

 

 

$

883

 

XML 31 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

10. Income Taxes

Loss before provision for income taxes were as follows for the periods indicated (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Domestic

 

$

(128,400

)

 

$

(121,492

)

 

$

(68,299

)

Foreign

 

 

(3,336

)

 

 

 

 

 

 

Loss before provision for income taxes

 

$

(131,736

)

 

$

(121,492

)

 

$

(68,299

)

The provision for income taxes was $0.2 million for the years ended December 31, 2021, which related to foreign income taxes. For years ended December 31, 2020 and 2019, the provision for income taxes were insignificant. The Company has incurred net operating losses for all periods presented. The Company has not reflected any benefit of such net operating loss carryforwards in the financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.

The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:

 

 

Years Ended December 31,

 

 

2021

 

2020

 

2019

Federal statutory income tax rate

 

 

21.0

 

%

 

 

21.0

 

%

 

 

21.0

 

%

State taxes

 

 

1.3

 

 

 

 

3.8

 

 

 

 

7.8

 

 

Change in valuation allowance

 

 

(22.8

)

 

 

 

(23.3

)

 

 

 

(28.5

)

 

Federal and state tax credits

 

 

1.2

 

 

 

 

1.0

 

 

 

 

0.9

 

 

Stock-based compensation expense

 

 

8.1

 

 

 

 

1.2

 

 

 

 

 

 

Non-deductible permanent expenses

 

 

(0.1

)

 

 

 

(0.2

)

 

 

 

(1.2

)

 

Effect of deferred tax adjustment

 

 

(0.7

)

 

 

 

(1.4

)

 

 

 

 

 

Non-deductible compensation

 

 

(8.2

)

 

 

 

(2.1

)

 

 

 

 

 

Effective income tax rate

 

 

(0.2

)

%

 

 

 

%

 

 

 

%

 

Deferred tax assets and liabilities

Deferred income taxes reflect the net tax effect of temporary differences between amounts recorded for financial reporting purposes and amounts used for tax purposes. The major components of deferred tax assets and liabilities were as follows as of the dates indicated (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

102,094

 

 

$

76,838

 

Tax credits

 

 

11,767

 

 

 

10,039

 

Accrual and reserves

 

 

3,573

 

 

 

2,392

 

Tangible and intangible assets

 

 

20,249

 

 

 

19,090

 

Stock-based compensation expense

 

 

3,566

 

 

 

2,843

 

Lease liabilities

 

 

1,955

 

 

 

1,733

 

Other deferred tax asset

 

 

282

 

 

 

 

Gross deferred tax assets

 

 

143,486

 

 

 

112,935

 

Valuation allowance

 

 

(141,729

)

 

 

(111,061

)

Net deferred tax assets

 

$

1,757

 

 

$

1,874

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax liabilities:

 

 

 

 

 

 

  Right-of-use assets

 

$

(1,757

)

 

$

(1,874

)

  Gross deferred tax liabilities

 

$

(1,757

)

 

$

(1,874

)

Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2021 and 2020 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The valuation allowance increased by $30.7 million, $28.4 million and $23.7 million during the years ended December 31, 2021, 2020 and 2019, respectively.

Net Operating Loss and Tax Credit Carryforwards

As of December 31, 2021, the Company had a net operating loss carryforward for federal income tax purposes of $409.0 million. Federal net operating losses of $281.2 million incurred after 2017 do not expire but usage is limited to 80% of taxable income. The remaining $127.8 million of federal net operating loss carryforward will begin to expire in 2024 and continue to expire through 2037. The Company had a total state net operating loss carryforward of $213.7 million. State net operating losses of $53.2 million do not expire. The remaining state net operating loss carryforward of $160.5 million will begin to expire in 2022 and continue to expire through 2041.

The Company had federal research and development credits of $6.6 million, which will begin to expire in 2030 and state research and development credits of $5.1 million which have no expiration date. These tax credits are subject to the same limitations discussed above.

Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company’s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced. The Company’s deferred tax asset and related valuation allowance would be reduced, as a result. The Company has not performed a Section 382 study to determine the amount of reduction, if any. Unrecognized tax benefits at December 31, 2021 have been recorded as an offset to federal and state research and development credit carryforwards.

Unrecognized Tax Benefits

A reconciliation of the total unrecognized tax benefits for the periods presented was as follows (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Balance, beginning of year

 

$

1,582

 

 

$

1,020

 

Decrease related to current year positions

 

 

 

 

 

 

Increase related to current year positions

 

 

608

 

 

 

562

 

Balance, end of year

 

$

2,190

 

 

$

1,582

 

The Company does not have any material accrued interest or penalties associated with unrecognized tax benefits. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change within the next twelve months.

The Company files income tax returns in the United States and various states and Mexico. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by federal, state, and foreign authorities for three, four, and five years, respectively, from the date of utilization of any net operating loss or credits.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share Attributable to Common Stockholders
12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Net Loss Per Share Attributable to Common Stockholders

11. Net Loss per Share Attributable to Common Stockholders

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to common stockholders was as follows (in thousands, except per share amounts):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Numerator:

 

 

 

 

 

 

 

 

 

Net loss

 

$

(131,935

)

 

$

(121,492

)

 

$

(68,299

)

Adjustment to redemption value on redeemable
   convertible preferred stock

 

 

 

 

 

(362

)

 

 

(134,760

)

Deemed dividend on settlement of accrued dividend

 

 

 

 

 

42,530

 

 

 

 

Gain on extinguishment of redeemable convertible preferred stock

 

 

 

 

 

 

 

 

117,598

 

Net loss attributable to common stockholders,
  basic and diluted

 

$

(131,935

)

 

$

(79,324

)

 

$

(85,461

)

Denominator:

 

 

 

 

 

 

 

 

 

Weighted-average shares of common stock,
   basic and diluted

 

 

45,589

 

 

 

16,358

 

 

 

858

 

Net loss per share attributable to common stockholders,
   basic and diluted

 

$

(2.89

)

 

$

(4.85

)

 

$

(99.58

)

The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Stock options to purchase common stock

 

 

3,533

 

 

 

4,763

 

 

 

3,757

 

Warrant to purchase common stock

 

 

63

 

 

 

63

 

 

 

 

Restricted stock units

 

 

581

 

 

 

 

 

 

 

Shares committed under ESPP

 

 

37

 

 

 

52

 

 

 

 

Performance stock units

 

 

17

 

 

 

 

 

 

 

Redeemable convertible preferred stock, on an as-if converted basis

 

 

 

 

 

 

 

 

18,634

 

Warrants to purchase redeemable convertible preferred stock

 

 

 

 

 

 

 

 

599

 

Total

 

 

4,231

 

 

 

4,878

 

 

 

22,990

 

XML 33 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Use Of Estimates

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, allowance for doubtful accounts, inventory valuation and write-downs, warranty obligations, the fair value of equity awards, the valuation of investments, recoverability of the Company’s net deferred tax assets, and certain accrued expenses. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results may differ from those estimates under different assumptions or conditions and the differences may be material.

Concentration of Credit Risk

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, restricted cash, short-term investments and accounts receivable. Substantially all the Company’s cash and cash equivalents, restricted cash, and investments are held at one financial institution in the United States that management believes is of high credit quality. Such investments may, at times, exceed federally insured limits or may not be covered by deposit insurance at all. The Company has not experienced any credit losses on its cash and cash equivalents, restricted cash or short-term investments through December 31, 2021.

For the year ended December 31, 2021, two customers accounted for 30% and 15% of revenues, respectively. For the year ended December 31, 2020, three customers accounted for 22%, 19% and 16% of revenues, respectively. One customer accounted for 11% of revenues for the year ended December 31, 2019. Accounts receivable are unsecured and the Company does not require collateral; however, the Company does assess the collectability of accounts receivable based on a number of factors, including past transaction history with, and the creditworthiness of, the customer. Accordingly, the Company is exposed to credit risk associated with accounts receivable. One customer accounted for 10% of accounts receivable as of December 31, 2021. Two customers accounted for 22% and 16% of accounts receivable, respectively, as of December 31, 2020. To reduce risk, the Company closely monitors the amounts due from its customers and assesses the financial strength of its customers through a variety of methods that include, but are not limited to, engaging directly with customer operations and leadership personnel, visiting customer locations to observe operating activities, and assessing customer longevity and reputation in the marketplace. As a result, the Company believes that its accounts receivable credit risk exposure is limited. A material default in payment or a material reduction in purchases from these or any other large customers could have a material adverse impact on the Company’s financial condition, results of operations, and liquidity.

The Company has a manufacturing facility in Tijuana, Mexico which it operates in collaboration with its outsourced business administration service provider, TACNA, for the production of the Tablo console. The Company is subject to a number of risks associated with operating its Mexico-based manufacturing facility. The manufacturing operations at the facility may suffer disruptions from global or regional public health crises such as the ongoing COVID-19 pandemic, natural disasters, cyber security attacks, vandalism, terrorism or other political hostilities. Any such occurrences could negatively impact the Company’s ability to produce the Tablo console. The Company is also subject to a variety of foreign laws and regulations, including trade and labor restrictions and laws relating to importation, exportation and taxation of goods, and U.S. laws and regulations relating to foreign operations. In addition, because certain of its Mexico-based manufacturing operations incur costs that are denominated in MXN, the Company is exposed to additional risk of currency fluctuations between USD and MXN, which could increase its product and labor costs, thus reducing its gross profit. To date, foreign currency transaction gains and losses have not been material to the Company’s financial statements.

The Company is subject to additional risks and uncertainties due to the COVID-19 pandemic. How long the pandemic, and measures intended to contain the spread of COVID-19, will continue remains uncertain and depends on ongoing developments, including but not limited to any resurgences of the virus including emerging variant strains, federal, state and local government actions taken in response, and continued availability, effectiveness and public acceptance of COVID-19 vaccines, as well as the extent and duration of the effect on the economy and how quickly and to what extent normal economic and operating conditions can resume. Additionally, the duration and severity of disruptions in the global supply chain, largely driven by high demand as the economy reopens and the ongoing impact of the pandemic, also remain uncertain and depend on various factors, including the effectiveness of recent government actions intended to mitigate these disruptions. As a result, the Company cannot predict what effect COVID-19, the associated containment measures and the related supply chain disruptions will ultimately have on its business and result of operations.

While the potential economic impact and duration of the COVID-19 pandemic may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets,

which could result in a reduction in the Company’s ability to access capital and delays in payments of outstanding receivables that could adversely affect our liquidity. In addition, a recession or market correction resulting from the spread COVID-19 could materially affect the Company's business and financial results. As of the date of issuance of the financial statements, the extent to which the COVID-19 pandemic may materially adversely affect the Company's financial condition, liquidity, or results of operations is uncertain.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.

The Company classifies financial instruments using a three-tiered fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Management believes that its term loan bears interest at the prevailing market rates for instruments with similar characteristics; accordingly, the carrying value of this instrument approximates its fair value.

Cash Equivalents and Short-Term Investments

Cash Equivalents and Short-Term Investments

The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and are stated at fair value.

The Company primarily holds corporate debt securities, commercial paper, and U.S. Treasury securities, and has the ability, if necessary, to liquidate any of its investments to meet its liquidity needs in the next 12 months, without significant penalty. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term investments on the accompanying balance sheets. Short-term investments have been classified as available-for-sale at the time of purchase. The Company evaluates the appropriate classification of its investments as of each balance sheet date.

The Company’s investment securities are recorded at fair value based on the fair value hierarchy. Money market funds and U.S. Treasury securities are classified within Level 1 of the fair value hierarchy. Other securities are classified within Level 2 of the fair value hierarchy. Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).

A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold.
Accounts Receivable, Net

Accounts Receivable, Net

Accounts receivable are recorded at invoice value, net of any allowance for doubtful accounts. Estimates of the allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of customers and individual customer circumstances. The allowance for doubtful accounts was not significant as of December 31, 2021 and 2020.

Inventories

Inventories

Inventory is stated at the lower of cost or net realizable value, with approximate costs determined on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The carrying value of inventories is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on the Company’s statements of operations.

Property and Equipment, Net

Property and Equipment, Net

Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is generally computed using the straight-line method based on the estimated useful lives of the assets, which is generally two to five years. Certain Tablo consoles under operating leases are depreciated using the accelerated method. Leasehold improvements are amortized using the straight-line method over the shorter of the assets estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to expense as incurred. Significant improvements that substantially enhance the useful life of an asset are capitalized and depreciated. When assets are retired or disposed of, the cost together with related accumulated depreciation is removed from the balance sheet and any resulting gain or loss is reflected in the Company’s statements of operations in the period realized.

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. There were no such impairment losses as of December 31, 2021 and 2020.

Leases

Leases

The Company determines if an arrangement is a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term. Operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.

As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. Lease costs for the Company’s operating leases are recognized on a straight-line basis over the reasonably assured lease term. Variable lease payments include lease operating expenses.

The Company has elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.
Accrued Warranty Liability

Accrued Warranty Liability

The Company generally provides a one-year warranty for defective parts and workmanship on its Tablo consoles, commencing upon the transfer of title and risk of loss to the customer. The Company accrues the estimated cost of product warranties when it invoices the customer, based on historical experience and expected results. Should actual product failure rates and material usage costs differ from these estimates, revisions to the estimated warranty liability would be required. The Company periodically assesses the adequacy of its recorded product warranty liabilities and adjusts the balance as required. Warranty expense is recorded as a component of cost of product revenue in the statements of operations.
Contract Liabilities - Deferred Revenue

Contract Liabilities - Deferred Revenue

The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue is recognized subsequent to invoicing. For multi-year service agreements, the Company generally invoices customers annually at the beginning of each annual coverage period. Deferred revenue that will be recognized during the 12 months following the balance sheet date is recorded as the current portion of deferred revenue and the remaining portion is recorded as noncurrent.
Revenue

Revenue

The Company generates revenue primarily from contracts with customers for the sale of its products and services. Product revenue consists primarily of sales of the Tablo console and related consumables, including Tablo cartridges, used in treatment

delivery. Service and other revenue consists primarily of revenue generated from consoles service contracts and other revenue from shipping and handling charged to customers.

Each customer contract defines our distinct performance obligations and the associated transaction price for each obligation. Tablo consoles and consumables are generally sold without the right of return. Revenue is recognized when a performance obligation is satisfied. Revenue from product sales is recognized at a point in time when management has determined that control has transferred to the customer, which is generally when legal title has transferred to the customer. Revenue from service contracts is recognized over time as the service is performed, typically evenly over the contract term. Certain contracts include variable consideration such as rebates, revenue for such contracts is recognized only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Revenue is recognized net of any taxes collected from customers, which are subsequently remitted to governmental authorities.

The Company’s contracts with customers often include multiple performance obligations. For such contracts, the Company allocates the contracted transaction price to each performance obligation based upon the relative SSP. The Company determines the SSP based upon the facts and circumstances of each performance obligation (product or services), which often requires management's judgement. The Company uses an observable price to estimate SSP for items that are sold separately, including customer service agreements. In instances where SSP is not directly observable, such as when the Company does not sell the product or service separately, the Company determines the SSP using information that may include market conditions and other observable inputs. The Company may offer additional goods or services to customers at the inception of customer contracts at prices not at SSP. If such contracts result in a material right, the Company allocates part of the transaction price to that right and recognizes the associated revenue when those future goods and services are transferred to the customer. SSP is assigned based on the estimated value of the material right.

Costs associated with product sales include commissions. The Company applies the practical expedient to expense the commissions as incurred as the expected amortization period is one year or less. Commissions are recorded as sales and marketing expenses in the statements of operations.

Operating Lease Arrangements

The Company enters into operating lease arrangements that contain both lease and non-lease elements. The lease element includes Tablo consoles, while non-lease elements include consumables, services and training. Revenue related to such arrangements is allocated to lease and non-lease elements based on their relative SSP. Revenue for the lease element, net of any taxes collected from customers, is recognized on a straight-line basis as product revenue over the lease term, generally three months to one year, in the statements of operations. The costs of the leased Tablo consoles are included in property and equipment, net in the balance sheets and amortized to cost of product revenue.

Shipping and Handling Costs

Shipping and handling charged to customers are recorded as revenue. Shipping and handling costs are expensed as incurred and are included in sales and marketing expenses.
Stock-Based Compensation Expense

Stock-Based Compensation Expense

Stock-based compensation expense relates to stock options with a service-based vesting condition, stock options with performance and market-based vesting conditions, stock purchase rights under our ESPP, RSUs and PSUs with performance or market-based vesting conditions. Stock-based compensation expense for the Company’s stock-based awards is based on their grant date fair value.

Service-based options granted to an optionee generally vest at a rate of 25% on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining three years. The fair value of stock options with a service condition and stock purchase rights under the ESPP on the grant date is estimated using the Black-Scholes option-pricing model. The fair value of these awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur.

The Black-Scholes model considers several variables and assumptions in estimating the fair value of service-based stock options and stock purchase rights under the ESPP. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and expected stock price volatility over the expected term. For all service-based stock options granted, the Company calculates the expected term using the simplified method for “plain vanilla” stock option awards. The Company had no publicly available stock price information prior to the IPO and limited

available stock price information subsequent to the IPO; therefore, the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term on the equity settled award.

For stock options with performance- and market-based vesting conditions, stock-based compensation expense begins to be recognized over the remaining service period when it is considered probable that the performance vesting condition will be satisfied. Prior to the IPO in September 2020, the Company had not recognized any stock-based compensation expense as the satisfaction of the performance condition was not considered probable. Upon the closing of the IPO, the Company recorded a cumulative stock-based compensation expense using the accelerated attribution method as the performance condition was satisfied. Stock-based compensation expense related to these options is recognized using the accelerated attribution method as the performance-based vesting condition and not reversed if the achievement of the market condition does not occur. The fair value of these stock options is estimated using the Monte Carlo simulation model.

RSUs with a service-based vesting condition granted to an optionee generally vest at a rate of 25% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining three years. The fair value of RSUs and PSUs with a service- or performance-based vesting condition is based on the market price of the Company’s common stock on the date of grant. The determination of the stock-based compensation expense related to PSUs to be recognized in the Company’s statements of operations requires the use of certain estimates and assumptions. At each reported period, the Company reassesses the probability of the achievement of corporate performance goals to estimate the number of shares to be released. Any increase or decrease in stock-based compensation expense resulting from an adjustment in the estimated shares to be released is treated as accumulative catch-up in the period of adjustment. If any of the assumptions or estimates used change significantly, stock-based compensation expense may differ materially from what the Company has recorded in the current period. The fair value of PSUs with a market-based vesting condition is estimated using the Monte Carlo simulation model. Stock-based compensation expense related to these PSUs is recognized using the accelerated attribution method and not reversed if the achievement of the market conditions does not occur.

Research and Development

Research and Development

The Company expenses all research and development costs as incurred. These expenses include the costs of proprietary research and development efforts, quality engineering, clinical studies and trials and regulatory affairs. Costs primarily consist of compensation and personnel costs, consulting services, supplies and materials expenses, and allocated costs including facilities and information technology
Advertising Costs

Advertising Costs

Advertising costs are expensed as incurred. The advertising costs for years ended December 31, 2021, 2020 and 2019 were not significant.
Income Taxes

Income Taxes

The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and remeasured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.

The Company utilizes a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.

The Company includes any penalties and interest expense related to income taxes as a component of other expense, net, as necessary.
Net Loss per Share Attributable to Common Stockholders

Net Loss per Share Attributable to Common Stockholders

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive securities.

Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents of potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, awards under the Company’s equity compensation plan and warrants are considered to be potentially dilutive securities. For periods in which the Company reports net losses, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders because the effects of potentially dilutive securities are antidilutive.

Employee Benefit Plan

Employee Benefit Plan

The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their eligible compensation on a pre- or post-tax basis. The Company is authorized to make matching contributions but has not made such contributions for the years ended December 31, 2021, 2020 and 2019. Effective January 1, 2022, the Company began to match 100% of each employee’s contributions up to a maximum matching contribution equal to 2% of such employee’s eligible compensation, subject to the terms and limitations of the 401(k) plan and applicable law.

Segment

Segment

The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for the purposes of allocating resources and evaluating financial performance. The Company has operated a manufacturing facility in Mexico since 2020. The Company's long-lived tangible assets, net, as well as the Company's operating lease right-of-use assets recognized on the balance sheets, located in Mexico were $6.2 million as of December 31, 2021.

Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted

Recently Adopted Accounting Pronouncements

In December 2019, the Financial Accounting Standards Board (FASB) issued ASU No. 2019-12, Income Taxes (Topic 740), which simplifies the accounting for income taxes, primarily by eliminating certain exceptions to ASC 740. The Company early adopted ASU 2019-12 on a modified retrospective basis as of January 1, 2021, which did not have a material impact on its financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (CECL) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its financial statements.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue from Contracts with Customers (Tables)
12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Summary of Revenue by Source

Revenue by source consisted of the following (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Consoles

 

$

65,133

 

 

$

32,871

 

 

$

12,187

 

Consumables

 

 

19,179

 

 

 

6,742

 

 

 

1,563

 

Total product revenue

 

 

84,312

 

 

 

39,612

 

 

 

13,750

 

Service and other revenue

 

 

18,290

 

 

 

10,323

 

 

 

1,328

 

Total revenue

 

$

102,602

 

 

$

49,935

 

 

$

15,078

 

 

XML 35 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Summary of Financial Assets Measured at Fair Value On Recurring Basis by Level Within Fair Value Hierarchy

The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

 

 

 

 

December 31, 2021

 

 

 

Valuation
Hierarchy

 

Amortized
Costs

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

60,844

 

 

$

 

 

$

 

 

$

60,844

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

Level 1

 

 

18,064

 

 

 

 

 

 

(60

)

 

 

18,004

 

Corporate debt

 

Level 2

 

 

124,178

 

 

 

2

 

 

 

(125

)

 

 

124,055

 

Commercial paper

 

Level 2

 

 

15,081

 

 

 

 

 

 

 

 

 

15,081

 

Total cash equivalents and
   short-term investments

 

 

 

$

218,167

 

 

$

2

 

 

$

(185

)

 

$

217,984

 

 

 

 

 

 

December 31, 2020

 

 

 

Valuation
Hierarchy

 

Amortized
Costs

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

56,056

 

 

$

 

 

$

 

 

$

56,056

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

Level 1

 

 

14,999

 

 

 

1

 

 

 

 

 

 

15,000

 

Corporate debt

 

Level 2

 

 

4,898

 

 

 

 

 

 

 

 

 

4,898

 

Total cash equivalents and
   short-term investments

 

 

 

$

75,953

 

 

$

1

 

 

$

 

 

$

75,954

 

As of December 31, 2021, the remaining contractual maturities for short-term investments were as follows (in thousands):

 

 

Aggregate Fair Value

 

Due within one year

 

$

135,766

 

After one but within five years

 

 

21,374

 

Total

 

$

157,140

 

XML 36 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components (Tables)
12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the statements of cash flows (in thousands):     December 31,       2021     2020     2019   Cash and cash equivalents   $ 182,348     $ 294,972     $ 36,926   Restricted cash     33,311       33,311       743   Total cash, cash equivalents and restricted cash   $ 215,659     $ 328,283     $ 37,669  
Schedule of Inventories

Inventories consist of the following (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Raw materials

 

$

18,114

 

 

$

7,989

 

Work in process

 

 

6,054

 

 

 

6,200

 

Finished goods

 

 

15,017

 

 

 

4,195

 

Total inventories

 

$

39,185

 

 

$

18,384

 

Summary of Property Plant and Equipment

Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Tablos under operating leases

 

 

2,412

 

 

 

5,158

 

Computers and software

 

 

3,777

 

 

 

3,131

 

Furniture and fixtures

 

 

1,494

 

 

 

1,399

 

Machinery and equipment

 

 

7,197

 

 

 

4,496

 

Leasehold improvements

 

 

4,864

 

 

 

4,459

 

Construction in progress

 

 

874

 

 

 

1,343

 

Total property and equipment

 

 

20,618

 

 

 

19,986

 

Less: accumulated depreciation and amortization

 

 

(7,654

)

 

 

(4,988

)

Property and equipment, net

 

 

12,964

 

 

 

14,998

 

Accrued Expenses and Other Current Liabilities

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Accrued inventory

 

$

4,808

 

 

$

3,576

 

Accrued research and development expenses

 

 

574

 

 

 

175

 

Accrued professional services

 

 

1,269

 

 

 

2,187

 

Accrued rebate

 

 

3,121

 

 

 

566

 

 Other

 

 

4,017

 

 

 

1,399

 

Total accrued expenses and other current liabilities

 

$

13,789

 

 

$

7,903

 

Accrued Warranty Liability

Accrued Warranty Liability

The change in accrued warranty liability is presented in the following table (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Balance at the beginning of the period

 

$

2,913

 

 

$

1,702

 

Additions charged to cost of product revenue

 

 

7,310

 

 

 

4,858

 

Consumption

 

 

(6,519

)

 

 

(3,647

)

Balance at the end of the period

 

$

3,704

 

 

$

2,913

 

XML 37 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Components of Lease Costs

The components of lease costs were as follows (in thousands):

 

 

Years ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Operating lease costs

 

 

1,759

 

 

 

1,070

 

 

 

 

Variable lease costs

 

 

375

 

 

 

233

 

 

 

100

 

Short-term lease costs

 

 

180

 

 

 

371

 

 

 

520

 

Total lease costs

 

$

2,314

 

 

$

1,674

 

 

$

620

 

 

Schedule of Weighted-average Remaining Lease Term and Discount Rate

The weighted-average remaining lease term and discount rate were as follows:

 

 

December 31,

 

 

 

2021

 

 

2020

 

Weighted-average remaining lease term (in years)

 

 

5.3

 

 

 

6.3

 

Weighted-average discount rate

 

8.7%

 

 

8.7%

 

Maturity of Operating Lease Liabilities

The maturity of the Company’s operating lease liabilities as of December 31, 2021 were as follows (in thousands):

Years Ending December 31:

 

 

 

2022

 

$

1,796

 

2023

 

 

1,856

 

2024

 

 

1,911

 

2025

 

 

1,969

 

Thereafter

 

 

2,523

 

Total lease payments

 

$

10,055

 

Less: imputed interest

 

 

(2,011

)

Present value of operating lease liabilities

 

$

8,044

 

Operating lease liabilities, current

 

$

1,151

 

Operating lease liabilities, noncurrent

 

$

6,893

 

XML 38 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Term Loans (Tables)
12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Schedule of Term Loan

Term loans consist of the following (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Principal of term loan

 

$

30,000

 

 

$

30,000

 

Unamortized debt discount

 

 

(238

)

 

 

(326

)

Total term loan, noncurrent

 

$

29,762

 

 

$

29,674

 

Summary of Debt Maturities

Aggregate annual payments due on the SVB Term Loan as of December 31, 2021 were as follows (in thousands):

Years Ending December 31:

 

 

 

2022

 

$

1,141

 

2023

 

 

8,073

 

2024

 

 

12,667

 

2025

 

 

13,233

 

Total future payments

 

 

35,114

 

Less: amount representing interest

 

 

(3,089

)

Less: final payment

 

 

(2,025

)

Total term loan

 

 

30,000

 

Less: unamortized debt discount

 

 

(238

)

Total term loan, net of debt discount

 

$

29,762

 

XML 39 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Summary of Reserved Shares of Common Stock on Converted Basis for Issuance

The Company has reserved shares of common stock for issuance as of December 31, 2021 as follows (in thousands):

 

 

Shares

 

Warrants to purchase common stock

 

 

63

 

Stock options outstanding

 

 

3,533

 

Restricted stock units outstanding

 

 

563

 

Performance stock units outstanding

 

 

110

 

Shares available for future purchase under ESPP

 

 

999

 

Shares available for future grant under 2020 Plan

 

 

4,415

 

Total reserved shares

 

 

9,683

 

XML 40 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plan (Tables)
12 Months Ended
Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]  
Summary of the Stock option activity

A summary of the Company’s stock option activity under the Plans is set forth below (in thousands, except exercise price and remaining contractual life data):

 

 

Outstanding
Options

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Terms
(Years)

 

 

Aggregate
Intrinsic
Value

 

Balance as of December 31, 2020

 

 

4,763

 

 

$

6.35

 

 

 

 

 

 

 

Granted

 

 

634

 

 

$

47.91

 

 

 

 

 

 

 

Exercised

 

 

(1,437

)

 

$

5.31

 

 

 

 

 

 

 

Forfeited and expired

 

 

(427

)

 

$

19.58

 

 

 

 

 

 

 

Balance as of December 31, 2021

 

 

3,533

 

 

$

12.63

 

 

 

6.82

 

 

$

119,959

 

Exercisable as of December 31, 2021

 

 

2,453

 

 

$

5.42

 

 

 

6.07

 

 

$

99,853

 

Summary of Estimated Fair Value of Stock Option Grants

The fair value of each stock option grant is estimated on the date of grant using the following assumptions for the periods indicated:

 

 

Years Ended December 31,

 

 

2021

 

2020

 

2019

Expected term (in years)

 

5.95 – 6.08

 

5.06 – 10.00

 

4.97 – 5.05

Expected volatility

 

53.9% – 55.3%

 

52.1% – 62.7%

 

49.3% – 50.9%

Risk-free interest rate

 

0.66% – 1.36%

 

0.35% – 1.54%

 

1.57% – 2.48%

Dividend yield

 

0%

 

0%

 

0%

Summary of Restricted stock activity

Restricted stock activity was as follows (in thousands, except per share amounts):

 

 

Restricted
Stock Units

 

 

Performance
Stock Units

 

 

Weighted-Average
Grant Date Fair
Value Per Share

 

 

 

(RSU)

 

 

(PSU)

 

 

RSU

 

 

PSU

 

Outstanding as of December 31, 2020

 

 

44

 

 

 

25

 

 

$

52.32

 

 

$

52.55

 

Granted

 

 

639

 

 

 

85

 

 

$

47.78

 

 

$

46.22

 

Vested

 

 

(19

)

 

 

 

 

$

51.03

 

 

$

 

Forfeited

 

 

(101

)

 

 

 

 

$

48.04

 

 

$

 

Outstanding as of December 31, 2021

 

 

563

 

 

 

110

 

 

$

47.98

 

 

$

47.65

 

Summary of Stock-based Compensation Expense

The following table sets forth stock-based compensation expense included in the Company’s statements of operations (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cost of revenue

 

$

269

 

 

$

255

 

 

$

5

 

Research and development

 

 

3,809

 

 

 

4,615

 

 

 

328

 

Sales and marketing

 

 

5,897

 

 

 

4,423

 

 

 

172

 

General and administrative

 

 

7,470

 

 

 

12,146

 

 

 

378

 

Total stock-based compensation expense

 

$

17,445

 

 

$

21,439

 

 

$

883

 

Employee Stock Purchase Plan (ESPP)  
Subsidiary, Sale of Stock [Line Items]  
Summary of Estimated Fair Value of Stock Option Grants The weighted average grant date fair value and assumptions used in estimating the fair value of the stock purchase rights under the ESPP were as follows:

 

 

Years Ended December 31,

 

 

2021

 

2020

Expected term (in years)

 

0.50

 

0.47

Expected volatility

 

41.0% – 43.8%

 

57.0%

Risk-free interest rate

 

0.06% – 0.07%

 

0.12%

Dividend yield

 

0%

 

0%

Grant Date Fair Value

 

$13.25 – $13.95

 

$8.00

XML 41 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Summary of Loss before provision for income taxes

Loss before provision for income taxes were as follows for the periods indicated (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Domestic

 

$

(128,400

)

 

$

(121,492

)

 

$

(68,299

)

Foreign

 

 

(3,336

)

 

 

 

 

 

 

Loss before provision for income taxes

 

$

(131,736

)

 

$

(121,492

)

 

$

(68,299

)

Summary of Effective Tax Rate of the Provision for Income Taxes

The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:

 

 

Years Ended December 31,

 

 

2021

 

2020

 

2019

Federal statutory income tax rate

 

 

21.0

 

%

 

 

21.0

 

%

 

 

21.0

 

%

State taxes

 

 

1.3

 

 

 

 

3.8

 

 

 

 

7.8

 

 

Change in valuation allowance

 

 

(22.8

)

 

 

 

(23.3

)

 

 

 

(28.5

)

 

Federal and state tax credits

 

 

1.2

 

 

 

 

1.0

 

 

 

 

0.9

 

 

Stock-based compensation expense

 

 

8.1

 

 

 

 

1.2

 

 

 

 

 

 

Non-deductible permanent expenses

 

 

(0.1

)

 

 

 

(0.2

)

 

 

 

(1.2

)

 

Effect of deferred tax adjustment

 

 

(0.7

)

 

 

 

(1.4

)

 

 

 

 

 

Non-deductible compensation

 

 

(8.2

)

 

 

 

(2.1

)

 

 

 

 

 

Effective income tax rate

 

 

(0.2

)

%

 

 

 

%

 

 

 

%

 

Deferred tax assets and liabilities

Summary of Components of the Deferred Tax Assets and liabilities The major components of deferred tax assets and liabilities were as follows as of the dates indicated (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax assets:

 

 

 

 

 

 

Net operating loss carryforwards

 

$

102,094

 

 

$

76,838

 

Tax credits

 

 

11,767

 

 

 

10,039

 

Accrual and reserves

 

 

3,573

 

 

 

2,392

 

Tangible and intangible assets

 

 

20,249

 

 

 

19,090

 

Stock-based compensation expense

 

 

3,566

 

 

 

2,843

 

Lease liabilities

 

 

1,955

 

 

 

1,733

 

Other deferred tax asset

 

 

282

 

 

 

 

Gross deferred tax assets

 

 

143,486

 

 

 

112,935

 

Valuation allowance

 

 

(141,729

)

 

 

(111,061

)

Net deferred tax assets

 

$

1,757

 

 

$

1,874

 

 

 

 

 

 

 

 

 

 

December 31,

 

 

 

2021

 

 

2020

 

Deferred tax liabilities:

 

 

 

 

 

 

  Right-of-use assets

 

$

(1,757

)

 

$

(1,874

)

  Gross deferred tax liabilities

 

$

(1,757

)

 

$

(1,874

)

Summary of Reconciliation of the Total Unrecognized Tax Benefits

A reconciliation of the total unrecognized tax benefits for the periods presented was as follows (in thousands):

 

 

December 31,

 

 

 

2021

 

 

2020

 

Balance, beginning of year

 

$

1,582

 

 

$

1,020

 

Decrease related to current year positions

 

 

 

 

 

 

Increase related to current year positions

 

 

608

 

 

 

562

 

Balance, end of year

 

$

2,190

 

 

$

1,582

 

XML 42 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share Attributable to Common Stockholders (Tables)
12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to common stockholders was as follows (in thousands, except per share amounts):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Numerator:

 

 

 

 

 

 

 

 

 

Net loss

 

$

(131,935

)

 

$

(121,492

)

 

$

(68,299

)

Adjustment to redemption value on redeemable
   convertible preferred stock

 

 

 

 

 

(362

)

 

 

(134,760

)

Deemed dividend on settlement of accrued dividend

 

 

 

 

 

42,530

 

 

 

 

Gain on extinguishment of redeemable convertible preferred stock

 

 

 

 

 

 

 

 

117,598

 

Net loss attributable to common stockholders,
  basic and diluted

 

$

(131,935

)

 

$

(79,324

)

 

$

(85,461

)

Denominator:

 

 

 

 

 

 

 

 

 

Weighted-average shares of common stock,
   basic and diluted

 

 

45,589

 

 

 

16,358

 

 

 

858

 

Net loss per share attributable to common stockholders,
   basic and diluted

 

$

(2.89

)

 

$

(4.85

)

 

$

(99.58

)

Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share

The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):

 

 

Years Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Stock options to purchase common stock

 

 

3,533

 

 

 

4,763

 

 

 

3,757

 

Warrant to purchase common stock

 

 

63

 

 

 

63

 

 

 

 

Restricted stock units

 

 

581

 

 

 

 

 

 

 

Shares committed under ESPP

 

 

37

 

 

 

52

 

 

 

 

Performance stock units

 

 

17

 

 

 

 

 

 

 

Redeemable convertible preferred stock, on an as-if converted basis

 

 

 

 

 

 

 

 

18,634

 

Warrants to purchase redeemable convertible preferred stock

 

 

 

 

 

 

 

 

599

 

Total

 

 

4,231

 

 

 

4,878

 

 

 

22,990

 

XML 43 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of Business - Additional Information (Detail)
$ / shares in Units, $ in Thousands
12 Months Ended
Apr. 13, 2021
USD ($)
$ / shares
shares
Sep. 15, 2020
USD ($)
$ / shares
shares
Sep. 08, 2020
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Description Of Business [Line Items]            
Aggregate net proceeds from IPO   $ 254,800        
Offering costs, underwriting discounts and commissions expenses $ 8,500 $ 23,100        
Cumulative stock-based compensation       $ 17,445 $ 21,439 $ 883
Proceeds from issuance of common stock upon follow-on public offering, net of issuance costs $ 149,100     $ 149,085 254,805  
Reverse stock split, description       In September 2020, the Company’s board of directors and shareholders approved a certificate of amendment to the amended and restated certificate of incorporation to effect a reverse split of shares of the Company’s common stock on a 7.9-for-one basis (the Reverse Stock Split) effective as of September 8, 2020.    
Stock split conversion ratio     0.126582      
Net loss       $ 131,935 121,492 $ 68,299
Accumulated deficit       (625,994) (494,059)  
Cash, cash equivalents and short-term investments       339,500    
Restricted cash       $ 33,311 $ 33,311  
IPO            
Description Of Business [Line Items]            
Stock issued during the period | shares   10,294,000        
Share price | $ / shares   $ 27.00        
Underwriters            
Description Of Business [Line Items]            
Stock issued during the period | shares 446,000 1,343,000        
Follow-on Public Offering            
Description Of Business [Line Items]            
Stock issued during the period | shares 2,946,000          
Share price | $ / shares $ 53.50          
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Additional Information (Detail)
12 Months Ended
Jan. 01, 2022
Dec. 31, 2021
USD ($)
Customer
Segment
Dec. 31, 2020
USD ($)
Customer
Dec. 31, 2019
USD ($)
Customer
Summary Of Significant Accounting Policies [Line Items]        
Impairment losses   $ 0 $ 0  
Warranty period   1 year    
Capitalized contract cost amortization period description   The Company applies the practical expedient to expense the commissions as incurred as the expected amortization period is one year or less.    
Restricted cash   $ 33,311,000 33,311,000  
Service-based options vesting period   3 years    
Advertising costs   $ 0 0 $ 0
Operating lease right-of-use assets   $ 7,231,000 $ 8,253,000  
Number Of Operating Segments | Segment   1    
ASU 2019-12        
Summary Of Significant Accounting Policies [Line Items]        
Change in accounting principle, accounting standards update, adoption date   Jan. 01, 2021    
RSU        
Summary Of Significant Accounting Policies [Line Items]        
Service-based options vesting period   3 years    
First Anniversary        
Summary Of Significant Accounting Policies [Line Items]        
Vesting rate   25.00%    
First Anniversary | RSU        
Summary Of Significant Accounting Policies [Line Items]        
Vesting rate   25.00%    
Minimum        
Summary Of Significant Accounting Policies [Line Items]        
Estimated useful lives of the assets   2 years    
Maximum        
Summary Of Significant Accounting Policies [Line Items]        
Estimated useful lives of the assets   5 years    
Capitalized contract cost, amortization period   1 year    
Four Zero One K Plan Member        
Summary Of Significant Accounting Policies [Line Items]        
Percentage Of Employees Deferrals Required To Match Higher 100.00%      
Four Zero One K Plan Member | Maximum        
Summary Of Significant Accounting Policies [Line Items]        
Percentage Of Employees Deferrals Required To Match Higher 2.00%      
MEXICO        
Summary Of Significant Accounting Policies [Line Items]        
Operating lease right-of-use assets   $ 6,200,000    
Revenue Benchmark | Customer Concentration Risk        
Summary Of Significant Accounting Policies [Line Items]        
Number of major customers | Customer   2 3 1
Revenue Benchmark | Customer Concentration Risk | Customer 1        
Summary Of Significant Accounting Policies [Line Items]        
Concentration of risk, percentage   30.00% 22.00% 11.00%
Revenue Benchmark | Customer Concentration Risk | Customer 2        
Summary Of Significant Accounting Policies [Line Items]        
Concentration of risk, percentage   15.00% 19.00%  
Revenue Benchmark | Customer Concentration Risk | Customer 3        
Summary Of Significant Accounting Policies [Line Items]        
Concentration of risk, percentage     16.00%  
Accounts Receivable | Customer Concentration Risk        
Summary Of Significant Accounting Policies [Line Items]        
Number of major customers | Customer     2  
Accounts Receivable | Customer Concentration Risk | Customer 1        
Summary Of Significant Accounting Policies [Line Items]        
Concentration of risk, percentage     22.00%  
Accounts Receivable | Customer Concentration Risk | Customer 2        
Summary Of Significant Accounting Policies [Line Items]        
Concentration of risk, percentage     16.00%  
Accounts Receivable | Customer Concentration Risk | Customer 4        
Summary Of Significant Accounting Policies [Line Items]        
Concentration of risk, percentage   10.00%    
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue from Contracts with Customers - Summary of Revenue by Source (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation Of Revenue [Line Items]      
Revenue $ 102,602 $ 49,935 $ 15,078
Consoles Product      
Disaggregation Of Revenue [Line Items]      
Revenue 65,133 32,871 12,187
Consumables Product      
Disaggregation Of Revenue [Line Items]      
Revenue 19,179 6,742 1,563
Product Revenue      
Disaggregation Of Revenue [Line Items]      
Revenue 84,312 39,612 13,750
Service and Other Revenue      
Disaggregation Of Revenue [Line Items]      
Revenue $ 18,290 $ 10,323 $ 1,328
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue from Contracts with Customers - Additional Information (Detail) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Remaining performance obligations $ 6.7    
Revenue recognized 3.2 $ 0.9 $ 0.3
Remaining operating lease payments recognized in 2022 1.7    
Consoles Product | Operating Lease Arrangements      
Revenue from operating lease arrangements $ 4.7 $ 3.1 $ 0.5
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue from Contracts with Customers - Additional Information (Detail) 1
$ in Millions
Dec. 31, 2021
USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]  
Remaining performance obligations $ 6.7
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01  
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]  
Remaining performance obligations $ 6.3
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01  
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]  
Remaining performance obligations $ 0.3
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 12 months
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis by Level Within Fair Value Hierarchy (Detail) - Fair Value, Recurring - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Costs $ 218,167 $ 75,953
Gross Unrealized Holding Gains 2 1
Gross Unrealized Holding Losses (185)  
Aggregate Fair Value 217,984 75,954
Level 1 | Cash equivalents | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Costs 60,844 56,056
Aggregate Fair Value 60,844 56,056
Level 1 | Short-term investments | U.S. Treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Costs 18,064 14,999
Gross Unrealized Holding Gains   1
Gross Unrealized Holding Losses (60)  
Aggregate Fair Value 18,004 15,000
Level 2 | Short-term investments | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Costs 15,081  
Aggregate Fair Value 15,081  
Level 2 | Short-term investments | Corporate debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Costs 124,178 4,898
Gross Unrealized Holding Gains 2  
Gross Unrealized Holding Losses (125)  
Aggregate Fair Value $ 124,055 $ 4,898
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Additional Information (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Securities in unrealized loss position for more than 12 months $ 0    
Other-than-temporary impairment losses related to investments $ 0 $ 0 $ 0
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Summary of Remaining Contractual Maturities (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
Fair Value, Separate Account Investment [Line Items]  
Securities in unrealized loss position for more than 12 months $ 0
Short-term investments  
Fair Value, Separate Account Investment [Line Items]  
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months 135,766
Securities in unrealized loss position for more than 12 months 21,374
Debt Securities, Available-for-sale, Unrealized Loss Position, Total $ 157,140
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components - Summary of cash, cash equivalents and restricted cash (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash and Cash Equivalents [Abstract]      
Cash and cash equivalents $ 182,348 $ 294,972 $ 36,926
Restricted cash 33,311 33,311 743
Total cash, cash equivalents and restricted cash $ 215,659 $ 328,283 $ 37,669
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components - Schedule of Inventories (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Raw materials $ 18,114 $ 7,989
Work in process 6,054 6,200
Finished goods 15,017 4,195
Total inventories $ 39,185 $ 18,384
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components - Summary of Property Plant and Equipment (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 20,618 $ 19,986
Less: accumulated depreciation and amortization (7,654) (4,988)
Property and equipment, net 12,964 14,998
Tablos Under Operating Leases    
Property, Plant and Equipment [Line Items]    
Total property and equipment 2,412 5,158
Computers and Software    
Property, Plant and Equipment [Line Items]    
Total property and equipment 3,777 3,131
Furniture and Fixtures    
Property, Plant and Equipment [Line Items]    
Total property and equipment 1,494 1,399
Machinery and Equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 7,197 4,496
Leasehold Improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 4,864 4,459
Construction In Progress    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 874 $ 1,343
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Accrued inventory $ 4,808 $ 3,576
Accrued research and development expenses 574 175
Accrued professional services 1,269 2,187
Accrued rebate 3,121 566
Other 4,017 1,399
Total accrued expenses and other current liabilities $ 13,789 $ 7,903
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components - Accrued Warranty Liability (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Product Warranties Disclosures [Abstract]    
Balance at the beginning of the period $ 2,913 $ 1,702
Additions charged to cost of product revenue 7,310 4,858
Consumption (6,519) (3,647)
Balance at the end of the period $ 3,704 $ 2,913
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Balance Sheet Components - Additional Information (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Total depreciation and amortization expense $ 5,200 $ 3,200 $ 1,500
Restricted cash balance $ 33,311 $ 33,311 $ 743
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitment and Contingencies (Additional Information) (Detail)
$ in Millions
1 Months Ended
May 31, 2020
ft²
Sep. 30, 2019
USD ($)
Dec. 31, 2021
USD ($)
Jun. 30, 2021
ft²
Commitments And Contingencies [Line Items]        
Operating lease option to extend   renewal options at the election of the Company to renew or extend the lease    
Operating lease existence of option to extend [true false]   true    
Purchase Commitments        
Commitments And Contingencies [Line Items]        
Open purchase commitments     $ 68.6  
San Jose, CA        
Commitments And Contingencies [Line Items]        
Tenant improvement allowance   $ 2.0    
Operating lease commencement month and year   2020-04    
Operating lease expiration month and year   2027-03    
San Jose, CA | Standby Letters of Credit        
Commitments And Contingencies [Line Items]        
Letter of credit issued in lieu of a cash security deposit     0.3  
Mexico        
Commitments And Contingencies [Line Items]        
Operating lease option to extend renewal options at the election of the Company to renew or extend the lease      
Operating lease existence of option to extend [true false] true      
Operating lease commencement month and year 2020-05      
Operating lease expiration month and year 2026-08      
Area of lease | ft | ft² 48,437     38,750
Mexico | Standby Letters of Credit        
Commitments And Contingencies [Line Items]        
Letter of credit issued in lieu of a cash security deposit     $ 3.0  
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Schedule of Components of Lease Costs (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]      
Operating lease costs $ 1,759    
Variable lease costs 375 $ 233 $ 100
Short-term lease costs 180 371  
Total lease costs $ 2,314 $ 1,674 $ 620
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Schedule of Weighted-average Remaining Lease Term and Discount Rate (Detail)
Dec. 31, 2021
Dec. 31, 2020
Operating leases:    
Weighted-average remaining lease term (in years) 5 years 3 months 18 days 6 years 3 months 18 days
Weighted-average discount rate 8.70% 8.70%
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Maturity of Operating Lease Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]    
2022 $ 1,796  
2023 1,856  
2024 1,911  
2025 1,969  
Thereafter 2,523  
Total lease payments 10,055  
Less: imputed interest (2,011)  
Present value of operating lease liabilities 8,044  
Operating lease liabilities, current 1,151 $ 882
Operating lease liabilities, noncurrent $ 6,893 $ 8,044
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Term Loans - Schedule of Term Loan (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Debt Disclosure [Abstract]    
Principal of term loan $ 30,000 $ 30,000
Unamortized debt discount (238) (326)
Total term loan, noncurrent $ 29,762 $ 29,674
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Term Loans - Additional Information (Detail) - USD ($)
12 Months Ended
Jul. 31, 2020
Jul. 02, 2020
Jun. 30, 2017
Dec. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]          
Principal of term loan       $ 30,000,000 $ 30,000,000
Debt discount on Perceptive Term Loan       $ 238,000 326,000
Loss on extinguishment of term loan         (1,567,000)
Perceptive Term Loan          
Debt Instrument [Line Items]          
Basis spread on variable rate     2.00%    
Debt interest rate     8.55%    
Credit facility, maximum borrowing capacity     $ 40,000,000.0    
Description of variable rate basis       three-month London Inter-bank Offered Rate (LIBOR)  
Early prepayment, accrued interest and exit fees $ 1,200,000        
SVB Term Loan          
Debt Instrument [Line Items]          
Principal of term loan   $ 30,000,000.0      
Loan maturity date   Nov. 01, 2025      
Description of payment terms       Payments under the SVB Term Loan are for interest only through May 2023, and then 30 monthly principal and interest payments from June 2023 until maturity.  
Debt interest rate   6.75%   3.75%  
Debt instrument, final payment amount   $ 2,000,000.0      
Percentage of limitation on pledges of capital stock of foreign subsidiaries   65.00%      
Other debt issuance costs       $ 400,000  
Debt discount on Perceptive Term Loan       $ 200,000  
Loss on extinguishment of term loan         $ (1,600,000)
SVB Term Loan | Minimum          
Debt Instrument [Line Items]          
Debt instrument prepayment fee percentage   1.00%      
SVB Term Loan | Maximum          
Debt Instrument [Line Items]          
Debt instrument prepayment fee percentage   3.00%      
SVB Term Loan | Prime Rate          
Debt Instrument [Line Items]          
Basis spread on variable rate   0.50%      
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Term Loans - Summary of Debt Maturities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Debt Disclosure [Abstract]    
2022 $ 1,141  
2023 8,073  
2024 12,667  
2025 13,233  
Total future payments 35,114  
Less: amount representing interest (3,089)  
Less: final payment (2,025)  
Total term loan 30,000 $ 30,000
Unamortized debt discount (238) $ (326)
Total term loan, net of debt discount $ 29,762  
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Additional Information) (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2021
Class of Stock [Line Items]    
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Aggregate cash proceed of redeemable convertible preferred stock warrant $ 4,288  
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity - Summary of Reserved Shares of Common Stock on Converted Basis for Issuance (Details)
shares in Thousands
Dec. 31, 2021
shares
Class of Stock [Line Items]  
Total reserved shares 9,683
Stock Options Outstanding  
Class of Stock [Line Items]  
Total reserved shares 3,533
Restricted Stock Units Outstanding  
Class of Stock [Line Items]  
Total reserved shares 563
Performance Stock Units Outstanding  
Class of Stock [Line Items]  
Total reserved shares 110
Shares Available for Future Purchase Under ESPP  
Class of Stock [Line Items]  
Total reserved shares 999
Shares Available for Future Grant Under 2020 Plan  
Class of Stock [Line Items]  
Total reserved shares 4,415
Warrant to Purchase Common Stock  
Class of Stock [Line Items]  
Total reserved shares 63
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plans - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Jan. 01, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total reserved shares   9,683,000      
Outstanding Stock Options   3,533,000 4,763,000    
Stock-based compensation expense   $ 17,445 $ 21,439 $ 883  
Stock Option          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total intrinsic value of options exercised   $ 61,000 $ 8,200 200  
Outstanding Stock Options     1,933,000    
Stock options, description   The options were scheduled to vest over the requisite service period if the Company achieves both (i) a performance condition tied to a liquidity event, which includes the effectiveness of an IPO, and (ii) certain market conditions, provided the optionee is providing services on the date of the event.      
Stock-based compensation expense   $ 4,300 $ 18,500 $ 0  
Stock Option | Share-based Payment Arrangement, Employee [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Weighted Average Grant Date Fair Value of Options granted to Employees   $ 24.74 $ 7.97 $ 2.77  
Total Fair Value of Options Vested   $ 24,500 $ 3,300 $ 700  
Performance Stock Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Estimated weighted average period over which unamortized share-based compensation are expected to be recognize   1 year 3 months      
Total unrecognized stock-based compensation expense   $ 1,300      
Performance Stock Units | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Performance based units approved based on performance relative to specified revenue targets   200.00%      
Performance Stock Units | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Performance based units approved based on performance relative to specified revenue targets   0.00%      
RSU          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total Fair Value of Options Vested   $ 1,000 $ 200    
Estimated weighted average period over which unamortized share-based compensation are expected to be recognize   3 years 1 month 13 days      
Total unrecognized stock-based compensation expense   $ 22,600      
Employee Stock Option Excluding Market And Performance Condition [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Estimated weighted average period over which unamortized share-based compensation are expected to be recognize   2 years 7 months 17 days      
Total unrecognized stock-based compensation expense   $ 14,000      
2020 Equity Incentive Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total reserved shares 3,665,000       1,709,000
Percentage Of Maximum Number of Common Stock Outstanding 4.00%        
Contractual Term   10 years      
Percentage of fair market value of common stock   100.00%      
Employees Share Purchase Plan (ESPP)          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Total reserved shares 687,000   687,000   427,000
Percentage Of Maximum Number of Common Stock Outstanding     1.00%    
Percentage of fair market value of common stock 85.00%        
Weighted Average Grant Date Fair Value of Options granted to Employees     $ 8.00    
ESPP Offering Period 6 months        
Number of Shares Purchased   116,000 0    
Estimated weighted average period over which unamortized share-based compensation are expected to be recognize   2 months 1 day      
Total unrecognized stock-based compensation expense   $ 200      
Employees Share Purchase Plan (ESPP) | Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Weighted Average Grant Date Fair Value of Options granted to Employees   $ 13.95      
Eligible Compensation Percentage to Purchase Common Stock 15.00%        
Employees Share Purchase Plan (ESPP) | Minimum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Weighted Average Grant Date Fair Value of Options granted to Employees   $ 13.25      
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plan - Summary of Stock Option Activity (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2021
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Outstanding Options, Balance as of December 31, 2020 4,763,000
Granted 634,000
Exercised (1,437,000)
Forfeited and expired (427,000)
Outstanding Options, Balance as of December 31, 2021 3,533,000
Exercisable as of December 31, 2021 2,453,000
Weighted-Average Exercise Price, Balance as of December 31, 2020 | $ / shares $ 6.35
Weighted-Average Exercise Price, Granted | $ / shares 47.91
Weighted-Average Exercise Price, Exercised | $ / shares 5.31
Weighted-Average Exercise Price, Forfeited and Expired | $ / shares 19.58
Weighted-Average Exercise Price, Balance as of December 31, 2021 | $ / shares 12.63
Weighed-Average Exercise Price, Exercisable as of December 31, 2021 | $ / shares $ 5.42
Weighted-Average Remaining Term 6 years 9 months 25 days
Weighted-Average Remaining Contractual Term, Exercisable as of December 31, 2021 6 years 25 days
Aggregate Intrinsic Value, Balance as of December 31, 2021 | $ $ 119,959
Aggregate Intrinsic Value, Exercisable as of December 31, 2021 | $ $ 99,853
Stock Option  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Outstanding Options, Balance as of December 31, 2020 1,933,000
Outstanding Options, Balance as of December 31, 2021  
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plan - Schedule of Stock Option Valuation Assumptions (Details)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Dividend yield 0.00% 0.00% 0.00%
Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term (in years) 5 years 11 months 12 days 5 years 21 days 4 years 11 months 19 days
Expected volatility 53.90% 52.10% 49.30%
Risk-free interest rate 0.66% 0.35% 1.57%
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term (in years) 6 years 29 days 10 years 5 years 18 days
Expected volatility 55.30% 62.70% 50.90%
Risk-free interest rate 1.36% 1.54% 2.48%
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plan - Summary of Restricted stock activity (Details)
shares in Thousands
12 Months Ended
Dec. 31, 2021
$ / shares
shares
Performance Stock Units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock Units, Outstanding as of December 31, 2019 | shares 25
Stock Units, Granted | shares 85
Stock Units, Outstanding as of December 31, 2020 | shares 110
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares $ 52.55
Weighted-Average Grant Date Fair Value Per Share, Granted | $ / shares 46.22
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance | $ / shares $ 47.65
Restricted Stock Units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Stock Units, Outstanding as of December 31, 2019 | shares 44
Stock Units, Granted | shares 639
Vested | shares (19)
Forfeited | shares (101)
Stock Units, Outstanding as of December 31, 2020 | shares 563
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares $ 52.32
Weighted-Average Grant Date Fair Value Per Share, Granted | $ / shares 47.78
Weighted-Average Grant Date Fair Value Per Share, Vested | $ / shares 51.03
Weighted Average Grant Date Fair Value Per Share, Forfeited | $ / shares 48.04
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance | $ / shares $ 47.98
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plan - Schedule of Employees Stock Purchase Plan (ESPP) (Details) - $ / shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Dividend yield 0.00% 0.00% 0.00%
Maximum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term (in years) 6 years 29 days 10 years 5 years 18 days
Expected volatility 55.30% 62.70% 50.90%
Risk-free interest rate 1.36% 1.54% 2.48%
Minimum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term (in years) 5 years 11 months 12 days 5 years 21 days 4 years 11 months 19 days
Expected volatility 53.90% 52.10% 49.30%
Risk-free interest rate 0.66% 0.35% 1.57%
Employees Share Purchase Plan (ESPP)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected term (in years) 6 months 5 months 19 days  
Expected volatility   57.00%  
Risk-free interest rate   0.12%  
Dividend yield 0.00% 0.00%  
Grant Date Fair Value   $ 8.00  
Employees Share Purchase Plan (ESPP) | Maximum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected volatility 43.80%    
Risk-free interest rate 0.07%    
Grant Date Fair Value $ 13.95    
Employees Share Purchase Plan (ESPP) | Minimum [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Expected volatility 41.00%    
Risk-free interest rate 0.06%    
Grant Date Fair Value $ 13.25    
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Equity Incentive Plan [Line Items]      
Cumulative stock-based compensation $ 17,445 $ 21,439 $ 883
Cost of Revenue      
Equity Incentive Plan [Line Items]      
Cumulative stock-based compensation 269 255 5
Research and Development      
Equity Incentive Plan [Line Items]      
Cumulative stock-based compensation 3,809 4,615 328
Sales and Marketing      
Equity Incentive Plan [Line Items]      
Cumulative stock-based compensation 5,897 4,423 172
General and Administrative      
Equity Incentive Plan [Line Items]      
Cumulative stock-based compensation $ 7,470 $ 12,146 $ 378
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Loss before Provision for Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]      
Domestic $ (128,400) $ (121,492) $ (68,299)
Foreign (3,336)    
Loss before provision for income taxes $ (131,736) $ (121,492) $ (68,299)
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Additional Information) (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Taxes [Line Items]      
Provision for income taxes $ 199 $ 0 $ 20
Valuation allowance 30,700 28,400 $ 23,700
Operating loss carryforward 409,000    
Net operating loss carryforwards $ 102,094 $ 76,838  
Change in Unrecognized Tax Benefits The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change within the next twelve months.    
Federal      
Income Taxes [Line Items]      
Provision for income taxes $ 200    
Operating loss carryforward $ 281,200    
Expiration year 2017    
Operating loss carryforward expiration beginning $ 127,800    
Open year examination three    
Federal | Research and Development      
Income Taxes [Line Items]      
Tax credit carryforward, amount $ 6,600    
Tax credit carry forward expiration year 2030    
Federal | Maximum      
Income Taxes [Line Items]      
Expiration year 2037    
Federal | Minimum      
Income Taxes [Line Items]      
Expiration year 2024    
State      
Income Taxes [Line Items]      
Operating loss carryforward $ 213,700    
Net operating loss carryforwards 53,200    
Operating loss carryforward expiration beginning $ 160,500    
Open year examination four    
State | Research and Development      
Income Taxes [Line Items]      
Tax credit carryforward, amount $ 5,100    
State | Maximum      
Income Taxes [Line Items]      
Expiration year 2041    
State | Minimum      
Income Taxes [Line Items]      
Expiration year 2022    
Foreign      
Income Taxes [Line Items]      
Open year examination five    
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Summary of Effective Tax Rate of the Provision for Income Taxes (Detail)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Federal statutory income tax rate 21.00% 21.00% 21.00%
State taxes 1.30% 3.80% 7.80%
Change in valuation allowance (22.80%) (23.30%) (28.50%)
Federal and state tax credits 1.20% 1.00% 0.90%
Stock based compensation 8.10% 1.20% 0.00%
Non-deductible permanent expenses (0.10%) (0.20%) (1.20%)
Effect of deferred tax adjustment (0.70%) (1.40%) 0.00%
Non-deductible compensation (8.20%) (2.10%) 0.00%
Effective income tax rate (0.20%) 0.00% 0.00%
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Summary of Components of the Deferred Tax Assets (Detail) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
Net operating loss carryforwards $ 102,094 $ 76,838
Tax credits 11,767 10,039
Accrual and reserves 3,573 2,392
Tangible and intangible assets 20,249 19,090
Stock-based compensation 3,566 2,843
Lease liabilities 1,955 1,733
Deferred Tax Assets, Other 282  
Gross deferred tax assets 143,486 112,935
Valuation allowance (141,729) (111,061)
Net deferred tax assets 1,757 1,874
Deferred Tax Liabilities, Gross [Abstract]    
Right-of-use assets (1,757) (1,874)
Gross deferred tax liabilities $ (1,757) $ (1,874)
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Summary of Reconciliation of the Total Unrecognized Tax Benefits (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Balance, beginning of year $ 1,582 $ 1,020
Increase related to current year positions 608 562
Balance, end of year $ 2,190 $ 1,582
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share Attributable to Common Stockholders - Schedule of Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Numerator:      
Net loss $ (131,935) $ (121,492) $ (68,299)
Adjustment to redemption value on redeemable convertible preferred stock   (362) (134,760)
Deemed dividend on settlement of accrued dividend   42,530  
Gain on extinguishment of redeemable convertible preferred stock     117,598
Net loss attributable to common stockholders, basic and diluted $ (131,935) $ (79,324) $ (85,461)
Denominator:      
Weighted-average shares of common stock, basic and diluted 45,589 16,358 858
Net loss per share attributable to common stockholders, basic and diluted $ (2.89) $ (4.85) $ (99.58)
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Anti-dilutive shares excluded from calculation of diluted net loss per share 4,231,000 4,878,000 22,990,000
Performance Stock Units      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Anti-dilutive shares excluded from calculation of diluted net loss per share 17,000    
Redeemable Convertible Preferred Stock, on an as-if Converted Basis      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Anti-dilutive shares excluded from calculation of diluted net loss per share     18,634,000
Warrants to Purchase Redeemable Convertible Preferred Stock      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Anti-dilutive shares excluded from calculation of diluted net loss per share     599,000
Stock Options to Purchase Common Stock      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Anti-dilutive shares excluded from calculation of diluted net loss per share 3,533,000 4,763,000 3,757,000
Warrant to Purchase Common Stock      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Anti-dilutive shares excluded from calculation of diluted net loss per share 63,000 63,000  
Restricted Stock Units      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Anti-dilutive shares excluded from calculation of diluted net loss per share 581,000    
Shares Committed under ESPP      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Anti-dilutive shares excluded from calculation of diluted net loss per share 37,000 52,000  
XML 79 om-20211231_htm.xml IDEA: XBRL DOCUMENT 0001484612 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001484612 us-gaap:ConstructionInProgressMember 2021-12-31 0001484612 om:WarrantsToPurchaseCommonStockMember 2021-01-01 2021-12-31 0001484612 us-gaap:DomesticCountryMember 2021-12-31 0001484612 us-gaap:ProductMember 2019-01-01 2019-12-31 0001484612 om:TwoThousandTwentyEquityIncentivePlanMember 2021-01-01 2021-12-31 0001484612 om:SharesAvailableForFutureGrantUnderTwoThousandAndTwentyPlanMember 2021-12-31 0001484612 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001484612 srt:MaximumMember 2021-01-01 2021-12-31 0001484612 om:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001484612 country:CA 2019-09-01 2019-09-30 0001484612 om:StockOptionsToPurchaseCommonStockMember 2020-01-01 2020-12-31 0001484612 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001484612 srt:MaximumMember us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001484612 om:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001484612 2020-09-08 2020-09-08 0001484612 2022-02-16 0001484612 om:ConsolesProductMember 2019-01-01 2019-12-31 0001484612 om:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001484612 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001484612 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001484612 2019-01-01 2019-12-31 0001484612 srt:MaximumMember 2019-01-01 2019-12-31 0001484612 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2020-12-31 0001484612 om:EmployeeStockOptionExcludingMarketAndPerformanceConditionMember 2021-12-31 0001484612 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001484612 us-gaap:PurchaseCommitmentMember 2021-12-31 0001484612 us-gaap:CommonStockMember 2019-12-31 0001484612 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001484612 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001484612 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001484612 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-12-31 0001484612 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001484612 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001484612 srt:MinimumMember 2021-01-01 2021-12-31 0001484612 om:FourzeroonekplanMember 2022-01-01 2022-01-01 0001484612 om:StockOptionsOutstandingMember 2021-12-31 0001484612 us-gaap:AccountingStandardsUpdate201912Member 2021-12-31 0001484612 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001484612 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001484612 us-gaap:ConstructionInProgressMember 2020-12-31 0001484612 om:TablosUnderOperatingLeasesMember 2020-12-31 0001484612 srt:MaximumMember om:PerformanceStockUnitsMember 2021-01-01 2021-12-31 0001484612 us-gaap:ProductMember 2021-01-01 2021-12-31 0001484612 om:ServiceAndOtherRevenueMember 2019-01-01 2019-12-31 0001484612 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2021-12-31 0001484612 om:SiliconValleyBankTermLoanMember 2020-07-02 0001484612 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001484612 om:ConsumablesProductMember 2021-01-01 2021-12-31 0001484612 us-gaap:CommonStockMember 2018-12-31 0001484612 om:TwoThousandTwentyEquityIncentivePlanMember 2020-07-01 2020-09-30 0001484612 om:EmployeesSharePurchasePlanMember 2021-12-31 0001484612 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2021-12-31 0001484612 om:ServiceAndOtherRevenueMember 2021-01-01 2021-12-31 0001484612 us-gaap:IPOMember 2020-09-15 0001484612 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001484612 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001484612 srt:MaximumMember 2020-01-01 2020-12-31 0001484612 om:ConsolesProductMember om:OperatingLeaseArrangementsMember 2021-01-01 2021-12-31 0001484612 om:ConsolesProductMember 2021-01-01 2021-12-31 0001484612 om:EmployeesSharePurchasePlanMember 2021-01-01 2021-12-31 0001484612 2021-12-31 0001484612 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001484612 om:PerceptiveTermLoanMember 2017-06-30 0001484612 srt:MaximumMember 2021-12-31 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001484612 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-12-31 0001484612 om:PerformanceStockUnitsOutstandingMember 2021-12-31 0001484612 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001484612 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2020-01-01 2020-12-31 0001484612 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001484612 om:ConsolesProductMember om:OperatingLeaseArrangementsMember 2019-01-01 2019-12-31 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001484612 us-gaap:ProductMember 2020-01-01 2020-12-31 0001484612 us-gaap:RetainedEarningsMember 2019-12-31 0001484612 om:EmployeesSharePurchasePlanMember 2021-01-01 0001484612 om:EmployeesSharePurchasePlanMember 2020-07-01 2020-09-30 0001484612 om:UnderwritersMember 2020-09-15 2020-09-15 0001484612 srt:MaximumMember om:EmployeesSharePurchasePlanMember 2021-01-01 2021-12-31 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001484612 2021-06-30 0001484612 country:CA us-gaap:StandbyLettersOfCreditMember 2021-12-31 0001484612 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001484612 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001484612 us-gaap:RedeemableConvertiblePreferredStockMember 2019-12-31 0001484612 country:MX 2020-05-01 2020-05-31 0001484612 om:SiliconValleyBankTermLoanMember 2020-07-02 2020-07-02 0001484612 om:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001484612 2021-04-13 2021-04-13 0001484612 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001484612 2020-12-31 0001484612 us-gaap:EmployeeStockOptionMember 2020-12-31 0001484612 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001484612 om:WarrantsToPurchaseRedeemableConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001484612 2020-09-15 2020-09-15 0001484612 2021-01-01 2021-12-31 0001484612 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001484612 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001484612 srt:MinimumMember 2019-01-01 2019-12-31 0001484612 us-gaap:RetainedEarningsMember 2021-12-31 0001484612 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001484612 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2019-01-01 2019-12-31 0001484612 us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0001484612 us-gaap:RedeemableConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001484612 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0001484612 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001484612 us-gaap:RedeemableConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001484612 om:EmployeesSharePurchasePlanMember 2020-01-01 2020-12-31 0001484612 srt:MinimumMember 2020-01-01 2020-12-31 0001484612 om:SiliconValleyBankTermLoanMember us-gaap:PrimeRateMember 2020-07-02 2020-07-02 0001484612 us-gaap:CommonStockMember 2020-12-31 0001484612 us-gaap:ForeignCountryMember 2021-01-01 2021-12-31 0001484612 om:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001484612 om:StockOptionsToPurchaseCommonStockMember 2019-01-01 2019-12-31 0001484612 country:MX us-gaap:StandbyLettersOfCreditMember 2021-12-31 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001484612 om:PerceptiveTermLoanMember 2021-01-01 2021-12-31 0001484612 2018-12-31 0001484612 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001484612 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2021-12-31 0001484612 country:MX 2021-12-31 0001484612 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2021-12-31 0001484612 om:PerceptiveTermLoanMember 2020-07-31 2020-07-31 0001484612 om:RestrictedStockUnitsOutstandingMember 2021-12-31 0001484612 srt:MaximumMember om:SiliconValleyBankTermLoanMember 2020-07-02 2020-07-02 0001484612 srt:MinimumMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0001484612 us-gaap:ComputerEquipmentMember 2020-12-31 0001484612 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-01-01 2021-12-31 0001484612 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2020-12-31 0001484612 us-gaap:IPOMember 2020-09-15 2020-09-15 0001484612 om:ConsolesProductMember om:OperatingLeaseArrangementsMember 2020-01-01 2020-12-31 0001484612 2019-12-31 0001484612 us-gaap:ShortTermInvestmentsMember 2021-12-31 0001484612 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001484612 2019-09-01 2019-09-30 0001484612 om:WarrantsToPurchaseCommonStockMember 2020-01-01 2020-12-31 0001484612 om:TablosUnderOperatingLeasesMember 2021-12-31 0001484612 srt:MaximumMember om:EmployeesSharePurchasePlanMember 2020-09-30 0001484612 country:MX 2020-05-31 0001484612 om:EmployeesSharePurchasePlanMember 2020-12-31 0001484612 2021-01-01 2021-12-31 0001484612 2022-01-01 2021-12-31 0001484612 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0001484612 us-gaap:PerformanceSharesMember 2021-12-31 0001484612 srt:MinimumMember us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001484612 om:ConsolesProductMember 2020-01-01 2020-12-31 0001484612 om:ConsumablesProductMember 2019-01-01 2019-12-31 0001484612 om:SiliconValleyBankTermLoanMember 2021-01-01 2021-12-31 0001484612 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001484612 om:EmployeeStockOptionExcludingMarketAndPerformanceConditionMember 2021-01-01 2021-12-31 0001484612 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001484612 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001484612 om:TwoThousandTwentyEquityIncentivePlanMember 2020-09-30 0001484612 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2021-01-01 2021-12-31 0001484612 country:CA 2019-09-30 0001484612 om:StockOptionsToPurchaseCommonStockMember 2021-01-01 2021-12-31 0001484612 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001484612 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-12-31 0001484612 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-12-31 0001484612 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ShortTermInvestmentsMember 2020-12-31 0001484612 us-gaap:CommonStockMember 2021-12-31 0001484612 om:ConsumablesProductMember 2020-01-01 2020-12-31 0001484612 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001484612 om:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001484612 country:MX 2021-06-30 0001484612 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001484612 om:WarrantsToPurchaseCommonStockMember 2021-12-31 0001484612 us-gaap:PerformanceSharesMember 2020-12-31 0001484612 2020-01-01 2020-12-31 0001484612 om:SiliconValleyBankTermLoanMember 2020-01-01 2020-12-31 0001484612 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001484612 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0001484612 om:FollowOnPublicOfferingMember 2021-04-13 0001484612 us-gaap:RedeemableConvertiblePreferredStockMember 2018-12-31 0001484612 om:ServiceAndOtherRevenueMember 2020-01-01 2020-12-31 0001484612 srt:MaximumMember us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0001484612 srt:MinimumMember om:SiliconValleyBankTermLoanMember 2020-07-02 2020-07-02 0001484612 om:FollowOnPublicOfferingMember 2021-04-13 2021-04-13 0001484612 om:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001484612 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001484612 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001484612 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001484612 om:SharesAvailableForFuturePurchaseUnderEsppMember 2021-12-31 0001484612 srt:MaximumMember om:FourzeroonekplanMember 2022-01-01 2022-01-01 0001484612 om:EmployeesSharePurchasePlanMember 2020-09-30 0001484612 om:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001484612 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001484612 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001484612 om:PerceptiveTermLoanMember 2017-06-30 2017-06-30 0001484612 om:PerformanceStockUnitsMember 2021-12-31 0001484612 om:TwoThousandTwentyEquityIncentivePlanMember 2021-01-01 0001484612 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001484612 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001484612 us-gaap:RetainedEarningsMember 2020-12-31 0001484612 om:UnderwritersMember 2021-04-13 2021-04-13 0001484612 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001484612 srt:MinimumMember om:PerformanceStockUnitsMember 2021-01-01 2021-12-31 0001484612 om:PerformanceStockUnitsMember 2021-01-01 2021-12-31 0001484612 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0001484612 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001484612 om:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001484612 srt:MinimumMember om:EmployeesSharePurchasePlanMember 2021-01-01 2021-12-31 0001484612 us-gaap:ComputerEquipmentMember 2021-12-31 0001484612 om:SiliconValleyBankTermLoanMember 2021-12-31 0001484612 us-gaap:RetainedEarningsMember 2018-12-31 0001484612 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001484612 us-gaap:FurnitureAndFixturesMember 2021-12-31 om:Segment pure utr:sqft om:Customer shares iso4217:USD shares iso4217:USD P12M FY P2Y 1 0001484612 false --12-31 0.126582 P12M 10-K true 2021-12-31 2021 false 001-39513 Outset Medical, Inc. DE 20-0514392 3052 Orchard Dr. San Jose CA 95134 669 231-8200 Common Stock, par value $0.001 per share OM NASDAQ Yes No Yes Yes Large Accelerated Filer false false false false 1700000000 47406856 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of the registrant’s Proxy Statement for its 2022 Annual Meeting of Stockholders, which is to be filed with the Securities and Exchange Commission within 120 days of the registrant’ fiscal year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">, are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</span></p> KPMG LLP San Francisco, California 182348000 294972000 157140000 19898000 25600000 6468000 39185000 18384000 5529000 6189000 409802000 345911000 33311000 33311000 12964000 14998000 7231000 8253000 156000 1356000 463464000 403829000 1763000 4948000 24948000 16845000 13789000 7903000 3704000 2913000 6340000 3201000 1151000 882000 51695000 36692000 721000 240000 312000 570000 6893000 8044000 29762000 29674000 89383000 75220000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 0.001 0.001 300000000 300000000 47241000 47241000 42722000 42722000 47000 43000 1000212000 822624000 -184000 1000 -625994000 -494059000 374081000 328609000 463464000 403829000 84312000 39612000 13750000 18290000 10323000 1328000 102602000 49935000 15078000 84639000 57035000 27164000 10355000 5937000 5716000 94994000 62972000 32880000 7608000 -13037000 -17802000 36741000 28850000 23327000 65070000 45068000 20259000 36316000 30512000 8919000 138127000 104430000 52505000 -130519000 -117467000 -70307000 498000 526000 2485000 1715000 2891000 4257000 -93000 3800000 -1567000 -131736000 -121492000 -68279000 199000 0 20000 -131935000 -121492000 -68299000 -131935000 -79324000 -85461000 -2.89 -4.85 -99.58 45589000 16358000 858000 -131935000 -121492000 -68299000 -185000 -21000 82000 -132120000 -121513000 -68217000 147214000 392284000 789000 1000 -60000 -287891000 -287950000 9000 76000 76000 -134760000 966000 133794000 134760000 -117417000 117417000 117417000 -181000 124000 364000 364000 883000 883000 82000 82000 -68299000 -68299000 147214000 409446000 922000 1000 357000 22000 -372567000 -372187000 57782000 126758000 41763000 4850000 5000 41758000 41763000 -42530000 42530000 42530000 -362000 362000 362000 65000 1655000 4288000 1252000 1252000 -206651000 -456561000 26167000 26000 456535000 456561000 10294000 10000 254795000 254805000 3126000 3126000 5000 419000 1000 1194000 1195000 21439000 21439000 -21000 -21000 -121492000 -121492000 42722000 43000 822624000 1000 -494059000 328609000 2946000 3000 149082000 149085000 116000 3434000 3434000 19000 1438000 1000 7627000 7628000 17445000 17445000 -185000 -185000 -131935000 -131935000 47241000 47000 1000212000 -184000 -625994000 374081000 -131935000 -121492000 -68299000 5162000 3159000 1484000 1022000 596000 451000 569000 641000 893000 -1972000 -50000 983000 5000 12000 59000 1023000 534000 326000 -76000 -235000 -293000 17445000 21439000 883000 -93000 3800000 -1567000 19137000 2566000 2886000 22042000 16287000 5020000 -1860000 6245000 228000 -3066000 737000 802000 8103000 9889000 3119000 5889000 4798000 974000 791000 1211000 1410000 2881000 2754000 735000 -217000 -882000 77000 -505000 -130264000 -99015000 -70292000 3108000 9108000 3293000 178432000 32884000 91878000 39033000 45908000 169468000 -142507000 3947000 74297000 149085000 254805000 4288000 126758000 11062000 1195000 363000 29630000 30985000 9000 9000 76000 181000 160147000 385682000 249000 -112624000 290614000 4254000 328283000 37669000 33415000 215659000 328283000 37669000 83000 19000 35000 1146000 3270000 3352000 882000 505000 121000 323000 867000 1410000 2131000 3119000 8849000 42530000 362000 134760000 456561000 1252000 3126000 41763000 117598000 1192000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Description of Business</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outset Medical, Inc. is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement designed to transform the dialysis experience for patients and operationally simplify it for providers. Tablo serves as a single enterprise solution designed to be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo to serve as a dialysis clinic on wheels. With a simple-to-use touchscreen interface, two-way wireless data transmission and a proprietary data analytics platform, Tablo is a new holistic approach to dialysis care. The Company’s headquarters are located in San Jose, CA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s registration statement on Form S-1 related to its IPO was declared effective by the SEC on September 14, 2020, and the Company’s common stock began trading on the Nasdaq Global Select Market on September 15, 2020. Upon the completion of the IPO, the Company sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,294,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock (which included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,343,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares that were sold pursuant to the full exercise of the underwriters’ option to purchase additional shares in connection with the IPO) at a price to the public of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. Including the full exercise of the underwriters’ option to purchase additional shares, the Company received aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">254.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting offering costs, underwriting discounts and commissions of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 13, 2021, the Company completed a follow-on public offering and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,946,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock (which included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">446,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares that were offered and sold pursuant to the full exercise of the underwriters’ option to purchase additional shares) at a price to the public of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received aggregate net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">149.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting offering costs, underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reverse Stock Split</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company’s board of directors and shareholders approved a certificate of amendment to the amended and restated certificate of incorporation to effect a reverse split of shares of the Company’s common stock on a 7.9-for-one basis (the Reverse Stock Split) effective as of September 8, 2020.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The number of authorized shares and the par values of the common stock and redeemable convertible preferred stock were not adjusted as a result of the Reverse Stock Split. In connection with the Reverse Stock Split, the conversion ratio for the Company’s outstanding redeemable convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was decreased in proportion to the Reverse Stock Split. All references to common stock and options to purchase common stock, share data, per share data and related information contained in these financial statements and related notes have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since inception, the Company has incurred net losses and negative cash flows from operations. The Company incurred net losses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">626.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had cash, cash equivalents and short-term investments of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">339.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which are available to fund future operations, and restricted cash of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. Management believes that the Company’s existing cash, cash equivalents and short-term investments, which include the proceeds from the IPO and the follow-on public offering, and cash generated from revenues from its products and services, will be sufficient to meet its anticipated needs for at least the next 12 months from the issuance date of the financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial statements have been prepared in accordance with U.S. GAAP. All share amounts disclosed in the notes to the financial statements are rounded to the nearest thousand except for per share amounts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 10294000 1343000 27.00 254800000 23100000 2946000 446000 53.50 149100000 8500000 In September 2020, the Company’s board of directors and shareholders approved a certificate of amendment to the amended and restated certificate of incorporation to effect a reverse split of shares of the Company’s common stock on a 7.9-for-one basis (the Reverse Stock Split) effective as of September 8, 2020. -131900000 -121500000 -68300000 -626000000.0 339500000 33300000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, allowance for doubtful accounts, inventory valuation and write-downs, warranty obligations, the fair value of equity awards, the valuation of investments, recoverability of the Company’s net deferred tax assets, and certain accrued expenses. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results may differ from those estimates under different assumptions or conditions and the differences may be material.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">and Other Risks and Uncertainties</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, restricted cash, short-term investments and accounts receivable. Substantially all the Company’s cash and cash equivalents, restricted cash, and investments are held at one financial institution in the United States that management believes is of high credit quality. Such investments may, at times, exceed federally insured limits or may not be covered by deposit insurance at all. The Company has not experienced any credit losses on its cash and cash equivalents, restricted cash or short-term investments through December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customers accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of revenues</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. For the year ended December 31, 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customers accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of revenues, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customer accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of revenues for the year ended December 31, 2019. Accounts receivable are unsecured and the Company does not require collateral; however, the Company does assess the collectability of accounts receivable based on a number of factors, including past transaction history with, and the creditworthiness of, the customer. Accordingly, the Company is exposed to credit risk associated with accounts receivab</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">le. One customer accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of accounts receivable as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customers accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of accounts receivable, respectively, as of December 31, 2020. To reduce risk, the Company closely monitors the amounts due from its customers and assesses the financial strength of its customers through a variety of methods that include, but are not limited to, engaging directly with customer operations and leadership personnel, visiting customer locations to observe operating activities, and assessing customer longevity and reputation in the marketplace. As a result, the Company believes that its accounts receivable credit risk exposure is limited. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A material default in payment or a material reduction in purchases from these or any other large customers could have a material adverse impact on the Company’s financial condition, results of operations, and liquidity.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has a manufacturing facility in Tijuana, Mexico which it operates in collaboration with its outsourced business administration service provider, TACNA, for the production of the Tablo console. The Company is subject to a number of risks associated with operating its Mexico-based manufacturing facility. The manufacturing operations at the facility may suffer disruptions from global or regional public health crises such as the ongoing COVID-19 pandemic, natural disasters, cyber security attacks, vandalism, terrorism or other political hostilities. Any such occurrences could negatively impact the Company’s ability to produce the Tablo console. The Company is also subject to a variety of foreign laws and regulations, including trade and labor restrictions and laws relating to importation, exportation and taxation of goods, and U.S. laws and regulations relating to foreign operations. In addition, because certain of its Mexico-based manufacturing operations incur costs that are denominated in MXN, the Company is exposed to additional risk of currency fluctuations between USD and MXN, which could increase its product and labor costs, thus reducing its gross profit. To date, foreign currency transaction gains and losses have not been material to the Company’s financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to additional risks and uncertainties due to the COVID-19 pandemic. How long the pandemic, and measures intended to contain the spread of COVID-19, will continue remains uncertain and depends on ongoing developments, including but not limited to any resurgences of the virus including emerging variant strains, federal, state and local government actions taken in response, and continued availability, effectiveness and public acceptance of COVID-19 vaccines, as well as the extent and duration of the effect on the economy and how quickly and to what extent normal economic and operating conditions can resume. Additionally, the duration and severity of disruptions in the global supply chain, largely driven by high demand as the economy reopens and the ongoing impact of the pandemic, also remain uncertain and depend on various factors, including the effectiveness of recent government actions intended to mitigate these disruptions. As a result, the Company cannot predict what effect COVID-19, the associated containment measures and the related supply chain disruptions will ultimately have on its business and result of operations.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential economic impact and duration of the COVID-19 pandemic may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">could result in a reduction in the Company’s ability to access capital and delays in payments of outstanding receivables that could adversely affect our liquidity. In addition, a recession or market correction resulting from the spread COVID-19 could materially affect the Company's business and financial results. As of the date of issuance of the financial statements, the extent to which the COVID-19 pandemic may materially adversely affect the Company's financial condition, liquidity, or results of operations is uncertain.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company classifies financial instruments using a three-tiered fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Management believes that its term loan bears interest at the prevailing market rates for instruments with similar characteristics; accordingly, the carrying value of this instrument approximates its fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Equivalents and Short-Term Investments</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and are stated at fair value.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company primarily holds corporate debt securities, commercial paper, and U.S. Treasury securities, and has the ability, if necessary, to liquidate any of its investments to meet its liquidity needs in the next 12 months, without significant penalty. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term investments on the accompanying balance sheets. Short-term investments have been classified as available-for-sale at the time of purchase. The Company evaluates the appropriate classification of its investments as of each balance sheet date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s investment securities are recorded at fair value based on the fair value hierarchy. Money market funds and U.S. Treasury securities are classified within Level 1 of the fair value hierarchy. Other securities are classified within Level 2 of the fair value hierarchy. Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounts Receivable, Net</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts receivable are recorded at invoice value, net of any allowance for doubtful accounts. Estimates of the allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of customers and individual customer circumstances. The allowance for doubtful accounts was not significant as of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Inventories</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inventory is stated at the lower of cost or net realizable value, with approximate costs determined</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The carrying value of inventories is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on the Company’s statements of operations.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is generally computed using the straight-line method based on the estimated useful lives of the assets, which is generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ba0abc79-aa62-4ddd-b409-619ca3e4e96b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Certain Tablo consoles under operating leases are depreciated using the accelerated method. Leasehold improvements are amortized using the straight-line method over the shorter of the assets estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to expense as incurred. Significant improvements that substantially enhance the useful life of an asset are capitalized and depreciated. When assets are retired or disposed of, the cost together with related accumulated depreciation is removed from the balance sheet and any resulting gain or loss is reflected in the Company’s statements of operations in the period realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairment losses as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines if an arrangement is a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term. Operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. Lease costs for the Company’s operating leases are recognized on a straight-line basis over the reasonably assured lease term. Variable lease payments include lease operating expenses.</span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Warranty Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company generally provides a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warranty for defective parts and workmanship on its Tablo consoles, commencing upon the transfer of title and risk of loss to the customer. The Company accrues the estimated cost of product warranties when it invoices the customer, based on historical experience and expected results. Should actual product failure rates and material usage costs differ from these estimates, revisions to the estimated warranty liability would be required. The Company periodically assesses the adequacy of its recorded product warranty liabilities and adjusts the balance as required. Warranty expense is recorded as a component of cost of product revenue in the statements of operations.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contract Liabilities - Deferred Revenue</span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue is recognized subsequent to invoicing. For multi-year service agreements, the Company generally invoices customers annually at the beginning of each annual coverage period. Deferred revenue that will be recognized during the 12 months following the balance sheet date is recorded as the current portion of deferred revenue and the remaining portion is recorded as noncurrent.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company generates revenue primarily from contracts with customers for the sale of its products and services. Product revenue consists primarily of sales of the Tablo console and related consumables, including Tablo cartridges, used in treatment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delivery. Service and other revenue consists primarily of revenue generated from consoles service contracts and other revenue from shipping and handling charged to customers.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each customer contract defines our distinct performance obligations and the associated transaction price for each obligation. Tablo consoles and consumables are generally sold without the right of return. Revenue is recognized when a performance obligation is satisfied. Revenue from product sales is recognized at a point in time when management has determined that control has transferred to the customer, which is generally when legal title has transferred to the customer. Revenue from service contracts is recognized over time as the service is performed, typically evenly over the contract term. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain contracts include variable consideration such as rebates, revenue for such contracts is recognized only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue is recognized net of any taxes collected from customers, which are subsequently remitted to governmental authorities.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s contracts with customers often include multiple performance obligations. For such contracts, the Company allocates the contracted transaction price to each performance obligation based upon the relative SSP. The Company determines the SSP based upon the facts and circumstances of each performance obligation (product or services), which often requires management's judgement. The Company uses an observable price to estimate SSP for items that are sold separately, including customer service agreements. In instances where SSP is not directly observable, such as when the Company does not sell the product or service separately, the Company determines the SSP using information that may include market conditions and other observable inputs. The Company may offer additional goods or services to customers at the inception of customer contracts at prices not at SSP. If such contracts result in a material right, the Company allocates part of the transaction price to that right and recognizes the associated revenue when those future goods and services are transferred to the customer. SSP is assigned based on the estimated value of the material right.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs associated with product sales include commissions. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company applies the practical expedient to expense the commissions as incurred as the expected amortization period is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one year</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or less.</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Commissions are recorded as sales and marketing expenses in the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">statements of operations.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Lease Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company enters into operating lease arrangements that contain both lease and non-lease elements. The lease element includes Tablo consoles, while non-lease elements include consumables, services and training. Revenue related to such arrangements is allocated to lease and non-lease elements based on their relative SSP. Revenue for the lease element, net of any taxes collected from customers, is recognized on a straight-line basis as product revenue over the lease term, generally three months to one year, in the statements of operations. The costs of the leased Tablo consoles are included in property and equipment, net in the balance sheets and amortized to cost of product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Shipping and Handling Costs</span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shipping and handling charged to customers are recorded as revenue. Shipping and handling costs are expensed as incurred and are included in sales and marketing expenses.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense relates to stock options with a service-based vesting condition, stock options with performance and market-based vesting conditions, stock purchase rights under our ESPP, RSUs and PSUs with performance or market-based vesting conditions. Stock-based compensation expense for the Company’s stock-based awards is based on their grant date fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Service-based options granted to an optionee generally vest at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The fair value of stock options with a service condition and stock purchase rights under the ESPP on the grant date is estimated using the Black-Scholes option-pricing model. The fair value of these awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Black-Scholes model considers several variables and assumptions in estimating the fair value of service-based stock options and stock purchase rights under the ESPP. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and expected stock price volatility over the expected term. For all service-based stock options granted, the Company calculates the expected term using the simplified method for “plain vanilla” stock option awards. The Company had no publicly available stock price information prior to the IPO and limited</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">available stock price information subsequent to the IPO; therefore, the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term on the equity settled award.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For stock options with performance- and market-based vesting conditions, stock-based compensation expense begins to be recognized over the remaining service period when it is considered probable that the performance vesting condition will be satisfied. Prior to the IPO in September 2020, the Company had not recognized any stock-based compensation expense as the satisfaction of the performance condition was not considered probable. Upon the closing of the IPO, the Company recorded a cumulative stock-based compensation expense using the accelerated attribution method as the performance condition was satisfied. Stock-based compensation expense related to these options is recognized using the accelerated attribution method as the performance-based vesting condition and not reversed if the achievement of the market condition does not occur. The fair value of these stock options is estimated using the Monte Carlo simulation model.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RSUs </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with a service-based vesting condition granted to an optionee generally vest at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The fair value of RSUs and PSUs with a service- or performance-based vesting condition is based on the market price of the Company’s common stock on the date of grant. The determination of the stock-based compensation expense related to PSUs to be recognized in the Company’s statements of operations requires the use of certain estimates and assumptions. At each reported period, the Company reassesses the probability of the achievement of corporate performance goals to estimate the number of shares to be released. Any increase or decrease in stock-based compensation expense resulting from an adjustment in the estimated shares to be released is treated as accumulative catch-up in the period of adjustment. If any of the assumptions or estimates used change significantly, stock-based compensation expense may differ materially from what the Company has recorded in the current period. The fair value of PSUs with a market-based vesting condition is estimated using the Monte Carlo simulation model. Stock-based compensation expense related to these PSUs is recognized using the accelerated attribution method and not reversed if the achievement of the market conditions does not occur</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company expenses all research and development costs as incurred. These expenses include the costs of proprietary research and development efforts, quality engineering, clinical studies and trials and regulatory affairs. Costs primarily consist of compensation and personnel costs, consulting services, supplies and materials expenses, and allocated costs including facilities and information technology</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advertising Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Advertising costs are expensed as incurred. The advertising costs for years ended December 31, 2021, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t significant.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and remeasured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company utilizes a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company includes any penalties and interest expense related to income taxes as a component of other expense, net, as necessary.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss per Share Attributable to Common Stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive securities.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents of potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, awards under the Company’s equity compensation plan and warrants are considered to be potentially dilutive securities. For periods in which the Company reports net losses, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders because the effects of potentially dilutive securities are antidilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Benefit Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their eligible compensation on a pre- or post-tax basis. The Company is authorized to make matching contributions but has not made such contributions for the years ended December 31, 2021, 2020 and 2019. Effective January 1, 2022, the Company began to match </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of each employee’s contributions up to a maximum matching contribution equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such employee’s eligible compensation, subject to the terms and limitations of the 401(k) plan and applicable law.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company operates as a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_247de4c8-0529-45c8-9fa1-966cf9d89bfb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">single</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, reviews fina</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ncial information on an aggregate basis for the purposes of allocating resources and evaluating financial performance. The Company has operated a manufacturing facility in Mexico since 2020. The Company's long-lived tangible assets, net, as well as the Company's operating lease right-of-use assets recognized on the balance sheets, located in Mexico were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial Accounting Standards Board</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (FASB) issued ASU No. 2019-12, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740)</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which simplifies the accounting for income taxes, primarily by eliminating certain exceptions to ASC 740. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company early adopted ASU 2019-12 on a modified retrospective basis as of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which did not have a material impact on its financial statements</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASU 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (CECL) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its financial statements.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, allowance for doubtful accounts, inventory valuation and write-downs, warranty obligations, the fair value of equity awards, the valuation of investments, recoverability of the Company’s net deferred tax assets, and certain accrued expenses. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results may differ from those estimates under different assumptions or conditions and the differences may be material.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">and Other Risks and Uncertainties</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, restricted cash, short-term investments and accounts receivable. Substantially all the Company’s cash and cash equivalents, restricted cash, and investments are held at one financial institution in the United States that management believes is of high credit quality. Such investments may, at times, exceed federally insured limits or may not be covered by deposit insurance at all. The Company has not experienced any credit losses on its cash and cash equivalents, restricted cash or short-term investments through December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customers accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of revenues</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. For the year ended December 31, 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customers accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of revenues, respectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customer accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of revenues for the year ended December 31, 2019. Accounts receivable are unsecured and the Company does not require collateral; however, the Company does assess the collectability of accounts receivable based on a number of factors, including past transaction history with, and the creditworthiness of, the customer. Accordingly, the Company is exposed to credit risk associated with accounts receivab</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">le. One customer accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of accounts receivable as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customers accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of accounts receivable, respectively, as of December 31, 2020. To reduce risk, the Company closely monitors the amounts due from its customers and assesses the financial strength of its customers through a variety of methods that include, but are not limited to, engaging directly with customer operations and leadership personnel, visiting customer locations to observe operating activities, and assessing customer longevity and reputation in the marketplace. As a result, the Company believes that its accounts receivable credit risk exposure is limited. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A material default in payment or a material reduction in purchases from these or any other large customers could have a material adverse impact on the Company’s financial condition, results of operations, and liquidity.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has a manufacturing facility in Tijuana, Mexico which it operates in collaboration with its outsourced business administration service provider, TACNA, for the production of the Tablo console. The Company is subject to a number of risks associated with operating its Mexico-based manufacturing facility. The manufacturing operations at the facility may suffer disruptions from global or regional public health crises such as the ongoing COVID-19 pandemic, natural disasters, cyber security attacks, vandalism, terrorism or other political hostilities. Any such occurrences could negatively impact the Company’s ability to produce the Tablo console. The Company is also subject to a variety of foreign laws and regulations, including trade and labor restrictions and laws relating to importation, exportation and taxation of goods, and U.S. laws and regulations relating to foreign operations. In addition, because certain of its Mexico-based manufacturing operations incur costs that are denominated in MXN, the Company is exposed to additional risk of currency fluctuations between USD and MXN, which could increase its product and labor costs, thus reducing its gross profit. To date, foreign currency transaction gains and losses have not been material to the Company’s financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to additional risks and uncertainties due to the COVID-19 pandemic. How long the pandemic, and measures intended to contain the spread of COVID-19, will continue remains uncertain and depends on ongoing developments, including but not limited to any resurgences of the virus including emerging variant strains, federal, state and local government actions taken in response, and continued availability, effectiveness and public acceptance of COVID-19 vaccines, as well as the extent and duration of the effect on the economy and how quickly and to what extent normal economic and operating conditions can resume. Additionally, the duration and severity of disruptions in the global supply chain, largely driven by high demand as the economy reopens and the ongoing impact of the pandemic, also remain uncertain and depend on various factors, including the effectiveness of recent government actions intended to mitigate these disruptions. As a result, the Company cannot predict what effect COVID-19, the associated containment measures and the related supply chain disruptions will ultimately have on its business and result of operations.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential economic impact and duration of the COVID-19 pandemic may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">could result in a reduction in the Company’s ability to access capital and delays in payments of outstanding receivables that could adversely affect our liquidity. In addition, a recession or market correction resulting from the spread COVID-19 could materially affect the Company's business and financial results. As of the date of issuance of the financial statements, the extent to which the COVID-19 pandemic may materially adversely affect the Company's financial condition, liquidity, or results of operations is uncertain.</span></p> 2 0.30 0.15 3 0.22 0.19 0.16 1 0.11 0.10 2 0.22 0.16 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company classifies financial instruments using a three-tiered fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Management believes that its term loan bears interest at the prevailing market rates for instruments with similar characteristics; accordingly, the carrying value of this instrument approximates its fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Equivalents and Short-Term Investments</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and are stated at fair value.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company primarily holds corporate debt securities, commercial paper, and U.S. Treasury securities, and has the ability, if necessary, to liquidate any of its investments to meet its liquidity needs in the next 12 months, without significant penalty. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term investments on the accompanying balance sheets. Short-term investments have been classified as available-for-sale at the time of purchase. The Company evaluates the appropriate classification of its investments as of each balance sheet date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s investment securities are recorded at fair value based on the fair value hierarchy. Money market funds and U.S. Treasury securities are classified within Level 1 of the fair value hierarchy. Other securities are classified within Level 2 of the fair value hierarchy. Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of accumulated other comprehensive income (loss).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounts Receivable, Net</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts receivable are recorded at invoice value, net of any allowance for doubtful accounts. Estimates of the allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of customers and individual customer circumstances. The allowance for doubtful accounts was not significant as of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Inventories</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inventory is stated at the lower of cost or net realizable value, with approximate costs determined</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on a first-in, first-out basis. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The carrying value of inventories is reduced for any products that are considered excessive or obsolete based upon assumptions about future demand and market conditions. Any write-down of its inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest that the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on the Company’s statements of operations.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is generally computed using the straight-line method based on the estimated useful lives of the assets, which is generally </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ba0abc79-aa62-4ddd-b409-619ca3e4e96b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Certain Tablo consoles under operating leases are depreciated using the accelerated method. Leasehold improvements are amortized using the straight-line method over the shorter of the assets estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to expense as incurred. Significant improvements that substantially enhance the useful life of an asset are capitalized and depreciated. When assets are retired or disposed of, the cost together with related accumulated depreciation is removed from the balance sheet and any resulting gain or loss is reflected in the Company’s statements of operations in the period realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairment losses as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> P5Y 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines if an arrangement is a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term. Operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As the implicit rate in the Company’s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. Lease costs for the Company’s operating leases are recognized on a straight-line basis over the reasonably assured lease term. Variable lease payments include lease operating expenses.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Warranty Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company generally provides a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warranty for defective parts and workmanship on its Tablo consoles, commencing upon the transfer of title and risk of loss to the customer. The Company accrues the estimated cost of product warranties when it invoices the customer, based on historical experience and expected results. Should actual product failure rates and material usage costs differ from these estimates, revisions to the estimated warranty liability would be required. The Company periodically assesses the adequacy of its recorded product warranty liabilities and adjusts the balance as required. Warranty expense is recorded as a component of cost of product revenue in the statements of operations.</span> P1Y <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contract Liabilities - Deferred Revenue</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue is recognized subsequent to invoicing. For multi-year service agreements, the Company generally invoices customers annually at the beginning of each annual coverage period. Deferred revenue that will be recognized during the 12 months following the balance sheet date is recorded as the current portion of deferred revenue and the remaining portion is recorded as noncurrent.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company generates revenue primarily from contracts with customers for the sale of its products and services. Product revenue consists primarily of sales of the Tablo console and related consumables, including Tablo cartridges, used in treatment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delivery. Service and other revenue consists primarily of revenue generated from consoles service contracts and other revenue from shipping and handling charged to customers.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each customer contract defines our distinct performance obligations and the associated transaction price for each obligation. Tablo consoles and consumables are generally sold without the right of return. Revenue is recognized when a performance obligation is satisfied. Revenue from product sales is recognized at a point in time when management has determined that control has transferred to the customer, which is generally when legal title has transferred to the customer. Revenue from service contracts is recognized over time as the service is performed, typically evenly over the contract term. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain contracts include variable consideration such as rebates, revenue for such contracts is recognized only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue is recognized net of any taxes collected from customers, which are subsequently remitted to governmental authorities.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0829166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s contracts with customers often include multiple performance obligations. For such contracts, the Company allocates the contracted transaction price to each performance obligation based upon the relative SSP. The Company determines the SSP based upon the facts and circumstances of each performance obligation (product or services), which often requires management's judgement. The Company uses an observable price to estimate SSP for items that are sold separately, including customer service agreements. In instances where SSP is not directly observable, such as when the Company does not sell the product or service separately, the Company determines the SSP using information that may include market conditions and other observable inputs. The Company may offer additional goods or services to customers at the inception of customer contracts at prices not at SSP. If such contracts result in a material right, the Company allocates part of the transaction price to that right and recognizes the associated revenue when those future goods and services are transferred to the customer. SSP is assigned based on the estimated value of the material right.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs associated with product sales include commissions. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company applies the practical expedient to expense the commissions as incurred as the expected amortization period is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one year</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or less.</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Commissions are recorded as sales and marketing expenses in the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">statements of operations.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Lease Arrangements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company enters into operating lease arrangements that contain both lease and non-lease elements. The lease element includes Tablo consoles, while non-lease elements include consumables, services and training. Revenue related to such arrangements is allocated to lease and non-lease elements based on their relative SSP. Revenue for the lease element, net of any taxes collected from customers, is recognized on a straight-line basis as product revenue over the lease term, generally three months to one year, in the statements of operations. The costs of the leased Tablo consoles are included in property and equipment, net in the balance sheets and amortized to cost of product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Shipping and Handling Costs</span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shipping and handling charged to customers are recorded as revenue. Shipping and handling costs are expensed as incurred and are included in sales and marketing expenses.</span> The Company applies the practical expedient to expense the commissions as incurred as the expected amortization period is one year or less. P1Y <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense relates to stock options with a service-based vesting condition, stock options with performance and market-based vesting conditions, stock purchase rights under our ESPP, RSUs and PSUs with performance or market-based vesting conditions. Stock-based compensation expense for the Company’s stock-based awards is based on their grant date fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Service-based options granted to an optionee generally vest at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The fair value of stock options with a service condition and stock purchase rights under the ESPP on the grant date is estimated using the Black-Scholes option-pricing model. The fair value of these awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Black-Scholes model considers several variables and assumptions in estimating the fair value of service-based stock options and stock purchase rights under the ESPP. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and expected stock price volatility over the expected term. For all service-based stock options granted, the Company calculates the expected term using the simplified method for “plain vanilla” stock option awards. The Company had no publicly available stock price information prior to the IPO and limited</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">available stock price information subsequent to the IPO; therefore, the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term on the equity settled award.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For stock options with performance- and market-based vesting conditions, stock-based compensation expense begins to be recognized over the remaining service period when it is considered probable that the performance vesting condition will be satisfied. Prior to the IPO in September 2020, the Company had not recognized any stock-based compensation expense as the satisfaction of the performance condition was not considered probable. Upon the closing of the IPO, the Company recorded a cumulative stock-based compensation expense using the accelerated attribution method as the performance condition was satisfied. Stock-based compensation expense related to these options is recognized using the accelerated attribution method as the performance-based vesting condition and not reversed if the achievement of the market condition does not occur. The fair value of these stock options is estimated using the Monte Carlo simulation model.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RSUs </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with a service-based vesting condition granted to an optionee generally vest at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The fair value of RSUs and PSUs with a service- or performance-based vesting condition is based on the market price of the Company’s common stock on the date of grant. The determination of the stock-based compensation expense related to PSUs to be recognized in the Company’s statements of operations requires the use of certain estimates and assumptions. At each reported period, the Company reassesses the probability of the achievement of corporate performance goals to estimate the number of shares to be released. Any increase or decrease in stock-based compensation expense resulting from an adjustment in the estimated shares to be released is treated as accumulative catch-up in the period of adjustment. If any of the assumptions or estimates used change significantly, stock-based compensation expense may differ materially from what the Company has recorded in the current period. The fair value of PSUs with a market-based vesting condition is estimated using the Monte Carlo simulation model. Stock-based compensation expense related to these PSUs is recognized using the accelerated attribution method and not reversed if the achievement of the market conditions does not occur</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p> 0.25 P3Y 0.25 P3Y <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company expenses all research and development costs as incurred. These expenses include the costs of proprietary research and development efforts, quality engineering, clinical studies and trials and regulatory affairs. Costs primarily consist of compensation and personnel costs, consulting services, supplies and materials expenses, and allocated costs including facilities and information technology</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advertising Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Advertising costs are expensed as incurred. The advertising costs for years ended December 31, 2021, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t significant.</span> 0 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and remeasured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company utilizes a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company includes any penalties and interest expense related to income taxes as a component of other expense, net, as necessary.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss per Share Attributable to Common Stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive securities.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents of potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, awards under the Company’s equity compensation plan and warrants are considered to be potentially dilutive securities. For periods in which the Company reports net losses, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders because the effects of potentially dilutive securities are antidilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Benefit Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their eligible compensation on a pre- or post-tax basis. The Company is authorized to make matching contributions but has not made such contributions for the years ended December 31, 2021, 2020 and 2019. Effective January 1, 2022, the Company began to match </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of each employee’s contributions up to a maximum matching contribution equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such employee’s eligible compensation, subject to the terms and limitations of the 401(k) plan and applicable law.</span></p> 1 0.02 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company operates as a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_247de4c8-0529-45c8-9fa1-966cf9d89bfb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">single</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, reviews fina</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ncial information on an aggregate basis for the purposes of allocating resources and evaluating financial performance. The Company has operated a manufacturing facility in Mexico since 2020. The Company's long-lived tangible assets, net, as well as the Company's operating lease right-of-use assets recognized on the balance sheets, located in Mexico were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021.</span></p> 6200000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial Accounting Standards Board</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (FASB) issued ASU No. 2019-12, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740)</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which simplifies the accounting for income taxes, primarily by eliminating certain exceptions to ASC 740. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company early adopted ASU 2019-12 on a modified retrospective basis as of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which did not have a material impact on its financial statements</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements Not Yet Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments - Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASU 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (CECL) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its financial statements.</span> 2021-01-01 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Revenue from Contracts with Customers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disaggregation of Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue by source consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.249%;"/> <td style="width:1.237%;"/> <td style="width:1.423%;"/> <td style="width:11.116%;"/> <td style="width:0.876%;"/> <td style="width:1.237%;"/> <td style="width:1.423%;"/> <td style="width:10.992%;"/> <td style="width:0.876%;"/> <td style="width:1.237%;"/> <td style="width:1.423%;"/> <td style="width:11.033%;"/> <td style="width:0.876%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consoles</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,133</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,871</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,187</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consumables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,179</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,742</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,563</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total product revenue</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84,312</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,612</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,750</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Service and other revenue</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,290</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,323</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,328</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102,602</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,935</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,078</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021, 2020 and 2019, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, of consoles revenue were from console operating lease arrangements. The remaining operating lease payments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 will be recognized during the year ending December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Remaining Performance Obligations and Contract Liabilities</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the aggregate amount of the transaction price allocated to the remaining performance obligations related to customer service contracts that are unsatisfied or partially unsatisfied was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which is recorded as deferred revenue on the Company’s balance sheet. Of that amount, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> will be recognized as revenue during the year ended December 31, 2022, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thereafter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The contract liabilities consist</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of deferred revenue which represents payments received in advance of revenue recognition. Revenue under these agreements is recognized over the related service period. During the years ended December 31, 2021, 2020 and 2019, the Company recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, of previously deferred revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue by source consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.249%;"/> <td style="width:1.237%;"/> <td style="width:1.423%;"/> <td style="width:11.116%;"/> <td style="width:0.876%;"/> <td style="width:1.237%;"/> <td style="width:1.423%;"/> <td style="width:10.992%;"/> <td style="width:0.876%;"/> <td style="width:1.237%;"/> <td style="width:1.423%;"/> <td style="width:11.033%;"/> <td style="width:0.876%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consoles</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,133</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,871</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,187</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consumables</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,179</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,742</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,563</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total product revenue</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84,312</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,612</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,750</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Service and other revenue</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,290</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,323</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,328</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102,602</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,935</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,078</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 65133000 32871000 12187000 19179000 6742000 1563000 84312000 39612000 13750000 18290000 10323000 1328000 102602000 49935000 15078000 4700000 3100000 500000 1700000 6700000 6300000 300000 3200000 900000 300000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.204%;"/> <td style="width:1.855%;"/> <td style="width:9.341%;"/> <td style="width:1.132%;"/> <td style="width:1.197%;"/> <td style="width:9.925%;"/> <td style="width:0.584%;"/> <td style="width:1.132%;"/> <td style="width:1.197%;"/> <td style="width:8.858%;"/> <td style="width:1.864%;"/> <td style="width:1.132%;"/> <td style="width:1.197%;"/> <td style="width:9.767%;"/> <td style="width:0.788%;"/> <td style="width:1.132%;"/> <td style="width:1.197%;"/> <td style="width:9.916%;"/> <td style="width:0.584%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Valuation<br/>Hierarchy</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Amortized<br/>Costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60,844</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60,844</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,064</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">‒</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,004</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt</span></p></td> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124,178</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124,055</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,081</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,081</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents and <br/>   short-term investments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">218,167</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">185</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">217,984</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:37.393%;"/> <td style="width:1.855%;"/> <td style="width:9.351%;"/> <td style="width:1.141%;"/> <td style="width:1.197%;"/> <td style="width:9.926%;"/> <td style="width:0.584%;"/> <td style="width:1.141%;"/> <td style="width:1.197%;"/> <td style="width:9.935%;"/> <td style="width:0.584%;"/> <td style="width:1.141%;"/> <td style="width:1.197%;"/> <td style="width:9.935%;"/> <td style="width:0.584%;"/> <td style="width:1.141%;"/> <td style="width:1.197%;"/> <td style="width:9.917%;"/> <td style="width:0.584%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Valuation<br/>Hierarchy</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Amortized<br/>Costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,056</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,056</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,999</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt</span></p></td> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,898</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,898</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents and <br/>   short-term investments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75,953</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75,954</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the remaining contractual maturities for short-term investments were as follows (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:77.294%;"/> <td style="width:2.356%;"/> <td style="width:1.47%;"/> <td style="width:18.203%;"/> <td style="width:0.678%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Due within one year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135,766</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After one but within five years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,374</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">157,140</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs. The Company validates the prices provided by its third-party pricing services by understanding the models used, obtaining market values from other pricing sources and confirming those securities traded in active markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Impairment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">assessments are made at the individual security level at each reporting period. When the fair value of an available-for-sale security is less than its cost at the balance sheet date, a determination is made as to whether the impairment is other-than-temporary and, if it is other-than-temporary, an impairment loss is recognized in earnings equal to the difference between the investment’s amortized cost and fair value at such date. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unrealized losses for securities in an unrealized loss position for more than 12 months as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021. During the years ended December 31, 2021, 2020 and 2019</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recognize other-than-temporary impairment losses related to its investment securities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.204%;"/> <td style="width:1.855%;"/> <td style="width:9.341%;"/> <td style="width:1.132%;"/> <td style="width:1.197%;"/> <td style="width:9.925%;"/> <td style="width:0.584%;"/> <td style="width:1.132%;"/> <td style="width:1.197%;"/> <td style="width:8.858%;"/> <td style="width:1.864%;"/> <td style="width:1.132%;"/> <td style="width:1.197%;"/> <td style="width:9.767%;"/> <td style="width:0.788%;"/> <td style="width:1.132%;"/> <td style="width:1.197%;"/> <td style="width:9.916%;"/> <td style="width:0.584%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Valuation<br/>Hierarchy</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Amortized<br/>Costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60,844</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60,844</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,064</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">‒</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,004</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt</span></p></td> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124,178</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124,055</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,081</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,081</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents and <br/>   short-term investments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">218,167</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">185</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">217,984</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:37.393%;"/> <td style="width:1.855%;"/> <td style="width:9.351%;"/> <td style="width:1.141%;"/> <td style="width:1.197%;"/> <td style="width:9.926%;"/> <td style="width:0.584%;"/> <td style="width:1.141%;"/> <td style="width:1.197%;"/> <td style="width:9.935%;"/> <td style="width:0.584%;"/> <td style="width:1.141%;"/> <td style="width:1.197%;"/> <td style="width:9.935%;"/> <td style="width:0.584%;"/> <td style="width:1.141%;"/> <td style="width:1.197%;"/> <td style="width:9.917%;"/> <td style="width:0.584%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Valuation<br/>Hierarchy</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Amortized<br/>Costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,056</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,056</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term investments:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury securities</span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,999</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt</span></p></td> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,898</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,898</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash equivalents and <br/>   short-term investments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75,953</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75,954</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the remaining contractual maturities for short-term investments were as follows (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:77.294%;"/> <td style="width:2.356%;"/> <td style="width:1.47%;"/> <td style="width:18.203%;"/> <td style="width:0.678%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate Fair Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Due within one year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135,766</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After one but within five years</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,374</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">157,140</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 60844000 60844000 18064000 60000 18004000 124178000 2000 125000 124055000 15081000 15081000 218167000 2000 185000 217984000 56056000 56056000 14999000 1000 15000000 4898000 4898000 75953000 1000 75954000 135766000 21374000 157140000 0 0 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Balance Sheet Components</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash, Cash Equivalents and Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the restricted cash balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million primarily relates to contractual obligations under the SVB Loan and Security Agreement (see Note 7) and collateral for the building leases in San Jose, CA and Tijuana, Mexico (see Note 6). The restricted cash balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2019 relates to collateral for building leases.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the statements of cash flows (in thousands): </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:Calibri;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.556%;"/> <td style="width:1.216%;"/> <td style="width:1.422%;"/> <td style="width:11.554%;"/> <td style="width:0.639%;"/> <td style="width:1.216%;"/> <td style="width:1.422%;"/> <td style="width:11.554%;"/> <td style="width:0.639%;"/> <td style="width:1.33%;"/> <td style="width:1.422%;"/> <td style="width:11.389%;"/> <td style="width:0.639%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">182,348</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">294,972</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,926</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,311</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,311</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">743</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">215,659</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">328,283</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,669</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Inventories</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inventories consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.263%;"/> <td style="width:1.392%;"/> <td style="width:1.706%;"/> <td style="width:13.435%;"/> <td style="width:0.835%;"/> <td style="width:1.392%;"/> <td style="width:1.706%;"/> <td style="width:13.435%;"/> <td style="width:0.835%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Raw materials</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,114</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,989</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Work in process</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,054</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,200</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finished goods</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,017</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total inventories</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,185</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,384</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.646%;"/> <td style="width:1.462%;"/> <td style="width:0.951%;"/> <td style="width:13.54%;"/> <td style="width:1.207%;"/> <td style="width:1.462%;"/> <td style="width:0.951%;"/> <td style="width:13.575%;"/> <td style="width:1.207%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tablos under operating leases</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,412</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,158</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computers and software</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,777</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,131</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,494</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,399</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Machinery and equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,197</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,496</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,864</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,459</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">874</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,343</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,618</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,986</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation and amortization</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,654</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,988</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,964</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,998</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total depreciation and amortization expense for the years ended December 31, 2021, 2020, and 2019 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.717%;"/> <td style="width:1.415%;"/> <td style="width:1.682%;"/> <td style="width:13.958%;"/> <td style="width:0.743%;"/> <td style="width:1.415%;"/> <td style="width:1.682%;"/> <td style="width:13.644%;"/> <td style="width:0.743%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued inventory</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,808</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,576</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">574</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued professional services</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,269</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,187</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued rebate</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,121</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">566</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Other</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,017</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,399</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses and other current liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,789</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,903</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Warranty Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The change in accrued warranty liability is presented in the following table (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.012%;"/> <td style="width:1.323%;"/> <td style="width:1.705%;"/> <td style="width:13.26%;"/> <td style="width:1.206%;"/> <td style="width:1.323%;"/> <td style="width:1.705%;"/> <td style="width:13.26%;"/> <td style="width:1.206%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the beginning of the period</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,702</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions charged to cost of product revenue</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,310</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,858</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consumption</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,519</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,647</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the end of the period</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,704</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,913</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> 33300000 33300000 700000 The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the statements of cash flows (in thousands):     December 31,       2021     2020     2019   Cash and cash equivalents   $ 182,348     $ 294,972     $ 36,926   Restricted cash     33,311       33,311       743   Total cash, cash equivalents and restricted cash   $ 215,659     $ 328,283     $ 37,669   182348000 294972000 36926000 33311000 33311000 743000 215659000 328283000 37669000 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inventories consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.263%;"/> <td style="width:1.392%;"/> <td style="width:1.706%;"/> <td style="width:13.435%;"/> <td style="width:0.835%;"/> <td style="width:1.392%;"/> <td style="width:1.706%;"/> <td style="width:13.435%;"/> <td style="width:0.835%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Raw materials</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,114</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,989</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Work in process</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,054</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,200</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finished goods</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,017</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,195</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total inventories</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,185</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,384</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 18114000 7989000 6054000 6200000 15017000 4195000 39185000 18384000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.646%;"/> <td style="width:1.462%;"/> <td style="width:0.951%;"/> <td style="width:13.54%;"/> <td style="width:1.207%;"/> <td style="width:1.462%;"/> <td style="width:0.951%;"/> <td style="width:13.575%;"/> <td style="width:1.207%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tablos under operating leases</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,412</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,158</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computers and software</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,777</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,131</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,494</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,399</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Machinery and equipment</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,197</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,496</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,864</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,459</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">874</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,343</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,618</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,986</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation and amortization</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,654</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,988</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,964</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,998</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 2412000 5158000 3777000 3131000 1494000 1399000 7197000 4496000 4864000 4459000 874000 1343000 20618000 19986000 7654000 4988000 12964000 14998000 5200000 3200000 1500000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.717%;"/> <td style="width:1.415%;"/> <td style="width:1.682%;"/> <td style="width:13.958%;"/> <td style="width:0.743%;"/> <td style="width:1.415%;"/> <td style="width:1.682%;"/> <td style="width:13.644%;"/> <td style="width:0.743%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued inventory</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,808</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,576</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">574</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued professional services</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,269</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,187</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued rebate</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,121</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">566</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Other</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,017</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,399</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses and other current liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,789</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,903</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 4808000 3576000 574000 175000 1269000 2187000 3121000 566000 4017000 1399000 13789000 7903000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Warranty Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The change in accrued warranty liability is presented in the following table (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.012%;"/> <td style="width:1.323%;"/> <td style="width:1.705%;"/> <td style="width:13.26%;"/> <td style="width:1.206%;"/> <td style="width:1.323%;"/> <td style="width:1.705%;"/> <td style="width:13.26%;"/> <td style="width:1.206%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the beginning of the period</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,913</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,702</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions charged to cost of product revenue</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,310</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,858</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consumption</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,519</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,647</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the end of the period</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,704</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,913</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 2913000 1702000 7310000 4858000 6519000 3647000 3704000 2913000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2019, the Company entered into an operating lease agreement for its new facility and office space in San Jose, CA that commenced in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and expires in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 2027</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This operating lease contains a free rent period and an escalation clause. The landlord provided the Company with a tenant improvement allowance of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company issued an irrevocable standby letter of credit in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in lieu of a cash security deposit. The letter of credit is fully secured by cash held at the bank in a restricted account.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, the Company entered into an operating lease agreement for its manufacturing facility in Tijuana, Mexico that commenced in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and will expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company took initial possession of the building with </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,437</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet in May 2020 and subsequently took possession of the second space with </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet in June 2021. This operating lease contains a free rent period and an escalation clause. The Company issued an irrevocable standby letter of credit in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, in lieu of a cash security deposit. The letter of credit is fully secured by cash held at the bank in a restricted account.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Both leases include </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">renewal options at the election of the Company to renew or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">extend </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the lease</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of lease costs were as follows (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.692%;"/> <td style="width:1.279%;"/> <td style="width:1.423%;"/> <td style="width:10.827%;"/> <td style="width:0.65%;"/> <td style="width:1.279%;"/> <td style="width:1.423%;"/> <td style="width:10.827%;"/> <td style="width:0.65%;"/> <td style="width:1.279%;"/> <td style="width:1.423%;"/> <td style="width:10.6%;"/> <td style="width:0.65%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease costs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,759</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,070</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">375</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">233</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease costs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">371</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">520</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,314</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,674</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">620</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average remaining lease term and discount rate were as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.945%;"/> <td style="width:1.473%;"/> <td style="width:0.777%;"/> <td style="width:13.47%;"/> <td style="width:0.777%;"/> <td style="width:1.555%;"/> <td style="width:0.777%;"/> <td style="width:13.47%;"/> <td style="width:0.754%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term (in years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The maturity of the Company’s operating lease liabilities as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 were as follows (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.654%;"/> <td style="width:1.763%;"/> <td style="width:1.705%;"/> <td style="width:15.741%;"/> <td style="width:1.137%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ending December 31:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,796</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,856</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,911</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,969</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,523</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,055</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,011</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of operating lease liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,044</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,151</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, noncurrent</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,893</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Purchase Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's commitments as of December 31, 2021 include an estimated amount of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million rel</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ating to the Company’s open purchase orders and contractual obligations that occur in the ordinary course of business, including commitments with contract manufacturers and suppliers for which the Company has not received the goods or services, commitments for capital expenditures, consulting activities for which the Company has not received the services, and subscription of software services. Although open purchase orders are considered enforceable and legally binding, the terms generally allow the Company the option to cancel within a reasonable period, reschedule, and adjust its requirements based on its business needs prior to the delivery of goods or performance of services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Litigation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, the Company may become involved in legal proceedings or investigations, which could have an adverse impact on its reputation, business and financial condition and divert the attention of the Company’s management from the operation of the Company’s business. The Company is not presently a party to any legal proceedings that, if determined adversely to the Company, would individually or taken together have a material adverse effect on its business, results of operations, financial condition or cash flows.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indemnifications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of business, the Company often includes standard indemnification provisions in its arrangements with its partners, customers and suppliers. Pursuant to these provisions, the Company may be obligated to indemnify such parties for losses or claims suffered or incurred in connection with its service, breach of representations or covenants, intellectual property infringement or other claims made against such parties. These provisions may limit the time within which an indemnification claim can be made. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such indemnification obligations and has not accrued any liabilities related to such obligations in these financial statements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span> 2020-04 2027-03 2000000.0 300000 2020-05 2026-08 48437 38750 3000000.0 renewal options at the election of the Company to renew or extend the lease renewal options at the election of the Company to renew or extend the lease true true <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of lease costs were as follows (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.692%;"/> <td style="width:1.279%;"/> <td style="width:1.423%;"/> <td style="width:10.827%;"/> <td style="width:0.65%;"/> <td style="width:1.279%;"/> <td style="width:1.423%;"/> <td style="width:10.827%;"/> <td style="width:0.65%;"/> <td style="width:1.279%;"/> <td style="width:1.423%;"/> <td style="width:10.6%;"/> <td style="width:0.65%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease costs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,759</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,070</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">375</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">233</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease costs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">371</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">520</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,314</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,674</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">620</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p> 1759000 375000 233000 100000 180000 371000 2314000 1674000 620000 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average remaining lease term and discount rate were as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.945%;"/> <td style="width:1.473%;"/> <td style="width:0.777%;"/> <td style="width:13.47%;"/> <td style="width:0.777%;"/> <td style="width:1.555%;"/> <td style="width:0.777%;"/> <td style="width:13.47%;"/> <td style="width:0.754%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average remaining lease term (in years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average discount rate</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> P5Y3M18D P6Y3M18D 0.087 0.087 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The maturity of the Company’s operating lease liabilities as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 were as follows (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.654%;"/> <td style="width:1.763%;"/> <td style="width:1.705%;"/> <td style="width:15.741%;"/> <td style="width:1.137%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ending December 31:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,796</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,856</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,911</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,969</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,523</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,055</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,011</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of operating lease liabilities</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,044</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,151</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, noncurrent</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,893</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 1796000 1856000 1911000 1969000 2523000 10055000 2011000 8044000 1151000 6893000 68600000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Term Loans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Term loans consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.44%;"/> <td style="width:1.403%;"/> <td style="width:1.682%;"/> <td style="width:13.582%;"/> <td style="width:1.113%;"/> <td style="width:1.403%;"/> <td style="width:1.682%;"/> <td style="width:13.582%;"/> <td style="width:1.113%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Principal of term loan</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unamortized debt discount</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">238</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total term loan, noncurrent</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,762</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,674</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Perceptive Term Loans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2017, the Company entered into a senior, secured, delayed-draw term loan facility (the Perceptive Term Loan Agreement) with Perceptive Credit Holdings, LP, as the administrative agent and the collateral agent, for various related Perceptive group companies to borrow up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the Perceptive Term Loans). The Perceptive Term Loans bore interest at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.55</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, plus the greater of the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-month London Inter-bank Offered Rate (LIBOR)</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2020, the Company used the SVB Term Loan (see below) to repay in full all amounts due under the Perceptive Term Loan and cash on hand to pay $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in early prepayment, accrued interest and exit fees. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The repayment of the Perceptive Term Loan was accounted for as a debt extinguishment, which resulted in a loss on extinguishment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million recorded in the statements of operations for the year ended December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">SVB Loan and Security Agreement</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 2, 2020, the Company entered into a senior secured term loan facility with Silicon Valley Bank (SVB) (the SVB Loan and Security Agreement), which provides for a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million term loan (the SVB Term Loan).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The SVB Term Loan matures on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 1, 2025</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments under the SVB Term Loan are for interest only through May 2023, and then 30 monthly principal and interest payments from June 2023 until maturity.</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The SVB Term Loan bears interest at a rate per annum equal to the greater of (A) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.50</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% above the Prime Rate as reported in the Wall Street Journal then in effect (which shall not be less than zero) and (B) 3.75% (</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.75</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% as of December 31, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">). The Company is obligated to maintain a restricted cash balance greater or equal to the outstanding principal balance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the SVB Term Loan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is also a final payment fee equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.75</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the original principal amount of the SVB Term Loan, or approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, due at maturity (or any earlier date of optional pre-payment or acceleration of principal due to an event of default). Such fee is being accreted to interest expense using the effective interest method with the offset recorded in noncurrent accrued interest. The Company may, at its option, prepay the SVB Term Loan in full, subject to an additional prepayment fee ranging between </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding principal amount of the SVB Term Loan.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event of default or change in control, all unpaid principal and all accrued and unpaid interest amounts (if any) become immediately due and payable including the prepayment fee. Events of default include, but are not limited to, a payment default, a material adverse change, and insolvency. The SVB Term Loan is secured by substantially all of the Company’s assets, including all of the capital stock held by the Company, if any (subject to a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% limitation on pledges of capital stock of foreign subsidiaries), subject to certain exceptions. The SVB Loan and Security Agreement contains customary representations, warranties, affirmative covenants and also contains certain restrictive covenants.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Debt issuance costs paid directly to SVB and other debt issuance costs amounting to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were accounted for as discounts on the SVB Term Loan. These debt discounts, along with the final payment fee, are being amortized over the term of the SVB Term Loan using the effective interest rate method. As of December 31, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021, the unamortized debt discount was </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which is recorded as a direct deduction from the SVB Term Loan on the balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Aggregate annual payments due on the SVB Term Loan as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:78.805%;"/> <td style="width:1.729%;"/> <td style="width:1.705%;"/> <td style="width:16.624%;"/> <td style="width:1.137%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ending December 31:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,141</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,073</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,667</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,233</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,114</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing interest</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,089</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: final payment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,025</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total term loan</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: unamortized debt discount</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">238</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total term loan, net of debt discount</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,762</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Term loans consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.44%;"/> <td style="width:1.403%;"/> <td style="width:1.682%;"/> <td style="width:13.582%;"/> <td style="width:1.113%;"/> <td style="width:1.403%;"/> <td style="width:1.682%;"/> <td style="width:13.582%;"/> <td style="width:1.113%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Principal of term loan</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unamortized debt discount</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">238</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total term loan, noncurrent</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,762</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,674</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 30000000 30000000 238000 326000 29762000 29674000 40000000.0 0.0855 three-month London Inter-bank Offered Rate (LIBOR) 0.0200 1200000 -1600000 30000000.0 2025-11-01 Payments under the SVB Term Loan are for interest only through May 2023, and then 30 monthly principal and interest payments from June 2023 until maturity. 0.0050 0.0375 30000000.0 0.0675 2000000.0 0.01 0.03 0.65 400000 200000 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Aggregate annual payments due on the SVB Term Loan as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:78.805%;"/> <td style="width:1.729%;"/> <td style="width:1.705%;"/> <td style="width:16.624%;"/> <td style="width:1.137%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ending December 31:</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,141</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,073</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,667</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,233</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total future payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,114</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: amount representing interest</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,089</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: final payment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,025</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total term loan</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: unamortized debt discount</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">238</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:15.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total term loan, net of debt discount</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,762</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 1141000 8073000 12667000 13233000 35114000 3089000 2025000 30000000 238000 29762000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Stockholders’ Equity</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has reserved shares of common stock for issuance as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.269%;"/> <td style="width:1.752%;"/> <td style="width:0.789%;"/> <td style="width:17.425%;"/> <td style="width:0.766%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Warrants to purchase common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options outstanding</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,533</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock units outstanding</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">563</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Performance stock units outstanding</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for future purchase under ESPP</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">999</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for future grant under 2020 Plan</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,415</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total reserved shares</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,683</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has reserved shares of common stock for issuance as of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.269%;"/> <td style="width:1.752%;"/> <td style="width:0.789%;"/> <td style="width:17.425%;"/> <td style="width:0.766%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Shares</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Warrants to purchase common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options outstanding</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,533</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock units outstanding</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">563</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Performance stock units outstanding</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for future purchase under ESPP</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">999</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares available for future grant under 2020 Plan</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,415</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total reserved shares</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,683</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 63000 3533000 563000 110000 999000 4415000 9683000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2019, the Company terminated the 2010 Stock Incentive Plan (the 2010 Plan) and adopted the 2019 Equity Incentive Plan (the 2019 Plan, and together with 2010 Plan, the Prior Plans) for the purpose of providing incentive and non-statutory stock options to employees, directors and certain non-employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the third quarter of 2020, the Company adopted the 2020 Equity Incentive Plan (the 2020 Plan, and together with the Prior Plans, the Plans), which became effective in connection with the IPO. As a result, the Company may not grant any additional awards under the Prior Plans. The Prior Plans will continue to govern outstanding equity awards previously granted thereunder. The Company has initially reserved </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,665,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock for the issuance of awards under the 2020 Plan. In addition, the number of shares of common stock available under the 2020 Plan </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">automatically</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> increases on the first day of each fiscal year until (and including) the fiscal year ending December 31, 2030, with such annual increase equal to an amount equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the number of shares of common stock issued and outstanding on December 31 of the immediately preceding calendar year, and (ii) an amount determined by the Company’s board of directors. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 1, 2021, the number of shares of common stock reserved for the issuance of awards under the 2020 Plan was increased by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,709,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares as a result of the automatic increase pursuant to the 2020 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options under the 2020 Plan have a contractual term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 years</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The exercise price of an option shall not be less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the fair market value of the shares on the date of grant.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company’s stock option activity under the Plans is set forth below (in thousands, except exercise price and remaining contractual life data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.148%;"/> <td style="width:1.104%;"/> <td style="width:0.603%;"/> <td style="width:9.972%;"/> <td style="width:0.798%;"/> <td style="width:1.104%;"/> <td style="width:1.206%;"/> <td style="width:9.573%;"/> <td style="width:0.594%;"/> <td style="width:1.104%;"/> <td style="width:0.603%;"/> <td style="width:10.111%;"/> <td style="width:0.594%;"/> <td style="width:1.104%;"/> <td style="width:1.206%;"/> <td style="width:9.583%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding<br/>Options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining<br/>Terms<br/>(Years)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,763</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.35</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">634</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47.91</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,437</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.31</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited and expired</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">427</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.58</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,533</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.63</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.82</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119,959</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable as of December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,453</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.42</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.07</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99,853</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted average grant date fair value of options granted to employees was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.97</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.77</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share during the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021, 2020 and 2019, respectively. The total intrinsic value of options exercised during the years ended December 31, 2021, 2020 and 2019 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. The intrinsic value is the difference between the estimated fair value of the Company’s common stock at the time of exercise and the exercise price of the stock option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total fair value of options that vested during the years ended December 31, 2021, 2020 and 2019 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the total unrecognized stock-based compensation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expense</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> related to the stock options was </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which will be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.63</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options with Performance and Market Conditions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,933,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of outstanding stock options with performance- and market-based vesting conditions. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The options were scheduled to vest over the requisite service period if the Company achieves both (i) a performance condition tied to a liquidity event, which includes the effectiveness of an IPO, and (ii) certain market conditions, provided the optionee is providing services on the date of the event.</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As of December 31, 2021, all outstanding options with these conditions were fully vested and related stock-based compensation was recognized in full. For the years ended December 31,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recorded stock-based compensation expense of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, related to these stock options. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such expense was recorded for the year ended December 31, 2019 as the performance-based vesting condition was not satisfied until the closing of the IPO in September 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each stock option grant is estimated on the date of grant using the following assumptions for the periods indicated:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.866%;"/> <td style="width:1.28%;"/> <td style="width:12.764%;"/> <td style="width:1.28%;"/> <td style="width:12.764%;"/> <td style="width:1.28%;"/> <td style="width:12.764%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.95</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> – </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.06</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> – </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.00</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.97</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> – </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.05</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.54</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.57</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.48</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company issues RSUs and PSUs, both of which are considered restricted stock. The Company grants restricted stock pursuant to the 2020 Plan and satisfies such grants through the issuance of new shares. RSUs are share awards that, upon vesting, will deliver to the holder shares of our common stock. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The PSUs may vest upon the achievement of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">specified revenue targets (performance-based vesting conditions) or specified market stock prices (market-based vesting conditions) and continued performance of services</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Certain </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PSUs with performance-based vesting conditions vest in a range between </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the units approved based on the performance relative to specified revenue targets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock activity was as follows (in thousands, except per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.631%;"/> <td style="width:1.039%;"/> <td style="width:0.603%;"/> <td style="width:9.887%;"/> <td style="width:0.798%;"/> <td style="width:1.039%;"/> <td style="width:0.603%;"/> <td style="width:10.054%;"/> <td style="width:0.603%;"/> <td style="width:1.039%;"/> <td style="width:1.206%;"/> <td style="width:9.525%;"/> <td style="width:0.603%;"/> <td style="width:1.039%;"/> <td style="width:1.206%;"/> <td style="width:9.525%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Restricted<br/>Stock Units</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Performance<br/>Stock Units</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted-Average<br/>Grant Date Fair<br/>Value Per Share</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(RSU)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(PSU)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RSU</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PSU</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52.32</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52.55</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">639</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47.78</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46.22</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51.03</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48.04</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">563</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47.98</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47.65</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total grant date fair value of RSUs vested for the years ended December 31, 2021 and 2020 were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. There were no RSUs granted prior to 2020. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the total unrecognized stock-based compensation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expense</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> related to the RSUs was </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which will be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.12</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the total unrecognized stock-based compensation expense related to the PSUs with market-based vesting conditions was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which will be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.25</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employees Stock Purchase Plan (ESPP)</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the third quarter of 2020, the Company adopted the ESPP. The Company has initially reserved </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">687,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock for purchase under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP increases automatically on the first day of each fiscal year </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">until (and including) the fiscal year ending December 31, 2030, with such annual increase </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">687,000</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, (ii) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the number of common stock issued and outstanding on December 31 of the immediately preceding fiscal year, and (iii) an amount determined by the Company’s board of directors. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 1, 2021, the number of shares of common stock reserved for purchase under the ESPP was increased by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">427,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares as a result of the automatic increase pursuant to the ESPP.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject to any limitations contained therein, the ESPP allows eligible participants to contribute, through payroll deductions, up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their eligible compensation to purchase the Company’s common stock at a purchase price </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ESPP generally provides for consecutive </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> offering periods. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective beginning with the offering period commencing on March 1, 2022, the ESPP allows </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eligible participants to purchase shares pursuant to a cashless exercise program, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the duration for each offering period will be a 24-month period consisting of four separate consecutive purchase periods of approximately six months in length. This includes a </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two-year look-back feature in the ESPP, with a reset feature, which causes the offering period to reset if the fair value of the Company’s common stock on the first day of a new offering period is less than that on the original offering date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of the stock purchase rights under the ESPP is estimated using the Black-Scholes option pricing model. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">weighted average</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> grant date fair value and assumptions used in estimating the fair value of the stock purchase rights under the ESPP were as follows:</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.804%;"/> <td style="width:1.485%;"/> <td style="width:15.113%;"/> <td style="width:1.485%;"/> <td style="width:15.113%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.50</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.47</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.06</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.07</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant Date Fair Value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> – $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.95</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.00</span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">shares of common stock were purchased pursuant to the ESPP, respectively. As of December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the total unrecognized stock-based compensation </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expense</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> related to the ESPP was </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which will be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.17</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth stock-based compensation expense included in the Company’s statements of operations (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.454%;"/> <td style="width:1.381%;"/> <td style="width:1.423%;"/> <td style="width:10.948%;"/> <td style="width:0.639%;"/> <td style="width:1.268%;"/> <td style="width:1.423%;"/> <td style="width:10.948%;"/> <td style="width:0.639%;"/> <td style="width:1.268%;"/> <td style="width:1.423%;"/> <td style="width:10.546%;"/> <td style="width:0.639%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cost of revenue</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">269</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">255</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,809</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,615</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">328</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales and marketing</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,897</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,423</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">172</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,470</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,146</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">378</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation expense</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,445</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,439</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">883</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> 3665000 0.04 1709000 P10Y 1 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of the Company’s stock option activity under the Plans is set forth below (in thousands, except exercise price and remaining contractual life data):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.148%;"/> <td style="width:1.104%;"/> <td style="width:0.603%;"/> <td style="width:9.972%;"/> <td style="width:0.798%;"/> <td style="width:1.104%;"/> <td style="width:1.206%;"/> <td style="width:9.573%;"/> <td style="width:0.594%;"/> <td style="width:1.104%;"/> <td style="width:0.603%;"/> <td style="width:10.111%;"/> <td style="width:0.594%;"/> <td style="width:1.104%;"/> <td style="width:1.206%;"/> <td style="width:9.583%;"/> <td style="width:0.594%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding<br/>Options</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining<br/>Terms<br/>(Years)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,763</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.35</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">634</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47.91</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,437</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.31</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited and expired</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">427</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.58</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,533</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.63</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.82</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119,959</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable as of December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,453</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.42</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.07</span></span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99,853</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 4763000 6.35 634000 47.91 1437000 5.31 427000 19.58 3533000 12.63 P6Y9M25D 119959000 2453000 5.42 P6Y25D 99853000 24.74 7.97 2.77 61000000.0 8200000 200000 24500000 3300000 700000 14000000.0 P2Y7M17D 1933000 The options were scheduled to vest over the requisite service period if the Company achieves both (i) a performance condition tied to a liquidity event, which includes the effectiveness of an IPO, and (ii) certain market conditions, provided the optionee is providing services on the date of the event. 4300000 18500000 0 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each stock option grant is estimated on the date of grant using the following assumptions for the periods indicated:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:57.866%;"/> <td style="width:1.28%;"/> <td style="width:12.764%;"/> <td style="width:1.28%;"/> <td style="width:12.764%;"/> <td style="width:1.28%;"/> <td style="width:12.764%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.95</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> – </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.06</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> – </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.00</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.97</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> – </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.05</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.54</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.57</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.48</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table> P5Y11M12D P6Y29D P5Y21D P10Y P4Y11M19D P5Y18D 0.539 0.553 0.521 0.627 0.493 0.509 0.0066 0.0136 0.0035 0.0154 0.0157 0.0248 0 0 0 0 2 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock activity was as follows (in thousands, except per share amounts):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:50.631%;"/> <td style="width:1.039%;"/> <td style="width:0.603%;"/> <td style="width:9.887%;"/> <td style="width:0.798%;"/> <td style="width:1.039%;"/> <td style="width:0.603%;"/> <td style="width:10.054%;"/> <td style="width:0.603%;"/> <td style="width:1.039%;"/> <td style="width:1.206%;"/> <td style="width:9.525%;"/> <td style="width:0.603%;"/> <td style="width:1.039%;"/> <td style="width:1.206%;"/> <td style="width:9.525%;"/> <td style="width:0.603%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Restricted<br/>Stock Units</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Performance<br/>Stock Units</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted-Average<br/>Grant Date Fair<br/>Value Per Share</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(RSU)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(PSU)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RSU</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PSU</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52.32</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52.55</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">639</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47.78</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46.22</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51.03</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48.04</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">563</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47.98</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47.65</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 44000 25000 52.32 52.55 639000 85000 47.78 46.22 19000 51.03 101000 48.04 563000 110000 47.98 47.65 1000000.0 200000 22600000 P3Y1M13D 1300000 P1Y3M 687000 687000 0.01 427000 0.15 0.85 P6M <span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">weighted average</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> grant date fair value and assumptions used in estimating the fair value of the stock purchase rights under the ESPP were as follows:</span> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.804%;"/> <td style="width:1.485%;"/> <td style="width:15.113%;"/> <td style="width:1.485%;"/> <td style="width:15.113%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.50</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.47</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.06</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% – </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.07</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant Date Fair Value</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> – $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.95</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.00</span></p></td> </tr> </table> P0Y6M P0Y5M19D 0.410 0.438 0.570 0.0006 0.0007 0.0012 0 0 13.25 13.95 8.00 116000 0 200000 P0Y2M1D <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth stock-based compensation expense included in the Company’s statements of operations (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.454%;"/> <td style="width:1.381%;"/> <td style="width:1.423%;"/> <td style="width:10.948%;"/> <td style="width:0.639%;"/> <td style="width:1.268%;"/> <td style="width:1.423%;"/> <td style="width:10.948%;"/> <td style="width:0.639%;"/> <td style="width:1.268%;"/> <td style="width:1.423%;"/> <td style="width:10.546%;"/> <td style="width:0.639%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cost of revenue</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">269</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">255</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,809</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,615</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">328</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales and marketing</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,897</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,423</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">172</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,470</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,146</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">378</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation expense</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,445</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,439</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">883</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 269000 255000 5000 3809000 4615000 328000 5897000 4423000 172000 7470000 12146000 378000 17445000 21439000 883000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before provision for income taxes were as follows for the periods indicated (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.397%;"/> <td style="width:1.083%;"/> <td style="width:1.423%;"/> <td style="width:12.207%;"/> <td style="width:0.949%;"/> <td style="width:1.557%;"/> <td style="width:1.423%;"/> <td style="width:12.207%;"/> <td style="width:0.949%;"/> <td style="width:1.382%;"/> <td style="width:1.423%;"/> <td style="width:12.053%;"/> <td style="width:0.949%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Domestic</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128,400</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121,492</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,299</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,336</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before provision for income taxes</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,736</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121,492</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,299</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The provision for income taxes was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the years ended December 31, 2021, which related to foreign income taxes. For years ended December 31, 2020 and 2019, the provision for income taxes were insignificant. The Company has incurred net operating losses for all periods presented. The Company has not reflected any benefit of such net operating loss carryforwards in the financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.861%;"/> <td style="width:1.309%;"/> <td style="width:0.649%;"/> <td style="width:11.246%;"/> <td style="width:1.051%;"/> <td style="width:2.123%;"/> <td style="width:1.309%;"/> <td style="width:0.649%;"/> <td style="width:11.246%;"/> <td style="width:1.051%;"/> <td style="width:2.123%;"/> <td style="width:1.309%;"/> <td style="width:0.649%;"/> <td style="width:11.246%;"/> <td style="width:1.051%;"/> <td style="width:2.123%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal statutory income tax rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State taxes</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.8</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.8</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.3</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.5</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal and state tax credits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-deductible permanent expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effect of deferred tax adjustment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-deductible compensation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective income tax rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred tax assets and liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred income taxes reflect the net tax effect of temporary differences between amounts recorded for financial reporting purposes and amounts used for tax purposes. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The major components of deferred tax assets and liabilities were as follows as of the dates indicated (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:54.201%;"/> <td style="width:1.938%;"/> <td style="width:1.423%;"/> <td style="width:18.59%;"/> <td style="width:0.949%;"/> <td style="width:1.938%;"/> <td style="width:1.423%;"/> <td style="width:18.59%;"/> <td style="width:0.949%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102,094</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76,838</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,767</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,039</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrual and reserves</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,573</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,392</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tangible and intangible assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,249</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,090</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,566</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,843</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,955</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,733</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other deferred tax asset</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">282</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">143,486</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112,935</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">141,729</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111,061</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,757</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,874</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  Right-of-use assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,757</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,874</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  Gross deferred tax liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,757</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,874</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2021 and 2020 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The valuation allowance increased by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> during the years ended December 31, 2021, 2020 and 2019, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Operating Loss and Tax Credit Carryforwards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had a net operating loss carryforward for federal income tax purposes of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">409.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Federal net operating losses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">281.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> incurred after </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2017</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> do not expire </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">but usage is limited to 80% of taxable income. The remaining </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of federal net operating loss carryforward will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and continue to expire through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2037</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company had a total state net operating loss carryforward of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">213.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. State net operating losses of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> do not expire. The remaining state net operating loss carryforward of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">160.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and continue to expire through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2041</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company had federal research and development credits of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which will begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2030</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and state research and development credits of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> which have no expiration date. These tax credits are subject to the same limitations discussed above.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company’s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced. The Company’s deferred tax asset and related valuation allowance would be reduced, as a result. The Company has not performed a Section 382 study to determine the amount of reduction, if any. Unrecognized tax benefits at December 31, 2021 have been recorded as an offset to federal and state research and development credit carryforwards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Unrecognized Tax Benefits</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the total unrecognized tax benefits for the periods presented was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.253%;"/> <td style="width:2.237%;"/> <td style="width:1.433%;"/> <td style="width:21.039%;"/> <td style="width:0.66%;"/> <td style="width:3.247%;"/> <td style="width:1.433%;"/> <td style="width:21.039%;"/> <td style="width:0.66%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance, beginning of year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,582</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Decrease related to current year positions</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increase related to current year positions</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">608</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">562</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance, end of year</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,190</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,582</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company does not have any material accrued interest or penalties associated with unrecognized tax benefits.</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change within the next twelve months.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company files income tax returns in the United States and various states and Mexico. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by federal, state, and foreign author</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ities for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years, re</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">spectively, from the date of utilization of any net operating loss or credits.</span> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before provision for income taxes were as follows for the periods indicated (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.397%;"/> <td style="width:1.083%;"/> <td style="width:1.423%;"/> <td style="width:12.207%;"/> <td style="width:0.949%;"/> <td style="width:1.557%;"/> <td style="width:1.423%;"/> <td style="width:12.207%;"/> <td style="width:0.949%;"/> <td style="width:1.382%;"/> <td style="width:1.423%;"/> <td style="width:12.053%;"/> <td style="width:0.949%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Domestic</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128,400</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121,492</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,299</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,336</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before provision for income taxes</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,736</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121,492</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,299</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table> -128400000 -121492000 -68299000 -3336000 -131736000 -121492000 -68299000 200000 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.861%;"/> <td style="width:1.309%;"/> <td style="width:0.649%;"/> <td style="width:11.246%;"/> <td style="width:1.051%;"/> <td style="width:2.123%;"/> <td style="width:1.309%;"/> <td style="width:0.649%;"/> <td style="width:11.246%;"/> <td style="width:1.051%;"/> <td style="width:2.123%;"/> <td style="width:1.309%;"/> <td style="width:0.649%;"/> <td style="width:11.246%;"/> <td style="width:1.051%;"/> <td style="width:2.123%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal statutory income tax rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State taxes</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.8</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.8</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.3</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.5</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal and state tax credits</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-deductible permanent expenses</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effect of deferred tax adjustment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-deductible compensation</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective income tax rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred tax assets and liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p> 0.210 0.210 0.210 0.013 0.038 0.078 -0.228 -0.233 -0.285 0.012 0.010 0.009 0.081 0.012 0 -0.001 -0.002 -0.012 -0.007 -0.014 0 -0.082 -0.021 0 -0.002 0 0 <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The major components of deferred tax assets and liabilities were as follows as of the dates indicated (in thousands):</span> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:54.201%;"/> <td style="width:1.938%;"/> <td style="width:1.423%;"/> <td style="width:18.59%;"/> <td style="width:0.949%;"/> <td style="width:1.938%;"/> <td style="width:1.423%;"/> <td style="width:18.59%;"/> <td style="width:0.949%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102,094</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76,838</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax credits</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,767</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,039</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrual and reserves</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,573</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,392</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tangible and intangible assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,249</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,090</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,566</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,843</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,955</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,733</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other deferred tax asset</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">282</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">143,486</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112,935</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">141,729</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111,061</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,757</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,874</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  Right-of-use assets</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,757</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,874</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  Gross deferred tax liabilities</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,757</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,874</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table> 102094000 76838000 11767000 10039000 3573000 2392000 20249000 19090000 3566000 2843000 1955000 1733000 282000 143486000 112935000 141729000 111061000 1757000 1874000 -1757000 -1874000 1757000 1874000 30700000 28400000 23700000 409000000.0 281200000 2017 127800000 2024 2037 213700000 53200000 160500000 2022 2041 6600000 2030 5100000 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the total unrecognized tax benefits for the periods presented was as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.253%;"/> <td style="width:2.237%;"/> <td style="width:1.433%;"/> <td style="width:21.039%;"/> <td style="width:0.66%;"/> <td style="width:3.247%;"/> <td style="width:1.433%;"/> <td style="width:21.039%;"/> <td style="width:0.66%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance, beginning of year</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,582</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,020</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Decrease related to current year positions</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increase related to current year positions</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">608</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">562</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance, end of year</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,190</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,582</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 1582000 1020000 608000 562000 2190000 1582000 The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change within the next twelve months. three four five <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Net Loss per Share Attributable to Common Stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to common stockholders was as follows (in thousands, except per share amounts):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.485%;"/> <td style="width:1.247%;"/> <td style="width:1.412%;"/> <td style="width:11.165%;"/> <td style="width:0.938%;"/> <td style="width:1.247%;"/> <td style="width:1.412%;"/> <td style="width:11.165%;"/> <td style="width:0.938%;"/> <td style="width:1.247%;"/> <td style="width:1.412%;"/> <td style="width:9.392%;"/> <td style="width:0.938%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,935</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121,492</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,299</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustment to redemption value on redeemable<br/>   convertible preferred stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">362</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">134,760</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deemed dividend on settlement of accrued dividend</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,530</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gain on extinguishment of redeemable convertible preferred stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117,598</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss attributable to common stockholders, <br/>  basic and diluted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,935</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,324</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,461</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares of common stock, <br/>   basic and diluted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,589</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,358</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">858</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share attributable to common stockholders, <br/>   basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.89</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.85</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99.58</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.006%;"/> <td style="width:1.299%;"/> <td style="width:0.65%;"/> <td style="width:11.64%;"/> <td style="width:0.65%;"/> <td style="width:1.299%;"/> <td style="width:0.65%;"/> <td style="width:11.64%;"/> <td style="width:0.65%;"/> <td style="width:1.299%;"/> <td style="width:0.65%;"/> <td style="width:9.919%;"/> <td style="width:0.65%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options to purchase common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,533</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,763</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,757</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Warrant to purchase common stock</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock units</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">581</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares committed under ESPP</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Performance stock units</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock, on an as-if converted basis</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,634</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Warrants to purchase redeemable convertible preferred stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">599</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,231</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,878</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,990</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table></div> <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share attributable to common stockholders was as follows (in thousands, except per share amounts):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.485%;"/> <td style="width:1.247%;"/> <td style="width:1.412%;"/> <td style="width:11.165%;"/> <td style="width:0.938%;"/> <td style="width:1.247%;"/> <td style="width:1.412%;"/> <td style="width:11.165%;"/> <td style="width:0.938%;"/> <td style="width:1.247%;"/> <td style="width:1.412%;"/> <td style="width:9.392%;"/> <td style="width:0.938%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,935</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121,492</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,299</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustment to redemption value on redeemable<br/>   convertible preferred stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">362</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">134,760</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deemed dividend on settlement of accrued dividend</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,530</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gain on extinguishment of redeemable convertible preferred stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117,598</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss attributable to common stockholders, <br/>  basic and diluted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,935</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,324</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,461</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares of common stock, <br/>   basic and diluted</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,589</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,358</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">858</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share attributable to common stockholders, <br/>   basic and diluted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.89</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.85</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99.58</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> </table> -131935000 -121492000 -68299000 362000 134760000 42530000 117598000 -131935000 -79324000 -85461000 45589000 16358000 858000 -2.89 -4.85 -99.58 <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:59.006%;"/> <td style="width:1.299%;"/> <td style="width:0.65%;"/> <td style="width:11.64%;"/> <td style="width:0.65%;"/> <td style="width:1.299%;"/> <td style="width:0.65%;"/> <td style="width:11.64%;"/> <td style="width:0.65%;"/> <td style="width:1.299%;"/> <td style="width:0.65%;"/> <td style="width:9.919%;"/> <td style="width:0.65%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2019</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options to purchase common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,533</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,763</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,757</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Warrant to purchase common stock</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock units</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">581</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares committed under ESPP</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Performance stock units</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock, on an as-if converted basis</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,634</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Warrants to purchase redeemable convertible preferred stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">599</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,231</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,878</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,990</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table> 3533000 4763000 3757000 63000 63000 581000 37000 52000 17000 18634000 599000 4231000 4878000 22990000 185 EXCEL 80 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 81 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 82 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 83 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 209 479 1 false 76 0 false 7 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Balance Sheets Sheet http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 100040 - Statement - Balance Sheets (Parenthetical) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100050 - Statement - Statements of Operations Sheet http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations Statements of Operations Statements 4 false false R5.htm 100060 - Statement - Statements of Comprehensive Loss Sheet http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss Statements of Comprehensive Loss Statements 5 false false R6.htm 100070 - Statement - Statement of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit Statement of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements 6 false false R7.htm 100080 - Statement - Statements of Cash Flows Sheet http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 7 false false R8.htm 100090 - Disclosure - Description of Business Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusiness Description of Business Notes 8 false false R9.htm 100100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100110 - Disclosure - Revenue from Contracts with Customers Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomers Revenue from Contracts with Customers Notes 10 false false R11.htm 100120 - Disclosure - Fair Value Measurements Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 100130 - Disclosure - Balance Sheet Components Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents Balance Sheet Components Notes 12 false false R13.htm 100140 - Disclosure - Commitments and Contingencies Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 100150 - Disclosure - Term Loans Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoans1 Term Loans Notes 14 false false R15.htm 100160 - Disclosure - Stockholders' Equity Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquity1 Stockholders' Equity Notes 15 false false R16.htm 100170 - Disclosure - Equity Incentive Plan Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlan Equity Incentive Plan Notes 16 false false R17.htm 100180 - Disclosure - Income Taxes Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 17 false false R18.htm 100190 - Disclosure - Net Loss Per Share Attributable to Common Stockholders Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders Net Loss Per Share Attributable to Common Stockholders Notes 18 false false R19.htm 100220 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 19 false false R20.htm 100240 - Disclosure - Revenue from Contracts with Customers (Tables) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables Revenue from Contracts with Customers (Tables) Tables http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomers 20 false false R21.htm 100250 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements 21 false false R22.htm 100260 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents 22 false false R23.htm 100270 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies 23 false false R24.htm 100280 - Disclosure - Term Loans (Tables) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansTables Term Loans (Tables) Tables http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoans1 24 false false R25.htm 100290 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquity1 25 false false R26.htm 100300 - Disclosure - Equity Incentive Plan (Tables) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables Equity Incentive Plan (Tables) Tables http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlan 26 false false R27.htm 100310 - Disclosure - Income Taxes (Tables) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes 27 false false R28.htm 100320 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables Net Loss Per Share Attributable to Common Stockholders (Tables) Tables http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders 28 false false R29.htm 100340 - Disclosure - Description of Business - Additional Information (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail Description of Business - Additional Information (Detail) Details 29 false false R30.htm 100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 30 false false R31.htm 100360 - Disclosure - Revenue from Contracts with Customers - Summary of Revenue by Source (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueBySourceDetail Revenue from Contracts with Customers - Summary of Revenue by Source (Detail) Details 31 false false R32.htm 100370 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail Revenue from Contracts with Customers - Additional Information (Detail) Details 32 false false R33.htm 100380 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail) 1 Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail1 Revenue from Contracts with Customers - Additional Information (Detail) 1 Details 33 false false R34.htm 100390 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis by Level Within Fair Value Hierarchy (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis by Level Within Fair Value Hierarchy (Detail) Details 34 false false R35.htm 100400 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 35 false false R36.htm 100410 - Disclosure - Fair Value Measurements - Summary of Remaining Contractual Maturities (Details) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails Fair Value Measurements - Summary of Remaining Contractual Maturities (Details) Details 36 false false R37.htm 100420 - Disclosure - Balance Sheet Components - Summary of cash, cash equivalents and restricted cash (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfCashCashEquivalentsAndRestrictedCashDetail Balance Sheet Components - Summary of cash, cash equivalents and restricted cash (Detail) Details 37 false false R38.htm 100430 - Disclosure - Balance Sheet Components - Schedule of Inventories (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail Balance Sheet Components - Schedule of Inventories (Detail) Details 38 false false R39.htm 100440 - Disclosure - Balance Sheet Components - Summary of Property Plant and Equipment (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail Balance Sheet Components - Summary of Property Plant and Equipment (Detail) Details 39 false false R40.htm 100450 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail) Details 40 false false R41.htm 100460 - Disclosure - Balance Sheet Components - Accrued Warranty Liability (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedWarrantyLiabilityDetail Balance Sheet Components - Accrued Warranty Liability (Detail) Details 41 false false R42.htm 100470 - Disclosure - Balance Sheet Components - Additional Information (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail Balance Sheet Components - Additional Information (Detail) Details 42 false false R43.htm 100480 - Disclosure - Commitment and Contingencies (Additional Information) (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail Commitment and Contingencies (Additional Information) (Detail) Details 43 false false R44.htm 100490 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail Commitments and Contingencies - Schedule of Components of Lease Costs (Detail) Details 44 false false R45.htm 100500 - Disclosure - Commitments and Contingencies - Schedule of Weighted-average Remaining Lease Term and Discount Rate (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateDetail Commitments and Contingencies - Schedule of Weighted-average Remaining Lease Term and Discount Rate (Detail) Details 45 false false R46.htm 100510 - Disclosure - Commitments and Contingencies - Maturity of Operating Lease Liabilities (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail Commitments and Contingencies - Maturity of Operating Lease Liabilities (Detail) Details 46 false false R47.htm 100520 - Disclosure - Term Loans - Schedule of Term Loan (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansScheduleOfTermLoanDetail Term Loans - Schedule of Term Loan (Detail) Details 47 false false R48.htm 100530 - Disclosure - Term Loans - Additional Information (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail Term Loans - Additional Information (Detail) Details 48 false false R49.htm 100540 - Disclosure - Term Loans - Summary of Debt Maturities (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail Term Loans - Summary of Debt Maturities (Detail) Details 49 false false R50.htm 100550 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Additional Information) (Details) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Additional Information) (Details) Details 50 false false R51.htm 100560 - Disclosure - Stockholders' Equity - Summary of Reserved Shares of Common Stock on Converted Basis for Issuance (Details) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails Stockholders' Equity - Summary of Reserved Shares of Common Stock on Converted Basis for Issuance (Details) Details 51 false false R52.htm 100570 - Disclosure - Equity Incentive Plans - Additional Information (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail Equity Incentive Plans - Additional Information (Detail) Details 52 false false R53.htm 100580 - Disclosure - Equity Incentive Plan - Summary of Stock Option Activity (Details) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails Equity Incentive Plan - Summary of Stock Option Activity (Details) Details 53 false false R54.htm 100590 - Disclosure - Equity Incentive Plan - Schedule of Stock Option Valuation Assumptions (Details) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails Equity Incentive Plan - Schedule of Stock Option Valuation Assumptions (Details) Details 54 false false R55.htm 100600 - Disclosure - Equity Incentive Plan - Summary of Restricted stock activity (Details) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails Equity Incentive Plan - Summary of Restricted stock activity (Details) Details 55 false false R56.htm 100610 - Disclosure - Equity Incentive Plan - Schedule of Employees Stock Purchase Plan (ESPP) (Details) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails Equity Incentive Plan - Schedule of Employees Stock Purchase Plan (ESPP) (Details) Details 56 false false R57.htm 100620 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail) Details 57 false false R58.htm 100630 - Disclosure - Income Taxes - Loss before Provision for Income Taxes (Details) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails Income Taxes - Loss before Provision for Income Taxes (Details) Details 58 false false R59.htm 100640 - Disclosure - Income Taxes (Additional Information) (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes (Additional Information) (Detail) Details http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables 59 false false R60.htm 100650 - Disclosure - Income Taxes - Summary of Effective Tax Rate of the Provision for Income Taxes (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfTheProvisionForIncomeTaxesDetail Income Taxes - Summary of Effective Tax Rate of the Provision for Income Taxes (Detail) Details 60 false false R61.htm 100660 - Disclosure - Income Taxes - Summary of Components of the Deferred Tax Assets (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail Income Taxes - Summary of Components of the Deferred Tax Assets (Detail) Details 61 false false R62.htm 100670 - Disclosure - Income Taxes - Summary of Reconciliation of the Total Unrecognized Tax Benefits (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfTheTotalUnrecognizedTaxBenefitsDetail Income Taxes - Summary of Reconciliation of the Total Unrecognized Tax Benefits (Detail) Details 62 false false R63.htm 100680 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail Net Loss Per Share Attributable to Common Stockholders - Schedule of Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Detail) Details 63 false false R64.htm 100690 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail) Sheet http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail) Details 64 false false All Reports Book All Reports om-20211231.htm om-20211231.xsd om-20211231_cal.xml om-20211231_def.xml om-20211231_lab.xml om-20211231_pre.xml om-ex10_9.htm om-ex23_1.htm om-ex31_1.htm om-ex31_2.htm om-ex32_1.htm img263710155_0.jpg img263710155_1.jpg img263710155_2.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 86 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "om-20211231.htm": { "axisCustom": 0, "axisStandard": 31, "contextCount": 209, "dts": { "calculationLink": { "local": [ "om-20211231_cal.xml" ] }, "definitionLink": { "local": [ "om-20211231_def.xml" ] }, "inline": { "local": [ "om-20211231.htm" ] }, "labelLink": { "local": [ "om-20211231_lab.xml" ] }, "presentationLink": { "local": [ "om-20211231_pre.xml" ] }, "schema": { "local": [ "om-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 678, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 7, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 11 }, "keyCustom": 70, "keyStandard": 409, "memberCustom": 26, "memberStandard": 47, "nsprefix": "om", "nsuri": "http://www.outsetmedical.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Revenue from Contracts with Customers", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomers", "shortName": "Revenue from Contracts with Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Fair Value Measurements", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Balance Sheet Components", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Commitments and Contingencies", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Term Loans", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoans1", "shortName": "Term Loans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "om:RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Stockholders' Equity", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquity1", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "om:RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Equity Incentive Plan", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlan", "shortName": "Equity Incentive Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Income Taxes", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Net Loss Per Share Attributable to Common Stockholders", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders", "shortName": "Net Loss Per Share Attributable to Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Balance Sheets", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Revenue from Contracts with Customers (Tables)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables", "shortName": "Revenue from Contracts with Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "om:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Balance Sheet Components (Tables)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "om:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Term Loans (Tables)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansTables", "shortName": "Term Loans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "om:RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "om:SummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "om:RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "om:SummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Equity Incentive Plan (Tables)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables", "shortName": "Equity Incentive Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "om:ScheduleOfLossBeforeProvisionForIncomeTaxesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Income Taxes (Tables)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "om:ScheduleOfLossBeforeProvisionForIncomeTaxesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_e4d6147f-9ece-4a39-b39c-0582d2484743", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Description of Business - Additional Information (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail", "shortName": "Description of Business - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_e4d6147f-9ece-4a39-b39c-0582d2484743", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Balance Sheets (Parenthetical)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:AssetImpairmentCharges", "span", "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AssetImpairmentCharges", "span", "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Revenue from Contracts with Customers - Summary of Revenue by Source (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueBySourceDetail", "shortName": "Revenue from Contracts with Customers - Summary of Revenue by Source (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_f964ad4c-a283-47ef-bfb6-bdb18eeac431", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail", "shortName": "Revenue from Contracts with Customers - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-5", "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail) 1", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail1", "shortName": "Revenue from Contracts with Customers - Additional Information (Detail) 1", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_20fb9b43-dd54-4008-91f5-8c052e378de0", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_bcebc8f7-bc36-43d1-9966-346150363476", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis by Level Within Fair Value Hierarchy (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail", "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis by Level Within Fair Value Hierarchy (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_bcebc8f7-bc36-43d1-9966-346150363476", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "shortName": "Fair Value Measurements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "lang": null, "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Fair Value Measurements - Summary of Remaining Contractual Maturities (Details)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails", "shortName": "Fair Value Measurements - Summary of Remaining Contractual Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_f481fb82-fbf1-41a9-9caa-5af8ac3904f0", "decimals": "-3", "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Balance Sheet Components - Summary of cash, cash equivalents and restricted cash (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfCashCashEquivalentsAndRestrictedCashDetail", "shortName": "Balance Sheet Components - Summary of cash, cash equivalents and restricted cash (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_921204cd-9262-4299-86f0-2343874dfa39", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Balance Sheet Components - Schedule of Inventories (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail", "shortName": "Balance Sheet Components - Schedule of Inventories (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Balance Sheet Components - Summary of Property Plant and Equipment (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail", "shortName": "Balance Sheet Components - Summary of Property Plant and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Statements of Operations", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations", "shortName": "Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "om:AccruedInventoryCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail", "shortName": "Balance Sheet Components - Accrued Expenses and Other Current Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "om:AccruedInventoryCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_3718b24f-2be5-46ca-bc71-dc2733dd28ba", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrualClassifiedCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Balance Sheet Components - Accrued Warranty Liability (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedWarrantyLiabilityDetail", "shortName": "Balance Sheet Components - Accrued Warranty Liability (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_921204cd-9262-4299-86f0-2343874dfa39", "decimals": "-3", "lang": null, "name": "us-gaap:ProductWarrantyAccrualClassifiedCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Balance Sheet Components - Additional Information (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "shortName": "Balance Sheet Components - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_0d090e2b-9bb7-4eb3-9c20-6cfc12030b61", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Commitment and Contingencies (Additional Information) (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail", "shortName": "Commitment and Contingencies (Additional Information) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_0d090e2b-9bb7-4eb3-9c20-6cfc12030b61", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Costs (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail", "shortName": "Commitments and Contingencies - Schedule of Components of Lease Costs (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextblock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Commitments and Contingencies - Schedule of Weighted-average Remaining Lease Term and Discount Rate (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateDetail", "shortName": "Commitments and Contingencies - Schedule of Weighted-average Remaining Lease Term and Discount Rate (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextblock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Commitments and Contingencies - Maturity of Operating Lease Liabilities (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail", "shortName": "Commitments and Contingencies - Maturity of Operating Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Term Loans - Schedule of Term Loan (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansScheduleOfTermLoanDetail", "shortName": "Term Loans - Schedule of Term Loan (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Term Loans - Additional Information (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail", "shortName": "Term Loans - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8d8a938b-0ef3-47f9-959f-142c9b58536d", "decimals": "4", "lang": null, "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Term Loans - Summary of Debt Maturities (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail", "shortName": "Term Loans - Summary of Debt Maturities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Statements of Comprehensive Loss", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss", "shortName": "Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_3718b24f-2be5-46ca-bc71-dc2733dd28ba", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Additional Information) (Details)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "om:SummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceTableTextBlock", "div", "om:RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Stockholders' Equity - Summary of Reserved Shares of Common Stock on Converted Basis for Issuance (Details)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails", "shortName": "Stockholders' Equity - Summary of Reserved Shares of Common Stock on Converted Basis for Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "om:SummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceTableTextBlock", "div", "om:RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_a8a523a1-6fe0-4023-9803-9a54b5b28443", "decimals": "-3", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "om:SummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceTableTextBlock", "div", "om:RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Equity Incentive Plans - Additional Information (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "shortName": "Equity Incentive Plans - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_3b50cf11-21fe-4a98-b149-afcd80a65757", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_3718b24f-2be5-46ca-bc71-dc2733dd28ba", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Equity Incentive Plan - Summary of Stock Option Activity (Details)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails", "shortName": "Equity Incentive Plan - Summary of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Equity Incentive Plan - Schedule of Stock Option Valuation Assumptions (Details)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails", "shortName": "Equity Incentive Plan - Schedule of Stock Option Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_cc15bfb0-52a7-425c-a510-324e4b1cb470", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Equity Incentive Plan - Summary of Restricted stock activity (Details)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails", "shortName": "Equity Incentive Plan - Summary of Restricted stock activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_cc15bfb0-52a7-425c-a510-324e4b1cb470", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Equity Incentive Plan - Schedule of Employees Stock Purchase Plan (ESPP) (Details)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "shortName": "Equity Incentive Plan - Schedule of Employees Stock Purchase Plan (ESPP) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_289a4029-0f9a-4321-8390-1ac8cc10f035", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail", "shortName": "Equity Incentive Plans - Summary of Stock-based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_1221f230-6415-483c-bae9-d87ecfb66f70", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfLossBeforeProvisionForIncomeTaxesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Income Taxes - Loss before Provision for Income Taxes (Details)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails", "shortName": "Income Taxes - Loss before Provision for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "om:ScheduleOfLossBeforeProvisionForIncomeTaxesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Income Taxes (Additional Information) (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes (Additional Information) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-5", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_60a6d79a-130a-4b55-a993-f2bdfb557079", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Statement of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "Statement of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_60a6d79a-130a-4b55-a993-f2bdfb557079", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Income Taxes - Summary of Effective Tax Rate of the Provision for Income Taxes (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfTheProvisionForIncomeTaxesDetail", "shortName": "Income Taxes - Summary of Effective Tax Rate of the Provision for Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Income Taxes - Summary of Components of the Deferred Tax Assets (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail", "shortName": "Income Taxes - Summary of Components of the Deferred Tax Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_8e56e340-5340-41e8-a116-868a4d2fbeb3", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_3718b24f-2be5-46ca-bc71-dc2733dd28ba", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Income Taxes - Summary of Reconciliation of the Total Unrecognized Tax Benefits (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfTheTotalUnrecognizedTaxBenefitsDetail", "shortName": "Income Taxes - Summary of Reconciliation of the Total Unrecognized Tax Benefits (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_921204cd-9262-4299-86f0-2343874dfa39", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_46862a0e-1c28-4c7b-b0f5-808e0c1f374a", "decimals": "-3", "lang": null, "name": "us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail)", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Statements of Cash Flows", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Description of Business", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "om-20211231.htm", "contextRef": "C_7014c6db-34fb-4a87-b3ea-e51bebb907cc", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 76, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA", "terseLabel": "San Jose, CA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "country_MX": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MEXICO", "terseLabel": "Mexico" } } }, "localname": "MX", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r781", "r782", "r783" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r781", "r782", "r783" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r781", "r782", "r783" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r781", "r782", "r783" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r784" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r780" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current", "terseLabel": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r777" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r777" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r794" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r777" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r792" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r777" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r777" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r777" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r777" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r793" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r781", "r782", "r783" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r776" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r779" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "om_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities.", "label": "Accrued Expenses And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "om_AccruedInterestNoncurrent": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued interest, noncurrent.", "label": "Accrued Interest Noncurrent", "terseLabel": "Accrued interest, noncurrent" } } }, "localname": "AccruedInterestNoncurrent", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "om_AccruedInventoryCurrent": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 0.0, "parentTag": "om_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued inventory current.", "label": "Accrued Inventory Current", "terseLabel": "Accrued inventory" } } }, "localname": "AccruedInventoryCurrent", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "om_AccruedResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 1.0, "parentTag": "om_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development expenses.", "label": "Accrued Research And Development Expenses", "terseLabel": "Accrued research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentExpenses", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "om_AdjustmentOfRedeemableCapitalSharesToRedemptionValue": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "om_NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment of redeemable capital shares to redemption value.", "label": "Adjustment Of Redeemable Capital Shares To Redemption Value", "negatedLabel": "Adjustment to redemption value on redeemable convertible preferred stock" } } }, "localname": "AdjustmentOfRedeemableCapitalSharesToRedemptionValue", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "om_AdjustmentToRedemptionValueOnRedeemableConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustment to redemption value on redeemable convertible preferred stock.", "label": "Adjustment To Redemption Value On Redeemable Convertible Preferred Stock", "terseLabel": "Adjustment to redemption value on redeemable convertible preferred stock" } } }, "localname": "AdjustmentToRedemptionValueOnRedeemableConvertiblePreferredStock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_CapitalizedContractCostAmortizationPeriodDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capitalized contract cost amortization period description", "label": "Capitalized Contract Cost Amortization Period Description", "terseLabel": "Capitalized contract cost amortization period description" } } }, "localname": "CapitalizedContractCostAmortizationPeriodDescription", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "om_CashCashEquivalentsRestrictedCashAndShortTermInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash cash equivalents, restricted cash and short term investments.", "label": "Cash Cash Equivalents Restricted Cash And Short Term Investments", "terseLabel": "Cash, cash equivalents, restricted cash and short-term investments" } } }, "localname": "CashCashEquivalentsRestrictedCashAndShortTermInvestments", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "om_CashEquivalentsAndShortTermInvestmentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash equivalents and short-term investments policy text block", "label": "Cash Equivalents and Short-Term Investments [Policy Text Block]", "terseLabel": "Cash Equivalents and Short-Term Investments" } } }, "localname": "CashEquivalentsAndShortTermInvestmentsPolicyTextBlock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "om_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for amounts included in the measurement of operating lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities", "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_ChangeInFairValueOfRedeemableConvertiblePreferredStockWarrantLiability": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of redeemable convertible preferred stock warrant liability.", "label": "Change In Fair Value Of Redeemable Convertible Preferred Stock Warrant Liability", "negatedLabel": "Change in fair value of redeemable convertible preferred stock warrant liability", "terseLabel": "Change in fair value of redeemable convertible preferred stock warrant liability" } } }, "localname": "ChangeInFairValueOfRedeemableConvertiblePreferredStockWarrantLiability", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "om_CommonStockWarrantsExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrants expiration date.", "label": "Common Stock Warrants Expiration Date", "terseLabel": "Common stock warrants expiration date" } } }, "localname": "CommonStockWarrantsExpirationDate", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "om_ConcentrationRiskNumberOfMajorCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration Risk Number Of Major Customers", "label": "Concentration Risk Number Of Major Customers", "terseLabel": "Number of major customers" } } }, "localname": "ConcentrationRiskNumberOfMajorCustomers", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "om_ConsolesProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consoles product.", "label": "Consoles Product [Member]", "terseLabel": "Consoles Product" } } }, "localname": "ConsolesProductMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueBySourceDetail" ], "xbrltype": "domainItemType" }, "om_ConsumablesProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consumables product.", "label": "Consumables Product [Member]", "terseLabel": "Consumables Product" } } }, "localname": "ConsumablesProductMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueBySourceDetail" ], "xbrltype": "domainItemType" }, "om_ContractLiabilitiesDeferredRevenuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract liabilities deferred revenue policy text block", "label": "Contract Liabilities Deferred Revenue [Policy Text Block]", "terseLabel": "Contract Liabilities - Deferred Revenue" } } }, "localname": "ContractLiabilitiesDeferredRevenuePolicyTextBlock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "om_ConversionOfRedeemableConvertiblePreferredStockInToCommonStockUponInitialPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of redeemable convertible preferred stock into common stock upon initial public offering.", "label": "Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering", "negatedLabel": "Conversion of redeemable convertible preferred stock into common stock upon initial public offering", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock upon initial public offering" } } }, "localname": "ConversionOfRedeemableConvertiblePreferredStockInToCommonStockUponInitialPublicOffering", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_ConversionOfRedeemableConvertiblePreferredStockWarrantsToCommonStockWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of redeemable convertible preferred stock warrants to common stock warrants shares.", "label": "Conversion Of Redeemable Convertible Preferred Stock Warrants To Common Stock Warrants Shares", "terseLabel": "Number of redeemable convertible preferred stock warrants converted" } } }, "localname": "ConversionOfRedeemableConvertiblePreferredStockWarrantsToCommonStockWarrantsShares", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "om_ConversionOfRedeemableConvertiblePreferredStockWarrantsToCommonStockWarrantsValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion Of Redeemable Convertible Preferred Stock Warrants To Common Stock Warrants Value", "label": "Conversion Of Redeemable Convertible Preferred Stock Warrants To Common Stock Warrants Value", "terseLabel": "Conversion of Series A redeemable convertible preferred stock warrants to common stock warrants" } } }, "localname": "ConversionOfRedeemableConvertiblePreferredStockWarrantsToCommonStockWarrantsValue", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "om_CustomerFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer four member", "label": "Customer Four [Member]", "terseLabel": "Customer 4" } } }, "localname": "CustomerFourMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer one member", "label": "Customer One [Member]", "terseLabel": "Customer 1" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer three member", "label": "Customer Three [Member]", "terseLabel": "Customer 3" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer two member", "label": "Customer Two [Member]", "terseLabel": "Customer 2" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_DebtInstrumentInterestOnlyPaymentsYearAndMonth": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument interest only payments year and month.", "label": "Debt Instrument Interest Only Payments Year And Month", "terseLabel": "Debt instrument interest only payments end date" } } }, "localname": "DebtInstrumentInterestOnlyPaymentsYearAndMonth", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "om_DebtInstrumentPrepaymentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument prepayment fee percentage.", "label": "Debt Instrument Prepayment Fee Percentage", "terseLabel": "Debt instrument prepayment fee percentage" } } }, "localname": "DebtInstrumentPrepaymentFeePercentage", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "om_DebtInstrumentPrincipalPaymentTermAfterInterestOnlyPeriodExpires": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument principal payment term after interest only period expires.", "label": "Debt Instrument Principal Payment Term After Interest Only Period Expires", "terseLabel": "Debt instrument principal repayment period" } } }, "localname": "DebtInstrumentPrincipalPaymentTermAfterInterestOnlyPeriodExpires", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "om_DeemedDividendOnSettlementOfAccruedDividend": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail": { "order": 2.0, "parentTag": "om_NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deemed dividend on settlement of accrued dividend.", "label": "Deemed Dividend On Settlement Of Accrued Dividend", "terseLabel": "Deemed dividend on settlement of accrued dividend", "verboseLabel": "Deemed dividend on settlement of accrued dividend" } } }, "localname": "DeemedDividendOnSettlementOfAccruedDividend", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_DeferredTaxLiabilitiesRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail2": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities Right-of-use assets.", "label": "Deferred Tax Liabilities Right Of Use Assets", "terseLabel": "Right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAssets", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "om_DescriptionOfBusinessLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of business.", "label": "Description Of Business [Line Items]", "terseLabel": "Description Of Business [Line Items]" } } }, "localname": "DescriptionOfBusinessLineItems", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "om_DescriptionOfBusinessTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of business.", "label": "Description Of Business [Table]", "terseLabel": "Description Of Business [Table]" } } }, "localname": "DescriptionOfBusinessTable", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "om_EffectiveIncomeTaxRateReconciliationNonDeductiblePermanentExpense": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation nondeductible permanent expenses.", "label": "Effective Income Tax Rate Reconciliation Non deductible Permanent Expense", "terseLabel": "Non-deductible permanent expenses" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNonDeductiblePermanentExpense", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfTheProvisionForIncomeTaxesDetail" ], "xbrltype": "percentItemType" }, "om_EmployeeStockOptionExcludingMarketAndPerformanceConditionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock option excluding market and performance condition.", "label": "Employee Stock Option Excluding Market And Performance Condition [Member]" } } }, "localname": "EmployeeStockOptionExcludingMarketAndPerformanceConditionMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_EmployeesSharePurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees share purchase plan.", "label": "Employees Share Purchase Plan [Member]", "terseLabel": "Employees Share Purchase Plan (ESPP)" } } }, "localname": "EmployeesSharePurchasePlanMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_EquityIncentivePlanLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Incentive Plan [Line Items]", "label": "Equity Incentive Plan [Line Items]", "terseLabel": "Equity Incentive Plan [Line Items]" } } }, "localname": "EquityIncentivePlanLineItems", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "om_EquityIncentivePlanTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Incentive Plan [Table]", "label": "Equity Incentive Plan [Table]", "terseLabel": "Equity Incentive Plan [Table]" } } }, "localname": "EquityIncentivePlanTable", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "om_ExerciseOfWarrantsForCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exercise of warrants for common stock", "label": "Exercise of warrants for common stock", "terseLabel": "Common stock warrant exercises" } } }, "localname": "ExerciseOfWarrantsForCommonStock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "om_ExerciseOfWarrantsForCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise of warrants for common stock shares", "label": "Exercise of warrants for common stock shares", "terseLabel": "Common stock warrant exercises (shares)" } } }, "localname": "ExerciseOfWarrantsForCommonStockShares", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "om_FinanceLeaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance lease.", "label": "Finance Lease [Abstract]", "terseLabel": "Finance lease:" } } }, "localname": "FinanceLeaseAbstract", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "stringItemType" }, "om_FollowOnPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow-On Public Offering [Member]", "label": "Follow On Public Offering [Member]", "terseLabel": "Follow-on Public Offering" } } }, "localname": "FollowOnPublicOfferingMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_FourzeroonekplanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four zero one k plan [Member]", "label": "FourZeroOneKPlan [Member]", "terseLabel": "Four Zero One K Plan Member" } } }, "localname": "FourzeroonekplanMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_GainOnExtinguishmentOfRedeemableConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on extinguishment of redeemable convertible preferred stock", "label": "Gain on extinguishment of redeemable convertible preferred stock", "terseLabel": "Gain on extinguishment of redeemable convertible preferred stock" } } }, "localname": "GainOnExtinguishmentOfRedeemableConvertiblePreferredStock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "om_GainOnExtinguishmentOfRedeemableConvertiblePreferredStockBeforeCostAdjustment": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail": { "order": 3.0, "parentTag": "om_NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on extinguishment of redeemable convertible preferred stock before cost adjustment.", "label": "Gain On Extinguishment Of Redeemable Convertible Preferred Stock Before Cost Adjustment", "terseLabel": "Gain on extinguishment of redeemable convertible preferred stock" } } }, "localname": "GainOnExtinguishmentOfRedeemableConvertiblePreferredStockBeforeCostAdjustment", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_IncomeTaxExaminationOpenYearsForExamination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax examination open years for examination", "label": "Income Tax Examination Open Years For Examination", "terseLabel": "Open year examination" } } }, "localname": "IncomeTaxExaminationOpenYearsForExamination", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "om_IncreaseDecreaseInAccruedWarrantyLiability": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accrued warranty liability.", "label": "Increase Decrease In Accrued Warranty Liability", "terseLabel": "Accrued warranty liability" } } }, "localname": "IncreaseDecreaseInAccruedWarrantyLiability", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_LeaseRelatedAssetsAndLiabilitiesTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease related assets and liabilities.", "label": "Lease Related Assets And Liabilities Table TextBlock", "terseLabel": "Summary of Company ROU Assets and Lease Liabilities" } } }, "localname": "LeaseRelatedAssetsAndLiabilitiesTableTextblock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "om_LesseeOperatingLeaseCommencementMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease commencement month and year.", "label": "Lessee Operating Lease Commencement Month And Year", "terseLabel": "Operating lease commencement month and year" } } }, "localname": "LesseeOperatingLeaseCommencementMonthAndYear", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "om_LesseeOperatingLeaseExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease expiration month and year", "label": "Lessee Operating Lease Expiration Month And Year", "terseLabel": "Operating lease expiration month and year" } } }, "localname": "LesseeOperatingLeaseExpirationMonthAndYear", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "om_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year.", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "om_LongTermDebtFutureMinimumPaymentsDue": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail": { "order": 0.0, "parentTag": "us-gaap_DebtInstrumentFaceAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term debt future minimum payments due", "label": "Long term debt future minimum payments due", "terseLabel": "Total future payments", "totalLabel": "Total future payments" } } }, "localname": "LongTermDebtFutureMinimumPaymentsDue", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail" ], "xbrltype": "monetaryItemType" }, "om_LossBeforeProvisionForIncomeTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss before Provision for Income Taxes", "label": "Loss before Provision for Income Taxes", "terseLabel": "Loss before provision for income taxes" } } }, "localname": "LossBeforeProvisionForIncomeTaxes", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "om_NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net income (loss) attributable to common stockholders, basic and diluted.", "label": "Net Income Loss Attributable To Common Stockholders Basic And Diluted", "terseLabel": "Net loss attributable to common stockholders, basic and diluted", "totalLabel": "Net loss attributable to common stockholders, basic and diluted" } } }, "localname": "NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "om_NetOperatingLossCarryForwardsLatestExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss carryforwards latest expiration year.", "label": "Net Operating Loss Carry forwards Latest Expiration Year", "terseLabel": "Expiration year" } } }, "localname": "NetOperatingLossCarryForwardsLatestExpirationYear", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "om_NonCashInterestExpense": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash interest expense.", "label": "Non Cash Interest Expense", "terseLabel": "Non-cash interest expense" } } }, "localname": "NonCashInterestExpense", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_NonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash lease expense.", "label": "Non Cash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "NonCashLeaseExpense", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_NumberOfCommonStockSharesPurchasedPursuantToEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Common Stock Shares Purchased Pursuant To Employee Stock Purchase Plan", "label": "Number Of Common Stock Shares Purchased Pursuant To Employee Stock Purchase Plan", "terseLabel": "Number of Shares Purchased" } } }, "localname": "NumberOfCommonStockSharesPurchasedPursuantToEmployeeStockPurchasePlan", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "om_OfferingCostsUnderwritingDiscountsAndCommissionsExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering costs, underwriting discounts and commissions expenses.", "label": "Offering Costs Underwriting Discounts And Commissions Expenses", "terseLabel": "Offering costs, underwriting discounts and commissions expenses" } } }, "localname": "OfferingCostsUnderwritingDiscountsAndCommissionsExpenses", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "om_OperatingLeaseArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease arrangements.", "label": "Operating Lease Arrangements [Member]", "terseLabel": "Operating Lease Arrangements" } } }, "localname": "OperatingLeaseArrangementsMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_OperatingLeaseArrangementsMinimumLeasePaymentsDueYearTwo": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease Arrangements Minimum Lease Payments Due Year Two", "label": "Operating Lease Arrangements Minimum Lease Payments Due Year Two", "terseLabel": "2022", "verboseLabel": "Remaining operating lease payments recognized in 2022" } } }, "localname": "OperatingLeaseArrangementsMinimumLeasePaymentsDueYearTwo", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "om_OperatingLeasePaymentsMaturityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease Payments Maturity [Table Text Block]", "label": "Operating Lease Payments Maturity [Table Text Block]", "terseLabel": "Summary of Maturity of Operating Leases" } } }, "localname": "OperatingLeasePaymentsMaturityTableTextBlock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "om_OperatingLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases.", "label": "Operating Leases [Abstract]", "terseLabel": "Operating leases:" } } }, "localname": "OperatingLeasesAbstract", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "stringItemType" }, "om_OperatingLossCarryForwardsAmountExpired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards amount expired.", "label": "Operating Loss Carry forwards Amount Expired", "terseLabel": "Operating loss carryforward expiration beginning" } } }, "localname": "OperatingLossCarryForwardsAmountExpired", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "om_OtherDebtIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other debt issuance costs.", "label": "Other Debt Issuance Costs", "terseLabel": "Other debt issuance costs" } } }, "localname": "OtherDebtIssuanceCosts", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "om_PaymentForDebtPrepaymentAccruedInterestAndExitFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment for debt prepayment accrued interest and exit fees", "label": "Payment for debt prepayment accrued interest and exit fees", "terseLabel": "Early prepayment, accrued interest and exit fees" } } }, "localname": "PaymentForDebtPrepaymentAccruedInterestAndExitFees", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "om_PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of redeemable convertible preferred stock issuance costs.", "label": "Payment Of Redeemable Convertible Preferred Stock Issuance Costs", "negatedLabel": "Payment of redeemable convertible preferred stock issuance costs" } } }, "localname": "PaymentOfRedeemableConvertiblePreferredStockIssuanceCosts", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_PercentageOfEmployeesDeferralsRequiredToMatchHigher": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees deferrals required to match higher", "label": "Percentage Of Employees Deferrals Required To Match Higher", "terseLabel": "Percentage Of Employees Deferrals Required To Match Higher" } } }, "localname": "PercentageOfEmployeesDeferralsRequiredToMatchHigher", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "om_PercentageOfLimitationOnPledgesOfCapitalStockOfForeignSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of limitation on pledges of capital stock of foreign subsidiaries.", "label": "Percentage Of Limitation On Pledges Of Capital Stock Of Foreign Subsidiaries", "terseLabel": "Percentage of limitation on pledges of capital stock of foreign subsidiaries" } } }, "localname": "PercentageOfLimitationOnPledgesOfCapitalStockOfForeignSubsidiaries", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "om_PerceptiveTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Perceptive Term Loan [Member]", "label": "Perceptive Term Loan [Member]", "terseLabel": "Perceptive Term Loan" } } }, "localname": "PerceptiveTermLoanMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_PerformanceBasedUnitsApprovedBasedOnPerformanceRelativeToSpecifiedRevenueTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance based units approved based on performance relative to specified revenue targets.", "label": "Performance Based Units Approved Based On Performance Relative To Specified Revenue Targets", "terseLabel": "Performance based units approved based on performance relative to specified revenue targets" } } }, "localname": "PerformanceBasedUnitsApprovedBasedOnPerformanceRelativeToSpecifiedRevenueTargets", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "om_PerformanceStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Stock Units.", "label": "Performance Stock Units [Member]", "terseLabel": "Performance Stock Units" } } }, "localname": "PerformanceStockUnitsMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_PerformanceStockUnitsOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Stock Units Outstanding Member.", "label": "Performance Stock Units Outstanding [Member]", "terseLabel": "Performance Stock Units Outstanding" } } }, "localname": "PerformanceStockUnitsOutstandingMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails" ], "xbrltype": "domainItemType" }, "om_ProceedsFromIssuanceOfCashExerciseOfRedeemableConvertiblePreferredStockWarrant": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of cash exercise of redeemable convertible preferred stock warrant.", "label": "Proceeds From Issuance Of Cash Exercise Of Redeemable Convertible Preferred Stock Warrant", "terseLabel": "Proceeds from cash exercise of redeemable convertible preferred stock warrants", "verboseLabel": "Aggregate cash proceed of redeemable convertible preferred stock warrant" } } }, "localname": "ProceedsFromIssuanceOfCashExerciseOfRedeemableConvertiblePreferredStockWarrant", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from stock option exercises and employee stock purchase plan purchases.", "label": "Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases", "terseLabel": "Proceeds from stock option exercises and employee stock purchase plan purchases" } } }, "localname": "ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_ProvisionForInventories": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Provision for inventories.", "label": "Provision For Inventories", "terseLabel": "Provision for inventories" } } }, "localname": "ProvisionForInventories", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of preferred stock warrant liability to additional paid in capital.", "label": "Reclassification Of Preferred Stock Warrant Liability To Additional Paid In Capital", "terseLabel": "Reclassification of preferred stock warrant liability to additional paid in capital" } } }, "localname": "ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "om_ReclassificationOfRedeemableConvertiblePreferredStockWarrantLiabilityForConversionOfSeriesaWarrantsInToCommonStockWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of redeemable convertible preferred stock warrant liability for conversion of series A warrants into common stock warrants.", "label": "Reclassification Of Redeemable Convertible Preferred Stock Warrant Liability For Conversion Of Seriesa Warrants In to Common Stock Warrants", "negatedLabel": "Reclassification of redeemable convertible preferred stock warrant liability for conversion of Series A redeemable preferred stock warrants into common stock warrants", "terseLabel": "Reclassification of redeemable convertible preferred stock warrant liability for conversion of Series A redeemable preferred stock warrants into common stock warrants" } } }, "localname": "ReclassificationOfRedeemableConvertiblePreferredStockWarrantLiabilityForConversionOfSeriesaWarrantsInToCommonStockWarrants", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_ReclassificationOfRedeemableConvertiblePreferredStockWarrantLiabilityToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of redeemable convertible preferred stock warrant liability to additional paid in capital.", "label": "Reclassification Of Redeemable Convertible Preferred Stock Warrant Liability To Additional Paid In Capital", "negatedLabel": "Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital", "terseLabel": "Reclassification of redeemable convertible preferred stock warrant liability to additional paid-in capital" } } }, "localname": "ReclassificationOfRedeemableConvertiblePreferredStockWarrantLiabilityToAdditionalPaidInCapital", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable convertible preferred stock and stockholders equity deficit text block.", "label": "Redeemable Convertible Preferred Stock And Stockholders Equity Deficit [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "RedeemableConvertiblePreferredStockAndStockholdersEquityDeficitTextBlock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquity1" ], "xbrltype": "textBlockItemType" }, "om_RedeemableConvertiblePreferredStockWarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable convertible preferred stock warrant liability member.", "label": "Redeemable Convertible Preferred Stock Warrant Liability [Member]", "terseLabel": "Redeemable convertible preferred stock warrant liability" } } }, "localname": "RedeemableConvertiblePreferredStockWarrantLiabilityMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "om_RepaymentOfTermLoanAndExtinguishmentCosts": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment of term loan and extinguishment costs.", "label": "Repayment Of Term Loan And Extinguishment Costs", "negatedLabel": "Repayment of term loan and extinguishment costs" } } }, "localname": "RepaymentOfTermLoanAndExtinguishmentCosts", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_RestrictedStockUnitsOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units Outstanding Member.", "label": "Restricted Stock Units Outstanding [Member]", "terseLabel": "Restricted Stock Units Outstanding" } } }, "localname": "RestrictedStockUnitsOutstandingMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails" ], "xbrltype": "domainItemType" }, "om_RevenueFromConsolesOperatingLeaseArrangements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from Consoles Operating Lease Arrangements", "label": "Revenue from Consoles Operating Lease Arrangements", "terseLabel": "Revenue from operating lease arrangements" } } }, "localname": "RevenueFromConsolesOperatingLeaseArrangements", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "om_RevenuePerformanceObligation1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "revenue performance obligation 1", "label": "revenue performance obligation 1", "terseLabel": "Revenue Performance Obligation 1" } } }, "localname": "RevenuePerformanceObligation1", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "om_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities.", "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "om_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents and restricted cash.", "label": "Schedule Of Cash And Cash Equivalents And Restricted Cash [Table Text Block]", "terseLabel": "Summary of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "stringItemType" }, "om_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash, cash equivalents and restricted cash.", "label": "Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]", "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "om_ScheduleOfContractWithCustomerLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Contract With Customer Liability [Table Text Block]", "label": "Schedule Of Contract With Customer Liability [Table Text Block]", "terseLabel": "Schedule of Contract Liabilities" } } }, "localname": "ScheduleOfContractWithCustomerLiabilityTableTextBlock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "om_ScheduleOfLossBeforeProvisionForIncomeTaxesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Loss before provision for income taxes [Table Text Block]", "label": "Schedule of Loss before provision for income taxes [Table Text Block]", "terseLabel": "Summary of Loss before provision for income taxes" } } }, "localname": "ScheduleOfLossBeforeProvisionForIncomeTaxesTableTextBlock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "om_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of weighted-average remaining lease term and discount rate.", "label": "Schedule Of Weighted Average Remaining Lease Term And Discount Rate Table TextBlock", "terseLabel": "Schedule of Weighted-average Remaining Lease Term and Discount Rate" } } }, "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextblock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "om_SeriesARedeemableConvertiblePreferredStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Redeemable Convertible Preferred Stock Warrants Member.", "label": "Series A Redeemable Convertible Preferred Stock Warrants [Member]", "terseLabel": "Series A Redeemable Convertible Preferred Stock Warrants" } } }, "localname": "SeriesARedeemableConvertiblePreferredStockWarrantsMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "om_SeriesBRedeemableConvertiblePreferredStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Redeemable Convertible Preferred Stock Warrants Member.", "label": "Series B Redeemable Convertible Preferred Stock Warrants [Member]", "terseLabel": "Series B Redeemable Convertible Preferred Stock Warrants" } } }, "localname": "SeriesBRedeemableConvertiblePreferredStockWarrantsMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "om_SeriesCRedeemableConvertiblePreferredStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Redeemable Convertible Preferred Stock Warrants Member.", "label": "Series C Redeemable Convertible Preferred Stock Warrants [Member]", "terseLabel": "Series C Redeemable Convertible Preferred Stock Warrants" } } }, "localname": "SeriesCRedeemableConvertiblePreferredStockWarrantsMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "om_ServiceAndOtherRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service and other revenue.", "label": "Service And Other Revenue [Member]", "terseLabel": "Service and Other Revenue" } } }, "localname": "ServiceAndOtherRevenueMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueBySourceDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "domainItemType" }, "om_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialOfferingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award Initial Offering Date", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Initial Offering Date", "terseLabel": "ESPP Initial Offering Date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialOfferingDate", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "om_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award Offering Period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Offering Period", "terseLabel": "ESPP Offering Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "om_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Estimated Grant Date Fair Value", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Estimated Grant Date Fair Value", "terseLabel": "Estimated Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEstimatedGrantDateFairValue", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "om_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value", "terseLabel": "Stock Options, New Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "om_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award vesting period month and year.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Vesting Period Month And Year", "terseLabel": "Award vesting period, month and year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodMonthAndYear", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "om_SharesAvailableForFutureGrantUnderTwoThousandAndTwentyPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Available For Future Grant Under Two Thousand And Twenty Plan Member.", "label": "Shares Available For Future Grant Under Two Thousand And Twenty Plan [Member]", "terseLabel": "Shares Available for Future Grant Under 2020 Plan" } } }, "localname": "SharesAvailableForFutureGrantUnderTwoThousandAndTwentyPlanMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails" ], "xbrltype": "domainItemType" }, "om_SharesAvailableForFuturePurchaseUnderEsppMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares Available For Future Purchase Under ESPP Member.", "label": "Shares Available For Future Purchase Under ESPP [Member]", "terseLabel": "Shares Available for Future Purchase Under ESPP" } } }, "localname": "SharesAvailableForFuturePurchaseUnderEsppMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails" ], "xbrltype": "domainItemType" }, "om_SiliconValleyBankTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Silicon valley bank term loan.", "label": "Silicon Valley Bank Term Loan [Member]", "terseLabel": "SVB Term Loan" } } }, "localname": "SiliconValleyBankTermLoanMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_StockIssuedDuringPeriodShareRedeemableConvertiblePreferredStockWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period Share Redeemable Convertible Preferred Stock Warrants", "label": "Stock Issued During Period Share Redeemable Convertible Preferred Stock Warrants", "terseLabel": "Issuance of common stock upon net exercises of Serie B redeemable convertible preferred stock warrants (shares)" } } }, "localname": "StockIssuedDuringPeriodShareRedeemableConvertiblePreferredStockWarrants", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "om_StockIssuedDuringPeriodSharesIssuedOnExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares issued on exercise of warrants.", "label": "Stock Issued During Period Shares Issued On Exercise Of Warrants", "terseLabel": "Common stock issued on exercise of outstanding redeemable convertible preferred stock warrants" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedOnExerciseOfWarrants", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "om_StockIssuedDuringPeriodSharesStockDividend": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock dividend.", "label": "Stock Issued During Period Shares Stock Dividend", "terseLabel": "Issuance of common stock on settlement of accrued dividend (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockDividend", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "om_StockOptionsOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options Outstanding Member.", "label": "Stock Options Outstanding [Member]", "terseLabel": "Stock Options Outstanding" } } }, "localname": "StockOptionsOutstandingMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails" ], "xbrltype": "domainItemType" }, "om_StockOptionsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options to purchase common stock.", "label": "Stock Options To Purchase Common Stock [Member]", "terseLabel": "Stock Options to Purchase Common Stock" } } }, "localname": "StockOptionsToPurchaseCommonStockMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "om_SummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of reserved shares of common stock on converted basis for issuance table text block.", "label": "Summary Of Reserved Shares Of Common Stock On Converted Basis For Issuance [Table Text Block]", "terseLabel": "Summary of Reserved Shares of Common Stock on Converted Basis for Issuance" } } }, "localname": "SummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceTableTextBlock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "om_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "om_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "om_TablosUnderOperatingLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tablos under operating leases.", "label": "Tablos Under Operating Leases [Member]", "terseLabel": "Tablos Under Operating Leases" } } }, "localname": "TablosUnderOperatingLeasesMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "om_TaxCreditCarryForwardExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax credit carry forward expiration year.", "label": "Tax Credit Carry Forward Expiration Year", "terseLabel": "Tax credit carry forward expiration year" } } }, "localname": "TaxCreditCarryForwardExpirationYear", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "om_TemporaryEquityAdjustmentToRedemptionValueOnRedeemableConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity adjustment to redemption value on redeemable convertible preferred stock.", "label": "Temporary Equity Adjustment To Redemption Value On Redeemable Convertible Preferred Stock", "negatedLabel": "Temporary equity, Adjustment to redemption value on redeemable convertible preferred stock" } } }, "localname": "TemporaryEquityAdjustmentToRedemptionValueOnRedeemableConvertiblePreferredStock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "om_TemporaryEquityCashExercisesOfRedeemableConvertiblePreferredStockWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Shares", "label": "Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Shares", "terseLabel": "Temporary Equity, Cash exercises of Series C redeemable convertible preferred stock warrants (shares)" } } }, "localname": "TemporaryEquityCashExercisesOfRedeemableConvertiblePreferredStockWarrantsShares", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "om_TemporaryEquityCashExercisesOfRedeemableConvertiblePreferredStockWarrantsValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Value", "label": "Temporary Equity Cash Exercises Of Redeemable Convertible Preferred Stock Warrants Value", "terseLabel": "Temporary Equity, Cash exercises of Series C redeemable convertible preferred stock warrants" } } }, "localname": "TemporaryEquityCashExercisesOfRedeemableConvertiblePreferredStockWarrantsValue", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "om_TemporaryEquityConversionOfConvertibleRedeemablePreferredStockInToCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Temporary Equity Conversion Of Convertible Redeemable Preferred Stock In to Common Stock", "label": "Temporary Equity Conversion Of Convertible Redeemable Preferred Stock In to Common Stock", "terseLabel": "Temporary equity, Conversion of redeemable convertible preferred stock to common stock upon initial public offering" } } }, "localname": "TemporaryEquityConversionOfConvertibleRedeemablePreferredStockInToCommonStock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "om_TemporaryEquityCostsToAdjustRedemptionValueOnRedeemableConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity costs to adjust redemption value on redeemable convertible preferred stock", "label": "Temporary equity costs to adjust redemption value on redeemable convertible preferred stock", "terseLabel": "Temporary Equity, Costs to adjust the redemption value on redeemable convertible preferred stock" } } }, "localname": "TemporaryEquityCostsToAdjustRedemptionValueOnRedeemableConvertiblePreferredStock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "om_TemporaryEquityDeemedDividendOnSettlementOfAccruedDividend": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Temporary equity deemed dividend on settlement of accrued dividend.", "label": "Temporary Equity Deemed Dividend On Settlement Of Accrued Dividend", "negatedLabel": "Temporary Equity, Deemed dividend on settlement of accrued dividend" } } }, "localname": "TemporaryEquityDeemedDividendOnSettlementOfAccruedDividend", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "om_TemporaryEquityGainOnExtinguishmentOfRedeemableConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity gain on extinguishment of redeemable convertible preferred stock", "label": "Temporary equity gain on extinguishment of redeemable convertible preferred stock", "terseLabel": "Temporary Equity, Gain on extinguishment of redeemable convertible preferred stock" } } }, "localname": "TemporaryEquityGainOnExtinguishmentOfRedeemableConvertiblePreferredStock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "om_TemporaryEquitySettlementOfAccruedDividends": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Temporary equity settlement of accrued dividend.", "label": "Temporary Equity Settlement Of Accrued Dividends", "negatedLabel": "Temporary Equity, Issuance of common stock on settlement of accrued dividend" } } }, "localname": "TemporaryEquitySettlementOfAccruedDividends", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "om_TemporaryEquitySharesConversionOfConvertibleRedeemablePreferredStockInToCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity Shares Conversion Of Convertible Redeemable Preferred Stock In to Common Stock", "label": "Temporary Equity Shares Conversion Of Convertible Redeemable Preferred Stock In to Common Stock", "terseLabel": "Temporary equity, Conversion of redeemable convertible preferred stock to common stock upon initial public offering (Shares)" } } }, "localname": "TemporaryEquitySharesConversionOfConvertibleRedeemablePreferredStockInToCommonStock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "om_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period shares new issues.", "label": "Temporary Equity Stock Issued During Period Shares New Issues", "terseLabel": "Temporary Equity, Issuance of Series D and Series E redeemable convertible preferred stock, net of issuance costs (shares)" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "om_TransferOfInventoriesToPropertyAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transfer of inventories to property and equipment.", "label": "Transfer Of Inventories To Property And Equipment", "terseLabel": "Transfer of inventories to property and equipment" } } }, "localname": "TransferOfInventoriesToPropertyAndEquipment", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_TransferOfPropertyAndEquipmentToInventories": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transfer of property and equipment to inventories.", "label": "Transfer Of Property And Equipment To Inventories", "terseLabel": "Transfer of property and equipment to inventories" } } }, "localname": "TransferOfPropertyAndEquipmentToInventories", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "om_TwoThousandTwentyEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty equity incentive plan.", "label": "Two Thousand Twenty Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan" } } }, "localname": "TwoThousandTwentyEquityIncentivePlanMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_UnderwritersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriters.", "label": "Underwriters [Member]", "terseLabel": "Underwriters" } } }, "localname": "UnderwritersMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "om_WarrantsIssuedToPurchaseCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants issued to purchase common stock.", "label": "Warrants Issued To Purchase Common Stock", "terseLabel": "Warrant to purchase shares" } } }, "localname": "WarrantsIssuedToPurchaseCommonStock", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "om_WarrantsIssuedToPurchaseCommonStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants issued to purchase common stock price per share.", "label": "Warrants Issued To Purchase Common Stock Price Per Share", "terseLabel": "Exercise price" } } }, "localname": "WarrantsIssuedToPurchaseCommonStockPricePerShare", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "om_WarrantsIssuedToPurchaseCommonStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants issued to purchase common stock value.", "label": "Warrants Issued To Purchase Common Stock Value", "terseLabel": "Fair value" } } }, "localname": "WarrantsIssuedToPurchaseCommonStockValue", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "om_WarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants to purchase common stock.", "label": "Warrants To Purchase Common Stock [Member]", "terseLabel": "Warrant to Purchase Common Stock" } } }, "localname": "WarrantsToPurchaseCommonStockMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "om_WarrantsToPurchaseRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants to purchase redeemable convertible preferred stock.", "label": "Warrants To Purchase Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Warrants to Purchase Redeemable Convertible Preferred Stock" } } }, "localname": "WarrantsToPurchaseRedeemableConvertiblePreferredStockMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "om_WarrantyPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warranty period", "label": "Warranty Period", "terseLabel": "Warranty period" } } }, "localname": "WarrantyPeriod", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "om_YankeeDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yankee debt securities.", "label": "Yankee Debt Securities [Member]", "terseLabel": "Yankee debt securities" } } }, "localname": "YankeeDebtSecuritiesMember", "nsuri": "http://www.outsetmedical.com/20211231", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r203", "r379", "r385", "r725" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r298", "r340", "r457", "r463", "r648", "r649", "r650", "r651", "r652", "r653", "r672", "r722", "r726", "r773", "r774" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r298", "r340", "r457", "r463", "r648", "r649", "r650", "r651", "r652", "r653", "r672", "r722", "r726", "r773", "r774" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r203", "r379", "r385", "r725" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r200", "r379", "r383", "r675", "r721", "r723" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueBySourceDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r200", "r379", "r383", "r675", "r721", "r723" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueBySourceDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r298", "r340", "r412", "r457", "r463", "r648", "r649", "r650", "r651", "r652", "r653", "r672", "r722", "r726", "r773", "r774" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r298", "r340", "r412", "r457", "r463", "r648", "r649", "r650", "r651", "r652", "r653", "r672", "r722", "r726", "r773", "r774" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r140", "r462" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r140", "r145", "r462" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r201", "r202", "r379", "r384", "r724", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r201", "r202", "r379", "r384", "r724", "r758", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r140", "r145", "r271", "r462", "r640" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201912Member": { "auth_ref": [ "r542", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.", "label": "Accounting Standards Update 2019-12 [Member]", "terseLabel": "ASU 2019-12" } } }, "localname": "AccountingStandardsUpdate201912Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r50", "r637" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r760" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r9", "r33", "r204", "r205" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r108" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Accretion of discount on investments, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r14", "r15", "r54" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued compensation and related benefits" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedExchangeFeeRebateCurrent": { "auth_ref": [ "r14", "r15", "r54" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 3.0, "parentTag": "om_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for rebates of an exchange fee some mutual funds impose on shareholders if they exchange (transfer) to another fund within the same fund group. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Exchange Fee Rebate, Current", "terseLabel": "Accrued rebate" } } }, "localname": "AccruedExchangeFeeRebateCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r14", "r15", "r54" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 2.0, "parentTag": "om_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r48", "r262" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation and amortization", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "terseLabel": "Less: accumulated depreciation and amortization", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r36", "r74", "r75", "r76", "r709", "r734", "r738" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r73", "r76", "r83", "r84", "r85", "r129", "r130", "r131", "r561", "r729", "r730", "r799" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r34" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r129", "r130", "r131", "r505", "r506", "r507", "r575" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r133", "r134", "r135", "r136", "r145", "r213", "r214", "r234", "r235", "r236", "r237", "r239", "r240", "r283", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r542", "r543", "r544", "r545", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r593", "r594", "r596", "r597", "r598", "r599", "r600", "r601", "r634", "r676", "r677", "r678", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r795", "r796", "r797", "r798", "r799" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": { "auth_ref": [ "r334", "r346", "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.", "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock", "negatedLabel": "Adjustment to redemption value on redeemable convertible preferred stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r465", "r468", "r511", "r512" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r515" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising costs" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r468", "r498", "r510" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Cumulative stock-based compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares excluded from calculation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r222", "r413" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r107", "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment losses", "totalLabel": "Asset Impairment Charges, Total" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r122", "r183", "r192", "r198", "r230", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r559", "r562", "r592", "r635", "r637", "r681", "r705" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets", "verboseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r70", "r122", "r230", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r559", "r562", "r592", "r635", "r637" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r220" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Holding Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r221" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Holding Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r218", "r247" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Costs" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r216", "r219", "r247", "r689" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Aggregate Fair Value", "totalLabel": "Debt Securities, Available-for-sale, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r469", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r6", "r128", "r176" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Description of Business" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r112", "r113", "r114" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Capital expenditures included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortizationPeriod": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Capitalized Contract Cost, Amortization Period", "terseLabel": "Capitalized contract cost, amortization period" } } }, "localname": "CapitalizedContractCostAmortizationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r45", "r109" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfCashCashEquivalentsAndRestrictedCashDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r18", "r110", "r680" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents and short-term investments", "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r102", "r109", "r115" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfCashCashEquivalentsAndRestrictedCashDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfCashCashEquivalentsAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r102", "r109", "r115" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash as of end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash as of beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r102", "r604" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r0", "r1", "r129", "r130", "r132", "r213", "r214", "r231", "r232", "r233", "r234", "r235", "r283", "r501", "r502", "r503", "r542", "r564", "r567", "r568", "r593", "r595", "r596", "r597", "r600", "r601", "r618", "r634", "r676", "r677", "r727", "r728", "r795" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in accounting principle, accounting standards update, adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r0", "r1", "r129", "r130", "r139", "r213", "r214", "r231", "r232", "r233", "r234", "r235", "r283", "r501", "r502", "r503", "r542", "r564", "r567", "r568", "r569", "r572", "r593", "r595", "r596", "r597", "r600", "r601", "r618", "r634", "r676", "r677", "r727", "r728", "r795" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in accounting principle, accounting standards update, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r133", "r144", "r215", "r238", "r508", "r546" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r120", "r122", "r146", "r147", "r148", "r150", "r152", "r162", "r163", "r164", "r230", "r284", "r288", "r289", "r290", "r293", "r294", "r338", "r339", "r342", "r343", "r592", "r785" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r357", "r467" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r60", "r270", "r690", "r714" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r267", "r268", "r269", "r272", "r761" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Total reserved shares" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r129", "r130", "r575" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r32", "r346" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r32", "r637" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.001 par value; 300,000 shares authorized as of December 31, 2021 and December 31, 2020; 47,018 and 42,722 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r78", "r80", "r81", "r89", "r693", "r717" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computers and Software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r171", "r172", "r203", "r590", "r591", "r760" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r171", "r172", "r203", "r590", "r591", "r741", "r760" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r171", "r172", "r203", "r590", "r591", "r741", "r760" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r167", "r700" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r171", "r172", "r203", "r590", "r591" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration of risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r171", "r172", "r203", "r590", "r591", "r760" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction In Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r358", "r359", "r380" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r358", "r359", "r380" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, noncurrent" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r381" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r30", "r31", "r344", "r347", "r350" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Redeemable convertible preferred stock converted to common stock" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r413", "r453", "r739" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r93", "r675" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue", "totalLabel": "Cost of Goods and Services Sold, Total" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of revenue:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r170", "r203" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentFaceAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "negatedLabel": "Less: final payment", "terseLabel": "Less: final payment", "totalLabel": "Debt, Current, Total" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r119", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r312", "r319", "r320", "r322", "r331" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Term Loan" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoans1" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r22", "r24", "r25", "r121", "r127", "r295", "r296", "r297", "r298", "r299", "r300", "r302", "r308", "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r325", "r326", "r327", "r328", "r616", "r682", "r684", "r703" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of reference rate used for variable rate of debt instrument.", "label": "Debt Instrument, Description of Variable Rate Basis", "terseLabel": "Description of variable rate basis" } } }, "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r295", "r325", "r326", "r614", "r616", "r617" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansScheduleOfTermLoanDetail": { "order": 0.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 }, "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal of term loan", "totalLabel": "Total term loan" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansScheduleOfTermLoanDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r56", "r324", "r614", "r616" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r57", "r298", "r583" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Loan maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r59", "r121", "r127", "r295", "r296", "r297", "r298", "r299", "r300", "r302", "r308", "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r325", "r326", "r327", "r328", "r616" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r58", "r698" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument, Payment Terms", "terseLabel": "Description of payment terms" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.", "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid", "terseLabel": "Debt instrument, final payment amount" } } }, "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r59", "r121", "r127", "r295", "r296", "r297", "r298", "r299", "r300", "r302", "r308", "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r321", "r325", "r326", "r327", "r328", "r347", "r351", "r352", "r353", "r613", "r614", "r616", "r617", "r699" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r308", "r613", "r617" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansScheduleOfTermLoanDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 }, "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Unamortized debt discount", "terseLabel": "Debt discount on Perceptive Term Loan", "totalLabel": "Debt Instrument, Unamortized Discount, Total", "verboseLabel": "Less: unamortized debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansScheduleOfTermLoanDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r225", "r250", "r253" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Securities in unrealized loss position for more than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r225", "r250", "r253" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails": { "order": 0.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r224", "r248", "r253" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "terseLabel": "Available-for-sale securities in unrealized loss position", "totalLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Total" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r27", "r28", "r530", "r683", "r702" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Gross deferred tax liabilities", "totalLabel": "Gross deferred tax liabilities", "verboseLabel": "Gross deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Tangible and intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r531" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "negatedTotalLabel": "Gross deferred tax assets", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r533" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Lease liabilities", "totalLabel": "Gross deferred tax liabilites" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r533" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "negatedTotalLabel": "Net deferred tax assets", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r538", "r539" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r538", "r539" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r536", "r538", "r539" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credits", "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r538", "r539" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "terseLabel": "Stock-based compensation", "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Total" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r538", "r539" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Accrual and reserves", "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r532" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "terseLabel": "Valuation allowance", "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross [Abstract]" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfTheDeferredTaxAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy election to measure plan assets and benefit obligations as of the month-end that is closest to the fiscal year-end.", "label": "Defined Benefit Plan, Plan Assets, Accounting Policy Election, Measurement Date [Policy Text Block]", "terseLabel": "Employee Benefit Plan" } } }, "localname": "DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Contribution by employees" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer matching contribution" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r107", "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Total depreciation and amortization expense", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r107", "r181" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueBySourceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r379", "r383", "r384", "r385", "r386", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueBySourceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of Revenue by Source" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Equity Incentive Plan" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted", "totalLabel": "Earnings Per Share, Basic and Diluted, Total", "verboseLabel": "Net loss per share attributable to common stockholders, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r153", "r154" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r153", "r154", "r155", "r156" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate", "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfTheProvisionForIncomeTaxesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r124", "r521", "r550" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfTheProvisionForIncomeTaxesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r521", "r550" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Effect of deferred tax adjustment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfTheProvisionForIncomeTaxesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r521", "r550" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfTheProvisionForIncomeTaxesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r521", "r550" ], "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent", "terseLabel": "Stock based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfTheProvisionForIncomeTaxesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent", "terseLabel": "Non-deductible compensation", "totalLabel": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfTheProvisionForIncomeTaxesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r521", "r550" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfTheProvisionForIncomeTaxesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r521", "r550" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "terseLabel": "Federal and state tax credits", "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveTaxRateOfTheProvisionForIncomeTaxesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Estimated weighted average period over which unamortized share-based compensation are expected to be recognize" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r499" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r499" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unamortized stock-based compensation expense amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Shares Committed under ESPP", "verboseLabel": "Employee Stock Purchase Plan (ESPP)" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r83", "r84", "r85", "r129", "r130", "r131", "r134", "r141", "r143", "r161", "r237", "r346", "r354", "r505", "r506", "r507", "r544", "r545", "r575", "r605", "r606", "r607", "r608", "r609", "r610", "r729", "r730", "r731", "r799" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r578", "r579", "r580", "r586" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of Fair Value of Warrants" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r578", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r310", "r325", "r326", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r453", "r579", "r645", "r646", "r647" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r578", "r579", "r582", "r583", "r587" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r585" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r310", "r413", "r414", "r419", "r453", "r579", "r645" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r310", "r325", "r326", "r413", "r414", "r419", "r453", "r579", "r646" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r310", "r325", "r326", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r453", "r579", "r647" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r584", "r586" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Change in Fair Value of Redeemable Convertible Preferred Stock Warrant Liability" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r310", "r325", "r326", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r453", "r645", "r646", "r647" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r585", "r587" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r588", "r589" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r621", "r627" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Repayment of finance lease" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r630", "r633" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r629", "r633" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r222", "r223", "r226", "r227", "r228", "r241", "r243", "r244", "r245", "r246", "r249", "r251", "r252", "r253", "r321", "r345", "r566", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r785", "r786", "r787", "r788", "r789", "r790", "r791" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": { "auth_ref": [ "r557", "r742" ], "lang": { "en-us": { "role": { "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.", "label": "Financial Support to Nonconsolidated Legal Entity [Axis]" } } }, "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": { "auth_ref": [ "r557", "r742" ], "lang": { "en-us": { "role": { "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.", "label": "Financial Support to Nonconsolidated Legal Entity [Domain]" } } }, "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r107" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r107", "r329", "r330" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of term loan", "terseLabel": "Loss on extinguishment of term loan", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r94" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r464", "r466", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r92", "r122", "r183", "r191", "r194", "r197", "r199", "r230", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r592" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r258", "r265" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment for Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r123", "r549" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r87", "r183", "r191", "r194", "r197", "r199", "r679", "r691", "r695", "r719" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss on extinguishment of term loan", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r123", "r549" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesLossBeforeProvisionForIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r264", "r266" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r124", "r522", "r528", "r535", "r547", "r551", "r553", "r554", "r555" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r125", "r142", "r143", "r182", "r520", "r548", "r552", "r720" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r82", "r518", "r519", "r528", "r529", "r534", "r540" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r104", "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r106" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r106" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r106" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r106" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r106" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued payroll and related benefits", "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r106" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r106" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories", "totalLabel": "Increase (Decrease) in Inventories, Total" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r106" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r86", "r180", "r612", "r615", "r694" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "totalLabel": "Interest Expense, Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r101", "r103", "r111" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r65" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods", "totalLabel": "Inventory, Finished Goods, Gross, Total" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r8", "r68", "r637" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r16", "r69", "r117", "r157", "r254", "r255", "r256", "r673" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r67" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail": { "order": 0.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials", "totalLabel": "Inventory, Raw Materials, Gross, Total" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r66" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r229", "r718" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Short-Term Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LandSubjectToGroundLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land subject to a ground lease.", "label": "Land Subject to Ground Leases", "terseLabel": "Area of lease | ft" } } }, "localname": "LandSubjectToGroundLeases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r631", "r633" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Components of Lease Costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Operating lease existence of option to extend [true false]" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturity of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r632" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r632" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r632" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r632" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r632" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r632" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Operating lease option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letter of credit issued in lieu of a cash security deposit" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r53", "r122", "r193", "r230", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r560", "r562", "r563", "r592", "r635", "r636" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r39", "r122", "r230", "r592", "r637", "r686", "r711" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Labilities, redeemable convertible preferred stock and stockholders' equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r55", "r122", "r230", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r560", "r562", "r563", "r592", "r635", "r636", "r637" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:", "verboseLabel": "Current:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r25", "r309", "r323", "r325", "r326", "r684", "r706" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total term loan, net of debt discount" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r127", "r282", "r314" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail": { "order": 0.0, "parentTag": "om_LongTermDebtFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r127", "r282", "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r127", "r282", "r314" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail": { "order": 3.0, "parentTag": "om_LongTermDebtFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r127", "r282", "r314" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail": { "order": 2.0, "parentTag": "om_LongTermDebtFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r127", "r282", "r314" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail": { "order": 1.0, "parentTag": "om_LongTermDebtFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansScheduleOfTermLoanDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Term loan, noncurrent", "totalLabel": "Total term loan, noncurrent" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansScheduleOfTermLoanDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and Equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r102" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r102" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r102", "r105", "r108" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r77", "r79", "r85", "r88", "r108", "r122", "r133", "r137", "r138", "r139", "r140", "r142", "r143", "r149", "r183", "r191", "r194", "r197", "r199", "r230", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r577", "r592", "r692", "r716" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail": { "order": 0.0, "parentTag": "om_NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted", "weight": 1.0 }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 0.0, "parentTag": "om_NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Interest income and other income, net", "totalLabel": "Nonoperating Income (Expense), Total" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "verboseLabel": "Number Of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r183", "r191", "r194", "r197", "r199" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r624", "r633" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r620" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Present value of operating lease liabilities", "verboseLabel": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r620" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail2": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r620" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail2": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, noncurrent", "totalLabel": "Operating Lease Liability Noncurrent, Total" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r619" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r630", "r633" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r629", "r633" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfWeightedaverageRemainingLeaseTermAndDiscountRateDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r536" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforward", "totalLabel": "Operating Loss Carryforwards, Total" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r72", "r74" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gain (loss) on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r54", "r637" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail": { "order": 4.0, "parentTag": "om_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other", "totalLabel": "Other Liabilities, Current, Total" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": { "auth_ref": [ "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings", "terseLabel": "Other-than-temporary impairment losses related to investments" } } }, "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r98" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investment securities", "totalLabel": "Payments to Acquire Investments, Total" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r97" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Stock Units" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r469", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r31", "r338" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r31", "r338" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r31", "r637" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Preferred stock, $0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of December 31, 2021 and December 31, 2020", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r10", "r43", "r44" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r99" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "verboseLabel": "Aggregate net proceeds from IPO" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r99" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock upon follow-on public offering, net of issuance costs", "verboseLabel": "Proceeds from issuance of common stock upon initial and follow-on public offering, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r100" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from issuance of term loan, net of issuance costs", "totalLabel": "Proceeds from Issuance of Long-term Debt, Total" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": { "auth_ref": [ "r99" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.", "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r96" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Sales and maturities of investment securities", "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r99" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of common stock warrant" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product Revenue" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueBySourceDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ProductWarrantiesDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product Warranties Disclosures [Abstract]" } } }, "localname": "ProductWarrantiesDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "auth_ref": [ "r54", "r273", "r275" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Product Warranty Accrual, Current", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period", "terseLabel": "Accrued warranty liability" } } }, "localname": "ProductWarrantyAccrualClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedWarrantyLiabilityDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "negatedLabel": "Consumption", "totalLabel": "Standard and Extended Product Warranty Accrual, Decrease for Payments, Total" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedWarrantyLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Additions charged to cost of product revenue", "totalLabel": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued, Total" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAccruedWarrantyLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r48", "r263" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r47", "r261" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Total property and equipment", "totalLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r19", "r20", "r263", "r637", "r697", "r712" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r46", "r263", "r762", "r763" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r19", "r263" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r19", "r261" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives of the assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r91", "r242" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for accounts receivable" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "auth_ref": [ "r26", "r685", "r707" ], "lang": { "en-us": { "role": { "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.", "label": "Purchase Commitment, Excluding Long-term Commitment [Axis]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "auth_ref": [ "r26", "r685", "r707" ], "lang": { "en-us": { "role": { "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.", "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentMember": { "auth_ref": [ "r26", "r685", "r707" ], "lang": { "en-us": { "role": { "documentation": "Purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. Excludes long-term commitments.", "label": "Purchase Commitment [Member]", "terseLabel": "Purchase Commitments" } } }, "localname": "PurchaseCommitmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r26", "r685", "r707" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Non-cancellable purchase commitments within next 12 months", "verboseLabel": "Open purchase commitments" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Selected Quarterly Information" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureSelectedQuarterlyInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": { "auth_ref": [ "r335", "r565" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.", "label": "Reclassifications of Temporary to Permanent Equity", "terseLabel": "Reclassification of redeemable convertible preferred stock warrant liability to equity" } } }, "localname": "ReclassificationsOfTemporaryToPermanentEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Redeemable Convertible Preferred Stock", "verboseLabel": "Redeemable Convertible Preferred Stock, on an as-if Converted Basis" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RegistrationPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Registration Payment Arrangement [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "RegistrationPaymentArrangementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RegistrationPaymentArrangementTable": { "auth_ref": [ "r602", "r603" ], "lang": { "en-us": { "role": { "documentation": "Discloses information about each registration payment arrangement or each group of similar arrangements.", "label": "Registration Payment Arrangement [Table]" } } }, "localname": "RegistrationPaymentArrangementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r516", "r674", "r775" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r115", "r680", "r708" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash balance", "totalLabel": "Restricted Cash, Total", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfCashCashEquivalentsAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r12", "r21", "r115", "r759" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSU", "verboseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r35", "r354", "r508", "r637", "r710", "r733", "r738" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r129", "r130", "r131", "r134", "r141", "r143", "r237", "r505", "r506", "r507", "r544", "r545", "r575", "r729", "r731" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r178", "r179", "r190", "r195", "r196", "r200", "r201", "r203", "r378", "r379", "r675" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersSummaryOfRevenueBySourceDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r118", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r390" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r369", "r382", "r390" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contracts with Customers" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail1" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail1" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail1" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail1" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail1" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r628", "r633" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r171", "r203" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Outstanding Potentially Dilutive Shares were Excluded from Calculation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Summary of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r540" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Summary of Effective Tax Rate of the Provision for Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Term Loan" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Summary of Components of the Deferred Tax Assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r468", "r497", "r510" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r578", "r579" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Assets Measured at Fair Value On Recurring Basis by Level Within Fair Value Hierarchy" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Separate Account Investment [Line Items]" } } }, "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable": { "auth_ref": [ "r701", "r739", "r740" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about fair value of asset supporting separate account.", "label": "Fair Value, Separate Account Investment [Table]" } } }, "localname": "ScheduleOfFairValueOfSeparateAccountsByMajorCategoryOfInvestmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r16", "r40", "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Summary of Debt Maturities" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Accrued Warranty Liability" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r48", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of Unaudited Quarterly Financial Information" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureSelectedQuarterlyInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r469", "r500" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted stock activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r475", "r486", "r489" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "verboseLabel": "Summary of the Stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Summary of Estimated Fair Value of Stock Option Grants" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r61", "r120", "r162", "r163", "r332", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r347", "r348", "r349", "r351", "r352", "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r527", "r541" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Summary of Reconciliation of the Total Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r184", "r185", "r186", "r187", "r188", "r189", "r201" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing", "totalLabel": "Selling and Marketing Expense, Total" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and Marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r106" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Service-based options vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "General vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r467", "r470" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Description", "terseLabel": "Stock options, description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited", "terseLabel": "Stock Units, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Stock Units, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Stock Units, Outstanding as of December 31, 2020", "periodStartLabel": "Stock Units, Outstanding as of December 31, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested", "terseLabel": "Stock Units, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Total Fair Value of Options Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date", "terseLabel": "ESPP Expiration Date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Eligible Compensation Percentage to Purchase Common Stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares granted of stock options with performance and market-based conditions to employees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Exercisable as of December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighed-Average Exercise Price, Exercisable as of December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Forfeited and expired", "terseLabel": "Forfeited and expired", "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Forfeited and Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value of Options granted to Employees", "verboseLabel": "Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r500" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Balance as of December 31, 2021", "periodStartLabel": "Aggregate Intrinsic Value, Balance as of December 31, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r477", "r500" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding Options, Balance as of December 31, 2021", "periodStartLabel": "Outstanding Options, Balance as of December 31, 2020", "terseLabel": "Outstanding Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Balance as of December 31, 2021", "periodStartLabel": "Weighted-Average Exercise Price, Balance as of December 31, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Percentage Of Maximum Number of Common Stock Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Number of common stock issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r467", "r473" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfRestrictedStockActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "First Anniversary" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r469", "r474" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation Expense" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r466", "r496" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-based Payment Arrangement, Employee [Member]" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting rate" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Contractual Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r492", "r509" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfEmployeesStockPurchasePlanEsppDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r500" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable as of December 31, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable as of December 31, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance", "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance", "terseLabel": "Stock options, nonvested, number of shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Percentage of fair market value of common stock" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (shares)", "periodStartLabel": "Beginning Balance (shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r23", "r687", "r688", "r704" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments", "totalLabel": "Short-term Investments, Total" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r754", "r755", "r756", "r757" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfRemainingContractualMaturitiesDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r625", "r633" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease costs" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r116", "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "This element provides a description of the nature of the event that could occur within twelve months of the reporting date that would cause a significant increase or decrease in the related unrecognized tax benefit.", "label": "Significant Change in Unrecognized Tax Benefits, Nature of Event", "terseLabel": "Change in Unrecognized Tax Benefits" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsNatureOfEvent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantPurchaseCommitmentDescription": { "auth_ref": [ "r60", "r690", "r713" ], "lang": { "en-us": { "role": { "documentation": "Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.", "label": "Purchase Commitment, Description", "terseLabel": "Purchase commitment descriptions" } } }, "localname": "SignificantPurchaseCommitmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Accrued Warranty Liability" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r274", "r280", "r558", "r742" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letters of Credit" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r30", "r31", "r32", "r120", "r122", "r146", "r147", "r148", "r150", "r152", "r162", "r163", "r164", "r230", "r284", "r288", "r289", "r290", "r293", "r294", "r338", "r339", "r342", "r343", "r346", "r592", "r785" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r64", "r83", "r84", "r85", "r129", "r130", "r131", "r134", "r141", "r143", "r161", "r237", "r346", "r354", "r505", "r506", "r507", "r544", "r545", "r575", "r605", "r606", "r607", "r608", "r609", "r610", "r729", "r730", "r731", "r799" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r129", "r130", "r131", "r161", "r675" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r112", "r113", "r114" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of common stock on settlement of accrued dividend" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r63", "r313", "r346", "r347", "r354" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r31", "r32", "r346", "r354" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock through employee stock purchase plan (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r31", "r32", "r346", "r354" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock upon initial public offering, net of issuance costs (shares)", "verboseLabel": "Stock issued during the period" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r346", "r354" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Issuance of common stock for settlement of RSUs (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r31", "r32", "r346", "r354", "r479" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised", "terseLabel": "Stock option exercises (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r64", "r346", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r31", "r32", "r346", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock through employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r31", "r32", "r346", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock upon initial public offering, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r31", "r32", "r346", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Issuance of common stock for settlement of RSUs" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "auth_ref": [ "r64", "r346", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued to shareholders as a dividend during the period.", "label": "Stock Issued During Period, Value, Stock Dividend", "terseLabel": "Issuance of common stock on settlement of accrued dividend" } } }, "localname": "StockIssuedDuringPeriodValueStockDividend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r64", "r346", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r32", "r37", "r38", "r122", "r211", "r230", "r592", "r637" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stock split conversion ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse stock split, description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r611", "r639" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r611", "r639" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r611", "r639" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r638", "r641" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables", "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesWereExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlanTables" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental cash flow disclosures:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r536" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward, amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "auth_ref": [], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail": { "order": 1.0, "parentTag": "om_NetIncomeLossAttributableToCommonStockholdersBasicAndDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.", "label": "Temporary Equity, Accretion to Redemption Value, Adjustment", "negatedLabel": "Adjustment to redemption value on redeemable convertible preferred stock" } } }, "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r284", "r288", "r289", "r290", "r293", "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Temporary Equity, Ending Balance", "periodStartLabel": "Temporary Equity, Beginning Balance", "terseLabel": "Redeemable convertible preferred stock, $0.001 par value; no shares authorized and no shares issued and outstanding as of December 31, 2020; 154,592 shares authorized and 147,214 shares issued and outstanding as of December 31, 2019" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r17", "r333" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Redeemable convertible preferred stock, par value" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Redeemable convertible preferred stock, shares authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Redeemable convertible preferred stock, shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Temporary Equity, Ending Balance (shares)", "periodStartLabel": "Temporary Equity, Beginning Balance (shares)", "terseLabel": "Redeemable convertible preferred stock, shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementBalanceSheetsParenthetical", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "terseLabel": "Temporary Equity, Issuance of Series D and Series E redeemable convertible preferred stock, net of issuance costs" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TenantImprovements": { "auth_ref": [ "r715" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.", "label": "Tenant Improvements", "terseLabel": "Tenant improvement allowance" } } }, "localname": "TenantImprovements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r206", "r207", "r208", "r209", "r210", "r212" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable, Net" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r222", "r223", "r226", "r227", "r228", "r321", "r345", "r566", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r785", "r786", "r787", "r788", "r789", "r790", "r791" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockOnConvertedBasisForIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r133", "r134", "r135", "r136", "r145", "r213", "r214", "r234", "r235", "r236", "r237", "r239", "r240", "r283", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r542", "r543", "r544", "r545", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r593", "r594", "r596", "r597", "r598", "r599", "r600", "r601", "r634", "r676", "r677", "r678", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r795", "r796", "r797", "r798", "r799" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r126", "r413", "r453", "r696" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r49" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentFaceAmount", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "negatedLabel": "Less: amount representing interest", "terseLabel": "Less: amount representing interest" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansSummaryOfDebtMaturitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r517", "r525" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance, end of year", "periodStartLabel": "Balance, beginning of year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfTheTotalUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r526" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increase related to current year positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfTheTotalUnrecognizedTaxBenefitsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r165", "r166", "r168", "r169", "r173", "r174", "r175" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use Of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r533" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r626", "r633" ], "calculation": { "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseCostsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/DisclosureTermLoansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted", "verboseLabel": "Weighted-average shares of common stock, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.outsetmedical.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareDetail", "http://www.outsetmedical.com/20211231/taxonomy/role/StatementStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=d3e1280-108306" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL124452896-108306" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131251-203054" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123377177&loc=d3e11281-110244" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12524-110249" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 3.C)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177168-122764" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(u)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r513": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r555": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99383193&loc=d3e16207-108621" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99383193&loc=d3e16242-108621" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r641": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504833&loc=d3e7104-158389" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124505678&loc=SL117422397-158474" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r776": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r777": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r778": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r779": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r780": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r781": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r782": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r783": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r784": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r785": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r786": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r787": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r788": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r789": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r790": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r791": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r792": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r793": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r794": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" } }, "version": "2.1" } ZIP 87 0000950170-22-001769-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-001769-xbrl.zip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

J MQ3._-FE@GW#I[-% QKXF&K.M-#/=+)E=?@_V'OOH*B>8'_TD$0006!1\J(@ M45!R9D$E"TO.24#)&11)"R*@2,Z2%B5GR1D4A$4EYYQSSBRPX2W?[_W=5^^_ M=ZONJUNO?K_:F@WG]/3,].GI[L_9.3W;/PLP?_G>-;#!Z@4O1EJOSU_0FPN[ MH^//X>.B>F_$K+ M0N]M[$44!;)?:5K;1<^[9Z*D&T)F;>\GD*8]L M6H-P-;/!3,@" LXUUUG7VJUO?)J.^]''\M^XGC/\_'L15#RA9YU*W-( M2DJ>[4\,=7QXV]DV;!]^M9:\.X:3'N2\]_GF4QA5 U4^G7-XTB53CJ)G8,_D MLIL8JAA:*\W=-EUZO3']?JK,M OZ^$([@I7&MIB<7W.2^JS$.!B3(,Y:SEIC MQ] MDBZB+F%9F>-T_%[19%0ZG.NS<9++!:EI])6MO6VUZ=%%O&GURNGQO3

$WEV^?O^>DNQQ.[1M3>/RPF@]1+&01K\69KT'H MJS?%?G?K/G-L9/9):237Y()EC_)R8:_U"]B;T>(<-((IT'Q;EE[HOQ/L10XE MQ1;@EYB[@GT2*,-#"5*2-[6B$I^G^"RBL< 0Y+ D#\P=+4^36PJ?5]V!#U6M M+%;L&B.L7_%V;RPE,VKJ*)&N3+@@J^Q)( \_2?DSH!Q*:7ZSXAU:4'D;4Q&W M@=$^R=^_P N0T;\/I3O3XQ]IE*RJ)G41F^7G+T-A]SHP"0C]F&K9:L4>UA[' M[S^6ZV_U7^E^+41)5XP(2WX>E@S]\KE^CC]^K"@ZU,=UVW4=

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

M*PMU M(-'\FXTK4JN15=W4Q@"%,)@#U]L7#!^K?N9LHW=B_VFDG_YB]L8@*'ZDVUF" MN^'C'S]2@5R%LKJ%!2]5V(Z;B!5F5LOLU=K&YTR?=B0D\NS"D6;I.TDOF=ZE M)0OL?>Y4 MB?1U9P1(=@WJ$[/?\<:O\A'-UT[*OX,VAQ+:O?QQK80 C' +/H$CE3JNLOI? MM-^J<"J9W"LP3#:H?%M%=6E2BV6?1WW/S2:Z;6M_D+A1^ZR?2>1 A;>??*OW M#+VOR@$S]/"!?XI5*6:37\9*>GSS@YCM6Z2=A0F:EFHQIO-.P/XYDLXGIZD_ M.&B;#P<>ZH3%D.:ZTQ:%/8-!C=WW1 M[>BX,RDL>E&6A=:0UG4NP[;JF5Z3M9ZM_PNJ(_DG+S!5QCKA00A9D[4^.WV' MJR7%7Y30^-\?-Y'6.ZYU=#SKBTXMZ&9@K M88/^ )TL'ZBU,X?[KS8*D@R*VA AW:0\;@M5+EO-VAW<4ODWUI.*7DZR M9U_M!B'#C.GE8V]D@X:/N8_D#.,:[['-QZHG<\8.D_A#7&FJ,*0K&@(B!*+. M<5 ?W,=TS[O$R5Z%)T?=&'1]<-N\8[H:T\Z6H*H23N?&+*MBW/X1:=^3B:RN MD\,A[4X@ ']>'\)*I+7GUE7MGQLWF&=9'B?-(8Y"7:[&<_'@4G+[2EM+EJ^1 M+#/=C!F+%=(_Q=J_0FFR\#FOTG/ M:6<.O()%#7'.2OC@1/I1U"E)'E]'V.H9G=0JFIQ:YJY*JG1N/&^44%T7P![^ MM:8'+9QS65<;RVZI)_'P-SPC,6&,(;+\FI9'DZ-24Z/_\]?IZ MR),;!9-7_U9[K*SNG/UU<(Q)B\>'N0D+N9KHK@;#QUW,&AUK8B6W,[3U<#'G M]5R/_9- I>:FT["XZL6%<>$H\"^TR ,EPE 6VQ[S.X8F2T]"Z=+2:W5^.M" MT2A]=&^4^#C_B_^+O/>.:JI[NT4WH(*H1 04$ A-:8)2I8E%0*KT M@$@+O??>N_0B1:2#]%"D2R^"TB&0Y(3W_97OC/.-<_ZXW[CWG'O^6(/LE8SL ML/?:SYK/7'/-1^IF4H8O42UR4]B ,9'/%?GDB_&J1F(?/YI$TY*)3A2S'G7GCN%=R=D#&N7K8"?OY5^[RE26TD!PNH!/.H! +\C%D\+ M%*K0HZ]W,U1YVY14J"M>+Q2TU4V.<@MI8V%X9KBQ(:S$'S5Q-62[?6&+.0D[^MXE,^? M<4)MYT7W O>B5D6ZZ'D7R=]0>)Z?QA3S_N%+X@BW\B?\1OF M9QH-E"H<-7@ 5@)4B J7VS$_ M,YT]Q2DVQRO:?EFXES55#SO*;?A259N:Y]TJQ?-7R\ZZPVP]0%E,#<7B8EWY M9!!YD5H!] ;_.)Q%+,L8'F_-J<8."&L]+24:'&.RDH% Y\I09D[FX.871465 M#[+VZ"M2YG(L(S6L4U76GJ MH:S##$)#RRJ>6EVJ 6JYC/#?$/.6XB;G+4YF37$K"A"F!*(HH6\*5>BL0/)0 MD#SP-H^T-N[N37XUM8A:H+%$>["V%/G'^D1&V,?T;MLDE[86E4&R=$=?](J( M(+P5/A10KR^- ?S*]37&/72*]Z6E>,H5X!)L$@15TBQK:L:^CZ78G_R%HJVM MWEP0>4/S$.UKU)#+H N-!(<+UZ*\-R>\- 5B$X4C9Z##+!!5FP B%K7,5G) MW!M4&:1D##[?F69S?FEME?F;W464V>B\L-(7>08 M("/T:G>KEER*QE=[>/;%O3(]EBTSHTTCJ><+8'E:LILY<-:^_Z>JI_MATX]6 M1"@M3RCJGMQC5 M8ZGGM*0WA0,]/V[QV!D5)BY^4A)7M/ZTH*N,D8+?6" MQAJ_=P-"F7$(KEE4QK\ZC([]@Q\Y00:8&!!\^S9CZ:K]\BV4_CZ+N8BC&][% MU*R;1P_?8YRO6Q3B9$92_4TPQ:"+J8WWK#3K]-50=[$;T1I$WVB!J_#7-"[D M1R0'RNC6&^/F\3UT7!GE%%?W7G(A>Y%P*/0#3GOKB"P&^)V+)O4YNHS& $M& M*&M7*5+]6T>CW;U%'?GTM#AVHKFD3?E].55$%/2#/S MZ<)<.=HEI;[Z#Q@&X%1PV=*,CV@D=.005'/&S#1(%,9D88!JI]X"MJ;9W3,S M"-Q?9_8DKJ'^(]=]X7CZ]*;R=R;9/7P?VRHUUT?USG6; MM=]-O?;@\A$H8JPQ"T_.X%7M-^XR.2XT?QC2!3-^+2AP55RU-7&GZ"PVO+.A MU7F:I.QY[;TKT[2 WN492+Y<.\O=OI*=H;#2"$B!:#ISS:-G2HX3K[FW!)W? M1":LF!G9%5[@J1ELJ26M](R2<8[7M8A&NA3.2$?%UF\8NX/G/7XTA?;-UM J M^9HA+$Z*):LM\#$ P7&UZ?W"'9;RGX]HWS)4[# S1$<@&".RN Z0" Q@SO@^ M_$*]ADB6QA6+ML'(!H:MC4Q40 GMA5GB'X]C/&O89FIF3DK_Y'.[9V;$G3G6 MVJT_RE!GK:+IADT%> SASF4=Q:/*5"0-S(-&U/5TSUF$PD\^/O^X%ZI5N)E4MJ-E\(6V_W>'MJ[!@/ MWRWVF]X@&[%)UU8P=9PRI&ZI?S8(<^6><"S57/J%>NW<[H0^:4[9PF-P=H%( MDZ):_DBI:3WB%HA]6PH;Z;) [;Y%L89/I98*9IZ?P,J;*B8&G_H3'T/2A>XD M9SAQA!=7Q_.=!D&.A[JUT-^G]WKH/B[A53V/G,[W@,5'CZ*L"CB$S&/%O[N7 M5#1_U$U;W=VH= M7<"UXSWF#3>FR@@D.6-2;,[!:>&'V=^.Q$A3B=9BI,U*V!&G#V]$5>(+7-D:^5 MQXVFLFWOR6$ J-4,503C#P,+FE=&^4PS'-J,T*['#0-ULV!0&@8HSZ?$D<>!(]!KGFS-34?)1S.61R;)V3".01;[ )3'\:,2:;%(!,1FO%S7?Y&6 M#<&A=X$GSB<#R3\7E*E=X/(Y<@>__*G'[68WHJ0AU,4V>HL!?SNCKM*^7#=4 M_?0M8YE.=!,AJ *&HUN3W49T*+J-4CZD\9^-T(.?=_+[P?@."Q5BEAW/1N?F?_R-FF@ M3-G'>B08LKK#_$E%V5@W?-LS]>TAKW[Y+#5@K*8#WV]EYT'J\7,8#G!!(&S?!GB#(UR7@O>'(EI$U=DK8+#<$ A<7X MNP;1Z].^[JK;VXN-I4?I6E='0X,GR*GH^<0J7,=)MI.B%0J/:.1DC,$$%M2S M.UN@Y%%LZ9\Q@ Y;#F1'F^I >S0B=]_O?H3#9=SF>'X+1-#ABG@E^0,Z7PY\ MV.TQ4:DD@8/J^RJ 1,0I>L'&U>_(6KNVCA$_/BMNA1YW#AR:7)!Z-5^ M^#A4>)RB-/_/-.1DHM5JRCSAQ;0D.L6X=I?"SH;Z(YRYF/Q:1ZRN8VHRE2X% M.&C?3Q4J#%XEKJ(Z[E5%JEOH=]<6,2TA"<>F5^:\RF=?C:R L+>BJ/>RBQGT M3(@(O1@OF^!,2=8[RW-\8SU7""2P#8T?=K-3J=$74V8BNN7A"AEO%E1VR,KY MW]QP^?_MMM;V-,U+9%*DRP0#T+-[S7M,CRV1*HG2[!AN0%#D=4!%-8$%WL[$_^+AC)?DT$_U7"$D1Z4D#H,7KSTYYZI7Q%_%M0.5V$ M".MM5I/Q+ _ KS@P8\$J,"DP!0LS:.H$-?]2P"^4,!4+J=-$DA'Q68P1;2JR*WJ5%?4V]F1EM^^R MDI$Z_-[WWJ6,W0HO[BVEB2YS"!Z3R D#A C7>.NZRD\J>AHQP/WJO._ZOMPZ M*6GY2QXK7JKHBN=GX:XOG>R9+%<1TX]7O"[>8U,46+R^*+U%U=#$-=,LF++D MC&)SPGUTV;NK6 A9LB_G2[KYA/W)=25*WW\ZRI#'J?YM47XMI/]+8G\O\C8& MZ%O/@4T?0Y#DE65L:QC@-JQO\]\=K*DI$S/8B_%]]/_KL?._:J8M71A@/Z6; MFLWV(KPM/K@5?SR%7F+*=NPB$N4:B0&DV:VTS):,+NVO;6:*DF6GR ;A^=Y%-;/?Z=6!0A=Q[7 IR>=/#*8=ID!*Y=MWS7^BYIFD/4G\$=% M:Y@+1D>P6(6Y%]#A/\VX24NZ(\'>._0I%Y6 UG3LJ+&R@\V@I4M^A$\=@HI0 MK$/!W;6LL%EPN<)+/Y;G :YSGWV,L\P.I<U()N6% ?P4 XC6*2DP'>&6L%D4 M\@^]M?YH(_7)D6H2+(T<9&+Z M2E)^/%*-$OUCM\S"7W@[NCU@Y H87W_$RNE 2\7?VYC_^+(1$F!K;S@F@,4[ MX_8BY4O7=9D%)./Z<25'&Y;O"4MQHL\.R\6&/?2B3^C3*)4O-O"O")-TAO7< M]8H@R;STLQ OM-&J]IW/PK_ 6MC[I>XU\2,'G/Z0.GAJ(FW9YVF!CL09'FI, MC /%&/D'C/)X'QZYZ.B3IOHV>!'J(C!B[($F+8XA E1GG O?:5+@91H6^#I, M)?4PXRJV-JWDS^2&O:&ITUP[7%_8)>CG+KD'V+O=A.;Q LGU.G5YO0X\UDTKXLO_!DL7-JP#"" M"$*8SU[Z:L;9;:0Q_W.9@=RJ?6NW<"]55MA'D(ENJK[WU+WSB02Y1R71QR4; MQM2B,66=+\KZ([A\W## @EWC:0G)5@-.@\2OP@I&H7;HN$*]81Z:5W"'8@>G MW,2@]TU5S B,\E-CM4(:Z"3DZ>-#7B6+NH7+&8XLR-XKV:MNYQPD]Z3,IM*E M/D,.6@-5:[BE7[0&&6VPTT,8SL>T#^?P(=]Z[[G?6NT7-7,M<*/R&K/# .Y. M5SM$]0F)W,O. M$?2D/O&(9U5=,!?;!V#-,$)8I@/=[$L?/!Y/2].( M/R:?/KF>7*G M1_H.4?HM096#>Z6,VNQA&S5-T4H3*A?H"X M[XOWMR""WOOGM?%A@.Y58^35;5](=EY#R%#$A?+P/N>I%&VMGZ==XR=_Z+^ M8C1315\4A:[8=E5(%/[(,7;(X(M&L4F*GYN5&6[EJC1\^6R:0$??O5&/UGBA M'O"5G\%_%YKY2)BZS-J'-52U^G/*SI2-$4L**8=JXH<;1.Y]'16_?W:7G6;0 M-+^\79=Q9$+.]'&' M&_'Q$W8\(_6=*Q_]6?([*06%_/9\$MMM0CI$FQ1=%Q<&L/WH6-;FL%(C*7Z$ M[PW1L@I49/)9UB%25H9NU-*ZV$*/NCBZL^R/]6XR/#96/^+' -Z!/G 6]).F MA+VL/ZC4ZODE_TW9UK<-8._6$##K9:;U?$,#?':1S>T^(R?M*]4Q,7+_MDR#SYJ>]Q)#N XH#+R$Z+=.WD^Z!U)SSWFEX"%$_97;)L:V\;7 M%_?6J:4]^$'@?L7&_E2(<) QN:_GGF'$@!4'R4#R[ ^DW#08"DB$]>*X(Q'L MS))A/G$-TD)ZWS[//S)#T^VJ*I0H"YL+4!"#^R.U_/A&CD^0][%T2 MTZ9T>UL^ALQ'4!U/9BA7(,H>B2[^A>*6Y6MZHU4-&R?-UC%.S5B*D39?K*MQQ4>=WB'Q6S-RT IROQ 3*6[J97UA](EW\3*SB$*M]*XN?YJ4$O M_[Z **X60$J.P^_A7M?EP7N0$*4VBK>5Y9S'2+3B1\'%SD;>8Q"Y$NY([!- M<:7XU R]$MGC%RHG5Z^^(,71NX_%6EFX.:"-@:H>V8M '?7O;]N.2)1#-$W% MT97&)4Z$B>D\?#R#,+>,T8'44W,L"@5,ALU61I],7TXHK]1@@ MY.86Y.C/=7T+Z$:D8)<\;/.ZA/RVL"%D1>8#!C"2O';_(VAH%L;^!7;KL\+\ M6=? Y=XD1L)N+A_< D==OOO#D33!-\X(_ROTP]B&-U175M#D4^B_L4G3A%G6QMM*;4^PR>'2 MXHPS&(2R8 #9*%@52LH6&V>L$LX>3C^SJ,^@'1![3H*3%FF-2+#\J6+F$D:# MXTK(?3[N&?Z./\/J=E% US,?W16(#-E3IPG\+2L 3R$%5P"-=T[()RN8:[(M MY2O/+:XU(@$AY!2[,QM%R3W,+05P6([P).&>B1LU)BNH]I5WE.83#6!?D-=AXS^IODFK.B+;$[WJB=R98, M?34 QWC@O5B/MW5)XQL*:?'L[$9BLT>);[)(^O<=-)23\_.8ZV47/N,.LG&J MAWD%75G7=0Y^<#ZZ&.\J\U&EF)7=&U$1^8*8.AT?M%DO$G!_2BCBF =":"H4 M0Q<58SX&C<*3=C1JJ4DK[;GLW)^&T6BF/M_70%Y^J/"37R9U>2]&-YV+RP^) M=\BT/;*GCZ#7;<#K?2,XK9S?S2!Y]AA'$W)? W+5]=ZRK'5HHR8B.>?_WHS M?X%*,5 MO^<$:U1?"/Q+O0GG[2@3(;>KNZ %:4T>W2H2VO\!Y9+8:^U@Y;C MU2N;5QD B"Y%\[1"PN%'4[]2_,+S#64C"]B7+6_@,Y) M?-,_LDM-5>P6@M:,%#O;2_'T/H1-,JVQ(.+NVD>#KHZ@JC>,YB%G8UB$[L+\ M-(JT3L@RH2L>%/-3>5BV8]@FTT!TZ/'[NDB&Z:?-BAHK?9Y]D.@R=6WJ8..< MCPX3(ML:P1=]Y#M6Z2#23-.7:KY#]4]$1!15GY)A@&#BW_)6]8&G*JZ1/\46 M-]M_&@R'Y/&&MS@NRFT:O1A,>VO,?UD">3WEFE@ G;4.%WR57>#"$)$$7C60 MH3@I,BLGLNEB0+&+?IIP[EK(W]%WOJ-F4W9O&:E^'#<<792I@K]E3;->'KQB M6RWF0/B+?^=$- MY8=N%XDBE],@S\P]H5\88*03&X+VR3_N^*3;P!&W%O14:!*Y8(+C0E&G=,%> MB,U=.1!45_3$4MRU$V4\+0U#E#NEP) =!DQ7U4;R^57/O'L?[N K/V$Y2Q82 M$"YS1UDUT*8Z;Y8Q<^\JM0JY^O\@N2;3BNYS,'SM'1;" -6L"A]O-1%-^,TF M%^-RY(Z ^7>/26LP0)\=3:NG&B7O<7N[L]#%Q]I=;@6&[U]ZS[JMIOX[S>9U MT (;-7#I,0Y.,?4C:4#'9>2-CB+D]T%*-E498$$*AN&7+!3(:4H<73AQX/;H M5>/>2<&G?MLGEWQ5=]*S%6QIG2G(*[IH; *:A1GN?L0WF#^X*JVI25*V(GV?RY3V0 Y^&@E]J,P69><3OLU_DL*) MG!Z1KOO;4N)A!IN&:2_].!CZSRI\?Q7%8[\N-IX41/CWJNKK>$'$;?5R M.KB'!DB]JHC&E\[Z;6&=M%6PY'6!/7Z-?A7"Y'MX3$6+&8)_T6FY_Z;35.44 M_O[&)^Q_JTG_*K57&Z/F72#0_[YI0D_^'@#-C8%QAMZ\\YW+8(5-\ M'HU;.OUV>4@HJ#U:?-Y5)E,<@78#^^4SF3ET&V3X_1S4J=V570YQ#0!,!+YB M ,CP%[=49VOOTI":6!LBFUST1,2((E?[,WXI]$&%EC.]K;:6O[R_T]5APWP8 MC?(YX=&0]*E>L>'&COCN%JD'X1=/[GFY)PL(?_Y!SF6<;4.+%1B)\,1C&_4P MV&K;YN*GU%N_C"9;I&SM.NY^XQ7]87).]+')?KP/SA?IH8*'H[>1F@\DEJX-+C;^ M-KB0(HWSO?[OY?_!SQG_NX1@;9SOM0LUGLDWHT.!+=@_#"T(+R2_0?Y]O(/\ M/\?@@KAM&ZE%7MZI8_'1.YSG54#98%LN^DOOW\86',>KX).#1W]Q<@K996SQ M!Q^N GA@R)UK7XLREPKU;@QP2#PV@N(%(RD1(G"A6]@+*"\X_G+)OAROJ(2B MS]J^IE/P5\9';*SJ*EF1EA\J]'K9@I/+K0^^+[D'B]>DBC;\2GE,)"U"98>5.+ MYW2IL&LQ7&THN\H)K6,R@W""%>,5YBN1$D7>B 'P&)%J,4H$^"D% MM'W&.FGW.<_AS@>]E-P"COBE*;BK:ZPQN/-45 AKVPX&ZY/EO3*](*VXU??Z M?^Z0J,WN$1&1+I]M1%4XLQKC??3?AG_GZ*,ZB,0 FE(DN/C]]U>K M"14R3XPZOPKCP$W89>A+[$SJ].+S7Q*#5NP[Y KHZ E.3WIY'L9>KJG@=6UY MW :A:B _%38VT;I]L&7>V^P+-IY9'-#K\F0U$-.=\N(74JT:@I M1E"?Y@RO$%M".&U;H'EL .%RC,=$S8TQ]X*O:.)SQ#V'(PLODZ.G,:;\(]:Y M;,NK//>2D4O!>\ZYPA,*EZ$:1T]IUS[*##2>+&=B!X(C]'F7P@B985_*R\"* MIW4RG8LCSO3A,L47RJ*=3\NV$]F*4!6NK]PX[!BCV"J6-:A#TTY^BE_9:.I MOT9]>\@?2V<2+E&" I8UB_/*;64-?M2].[Q_H\TH15DVA.TB#3Q>^PK\G'UD MO&F/U<);?LG3].&V@8'BOIH,]PJUBS#OC<0/]=KVQ@"[$RZ^QN9YH*-H8V^K MB9Z7]*A=KE8C_/!F-"R"=ME_CE7Q0S6]PN->>GR9F[HZIB]$Q&GB>W8SB9P] M!P6(8FT>9KH^6M.1GDD[Z612[G(ZV3;0L0BR3VAVW6^F0*C7+1M-"%MD*];_ M..'1OE='Z6)Y5FD2 XS8U=71:;"Y;$JNW39ZHR5 3#(:J=0RG1_2?_%F4UJ[OO[WEI-:]Y&H M;BG-U&KT;S\D'/]A]"4N/Q+QR6LW>C&9GMC>UX.S\L8^[?L'-YRIJ@:)NE(" M%A1P8D1&G-2 ;T]NBAET 4J>&M+T^PR&*(&L5SGSWP/\<;;P)24'&/S[&T.2 MB-(P (.VJ@;P0JR'/]]-,["7PK!W/.F7E,E[,W8*C@XQNAFG$9,=6)?F-[) M55&[UN2?)X:0U!=G&, CR3GOB"]HMX5EK8W?M53Q5P@38JK78E% M3XJ-I!H5U5")6!Q$IS2=AK1_*Y M3\QO&3J18#7:8]-?%B+9>PS> M5KY\9[&?U[O]6.7A*UU- 05\IJU<)(+]R3>AES\H5",$HF5XWRU$<;%O,J"6 MT*W<4^'95+3@$4JUES MB,%CC\@7IDYJJ7V^.W*G%%G/DH-/A]8'TGC\*58I*+98O05T;?<_AHGB,S6 MTW43+!D7DC(S+N^]5+IH&Q5[8I0EVKH=;2N' 2:[K>'=B,^#-"@E&&5:D>B.C8.2C(@,= #QTX'QI6O+HGAZ:>9)B>Q\T.Y,QB>\7>UR"[F?2S3+ M3H'2EP.P9IER/N8MW9PHJG%$ JGJZP2-0+[H.<)614"[/3VK-CKVEAHG^8G) MJ(];WD3YS8A,^W><20@[AB\N3 >,*>]8S[B\"\R8?J =(45B1_RG);6+T%:VSUC7YR)2@?9N2Q=R<'R#*FR*+ M>[ +_6A]9JDU3I)*0'[??7F@$Q'9+ 1R^AK].E9L?*->]^3QB7K)TOVCZ)&$ MW/TND3@JS[2,D_I;-P&UT84.-BQRDWW[GVW@T0>'XU\IFD".OVN[ZS_'OGYM M OFE@L_%8G63@R7X?7X>35Q.$A'I3T4*GI]P,:%K4H]?!:]7_GU!!.*G&%$A MH64A(=!4"#Z^INQ*F@P@: @]=H0WEP#2*CL:QR61UKADZKWY>EG8U-X35UD< M'E [,4?6IN&A+@^2!S850XN7";W;=FT^\5/1!-:GB"J397Z@^:$RBF?:$+'! ME'(W"'\S\Y9:$SX#6;X)ZYQA:<,\A UDHF8]]59O^#69""R?+MYY,$#W M]0-8:2*0*3DS-?^9'55S$!KOIP MH$%3Y)XX+:.#&(61@]BGN-_):2%1+F1L=R=>_-BRQ(E^NCI=SL8Q]74C M3H'T+E1&D^;7+=:'4\X=@F)V*T?@ (K=\TGF 3TZOH3U(J3Z4M+IY6CP(_K4 MY_,,BUDYC>1,N^JT13+JZOF<)(76G^,-!.'5<8$ZAO&"QT4/"J" -[]S =QM M6XQ0<"* A\CJFQ]A+V[IB4?\C$E1D6:B\.>K+8I4QU2[?)I&2+YBP;UI ?3* MA#V!S;AX'XO:MBEM=(3[*GQ3X2QPZ#(P5%.W%YJ>-_+*NI*-$QM&+(XJ_'%S MPD1TWC;C72#X8R'.H)XRZ6KBCQIX>W*EI?=$9+.\:XI/5BH^K]3T,<,6>-UD M&G$-@D5/2"\?B:XZR(OTD9)'>606YQ'XGTM9BNWM0()]G-V+4:OGA"J/+G/2 M."/B@!$1SUN0@%M:(@Q,!X4;'RV):;:QCR X)!_U$[U5:)[@%S;'] %OB\6K M7L24Y]D-+5 W!8&F&:Z[+R8L/J#C2"1 MJ)]BCRWF'F3U1+]$>3>@/[(^[&X=^W9N$TG\H^$MZ^9193;;)@8@ M!!:?5*N/#D#*O7&4'O_%XQ7]5_!X.'Q'4['V!1!6%U)@*'.3K/]\5R9(M[:Z M+@DWPX:*;.1/M(&WR:Y)JM'9R&$A==<(B_]75S5H5[=QOQ3CKU/DJ!?>.R+5 M..^7H%V#UAP,D-VYM&:TKK9'5HQ_+:43>H[\TD^RS>./G CZ9#^!,BQU;=]? MD#,8[I!)8";N A'M1F. TFG[Z6UG##"5CHI<,;ULHVV[,L>_@.\)5VV+A7FD MX$F&7H)"I_?//VZAY,';"NOGD_B#95]@K7=ED-H6ZW#A-F:\L".O]R#*3[;H MDQ)*T875..R0.PT_J<&_X'7UT61*W+>\1\1OC>93*BYLGQH*0@\I46* , WJ M69^,1?1K?^3TVW4'N34XL#;=U<8J/AS^9DF9Y]HW77OEQ8M%<#5$SA1\R>YB MJ$FC"3B&KPP9M$^=VST_OS<(TRQ1VSV[40/[)N+TF*: [3,W!HB8?F=R6D#N MM\-2,)KR^FAMVJ+^ UNV0=0F$Q>=P,F.0"FQ6T>,BNFHRWW\Q_&YYC2-FV3S M%P(BW'NJK7'L9]D2WE.E&0;=OU80W M]JCFX@$_6'53$/W/H>'+21?"HKC3&IY#:QDX$=Y1& M,W7'^FT>%*=6+YMF)4CM-1E_3GXA_(KSX2N/F-R,.W*//\(>L.Z<5W;^%>-_205 M-??%%2E?B)QF1M^92/.>."^"C)="?&LW1@;:PR2BAG^:A00-LH)S\=2(9*A0 M;,-+/QH'5YC3,U".&1Y+)<+$IS;1"] MUQ6*LAK\*6),DL3KN28Z'8GF"2C>!CS! Q%!*4>5O^S)I-"5!@C8'R;(<&2- MVSCD2\42%U\6GA-KX_6(CS7<$* UC?QDX U] MBS[]>=6-XV3/DUQ6M6)P.Y)R*'+U!7@XCW(_8H'75A@#S W P@'+C7A%% M)*5;A288P(\%S7,RR7/HHWTD)-[9&HK M#VV7?^K3]%0_^$GN%0;&Q[<:TG>E2V!=*#5_(*/81?G=)@KG9\UQJ:!+?3;/ MLQ!00L5ZP]#A'X>Y<"@$7#Y M2AU@B7>AT2HOX.U2X\,YH[GP""W6T+Y'?E?29#4%0QM.R,$2E]<;Q=2$ [J5&[PVQKJ\/<+Q#+5LLPF[::X7),AQ M)8AC;O&+RJ-"@RAR8E07VCPO1U$RM7;U/#'L8%1]7YJWKUJ0TNSB^X$I!B"_ M:\[:(7[ZL@@P$F4WJ#!H<'8'P-(9+W^GIH4*$0R:MZL#&K; M>THK.V!G*%K0M'DSRZ2? 3_6E[-W5<^0(I8OMA?U@PMR'X(\47[+/C3 G).7 M]5\PS_S_I>'YG[+R+"R6]VMSKO>D@TA/_BH(QX78'<^23_=0(R_(\D@Z+C+T MI;.K[52V?EM 5UNKIH(7()]N3:>6#[QFB;!:S>?N#_+8L6, M8_D/ ]QK\=]?BL!_$Y?_T@OF_:T/Q(7_W8&CJ9O$&E9#A?/;,+]03\;,BJS% M9#U<8A,147C47PGY2;XR1?, -\G[?NLWKA MUZ_5?Q;WT+@M SR,"<8*)#'*3E#*R;FEG?$O]7MY8J(QL%:MOE=<&*#,OOS5DC.*51G697//*I+M/!"?OI.A?4 MD"-ED"CII/=0+SJ,=P;NB>&!: MV(["ZPX9M=Z(NH\MULW)&*"@% -DL=MK@135U3% Q?41X35+&2!!<]![QG#G M8FW2?[Q8ES]Z_\FO$;]C/#*'8?Y2+G(E178F#Z@$(?0F.V="&61* ;UA[L&6WN1;O!H$&N= [H*1;3Q#?O10^$ M0>7:-_S]^E3[BWG?17A=2)%4_HG5HE=[JRT9&R%3SMF;%H1W0'V/\=DV^:H? M I91^T#(XVV0=-] 1JN4!D+GJC1#$%'SO<+_]N6H]#=O)\TZF5GQD3\I-X9M MU)LL ]=YE48THOIPK.WR-PSZU[JX9!9%@BZ.BVM1Y,!M]4SUJ8+OJ>E2M:G? MTDZ+P:*V4B:F V+:#A&M('"XZ>[M"LNIAD@A3C+>UIRS-C@.E#]-XML>VUH(@76I?Q ?V;V M'H-\X_VE>0[#-Y>OY;8(AJ=$&Y>=#&'+H( &Z,(\=+C0P_:X*TG1NGY'[R"0 O <9P)^@*#\] MX+$J^9K!,/9@<5]4,_Y08*NSQE'$;:-EL#N#J^9/_.1PR,]P^JD1+O? M6QW MO+6K3E=I;R+^/GA>;! MSKZAZ/Z+D=(4U;I#QENHI6YNO;;0/IR5I MPSOOQ64('T4Z7$2P3;^S?X-XE_VEWG9TX LVO^ \R6]2,*!87WSP;LO51."[ M9&;7M#@3?:+:>.XX[XOZO@=3[PV(IE0$+SDE R54H'=>F?!*_ MO6A*WCL-KV._:I@-FXYMM-IGM#"^]9)STP_%UOSGN5]%WB3M-&^H:R!!L*1FK$G%A$$LB7:ZU6[92L/\6Y8,V-])") M7R GCA_A)WLL6TE+>]20XGSO$E68BV?TP/,1G7I2OTC:Y!?;G+DAGQ\E<[BE M1;\V*K[AU(6](?LZ! 1VNE"UR5L\H(L"+;3FXYL<\Y,QA=8 MBX>4:RQ]YHW]8RILZ77&+9W,A3W0C1)-*F4,I;:4 0EF'ABWEH[R'S(/O MJ*'\(?#7SCODGIKF]0TZ6K*K6BG[X*9FX;>A>Y9:PLWZFLY0U/'[[A<(/FO9$:[%.FTB17S*O6X6;8 ZL_W]^0 M^-%>CG40&[?UXL'#W"(ZFN<-I+T-64A]W"I,Y)O;TV=TS!=QE[@_,"&0L09W MWW^_^#XQ@"(B7SVDTD[7YBZDHO(IZFKLJPG_+@6 CEMK3.'#.>,342+W]'_EQ)A>*MXE MX$EMCD->=EC^L(I(4#8,]',\LW QM*B)MOF/+'G?2;?@)N[I&&K&)WY;JI@M MFXM+=,19-BQ*6E2,ZY;<55.QZ/CFXS?1D0A"A0+'@V;4Y(]=KU:$K%OFR]#<#UM%!(2?HEAVC0E=7IV !532.K M-MZ=,)4[#I\?-&@_[';KBZ(Z"-R-[ (/ETL3C36N!]V8M*FS_/Z!5>_,@@C? M603&T1Z@HV_*_ZZ4J&G%+T@'PC-SQIB';'_[%R.VS[8IQ9+4LP M"M\0QDIY\\AK\L*(G!'V:"H^A(L6;QX1=S-07?W[S89X!@C'K15:JGTTE.$\+J,DC]_%&88\,DX9' MJ3:B-0!?"T=G:/]GVV;8@@Z*NH^9)MD:*YAZ,,#!V;6RO19G *["\H^] M(B]HL.B/!>'[_F\Z\_VV,F[2/7X5O.Z_V,Z;NV2B7HY$?I]MBH[+J.GI>!P+ MWKMUG)4G&22[?NZLO.7+^$_.YA.1=?C.U:#VB$>QR_ ]0(59@0H/6I6KOSWT M&*^% \(1SQO>HDC@V&0]"G^B)HOK*SRA?W"S/D!0W.%Q2\5+6\/.Q? [O0\_ M3(AFGEII#ZMI/Q/]LZ;ULCL4QM15OR_Z*PKO?&V:V,+I23K"J6?&]$UGRDG1 M\K82/%'K/:)+B9=RRU,J,33F<$I/SI;"/(AY9VC(T:,2;E=[61#ZB]8I_ID; M?4[&[U^S0P6YY#12R,"W6\I&Z]#FBNB'I0_VG^B XGW+XEE58QRAW-H"_;R/ MBGV]S(I%A^HY[V_>\76'I$,S]:;HJO2R$I;X1,7RHC-[HGFZJR9>O538<'=\ M!'#(43D?YUC4Q[[6#1L.KK:7E4C_CK.L54&:JE\UVBUO?37.M7Y@6/^#<.PI MP7M+187I_W[(V(X^BU$B_%1U9 MZQ.IQ0/Y'B<70;Y]39O0T/ >N36'",?)^Q>R#$7'%3$C'1ZUR_N:(3H?-BH[ MEO7[#H8\7A;<87U.2Y-N(Q.2>X]#,E<+FN>,%/G9,F%K81*S/3)5WM?+7Y*B MZ#M1GC!DL& BS'VR4:[0.>TGY-1F$*GU^%N6TJ39/;I8AH:K(UYF*Z&GH@5)0?FO!56 '/61 58I7:%& ML+AL'6W6C9F9#\5#SF%?=]7+=9&%G,8-O7O]Y_EMJ"R==+[[GL9KK6]8FJK+\ MY=_AD\_,LKD#. @![+?-V#$#KW@[:A+K$KDC?SGFM[ A) M!]PUBT:"L\''")C@EM=[A_Q&#%!8",XJ>TP%)IX+@PVJZF7P,5SRMN[GH37O M&"]NK5[1YK>HF^;>N&@?G6[3_N3&"#Y7> ?W0]=,STQ_F0CL$/D&9RZA_:_: M!L3&H+=K@P$,0(?E3J-8L.16CX7%F:,3$2N>Y'R%*"+P&?YAL?5C$W0HZ-+_ M0J.N.*E6S3QL%'P$AH3ZQX"L/DDH2+%=5Z7D)HB<)IU%;RR% M&<"-"AO'AH8O5A+C8RDW !QQW(AC<[\ ;.) "&Q+CPJI$0JIX-1ZJ-:J;<)? MC^+4JKTCK:T%EIYYJ*Y'RKN0 IWD(D6'J.*+8K-]H'#500$MVC94[E']&)15^0=A9^ M\^@ H_ZPR>3?\N6*B+=>L#6&_,%1K0\R5;[RD,( 7E/# MMR'7MBY!:=2 <, MD/@*)26]2#DAAP$B52]2MMZ+,,\RXR7;$VX7H@WFT,@",(%5$%KWQ57[M^;T MG*BB+"+1W8Y9QQ_SU3T?"/0C\,^4ZYP]..(?QMLXW, C-,7?7TTS06J4]"^0XJK M6P'1@NC'("$3IG%?@7N*9TM]3DMD8U:[-9V;#?LST^RN+K&\(_:52'Y9,S?J!]64U(.J[Y)I)N--[(XD M#TO9B+N*8D"#]NA! X^K@<'M"9%2O*YH$GN+%WCKSTE@6Y*0\Q/]#XQ?@WX; MIS-!32U RE%'T ?ZGS$ M&X\\X1%?S((B:B(P@#%JGM:]72Q0[&4IK!!,K3S M;FZ\\AD)\D#. 9W/CP$2V*ZV&OMOIUD8NUQ9RS.VJ6_TCAR *L75] _*)<1' M&,BH?R.WFE?=T!)YC8R[*FMG0(8W"V>NML**3?M9M[66>2*Z^0AU@+)1JDK8 MJ+K>61<=\,_4TRF#@=S2>ZP)23QQ5!'1A $>$+$?\@MU7/FAXW#B/M4^".]V M&\;=%+DH?W[WY>_*1S] 1V5%U<:;ERU.OOSED+MO]!=P4)-H\])L$:6$_\S& M_/_F=M0>UDM#U$#3$()-D5O=V#W;>_PC;T,C];##=Y2RA?Y:)4?H5L#^+UI) M_7[MM65=;5PMH"I%2J"J1#JF1/KU??'#7#+ZT1M]UF;;*NRO:P-9>.\@"K(] M@. )1?X)1RWKS MGQM;L2=1P1V3^P^2/-+_<.J_3K_=0M78W!)+%1R/@_S,= S=E=06^$G@.U'Y M=-_\U55\Y$GYU;0PFL'MW0?1A]48( 0V2P4K,Y89==#-)+%OZ_^YM8*/*_?R MQ:EJYB9\EV<05KV=,/I!ML>G=7=(]/FP:R?!%BW3T3L-=MW<,1K!9,:J'25% M^9N\4J)?B/NZ>'DSY2"+18H*5N/*9T5O@LVP#\T2- 2]C=3 GJKB]S% ](0D!JC<@AUS&FE/#XB" ML#W3_^[1TGS)6_A958HL.>L?5^)_VZ;%V+Z;AYU!,8#@7)GN>6,L:E61F*XN MV96K\U]B-\%E[+7;JX4A*:_IHZ0*[1Y]_6V+<654DK866]1!7NFFGK0,ZQW" MD'?J,[_F?K^<"EB#PUE>CWJ?(2:ZWB'5A;^ST[=96?E5:KGQB+1+@*"K*=$E# MM[\TT+QV&7I,1JT@N9O<%M4K^OGKL]?0V$RN35N^8E/X' M^H(N6E3"U.0+KD-F"/;!P=$.Z7]:[5):R7':?>N%^;US'+^K7>T"5P$[XF)].F4.=10 M/63KIRG,*M.[F/U !)="+ VB@]=4_X2 Z.#]S30O"OK+89D%01'LQ>DDX.= M(CTFX LRN F\L[Z$=;@;XK^XQ1B520VA;S[LZF8P10[]65]9A3!#RFVBNBSP MMFP@6C1VH1Z-'<1ID5.Q[%1@W]M<2B!5RM4=&H,\%7+WJ^Z MH?IY"1A%H)49Z*=\G\^-R1\Y6O^JIJ7,5EOIU1""]1'3INK$KAZ_:-!A07,I MBS:>S5VJLYQ. 3T=K]V^T8C;&\T)EC_#TV=8I9N,W7!D>(/R>QO46&58HB\T MP/],4W$>D \#RP ^H)UP1?YGJ,+_0R7YPOK[-\%" M17=Q%-?>>,NL&S2$VG$P?K91T'1E/X.'96:=%<0O!+F0SU]$0AL2M0]&#"XW M<$*$ 2*]_\;>>T8UV77MHJ$C*HB TH."5%%ZAX!([[V#THLTZ2!507KH37IO M 4%"1Y#>:^B]2.^=0,()/F_=9X_O^_.=L=\SQOZQ1G(OPLC*?:\UYW7-=\F99L@+2_!@299.Q_I^PK@GYV 2\W=4\.'EX^(K-S82GL'#DN[)24 2!$ M@%5=Z)]LWO81&O_J+;6DRP;5CR2'Z'D<6U>ZT5^1[57TY3@7MTW-+6+Z%Y7QC.ESE M(028[MH*;5U@T6G:L^>5V[:OPO<^J9 *T"6B/8C1 [*3*-[;E5I-.;8%K91E M(/+/=0<3G0JZ8IZXF##> OP9 4@=N!9T7B]O('?B&*/Z+:,CS-2X+MKVM\*: M/C.D%]$# ,B#&H4)"L^+0R,0:W+#Y07S6S.0^KFM"^4Y20]LGC5OL34?[F'6 MV4KPMY1,HNOV5,]4V*8?I0FQMM;]6T#UW(R':Z*O>?0@YBQO'%4W&8;(E]/3 M,D&Y2Y6<-B+O2B3R9,"7^S-'IPZ8[@?C7'OJ2;1!)RYAN.>8[#QGJL .7$;0*R>MCI[/N/ 2L=!I]/ )I770G78;C/QP< M_.N7P!MRY*66A:'HA2T84)[E!U$DE(0![+M..K*JL8UI?;+=Q3GK]F(*<[0) MO'8 SY0W% 6 <+Q0Z?&NEW.448^.+D^+'@4;7"0NA_20V#$1TDZU4_OLJ8=[ M)%.H$PW*##DP;]98QL4Y4%!%HK8$RKU:3=^#X6GHD+/]:CV*RG2F3BYZ M'B5':L_&AMNT MOJY1YUF#>HU1 LS4X1?:MK^CAWI+ MYWWRTTNC?L5" :=;*?VPO$!R$N6C"7*2JH_VK M*^_3]5*PO!SHS:(.99LZ>UX[0-V[T:[;?9)K_D,G1!L>@KO=-44]WYVC\3-% MX=F+<#3'PFX[:>2.[)R/'+BWP0AK:\O6;H_\O8D*.8$H2W=_2:U:E9LGN:J! MSOC4M!2ES6, K2& 2GNB,G]\)@G@HS[K7IW/QG?EVPX#]^Y16IR23 :T2A$H M6!T(]Q$6H5VUU+:9KK< M'0I;DVT6V4[UNK$)GF>A$:4$AH)([7(0;AK>:-OIO"=YC?M<#1VV0:VKE/[R M5[XAH]:DB?;(7 0(H1[Z0IE8/Q^'S*P'Z?RE6V!!4B24991.Q;+_XP #X@)) MPL6S0M]MSD\UE5)LAG%@6'$+<"8X+)@E33=^LF+!M]E^"_#+) EK\"XN963- MO>;O"6D>7SN]!5C<@.#CEL]7Z^"Q\@F8*1R1?"(WX#PL+L'?&#C " J_):== M9ES_<%RSOAH+4,?910E&)"/FQ8U%L2(UN)6$/JN _@_M?+ MW' MAV9C2/,ZS@,!\J[AGR<(%CL_V@7U3]M2M6LJZUV3+B"N))SOF=@>/=M* MPZI7.94UOY66\&'F?L]?S>> (C0S//3C 1839=1GNK_=&,92 #7Y/.]HAR=" MJ<=C\U-QR"X@;^WBT+Z5;GHJEO;QY-E21CR:*9WW+[- $C;1(99,/SK/Q#XG(W(?H2663!"=JWSOYG" MI8UVK\V.Q8Y'OK^9""Q5_J8N(D^VZ5K88;X5+,_Q9O@MK;,P4+!9MSG_@5ZE M0'NM7?!TZ8:W"].3S/#]C820=]F6OY*4GH8]TQ7C3+ M#O!H1-JKCYH$:M3\=!KE+E7+DRY]TR8HN;K>AR^\ VEB/2>P1!1HV)QG M)O!2"ULB:/>G]/GSFO!%UO 9K;JT?'$N-0]#Y>,:8&JUS W+M]J _=>/>TJE MW![/9LT^M[_N;1(KF^AM)3%Q>!;#A"])5J_!?9@>00EFF$Z>G_IA'Y5NG:7) M9OLS.XXRYOL8EQK' -H\93"94F%Q(L"4O(Z+?;:WXJT_K7IKX29S_*^MTS(+ MFTV;X1#'6#56T:_\19,0@&):<:^&Z9[FXZ@^1O>B+EE_ ?4^40(2QAT5O#B7 M3 RHY$9*5#HSMM PQB1$0'/:;F^S*I@IL<#VFU<4D\PTFUZRM>-+S+/YE)&: M%EB9Z*8-ZV4R:+K#4J=Z[XU:>HG^Z4+^F.Y3W20$TP:$O5Y+)D2G?K@@Q2G2 M*L"?*+J>QTA%?;R7H\;!P7J%&DLSC4?:@<].PD+%A>NK\05.M,+SG.K83Z+4 M)1VRUF/U=0_UWG#*,G+%M>B/*BO06Z)92?!R9?M1"XQ]Y?JE1,6()K:>$,LU M#33]L#"G_/R;:1=7>@$Z1/0;C:@W\U.C>7$"5\$4B DE7C"KG7YZ IMFV(] MR\OE>B _>KW@-"$*=\QE8GJ1D<4^CPZ<'Q6ZDV;0:1':7'15&+4N<'#2'!S MGG@%8PW;=A+!(3VRS4 X@[HGZR>_7CZ4NGEQGH9T0O&SE L\ARF&6M1(WOZ/ M;>R:[#1_G$76WP+$]4C Y;[%T%M 6?,U4W'DBA>.(HHY(=$XK-2HQB=J,^ZJK#: NALDR 9K4[ M BCU7F8F(>F^!'%R)M:=>.#I47:,'^JI36\I9$?=WY%X056()@6E3)$?7??# M,SQ-*V)$%VR^/*Y#C?CUW=UI(IB/Z$H7 _?5DKQ^A2=#>R M:F)E4QKGDW.!V\ZLOR0'Y]Y")(JN58I?(9@I\F?O>PNJWP(RN#.*NI]@8Y2O MBE(VE%W'1NX9> ]/Y_+= M[AK;\T/K'7*KKZ8?"J\,U6NQL=7F1@4R^/B7-4 M>0ECUZJ:S,6@E/BPH_QHT,Z4MU-&M_HDQD5$EV?8 V?,KYB/^;;YN-,@G8J) MSI_3 HVV/G^&$VF9\-' W8KH)3@(V#"(PZ!?Y3__RO=/]Q[9ULK7?S-10X"! MN$S*$JGERV.@T0P.,OQ[2(;EM,RZ#6$]*7<+>/G(]>ZP[/6[2NZ*[]7@8_N MF<_5,&15GQ\F80;A4^DF; .F-PQ3=I_ MI"ZU'+V>0\T2[P8+J/TD:,6.MGKH(ND6L/HS#@V,BY@6#CC?J/$RZ\3'P MK6WNGS!.E6Q?6S*A6Z6JURP(G$30'Y[C?:9J&'=F*!H=^;\YB__6J&V.4&2Y M@]T4M+7KN\EJ^-1P]:@0U2%<4 [I 5UNE>-#WIFQ]RD1CQ?@C9,1_-'YO".N M^A,>(0;<1698_YR$_>>4B?0[E4_):+9NE"II+DS>6I/[OAHZISS7J@(7[EV" M';%ZB0I>M"6ZRFATD03W)ME]E\(!Z7&R3''+OP6'_B[E^?>SK_]J?XE]& ?^ MELV(PA%H,Y=J8 )%W[N1DT!QYX5LMEM\H&'+2E=/+6X!Y4.(F!I6W]5]('RS M>;"NX(C3?==S4O98*:SYZ!P'(?@:&60SL=,C\LJW:PKU:;-;P' $(\KD=,5& MQJ%^I99.][,B6P'0]3CAGQ<8>S89:()W(L>WUB?NZDZCDV-?:XWW=XG.OYXK M0?Z_RR9$W>Z[.F \C5QG^ZZJO^EJ[38SD;I778H M"Z?H?X ([+]LI389E_!8Q/9T:5A%6)U(U0C15%!A+^\*30S-$L0E5\&]>< MAMXO0CP42XY\59OK%L_E< ,B&EG8NU;&X_*K[\E\\/J9'#_ZP9_A.3'9#?,V M&YVWS4;&I8' J8,4\9M?3[CQ.+%7_<^X=ZD?',D;LAPBJHLHC9GND^:'Z#TS MI7+<=:?=T2#3EWU+E+9 ?-=R$"YH3O!SZ+N*F'CT,/%U<98$^0U]W0-O!,^ MWOT,MG;CBW*?P3Z0FY)RH]IF,7W?=HQ;P.,_'=^-ZIMEOU@*%I5FT'5X>]!+ MFB:Z(05P3B'\9H]$C[^_4)%[))#JJ4G5U)XHM]8#9@?#.S:=8-?&$$). I4H MD3I+_=\97DF_=+Y$3O+C L*LDJ]0^V<"]!V._SVX_WGM&-9 M-R%PNJ&"]0I_NJI45D ?;;A&M[BE39#:@KEW!"8?P1L#%VE"G4[RUV MA%[C_04)S+\)K&&K:N" MIDDR[O^6XK:^QZ/X)9WB-VC4/T?>VSH],_3\1R3'\'=^;AM?*OYB\A;S$9<' ME.S5L9B.X+A1LU2"0';J[YNX# 1C)Y"'[!I"\CWC.^OAMH>K M>_C%"!1N*JU9)\2M;4M[53MIW%B\L]LO!>YI?<<=U;^OH\%+5'-@IB?,V!0P M*94Q[=ZG==@,2HM?UW M/=SIU1H*PHL Q_12]LG,/4/6%02%\N$DF.P,]P JC(GUS3/5?+Z[>RX3ZYV4 M(;^RU^0P->EPE<:P+=W(@=T^UY7:)T6[^T_$!^?G'??2!=1J&3D0>TBPC=T$ MO;K^PY_J+(WYPHD%J]JN%XYR-/YVA)PM%IB/A&W*:J#5U=6/9L4I5?##R .! M>1]%Z [-.JYSJY].,JO'T%J!N[W5TQ>ZP'E\T._%$DTJ8U)VMI 5&\D3UU<3 M%#\O]\6V4F\!@1[."Y\6!'@5,*.>-CRL% L"L&& _(!ISBED1T\B/*@BX%*< MTF2)IB4G_I$YA3L3]5QC[<<]3AX/C*RB@EK3?K&WD!V,\>>>4EQ$Y]Z8%QG, MM+GK)_L8@'U+#.3*>D10]+"PNM[J2B,+#GV[#LYS15Z &_4N@ABBEZ9)+ MGLJ);TL$/TZW2!Q6(/'NDX-O# 8BB5?9)H220EP-K[0D7K. MLYH!X5KX;!N2(CRP0U-\PM*;JR^M#[PR_VI-@&0Y*HRHHN<6Q]3SYGF@\NX' M@X[F<^UX0#D9J!>ZFLZ$UO8N,JN6>P"2"[)9Z*F-G\FJISE5&58SAN7_2#9I MGAD6Q)*+)P6D#X*^[@R/866-7CFR),JX/KE&+9AE&2&5.=$CSA\L ?C,+ZXD MK94]/#T@3JVC,.TJ-[E$H:_IX/9-+<&C^.X/*\764V\#5,A_W'L3 MX[F*TZ3^G7X4Z<[+D4PQ<-S3NW:!<\A?4$]K;OWK.Z,]H_W2VAEVQ8W<,P'; MM:2KA!EYWT5LZ/(O_1;;AU<3E5+@GX&^[. =Y7.*J<,2_WI;0@?7]6?1 M>V3<6PO$&N2^S=^0).OA0FFO6I=AB="IRM<7NIP5MX!7-B.-G*^Z-[Z<2N^\2 ^U++\59ZEP.WLA+\E MK_SV"\$*6=Z<(+HO'E^W,;N?YS 6O^BL.X$\QN7(NRQ(I#HE?Q=9_AS;DT$E M'8K3(N=3)LO<,V/=QBN1#Q]KI)'Y84L,4SABTA)"HUH>&(YJ.@2G;[N#R\\I!>L= M#I75.+6K@U+?CD*"$C-/5$:\&,-,4KFQ:LN#%#LY@">&-J3$0( ,LJN31;G_ M/C6TR<2GQK'H'7&-O%N!L87P=Z0FY5 .J[_K>9?_^6!>@6*7*6 M=6Z]:P,^ZKJI]VTIQ #?,,$65M+4GTGB/.990:@H8\&?#,! /C7- M5$:TE52F['0LP(=-J0OP*>3G9:DP <(&P6+?!"#[HWYF8LS$Y'[0[(Q@-E%N MYL_$4 0UO=^&0LA.2VV%5C:] E@,W*T!GT:K'!,EYEKP69YJ:M9&>53WZCA6 MV6\__,!._4XMG&3?.J)?ACN#O5V6!U\//MXF26^A\S1,^J!:JX!B"MZJ3^:0E3!QBZLC<&YO[LVU!E@>R:K M_7->6&3%@3=U/BJ/5!#C+WWCWSZJ*HF/NYF/8\R)9FU=F?MY9?*)L$X)^\<& MR-E+,_[@*:$/=[+(1Y;GW:L'9R7W)TJD;G10KZ(AHZ5YFKJ5<4$ZBO$#2B;R$N:ZGIU3 MI;W4M!*B'X/\@E?W'C7IP,@]+8PGR6IXV#O1E9RB.4?EZ,^B(8^.9!R^K71O-XZIKQ2HW>4 "A)GQO8E6>S7D&3: M\+B'LAO.BY5HQEQ%VS*L&SZT4)@^KEPO+V+*3_%2(X?2O!<:2;>ZM_)-E(#X M2"7TXS!F0"I30#HCFO7] )W19XLI25%H#)D[ZN'?PO@/1K/M>CM0#R;Y%=DU MFK^F551!XB.J(?H,1>9NA?E 8E4-7%UQ2:N_1./,7B)VJW 8B7#BC8^4*(5& MR$H."MQ84.?Z"LR6OGY":3D 5KG9? ?F'NY<)-8#PVUT%[@9=MF![(XT:A#-WT:K]Y?>/K&*A,K_V$EYVO +>(D1?.\64)DR5>KMA5"H0;@B@XH%0W:= MJA>/]H#7V7D#$O:W .JM4Y(7UN:"7"Y<<7& _3A3-:\14?SL\%%SOZ=<=?DH M@H_Q9TLX1;$*Q2\ZF>ZR"!AST4=D)-B>A(\IL-)0I3#599)C"X3*WLO$RLU4 M'49]OP_7GQW'*E654 #GO^XHXS'FYG !ZC*=<_,& *Q<9WD#+P",J\3FX:/* MZ$CGJF34)<<.4F@?M!-[%S,HUUOZ@1!#NKSYM[X'B2*UR"K6]O.7O@**['(W M12#92M'T>Z (8^O*!X27FHV0P.X;EM2?ML>K#!!Z+H7LMNO6RY4JEZ_M*N6? MUA/EPDQ9NOCV-%S<^I#=QS$S@)O#QL/"##]01T2J7WKPR M0FEL6;[ZMP#9=*<0T[TANS,J[-[,Y2%ACP'=&>J!( _Q#'G\KW -*S1E*J=? M@XY7&F$RZ-T4M';\#&/-6W*%@[SM3P8>7B;B]"6+OX8Y2*US7DY\?*390&7> MM1) MYX<*$:%@^"V@T&A#L0[8H.S1^MJH*#=I'7>HE.5FR\YG!7S^]"HE3OGZ%M#\ MU$?JN$ ??)G:0@!D(P/*FF<%IKQB^]CGXO;81;+!QO#Z9Q)U&TG=LF7U[)S"[R;VBL9=!H70C3C25Q/248:-1=U46(P.<(_A>\$C]:4 @BR2AB7_ALX9T5M _A(RJ-J' M9M.SY/*;&FQ2*74*\&7PZ5J+,F<&Y.E$6W4B7XKNV.@G_E*;9 &7+S\R^3@< M"@GR5SOD>+^<77L=F<(51FJ9#32T7'^3]F Z.$9?C=63)$>B":.!Q"0\?=OX MJ!<5CKB<.BJUHUA*(M4#/X6N[ J1K0A+#MA!JI)GGI!I?J!?WKU'5K0.>PQ%HAC_JB>RK$0/@]ML+*;T#H_,=*MJY;"%JMQZ!IK'LV#!7R"E,05J3MN MJ+@>V.*9T!9>%$"=#,9Y;A\,B M5%(P>?YD2:%:0LR_G-SYM\Y_Q%SR_I>4*W^J@D#0FL$W9#/H7'8>>@L U_KN MW%5F;#TLOPG[X3NY@>S1JVX^NB! .!MMZ(]=)H]0@77+Z2[K4 [3!-F4> MX MP[WCLN;[%+2ZZSM9B3)SDG%N$G+F'J(%:E*R+BZI >K534#$=F@N]+H<>?; M,LCH+.*L<':?/$;I[LWB?D:>V%O6BV\["@6\"_^LK2ZK^Y<_DT6-,>3O6A?5 MNPVEN*HXOYE#WYO(&2#"5_P6D!4*K_^I\J?CZ3\Z*HOJ(,(H1%!Z2!*(#F_ST?FBF (1:S"6A?40L6;BQSELMF"RU->JZ.<7$$+]BXC] M0'!@^2N.I[ABR(PRD(!;=3Z)0>;TR4$(5.Y;25_#3IVN7AUPW5Q8_PB<'0F M:Y%.#]&9-RCA:^M=?FN/T5WX\2*5AU>-\[G].TT>0;]]L5\8,W5Y(V6&PMO$ M-PU^\^$(8:71[P66+#W;/=GQ? R\)9S!OSJ\E%IVVAY&%E#PT!+1/DC/8!HZ M)EE+<8WU+IGOLC'Y<-+?AC&Z&]ZZPCC\0_ =]4:T5YDPV"9 \H#FHF:KT>1;M[VPZ_IPVA M51;&QG+#230Y4#17K^9_'8PA( _21&I,,+^6M0=1=5#-BLFE?C[CY"C6QG]1:@">V^3(PP %=JZ=WK9_0NT:H8HIJ" M,V;G5K.^0$V[<5)3RT]&A)(LZRTMD5U^DE(^06439JM7(L]'Y0A;0\$"XB\5OYL?J,?J0/JQ[YDF]AGS8GTL M^)R>DZ+%JG\R?__7<'[)PZ[SSWZ1,H\M4@,(?#UGFFH4*#1/#/<*'G=3](JU M/LHT/?9$L,BRTO.$/F,2K,PLHKXYF2C_F6%F5VH,#=$^,ZXS.6-(^=2766J9 MM_;0@JJ/[ZW+ UYJCS+/:PV!+WDF6.\E:3!@Z]"KK>OSX\M+J%.B7 MIU'$F"^+8@KJU,:5:O-5+1X6W/@>QIT77S@:S2B 4V@?16'LMAR#T-1=RF<( MI /?ZN)_<_%VN,%.]; D0.&EK:Z)\KD;K$/305W.(CV"_;P66A0V5?75G3K< M:!VZYVZ]JS\])3P^BIBV6^QGVL<&X"R297?4$1Q*I!)FX= G,)C4W:)8MJ'5ZD4U_>M1%O!:N(T:MWYU$&YPLR%^?KE5VN: MEUTSWU^[(%[+4=L5%>GJ*O"J<&7)7N#B& I>C[DT-%)8XLZ!7VT8:1@ZW@*\ M2#7VQ>+-HTOW;S3K7 24S=2'T3OI:IM\LGR7D2V*4U600PJ"HPD M7/G[6LBB3,8K_*\FBFEE+K3X2DUKI9]%XAI+9X7;2J^B:4AE8O@;D/AA=]*# MVCDO>2^E2[A M3#0KYH3QR_&Q E&XT$=&L_?[#ST22@Y=%_?EIG08=\"S.77 M" JYOMF8Z+(7\.OF0C9LTJH3:6?E$*G7T^CV-:X]$9AX7G(OJ<&AV<%F)N?B7;ZU7NB3N(R,2S'K?1;0)Z%'%%I@M,!8=7KWSW1 MJ46KP/293YY%]8^2R)[<#YS'[)W6$2,C%8X4-"Y@R\;N?M5N@?^1%'R2,GR4 M'ME1V#G50H4E[@),)LRKJKM^$R.)ETJ>'"2&G=\V=]3DIG2-7>-EOG,=-C#I M8-% _4)I;5&2ZR<%; #:^XN)7EM4SHT@11)$;9#'(]],X)82WOG* T=;X!M4%=V8P>-\37 M?![Q_W4+V)FD)F [9YE:X;(L&FNHYU:B/+H:H^,'LK=&^D#E]O80KYN-61S6B-5]SSAX#U9T).=[3)EV^D95K8CE>S2S'NCR&K2?L:6B M/N%[='8+0 .-^NFE<*G(I#R4&-#P@HQR\6S31?L<(8GA&4;6 =LRK_)YJD]P MQWTG!3*2,&Y8-I7*[<;M<$T"7D32X84-X[G27TP]YL VM3V86P6WN)8J:%YA M-EN<8#K:JUN8=,IL>I=D=GP42"M*D,EYG_"81_T")Z,WU8VS))M'I,?K@7A? M1K^RR$I:HYPF6%_A-77GB MDH?QIR^R0YG(_]O=OH\B?,"&'R*[H'B7\9[+181$P?4 @A$CG#@[)I79CPD6 M5P7(3F=J*EJ ?6$LP!.3$\6'JW7\.0U3K8--K0/PP=)WY]N6G@7D_>;7B[U3 M2-O$GSVN.UR"G1*Q+:[21$-3+6@7M?&3QY/:2D22;K.^K5A(8V#J6_PVH'V1YI M[(A=?R9[,"LI2GM:N!;>=R^));%SM*$H02([CDF>22CA4XJ].M9IHFF(>OAR?=_PTT CAK[.(-\I6GE60:XM-L^4 $8X9D]1#$.[3US MJX8IM[E(7)".;+*7.I/::VM E-H/>>)M@ VUI8J4Y\=00+R$V38#KZ@GJW5D M/+@0>#H)QQLL;S4 !5.$D4J5?H'!?7DYKEDUS&\!DG[>2CN:58.FR3\#*L'M M88FM?1L0KC&PKNP6.^WSK/<#BM;TQ(!?JD6%1;U6P!EI^5]<53NYN#2ZVEBKF^U'.XQ+]0[OW(]-!"BD6/9XGC:R$$L#S,D?I9 MX][),UD>62!QG#*: MS-^4V^KG1D=70!@*:P64:H-/IQ _;@HQS+\+Z2N=BY*UO.+4._-?&<9/R,Q8 MV1+']%@,ZORD98^\0FKDK7[P#B(HN:,3/X38;P&TZL #WF,( 3G/!\BO4R<4 M3R$/K/"U[+ET0_U-UYN\J;A1;WGJ%A":1S#1E/__04SJ%G#C-7L+F+1'Q$UT MF.S< HX.[&\!!LWGFG]4+J?\CPI&,^3#$+H(IO&[O">5!;\GB5QQ=_$C*6P4 M%\L; )#EA>.*OL3CJ+5LKT%A$4/ MN\'']$)V]9# B>@F;\8ALM4M%<'5Z,L,V4K9&M54:IL7M!P#L9IEP)<> S(6 M3VFBI;W('5Y-M5#BLV3 C+S[O&U\).\]^L?>N4:[K %/Q3 M!B1K.TD4PSR?$KQGHK@L=5QXXS_/2\<.4CAP#)14& >-## M(=U0T2?OI.9I\ZU)1SR7W6;S6AVV+KX+>)(O<2=)_*S@N_>[)&H;L(II >ZB M/2Q#CK[[:N+=>2:D:5Z7=W_'K4;>.YNV?OY;$7#NQLMK3)Z#5CETDJ9SJ2=@@#1+!%_*_V7KEL[U1^?HD+\DW)VOG M.AK5H;0?=POXWCR81PQ2Z8EY[!6/5+^. 55#>OC)@+W)A>!T8#%J.GM/@*K? MP?OXK]+=_R@FB&Y>.WOUX6$.4:C5JM=$@YP]<+T*!.M3F'.UUIZ#@9%8-?YR?'7-3*5KM; M)]N?=,IW!+Z&O;IAHFJW,7'BQKEZ0EK#LZK:%BU)QI8%K-:7B2(ASYJ)9=! M#Q 5!@PY!6?P@V[,:&;.@[<>3JDD./C*[MB[T/O'FK[=LCJ8\)$[V)]C79OIR<$J^H#]XD>-[4D\4>Z3*M'9H%3 9*![X "1;3/>FA! MXFJNU2>L=#.JLW*ID/G1+78I&^N2QO ?U-8LK,9::<9U,T=ULVFUG;YYO+K5 MKLEV.5BK9H#H06'FM,#21"UI]#2_@(%(0+E !*70X<_1_ .WB8T*(\+0@G#U MHGFZ4;F\$*B@1E4C\V?<50?J]'%US: :CA[/PERJL,]GI4<&E_RRZC0;36!. M(*DX$=_8S%J)*H8*JRQ+[AJ&"E0(9BM*F"*NR#4F&C0BENU'R=0G3WR6>4]* M5ER6B=P_FEO26K)P )W<\E_2W_[?P;:8A+^FHZXLUE_9:'_/2'--)[D%1+O: MPV]N =,LKI-(D664A0Z[Z7COKH64V&K>.;D%F$+ZC"ZOOR+K7Y^46=W(+PC2 M3NQT(_]5TN3YVP/8,71Y SS;;883YE&-J$ZG*PNH%66G&5C0Q+\HG_>]*!:( MF=QO_C>%4SQ=Q@[%CDKS/$@V(%CO( /"DWH+<$=85;7<%1H"_*NLJ?U?2Q ! M5%5'E;$7/S>ON0XW[\"!"%RM<>AQ(NK:;1C%!O[6$:\P8+6+\KGFEO^5$OP_ MH9'$>W>,7*!#;5XK [< < B'687N]T\&RQF7LJ=)52>>$Q6EK3H\G13]*AF) MY521'EMZL*9"ZW5; YU4\\2E>98VE2LX=Y07='G&=>ZD*UQ(1XCQ_:; 2N-7 MN4/NSJ;5+>>^Z?29UD<':'R:,72TA 7O+FF%'9Q2X-3NY]6'(FHW.T1JP[90 M>AVW'JS66I<$VN[W-X8#X>&16$)(HR9;@^!T>KIJ0'S<>'>OB M "YL.]^A&6Z7B5 :[*AM,\G'^E :QKS.V67'#AZL.WAJ[9;B$_]SPHAI;2[/ M[RHQL@MJ7_0R%&T5/1/FR$]JU+"SHZT,OOQF;8'\1H# U#P';&FC;'6WEBIJ M$;1=X15&JYDD'O'>!!K])/&-=W'MXJD GDM\]*%'V>_2YOWRX[+B[O5>HNUL MJ!?ESHKI:56<^I,_3S2ZC"W46\1U24H >..NV63L7D2Z6=ISD4@'_&2J1B00 M]O068/@5J3/8=P,^*S$]4G\I8L+5? ++_7HDAB1Q$]*4>D,^KZ .VIF L.]H M*!&53R0E^]H3=RHROQ]6?<3TH+!G@+F369)RS&\EZJ%$D6BNV$1\+0YU7*>6 M=*5X['"L_P%J'7!3;OSFYNM6T?B-Y=\AG=R_W?]D>Q)6!RQ \=\27H5V2Q-E)'+#8SC2?E;AOL=A;J,=^:%X?-RR!G=29\H6&Y?Z;PM5;DEVYGR N=[4VG_ZC[GSGO \Q6:_>$QRA3P/@K9OBW;=) MD\*. ^8VWZ5="M>!;KM3\*@KI-0IA%2:L6 F&1?GE8*+KLK@-X+OM&=EZA;> MSG#VP=3DW:ZKX=X0]U'54-Q<2X^,CAU<[#2SHD!TQV>!WZ[[ MJ.:9#FC0TZ MCL)?/EJDXAV(L%V&+JSH*>#-CZ_Y]__XSH\WU6)4QIE16"Y0)U-.?E_.VR?2H,A9 SAJP6GI1F8F\U3AL"JL>,'(8G)_MU6! N_3O7*< MWM-0*[NRK5XZ.(&14.(C).G^.H&GX+:!R<2S/F2'OS"08E<2WW')=-U"6 5-PJV'>2STB.=Z(6"0=A,+\(]S.K3FZQ& M!9#K;]QI,4<+WJ2! I@P8KUB?1_1YO@$I:ED/>ST1 ;EJI*);>WI 53DHK=! M J+J&YB4+IEB&O;V+RK"%7!5.P*6ZTTR#DME(H;"9U;&WC*#.M/]AT ME(=(=[2]OPJ+UB$X$KEYG*-4@U,Q-TY=8&>J]]>63ODFGLGJX.Z;7,A;#6FZ/XCMY!7=S&W[9[/;^P&X1!>@''@F;V M,1YAKQ-3EPI[;@1\7-:WS-X7[$RL*B:Z0-=>"56;OR!U&@^A;P#=E[B7;F&* M;:I2 7[GN3H&9=*=?/7-6E.@>..3:L_#2MG,D) 6FO.RT HA&4N[EV1QIOZA M@750I2]KT.=VSIO)\=(MU99<\P:BXF$9D" M<'!FF9Y<@-ZU!!3C(L"[6103.BT"-4S5T^(^,%MS-/QAB]F MPO!]%&6D1]>E^J'\\)PD@,\)##&?L@OM*>U?>CMXO"*>P2HS.'Z.PP?T6]*L M3GP\0#[']\*?^=[661>$X'V>6U:1!+&FA>A_EV&MQ;1J?WE>C0($DUKZY1'^ MUZP5NY3#."0+":'ZYH58Q#EY+_B4,8JLF"2>X5,QS1=A\2FC^ROF$M\AI)44 MIE8_[E-Q9-2B[*RP#<%;%#O__">6]'=,3EA,7Z2;8RTJMF[;Z_KRH?4MP $> MVAD;PF)*V4%V3MSRBA]7]$"9!4O9U<^;%W9R\OB:K3CZ"[_FE"@.0-)ZHM4T MA)9IO@*--NO#D1*;% OVUSX9P4AY3_I/5&RHCEGLTDE=#1J. 697.32<;:X@!!M^CT90-1LOX87]G7MGX0#[Q? ME,QU+9].>HK=,.+AXPB)46D3YP]%[P.8(X;L(<:]+ PO?D(%U)E@L#Y1HCR= MR!(&V0J@K/C+/,6F8LP=M7)K@'N>L!76*_Y,#.*S_)54'"ZT%\;;^H8RIR10 M'?)B0OYW_&:DI=LW+T8O0T.G(]D1XTAH45X9C5N7)E(CHL%2@W)2W.IIK!4Y MX>?P#(B%C*'6JYS1]J"85"OHL#'7&*EZ4(H$X(T$39%T?K0H@&O;B7Z-4U.I']F+'= M*C+WC O."(FI2+JK/OIO$4_M[ZC9!8,#?VML#WR]\6% 05!FP%295\<&N;/) M^$Y6F7TG782(D*]/$.[2)S9>]S)*SPK$0[VCY%N 9 U5+R_RBW5Y(/A&0X4( MN7C,;=)IM&V+[=C4U(UR!\'N0T*XCG!M//103?7\3H>Y&-+7Q M_A:@7G4D'X;0AJM=:^8;H^Z%T##ZB+3E7YO\:J,QH4P U,HD5KO+HU)%L\S- M/,W$427_JXCJ.ZHM)X4<+L#NB+2 2@K@[EPJ:0PN%%S"#F4D?L#D-6JZGN!_ M7X(F3YB15$6":A.0>X!:[:C_#!]&D[*^HS)8?XW3]6_B 726\LOCVKN(TDV$ M7K6=S) Z9KBW==[DC:>6U]_V*18=U5&3SD2?#. M26U!7@=,7VZE^8O(8]MC@'7JG"?V2Y=UB0/G9)Z.6I=UP >3=5," :VF7$XVB;*JQ0".^.B1HSI>X]2(^_- M7_EF6->VZ.NA\UQ%1WIL@H9.BQ\729X >D%T)F1%K 6S$97VIH)Z0L!V;_[2 M7H[7I8T-'8U@OBA_9CBOR>7%!7S"#UBOV%17XM15>X_GIASF E\O8:-0?_". M^C/4YFE>^%I]0AG[N7;%+4!(#'XB\Q'D!$0X&2)/?SRV?79V++7:G7V 3MJ% MX%1:M_*K]VL31Q[? IXI-:+@[4"UL"3HF8JU%/9+EVXA!):"6_PD:^T0R^*4 M>D6.E@)P2\L"D86PD?VQRU?7 ?OZ)*$UW#K_3.^1**D_#.R=:Z[ZY6[Q- " M%QIXA:Q&7P+[(![-E73?'=AW5FH5K/YK52A]G$7Z6%"!\TETI'8TTDNME#4R MJ["+R/M7W^JP;X0JWH:J\O_I(B#_ M80WM-Y!B"(X="=K*;>ZQZ629]N'-.!6F]*UY?:Q[5#Q!0:;DV/HWY9.2K2-K M7K\6&W^D9:H WS;NIDWQI ^-M>$SE/'Z\0IB&RW'(E2QCQ5Z;8%>1R@G$8LY M.-9V"WCL8H#_ZX-I$,NL>R?MB78)S6GWM@C4#,EB\[ X;PI:\RC7[,FLDVU/ M5[^2JCO"YG-VI+J(N8N 4:2]<^YX^Y/O^[ \*YT:-G:BC(;3(<^Y'Y<-A;]L M*-T$;)O:-VM/&EL#F[I_(5@&-[,ZV-;-FX.%I'Q7#-X:&M8:?":4 MY_=(Z" MH%L4*Y%%(H&OOCE9V+/TH 66\;(9XW9*;Z4L,^;$8TUGF90H6) &%\:P#Q,% M,/?/[):3:1MK_[C1Z0'*=N61#+U\0JVVX0C;"3()#019D#7X&K@!8[1C/BK1 MC26@,$-]Y'.-@M (:U%+4B*56"6N-M$@:J;\5*O\/WM06,3+"L3+HH_Q"&2Q MGFV)=G)+6NW)<^':WF5]COS],E9B?]9S@>@.G+7*?=/E\'ZXBZM[)_Q M%9(ZE,D'HECPI 32^/L-TRW@^>GBV14*1>/-5=\IH$!W"BCV.[%3HZL49#+Z M1A_5^PO%(?MN 5GD9[W'K\,RCBY!.].^I[2R@MEY/X1RG?-RB:$3'[%D;"^, M$-N1N=6;MX #(*Q"QACK7Y68G)TTWPV206\5D7;K#CDE3GD6ER[VA MA>+?DKC9)9P$L)(D:7-\$>0L3X@Q+@2 MN>O;>'=5>FQ-;R/_^\89Y_RM$0H-C=-0A:8RD$PS^ XO6EBRKZW!.1;RI1'VWNK??F MVE#R0TT1EJ0CH$#5GV $6(I_=.D6X*Q9;I+V26*&<4]"YLX8TQ23PWS,8U;+ M^YD1&K"XG\D]V#/V[:-!(9>)ESB.^OM?S"I& M]XR=IY]+;O9ZF1TWY^F[H> *&/Q>9VI$1GO4PC"9Q%"1$NB95ZWJ.^$3)^,P MPFQJCS4NLQ4^]MV)-DLL#F(?&4NJCBG9 M$Z_HY.*4V-C0.CTPWRB9$-:(6.TRJ4U+[.7Q5C?4+CYBZ: M(%R0-23^UJ&-%(M$K'/8^\=H8(V$_BK#W-@77!DL*3L8\:O+2;]M$+D0:C'\ M)!CU?V"2S7C#-/MT- F]&]]U#2'!^R)2+^.WJG_'&WRJB@& 4(R(QK95M[_G ML14MI=U902C ",)UFG<@:X4FN>0D8^=@K1?876BL3XZI\+&9YCW*_6HHWV_= M]NBBW69&\C[P'->@UH,_6"HM1$NH)&'1- M[X7+-P;1:9'EN O,BK9.&5BK2.)_BG7M!'TJ4!JM3]*HO,>7_;M69W/ O*EE M<$X+:X5*KM/S=W?-(2(W0< =RU G[5V"6GJ.6W_)+TK HORD,0X95Z3&H^8+ MS]5T)HZBOAC]B>:B-:/#TG*AS1>PL[>\6AQ+'?9DGUYK&N^%FTSBQ+#4C'QB MR-OBY)S1BS??$8+\%-^]MRF2-.#L>BZX89.,C3]6$5][633./-\F.D.7F@+R9DRW),S]AO\KS!% MCW&H'(29S$97?C8X)T@1%N*_.4I=,P&)LN@0/@MY'H(N^1DO!VKYFX2"M5OE MT^0[[X=23#-05C''"Y;GTV^V#]_DKO*5<;PFLU837!+-% 0(-2YA^!M@%Z^] M:==*U[NIX2SHRFLE#<\RAW:E1%C/^#)T#1^F?R M@Y%?+R5-&GXK!R=Y;^I+GK3.54JL\Y7:/Y+Y/2,6.X$" M\9E0ZQ]P39XZX,P3W)/N6)]%%>C7,\B3WWTFR0UU"=+]#H7FCN'I@ ON_OFM MZATW>XRJ"+JO@?YH3D/O%+$]39&U'2XU;'L]X'< Q_0,HSPGK>H+->NHK@_F M.IBA"Z:.=AZI)I88F2Z>3R*=NWD'6&0T1=4#1$H=\=/*S$W>#!VO8AW.Z=6)@60OVT?R(BB%<[D"C-%B)+0+ZU#5_BAP2@,I\/I0E)B M/Y#K*PO0 >\3P#14]PL>F \9HJ91>,NXD[#3H&TC9*M0NLY=:'S6[KA2EO48NNYV#0^@M78:?TLZ33U^(#NSLEB>A3@,_B@CZAT&$^NSPV>PAIT73C*5[NF(FYF?DOAZ:GI.L% MIKZ\#CIZX<[H0351F8A!K[2AX=%Z]+AL3<%IW-6H(7\-:KJ0>YI@J_.7-JIZ M9&9B\2' R7+B@(YX42NE/L1(*/__P]Y[1D75;=NBBXQ($"V07"0E"8+D6""2 MY[S[WKFMO?/: MN>>U^V.V*B8*Q9QKK=G[&'WT$2=EANFQ8)VX&NMOGZUGHLGE[6NKI@-NNI*Q M&!I<*#>?ZY/1NZA5;K6!+ L5D_NS*'X$*Y:]+^EW(ZQ.%'$ONE.NVHI#SPQ: MG$QMM4'MBZ9_+B@G $>WI4Z0-+*0N%4BT32,JNG#6%4B\;MNDU&?HD*AX_)G M:V'L9F2T 5];._EF/ M2LV^H,+Y7",/E"[,7"U,$+'B4E,)X4% .E.-_.[HO M"=20A6OB1=+W[GT4&P\*+''>^Y^G>DP[$!#-#5BB;JD >/\B4UJ2FJS?HQ]U M1WX1OIP8F^)8-@MGA"]S?QX*_ O9-=9F=!X12P;10L85)%ET3%PDJ-\R52 M,UWW"RWJ> E8<]L4 :&<,-%AS+4P1;3<)"?FIIR7]&C",'U._"C:-@6* M!R M:,G)J(8\5BNH)@& 1M4DM&Y@6 VP>!G5 .JL76@;" 5) M;CO/PL+#ZTVXI( M@$J6.E91P3 KQCA4_8^; VLNWQ]IP^CU>L^' 2%_:4[LKR+%P2O26V$PQ1?_ MC \\HZV*^B%WD.T ]+QDOZ\F5,B^,MZ^"^R/E@5\"Z8[UEDRXHE7>Z=6P)X6 M-[0M2?K 0@'/8*X^@MDFRZU$Y\,R=L!D32X%5CF@R!MTK@5U38T9H_-GX^[8 M'W 6$4<"T\?4&L++[O%LTJF$&NM8_2*Z+4#DXO?IGCT445L MHKEA:-#TA8Z?#'%=P^TG^-B83KUJ]%$]\^_D>TTZA,2).<03<]*\%LW!\232 M<"(KN?NRW+)>04HFY/I/8MB/V.AFB4-C!Q1>(7+$,L\M0G]_+4B M6F,A\+6;6VRN%\\Z6+U/[K]#"HN)*V(J@ VP.\3AKG):9I\:^T:6MK\P0 MW2)^BIE.]YS Q$:/9MX(UB)J-EEC*]"#>?";9(]DVT#[KV! JC0!:^]Q&5Q. M*Z0=Y_(@-B;HXD(=)[RY:&?Q4=\T+5ZQ1&"CTK=B1P?":J*VV6?P$03?UPJ6 MIH1OHIC+,:U)GW!T8W\#T><95G(XT!_W M/-?W(@J;4SZ]?372Z5ZT,["]%\51EEV5A[K=Y+_\5Y=2_&\V2)C/?L)&CIXC MQAI/T8%VV@KP'4#1"-UKGPW2?=Q1H'W40&:20@&I&5 NN>2V*[PUC M7+>.OS9A(0;M*X/V4338HZ@+PD=(Q#TVP#W,4)!JK<*0A8VV>_V;)Q-A!EI1 M4A8-R-OP2H:D_I$?_#O7E7]V4_H7I0)YW%_F+.A'S:X/Q[_2X=I_TF$]/[1T MPN:DL6^]/')=>L^!()./QAR3/_]FN-.3+.E%7& M=[%>T"G]7K)[]7.PTT@YM6N>K-[])@]%!A<,(A&+Q56$T3RL!*)%77E.E;4M3'& M>Y=RZ:-G;.[N>1XN.Z@DLIE.0XM"3WZ_C"0YI&.2U5XJQ26-"_)!I>_8?@V MP3+SL06LI&$6VY:?375Q:;4F5O*^")-DDJ1'2KXE-[C%&EZ$MBDRP6K5_?QH_XRJ*K428_;JV/@0;HUA=HY"G>WHG8J2Z9MP M[M"NHR0SG$H?OJ]8R$\SLK)'E^R83^!1C)%E#MQN^"4,7M08LB?KOR]\U\TR M0XC^(FAZO+^9@N2G.$EA/1(P2J+5LYR%8MV7YS+!EG$-WS*EZ;D9.^2V*$ MS_>5R*=[F M%3C40L*.Q@;E2("36$X1(_[)C>=JZ4MBQ&OO'KSZZ35!UF:1)J''L+Z#L;E?B\4W7.S;\] M>6XK#YLC6ZDL%+4=MC%UNP&Z_Y##^BOS\8!7?EY$G3IF[B_BM;1[5@9,!X6= M2*#=[_<@7E')FHXX@/ HB9FOJ=JX\A7? MY+3[;D$,\722PHB6#T#LG1U+3)3PV5S0!,-;JGBIXZHBS+NY%2]P)3[-X;6: MET]TC>],!B^[+;.EIT<[VASS#>^(5=^OCW)WT,\S[,SL_OA4J;9VWSW5;CTYQWEG=L0=O$@@) N5 )L5\J6,9*OQ[/OG[X 9IZ' $:I_4;L_BNU$7=9!R]H5;U1V\ MZG4G].-,'?Y8IR0JSVF*!'2Q;:G@0#M"VQ!_2R\GC%WI/PSVK5V90Y:>WH6[ M(4*:%-=]S'GSNF&;10A9?R%UD=%34&!2+3<@SH9:5=4L'+JCQ!\ M4& Z*X:,$!0:!ESWF0D#QD;:EO=^EQ^.3^)&(@$P+-B1#AWOI=VX%JF1*)II M#BD^SR(8(\XT&*L5KHGZ:+%Y-G')BPA+P!"-^(($%+,3B#)T\2K?J5A]Z%([3/5LA>Y$FT=QSIAZK M^&:!86Z,B,6F&?\#U\PM9\)J6 O013_^[&O]5VU:%SU,O')M@6^QK5HF-&#N M]-$'ME$^,9_]S+XN'^:^8W"7YU=H^5V^\L 2TA4?%C$WMQ*23,Q[\$2%EPEO M?5F,+*2LFKAWA-R=;0;FT9:W$;\6_(0HGL'9[4+=7RP8R[CX-$A_V&ZSOJFN M^.C.MFK+)Z[/=*0$[E]7$*"U\R=V_B"A4K$I^S8FIOJ]'*\-A(S<00Y[R+"\!!TP2- M/_%H=2RK?,:X@! V'B490!!DEOH2!"3GTHR._ FWW^,$ 3/"^=U678! F#L; M*P9K?L[?5277HVP3">R?M4EKEPQFHK8S'+&9112VTN+2;B")OYA\F'FX;6CO MC$!!^F@EQ]-(E@^3ZTP_?Y*\N?&+,0:1\.DAA!ERW [C5?@Y=$XB6/,(QJYV MUW4E:HDT $W+#,ZT>$J,4 " "[)70]*/;FXX7]SQ7 M]'M/)B:ULO99""&)@_?CI?NG]%54%<6^M&.G>WB&OV.?,1Q=KY;+) M@&ER**-9(9E(4-1T 4;09IA''N9Z4/1H\IEXM:AFD^MDZC3+YB K9DM0J,3$ MJA5LM!*R785XW*JCUM0S/968$UUC"+ZP4=M@-7G[RC*H]Z@P_;W@ZLN[':R488=S_C*+7!J*XV=)7F#@)V<:R]>Z D=W") M%:%EH6\JY!PC(0$$M!;="FK&6"0=IU\UMF2_= MD055(%X5YA&A1X<')LN42(!JQ-!;K8=72"*8Y$Q7H$OA)^N%)KZJ.$D]7UF* MKHCE/FYZ5BQONCMI_9FV?HL2N;.C(T>FCJB,2:1_A:RJC&"_EO$6K&,_IY?+ M2J74V-"G0/KV;=SI,W%?F[?V_LVKZ2YRE14VY,G!]((4[8A$T$>3=-_?Q(]$ M]V.L,#WO,9LY$0@A 8*J?.O=DD&]*B5SB##E-["B(8MLO$:RDI!Y'5Z4D]J' MBN[Y20ZK)T[=14%96*T<$7I9\HQZ2Y)54?[NQ44Y,?^'I?U/F!H#BJFM$$"V MZQ%?C2!&K?OM5Q?<)TE(X$4E0WEV5<+I'Y53S2,:MO%KHJ:@I(SYQTQ&21DG MOV L&).&[0M:!T7'MI2,>@$=%:1"K0O\J:R)V/+01 UU3SM=]Y$*DLI2M\(4 M**#RUB1"/2 -%/^-2^;?% WGNLSG;V6YXC\HVA]EN:@: 8K6M#Z$^\%V NOM M8/VP;_F0R?="9S(5+=V,X_E3%5,QU M8G/L'XG-/Q2-*5\D542SM&SE=E[=925BOVA+R;'I3S(3=)W,K)_C_TM)/@M1 M#.REWLLLO\?A>WB<5T"?EQ,FB8Z1HJD:.@#W[QJ3H!8,=R$(LN*!UI$_1,O& M$P^2@F KK_[^^K^3C%P."FY&X:9:W9*,7$0V;#Y+S8P/3= >W6VU_- 9!9GA M]]%F"V&!#98P#SU/T%#2,6===KSL.)_,-__0;X<')>8P>IB,*WY>')M'[-VY MV9AU037Z^\),NAXK:P&]'0KW]*D?/; /ZE[%P\RH%[UK$Y/EK@Z0B97Y]*W^ MMB42GJP%GTY=3!RUT%E!/1Q"YZO+UFYOS_3BB=+Q7_G9V,HJIUJM^\@@ 8:W M/:BCB/W[[^](X*T376+X$A/J1"R-[CC7:0N!++?#;75_)S]\,]=%D9^3-:P, MU2QFO95(L\Q=_Q-F$ _Z"AMO.,DBB&A[6.M:3ZY[%WJ'9O])49>?Q6?4^5SN MUK!4]1+_*J7>\U2Y MVX5;AD6:W<+.J[PO]^L"OU<#)\O'Y09=PT]78MPZ/B"!GDA[+5KU:6F5+HFX M6&GG+MU8/[N)U,@I1G]J<+YX$A;_[;B"0AU";BL,$&T+#RA'#+YF)B^A\WG# M^@A(OMD.$+#RN:.C ];^WXEO!8SO:_RHN%4GS)+JUO*^K2^CA;ZWQP>*OHU, MT$V!,&9RGZ?&IS>OBO.%^YQ\V?+>SW$O-]#ZY?A3LG:15M&X%XJ6$@H278"[4TOK M4Q]3Z$5V4'99]HT8&CZY<9O/,3-A,28*180>#M:\YSU\5:+B<-O"[=PP] &> M<5$V<#Z_^&":R;-D@8V6AJ L3DY83SM0@8>T9#VF%85;J^A-!45^NKZ]E5ZY M^-C@QS.>5YB:]1BA>.#U5G62<7XV.Z;4)]4DA/>T,GFQURDP'L?/NAX7RGGZ M]9><,% &T%-B;![3GQZ53 F,/D[KH$XF#>>SFX8UZ5;Z8"E8^$WQ)XYGVL0= MS'"6%6V].:>)"VXSMC&CNW@_R*7X)M?6CI(TYGU'Q&*0&9-$ND[$V..TV()( MQ?1;S\PM"VR);6EU%)BE;G$W]>'UQ\:OT:R>V_V\P# XI7KQ_IO\:%=#KY0/ M#R53H;0\01+CPX]B/RE)M:H.SA_@/?.:$KU7%\NY.Y1BM>01^ [;I3TN*^). M;&QT^Y3A2@^!721F(>2A@]<$V\ZN$=:-0/Z($ZGZ3]X:+E2/GC[^<#/ <*K M&J,8=4MQ$6@'ELD*UB,F=(/7$CQM!N?#>&6FRR*FXTRU4ZV?$DMCKN<_JZXE M?=3;KY2>>]LU-CVL%3>5:=:!61N/AE@-17CRH[\%O#>SB.E=Z!H4#\'AE(UE MEVM>:W^RV1C*LL&F12FAI\[^RFSAREH?X[S".&#D;MOJ51NOQE<7FF5JW6J" M%U;RBK+XT97N_'Y?2+@8=]\/#4DDZLP,*DR+E=;Q]!JMU7JK/]-5+^N-4_"1 M=A4&-X7-,:B=OGVP4-#7QI?#&F[FO%$B$C^MI>.^AL\]_4B^6P%?7.\8"9!\ M":C^XG9QJ)KSIU<##F5.[COM, 'W'=Z <3@KEH1^RW>?@5";^F\99S_]+(_( M+'H_>@Z:<^7W0KW-QF:*#0SF:]B81TL4&$.X=WO?G *G/6K*AP95LHQOS8S" M@!(+9]53L Q(ZS_N%^XZSX,$8I[ CJ=A3(9$K@ANRI$Q1#/)BA76Z_PN4):S M,E:^$('4IBK6J/]=4$ZJ^.92 &.$!2CBQ4$U"S*L\D 0IK!Z&IS:RL4X#\_ MTSG?UJ."7/F1Y#MFU/PQ\T&/+VS?"S(2,(S\$KUZD4!.956))LF["CW4\Z!M M6?YF;@+3S$<%C?22P]E WK/)N"/^Y+V'R7?[)8SP^LSF#"25G5^B#KT'44+& MAV%R#$GL12!BO\>>!5U\Y[X[ C!8-N7/L=*+"%6] M(N1&TU85M]KXDEEH"$W\W+Y'E"?<=W_V$OOA41'S;9"00M.K9 )K#-L^=M>J MZ,L#0O5W.QN44/&Y01<.\;*YJ"E)H?5'=PSJ5GX\CJE>]4=@=+%9U6 _LR@N%%&F*(F/"/;^MMD#F0;;S3? %LUT52DXGU)IQMA]?L2 MMZ([M:H)_BDV4AKE\B)CM[90].#OK4*3KO>;;%99N".*UF@]Y[_-C4*A(Y(W M9%EW90 6&S9KT3]9&PTE>13F>!?G3_"Q$+78:$V,3:T!"@XL_X8U66$9-2 ! MNO6=N@5-PV 7.A$DH&&?D<*7T?$T_57@[Y>-:FJS7Z^*??3C1DQ<&)YI^E#Q ME ^@6(51YE+FI\SCK[!$M<>?1G)_E\'RMU@0*96'E2J5O&=ZD-&'2>-TH M1564 '8+W84@^#^Z#/^7NQ"D=.,_-\";COZWG*T597WI M%(?CN/V)Y3:A)8AYIE-EF0H5 M-2^T7C33L9*">DBKEOT]*WG>PCR=8)N%1V2;=WD#**D3I4E:%A;G6XZS#QYR M,6+'MI@D=LOBV0"E])]+5F+F;':R+,,*&:_&;Z2*./5GG59,@H])2:>P,A67 M:CY>=AU7#$C9FFO;E\EB88P6VW&\<] H^WFX^N) P)%+E6<00B7%V*9,&L7[ MY,*^1)HPBCE5.UIT+:9QT!NK_0HH?;61:5$?P\JY6DGOJN^2^BQG6+9#E-M7 MZK2(#K.1?1X)J!D,-]7+KT7(ZFN_P5O;')N,6_J:.PX=81G<[Q Y&AK-[XKD M??!.\Y '%+P@-.OB0>,&091,J3#^TK\7:?XZN1=/&,668CP&IM@W._XDZZFM>*$UT[IPN61? M521#2R:+(T0(I1BA4 ?:>[(*,0*4_NMQZO^NPV.O^_ 23@/[R')H<,!C M5+O?@@0*K)D0*5^ONCPY[8DB"AL6U4 CJF39,8NJ*.94@+I'_Y N]!O)P'2V MFIQD$M B.CM&#+I -PG2O&Y+ "0D%*1="R@Q1\/LTLRF.7C\N6,_FW[6[QYXD74-G M",B_U.Y"132+<_-%F@;5^;8=HA'[!52^U^DQ0E*:?S N)OC)Q;C]J0I:.SHT MF::XX &W9GOS=WDNQE\.>82*K'_%VN+0SW74"4'M1X@$8I40XJ&77RJT55!O8#\?!XA']+'AV:WAWD3M//4AMIT8^'I:_*+']&;O_"AS[&\E.LE==<^T))>CT_*ONZ._ICOG8"%5 M.A.[R^P_U\5&PS\MLOXP;99?L*VG['YZO_3,I&9_P;A.JJ79W?A4K@\26U3; MO+"SR[ZT*7VC[MQI/\ZP@0)LUHM_FY_3[&XVG:J=THKG_" MC1JO;A/L9/_I)ZKVCUVN=XDM4N4@G9U3,HN3/^SP:JWO_4HI'WS#3UFP%L^? MDK4SDNI@-0"(\D4(LM'E@E)R^3#>B^^06[[X]IHI_>?/L&B=,<<*^LC=W?"8 MJP,1/S?;NL"ED2BA&>VJ6:K6Q7*EW1D38AB,\CN7B -XB1MV1^%#F,KW].U- MW2(>QAS![.<&J:X*MB_(FHLLH)Z4XMLY+UG&#HKT>:?R.1)W1BES*^,YHO>J M[+PLZCEN\Z[*4^BT0/$TH+:T90H*,IR,KPMB57/\&5X,".*HVIBRX6=A$U.8 M_+;AY>DH4X[HC[#R,BN9R2LVD'=6 M';-VZ(U%#+/S]!>*9=<,W[96';):^=%-+@L-1NDF-J89K4\D?5+/]@..AVI5 M; Z_45/N^L2GVW.5QVY_7BI@IZ@;Q%,65'SVA>YT\G>)9W5),[UO@S#3)K1# M3)>Z)8FDMJY.E,;MZLW5%NOK![?93.G,K0"NE%ZZD(PA&C,;'.P3S"(+^XP/ M#V,M>'#DGL54ML8LQWAL?X:+V^K<&%TB2Y38''+RHG%?KN4QX*<%CMN[?:V? MC##NJ@.TP0QWH!.NKA1[*H+6RESZ.274XW0)8WX9.?Z-[C$36$65Y7Q;8(,' M'2E4%'E=%K32V\HBH?7;,LF-L<5=E'2U43.A;=O*]M*S&GU=@Y&![70U8XRQ M(<)D85-(8'?P*FQBFJ-63/7TU2IFH_=! M>QP!M5_IKA"ML/<<#+,?UW:%::(UU./OW%YF10+SQK^+.EU")9Y&7-"XRG^1 MCA:8C3X9CO![$N;^N/GVXFK"F^20\,BA=!HODO*GC#>S;@6;XM'LOKBR*9R. M\'^D*'FTK=BD*7!3+6@G$^[EA=GHVM\4NN+<\!#C[6>)=?'-D"78+\$I4-6/ MN#L2\(KY MLA??0/B**;7TMF3L(A+P6"[P(!/I6[$/9SGW>YSS S.VL;]\5DY-"%$!@0*L1<-$G(@/] MRTT]W22CE],<5WBKZ\?E*=W/8RPIH;QZN'.(;S0K(8=:I#7>VIU]Y0.T$DL* MO_)["4NR'$[+17(+#-)L'9-O];O(&!5[)V&/CK/^@SO^/PT3CS:$Y%6BLI-?/X.VC4S FBJB&#<-NDL/ MU>Z3%!=0ZP'G%3MF[9M4>F-!#O6+FV,,V?]VX1__UREDK,SG$Z(VI_]<; MD9D1>PX\6I.[ B4!#C==T^^$C<5U.!DVW[FM6->TG';$^%=O/O7L Z-GZP]46>.6QGOHL",;%K6(%4J7\#N]":X^ MA;SE:\)D%16V(D":!5:4T\;RQUO4 M[$^2_,A3H=>:\Y'P=DO8@(.]VK!.UV_X]S)7-(N"S_17Q_L>%Y/G^I6J&9@^ M8+&IHM61UC'+>I%0/%J:KZ<()-I(C6O90HEK_'U1*Q?X+[%I[-Q:D+,DOE47 MYSV (B]_3^%Z;?]]%!\[][IJ!!UW5?=+0(,!3N#>-9G;0Z!8K_X'H1:-+2+ M3I=VN0X^T2#.W=U,M=3B\P,ZM3&.YG3U02XO/:/AHHUY^VH774B@0N$JF.ZF MW582"^+]P@74H^P*"9Q\A1R1HI-L=CX/:!8R7R L6AE;MA=-X',H!O/J8BIG M0NZYDE-.&%OSFK<2E>"+M&FH,DD\^^W M]XSW2/JA@22/>;3[>9' T ]PF8VUQ)#SU% $W!1DW/O $C7Z-+B,7PHZP\W MRP?;4M 9-GN[0,II/IM.LI;,OQA>F>GVB[*Z5&YW-5]X'7K%NG:3/+J63'=7 M97[T^9&SW,RXDVDCWD;AQ>B:5-\W+6WC.NF%7:QM6M:6^CW1AYZEYW@;8,0Y'3 71",BYB&'-$SH:5PD^+BC4+*U540V'>GZEA;48#T0%C M@FX^X<]O)NV)R>S5HZ^VHZ6UY(,@ZZULF[M'N71!F=+=[)1<3-$,:0^(,:/:X#:X2CU^;)'T MLAVW\ K+H8+13&31KH*G9I0]XV/!I2$+8BT9[H5JG<=\%5CYS3U8@5Z6<3 , M[;E5YZ1SW87X<_?BL)S;VNXK9O1:A!B?3_94OS1BE:Q\>C1?&/\L_VRN="[3 M^:JTPFS(&-'J4A^$N)]DCCHW2$;3L"UZQ6W*@E+;V)>*%<9'[W!9=YP&D7WO M0N0\_-( %X3;3+T 7Q15[>K4W7DXEWG$QU04GCF8]VFM[P>BL?"0GVCARHOD M8EW3.-W@!]8P(XQ7'7 HL$ M0^WV5&9?/+;M-!+HV3V][+B8C.(0:5^[N$0[U\M^\$[C#$)=[PS_:;&0_Y\. M.M[]!B30V:$(/D(=7,F5+&1;"]1M*VSYT1,]24:BY2JJ#/:FCB MJ(CB!CPW94":%->R2B4%&7KR!'2W21JV+VFJ(&!1%<4PLW &!!+&5 "&O/P\ M%'M4MT:K3S1E1/QI6/D(B "^,2*Q,=3+*#25]9_D\&\?];^-U:_3= 9_4\:_ MOF, [(K==\U2%>-1=9C8@TBE^\C*[9$(AZ^J#X UP./-K0%BX@:R@Q M_Y(FT0,)%"&T>68;[3QB\K/<\BLZ(A3_D,='F>A2Q&6%2-*VB^Z+<<=3%7DD MX/NIEAK> =7'\ET^SLMW_.17D]!Y;:B.8I)__C#6G+B X+\*$#$UE/[D\N@% MQ2B1 %-W,(H C\ V'G\JJTRXNOMO9_X;-;@KF>H0B-X-NIA(#?QM,6JT!\02:?&">FVL>TVJJ!-[UK#3!D#(EZQ# RXFRCHH=H%0@-8]L*BTR@6'I M%R\.T%%&[%OO.QY96&H<016C^W(3QMY/=T4H+=&J4J^_S1W;?2LP4O4YL>V3 M;]M0N=T6KV^:\DL\PF4K1*VCE9$J<%K&^1A6JW: !$J-[B[,ES.1FX/X/V9+ M8(#G^*6_+95OOI9QK?E-5[ZC$I4LSK6LSA2A61_67VTW:I%SB(,KM2UY>RUB M7,(*E.%TG//EOE-%\-/L"L='&R+U,^.\3]N^/:I\N=/N%;V:.G^'(&J1J2&B ME'#$1.!Y0]0:V3M!'5E*;)I 5@O,1J7GGGGR,A\.[16^AF=#O1)9(F#5'AOLB-XX*TD6TMG<']9M:K 2$]M2LH.Q)H5Z'"^6XR M3_R]*&.EWLMRFIK2-A%K@PTG'5CYJUI98KB7OZ?9! 4TYN_!)Y M5MR%6+T [W0O+&H[W)MJ/UB=,"(SZSYB.O^0^\[PR_[.*^DG$22INI H MMLC\&?IORGB7 \\POV_%19\3*+!M828B@3OR%\3%["O4=1>PBZ*5)&=7KAX/ MDU%3)*#_"I (T4#P@Y*H:,S2FIVCY09<9TA"=QFBU'8C[R.V[!<8&+X_AF-@ M'56\NTE[_UXG'>5SQ'$UR42D4F280J>.@(WQQBT<7O_1ISF1NSZ MQ>2OKO#$X?)ENHJ1RH.!AR?O.\ULI N[Q8FFP;W05>GZS)^NKR38Q^S:+<=^ M)=Q2->+,\G_D=4'LEYC@QV8E&*55GKN#ULN*W1TUK6UQV7 MI7?/DED^F/K,EV)YOF53@FIFILSY?AHCH_)](O$SC18W(5%7G>("E:N! :6E M,G?=C].1D+N3*V\YHY18*CQZG.Z R'IP4^>3YU,R8_2F'S M2\:$ZMYG]YF0QI>E"B[)+PO3WB!33+=?8^%\):)DS]'9_[GB_I@&K E+ B+UE,]<0&/*\&,=5+WYEZDR=+1_6O&_GQ:GCX'5-$#ZZ[*TJS,BQT8" 8.[<&O)-ZXK,R279LWGJ<(4KHQC\E7PM3JUTP(- MN'7@JMZB R<**QMB%+T.RW1F-'Y9IP%G4SZ@,57HJ68LUV6Z^XA3-@+NR'!! M_[589Y"X^IO8IQ_RB$3)9J&.FP4HUF[*%J"5>7:"!]^\@4APP7NT8R][4K=, M^D4+"30/$/DH?,DS@=6S@O/-RS3B!\KDMA1*>8J,GO"0Y(RN2*^;%VJ^9U&? MW!BQ?!<9#E[514S@(\3@&/PJS#^NV$ELTH;L6\C 4M"E)L9K=0N#:0R */JR%Y__MEN5%];,8C,/7XKF.Y)>OTY*-&?I &5.]/_)$R MB\ KG.1C@@5[WNU.+V);7F7F;Y;X2$";@"R"=!"$,;3&]O)'>5T7*.!>![X9 M]H$NA <<8C-0]I0?7Y8GW-WL^ '[KKG)W)K-B P9[N+_DN^P'P<2B!&$UQIO M/TU\NU1YC@7[(8.HP?BR##*;22KGY,$!09?\01;O I0D"=BLV:PP9![:2*$0 M#5I$*S*,&Q*/!,"YFT]W)QOAS$B@D!/%TX%[E%WH1MEHSP1--8.7?,=9^.9@ MME(!.0*UHB*J=S=\ZF>\J*3Y_+\1/#5B/)FUB@@:LGEJ?&SY?4 BD 52SO,! M3XS <\,F\6I4AGQE1K>!J?S&LQM$G4QEQ>=C1'-MUEIPCGMKC^Q%M>[TD*Z# MRY\P)UBF<$.FR2H_LB0W,=8&'@Y0__94QZ '&Z0OT%.2]GKV*/8]YPU(8;X1 M<2 'SN>H!C$_(@UH?J#*=F#L_*R5*T?3O[3AZ!M!*L?K!K7$(&XP-VTIK5@5 M8[#&U_;GE P0@^'JP[M>CVA@0])76H6@F#%SP5Q66S"XL6=<9^[GN8H9Z[F> M=VKG1_$>CN/"2@-;=.6<44VGZGN;3E^;:NTW&Y36(EK;DUFJB2+#C"^*V;EM M% %?SGL@_[^K,?)V_Z*D"36OMB5O*"C^ 4O_ES2KA@R*?J/UG;LH),B#^H["B?2*16!7?D]'![&[7):N/4QW [VLK2Q KQ$,E%'RUPY?\:G M7:*V3)GZ0M-'#^8G]YP*ML'X_F<0(L4=MAD$X]$X*UO;#,U#_0E984E5MDLB MX. POP$_6"@[Y+W7/<_3+_V^(4@ ?HR0;<4M$;W#^26,M> _R:^(X86Z CW& M>+SD3;T,QJ69'XAFV$XY]+U7A_OHWO&T+41_W+Z2/M@DR5G_%6E-!%'>JXL) MYE_W^ZM%1M5I8:V*\L?E^-2R;!ZY8;BT72 3K]%A#$FQ$:7S88SX;3D^TP@7 M;C; 5]::H%BLZ*K86080_!9=\/F<390YJZLAFAX@@9"3 =B7Z/O+"#_= M_4BUH^)-Z^\W4Q*OBGMT7\--0;OQ^P&XL#G(LJ9;ULN#HLY%/ M&[!O^&D;.^Q=%*OC MMY"]5*^0((39Z1/[H[@D\[;#;Q*+P=(G2BZ>@9#+%8T3)2>/MW)C8?Q$-SXY M3[+ 6;\B5C)/!^16Y*($HW,S][,>XRG< Y\,CQ19B7T2"4("/JEJ_.+.9U!/ M'V>^902N]2?-DZ9D/WHDH,C5(;6D-[1?"3]6G2W,)1G,/B@4?\A\I:%V5'!^ M%T42HO,@>C)WGYOKY7\NR:'.DH 77W3(_F@74N(]X\Y9-)V@9?]T^>ED6'#4 ME$UY"O"9%$8"+EY_>JYPH9%TGRVT!O@ MU+XT9RHQK)QDE_B!NOK%7^#!B]*N6->D^M"MZZ,]Y2Z)KHJ&/]E22\+6)ZB1 M *W!Z]F9OF"B+08367W\+9[Y-#.75'.GF?/)7V^I.C_><&T&7&M<,T3<"O(J MB$1I\1<5*(8F2Q4\J>(_/L#S"X-0/:EO:J(0CN*=U_AZP8JHM7:[5"=3-G*8 M=V41@XMH/TL#W5HPMYKY_>PSN7 BE.Q;S4K;27XE34#OUVPHZ@T%M M=8O :GTY8J.MW8]C\JQN\VEK;'"S"XNX7VB'@-D&(525]!0LQR5/JM,B[@1O M?Q;>UDZ+6"X\*(7ZD^#AT1)I,YOA%L7=[19>:PR/18O8VTY[#BI2&KI<-5V+ MYI! &YP56_N]9]FYW&#'?.T]&AV?Y34^##-5R">ZB1D91,&=7QP18PF4(;8U MT? G, VMNGOO?K4M3[M&SXW/^'?5?J!U9SGD)QJZ\B9&'<;%M>"SXWHDX Q) M*?MNI;2/2,V%5TF=UWXS+H=H/#.2]>U6^\E6B)"NR]S3&!9)/0'O7WHC?B-J M\_4GI>].Y<+S$;6Y>DJN+SZ@GA8A_]6YY?_=AT=]]QAJ0^VY86.X2&"XM*]T M0D( "?1:*B.!2O?KF6TKNQ?B/00>!6%.Y82A! 92BFQO#%ASDKO^:MSFCXYC M##-\26=#5\LLO5?!?>=/H&@@+7E#WAK="C1K1!*'-2\?!"PJR:.;>5@74EEG MX8Y"1]'QOK_,D3A!"4"-QK7.I0;0^,OQ@-]6J<#P*TU6TT6E\[E%*V4N3^](C!]4CC]8NWR@ MN)6X_K-NT(NN<' RF%_B/?8NQ?W"]TJ7 M+3/FJOV5T5(KJYCFCY!>J[QG<"FRE.R#UG[<^2WYZ-_U8-4)04,65[1*NK?4'B@*Z!1RT-=\X_?*_1PFNT,9.#QT.$ MW/N;B+84GJA/9BO>HE;(1B]31/.*_/8R$I J/=3/8KDY6C1@%Z!& MNQ5O+I1=V$7EQ[MB SG#>'BF_HFE"IL[2*,7!6O9(%]B'C=L*JT&=./H9/>% M*RUS/!:J'_^(!(S4U.AX:H60@.RX7&.U5P$C74JA'8B@MT;L.1;Q@V/(%3;3 M>>JKJWLQ2& H W75^*/0DU?A!\M\:KE"B9HRCCX[XJ4D,/9NZ6.O>6+Z1P(\1DC8SY^@RXRM#=3TJM8;\ M ,3&@#+?=N'ENX/8[9H1D]4G5(@R1Q]QV NSYR)SSQZ/R.Z@3FI8.,/;Y9E& M&)X>),2DNK%E;+%A@JDQ=L:E6Y:TY@5F=!H-G6O/9-/46+Y4"A5KSZ5+$:*& MEB]#I:N([I,5I"]*JF"TFN1,L3)ZMIX=3VJU"%$KBP26:+L3% ?CR ^NQFKO M_/KU8WO+YH?^T^+/+= Y'AK5A0J@1->(=*SV;5[&T5QON9W'=PWB]<_BRZU?"0PKD-Y?^[&+KZ,,-+#@ MK6YW::J%>G%^VL@9.=Y>GLMKU!N_]"FQ-4; Z/R:G,:/H MEA4Z*5DYX'C<&AK)WZK#[);T;>%NJJR2_3K-4?%3K-[>^"-%$A (.>S M6;0AU8F#6'BU^%Q;=\@P(6S[W3TFA-?0T(J*NYG<:Q/'6;P&\+)F3[X^"R/] MTPDY2%8!N5!1#?TYUHZ_]ZV%OJ1+RB 3.4K*R[Y()- YY5Y'2AH "OWMN%]8 MD>K_W/[I =:5U? #YQ&KF%LWAQ@O'TB"Q\=+\PRP_!_>A^RQDZS85C\EW[7* MW5J VSB-O6"14#:Y_$BE*[UJR487;1M]CMMX,=AS3I#HEJP5F6K?5%\6,7!A MT30QMD;C$.D7.S:EZM!\?J+.YOK$IVS=9*P *[]ZN<9]^VI CWR,A4BTZ$BF MYX"LY8&ON8M$+?6/GCN KM,I\^BZ5%^_,R;@VAA=EBEX6/"5PKZDZNA7524D MN[Q=XPV&EB\.Y!N%N-7:!Y<4GK?::GL.=[][(!)QOB>JD_)O'4X-.F[8:N>N M\X-&SL-KCDI4"+JATB^%S^\G1Y_D0\;'4==^O=2C0>H?OD9O?;+#DG9O-.!F MM[I).:RI3>>)46@A@?:VB_%:M.R>T^<:84UFI)%5 MT6>XUMNY%9Y:5XQDY>L/[:#G'1\&N#Q)$D%,8WUN%E?<[,8?+(LA*:5&'D>Y M WBM:GRA5HDA&4$?AI;5R-DV(.QI Z 0$]$1=W)IG#@2QWS1G:H@>4M0APN> M\_G('LZ2THF5G(WQ?89I;3/WS'GP>]FIM_!]M<301UP4BT>@448R^;EL&@'K M')-UX(Y:;'C*W5>=1.)&O*/%?816>OM1M0,V\RQ5HV;6E0Z=^+S^N/K1670U MXUQ<9C7T9,PF$Z])!((-XI?$C (61^ZT=O J96 M6[>3AS E#>F&9WGIBY\ZD14RI@_.:Q_@])%N\6@^Q;WMK^I*M7(1V\5L M"RV\. +O@->?'5CLRX2QYGP40&M2"2?)ZTLIF'AF&BV)JE6R:!M_DI3;SO8- MSWQC9W!_\@#TTA1/\0#^^+A._A3/(S'L*LA!X;)'8@6AO;8FU!,:IC&7,IX8 MZUDK].10<>3="SKM$@F\V&%>+F'JQLW-L*T'M>'/BWX\'3A0)BZ M. )6(^>P3%(_.K]JU61O.5K+6J#4^/ >+KE6JULE@MW'P-[LW-,O23,J^X,V MWDF(KD:8E\[31.A<]%+3YPOU34H3U"]9RY0BMQ]EP^TV;#_4%9+9:IGYUO)(I%'_2MSV??PM M>$DR5>CU56LHL7BO(=VL"X>J\6\ M;Y#4*ENS/QKS%4^1E18'A/\GGA+W5^%L'EJD&#$&Y/W3\T+Z[Y):10/6ZV^( M;UQHC,:C$*^:%^L <%U;IH\6-1R1G"B4C"^(_TQ^=/L&5"B+.*H!\F:0C//S MK]#SR<\3%1B+DYY"Y!L+_C_Y2BQ/6X0M;S,B=^.G^?5O?+ M1/=[/]@F"@-Z:Q?G5) ^(1#@;Q-#3'!42 &OO8KXDU:*N<4E\-JM-%)JGY%-G M QSX'/@T9/P-NR.[8]QR07IF]7>F-9IGTL(,L$5AM5R+F\HYX83NBQO64KU+ MJ1@L6*T,=H,?Y+[1*>S*WQ"B5=%-MM ;4A=! @M*.O>9_/ <:L'YY#?C-"+& MW32>WX[MNB]4U -&-#U+?5VF %]B2W%5HN4!\@G)LVC$WP4J-MQI\\3 4Q[D@7$BEIP&TU+TZ$ MD;1PD*L^K.P]NI3DLMZV*KNX+8^-&6:<-)D4K2%)Q!BAV7"2$QXA7WP(=C%[KR7KK\/$C@;>+"Y1%/CC#[Z^6U^Y5?M=964A_? M'^N^9[##"&F(WN*(_6 \'^$U90B^>(/(*;Z1Q,5[8GQI";?ISD<"=.[K\->( M6ISAKI++3MA[E2(4:918@,RJK=D^BN7*#W*])5%Z%2QS7[;5,FH%QIX&%6J- M!N\@ ?8HQW.*!V='"*TFDN)2RZ[C]0E8N=6D;^85;-Y7]V(RV/3T7]VD_\_X MOQMX;Z]0W"AF/@U%+7K0O<]76[?'_=#?L$UO[3"C0O#YD1Q\RR\/]510M!1 @/ 0%I)01+?NJ9& M'9,*Q3P! PT%1;37&@$K!A'?6"3W,.:UT%ORKPI@ C;K/Q8 Y&B;]IJ$FG^1 MM?]+W!9-[\DVJ3@7Q]V\;4-BQ$K$4O"<=/W5)IS/J0Z]-EH8BF[:RY2MOI2O M\ ?JI>@OVY17HKMS5ND8 @+]S/Y5C5'&VZ @0!&>,P&L(I MX<:[;VO.CKT?46"Q!]5D+#=44HZ[G?-=ALAJ?A3"/CF1.-Y-P@E(OVW3: MPN\LV6-*/W(\W-:^<5!M26?VC>U=^\>A63Q$8#U7"X39=3?R2X7G;1C)V:36 MN_A-@^"!EF62EO@-J0VY*@K^X;R,;K%R!QW8)^OH4Q7Q*+U,+S/XF+PY$9K$ M)W[:OQC5O)4 '87^*3&^EKVC#H]_\8;ZB^#[S_W6O8H6N0OWZT)M$L%%Q2(/:;WKR=)$Q:QE" M3-<@!]CF!X1L!<9DOYWU[][\S"__ED*0 M)[+[(XLRUM-7' ,OGE7BEM_2P$P"F49HXZL>96E$65N_X5$(>TFQYD\=D>I5 M; I0LF2!, ;L-@6>A_7U$,[*+6 U(A)&FS'LCOS]K#^[8TD8?%"7*(?CHHB8 M$+O?SM.G15M/9(;6>C+[RN6H IFD@FEY=+-E5-T#YSX.:]>\:X\8VCF.Q?SJ M^HJ^9RZ:-/JK9!ZBL^YYD"T;>%>4I[RUWSM65;+S6.BTR(63Z9:'WX3JZ@?C ML]OQ+C51CEB*XL(FWVF0]SOP(I2:TG@/ M=<(O=, Y=.G&1S=:NZU=J_X'>^\=U'3;[7N'CE114'KH55 $E"(D@/0>>D"0 M3L!"5T!ZD]![[PD](+U)4ZJ (%411.E5I+<0WL3;YWGN??8Y\^X][YYYSY[9 M?UQ ^(4,\RMKK<^UUOJNO4))]U7=O0KUD^OHX=M'3\)W5#J.>RSV1(WJI_NKE7_#3*D\[L8]MG/[2FV3LSEA7ZOV+?EU M!6?XADXT^&X 8W\0+$H M6^_$@/C2WV/08VD"IAMYF=D]U3Q+O2]KP][K>>\NB&S*XC6429VEY31,>< P M/H7OER17+:M@8NV)#U^$SNL&*F(NG%=]5_Y4B2Y!Q2HI^-T YVU0.+0,SE;E MUCSN47*8+2XN2&KVN0&Q1Q0O?G72O1%XC5P M_!OAL?):.KOSSX0>%Z!DAUN$KM12S.4. M-_VB;'+E&Z(U$7VA))5XBH#S:6;/#7^UJ3[\VDQ&14UM07MV\Z8JB4D,R[W: ME\=&J2+]4@)9Z$*T3RZFWCM1B9OP3O\# ]MZ6VD6"C@Q'F54K#>[K/Z][!&) M<3]ZA.>NZG,Q=B!(D/@C'N>9(1PM5&.:*VU;M"*-<*TPCA\_K (WAK !!4K, MZ6X6Q&XXVJ_#(S0;(#'ADFZ47^>@PSY<%!OT MW%I;W&B1-95'< J$&7SK+[ MF^?GEE%[3EI?7M)!:H+8G3@FK.'7,;+A%VZ8NMU.VBYLZ&R-:<:RTZK=6O5? M3<20&V17> $>>11SRH9!8[:U\YC4NS>B28I<FV5JXV^L7FE&3\ MT?)5P115(LGC9?45?H_=3P;KCH74U"AP_A?.>72L!X/=]C;*>JGAI MV-\K_#/#7_1X3RFR\6= M\?.*&38UQG#Y3S595FO9/#T]/;>3Y#6)&\H2U@N M%Q%SO8%=158'A,[BAR<:#M1R^> MVJ4?CL,A7V*?>=%VMG[<\I[4Y8O@3HM*^"Q1_OA 7%?^+55H4,)JHB8>8:4] M7G/7EI%$T>O"7GR ,N\2\T0T_6OVN_Q]\CZG-^8@GJU#^%Y7W;TF^L5[K*97'3V2X-;G^.+J^)V[PL/(V-)U;>IG M<++N[L9Z,02;/96VN2F*:5&'.L7;FFLE-:_GO@#3:Y+)&(&)9S4\RWWMT@;L M;%W=+H$_^35JV.C9;A=$01R$53T[6GG>W-P1.70<:\Z08XIS55M,-$EY.(A' MB/Z^GPM-R6"T=4J^V HP\"@W4CZNE"DK&,-W+[\R5^(.81Q$\"1,^E!AWB%U*"9BO4*(@CA@WF.AW M5DF@U#I0=1H.7\_F5%E@2+&;Z5A%'R.ZJ)74(\.TJN5%^SRW,;YE2E:K/('7 M3!]R*"1.9I[W9LHSD5'2U@TT)=5!?$9OTHY!,M2(:9N6&$5P)>SH/U>],$,- M2L@@6_=,M@YB%QC9=/:IK91O6S' \^BPF/V%0G05;&+>^ 6LXB4^"Y\ M%\3HF."FYJ4WPK(&X/+>DRAZP^(_HN9"?W9>M"TD M>FK3&/F;N;^ FT8;H552H:MHDK/)LYZ?CD'_ZQ/U/^O?+8)NOWO DQ*QW4N M5NZYM%$J_. 2$!V.$1"D/L/^]&7F[;L_;/A7:_.N&G]!MH;8I!1_%&'8>[?]>F_U93P''"U6S\4\>$ A;]:GF?^+O?[ MKPKT/W.(_RD?A7W'ORK6<;7IHFKTI83,-+-Z, >"J06+I!??K]^U'5LU_?JI^6 MSRC7: X-)EE/5D]JGRMT5.EV57KU#GV[UG)CY1;[0O-Y?'VTA]'N-G%S9/4^ M8]"0:=.8W#[%&>/**[7J]G0:#QX',Z[GF*Z!&5^O)6^;:3U7"?$/)[$8N3Y, M2]5A6.5&CB&#C-Q!4S?"\;U-50QZ+N'^5KN-.S>]F%AST M_I/]:"$0@A==H#T9!XO#\]^SRM)F M.W!#KPM$I>'ZU^5O)'D@: O"\.Z?!?BR:&\:04K,=NWY6<(<]UQ?(AH9B#Z? M.G%\M]5\,A>;4L/#S(C0B/()G*IY1@*=:6+!'G%U_)2>->?0(TB=B018E<3U MB>5! OA=-(@7DH2DF2&!< #^4N"CIUE6W#9D=]+ RF^ "TX9#8^F[P1?[*(W M2U^CHWQ-HLT M:2G S^U!.6N+U>ZDY?/$#4&:%M(^[-R-0[H(@*4].EYF\QPF^Y1S3/0TU >?V MD/?2QOCS<648WE'_AB5%#Z+\TX5;W13'P!0G@?EW-V_O1^@S6[-O/GM84*'P MM+8RO.?&WC-R>[?D1^?& K4!+GO"JM8))*P%=5/;18WP[P^MX4_H/[]YLEJL ME5YIH?5K<^,R[IU//Q:)?&TL2NH/NG$U=)&=O-V0_+_Y0K?S4L:S$ M4(%3PJ+E+KB3GA5M2*UZHX$[Y4=B=)_+FD#FW$B"W.:.H0F!BG&,"SQBU-O MS=A00'SIN_O(HH%M>S,#IP/Z2GF-D@"BY%X&DN>&Z/)$E5L@1VR!/F6)>>[I ML_F@P L!U<*5/)%S@[PWT>(3G>5F0W=%DJU$3@V3((/T$);7$OV\XI!OQ"\( MJ5.GZRT\O@:0- BJ) Q'VE_K!=)YB@^!?29]I6Z8:OF^O!! J^#[B8=\0W)Y M]46\$IYI*+&#?7@25SF7&5Z-+DW)P:LW/E9UKFKD2KQIT2>^-@Y;?]#^6-KX MU\OOXV-=M*76<6VT%&0=3RJ8*Y:$VEE-^IY],XM77A5FNO#JB-:]I1NB0^B2EO%.>MVME#^+C")L]^@ M3ZY1DJZH'UA2=)%-ND3VPK#VIC"2N,Y\[_X2R6'1!7SV8F\50TRR1X<\)H#DB\VKOSO3V1WFI^57TG8T3A=9<##K$7M2.[*.RXV."HF[G%:9):E0_ M ;\K(M$ ( !10/V7(6.#9,R+S\ZF2X?T#X[*ENU6E(4]*$+)RGM@[XQHF,? M%OON(2ZL^5.:2Y0>\=EX7ULX]QNM5W7L BUQ\*1\I8ANQ]"Y42[42<,TA"07 MFD'J6;G@);/^M.1Y@>CML.?YNI\9QQO,B>S,]LN) %FW#U%I.A6^5(XKV[0: M=%]9->]CS#EERQ2%Q]7*EST:6@)9 M">5V+R3@H%;,I\-+ )E#NC3GM4N 6H;#]M;BS/S;ZZHQHC$N!VN"^?4!IJ9< M7@,$*[+%S470;C#,S$J52N6 )=2D+"ES-$U.2 MR[^[\!H2FUT;W$I"'_8R) M7QNQ6TC+3Q&<^V4M,XI/$1N-U7X_+?B#XB1N1]UF;7TM>UA5-.,;KM78(-1< M&&V0>=Y-I:F/R%()\5V8H]4U8?H/];/9G,1= KI3=#<&T9O0FE=*HH4#?;MD M@!^[2OP.1>S\+NIP:1VL(^"$SO FAYI:@383?#9-9(;%A*VDZ8-KL-H3],J[ :<1#L+R2JUAQ-G M:C,&MHV(&IF7LHSD%?6;P1_<5%NC.9.:GJ>_/NQY6.^Y,LT=("'97V8LH,)) M''>MV/%-MF.+9^EX/8$0M[%6,A:+QFCN3A0B'];S/= 1640*L:VK@T/^13UH MF+0>H"!FXB_?^&?]K41/-0/PAYE6 LC4<-(A_VB3NG\)\+N-,B^[/X_]!M ( M7Z9='$O+==>KA5O=B!L[0,,H 7>$-TOT#X0%RRO-\3+/73"3'O\5U7\JW8$] M ,/V%E-I^_0P%7K=W+?:BI@HE8#]I*\@C@V(#H9CU. M+RM)5QU,+$"^'G4GU-SDG KA8Q!J]LN1%-]LXYJ9R >YZ.#YQM-C1&\$9_!6 MRB:K7#P&1MTN1>THK9>68M6'XA9CPT50:B+JBOA-NLJ+2@ZX'D,X@)9*]3N5 M:DG%YT&QU"=O>0>N@JI.CXO,6V\),EO?YI\A09GPL8>RZ<4%5Y7^=%0>=1+A M2G#U=$/"?0KQO 50'N.!& MB"11A8\>\DF1C87QN;.,)NP.63ZX5]I;_UX\$63)U=M70/G)JFPR[-K0*?'7 M72MQ!+ @':[$&0/2=P(M6+HO;F+WT+*8?H2G=<3:_C<.[SYT96) M9V;6A\C-6.U5E3LD!#E:? 2YCZ7& %S77G@6O3EMSQH_63WD*7RFS+820F'M ML>9/5L4+.%ZI:*RJ-TR\!* ,(VR]0/UE0IU; EO%#5Z'9<\3VGM1U\"G(\V5 M=HL8^=3@BWQT>8GM&HG:\L^FR?139$SG0]+@&"_8.EU"<##U/N50"\!_?+[&.QC7VMP-O#3H0$GG_/N_^^= M_O_+%S7UR33V!'/'7GA37U"6#Q%YO^BM.F5XTK$YY+_VU-S:5,&:X><#7)ZK M7$'D7;8F;5TW[E8F5^06$L$Y!W(U?GZ'JQNZO\=QT=;->&"??KD\0C%<128N MC*>MPY).00H69!AAOT>#X@2<\'$C/H7^,0@4-R*:_!\INK^*5O], ZV#_#GR MS]_^@,[PU,O&>G)%9PYRW3"0D&0A/>#$WK??:A2EPJKR>*UGW2_\*%V[S*1. MO[JZ?.HKP136VYO[+II;(!WWUXWP%NU$$E-TO$@F?"X!4@?DFH8L6G./3-1I MOG:< !U7DB2U7@^F!:WF5VIW^^]1@PXG_5$>C3*;B;N\Z."1"P^+)8>8Q90^ M?I4Y?A@3\MEC(]P$T']6H\+_2#FI_FFZ)2#[H^7T#P%=!/%Q$&C)>[1C\PAT M0=9>5I7\B@9[[K_A>G"K+P%K!H<&MGIN4!^LG3#Y?Q=W_+]@T;\@N F)/5I/ M%E_K6\.Q4R-0EZ^%^THEF>>HHK;H[62:KFOO MFDBXLA(WM9U)BY($U:[T\E,R'-.T7#-P.S/P#//<(8OU$K1VS"$EU'G\.BM9 M[Y#VI[#>]:W,]L,)SHOQ#*ILJD-8Y+,??BI-S,1I<-+JQT3[.:1_ M :/2V'>"8Q<5_V]F1HI[5$'1@^N:^E;+DM7%VD'7;I%E4-)6SXG&^0 $7PSI MKJNN5-6#',[(DVFXV#E)"\F( 0?% 8 >]B3O<8J"0D.#3\*^:\-RJWP_^5'. MA2>AS!5&#[9MD0'?+2+B6(6QQ&Y!Z7C=5PMR;4VL6Y MJ%0Q 'U 8$UB_8-$S(E8F,2XSRB77I8@AI-VG),*G^#P^:\B#MVQ#",//"1G M06P>3^JUU1W@.Q"FC3W^ZNX]L$0IQ.5;ZH?XED%VUC1=<(/6FO;D)>!=V+1. M+? H%'$N?P;7KN[UQ@:E[1&8NL/Z"&^EW../, ?INZ+NP:7 [/O;I9]CWU6< M"DCSG?$5$Q(4P1Y1#94?A8_$E^ MX$R^[UU--7J]&OY',?W.?%F$!+^*O<+?+!3VP@CH))XEWV/Y0.DB,@F_\8.6 MIL?Q^>. Q&$;48)*6=!JQB5 %"/N>+3]=)0*]=DP(:8_5/!12CX>$-TBU=)DQO6TF+HLB Q:'U\<[ MDY^<)+R>&?6KL!E3GR'^1-7FFN"-QV]NW^J^^(&AHQ"83HC(]OQ:?(98;[TH MO.#?))B3\)I^ E[F.#Q^_JL\K?A-0GL%-,:(IG?(A\S/,6LO7X@KNH'4=4A; M(_87(FYI*RK:TF_<#0ECD&S*,M,"?.2,I'#;,GV,=D)L&[?FA& M__>GHR24BD*TW=A8$:?M4!=&BPO$H% U*.'ML90X"-Q:"'8)V#T'3K5F56^,_1T)'_3."3.@4H_B+Z<:B% BNV0C:-Z^Y#5 M\Z/+VF1>0IB.')&OHLB-6D41,ZO<'*E1/%4Y&1@U"L!>-DVP)&Y5D/Y":0+O M]0977*RYX+V7_82L94[:L.O4UCKS2@6/WM,[*H@FUFLE ^BM9#;HZX]P+XMR1"#:<*S@N@%/B]K=Z[I!I36#M)&[?4)%6[ZJN M(C=[Y.\]L+&4A( ;"2F)ZV B8K@:@$^L+OV?BH!_K7Q_3(- A\GQ_&9!'OF5 M8Y*QE'A).76X%16,'\:';TK3JA_\E?>@,J'Y0OR%(YE_BV#>__>MWZ)&-0_Q M6#7 CVL*8C!^T*MG:&VQ+4:D@UK7F^LATLH_#.\WHI[9J2DRG^L]>*^<]CF/ MY)/&/O4K/WVOL "@.CQVZ AYS1L.\%?C+Y"[F+$0\5T',/^DE[!8$-O.RVW3 M_,;_-7!'0^->[HY?4JOI!,166ZD@,+*^K61F?FZ8]FVP"@&,/$%$L_C51%H1 M/C;T9Y#((SNNOOTCC#UZ6Y'BKD@"24D>D4R'@$TH/?+=>6QOZO*A(T#MC@P, M&XS3LV+#%+BT7J>YW_.Q3/ 5+;FFQ5T$'=%!NV*FQ%(C$ O7T^LJUD]M;]X< MTWK/01-R0'@),/.7JAV0E(&] 0L))=P*N@1XC90#?ZUK[?20TELEI,3%28IU MLZS)\&N/8O33Z89!XJ1Q(A[@/,(5N!X6&V1NNN%MN&CV293?JUX>]'\!S"8EU\ /!;BSR C4 M=R=0"_,%B*IU767]5KQ&I/$1O_;^'" Q5LU4VBKM;1JP[D.3 0N'PM?-3 M;4[9)/?.$9X,1( _2J7S0$;91<-Z'@42G,[5JGLGTSH.%DO\X@\-'+DE.8+4 MFI/9:#UFQK7%5116BF0=7P)DD[6TM;ZMH :#EBCVI\JET/-($RZ+GMAEL[95 MQOH5_[>@9 ]@KTLNRNWF%\QT:_^J,T;_SD,J-P.;\UZ4C$%B*8*H'-A.Z5&= M>^"!%DS QDK&]5-]L;6ELI,J*8_2K'I!+_U1JMB0CNVKWWRKQ0J,U^(DQ73W M$G!+&Q/"U\YY+D75O#=]FC%\PV3REUUC7QFN#_+C*T7[];X]Q.3 _O=+0,#8 M'-8X]=ACG4SIFB[2Z1+ +HCK&=J:Q()%[$G:-]_KEP"[\L-$L?\IL_N/E-F% MH1TO ?$Y@YBW?9BPR15KE+<]CBNV+@%_@87];["0T"LMR(8RQ-!N.""+V/_D M/A[_9H:ZND_J8*IB,@=<"YQ6$? _\0^ODM99^0G6J94LK]DE*?13H+=(2R@X#@;\UP%LV\K2A05!N'R5*2E M/!/"=@U.7LQW1<,E=;,"E"UZ:XX\7RB]/3:T55/ FN<6@[C_$R_@LAV0?S6O MJ?T1!F=J)\6>PQVZF\[ :VQWH/G7K[*AR86)^'OAJ@>VUF"8:BHG=.J#!\0)1.F M+39*Y*!2D!) 1)]'@,)/I:TCS=5FZ(C^1YE.2O/3)]?B?T1&8(Y"N'K5%_1W_6HQQLG%,$_1* QO0_YPAD M5\B9Z/,RONB4#3Q3NI_HZTHHM0 MZT/9.T+H;@@)+,4/!]7SU49[HM6/YH9+GGR\^ M?]TMJM^:*[QP_!7H,NJ''\NE]]:';.CCN>;7 PT__Q_JF0T;_NQ0)A$U+$0, MM9+P9R[-@7;OG(VALI;0'[47H<:TS3W,6Y*Z8&.1![D3$^6/\Y:^YR)-YY3. MH8A>$M9QEMNECJSSEF/+G>JU,JL]3H5UC\X,='9]CYPGM!*+WHB&;V MU@;M-C>R"QN"LXE?+1\"%ST\9!BTY,H4MLF4DXODVU<,@/V,F9I4I M6VKESPC86*ED-J"CB$<,M,4KA(Q0LMV,H<+L++J)I=2AK\M/ ?X^7)\D$F , M4RHV(Y:\()1 M298_7?5-;B!\XCO!RR!3ANS2=8V8\+(FJ%J'A.K2X"4K>=0=Y3UE>Q+WKNIVK9?(X M/YUB"=8#X\H7/C<>#>5M2UO__-:A5KI,*9=\;V& =!'C37,!RH:>2VL'R]Z+ MB2]=W#TL9W<& *S'(C]+FLX".I$%\$3P?S1RK-AVMU?.70-E.TQY-F/=M$]L M'L8=[]TG=45==D5:"'T=SN(W+21!\-3!H;38@*>'5E>-/]#Q/0;$@0O]IT'6 MEP!@O*^3;\L8SD2":765^ "(9TD0<8#(J9[^QJ)[6=KW40)^2NEZ]B)">Y38 M^(B:Y4)<;R*DRXV+A,^U;6*":US+1X=XLG[);;>)\^SZ5"4BA/G.2G. Z''9 M!6I?<>^#.J_UK [G"T]_1DHCD]&\QU^(LWA9U@/YBT!L<,*2.4K"73!#JDC MD]WZBQ-&GE9\M=L@EZAZED=ICJ-J; ML'+V9N:*XI)QV$3L_ MOS.,FA;OA0I#N]M:+O7_<]N,U7W>[:^Y M#UAT-7/VWYV9$+4;/MONXJ,M-J[>V; M23&[X"&0U/BN>_S,B=7/%1N*:HIMR_?7.TEVQ?>S!B),8V1$]9/[G_4UYL*_ MW9@+%/I"T/%EY&0RTC\BAS8WMG&0YA)0%'?G0LFI"\Q;SP?VT;5T ZI^>9DI M/^$L)!XI27\)H,Z@Q2@3U^-Q&P1^R)%C 4F=VG_0VSXQ1(755ZQ'-+PW: TD M>6A"!1).,I8<0037\WNR;%Y_EY'4TAA:M_DUXOX(E\5;Z[E >UU4X;26_YI M\TL3\?W=BS**8$T9*J;\/#M?1(7X(WG1(%KEX.UAARM7M@2E\4%79V^C#QJ5 MT9'4O\H+0JA==7G/Q;QRMR9NWJV[5ZM1WEPHW_7"VE/:[NV@_DFMCZ4/=]41 MK2J7/8EOU_.E@K1,&:,A0M]QN,[BZ'04,"JCTN\13R>UZR4 ;0#\U>RA<%SG M<_W 'C@5^(AUI-EW_86PU'2\*=K>^?VV%"/-;(]+["C*7=>G9*A0SZV&N;:GQAG/ZD]MLS5',UZ\'QU8AH=LJ-M^ITNF@ MRZ^VY4E%]]ZGJV!VZ1?W.;"NZ3JZ!54;<__==XR3 O]-+=6!325JI#Q#]52J MF_Y;XYVY$[,/!)? MX:(+3/4.^)V6LO#$:UOS[OZQ\JJ*S>K/&*E]#85U_@ M%WI[9SP6YNMA2IR*BL6&.+S>SET8=B5B;SCX/FW=EB_?C -]<)5X/B/] OE\ M*=HQ9314@2:%S7K#<5V2<#5P8I)=),>D)5LHG+QQ*/6+W/K)03DB-:[?:V[" M&P+M69KQ0EB9!K;53MRVA @KFYT%;VZJ2F]0:Q)&[0?/,Y3VR6WJ*J8PK*F@ MRW0DN1;IE\8>A]N3,/1)%HD F)F9K7)WLBBLX8_["-@H#@X1(CZ>78NT[]P2 MT>M+]L%=1:PG0$R9@P)3<8>ECFJG;+(D@?/9Q#5O/\DR>5ME7DD&\4?[C?-C M%1)=#_S$S;6RR&I,2"6?":9U@'8E6\]BEQ])\$JBRU/;5XU;L*\4".4O'"O" M,VK0DR92&7@I%1+Q?O53/<,M+SX*)M2 )"H;@(=7UGO$U,6%_9<8GOFO)_J+ M:+1= N(\.B[6/"2&F:\ZVMQX='/(=#&_FT\?*38,2=8#-6QQ.GIFXA#LTEY;)#<_6$_RCGW M7-RB(F?E];]I2/R?];]=#^XO&J&CCOP/5SK.F(S2IXM>_1MNLVH(ZQ6==2[6 M4Y2J$V7F5V1#TG;_0U.$2 B7 \)^P6?!%<'ATC^?M/+PHSYA<8;[GZH<8Y!1 M_+&Q/TU08KCD/O<_54EP6:2_O%G=[US0GR-"W'_U/?T^\EOPY$^6B K+B<5V M:0$X05=-@-(D32FT0/P6@IO3'8F-!<+^AE>!ORN#<4[VMRS(G^F%?_ 1B4#\ M3M(P84C^P5?].+[2LQ!\"<0H#V/YBA/+5YK_O?B*(2/M8@]XY!A7/E-\[:%O M[$&9^".*;S_45=7E..!0-2A81O90=M2*0X8E?%.WZAN=4,?N): =YH$/\U(P M$?40K^*=K4@/Y\FX?O6I.WC; M9_D\)\_^D*<>/OI(*VBH.)?C;I#$YDS=0Y=#FA*TX(WKF+CM Y2Q;3]@RBUR M=HHB2R &7KC&#\,;%K)Q%+JM6#3J]R./<(-?1#,ZL!_)DQTB!;>#N8&I"A*" MP9T+&9K$&9HBY"W1[PIY$K*Q(;ZE)D]ZL%8O'WEDAMDXC _+%\*PI#I2LT\9 M:GPL?7:)8C-\Y+'$V2V%Q-F*@2(3:06IM&$\L FK*%R!"B+OL0-.<:<@.\,! MBTN<+$9+&QB6VYX/3=_EGI>7 Q= M*YAYGEI4]/RIYD+-X%/ZNW60[S?8Y23[..,U:XDE*SEA4(5F4S>\Q&36M(/" M?C;+2F'L+1V[)-"61^.8ZL#0+_+PU/.6=].&7_+P4P;DL Z,)]%&?]2Q;1'] MUEL?Z7EO*\;[)/VY_"&+IL.7F2X!$I$@WV$#8]=M_@W'E:P>D\31W4?BLDS" M8>2N@^]TXQL2:Z6-*;ZSYDV:;FM^=R&3![^ZMO2J^*MX79M 0_Z3QAL)@IX, M9S[3@G:5M_.)TXJ\BM+AJH0!=)B#IW-^V=2KT*!O[&A>S)EX?Y_8F6TG2U>O MCT1EV* A?'DATBDL[AHB1F)#=!/R27\E)RKHL,"G/S^*PCZ!6F\=W2$U#1=A M=BQ\4[99W-DH*$'99$_P IALBOB"L+;[BC5C\?^I_3C]^L=4Z7D\2QWG M]RAR+V8 WTMP+=]0OCRB'IQ!NY&22%N')16/*:)4 MM&_?(6I_*HZ4#^/^^]E3(42(;3CI$# A#1Z(G$T6K1N8[C "8(BNXL ,,ZNT MJ\FR26/),F)P,!B2H21@Q1_BUIEG\Q!R@WQBO!^AHA$[&C]/"_C$#_1(\Q4X M+)L;(@_G$%]*V=$XEYWHG(G<&2CF0F4'/;Y*<8U$#GS=MUUB]651+),V1=M& M]PN1@6Y7@BTM0:H%;2D[R_XM;6][SGQT"8''ON"6QCVI?:BY"O@^0&+;K*VB M72,_0D;9>U/H)V>+YIILRYGR4< ".5&ZE36-MCU@D:&=O%;L_CW M^#585#W#2@7[NH&UC, [1D!-_=T),D<#,=(D]^)#.OIB,H#YA%VPZO]JAG#9 MC"+<6<;97 2>\MAO E3 %4=+(G &N?,/Y(!QUIW;WOP2T#?AKS96\77DY$P; M"8!JMZJ?0'CGD'C9[SA2K$?)K A&"+BFDF.RM+BS:$9(_5':]D45%-R>LR?K MGPW._FO\NQ(2ZPC/(;%;[4(=L05:I;=7[N4N.85-B;VL[(:O,1$&D?97*>ZZ MFVNU%<]2+#B8WP#)DV+LWB#K@$\3.=EC?AR(OV4-64Q* M_&N^H?A38<)T2).E4=WVM:<&D4]EM9Q!7V63OYKKN(S^*+S2_(79!DIT4,:K MJ'=]*2IG\@"5C"#1K#,,O7(U;UD.0V-NZ5.,"E0AOA/9>%"ET=#BWA#ZJNZ) M4M[5U2+07!6'6E\K4V+VW1[,(8)WD[XHFES35:Y>#K,SB"Y=V#J.W'.Y<'2H M#/0_?'Y:=3+!2,_8&)S?TNBPV-2T%S$H/W;#$$WII=7X/>*),)<-E37)B9++ MB=';]/U+P*VO^\!%DQ>CJ/>YLZL;$T)78#(C.:8J<L+<- M?ORNH1&2NF=X3T;MOL5[.HT3(1*^S0.V2;,8A<%QQ?C6V*Z.LTE7(1*'V6Z_ MA].(OA\6MRAJK'>+[T4^)\ONSK4L?$_L"EUA(]W&9< MO4C2+#[UV?%F:F>\ QR\O@K$\+PI"+T9B@=>$WPA#Q0+_JR? >U_ZSUB3 MN'W[$@#-7#$KO03$,E"?5W8L0B4[>U@<:(8VC%#6"])7BH.LA%%#Y(R6KY]V MQISLG!E< K;IS(CKWNKM7 $-BM]HIO>U5K@E&MFQGO'U^RK9 M'0J-#Q\FB)E7^_7\9ETCX\$.=W/P,SK=<"[K(%_530N57ZXB4?"EM]K?OVJ: M="/5!J)L%2$V]6ZK([?&7H\ %Q_]+/Z%69F2'RU4!9KU@I V_N\D!1K(5*@+ MA0R&*CX^_W T+"%/S>14&OL^09+9>D/0<+#K^'HC42?GB3[>Z4)DWK+M3HAT M?MLD6QM?QV&@VJHNT\$0+]IRL>?!,4T#9V2;T^K) M+Q^I[>_R^6=,B!J7"ZD# I0M#:J8A::R^P>E>T$[0?Y'T.0GPDGHEI#PB[7Q M,S(3]U,>XZ%&IF^\W\(' 03CC8VT<&8)9+]8V+>M@Y?4%[66EX!:/4:FY?4C M*]\KEABQ;C6L3WB0TB"J#8CJ+^]+NRMUW 7\F)P*81':GCV[ K\$;-6GEFQ( MA=QSJY@1O7-EDIM*]"LG0Z\+F!56\4IKUP!UV)-W3M?Z<%EKT"_W^)-XU"7@ MVENS54XCVR/C47^UD>FMRFG]YH2E9PG*^_25*JNY8S6OVKTG31C<1$LB%RPB M%Q_[UQ.:>9Z[ M((&OXW3VR96Q#^68_2%XUHI;0=.WAKH0#Q[C=1XPZ]OC 4:@R>%LUCDG!STB M25YM=\$]I!K>WSW7[E"JSA_T* (_B(ZP^1D([)'DKX2)L>@?B7T+83Y:UY)M M*VUB<94\7EHY> $K6E)^$?ZZ?E M79X#)8O4Q9])C@EU;M-@K-+=P>.H2\ L\",B%R/G;)T[F[LB(%WIOODJ]M0. ME&T7S7"O>M#T$M )F^YC9:]%\[ @+TJK!X>86H>$(_:JP!N"O:>L:+ M&3;:"&U$AU2!YK0O,JJF-#[]3U;O/Y#5"_]-AQG_H$.#]7G&/K2^)R\FFP3W MFN/OM,BBCBL6E(+_:SSC8R%L; 7@0](&98/)<"R)93*H&@#7_X/W)QGG\#M= MIZ#Y9P[D7Y#Y&P1QY8*_!T?^!D=5Q;\A8MV?)9WRB&[9.@+V_#?W2K^%&H+1]@+]2 1R+QX&(P?!EC> MX/\%S)%;>W]*%NT]_GW!JX-Z4X5<\X,?7;*SK#6T[^?4H\[WC(^'!N%#62X9 M$TUTF7>^3Q;RV#6=EB:+!6=-&*.ND$%U^,%YA#W"_)V0AP";HH%Q8WRX8/YWV74L]&FC>)IY9&9Z3?HI"&1! E&1]#]3OQFH)V M^9J6 @,3J"1F1?N/4+#R.GL>LY -95D;S_C M8^7@%$#510;8Y#Y2,F[!/;9 MDL\S3/0C0CG9+09??:4^4E1XO@F@DEWQS[;:,+H[X[C%<87EK;FJS7.#%K1B>R($5XM6U08QXQ@N-YZYG&54>\^N0TI)5!G%!ES8X#/@S MEK8_-M6UN.AEN5J'L*A!T:,8IF_U6F<,M8ZWTUY#\I MXL=A;]H==0W\+'XB/JP3L=@]OCG5. +MK,5&>4V7@&^HHTT5W @VR.]4"S]C M2GP+CM2,0"\GP]8-TM"]@>'TA6(ABRBEL5!F,BLN1)FKV"-$]LU9XD\RI&:"F.?K*B]ZIABM B9H?G MIL"5'X:U7_5;O2AB>59D^HD+SI_\:"3I.D2(6FQMA(LVWP(M9V3E=D^XI3C+ M&BBRT#G=WJ[-713+= >_D*3?IP0X!#;N7!58 M#JNB3"KVN58\7B+!B\S>Q.8QONW>]<%E5QZ!>]J$ 1+UHBD_DMW+R7]F16P<6&KTQNJ M39\DR:/G29< $6.XP;MP+N\[2[&8>D]6MMISOU"?9[+[#]4N 6\E@25T[Q7N MK=%=Z /'Z@.OB3Q0+G[""OMX5X4SO^I6$\>T(3V?K[*6L@5E;L)K2R9]P%E/RPSFTGFIG4] MJ\R:2\OQK5U M"XJ67]5I,/@JBQ<7# U(%[VTC#>^[C"FI-J8G=S&%#MA6)GRL_%.ZGFW97M3 MGD\V*.MD@__5,6LR:4$ZCW9$Y5(#H\=&06.\Q!/6<-!M4.ZZ:8[GF)($2:SW M^UV9YMSWT])^9Y3O-T 7!OFP.\UU8+^0Y W9F]Y=V*')J,'!0AB'$,U M*3*UJ+TM78;Q/:%5W%'7?$^2V\LH+3HY,I2D=8A=UZ<&^ANC@,>P6CZX+*>9 M#[/!T:*XUNK/7"@@_ZF /ZRG:1N0HSW60A1/K6SQ\^[#1 M?A$NQ_>S^A:?CP)V\8,/BEU<"X?9?TU8!NXI (_=H$?M+&#E['>7 '^XL M%_:]B=NCADXIREO*30B("OR]U* MTN9(/ME?2XSK/9T$/R7/Z"X!C KLC.*O>9]H=/S\\/YLW'Z<0]T+*EEI_3A* M[GHC"3-KO?6V L9K\/!+[K(J]X>ZNX :FU+ZO:\YLDEUC,W+WI55"]$2HN_+ M/_Y05C( 8?'F)':1-)/2)Q<\>AN$] Z&!2U5ZFU0*K[X8AH2W.'J08B1,-K=NK] MQT=%Q7+K9H>K?&W4RD3A(=/ME>[1B]D&RC=2'IZ7QUYDU%3)\F^D^$2NWWM" MDN]RX1CIWO/8R>7TJW44Y<IK)RLW;'6.;YRV+V>FX"?$@2?JF/WU\VT0_--+WYHSS-@4]G#.=/EP6K-G,W'VGLT3C'INT'@++E@9Y4=TC7I/P\;A4#$GS] M07N.I&&JLV[C]#OK^@WCGAA\7NG>-LQ+E\:2N9UB>+62IS!+=.;.&(]BO'%Q(3UQ[3' Z\7[-3:==%:3] MH?2: B_;X6+4I!$]R\9LL> (ZZ'F"2&%J\A4Z96X[_8D^Y46.EU3E:<_0 M#(/>OH(I$U0>K1VNH&0*&H))+&N5DI;5O$#PF-3^+J)\/URS&I-6J31X835M MBG<)4-)^9< N:NY_2OS^$F!F>@J/V<3(>:YBTF-7(1K^"R8D50GO#^GHID"U MEF;N41YG4PXUO55=#:LU>E5-TUOMY9I3+@VSN-% 4I< C,(4:$=(52GY36^Q M%V8#>$%6-4G^6R>CY7>&+KW@?QJT_@,-6C0GGT$+>>,C%U+^6]OFC\R1NV_\ MNX^U0 <;_@>BYH_^7D<)QX:Q_+#74.C?/B(E(26-BK8@#J=(@9MQ^-OU_\8= M7 OE[]XK=14L=U&*C64H@"D+_@A+\/VS:A+Q#\4)HG^U;.&&T^*T7/_1MH4_ MRO^GCC(E$*\HPZ4HX[%(&2>6N!Q-5-24SHM2XMO7$7=;?10]^L^.C8#>.&GC-[<@)]:=,[OR3KX'Y[D?FPO M^6\TK1"[\',0HDZ7 'RZ)$&K$[N/VD^ 4]4]$-&4A5&^@B!%VKJ@E#@J%D55 MX/7&EF#T!OM45O@%OW(9=WP'+7(%-+ MKJC ^ W)8LM'U(6TV5+!ZAD !=6,*Z=N7Z>J=]YJ(DR(YU\F8*T!(4CR0J(L MA/N^0WG$@-!PU-A*D],(L$2BNIK+>D<+-U95^63:I%C\R_@/GX4.F$OS.V'\ MU8+88CJ4F;B:+B2COH>A](E948;9&&-GD=BXFYQ8>AD7%"JG1NQ-,8JG#J>Z MF;*XV2-_/.7"+#-!YA;%0 QS/,)_HD/TL#%EQ/,H4HHIA,$A\#2@9!I2Y_0% M=4/>/I2\9?L!7LR%-/Q5S191ES:TQX+F2T/&\3KS-ID*)Z<#"9?]-%*S9%/0 MLDCA%3OLQJ.F1Y][Y1Y,^O!_F]HCXG(:NP0(]+V=7'H-1=9W9(JM,?/+X&'L MBL>K;C\SUW];MZ<&D%NRR;6^$'C$S[=_MSG14PS&[R">+H_+2!- T[7$WNNK MLTI!X YB/\#DOW<\\ C#2N:_BB]'36UTF3\4N+)&:>X=%9>7PH8W.Q7O*6H% M;@QUXTK9^!;!P'GH"']Z9T1J:+]OY?:E0#H($GU672T"[DZ?9LUZ!Y9M73!+JC3CJ7_&A MN%X%GABJ$3"'>(I;Q#V$W;1N,W[<$SP%K MQ'"C5_*LL*:N4U>+-NT(28MG-8Z1+90];)\5E+4 M>)>FB,_)$:7WNI 6, NQRFV(K@/,ZL(]9^Z-$L 4A?G!>58HE;I1 45:TF2! M;@]\>#81P2UNK7I\_4%P1"KR 6[,>!)@X__ 1%<__58'4&X3(6GCYL<:5SDL MO9&K_GO9@)D FB&!=JG\;RW9M-( XO+%MB 5 K0^E^\:TA@;!\:E5TLYE0"D[RQNF.?D[SLC>89M)@0PN(28C]U[?]A[[W#FNKV-N$-J!0I M*J%7 8& H$A JJ%([UT#B((" 6DB70A%42.]:D1 0L> 2&@BH @"TI, TI46 MBH#TGDSP>9YSSLQ7WO/.=>::>;_O_+%R9=?LG;W76O?]*_?O@ RH]']:,(Q# M6-=I"E6FPFK^7AH%-1IQJ$[R6?W2" V( SL)?F90^=#&2_B)6_/+QKV0++744!/0UT]%J45UR^J%BB8@)#H]&)3\7AH,Z6.E8#C6,F />V.U?/*Q;J?Q\JOK8_EBFT M5AN_9K)O6EVSCE&Z@SW9-#U5"G?C/O5MI)8ZY/$%T7LE?39S$KN*BP,)WYF5 MF FC>%;':J'"44'!_E$"J[1Z/NWEP#I>7LM3,K9/OB&"L5Z8CC-:CA/S^-$F M=M'AA2':O.-\-T73Y8C11HY]6Z$YWYT.*_3?=V,X!-Q?KA)W<;5B(7Z"M"N"T'=YO$RL+^_Z)*HV0R]\+%*)A$4)84WM-()U M? 4=;F60 0L=4SE?;?AQKGRA:5E/'A-82C_0S"_A5\/''R[B5N"+7RV1$DK\ M5,@9#6&,'K]PGG5TLZA"#R6K2VMF-*]%S8&BSXD+5FW+RWJV\(/@T+G$H)]A# 58@.2#M!&RN'@UU2*71FF5C-8Z+_N;%:X^&E M: L"ORN7QH!?S2,Q4S6G#/[^?HT1M$5Y:-W%Y,UN&XI\;Q<&%$_?^/Q)(_NBN>;-*]:WI1,.:_[VM*E2M)"/?1]:G/0IR2^SPLL9. &UETS:>_EF81F M%HS\!8M!7O/RX]>V:..[,]!ND;ZD4/B&B,_'E8@)I&S4LO<5[,-IRI@!66J. M6AS$0XDH39Y,]44CQ6ZE+5#V]B&\ME5LX/E#E?C7^8F94 ES=;[&/4*,MVR$ MX8G@J$\]1+/+4(RN"=$LDT/0I=[\7(*NMUY/O44R#XN"BG>(5?6"FH )QNIE M@WI/GOEI.[\]&YE0,G"VI)S":^Y/%1W;*G7<)VERA-7^=B(M5$R)OJFW3L8 M'>P/E :O>Y$!_J(LMVF,@E]IU01)U2)3(?]AU].WD!K%15:$4B21I"*\I7ZP M$+1ZF.ZQQ$7R8VHC T_ONQQ&'"R<-BQ_\W;$J\>O2]FT=6LI46#<8=YL46!A MJ99(?U!LI$8&FO<#!3X_UYE[\$44U!SE/WE MY^HLGI>;!VIG1_Z#+MZ1=MI-*04+>%,X>UK2GR&$H!2LZ1]2ZT?>HB.&0LT- M+[ P^E-1[F_QA:@_:KXSXG!_UDL[:G_53/O3P:3WE_R$VF\A/XNB)TP7\5V0 MWF,>9JC$8MF!O)2'N5[OX7">993F;UT[#\6&U3V\ZRFS/TD6*,5,K>E/3?._ M^Y1^5R:[SW^<#"2N:Y*!LF:2WZ;6@[+O#KL"$.C>@0G1P?*_F*[=\0GY) KM MOQ9977IB,4BG.&OFVLE>*V'%>,JCBM0ZTM%/.*G?N+HN\+[RG'#5$":^9.G@ M4^['7@'_PK$XMX5#O)5T4=2E E[N[O1Z>*?2P'UT8;'VW9X$7S/'@@3'UW+% M@NH&:GF@GX(TH 5P<"\U\91AZ F$)JP<4:Q.:B-9)1NQ\@GCQPD$ M,PPHT_57$A%]B%3]SZAH_'+6YUU+8I[!*)8Z@[Y+%D+3)1H-TVXKB#(]VZ*? M7^&:V^ZKA^+(X\R]WK-3=I6[(:M!Y,0" %.Y(*U(Y&LN>WVJ8K(/]8?Z8 ML!B5DOW$I=ER@41,UHZNWWU.CD[$N!845T8&FHX[)WE6-[Q_$GSJ#30AQ^3$ M:$R03:("&Q\4ZJ< MFQL9B)3\5EW[>2>@:?N>F^GH^##6OYQO)\4I: '@"Q[,3E[4]NT2=>]J=A2[ M88>3?PAB2]2\3K#5QY_[<.W#V"/ML9'@#+\#=VH!UL5TUW>V<^=R/#5CIT\O ML+"53)9G,4Z$2&0=!%I?CKY;F?[8Y+V'.J+"1J%ZU+T\*23^]< MR&:CEY#(A%Q"-6R\[DIM2/Y\[\CEH6]KGU_5?C$V5D;JRAT:>T"MJVK,V%_? MH4]0*IRBI15.S%HM9FTI,IKR,):2GO=8YC)@AS;76,0]K@61@9.YEV%AV'65 MV$(58Y$S_/[?US='+R(8%E(E? JZOF+--@=&=KGR=QM6[][IKW1%BS6;-J^5 M6SULKVS?HQK/[5^^TC<)/K]YW1+OU"@1U?/K4 3*R%'GGT0>9'8L*5>K<"+NVJ!/R-IZ%C M3?(^HQDCK0(/Y5@D33G*5QC?T)\%;GUAT1Q$YKW^E#-FY.$A8B.Z&J5<7+'!EM0[=G]1N-5W^6>W2&"; M4W+6XO6OJS&3F=7+Z<9Y4GC7LC8FW:VISH.!X8OJ>Y9QUA7XP.1/:9I@XZ5;Z_OW>(Y=CH27C7.E]3:G#@^ MDK(O>'[$X%[ML9O,F^F5!>T=4KL>9(#F5V^I34CI+'O6>N!E2\T!Q2EH(1NF MZ)+1=P.;\PK7PHDUW^/+8!6Y.Z$_ES9/AE3%Z4K',SR<9D8TAUF90X]3R;?[ M<=WH-[X:XFVR&+%)G5&"2QFY-S0Q>%7Z^KDU*=4,FV#K=&5[3.6G"+.3&2>F M%'J/N@*LN_8,!M.S]*?@7##Z?,\E58W MB\W=WC_080GU9"EX#FZY_/9EN2N>!>:3S^UJZ%V C+%H 1Y!!B +\&RZ&]D9 MSN.W%GD0$F_[N:BB\;W].5SGT-&5CR)V87(J/L/O-G?.N'YW4+J/@K/3;1E^ M18N))"C]8K*OK' ]JTL:]%Y LMVSO,F27:!W!_1<&I_A2ZI_O :9W'7I9+%R M-(V$6)IZ9XMWZWTLYH"3TAT/8@P_9P4.9]SO$%'^$-MZ6.U,@U;0P M6^JDI-XF$\/:P%" X1Q#?AB)[ASB%-T!'$<2&AC&A 0A3325F];AR:/#'SC2 M93NF.Q-?6-Q,K5Y.4Y,ES 2JEA3Y)#'=4V)K?A_W]G:\24UU=?2:>UK0U! 6 M<6F!X;:%S=%-CO[[T, M(RXAIF:AVR79D'!]\=SWD+? 32KAV,;^J]\E3<58FH@>&P5 M;9F].]IN@-VS' %KF%X2K!3"J$@I2 $,$O=!_;!4+4 W"OD"CI10$S\MM%& M=#NJXN3W?PF_^)WK;;A^!"Z<(ZAR#\31E30,XF@(G?[?>?S?':Y)1RIU WB= M/?$KL^]"K!M>4=!MU((K]=B_.BS$FU\5N[8I:=#S(Y51YUM4XD%7P&;'SD)_ M?F]+TV95ZFWAP^2U+&)64['RTTRMJ:B9G; !&3(@)1U!!AHLLQ:OW>",1SS) M%MXY_9(,\%$>X4!K,VU+0S+'-LKF$(2 ]?R*=+%-;:RE"0#)'9JU&CR3 M..?OT'S[/?X4-F$:VS&=)MU+RYS1%JB,)B;KV6 MYI(%]"X9V%S45G\WU4F[,A5?V$IJW\-QW0[N0[DJH%7G1 (AW)Z(-C0$^-F' M,MPWIU%C;LLKW+.(Z *4TI(A+[)IF=&+U_:B8\^G7S)P]U[U5/SHA!PLD2F\ MT[ZB]QH=D]9Z(WQ6LMH+G;5HMIMY;L[KG,,#EE^EBVW'",^ /=P[ONY+>),! MZ2R.R]72CXN7!;GG[X\IWK4)I]I:V<2H1NB \,9--32+ZD(OM5VIP382[@*F M,;LN;%4[K6S:LX(+ZOFTDN3(04$GCW+2#UD?LWIU:B'YCZQX<2B@!R2[[[V<7 M<1VTW,/\J$UPZ3(9R,5CM[&$FP&)WN^HO57GW43B)OS!(SN%+;3A1C)L7D0A M=KO,E 8N0;T+!&XT0E33JH=I%1)%H-$8#3VY]]*C[N$4VN^@:'KVQ9NB79'Y MQR/QA= ?NCR" FY>/E*/2^Y)#+P4? :K$@O_@3YH%?A:5&9F+GFWKBIA_9VE MPE;/CGD($Y^8763@WKHQ;;9J*)R%]5)F=A;1F.88MR,'%^\O5S%/V96H.+CL M6KS%R' ,<2$8!_3 X".9)K3C*42H3&ZWHEA!H_[-L^W\C;$77W7>TU9E K@S]<8Z8MT \@ Z7/1QF3\=5EE3)LTPH;1&09^-CMT/$7 MT%?&8R8/UG$E7[5'HP;YW'I? %!HI>]E(DG,QL',7FV?-%GK3@9V&<=8? Z* M+FH%%*_YE5S8ZX>+4[MKKB,7,=T>K+]*M?$K&+^JSX=,X)SK%6 *X;2O@8YZ M$ B^AV99>B8\$DP&])-B;;UV&6X@Z@1(73:+5XYRX7#K M0\(D#QC;OPGI/T=(R0"/SH$1Y#,9,.0A QIEXF6PG6$H?J."LB(C+.=#BG7O MMZ\A\:"%FP4#T8XXI+J!8:)K;M[OB>NWC^R(H7Z$>>?C>FD>_16W>,0 CY_[ MDUHJ'7F]('AC"/Z/TA5_IYU_QC5J_5G1^V]F6NS?YHR_D52:1THHRC3XV\_& M?5.F6/;_V<\F'_&75^TH]8+Q;TKKU/^H2DBK_H_$T^8KZ8B7;O^-E_[7BFND M^RRA4U@:Z--RWZI'H3D..@SI.\.\@4VQ$/2C3C!'JBFAL_+J@@TKSVG=&Q%D M.1P"976:WX07:%J5/F:[HTS@$)[)9W&2N/7IS;R.*#9_Y?I:G)&YK/,#-"J* MSY<;EJSYNV,>.H/O,_YFHQ,GO[FCZ#KS5.CDF)Y*Z\)#_:?M+#2UK;;N]T M0J PJK=Z=2M+\'#I5:=+@WP-R3%O%?JHL6HFPIC3HFW-MMW%GPO6U\PBMWOX16<_-*;>>6 2$/:%9BZ M;AV *GOJYWIW67KFE"Q[HN,N=?8BOJS@"O80^FDOM8WI'ON "AGH,+9=$SAT M6[P?2HW77N=G3]++M<<(9^HNABM;$C(Y6-B+%B]\*"QJ'[?E=BLN9E-C. 'P MIV#-;9+N6A'>I)OCB14N,F]*L.]B$L>3CSO33?_GH@CUYQ'D6%O=6XRO2"B86]RMHDAS.:\/1OPFEJ M,<:T:MG!@Q9- T9%7P?>+:YI/UC%M:W7\Y!10MQ-[^OH]UN/,L.V\ 6>G^=?2CS*CC?*R[<1ZU:D/OZ*K7?.W;%]* M1@__B+\;'MC^B8M6"+W0[6.2N33><2/SCN_0SP#P>6T3\.WX8&:S:W=T\)76 M639XC"'56WX0-$L#9_ [\JH.S9]E-:VK$2FS2K?8B3GK1TB7>+_FP: M95ZUOM3A,6H9S2F(;%VESD__4?C3T?GL<^V3O!DN 1O%#3RUT7C;.OSK5W>J MDEE.@MM$6!Q>0U.O>B]8V@V0@1R>U#QG#[A2)ZRF1D9+)$SS^-FVZ8R]4$D# MN:\[)C(+P9V^GPO*K2K3;M4^/285J1V_>KPNX:>0B9N M\/%"6]=KG16W3Q!I5(.]E?U+AM&?BQU<\7KQTC/RNE1?Z.Z>WD6-#'V14T17 ME2R++GWYC)WT\-LJK_K@7@(_>[-5$5@2FT] O+H-OS=O:\[3<3WOU30 "BVF M^LBWZ&Y0[<'3O [CO(Z9M=,1'5WBTS;Q_$YB,S%66GX!ZK.%AWS6O:;R%%_- MBZP\A\F<]ZO<9LN:]?<@X,%O(67NK,9UHN(GR]!.B;OXDHX136?Q N3-@BB] MV)-&;C!W4\;8A2L;6_GQ#OI83>YJ5QN)9 4RX"@*+94Q>TDDLE]68S90N$JS M[I9)H/)$TT1^%O@E?'U'W M9^WR7Q2X"UM6U@[*A< -;5&2KDYT 6P2H?0?1=^GJKA4JF@@L^J\4I=V'O)4 MH5=1MQ.70:O:" FB]D/YW&8:-W>A^@3M4>0X6HYU%)D*2O?Q5\8?G.70FUMU@Z+'KPO?Q>;\C%>_0=]M1/G0&8H-;ZY _&NY>$ MT)7;$>U[::T;Z$]/7XX,0>LX'3HI_*_8X:DUQF7*I1+J)SR:I>WLM;AGFXL*'&K><8/1+J=#'GT C&\+.&K=AIUJTL%SP(#P/#Z MWX%4ZMET>7+QP8UR[OH^J/8/BJ+A6AYR"(3D'H5FD $K^]0G=X-?WR(#@" 9 M$)5S,(G)-9P.W6K;LWH1/L(S]=";YW!@%U%X4*2*7# L$,8HJUB>*E_[*#9[ M@^5'BUY6L*- EKZL$2W$!?+P2@S2&:X^E:C&?"+E8GY4*\@%!!ST&<[&3$;$ M=\&J[T8V9/2K]HN8W_4.,14V,M+-?ZW-2$4;-9YKT746.28A:R[35ABO#QCB M7"#F%J?X4UE+W-%DAL*3&D[A(YI(;-;.W]?514/;1YNM\Q^MV4_UNX-W@_MQVB-SAX3X M&8U1+R>=ZP)SAL:!B2;K;##V3CJ3?(GQ=[).E_GZ&E=_D.1>NNZ_;GV=WUPE M1=.E9'XUI-6LK?!3B^XW5Y\E7>9\;0N96WUO/^);M#V*1TW"B%1/+&)0J9-G)M(_W.2@I,O1L M-0F>J626*RG[O&M^$[EBE;O@UM$/O[)*Z?RTG9*8:C(0;WD@F83=GWS?$>9Q M*I1"%\LI=%$MW#=+JO&5/)&D_I8,#,JT3AE<8#==;4T;)4'2!=:8'PNL]W = MN)UVVLR4NC6?<4[9LKW_9_R^P2'X?6W7!^ARV6:!FXX2)KYTAI1ZG#N-#*RQ M?1#XJ7,PC'57FB!I#&8MBZV[]?T[*O.?:LS0UANT_!>10TD_;4V\:JC;:RXJ M?%]O-1GX,(R(NB(BJVWUL-6+;DV.O M/RB,*[!!^KWQRK98# 7U[LDCP_J>#:%G7ZA03=9$VUZMA2[_:$Q\$VNB3[CO MK%XT9.)ZN[M'D6&YUCP]&AODQT-LND 7M:([EA(RV'D#O,JW\E0. M[G=RD&=DYJJ /^0G>KC(\O9[UZ*MYSH'E0[=&6)/*/#]ZL%BYO.98FJ)VO9I M'8O9+XA8A)+_!NG7P6*B4'+B:%\W?^?B-HN90>*B7=@V']_C*8/9#C*@*D#: M@_@^KE ZP,W64!B.P^X"&=CNR^.0C4O6(P.AW*K9(;)O3Z1P3Q\?:YOW$3O< M--A:+"<#%\Z$W3_,8=;V!WX?5SU&!GJ:LUX)#'-DK:^*$76P&M,NMU"R=H^W M'DT<'$")>EO[/;L[R>OH8<%I%P>4(7(Z;"* #$ II\GRK%/U%#F8VWJBR#4X M;>YPNB1UNP%7FXP\J M$?MS?4LT"3^W&>R;:LKD'7;GCBX?W95."FZD[!.BMN7B:B2JY=-P?V)]P&1_ M#O>WP_?5II49^U"_[TLE:[M?P<$^?C<0T1WO&I7XRH^M/5;[%Z+#_Q#\V;)> M8.T;22/>]5%;=S%R)KHL&#ISI'<._WS]@T!SXW87?Q^ML%*P)(HT7$<&G$B[ M>=PS$]M.!T7KV=,N!EJ^43=JEQ-)V!]E)N,B!UV\2_,TE=PQKF>+45N_\8B9>8(QT?7P8^>6A=OF^+U(KWK$R/^+CMME TH M[X'S\0=5 HD%G8^<74TEGO2_B3^HAGD3?O83Q-(>R/[X,U E4%<-71N&[L]9/&H6(\'$9L79GH+AD==Z=!RZXV5" MM2Z> U5R^FV"EJ8&POF,("];,6=]%M68W&[E23?DH"]]46H+#WF;^^4QWG89 M]:@,8X%I"J.%$.JC_8?89\4:+AXWZK,^L=^Z:)3W6]VG_2]MO"/S!>?O0NN_ MK1HY?VBGJAV)#E'U!G*0=,982 WXW<%^MK7&".AT:"]ED%Z"O@HUNVXY.I#Y M20MD[1SQ?T!*[7_8KK$RVNFK\E*ZW,0;Y4]5:PZE\!P1+2W!O'PU;$Y26L)) M4S=%I3O=2@]%0G7D%/([7V/N6/2^SOW8R.-)51^4;Q>*UW,;JGZX]Z5@H\!D MF^GBI7P^]RMFZ]Q]*5;TC[LL8X8TCLP:&'V).NO$LS'4:6GIH&91L&L>Z*-% M)V/#=S(@,6#G)0!KYZ.C# ):;F72Z/%*6ZK7M#I[^#J\X+S80$9P'^%V9*:$ M7 $R3:8IE_J%B87IE\=E;.*%T;[F-.8=&GA.YRPC2+2VEK/;\*B2^--EC]G MV^>N)H9_\]*@%YBV?E%)6VWQZ773>E;6HX@'X!R]7-M1U:\1OI*I;:3)#);. M]5T;=9LGEOT&YD/'+G@%ZNM;Z%V+0\@4="Z[O@+7,.:Z8Y"S M=>'G16)PIZ[7RXB5OOLO]E9NK;D ME_G'$)F=7W0$.K9@)U@78"%51 -Y\]!?N61 ]MHPX]XQ]EE[:\GT6AL+CM0, M#R!8 +91N%$GOLGE=SS\9*V->T=RTD5:PZFW^9_0(XQ9E'MU#F$EIJ4U'7GX&5 MMZ%M3:^0P^;C H=@1@5>XO5D@*& ^>4DWZG1Z]<$4<-.J:D^K7?7 A4.)"N_ M!..CW:&8#G?1-VD-]OK3.K+R487V6@6V]MVBT6<,.V\3D[?5%[QI+B[W,2PAUSF^?+\M'3^O(^'[_Y!/BXW.(%M&X MSK7UY165XA??+G?7/0W7*A,/WC5#;LVS+@"_&N>AI D(!S8Y;>TSD]P+.A.@ M);DDU&'YS?/UZ/RKTMP2JOG$X2SVV(+/K@-%=U4*SF:PBY3S70KNK^0LDH3" ME>^-?<$9G@SCB%'%]9$+UO3%>D;(1O1 M\Q8295RAWDR'&.] *&D^&+^;V )7J>.!^TEP*-#6;A>6KCA752<%5,<*:W6H M5#QB4-4#^F$VK*Z)2U(Z!J[0E6^4O[ICT$RHUW-+*-N2J6D*37,(KMJ+>UUT MU;G<0^8'HTT@2F?:?__9@D1^33H9^';YRW6,SPSODQ^>H>]L]ZQ[GYGK7[WL MFP\-;:CL"LPG R;XO'>9NRMA7O+BDY56C;W-S4.?NCSEYPP;_B6V"(Y=-T_Y&.G&\F*9OM1%4H]W*"CZ64'(]R*]@C M -2=%T$W) P'#KUU>PC63^:MGI1()'\H6_<@W3I^6YSWP>MV%2I2)@.C7C,V&&./LV+O+ZP5_Y*>W8NQK'*1-\W:.GXU%IQ&&8*C M3/^S"1+Y^IRCQNC9"-,/ MFK9PY6P"/[2LR4_L@5"=!HU5RH!>NE+S-1!>NGE\Z*L*/SMB4)4WH@8[IE45 MV] O/6R/97SL5/CYOO\%SHYU8LOC"ZMG[K3O M2OUPF$5@+G\J(@-GG@ULUM"L.9#JK7;B+V>M"EM"1UWQ:UH8 =I\%:@L(FRF M48NZGC;O6)#W()OP/9JG5"63%4(BJJZ>I4Z] H0^W,OW,;/A EG!:O!:"J5, M.//E9PR7,1U&_(*YH>0KS!YWVUC<1EUY%^!U<>&>A/R2/O&Y1?D1RB'WRU=?RFSK+1LCH3,-^H;0HFECJWC!X\ M>?^/HA6BFI"']\T(_;4N3$U1R"AASA;@<0O MYXWU%$" ;[?/T(A"!P R8!BG,\MDD&B%E^ELCT])^OR--2/L6.*.Y="\Q@EH M-"LHY'5=AJ0^:^2D,.;_+'Z2K>3^P6G+U\_N-_CRO_BXN9WMBNWZ(O&FJT6? M"/3;*&:?9K_47U#@$TJ_%X^K2%]AZ'TWNDU^\_ M2^KLOOJ\V_^E75&1F.%W M\USPP6=6NE8I;FP6X];TNI50CK*=*Y/8._.X1%/]B4].TT& M[B 2"Q9NQ^JW[1>USI@M9 Q=10R9+!H36@\,[YKLZT-3=;N>(79/4HC+(.1( M54FC D,&IB]02(G=U-&R=KESX;^51O_)5E3D9OU>^Y7JX<\VM7AC2TBI=.[LCY=(_1#)EUAT?\K5T4Z'G1P7L'Z6?' MO^Z@V9PZMM!?*9L;F'B,KJ\5-4F)+A MO+3CXQ3X@V08]<1PAE1KWA736=D'*)5D6)8+?TJCRQ8ZQ>Z+34*H^)I)GGMH M1K#95K"BYO/V-2:QA/%4S!;"[4K/DHZX+]<5 [/I2K?#K.'XBGVSK[Q?3)(( M0:*583U+>I1]*$=TK,7RFV%,*O;-0[.&X\S6N<+,T!UR!7^V(KF^A8'D!??P^M%)LZ+!PAMGI\JT-]*T-C #E%_[8I?N/7?K^O@O4 M@\==\^OHPA^T,&%?NE'>[,/"?3EITUI-#QZW[:$BR@]J1; M_'/CFK0%D8";:?R 4*K>\G(SJ0@QNUEKXTL&@AJ5[-<0H8TK:.NP+@/*IO-- MZ+%E/5EDM M&:FE"SUJ>)5TTKH%>_(4IYT%6GW'\C.R3_*T_U>C(W'7U(;5/9RI8,[?RV5$ M//WMXOZ=16K^!V^B+.@R/_Z8M79E#K&YE;JI^J#\N\FNP'WHWK[^7N:[HEJ, M:B12_$W7_VY+TC_5RKUVZA'9)*O*Z]RHR263XOA%(U8I)-;<'"][5&P>1P7W MJ>4,C@2#FY*I[E=?*!A))@@Z=,3/6SMS:5I!WEH/>FW?]H:NY+C]S+K?6T4C MX?8:"NM[[E?,&H/$:HI_52C&#&#:%(H[%3&G&>^ :M!L&@Q@N!:=AIBTSEN2 M8Z73K!89"+0.%ELY=4A_0 ;V^OW91:^M'OXX6+3$G@X3_:RP713>5BC$Y7QE M4P$RI!N,]#L98Q'/8"P;%_AF1!SLBP2K=>DRO'$S=;NH6( T= US%4-ZL,E+ M3'+#"[CU'4_Q!J A-;DM@*@KXY\C!0C_,Z"HN511LJ@Z,+$ASB+6'G4N4<*S@GF46HM MN1!L=+B3;AYU# YY3)..;EMEZI++NE7Q^Z86W[S1CS!YZ>?#SO29P2X95M78 MJB2+\VFK*EGCMX^1*@6OJC^\ZI 38<4%T]?EQGUA3U32]+IDY)N 9T?*)W?= MUC@!>ML=U&50I&(!3S>[^Z+ZZN[E1ZIQ4P*]X)Z/.H;E-E!:^DY]WCU@R,/%RJY%S" MEBC;YB2UL>FA='L$6>-J2FN#?7#O9>+6R4"4CZ:C&OR=O(S6,>>:+OI)3U/F MV3SLY)C:W$D6 H%]:E8MU"W$9),7$=2X(6PFK,O:I\5VXO5_UCQAE. LQE\, M)PSNQVY J(A)X.OVH9Q(UR(Q"HA]"IV =J-7#!-=<]*>4SHF[JC [F\ GTUK MCH(X&84VI'6/, M^W0='6,88.!P"MZE^ZTO!G;-E1'/B<^[R'!,SV._)=/DKFJKC2S#EQMHCN/,&^)''<0 M@K0;I?%-FB1P+G^%;G-8%J[VPJG&EU-2GL:U#5D;_@*X.OL3S<.!3OI92>EP MX7M*"O>@:9)])7FDJK/G_W^R-;9N3!LM"$3V"UF-EUU_HG_"LPT+.6K+/*$'DH6>1/B M'"Z @L5#G"/.T&@'Y3M'NG(>X A!&WEC:NQ+R\.LE7'3&R5%/J ,2=^5%J,W-;"8&B2<-R34PLP>^VU0'KBO/8\_H'/:G:Q.822_OWAKAW?0?.IV=\/CHOR'6[S7,G.Y#:<1CT0#%>:8.+]N'F.NY2P^ MQ6JX.%)_022SMA4TNDFRI'- >'U]'MI#BP$+#V8%:U^AC,";\^$O1,B 4BQI M_@NT!S35_B4X!!\:=M=7[8E=G+?/!AM,0Q7!\"J^Z$HE37@[\J9,J._&%@5+ MDX&$SH,]Q%G[JS>)X[6Q%B1-7Y) F^DG-@>,=3+F>G#)!0NU2^X.#9(E4215 MUGF[O*+=%C__B=6YFORGSIT%I',#Q,,T$K:]XO#5:>+A=9*?2-8:<[7*X>#B MIAR(#*PQ/"P!K'!S)0"B<#%=:Q+A1&W^:V3JIM_;WHV&5JIO6OJ$C^ M__5V(W05VM*%AG_6>_?@QOC9\>_KH%"6R2":U?S4L8=C<3J3 7',)??V1%^" MV2]6B26:[!'Y:A;0F]!'0(674F%HHZ]$@.D_Q%F40I;\B98Q;."G#?2SVIQD2\!R6 M1_J+MP"77=&N!8[I("K^3_/:G^;-'6/,;@I_4Q7_IBIA:(8\?RSL&KJ#/U54 MO(6=^L)YLYEX_720XS,JCA2PRFN+HWW/KFGQZQ:5:XN_75:?9E")F+>8I*RM MI4T JT18RU!6VV&V?'2&6JZW._15WB2TK6IR)IT:T[;^FL,YA&\)FJE$7_"?E23N[_N]_U?[C MQI9>'#_>'/H$H]_5KW-: ,QK))MH=Q^9POHM\O"F$\M'^F]J$DU($9MM9% MRK9JG;<\OU.;-7'K4.908G(>E P%>P,04_ +EY M7>< 91#VR!+D)YX_F^YW]MEX!I,L)+M7YDNZ B@J3Y@;H,_M$EPT%@H'@HI M!)%U8W-?S9/)S@DH#U"T% 1EMVH(:6X618+!2=)P>$[&4;7"I'!FL)N8(PMH M1J0,\M'\4_#J9N'M#U7QAW>:P:2-< 0LTD!7E-!AQ'AOZ:''.DC^BA->[A8Z M&G1>6 M@3553LGAWVG!A+Z2*4!<[TG=IXFM.79U.Q7,1&V9#C^V;",T%R\%3>0-5;^A0ZSV6>M.O@M69IS&,DGL$77P MR[<'2Z66AJRO8A]IO'%2/#V=L8IG&V986SSWJ].#]VGNHHVALZE8ED1=A[=O MXGB]IDK&H+6I>"#7VQZ.-#QT,W Y--3C+@T?BBT!%: M[X Q@I-RR4##1'>.=L)YL_\9L*H[R][T'G(NA"7/ MMY<$V9'ZOQ'L M$0P-_UT=TTQ+D (5*8#:3)M681KBZQ=A M_2]5L*]:KU3Z"Z\Q/+.H]%"VJJVX1<+\RMV^48R0..N55ILXER:K?012FZ$0 M3PI.]%%CD=)#.2_(KJBQC&F;8&0AS@DL/8ZN79?2(<"O,==N\!&@/<#-HKND M7:D^XI8+U[5=J=78U1P1[[\7';@I\+T*@$ZH5.^/L2PP<>7+!OE6T*RU!5S< MH&"K)[2DXVKLZO,&==F_CS+L0\7[\/>NN%QQ6-$3HC,09VO44]71 12(U QF^KI)T@WL\Z#>ZIP^MV=UL'5W/.* M1%"S-I&+E)-]X5./H!/;^8*9K>+I5\VD^X+\68&#%XJ.()Y7-DGC_7T!\5;8 MS*:Q7VVT,LNT^$UD9V#Q.[\2([R9Y_#GFD)??DE,C!] MV8]R+OQN)=S:H_H@VI,,+*(0,-R;Z\7_#HGZCQO=LAAR8-CV:8:(V=D IU[@ MDM&#%LQ"A7MP_WB>XBXQX:W V(WP,!KJ^I5)4*Q ^*:SAOI:^%3O6]H-N?4\ M=R,_V9=SPOP2['+"!",85R+J%E<1^*$I#4,?TN\<]6\@>.XB*^@Y:$&R#A:;B,O4=U TLT(RUV)[XQ:90]4AG3&S!]48E>%Z-;S3;B'-Y>5EG]AU/QPVD8+6F>2$ M<\V(%2SJI#1L[(E399KOH512-R%'7W5)J[EKM-N-^I1#G[61 ;=XL<-BRO?' M[5=RXL_5%[N!J5B2QB=>B26-1Q;DA NN9>'BP62@SEH\FX%$(6KW^V:JMXVN MY74!5M\FQB!WKT1CG&-0-ZV&0YDXMTJN0TR/VYF'FZBY]19-B=S/9M"@I^MN MHFT$_: 3""1^LZK54]63H\\^P4L5?A%7R9F^,O ML:=#4IQ0:DH92G@MRMM,F%S06K84()"!6(>%RHPH[H>W$:"[++/Y6)VQW'"T M-P69BG\?2&V;'GA0OY!X/F<*8W7+>J+>.KB/ZQVO>82^:XN9D&,X&!YB*C/? MLD9U.$@&AMS6VC-N6W'NUEF3@3N-STO"G:NNIA-N*U)>C!1^>/CWMWQM14"^ MS&*/G#COJAE#JI$FF(4FIF\@!N>ODH^GS4S1,O4'?_A\#71?XCQ]J^NN()OB,S* M&8[AV/$\;\\++O! DFN*\LV6B2;\Z>>^>5VHW^ZXK[VF%MIWOTMF'T_P>W-KV:<1+6& M6A?,+:^X])#[,-0C]\CP:G?FG@VK0M34$LSL(7+@0NZ=QA>EV[JU2=O:V-J4 MJ//ET8XG+@4MW1 [^0 ]?Z/E1\#$CQ#*JVY(Z:JML<&[F?RO)."?;"U>LBCJ MU55<0]W*$T6Y?]&Q8- '@Y]0X#[2[PB:B0,?5>$ZH!338Y=:P,_U>)\4W+*H M/1G0XRB!K1I,XI=CY=R(.TYRD0O$WY+2?ZKHL"2:S4I"CJ2:\TQP9*7 M%:!3-Y[(9@9N8.'M^RV7;RJ4.AJ9+QLSYK*XE3K[+_P,WBZX*>L)G9IU MV![9)=R_/ Z%*68G:H$R-[ ?83!],]W?JGU@G?H_2DUDI4H!!BQ[A+U!]6^A MDIG/#MU"M>Y#FZZD_(X2H?7YC9F'DR$A1^$B+WY7AO\;W ;^!]A]]G<:R)%L MZJN]ON&H+J[9< 9Q=.5%!N,-)Q08"*-@_92/?Y:VNOBG13?AO\M'. <*%0>R MCVH7_P7:_[ ^1ZG1&7G!$*VY#LL,G^0:/<@ ?Q\9>"].#?M7VY+54GWW^1FW1_-L%U-TM7]9W6E]TK%2?'+BW97*= M7[Y3EZLC*;'BTF(R\;,%L(A2SJL9R9-2.Z:59[]*Z-&-N_%R9 MYYL,(/!QJ< YDEW+=6+YHL2WG^)4;?L)K,9C5E/2]-=EZL04YN%F'PI(ACB_>!]+H!)U'3,\$=-[28W@C*;\ M[M6(H@#+(#3D:+T9$5*;3;L\&]G/#[]L2O/TR,B.(P"3<%FC,0K+L%(A?#R( MW2A>""I2_]Y+:^4\\C-EKVRCU-UR=L&7U%<:I>\Q_ "Q3'4-EC.Y=FLQ:K>P M..1,M>S-N[J25Q.KY5(PE0M[\C-LY]@=[RK,8B';0T6OQ:BU[EPY;%TX?CM: ML+]2/'>XH0 *>NXA@YT8&1172-_,I. M"%0)F'W.F%CQ:3X+%AZSODN(\=GQW<'3?5(AEF]G'P<\/LW;->0C)GTO>]*N ML>'C:R33"'%^+TA1NPR<0AQ'L/\"7@Y&@?TB5?M-[TLHQ-4A[UX:&0BTL7+U M=6W4=TWSJ(4ZA@MHDRI!!:1S8BK@+-"=D\#R5AOZ#=J=_=IK MY/#$:",4APVNQ 897-H [9G']IFSE7G<:0HU[C- MNC?PZLXP!=4XKY!JQ38Q^I^6[U;]&_'_QXW9M[6D[N->(72]#3>7#W3-#M MHNG@0=RX ML[C69[WBZR1P^^, M>X8UU;;;HI.N2+'0$8+T@"A502D!I/>$&IH* @%!N@)"**(8D0YJ0(@00@V( M@C0I*AT1"$U!4'H3D"8]V0F^[_>][]IGG^O;:Z]]K;W.V3\>KL29Q)DY\]S/ M&/CS6O-]MD"]+I M-Z6USFW6F[Y8(98VUM_H(EZ@C/N5TW'KUJ=PH69VZ8B&M^#%FZR6:N$8QG[, MJ1Z74JFWDNUT];BLA"P?B[#(%?UN<_WN4_R,'0DTPT_I' M*]L_C.7(:\XB+!1. 5A=K\5[(.+*W_:4SYX->JLSR?P@(,C MVA\TRET@'DU1,D S\Q;U#!,.Z_(/K>+^KF?XLW[_MYX!N:;F]@\]@]H.J/R_ MI)ZAZ-NY12759T7LS#U=Q0W+:-I?TM%2 KF%LAQI26D)C!0;] MAJ9X\HA(G<'0.IGUH9\9:LP4+O \QCUQ&[)Z?=:,9;8(!+F4O&3IT:QLX:,\ M)MK >4HYTW"%YY;2D>KOK.KVGT^+#18J5CK'+I@DVKV>N'7*:(*W8AC/GF&S M]D+%./@ULARIW]3= =E0J+TU+MF]K7-^,[UG<)Z)7E=0B/7,IM K(NXE5;M@ M?1;K#W/[2Y=U-%'NMIT%*W#8#EHAB@0$#PJ1@#C&<@^Y#[<:WN_"@H=U2 & M15!>=>2U@/LZW-R ]:QE\2_0+S9U,YR1.GY%:5E[1BT?%&V]C<1IY;OWV7W5 MFM%QCT@T$0HYS;3[G=KC^="R:M^$BK'CBKVNFJC0KI7?SS9DTVNSNWZS&#)$ MUB-6;-Q)F;LJQ=^Y^G7R01W\Q[RR3BZN*/OK%0O#WH([UG$6X=T+BOL>[J1P^E4$?ZNY\=O MZ\4,.&QX]2T_&3S*0+SDWFE^4>A" MA^\%>>[A: H0=&>P-*_U(/1D %C^#.L$.6XW)LR$ZA2JG777CG[8ZI!J[?AQ M]AANS&G@E_@!_+E/8J%UR$X1^5:X[EK@SN@(LQ8T.SP4/.?Z7,/&)6EL[+)+ M5>R-"8^*KSE?Q85AINY+ K+'CO2I/&I#_H*W/NBH7+6UCX%^&H6:)W0*7[,N M8P@^[FMP.CGS_9N<0?\=.V$K?@0)P+EU[4=[*/J.I#IJ6-;&$=;D:[UUS[)% M0AK;G*S8'C?N[5IX 'BG$]PC:=]C06\''.&5]55]SH\,:FP]ZMXEZ7 #-$FL M#)&*\Z9#\C]&2UI[9HQSCO:5OE5@SR"0?P?Z<9DVP\T9E1FV..H$OR7[Y3"G M.(\X?M&!S> S M@3(D1*$GY47"[TXN6DHA!RKWEO87N!Y(;A9XLER_M3OW[=/KQ.)C9(RL_B^3 M!2NATD7WX?C/QQ/*?&?5[NQ:V3LXX:]\&S[9026HK*?A^*U#( M9>?!(ASUA<\]_.@LZB*4QV4!P(61HRP*H22V:*"K,9.6 .T[7DY&\X\,="GY M?0(4!<#AZH-D#I<(&LOKM])0G=NU4N$D*!A(>9XO#P5R M^Z?8\VGD/Z,:)9N2IHA'U,EQ7#K[GQE[ MBDLHQ9,%_+MKG98(Y;V](0+QUPU=0Q\O+5NI M\UO-@XC]?&K]_VB.\%WU_-@C1YKV(XH>!9./?C+XD-FT1T.I^/:H+]W]1-N6AOOJ:CB/!?V=Q?&*A+KM M*#?K&YZ)T[O'I=5@CAJ#V^T.N;6G=^YZZA\TJ3 '-3SVS[E1^%A=;LH>E-5K MQ[K ,.=!\!!J"O;N+^>M4HL]1^@+#2]4BVVKJZ6ZZ\U>/"/RML8SAUY':%WAVW;80L#/@8J, M.'MVS3,JYL%6SS4,(':S4EW!EO''+B3>5)M/"L-8.0CI-JW_]-H4-N;!TJ=F M"\RR?9.JDTS8T*'1&==E0UTV/>-GD G&DO%]($).#RU.]86:3"L@E(V%4WIH MPXW?-$/;C:J$6M_&>O^#,*@1-+_3_VSBF< W[ILWDJ4VN:;"[ X@6,T6N0R? M+#A$#VU'?KV1-*=\-6Z=_+XO.?*4?8KJ7/KT3&8R3?'*[9)3ALZR 3_V>I@O M4%@*9=-#D3H<5/-$@=^M"U"LG)W7JTE':P2M0%BZSLA_7=>%AW/>KCBW0!'1 M)!<46!2^JE00]W([T><6"V^&+"7N#GJ]K*H7RT(KJ*BQSEOYTW=5\\>ZX\IE M KA;QV+CVQ_#/J=6AT^R6EU5@A=)K"?"&KWEH#9.B@K*GG6,Z'Q;=!H#U<^0 M'KV^SW:AV9\NMC'1M_ OMB[(6(8X55R?/W43;>L7?MK++G.2O%KO%]GQ^QRX M#S:IM.X1^6K(62X\K4*YC@1 MM628E"9+'5)HLG*%3L1EX8'=#0Q]F9("B$M@#3$UE?D>K4<"&*^*0>A\MTC M&E?ZG%I"2<8>B^23!A*0T#0:S#JO%WG&J=DJ&6_MTV7U!"_@M$3<+L%]) '9 MI81J6[]UU,+-G7+^JHF"DUTX\CP25_ON.)B=,M.BML6LVWIP$K3-N9F/)1_@ M(@&C"B+'[OC=X#SP9& R0Z0XUDDW'99M3MJ7RAY&\K= M@/B$OX.<3T+"!XO3!8WQ 8GQHWF;>/?WMNC6J]DH"?W_=,GU_^%#>M^Y]BU? M8?SN58\998M&KQ;;$3C% M])F\>E!3WLT&*RA?H&?+3DJ!4;W/K. JX @7QBE<0O<#'XQRY5..'/86=6-+ MR0X7UD_8R"=@57$8]DNFU'JF:+3^O1X:GH2 7/DHO*B\%.3;8O3]7!*,UH=1 M$NX1=")2(H=):(H-=5,VZF]&7&" 8EC-H/DGHH?O9M;;_ 3MQP^##D+QH4;_ MQ6I6#1.\'K?FYY&_T25POV)3K I7+SJ'HM<^/FY@Q+:\$8X:?^/IU',<*WM2\MSFQ>'.N!>\H#1D+N+*2 K(#)U:Q51UVM(_)QGN%XMWU5V#7*):+R,!SDCXFPKHU[5O6D6ZOAY0 MHR/=)UE]#+MX7Q)8??;S:>1;E(ST*[C8)?K+XBD]=UZ+RVFQE0/9&>#(YVA- MIE[=SQA3FH*\7"GY'AJC"QD(B7#]MLJ?@T_H2U7S>[A+15,ZZV%5VB9;.NJ; M4X-U[&8%XHZIPQ.O9/>-:_>E"J/ZA]OWBYK,UQWF\;@#&C-'6QOD!HW#<5:! MH9ZIK/?H=26?RSE?E05'W@IALW9OTZRUX5]D1*U8JS*IK6K/NQ($U59_X=][ M-#:5?C,9(+H:.L3\M#=G&RSMW^2$DH YESK6\:AE0@7[LI@F&5ZBQ_>M0(D3 MHY8R?4MG/Q#IUI'P155..^;AW,J[.N)D7/M@VXK@=+#/(/LC:\H71B@="Y;- M>AJJ=<>S?23?OO2:,AD/\RLL,WHW_J*UBBPG!GPD1"4*QWV8L\Y:M%.2J,WJ MW)1OJCNQD FT_RQD-7CHLS-D7M%]YQP-P[WB=JYUIB2BEX\]XU!J[.W2"[6O M@Y&,[(7@H(>MA:!I:(7V!XEO^K-:F4<>KXGU6!7MJRK]S)_-;6(=3#8USGXD7I]W3]&9T"#IT+'@MR <$\MW7HN8==G1&2'":#O-$[6R/>W1J,6S)E?6C%@+\&3M[*CJ1 MQVW: SQ/EV%]N6*> $F 4J-8G(>I)>S>"S%N27GH;2L-%"MOQY/>)D;>^1$JP4;PG_L6_'EDA;@*,9EQ'\<60CWR M8]X+AO:K;YB"#?CIC2ZS]0U&L/N3@.UUL\PD\LJ4PY,]D-LOV#=:WB:$7GIF M<5(SFEN 0[71N;\FJ"N+0/XE.%DDSEN%&/^JJN&".]Y/DTSMKP@B >4!LHJW M0;6/AA66-HD6O=2(J+$,L'F!1-R:DYX(YD??9'ZK*$Z__3&'T/=XO.K0@2VR M_MNGIPU!8>5[)E5$@O2!QP5/OL[_.2Q-57@N@'M]]+4]T2-J@&'?$-=M1P+T MK[LP]3P%?=1L04KTOJY=9Z,?CQ;"7(N45#7W"+IX+G"WAT$](RZ5U]N] O_C M%K]U>,A FN=3DN%1E/WK,,0$"*O9TW[LN M&99#S1Y.VP+KW\3:HAW'K(G?SW8$)VY4E M$.^B5=.TY6VM[NR[Y#FK7O+V=%!AAM*]';<&N8IMN>O._0J>NI/NA2/Q!9?C MY^A"^+Q!1_W77;]7/!]B#9#KVG2(VK$*N\384EY=>,'_VGB[OCB8ZX9N+F:C M^'&\"&/9%3.=(Q\;$HL??4LCK,%Z!1(;1!3PEZ_A0!L#)&!#R"8X_\OXJ*7F M,/F9@QK>7^HC=L/UV94+7^)S0UB2$6\^*9* 6I[X'JO$EF?W18CKU^MJ6J1S MG_10V2MFQGQO/,!I>])I>\KZP6]0X9XVEL#J9ZZ]9FMY[=A2<;<0$6/**5O? MQ"S_A:6EXFUI2W([YISSP8,Q]."5V_AX293V WFZCS"7L?+[O7N6W0E@)NJ$ M92=>5[Z"^_3LE5-,T-"LL?#J1]/2N*>? ]52/=-]YL"X_F ?B%VK?4?C9&8% M=WR'-X.XE>0/%346G1[+WM<@ B:S)QS_15TM7(@$H.2?]J*IW8(#6+8 +O!0PCAA %2]?A+\]R\?E,H!:XDZ,@ MED!,N<_)IR7-C;8C['C.(1BS-"'T;O3)##V]49!C:(0\U)1Z)@%M3*:.7-A5 M/5WR3ZPZA[(EI11, W4=S.%#?,'H:(X/[@B#EOKA)."4;7+CY2=J,22 QY&5 M_P9HB77::%7\_4CEEK/3+F-EF>2$W/!EP3U>TX?.Q/EL6R7/H: /.@=32NPY M.?._%MW6@_2OS/HP859CF0;M",@;"[*:'$;II3+)"=C-UDI-F(<[=$A=;NS> M744%1J4;;"_NNT'=/D;I4%G?D1 M=IK3&8&X>XJ):&-M9*K G#&8%P48KOG-:P>UWNWS/M)JUQ,D%C54 8CJ@'+] M.*>8W;TO746>L0>!# X7IP MW.H\P[<2='M#+^07[J'+)&A#D8+=7S@1HT![>*@,";@2E;6"A#_>>6VR9<). M=S2@*\-Q\R,9IJ^OC9SZ8K7#:!!%?$"&]5>1<(-E2YHYA@V,J^8U\G]ID+4[ ME5IF/0A:8ZLA 26Z'BXOTV;*/E.,RR/_=Z4^_S\RF+I/E) IH6B1<1Y8J3' M=#5Q9W=H /Y^I??\T."8.@6A[, G'_(NPB$/$QB]<014?U. .#;[:70N^0]E M-3BLWT,@P&Y,(),FS6,U0_[,+"J&\&.2FE&VSN M84)![P7W,_L[KO^AGT[[*V+_$\K_@=C!8+<_,RU4"/'LY@RXB,WQ6PDQ(>EQPV-6X0HV\ M$&F4$\Y:,0^'"NX32,!;M51%J+@I>-$P#R]*TRPED%O<04FL4?J2WH\>07A Z@R97M$*IAMC!9]2NIJ><#2SWS5:V!UI4UO]X$!U,+S+^,.EXWOP M^TD2P*>P_OT3VXE/DG.O+BYW!8?EG1-[L51_E'P_Y0Q)@$\K476@+DZ&C)(B M/MWES@LF_D1.:9=$OC5TW&LZ<)SQUQS72=[7[>LJC3FY>3QF>8(N_32G8PI1 M<=CCXKO=!;=+"R9J'*\*[OOFB*A/G;[]CN:G:)VC0Z]4Q8',CV79O,L3"0&/ M]T[L1JHP!['DC7LZZ21&-\?&>/LA0?2]B=Z+NH[>T(G\4ZA+%F5_)-1G)I'9RD#O 5>:[RH4]@UXO@?HW M=X1#'B\4:^LOT2B?^FH%T[U$9*N8'"QC-/KO]5[E/5OV@3O)YJ0\G\UG0.T2KN93QM*;R^4)NU>.D:F60/^0M2 3 M">B^LWO@[MF*,R&4= R3/RJ 3NMKVE RLMKK PG0:+[RY,FI_0^&-8;^Z\*/ MU7XYV6VCAQUC]$Y;<9Z7UXHM;OZB!XXX&7XA&G0G^>MF2:'>A/HSD<<^!S/4 M%04F7T:,!MJ,I^VERUY=OL_[*5U(J76%-W:KZ%M'/L*0O_VYM6SY^O'&J1,S M"@Z+-B83-UC8?NP2&.'A; $%22\S._?3(74'PC^6"@80KL0]P,//N^:M1T%OHT ML[8AEQK60B2TM:#MV;TWE>@#\U<'#JNR0/L@*6I :N9#$GIE I-+G; M3=W->[%1F./O2H]O%4B\H/;=_6)L:.O\YQ[J5M&0_N\#)VHNO"LZ4:\%V-"G MY=!G,E/S:0GD8JZC#C,ZXT:4S=B5^/R2>Z'-NU:7LH+"*GKBJQKT#:G_(93_ M[P8EC9,L?U^*')LI5BK2C.(YP!:&1MXL2F\XXICZ+VR.:$0TFZD1P <&!T,/ MUQS*NRAA_/K?",:AD/X))<._J*.O#ZBF^* N']JNNY"IBPA].$>R?(I+.*>\ M2SI:C@SPY(RZ>/.I/(*;*[^TA-)+9DG!@XW:=C!>=9;A"F[_+P6E_YX1.>-< M>5]O:EQ0XT )?5[J/J0JO.<5#)#[4^D MX5"4#6(IWWX>#6?-7+" D0!J1;6$KF NA4YNP[77#%V*,'N;C=OW;T;'1V_4 M7I6&#DI_^.;6O0C?^-RC4&ZU;Y]D32HGW)+_\("^&>INEH+[C;PIRSQ<7D( 75J4VH+$Z_XFL MMW%G&1J_/0N1OS<32_"Q>^ =V"7JMF34!2@KG.;QTN+&,)@UBR+D(*VF0*N^ MX<0395, @LEOU9=#RVUB:#^+?P8;B2MA:>Z6$9[),DUJB3R11_WFZ1TA^^#P& MQRLS#P^S;CX3>P+R,>T5._6!A36#_=QZ@;AA=N-]N321BB'NQU[>G^@#JSZ::#RE\^"VYXBYIS3L=NY:[:$-\TUA(-G;B_M MXC\L6-JD;+;E-#4^O4:C)'=B!V_3UZ.#%(P;-UG/L8DQ4LAV(CJHJQGABC U M3X34Z9Z:-5I05SVO@X1RPT<6IK^_$:MQB.5(PJ3>Z8)SZV8MVYU M[34SK"*\@*_CN"J(O3K7T+R=2HQYO;1LQ9RCTX/&ZIJ)X!K#IG?>Z@3Z5/^7 MT]^G,OR,Q,22$_42+L6NHC5"6R<\-&6X,@(*IYY_*; )5^"0#=[ T;P* 7T8 M1!O[Q+]/R+B(A!O&MPZ&4T7Z[/(8LOA2Y40D;Q-FRS#T,NTE[B2 J+%.!!%J M-(<4NKZ1@#8'1PQ1(Z'WV$#0I8$'A80 G.@E4(.]R+.#QA(OU@9[]H)F2N'I M(FC#+0Q_@(A#]L)&=?- F\&!^,-#7,VK&A<9+3]I>:.?+PW@UQ2*9T1E(HWE,E,2MW,L MXU?T:',.L*UKQ5]Y!WC V-OIT;S1/NT3>V_O_O(AEF*^%)*")P>YZQ3M:'VB?[>/+C_YONXW_ MX:"B6UOI6X;M]4H?,-_-"6CJWBPMQO)F^RQ@K=J'HDY5;2EX"]YP)Z\(7[CB MLB.T9(Y1'+-R?X="6O'##O84\T.9]YGE[TS8@%7=_FQ*ME]/_T^4GIV48DK[ MR,0KI3GOHKZFH/L-Y3YFF3^R[P9_U^K\%?#^L83\/D]H[Y_Z'XJBIX#P.]EO MQI.Z( 1A(E,%,)8/(?/"G9,$V"$9T1CD9NM/[/U? BHF@TDI%-) *_);*2I" MPRC^]VX;ASO%A\H>/L[PAJDPBBWEO,>"^XYKH^.AM&>C8E/AOU;+#TC[A*#+B$QM_4BS"I1 4FE)74A+ M.*:G)4+#@3(T@QPSRH.:GJG"4$PCAB!S;:->3492>'*.6,, 4%W];6"R:Y(PL8L+_P*S)A MB+U9[EVVEE=%;BYHHS^)"S.JI?!#4N7($QOL;U]6."D<(P?Q#A+P &H^ M4.*YW%8X5&G@ZJK25W1)DU?7(CB!WENBY%&Q[2+:=W2$P?$I-K'J@_9D859P MX,O:"<"@HXT*,Y+Z[+7'GFBE'VMN>/FF5LO99M*&W3:?UI6^>';L M+?$#;-5D7^C-$$] =(V-S8C P?;')U0Z(CI;=\A,8$C+?S>N#F/=G6-_C*%F M1*CC@Y_@<5\&/K\(6XOW50:6^)!;(<&?S9[WUJ$]VA)C:PMC)\\V4B-Y)G_8 M0GOV;9WR[#Q,"D:^Z0A(@GE?!/"^CLV@(3SG>'QKHLX55C=PV\ 3<=EFQ/:! M1([71:567R-69J[:#H>E4O^W2Z\K36=O.;W4L?HT:/GNW;M/K+FJU:5T(ZVN MN 6.LMG.!V:9"E+]$97DMVK!4N(ITD5<2D0B;Z_,$)458S1^=*+@0 M?3UVV"B6'"1>R,;KB02"$N6W_1=YS6+.XG/X'YZ,G[?4PVSD/%OR!B.B#D[\ MBN,(>@#:["W\60B_VHS-VER]2(QUKQ%/^\$ 1:D;YP-\[C<4CA=8)H-/%KQC MVY-;MV/50S\-EQ-7 0]FF/BKS9<@U6W:")>?4&P L93[X2N&#J3^,VO]*J^<%WD)C G:ZH4?[W-,+N_VT#SS2[G5 MN&MN[?:-OCA2Q$%U:QTG&_4AC#[\=-R1 O7"+-G3)[H,XS-,Z2*,\]_E14&B M*<8RUWMUP5K2_%EWK:XT+/3-VRV$CMLS(@M-XU&=>'A($I]ZD53FC7P19@L&<&R2NG"T]'B MQVL+Y+1$$>'E9()1 5R6O]=WC!&1/)9PTN5>:!(#+%)"JFDC]\C2<$3ZX),/ MG1;7$C^C>BR99/,$J^?N?WZ2J0.OI.MLNC,_YT;C@$))WDL!6+OF_]+'^']E MZ!J#$?A^4X;$NQ[]6WR2>H93:=5A(:RI=_:-KNTK]+6\F.Q_5C;]&4((4QQ6 MVQ#:L;P==[ZE=/7DKI82ZDMT3=86F:U/-A>]WE; O8RR&.1R^N1#Z]K/8KLI M6,>P]_9\P?3YL4GD^^"V>2V:7/;9S'S38#/U>0B_EC@),*P!;8R9D(F&VN-T MUWM?O,,\8EJ0)Y&Y7OH,(\L-BQ/D0T-JD^N5']X4'2Q6'+ _#H!M)W;;##-- MERM\FV 6\6GYCGQ6:EFFE/"K]/S/X>55E0=[1VQ) )]HG6KK@VNVU^OEG@ - M >OG"?QNW:#!A"&9S]Q8>6=_+)DRUB'$N]F :I5Y1'GU1,2C##,][3L8!AH= MO@)P6 I ,_RD0F F+B4\0%,N;.U\#IGTB.8NFG8WE;&ZDH >9B:.J?DMJWD# M0P,T=Q/% $+IQ1$3N! J3!WN#R9_Q@893UG+\+!QRJUK9W[WB9>:TB@T1 M\OSS(%14KPB=DKZC,\@S$9 J)3]]$WXP,\FN'M<_K]NRE^R$1 M2W8_0'>MU#T^"M7)&UQDW0_YL*E&YA:>L#DCL-B/GBP_3: M_D@9>?WT&@GPA^&4*DS\B16"[\^)O'F$$7"=HT3YN;"OW?^+3XO-\L;_=->8_Y^,(T&T5AT\,2-!TAM^ M^XN+C#L&5KP!DHGS0LA+55Y7?LG-:XF(XQ-C%L2SGT9GHRCE6(=0G9HC0H\< MK/NAT#ZN<6.VW^@?H74&2\,L L;BSAP:=I'?BCG*D3D*+M ?!3,]+$CYA8,= MIXAKI,G4(>*8UE]0/QGQ'V:-?R-^@MD_%?^'Z>0_5/^,$L[Y6H8I@)XI.DT_ MIH?&2&!1'\$ -W0+L*+ _B)V>Q(P!'J?Q/LY_/=V <'T]YG\;N%Z*-ZG_LTK M#O4_AW81P-Q;&A(@].L!"7 T<(19=3I0D8!$$G"%!)3FEA9X2*2C^RC;4!][ M_B,32?\[Q\1$/$PF>P1%>B M*,X],5WB(MQ33V F>P4NR,#H..$8"/J4$/"BIG2P\/+#AZZ)"%#![&:1N_L1 MB'4.38]Y@>T1PIN]^$U01V+]IC##"242X+'+:#B36B%NMVX,]U3DX7IHF2DA MHB"@D X^]C>6KH>"_\./AU=,_,-!DN3#GZJY6.OM2WU+MP.EC>J-QIRR*\<4 M/P7-V]2TNM1'VE\7\D(3'X3PFOFWVU@\[\6I_9Z MF6'1XJT'XM:U\:YS8X/L]X\$2'K'/&?S4INT#) A 9QJ5S;WF+O7\6XMC)RH M49.U'N.MO5@5D/I R5WUDO=$X9K[NC=B3:1JOG^RT;-;;Z&G0[@/UL3E3B+D M]XPT#'1!)IK>"WI7TS\%LD0\;.S.M>LYC7SO-%&UOK[S9BEN>VT5C1:*CZE4 M^\5HTKJ5"BLZ[S;R)M&R-_#A!H[*NX5N.N8MTKS^M@QJVM7&JXK462K@(MF]5*8(URPZ7QOK3#J#.I91U MG5E'#NQ\B!X=Z2O%:P\/9A7=U>K-Z9O5FWP3.0Z_ A*=J'Z_.PG"VZO>-JJV M'Y-%CMH>+"]V8B[;E8V'7FA6*#TI^&5DXMB ]8.TO$[[9XW=ZN@'!!QQR;1^G-WLMS%BM_2R.OU])GLO8<;@6GZ:GG/\RLY5 MN:O\7XK,MEV;/',_8$V*1\YE'-<12^5>OW ;XBU[V>5-!9+%UAWM69$!;7?] MIQY'LY'^TKTST^V MRLFW&%:[WEC[=+2[/E3"4]*QK_PRWO<#K(KC52M2>.$T:$PH7'M,B=+(.2YK M_-BQ8R,AO] +$[NBKAX/G3OUK9V8?S"HCRADX1>)/.6#4_8&1H@*7J-ZVX,, MI9OA'Q#=#<&Y9E9WT=U&CK:CM8M]MLPE]H'GML_-+J&]<@+*)D^YR^F>:.%6 M'_8.7<06.QX;L1N9F_'HEQEU,!'YFIA9\'8*O _@"R>:RAS8889GBBN9OG>"IXXC!R\Z6=&=' W/ M?KXS@0;[-$-:XRH$<.?A"5 GS:'*0>R;B87%@^](_7L7).XHUF:$@ \DA!%\ MG>9F6BXW_Y6=5)D:Y*5(XSSTRV!S61:_X7!QHS[^S0Z'YT.^-)^';&4W?Y7H M;U_?O86788]8,M -I12%YE."J@37U3CQ7 QC,?Y8K/\/]ZM7_[/-V]WO 3=?" IAWUE.I ^GO8MZRE,4B8^"%KF$ MB]&G/<5E,%.?IK@9Q08'@.!SL -HJ.1SA^P:+A+0GT=(INI/,=.]IB7 Q@/ MP?0(MT,3*@Z4)@1#1^$VXMED,D,P968#3-TH>^WS6M(G471L@']VO+L^[?DZ M-A^]X8A':'UQC ;!3(N&$2RGC0#*87H41?MOG_0 $?D*T65QBFUZ5W]Z/M4. M=M1P5(]2+OL,!W6)8)6:U[7N.YH3(,V'EC/\I@M/8"6_<*P\O7$%L+S>)L$I*W7@M669-0&ZR-^TJ?5.$;*M^D_ M7M.:K68H0*;O'%=CW!GI"((.?@)M)ATOVE1FG74T_](H58RIM+LN/D"O C3? MGK1/N5K#[V+/\75!%;MAIA4TFT_I*,<*3@%5CB*'FK)V3Y1X3/!281%ELVE5 M+C2?SY, AYJ'G >JZ\1Z83)W>>R3=?P&:S[B0O5>HOR]8*^K#,0H^Q2+F3A# M6(5HA\/)V,J'S\,GQ'EWJ X\>HL;!B\V!(\K[3:F=QX2O4M8);-M+I<4*(T! MY!AD44_;C[I'NHX'7:F;XO7NO>0NU0%BIOY.!)@R[K/2@(@\D][ M94&)89%/QM!9/F&1S[NH*DA"N&4O[B$)Y1\\XZ;K&HD!;B9^]..5 M=FVA/]6Z9V$0-5\C"Z=/(0.?GQPW5^F8T^1N2L5D^5NZ(XOW/33D4IL!Q?Z+ M60LFXS"63;J9N\F01]BU,%S"!G9!=[$=,\DG"3WR=),&Y130QBX4L O2C]WM MD<6K>;NP%"3B#D#OX]K/DX6._ MFIB60A*P3%Y_(+TTYB<#"H8QR7CJZ^_#KMDS8SY*;I0$@]Y*OGA]ZRL*J_<& M.3D,,NRS%?QRV4G^<80':#!EL@T2NL!XTF3[EXDSL<*]/?)KTU3L6>&L3C(" MM7CS3#"":OIESJH"YR.O/N-H@7(2$/]LJ#U.YEL/$32N%]M956^OOS8Q(]BB M,J/*<)7!I"FK(^$*IZAO5_E^6=G\)@E@+,W3]I0:9/,_E*'R8!-O(#GYXE@*/50]))EM_4K$QEC&C3,%^*\*$.OEN\U"8F R93DG=C-7*Q>;BSI"G#NZ? MS(A2.DV7BZ7(YS/!D1GB5!L\=/3A7 BPD8C,8;VR/ABL!>B7XPEH\DAH0Z<; MRP]?_ZV:(H^TI+^55(C_L>3\[2CV=U/U[-^-U3%T[++F0G@R$XLWX_DW3 Q" MQBCQX["!VX?[,;JWKM/T$Z"9N*2(OW<^S_[#,/Z/)W_HML* OU&OZ5( V48" MLI%#'92^?&FO"JHK#BNK._^S*V7^U0%><#HX-??^E8?+M@O!Q,N#"W;%P.=] M"A2*$AK0KKL6$1:YZK\R,KM/A6'-RW@>$;(S?*"Y MLM>:3;E?L518--NE^+IC(_''.UZ9B^%-1#1T%+(%Z"YHQH6R91$R)"2C8G)5 M$]%57J(V\\R+S.(4"SCS\0_/O2,6-(P1(Y_D"BMKD( 57!)B&64_M@!'?BGQ;'[\-?FZXL>FW"9WS0M##I ; MW8H,Z#R#*\N7GQ_IMCMM:G^1[NN+F#;:V"Q,"=<= UA-FMMLO4QJC/:Y*"77 MCX:U]";B1[F[Q=SPMJQ'\3F(M;HF%UL=G0[MH-;T5-J,\+O?]@,S"OI0VP\" M_H7#A99YK5?MZ=C=/=7? MW5S:=MQO]O1RVD[62K9_&3FLE,2!6@!WRB:_STAL]8/:N[V?;1J$=P\SIEO? MB+ERZG+E5O=-RSQWB50;;%*(X^K7LW&WK7^Z/"]>D H5W@I<>WM=*:Q;P%&> MY=ED7WRC90WB37O1!1Q-:"Z^N?IRU6<6'?[J(O^42P,B[!P;\+N1;47YB,!+ MQ>=;#PN!;KK0:@*54/A4D^/OF; />)CL';3E= M'W'MSB=OV4NG_3$^/6A],@1S--$G3TRN>0D.#@]UZV+[ M1X^%PUU.:0GWFYW.@;5@66U9;%248%1W#SK.GM/X6:61NZC:QIEZG 87F8(VJNL& M6.'SD(W@%#+:U;Z)3U>%59ZJO<^:?T#E(_.M,[".7PKT MB!@ZJ8N*N?3A?%KR/'#@=K VU7U6?7V['EJ#I]\8?BJ<2 T2W_V ?R/1UPLV7$(,!,3FCKC/R36H!H@O7KNDZ))QT258XD930#CDY$XL*[S22Y0%> M6D,YV1U]Y)^)1B0_HY-O-R7,A M_T[4=R^EB P[ZH[LNH"#G)G6-V%( EZ2T M)(HE S>&.KE.2M37C#ZLBU;EG'R9@QPB'NZKZOQ+]";H5MJER/U%'P/?9*NL3WDDOX>3-=K.Q] M/F8IFG]O&#Y1PXH/TFG!FY[+PLVM5G8IX\9;]R0;#TSF'4I&)6<='U[*'[@; M&E!6J>5<=+-Z/G6Z875"9]QV/*?+[/3GZC6H$_'T_./"[;5>U(RDM.O=>/7H M ]W]HKF >0?83T<]Y]?] 0_L@@A'A%0+WV;U$U,7/BC.Q!KN%,I<'6_7HG3K M;EQ@%,=L8%C/)[A"WY(7MV=J&W(.?A/5Y,?<7?&UM]@\2$#S#L7,#E MLJ]?V]16UQW,\(:OMJ.L,D['*R6:]"P1->J8)+:6@SYON5LN!Z@RAN,>^'B/ M>IUC87T5BY3UP+^:?CCS\NUESN1Q>R692#.LVD]1L9WKE3]::3.?+_+$K=V< MPU8CL/ -;*XR/YA9_;K9O$Z=6#"99BKE8JCC^EE2 C% 0.Z\+C@814\S]CQ1 MCY!$$=F1UW^8:1?Q%6@;1 QWOT9^6'/X$"&3;;'W:(.MG+Q@%QF'L$X;LQUQ M.'!;TNL>UQDWI%G%0*%Q&^%P1Z4X4W] M0X-#RBT"@]VH$%H74J!4UN,>EZ;7T;62UYA=/GYQ@O26C6\V">]6*[BX"![U MB[-%Q6L:PL%"&:?Z%HVJD*-$X8$-D65G#KKV+;R #&.\>Y<=!\U8!=_,$?K4YG)P!\:8>: S+^52RW%4A="X/?3-D8U"$^2 M+IMO47NN,Y;Y>2._FP24)!P))@&9Y2E5LS@$*QR@]VN=-UDR,FO[#NO6I]4P MZ;(CYGW*_[8\I.'37A("G36_M:6SAG$K&7 PKKA68W%[K[^=CW6,O<[-[SA[ M!/E!+8)8#(-X*35GN+Y!V!YH;*@@N%R^J);G$56>9%:STXA6:HB^8F(LDKYJ MPOUNT6ZY0+%AE6Y@^RI49@JBMB&T.[E>DMS\I&Q^V-ERM60/=T; ;"A0;7>@ M59WARW=K@Y5K6^E['XWU]MNS+RV<_,$:Z/DY@C:9<]Q2)E.GX(=*E_G>93N[ MT%<[9C-DDNM3T'%%IXF9>?R6'H]=G_[.3V?^K YOZ;+6=].* /!_\& MQJ7/E)W3E:V*SA^HM). %SR[7O4W5Q>65M,*U>;'XV>MF-O36J4,],92+-N: M490,4)+47QRHZ0Y[*6:G):6%N'-9>C#4Q%&!S58PN1/QI@"3] MEW+I0R45ENJ/G16JWFT:HL[!*6*]SB8%P#<\( %KIO(FNSN@MJ'^U%2CKH+# MVHO_*DR0BF**E'.0;*U1P\WI?[,>@YI57S(Z<68B@TRTP$FJ*+"6+J-$[BJX MJM11^.5N$6A5 M1Q^$4D>=9/'E@0)4O]Q 0C&?V2;!(G 1+G1!%)STN.W[+M5NWX(2R\6]5ZS] ME@E?TVSXW*^<1L7"MJ[&X]WOV6H?C% =K"%DT+HT7'8O6S]YAVKI \V6'P2% M-@L)CG"-:9':RMBX%],60C]%'^U5/B80^B7'/LI&W+=4X+-_@-E8OK.99VMC M.ZQQPESWRUF"+M5MIX&'FPKN@[4G["M&!05ONZI>O M9D[7NWK[OA3;:EOV:^3K?JE@!7]B@;*O\9<-S>IH#W&;0-!,;; T^K!UY,6Z/*S*' MBYNY12;*;,3^)6&8HZ$2-3$AX+_W.#Q&Z&C+[!'@G=4BH:QD<-*D;V-^YO8: M+G7J/@?YTK%PK0RCZF[[3_+N-$/C+[^>/T!:9<2(S5)+W?9MGR7B-C+)>FDOE MZ_(:S^;[JM>;2KF[:4J#B]S\V\_FK%>(% M]%QVY!.=V9F>@4]U,YGLQVZ7?&EJ,1';\LX>)P&UZW)^!GFTM56(\:&2DN:W M]Y4$^:V-/L\%8L1^JA31,W,:H\6;'(<)05"&.-UBN"C (> E(1OFE+8"'V9' MN1'T/! X1^RISAGEOJ?AQHI<##Y\U;3KUI]DS *#=X450M(/5G4180UPR:7+*7O 58=3&4=MIN^&H:6(.RFAB=*CB?[< M8;Q+HI1LR9&G0WD*14X&?ND[E 2K3]:L67_:MU42CD!P.4*$0I(/\TLBL!.)%-\:US2T12 KH?V MHDB2ND01SR:2E4UITPOD#+M$W7XGZ%?TJDP%C?J?Y7],Z1,CA(MT<>C\=>;NC=X<12<^BM(UV*# K^W%"B#?"9F:+ XETLR&DY>(I(B('\*?0$S8[9A MWTW,E=Z!E,+>@6@<[7M*\&.6YB,#?&K.7*D+\7C@TA/YKSWXI#M"(#Q@%KL==8HV6QFN]78?2IQU&MVY'H]39K@JOT([[_V=_LX5?+SE3@/> M/\#**.I'S0U\O_MVRI'BH0C*=HRS$9V8OT\AE7F;;4!=X!! M^Q'S2#VL\*]W3ONK#C+/>#[*T+;++>]FK7GT$@7&'MD+[GZ](/RV[DXCG_Z# ML]_:6%NJ69EM>$G R?DWT[>%KQ@(M-[8:6]3R(C_(5_U MZ]<5%2M,X@\6V!A[7X-JNBQKKO=5JU9X?;Y^8EDR94/*V4@708:D&J=VH.0[ M%AZ8':'M]]NPJIR1CBWQ2A(0 M1 (VZ+'O3HKMEI, ?Z3$';8F$F"9M1P_;4)/1N(R!H8T%7SBR@1O,% ]@1+O M JB?U%UX4IDKS8$"RT&H<&B8KAM5.<7S15_\]TTT0.MK*](G'/_XE:?;"XXW M''7/YQ9]VMN'D'S5Z!H_.L![_Z OA+$_:BLXA"6#:K!L.4Y0#9Y7)B)^_X;9 M"AS?5ZG_\0WW\[ *W*@$XXVCJ@>V#W(MGJP,Q!C[0![Q+4AV;S)O%&AI!1%? MU*=0*7WR4Y_7V>X)E=30'=G \9L4Y&4B&O0!XPW^ADD#E(8XN,D2V,[QD>)Z\:,DQJ.E*.ZV3XI@\)]>_9^'KXR8Q M6)G/R\JB0TM[K/"8DL7NZ?5^"?SHG<[!$.V?B\J.N=SGW@HZS-)( WM!@ MUD_YDW$I16S>+657OIA3J:M8;XDM^"(^SW(7Z3TYR;GAG9$*W]7'%^:U68J1$3K7LY\G+! )_>7:E]EF*>]%U MQL,_?R984.)LP )Z-.M0Q@);F);'IBSDK$WNXH5 M4@!]> %^5T,??ARE7:,X#78;20)$:"@Y],3]QZ%ZCE+[JB0@*2(;.=1(U*[' M%A=Z>9I334_]L__AJ32+9J"-E+9FR%L1.JL6\S8TM*V3*6)%L)0[(TUAAB M9 F#L2:[LB2B11B#$I)]"1'9^Y[_OW/?=]G^\YG\\YO]\?SV;,T9CS MFN?KNA[7X_FX'I=WJG3WYP8M0LM%DDOA'$0PJSUAD?^RH+NB(4Z-M?9 MJO;H541V^2J_UVE4XWES0K ,R9.D:^OOFB3:N6;/L,&3#)[&BBW77_XVL9MW M)-K=J]!,=0_(_C3OOC4G1\Q;-YK2+[\_##XB#;61=G!P;+M]9S)#-$5U*HL. M-EJC>[SEQ\AKB>\,#C7FG2,;N>]'8R$SWPPVC9]D+AM8MF\^W4V48O:?7FR5 M0>)%:ZA_;,1NO9*H*=-:,--?);@:\((B\!3HZUXJB2Z8[N_G.4W"J+6^O!>% M2GO O"KV27&NXV)65X_!=$689&ZS\CP]5AAAX_[BJA!FJ7R+T[>\H6=^X:D) MMWUU%+G>&,[[[J?=7'J#?G#]Y9NZCA__2N](J.]'9[,=[AT]NW?()S)HT=8K&; MSC7;2KN)[Q1:]*]\BM5]>7V6++P'H*\5XY00+EM]F&%8FMPKCC//*I=U6, M/1R8GS\#7D3%,^A%[AZ9Y\)^D.K:L3M8T68BGD)QKWQQH_Z16=\!">R[Z3V45'Z*++[AJ/ NFR1-"B!Z1)W[=A&?71B/C;AI:S#L_E#2 MX1QOA,'GN^KD"T+>7^-]MFOIL1$W8HG>OS@3Q%/GWK#=$Z/";,Y3*RG+"L?2/3+=Y1WW$WY1&_RZKG,L8S'9:H),8D]-]2C':SR9'1] M?NY6!#RR!G0X/2HNR/D(S24< MD)J5);A!O@MK8#P-(-]T[,H1?#/:%^9B8$!R%GXU)_.ZEE-.KI 3W,2)"]S> M"1Y(J*ZG"?_CDZCX$T5&=9T6$2+"3>B0"5$^'S&'LH(/&T&:,$U=TI1OAD04 M:#+GD(EIT.E2*:J)_KR'M!&"=]-R=SU9GV3FBFD\L0L-= AY<5! M1G406C(R;(( S2J7_^_RQ%RO8YL+V^NU)\RC+\ZU04"/5>\>+%L8>ZN>YB5[ M&N%HW=HOG,Q+?,?UY0XO5MJ008PMOUB\1F5KI5O?9X%C-@%Y72< MK3P]>T&@+IKR@>P8Q&^5X"V[/[+U/.5#=UT07UU4CP+*,>A4)R0E]^9:CH2: MTY'3&%DD-SW\'93.C5I ^'_UNYX4)+&0(R%6%D? >"+>7)(!&,?X M(,XH,E+G#]/$0DMS>* V!X[4:,;!5+9,Z*;@U"1U6C$K:;\@HB)Y+F(K ,T[ MX^R4A[,];97H1]$3,YO3>(A0)L HS+=H1]DTIR@ FI/C: J4-8E"9@& V$1C MM(HU?;J_74XLJ AI\%A'@3TLEL9J%:?[/ MY$,P-CTK+44KX.>9:-]TFS")HE>OK:\4VGTVS9C"+2\>Q+29+84]=BF_O3&J M+?"]] ,VT?LK3VE+@V"/*\=SP6K,)6W;CN!-6'X#RR?N;4/O.Q:1+@%/ZS]1 MPV#)]#W\"=6!]%V85%M=*5W2(S]4_Z&9_>LG-*-OZ,,4^A!@S>EB^'A5_85" MP]FD#K:W+A+!]8=EX[$&3%WK <[S]_)GZ3W8D70*M4KJF0)IGGZ]'RRN"O;) M,3Y110_IV6(7Z=H$B'X"#XI#'X=\?W.6')92O\:OKB'>0UI (A?N0K!W'^(W MA2DY%44!8/T[K]%+[-&'4:%07 M2'\X'J=!,U4_C!"ME 0XF/> N?G&8?<=4('S???UC0)F,+B<:-9 M>--&=>SS#?MC@2#A(:ACP683-V$@JPN&$?Y-=B3P3[CT6]+\<>\6_<&:MF\= MTFF01I'[479*<@_][I@5IXY5'M%2\2DZ4;XUB+9_ZOI8]@:YX@0177:56K\1 M=0V>GOE*^J8F=JAAU?#0=OX1=W+6BSW Y*M> CG[]Q,@F7RL US/\13,1OTL MML$/FW):%7$&)@ #?')&(\?Y@*9HH$LZ17U<&#M4$J9I_8LF_CFVN[B.X@:; MW54>+:KV*Q6URKH86WSS$G@BRKO5%K$6ZG[)@WVUE9'U&2;+C<->JX6H[S\D M;5U%\OPUI-]A8:XCS*X%:F=8_Z(>]K6I;[*T(!EN*5&N"T4B[A[CB:)^YXQ9D-MD_8?H=2\"Q.8'-[Y6SV<3K%IY.KM1O M]%+2O]K3YM]NX7\/$Z"SZ+0Y]M@]1H[M=O@>P&NUR?,2//K<;:GR\^ZR%G;I ME1G?VZ0V.K]N/3^R^71K#$V-([C_SU^L.B?M3 !IE(OS!B2A-$K_F]&\(:0" MZ#',XW&3IJ=U-N\3^6\9]+2(D&@=Q@[Y)YC]<"?X)PLE[]<--!OJUJS?QM3[ MU-M_Z(CXAR[IK#R](-/?101_]I\B0G!.%Q_>>X.Z:[!,Y68Y^X\Z[K:ULQB8 M,5I74^@/7\^\?_SV5S?=GXD'<32.GT'_Q]JNWL'(/< &O,&S&=-@O7Z/6E

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b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�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Ϝ^CL8]6F/(NQ&;O* MC+ :!,XL1=/:J1E[T_@VPXG2E?]<4\G\)_/SM95YV5!G>E]UIBNM:N;Q4)PG M@(669CH-.!8<0050JZ8M+#0V1ZFER_E\3].VH6WQNP4H0XPAE;^/Y]-R\=8* MJ^+'@">HA#?U**M!-*R@SWDL%DX0?ED@B:!B95C;OFFL@67)WJ=1.$NM<'YB M1?9A:W]K9RLKN<3);C_CFY^_YKRIJ1V!M;""I+%J3KHN!7#T$X,7 5ZG)I(^ M[=C,?#6=[^ON^A(PJE1>>ARH[001HK3$E%$0RUR,K(PEC^Y[+9?7+C;;^#9U MLWT.U-V1.>JAX7+C2IJ;&"X#T[B3AB6I.+T]#J/10AQE/UW3=O6SI=>?Z_/1 M__X,O6\4>$=LBN9.2<]!PV>&$X'%LBK22 JN2A[RPN1\32VU]A&M^NM761][ MZN76'RA9/HBV*4/[Q=NAQ*)I.NN$ W>0@D"KG6NS_:E$.X82A-HT1 M !:2.BNF=B@1&Q+"_>U"$IW?]S2S!JV8V01U7/C)C>H6E<,)$&IZANGF$EV] M]?(CX8__F(U#EM.G&:><93_A]2/L=VCG.5+8]?#:A4[J%A5-'$DQ.NN,KH#& M&C"\&A3Q?\Y,D]IQI?99J(YV?2/GDQ/^,JJ!(RY&)Z07 :76XXEAPZU>$\;_ M_%YQU9LWF4O-W=3Y"X P[T09:2EUJ0GJ\D041A!M?([3P$I7\"B%C9?%IHPE M-<9&XEF$>X)R1%$A2&YT;G,A=(&]>"^+S7?)P-D=U6;Z!$RHJEOMP^&'_9=/ MLM89/%C]!%0T5\'+M;\^(>J"='T^GIWX>CK__MSP_&9'$0"R" !54?&%1B>=>PRW.C?Y7U?6F>V].LGDV3.PBYJDEK[@;; M $<[RYA,K))_EDT](D90E!2(6EKB:4Z)8-X1ZXPAE@(+X*7(A5:7&8%A3@19 M1"(YTT3DH'A;X2+A2C"9V\"+TE_3DC:!)HW3V4]PW#N'P 7.T$%YE26\?KO[ M19X@RJ>"RJ>JD ^+-6Q=M[L-Z-1SCN2KCVNTS(37-J=!P6T",,L5FBBO &G@ MLY91*FJ^>]+(R]K-4B/GUV-7-Z"!8(W=[V>P6FC"V(4#6/KW$6#O_J[Z/M- M8FE[/)ZA8AU"Z.>> B676K>C-WWI_D+^7+4M MB@:\ML+A6EU#],]O%-9&%2X["R!INX#-2S 7DKS.66=P])H#/\W0B*I6N <: M,,V"?V!TH,[>@9F3O7[]>MF'> Z ]\NPQ"X\.V.4_!6/?!F_FF+ "9<\AM6J M"PK@5=\+,-^OJ(43XU%6+I">W2I+ZA;56U3E-^WZJ;XI2YH7Q=/%_P&I M%\QMCC6,5N.;9>Z<5-X#'UK=P"\?U7_5O6LZP+5?/KN *J5K>W M(VU3]0Q$%T4^G8O\MAY5/KMX!M<#\YK#[ MP-R:&;V0:@"[SC;4I<^EVWVP7 M$R:_CY WE=7?%XWKW?;[@^SU[9);!RBNAQ_?"%!]8LQ?9;?G[*TWX$M[[2?\ M[I6OKL)!;JD"5E\CD:Z:)_/5-PWXC7GA;H06KZ?A)&-; P.^.2!-=MR@H_Y? M " GA^QPD4!P:Q@73[5^RG1^AV!>-()9PMEL"M:/C87WAY3SC>O, V_O%4)T MO'U[8.ZW9^[FL*G:/P^C<=/Z6\=AWR^'?P_[S':[?0Y<_A%S>3:P^8'-7V7S MOP]L_O9LWA[.QDUHZ]''X _;J8GQ$'/H, +89Y[_8;EI3)*(,64O7 A;#@+@ MT0F D@\"8! 5P0 '_C_K?D_/YPT]03?)_2:W[];[G)@\(^8P0^.G('!7V7P M^<#@;\W@\\-1.#(C9/,N!'R%7O/Y/W"SF/V\V.S [@=V/[#['XK=BX'=WYK= MB\,3>,9A:V*8GAWZJL7"\5G3;^7^#6PYVT];SEZ>;WE@_0/K?_AICO(AY\?) MAY(>][!X=O\2X1X\3[T',KN6I7ZE]N@F!'2KD00/EA\^)B7W]FG?0][WP"Y_ M2!7T3FHU!]_!HV*KW^$[* ;?P:U]!\5AU\CN,-;-X7FOA_:P:ZIT&/XYZ[47 MH>LSAYTRWE_34:-K/Y2]^N>LFIX]A4M&J37#2N>,[ UVEFZZMABOL=]RD[V; M->[8M%W3J>[>E08:@X?B$7LHQ"!@!@%S1<#(0<#<6L#(PW8^[N%PV5__T)NI MN5>QDK;I@\-V/U4]?I[:^N/+?RL^_+_?U]GH/C+C0QN:C\'?_T;7=LC_WR!C M'[&,+089.\C8*S*V'&3LK65L>7@^"Z=- >!9ZNEW"-^.SMJJ/8S]-N*N#O)Y MN7R)9)EMSU\DM>Q=CNG9J<>^&Q.%UX#@FXVFZ9*]2>ADT&"M/69)(@=),DB2 MJY)D* '^#E%B#O^)H_$J',OU,>"'T>+O>691GT7)_UG9>Q(*_^=\_ZMI1MFV MK6?3Q9@*+"8>!,7C%11*#8)B$!17!(4:Y,2MY81:\>:UBX[E[6$[FTQ&Z6_3 M]%E.G-L0RW;K70AH?^4%SK*79FH&P?"(!8,>!,,@&*X(!CT(AEL+!GW8C99H M#ZLQ6@SFJ ESX8 3)@Z-!AP&DJX'S13'3I>#'3VD#I>#"TO!G[Y0RJA0\N+P>-PE_-/Z.!QN/W\$WKH MJR:DV5&'X5-PLY3>'BL7&FQ\T4SJ?CL=YGM_FKU:;#[;B]WV4P!R!U^A,=.0 M_:4&N&%&RI"$\JC]#$."^R EKI$2PZ3;[Y 2;$4VN/ID$L9MBO#U63:<"X2= ME1T/O'_@_0/O_\%X_S AZSMX/S]LNX9O9X?UZ1CTZN-J<@CZ]=14XT,;QJ'7 M#17FS>K.LKW%WK$IPDZW_>QWW'Z5XA=/JM>U]*^6^Q]M4AV%_;>=5I(^Q]JI :I\"@2?H8$R(UT7 MQ\/6'??9K?!JOO>GV35='+-]=QS\;#3X%1ZW7V%HW#B(A6O$PK4M>0:I<".I M(+'^'K/C_SQL9R>PQEF?I< NW)4Q2OZ:[7>;'?C]#\OOX;_&CD+Z\W-'^J_? M?*)L[=SR3HRBX:6'E[[_ES[G8?WD&-6E*H03+6+?QZNZ_>[7S>ON/[.W>P:OL_:N_;+]_^?KM7[+= MO?=_AS_)'WM[?\7/^P?;!Z_>O'I[L+^FQH6C>H$&;1 MN.EB.\%GZ8%77L@TX0L[WPP/JDY YG$7^-#NK9_#G.*L0::IX]J6WM&<9 M4-%)F[4S=YR9-NLFZSE BK.GW=_^Q?++]KB>C?S5[\,G[%+57OUA,C+C:[[& MV4N8\#$-U_SHKG]&!>0^]M=X60RNO[Y-HRJ\/&Z M7T([K4ZNOPDP&CMX7?=+/44PF-'RE[JYL)-J/ NKOR&*C<-1-XJJ0[DVS*$$ M/W=8U59 #Z;)X.2;D,8? AX9B-8"I,SI_73 MU6L-#KYZ?HDM^>KC]8Z'Q)A\U<*AGCV/H_!IE2G)ZWG2/V8MHB=)X #VAK<1 MV$$S?9$X#T%SLWUN :O3<.#K^-0)?'%:^>GQ\WPKS_-_?2B,:W%4U3@=2SJQ M;UK@"X>W>B9%R:@23'$A\H+J?TUR'7"-\Z5D7X'IQ5WU]>R>_%;/FBS.IMA. MKSD?YEDOAWFFO+&EQSJ;U&V:_OET3@")E\\2\0"#6+EESC+2YV;9IP\O3?WX M9O.,M/F'# [C='J<80$]D(X9I7$0TSI1\#$RY)-N;!S>D_AK=PUP69/!7E&# M 1T3M[Y8_BG(@G9Z\9OY:\%&<+]C8/'93^?O\87%?GZ*.VS;K",<6-M,JBF< M1UK'5],TX XWAV]H;#7"4B#8OW''R '33R<@F%)6]_R\X8@B+-)=_");\@? MHOF_!SXQ\(E>G%W')^RLA3T"%;13)-2CLQ<#S@XXV]>S>_);4ID[KFR3, )5 M%+GZR7G=)6AX"W9\+O,&7CS@=9_Q^L]PEJS=N@';.F1S*RLS,0*2)PT$4#EU MQQ^[<%E32U?'N5&2]*MZ@J;Q;-S9WV@$H3_()X.V,X/,O/?1)>4&%#$'XB#. M1J.SS'B/YE,60.4YM[46VT0BQ&>=FZM@H9_ P703O5:ER],5==-=F#;?*:@7 M]=-!! VDVF-2O6(;G=M"R1W6636X7DE( NK V%%]Q>):>%"0'DSG MY&J3,8(7C#,/=Y^UU3GIC6% ]/JH1 M\W?V_O;Z)6$:4'KLPTGE+BN)*_K@)8=E)Z;FESLX7J 7U%W3F/1JT7KG(PA* MT$L' AD(I,<$@BB<@G53-+= [L"3+]MKJ&7A-D-MT#CL?6L"#%%4%CN]G+B11L8CN3)H:OEO, L=&.1/\ MT.E+/J1^!U^*S,P#5;!^6C$]8:ZI=6K:"*X:I7CQBKH'ME>(C0%5[#0L3;&! MW@9ZZS&]+6R8=BY,%D0!O\[03S=KD'"#"4L1!+^'Q M4$]2%"E$P/)I1U?C8_2Z UE4;&+'P;:&&CCH=#&.3VL M*F\+=]A<>9NGYJ2,%W1N(1548]"6VFDS0]$07N"O ]H/:-_7L_MJX&;6SE&\ MG>$4F"J,W=D"_Q>Y82 NX".8'UN?0?4A,_W&F>E?R<7]7*IW/1Z=9?.$XF5J M(OZ %.^S$>8[PQ5+;V'3)''^I63&SG\_SQE)HX4OYTA.&\RN[J8/KX3G3\S9 M:HC^IN'N2^[-&Z0FX_NULY3QD@S=EK&0=H*L^MZVY#L F+[S\-#;PEG+>O MX!S24<>F/H'EZS8L\J\!+.C1.D%G[2('X8LI^_N8#II>8_YBJV\R3].>/\*' MUC6515_",2#VT7$7BKF,.JO1F+F]WR[ /ZVF([A_D77^'IZ;[79)#LO,CITNWQ/- #P#MO MO;!S 4_>G^/)WA)/KMW,8C=EMYDE7]IP%Z#OKM3A S^\&3_LV-YL I@#&AD^ MN\.BCZ8:I4 ^D.HLI57/ S(>)YJEOZ^N-_9/,WC!45CEW5M_ L3JYM@ MVGJ<'@*[J#K'=9?*O=SYTZNW(]ZUVS!/Y5K=\NEQ2+4SIH/L(BW+C,^2:;MR $\7HG+%7CXOOCF% MY1='=$F"5>/C)"+@59D+TR[M_ M$%SOJ\6O=\#S^EY?S(;ZXC74%PLU"-,+A_=A/,*$@BZF-,9M+WAG>\ZD.K[? MA*2VNO Y&0O\9Z'+!GTP7]5TU%L'7J M$G=AZU'9EL$EY6Z&115EL5V\P;OXU&FDJ[H,O.*X14V@6HCYSQ["Y;?O2LS7!SU\5]P>8@F\QMFY<@9\ M9-(5GV3=7+-! 7F@"@@?%)"A;\[=-*U>#TG>E6C.*O_KDZYCW>%"&/7T.#MO MVU;V^W5,MB^;7,CSM0F"VVRBMV*@SRWF]T [F6O=@_/R=E)T;IM@95)VTADH MV32XXS%LX>@L<]WI9A/TZH2D<9DL5DT[)74DU;0E?U:HRIW?<4U>(.IOG9?P M4]7I8HN*B:WL[^?.2KP^)0K.%=M_#R?ULK1B_ZP%7O(TR MW;KVW="]9G:4;?N3:EREHGATH?VT^W+[YZ2C8[!D'N' TS+OL4BF7[]%A43:;S.,ZN.WQ M$:CC2MGK4Y7.FO6(');@0OAD!EL#!N=1+8V%Q5^/9[ 1AA)5AR="N M3Q'LRW?JGN,!:!]#DYRU9YA_B1[/LU/T$G:^3P#0QZK!L!2Z1\=G@#]K,WI_ M/")M5DFLNIB&FQS=TW CS.M@>BH,G$,9^, Q MP#&,C]!4P]W$VLU2K3"F(51='N_3+)@VQ2>0TE+T#ZRVU9TD,DG=J7#?\^YC M7<%RQS.245BEGF33:F'ZQ>I3ZB"VFK.R< K-HX[OTZ>NUC*A&QZ*FW:MR,!> M'LW+OZ9FDIUBY#,9\XD 5T7)(6#V2Z6<"V/:$EO=M9X-'-/PF=VY%>6OG"@ M*^5H[A@UCN1J3^;XT9Q7P=%UNYO,FL1YEE'%>DS0-,:DM;0,+CY/6:M2^.B< M\/,"2 E,_\2ZNR9LP "0(:"9WL[?%G-)P:0.7=!@N3<'1-75]P IAQ'RGFIZ MG!9'_@WD1Q"XTWKFCEL')S;NRAVB28Z/TYJ I96=5AA] :;BS=1T4#^ISL.H MYH+W)EUC,+(ZK5R+V4U3Y*0+L"3)A&&,XWJ$27P.C?^FQKIV>(?SC0.Z;F4? MQBE\LWKLQZM29''T*50&*R17TB*:U;T[W (8#P?NU.ZW(*'X)@8N/4U M\>"$'%BHT!A@F #=>K:J(CT%-$QA1Q#T$\"4"KUG%R1^XH[UN,+YP:M%$],F MF&D7E /65T_#Z&R9Z[&L-TV,JY[,1@ON,:>LCO6;&9PH?YOIR/A^Y_ R23O'H"^H !) M2N=G="'K)7&525TE5HY.(,P. FZS/,*D525>ANY#O/SI/)/R'[-QQU71V9H\ MH, _CL9UQWR26.A2F)![CH[J!BX[09WP$YB]W8!]&3G9DUJ@AE2HM+3;JMX(DUE9W,I:LZ+9-(3YG[2 M8]CWG-G@]ZY)H(,+YFP3OT_9S(HO@ MT JX8.NL&":(>5T^987HNEH6/R_S6BW^FJ<_+*OAFQH4 MFY/4B[6S3Q3]UT4*5XI"M$A"23QB_63VT^N=#S\GA,N":"NM=#]4B[&-=K>BJG;W15.)O4I0N)< M.S\]KKN=K*@PH[/NW2>F30<&#+N:5(N>NYV9EMCS44K*.$K9KTEI3 &.XVIR M#IP5]K=4K^:)EO"82\8U6,Y+PWG96*$SFY\N-<7F0N>0@:$\4(;RUXLM9^:J M[?_/WI\VR6U=6:/P7T$HK!O%"%1U<9(HZ;Z.H$C)8MLRV2+5_O@&,H&LA(D$ MTABJF/[U=Z\]G % %@?35J4:'<]CL:HR,9QAGSVLO1;8A)L67CJO)QQ(2;>G M"V5UT0QP=G-IS:&/,X:I.L H6"+)(6A3A!FE)AGT(!+^&:6Z*>G4]0HF=W&( MY,-XIF^Q SIW]^<8\15R'M-9S?0IP>=QINL\]F$S@$7R1W? M5$,I"/V<(OIUSWF:':V;7!(BF9U&-VJ>5[+2[OKT_P)GYB+.(JM9TT!!>.GGX_30V3EV M\#'"8#P . WI<#WL80$1GWEXO<0"0?K;.0<\QIQ'@(?NOC#-'. X#OYN7DI= M%'D7'.D8>9__=;>+$\$:9T51)R*3')TU_Q2S;DFE(/MH"9KEJ#_1H_YY6U[/ M$UI%S'"Z[KSOS;V';0FI,CSR!9J?ALUNU M%J< KU32(9(EUXB?,6:N:=%]V#K?>Z0 V+2%,0LGF7N!!M9,9EFQ\4!]@FU* M6VPUWG 99KZ\4A*%66J-6R31'?P^&AWE%,/@!"%6/DEOV.,'>?)Q]2?,-T;Y M%XUQQ*-RT1V;P2Z[9IN@U:NX5H0&T:AW6G-1-ALX*8J6>U=&.6S4=MHFRW6V M.5-1H<-FE76C 6#;9,QJ"*VJ"O_-=7%)>W;4F(5G$O=RZT$%S;HJ#\(W6_?B"05)XR!/'-4G.Q_\<3['XE2; M!XG]N#S8<^[/;I$*/%XFA,^4AH>J\"MP/[1K>BD^S"C"ZZ(<\&+C/B4'6VI& MD1=G-W"6?Z,1Z[ETW_A*M'R%G*'WA,&9A2[PJ]5+YLVPR=:RO^E#KXL]Q4[H M\R-#\ AM<:N./!P.LWGE_,S4!0\N'URF[[^SI7:C0!QNQLN81<<*[V$-S:4X M:+TU^V;H4TV), %;ITT<1RM9EF?Q_E7 L AW2E9QX?MNV7\T>T^&F$R3[SP, MO@KST=#E.5L#2["5Y"A.$.U_@=\HZZC)FZ M[L2A,$G:1$\2YFLD,1+8^<8R5&MT:M+ C=DDU8%]TY C61=F8SS19,C$S!9$ M=([6[. U2+IM9'[<6^? *R"GR[$R8 8=%\-LIG#P=8R X%'D^BT=9X.EBK-6 MFJL$C$Q;J,Q/P3M;8*W3@7NXP%K__;#6_W/G84<^J/CIS/?,AV+33 M#9\K8<1,$V=2CB@XBC56(0:X#]H^%M MNJ6@OM^NI=LKDVQ,AU05>?Y]G+4LZ[JYS@PEP4RB%/$D#R^3 X5'G24;>/DE'VCX1)&[&TKZBM55WR%!6LN:/J(; F>K6!W,H;,XU&?0.(%!]F2K\>P8 MI<][XX DE0,5\2F'FH&NH6.OK-5BR>:U1<7[("^R?ML9MPB=R6A(6!W&P"5> M#N^YU-,_OU!FQRH[2'8'P"UA[%'4OE4IG_WY>;1H@'5'<^W5%C.XIM%O>@?0 M8MHCBN='#/FSS/BWSSD-JU$B27(@;Z3AUFDQ:4L!KWZ]*B^5(-]-:T$?A"U9 M4U^= W@6"G?:(X:[^&^CE:G2,6+H;E60.$;KX3>=TUMA ,LL?V3F?;9"I,QO3 C5]F*L M@D]9=9TYIU;G\A=OUN8^F9S]YFWJ.[,2?*D"F@/^)C<^C]/'EY?S]II;J_M>,/I;GX+_C5N&]YT]@YPX& MQ:6'Z==TJ?AN]].O;K^\,#/QR.9&BQS*>DTLNAP!3*@X_Y(!Q?B6%D$1( :3 MZZ8:,-OD'/E:!^.PQX\H?M;0>1>33MDK7*A@E#NN;SDC=PQ-SQQID#%T*2-" MI %Q##'%Z8/'30&Q$-R%%C&XL*B0$OR"&:] 1K'/^) <53YX*:&"D$EO''D* MF\VD27&7_1V@;ZXM^*'S,$KR?85K5#_MD"RW8&09;$%N?HN<6ZN%8+"O=3P MU4$I? _2KJ+7"6H_# MO*KYE4/MPB2[&Q?[(Q2\WV4(DB5:]D[3YM*J50$G*Q565+*KRJT*?J_?VB-8#HO/=N[^!$]O\0A^/Y-,7IY$ M*<"'OO\ ?ORUM/2X5,5LW-$6ZT)P)MQ1T[$DQF92I#Z"4>=C)33B@NQPM^3' MXG// 'EQ B.(%#4]Y=1"\4B>X#?HU^([E^KP!.B&X!3/M)YMO5HH>_1-780831NP$#Q*AP<@GP\N M+[\Y=W,X_=A4^>K4'Z8-PXI%EF5Q=*T6"8;@9I^QD M5663177_(;MU'W1IFI<\.TQ3'MQ=?:AID:_=^JJ;^GSJZT[R.MVVW*"9#9RC MG;2O!0B4<)'$*:R.85N5DVV.$:F89!KG'T2MB1[S)9^6]&Y/.=&!SSW=%4A2 MU087_HD3IC)UD5* 2_H]M4H;'MSO"*0M.*0>'AV M9O.%Q"$9>5;Z3BZM2%Y.:W9#*A9MU<]@A73J&IJ$E5W '1/F!E =+A6=4X;E&$R,S_-K" M_=%Z,IGFXWAGP5+RN?/>@%9M#LEVH-]8@XGT%73:C!#T( @A@N=?X/X"+ 0S ML0W9&^:P%JX"L"-F2OP'QYZ0O4WC4-3 MN\: N-OF6^2HA7C^SR\N^ ?MTM$F'HJ+NO![]K)2$=@A2Z_5+?NN"X]+"E:! M.^;F:775:([]P+]AS:Q_C[J4EM/M] MS#S-,Q?$X=.R9X?2H[AQYL(:0%HM6N?]*"NWKMZRU1^D0YKL>1T< M">%!0 '9)L%<)$.MD6$J?BR[I/+"IV"_%LCM=. >+9#;!7+[V5<5<3240Z?,@]P M20W=XM QEF+7AK$IC."C$GI/[H\2>CZ7<'MU;)SZLLQ@E)WCB[DXW-Z @HFL M9/@E7XQ"!_Y2)2G#&V$T4Y^9DW+HF.MEHB15P<^W*:^TMWI4)+S\TE7'4/[B M+(0D_5P?BD?AD)/?M&'AS34<8['Y]C<#-IDVZ0[5ESV-A,O_C(_.VR9R#O[D M>L[ZR8)\&[>3@\:D+I*=0V&X[")6UX/+AY>+LWZ29NDX"D,3+2^8B"-AZHC% M3_]]3#I-L43HG(IUE"Y'D@<2SV]::U<4VI=)S"''F:=G[,$*WLVERF%F MY0>*%5X+[UJ7G#W[^?4]R; ;#$]:AM=EUB)%'#UFYLKQUBS-: 46Y> V4+Q' MW@RKRC@W'EQ>?H4"S%>I'F11'87-ML((VF9E^(!IC6M5<*FJN&$!2!=BX8K( M%07Y\$UC%,#W'X"5L-_.H:5]Z86]E$>/Y;!&U9^)/V7L>!W.N3T%^#QQ7I[$ MN?)[=G8_)1FN9X=E>=ZX8N/3$-"!_8+*/NT58319$OBG>);XV9TDK(/\/W@-6PG+Y[]:GY\A/$> MF_V9 OA0]V6E>"=+'8$#E1ZV598LK]1-:@16H>X<<2G%*9D67ZS.X:K64@H(ZJ,4QE 06I1RFJ]$$'+Z MMN%@N ':F)94$1)'XGT@!*70"G\-;=OIDJ&3 @7#ZI!R! UZRS5=*?N"X8J+ M#[K(O!PH^QO6TRHO )5B%ULY5!V3+)C&JEPU0&,(O7B\6@6!$;RRX]A2*,FD M828^^T(R@DSCS]O@%'BON%A,R>LL+A(Z7'2_/%.EH M#H@6][^YC$V&\V6TP0(*V[*Y.3T<[[6%:.53(XOJH&\ZG.&Q)HI@=<*",?'[T +O5 M;%VYZS;KMDZ[$5K#P5*T[T1$<[6P7F+/0XEA0]^'L3@%!W99R=.!^REB2G1' MC#: 3T+',,;MC%BQZWYS6L7O^9,.+V'G!WV$1KFW4X:_]T\X-LP% =M8KE0-,.*P@$L_E.NF'%RF_K6Z M8E?2Z;@KI$>AV*WH+"AD]QG,'RZ)(RXT#X IW4J.TS>JE@$/B;$B/-(>D4'> MSP_AN >AK8QJV;DGU]_;@UHJ?:?$05Z@@\=7<\!6LDS.^'KW/&#=_\6]RKV+ MY%E5T(&'<8JGRMU5,C6 T/5#6WNG5^>2SOEDOZ59ISFJ_5@&N/VB6[>EX.!P M0E\CVQ.7$L0]U[;F6=0;..,J]C760U@="+OW+I(_TQ%:5,JJA _'=]?FE,#[ M)K=(W5?_.\TUK0'-D2&!2R':+'X-!+\D_Z;--F5E&D_.;?6?#B$YW#(K'@:- M'8L!!+MWM$O((7":!'YN='L%8!CZG.2J,)&.M5]:<(?%H?AT=LJ)@17C\N_M M.E=,>&#P_?)41"E3"V"S'9:\G7[I"W]B9/]87%K\TQU.CM[A(?N:P M9_)NR+NY=T]%RPA4KJ->N% VBF_%2#H1*DGN/PGB;8#H6"$B@*S%;_@U8ZKM M"68C&\D,NIP /^4>+/[ENR3/#M)*=E,4;]4:<+TJ &D#(\>VCUY'4-3R%09H MOZC/%=_OI\K?"R=5I]^D2VR$:LTT,8)8TJ\K_7!I/6YXL(LD%/\6 @*'>"XV M]$U=G@&]FU^<'/HXMCM'Y'NCM=*1'(#A:)!9*$30C@EJNL@9V1<5:[)<9]4@ M L=JVCPY@?H,EMF<,>;_;_.+O:=_EB"I, !KC0AR>C=0B @/-H%#?XQMO#"MP:S\I M?1CMI*$)\AA3-0K#RH%GXVX.;TB=E+L1;,^?'JK'9MRKODMWX_J-2C;\('Q6>+I,3M#/4Y(L)^$PF (V-=UD%^:X;IML;XC[" MSY*@G'&MJZV-M[\*7DDF>ZY^:_Q?:FC?6I^*[EM M!SSX*:21%C#I=. >+V#2!4SZV5>5[V26-BGE3QTW(O*YG1?.$5%6UZCLY<*$ M47OI6/'D/=1KSJ?!G"&9)"QLSX*(%'JUAF-Y]O-K89$-M2HE902HJ:O3!8W* M 78@Z+@V+3[6&M%KUQ5IC\0DDM]P &W6OSY5W M/6Y1Y*%'@KE*6%&)6/N=+?4B8B9F",>W\(X6$+\,%/SR8@Y@10U!/-?-FY! MZ&1?T;RR-#.'-^)^C 8V@%<;60 7\1GGP%DIN6IB3SM ./9]5IN_$-@Z M'@5(S8@+6;:>G-)R<:?@H?V^([-/&S@'&!6AS9O&!\_K;<,@3A,),5((61B/ MOHL" R!2I^[_*(NP*OH;G"73N.)8^%!V'W1$F^&G ^E*A872]V0?PI/ZZ,IW MXB'KC 8>UFVTSO+RVN94EP&FVU9:7@($<_@6>DBC7]R4>;_]]N'%PX(;/DGR)E #O=JX#%=X L-@I4CRT'IJ>DP/5<@:WU;>>"Q<- M/E'66]4/%&8\3AMV7;,N?4]5J(8UM5U>'\MC(@$'W)1MI\SW5XVS7BBD=&* M^K$(FP(>.$OIS]JQIZP%UE5!>]_(DTSW/BZ9^;-:#/%(Q6=V#!4LJM0\UODP M,1=P")$AUA?7@V^]%25 M7(DJNVZ :^>.&;)%^K_+<;,<-Z=XW+SR;IV#,YR]FB>^N"NK0TX=6O:;K5#ET;61M1P!L4CA$/:\ L+SF-BE/+R%P,QV7F-K( M $H,6-"CAG$+J<>(!8.*-]*JWACR%X 'Z:7<\$N$+F.-E!2=-@JCDR>C^5B; M$T!'8;?U]^0AZI"'< T'$3#'GGG#)[P['QFM\6H^TK% O5)>6R0SAQGN.:7, M/]HR;97C-0A .CZ#M@6:X:VC.9!QH"&.0,M'@K"6#ZSF8JIDS0$T3$X9#L>SG$B8L8<)= M#A.^^./+< ^[+7O70X(W[S57DD-8;\V/,[D%<2>E#1?]*N/$CYG?B=Y"6*WN MQL[:G$J[NPU7]!"B )P;U9*^60_\_E*)%#8B2QI9NLOW;RY)E\6: MGJ@U?685WM^=*74M#.QZ \?$V^0,3DHH;!X/ES<"UU%6J/;AML8"D"<( BL MLEM:'U0YK7.6TYI"D8[:J"7C\DG4#U':PP!P;MJ#' 7-(Q$0T\"S/!-%BIOJZ-FPM#0B70\6$X-&?.Y#_4FO[IT*M]E'3>5]@=C BY0H.O*_B00E$N/RW3@ MOEIZ7/[E'I??]Q'V:>OJ3]Q%*R;?(=-"Z=MLT MG?C"H5SKC#AK&I3S5\5'RK&&^JNFRRI0@[?%(72+/O1\6\HO2V"_!/8?']C_ M1>$E<_FJ<5UV=PL2X*ZL$SC*YM#["LA[,W]CPH!2JL9KX3!I1[ ;,$<)R/0* MC#(AA<%K#>T40S/JN 8_JSV3OR=?TST9^XB6W)26-+1P+A92$\W='=M?8]NKW)F+G[QZF6?SE_&Z9L M_11]8LYV0F6!%A,@<'%>I1'4FR4\"U5'6B_9VL6HGZI1?^T3@NFQ9.-=-^+O M-RFA) "X!8NLE1YLLC"I-7*YNHSJ'0B._I:,ZZ9BYVS-"ZW M'!S".CB+-M(SPNEU?=K!66%0(:OL!WV?TM;!:IW]+:\9&N_L+5-T%&^[5'QK M7-+/_EY:8#M1PLF3?=,SM97#F88==- 3[DS=<[>W M]UF,XF(43]TH3BHX070<5VJLQ?JTK:4' N6T-EJ4\68!/[!R#A*T:U9P*I78 MU;.*&I4!NN[VYT6WWXT,X8/_=(;P/_/:IU7C M^L_1K'VR#=L6KMLER[6;"@2&DP[5$FC"]@I;.M3>ZH85OK5#NM.:81B"R;06 M9@EVY$HE900>'\$S(TB U+92;<^L.Z?_E0FYAREMS#+TB#\XXK,Q!.??HM+P M./%)MN2N93.7A/WGV)%8$J]L2=QY+<'%KU_\^KOMU^,WYB,J@S=:(B&.8K;V M%$Z^H"G+DJ0?0,TP8OV\O%0V;ZC#(,EP#@H$:RY('7-O5G<5YW.YJWA"2('' M*!4^.]0!:,1 (7P89@9"$_8K#"B=LS%+6"8YA9[)>RWEHJVLQJ3#QRK_K;<, M+=-"^*?PTQLUC4J&QWCL "VI"].LDDZW6]V()9>QV+P3M7E_04&FX.2=+.Y3 MLG0?Q3T3\BNJ$DP@POLA'#1J4APC ]^\97)&(:,)=.E\X4FNQB_K32I3UC") MBYG,,=T-9TN1-T!"H5]OB\XWU[(:R[;(\JA<98_7,7^EM59Q&GNN*36BCB&K M7#>#*K0[A8^VV9^#YX9S%XZR+>9HJQ7M9C-AXU[:.#YZ_&6D=LL,1JQ$NUC- MQ6J>IM7\6?H#39*,=J'K!#PMNWFKE0R9L=0_"M*\Q15=O5;>*GWY<3,I\&%V MBZ)M 0L3>*Z4L6:4*NWR5PWYBW5#-HQ\M:'F?DVYC1=L<')=;/>X*Y1F LA7 MK5W)O;J0#$N:9O,!)2Q%B_EF_-=,,&*TL9;KIEF&JGH(# AES8T:-2+ODMQM ME5TIV0 _LW:5^J;1O*@R%L<-OHF#0!W=D"GL_=T4,Z;RMX;9WF73^"&YE5M< MH26ULAR8RX'YX=W$ <*"HVWZ!,:H&\S8,>CBM [/$5FY=WR/L34,M6M;@6BB](E &E]IE303,I(#D+Y>@/J[3; 93IPJUC@N!+:+!8NM.T=..D M '8K>7?DA'4QRZ-39?V=6#VKN**O&4E5#R#K!L7">B5F96MTR(W.UU\]5LU9 MI" CX\F(P[1,A.V0?CG6GBCRN0$WGN2-E'(+G9]$J1ECQ=YT)C4<"$,8WF^J M4<$ZDVR0UQ D=K!I 8&X=PLM(6>KD>)&QL=Q&V=MR$MI6KAN("Z2OS%H6]HR M-;V];\N&SX>".[TC.5[!MW#DRJEW4$T*N^7]K_"5!X_4X-L(6\DZS!RI +.F MBH(4XI&$T,>U@R]-@=.-^/72%/@QD)_%55A(4,Y+@TT@FWDJL M[_-<(L(*&GV."&+:_+#9_5K$;&E#=*%^/1^+6LB(=.FO*<+9027!4>\[9GV7 MO+QR/:_3M&?>%$)GP#K0(7_0I)M0O3.>JP[(JF':&"T-X*LU%8D@AE$-!:#M#9ITQ4D*OD48M 9SH#%L" M@J+577<+[BY@\XL_OAS:Y+5&^0O$[M.LV-\*T:FB[0NF]LT@"Q9&" D3'^I8 M.D42%7DKE.(Q>>^(+GB3J;ZT,/?/MN@H"I[CAYS%U;J&V7XZ6)9>>MV10^(= M3V:CON8=Q.K4_GID-M;%OH\8F+4Q\A A1-]DJZKQTKD4PE%P0K>E%P\PKEPZ MSJ]1,W'2+R/.ELS$R\6B@(FE$BQ\1,=2U\VU6&N&[Q?KC ;W[I 0Z15.9+G. M50-D0J]'S;.SS.N_+2',AY0R[N)"*'>T)]OU_^\+^L>#KQZ2EWK_\>/__^7% MW_=77P"C/?\'BV_8N?WJX:/]N^_TP1Y>7M(/",XL<+F[[W[W3KW9+; UNQ8M M^]=L6I,S_M.L.,QO^,QW9^6?V($M$\T"C\F/SY^>([O6\JG#S?^EG(O;DNVUZB+?I3@V3? MKQ25OXT]E","=_*:]JR8D:[(=HB]<+G;A"%DB&FN\D*3F'@9R\IF>ZDX"J\% M1+!=*$0Q8+$I>\'M()12)RQ@[DZ375.7VF0G5$2<-&80B8OZQHSBS#K.E; = MA5^8B&AZERZ<$[4X[GC1=5)VL0%A8&-C&PA_HDU 7O-=Z[M:A1D@$49$9H%UZSDS- MS;#>=NL6>M@LJ8?\ YW%TC7N?!%4HDWOSAR>;* ]R>B-W<#IP5C\0NO8_GQT MC3OZ1:W8LKRA$J5JSZJE 8-2\:)'NMBHT[=1- QMF5^=@)4BVT&^2D$3=S!% M2NXTUP "I@-W!(T)Z]+KBTD4460=F(G(KUZ_56P79_W)YI&GO2O_J9JD>R[# MP'CLF]*ZZBS4,1]<'"3F?BMZQ#*QH3$:"[!G.,7&^P]P)^ .!.EA 8,])8B; M7=#$,!%@#3<'Y\I,,EF$#MY0N[MI$?S+6()(NYLGU[8]# M7?YCH+"9_%1N]%@WNQ5[KHWAFE!T=^5ZX!2,OKCD9$*48K=B0"KH)@-B^3RE MIL&7+.7B5R]^]4>MV-<<8H)RYJY[TR,+X_K/4DT=2@UMOR]H,7,CWDP&D8GN M.C#=%5EWB!F2[3?,E'PUB+@38N?.5\F"!HQFE_#J85IAJ(5LQ2=_^)RNAHXS MD4"OJH%U1' Q1HLBOW"1_+!;%7GN4Y@^U(=A\VE* M-<^,[\1=/O62FYP8W7*ICSX19@*>#V)'/7C5'B7.@V95T0I&B[_-65]^AE4% MQE/I[!"+7M9"'\MOSN!.,MS7]AB*XM2N"IF9BP2XOR"I,Y^]F61L^+;!X4++ MD!9H#FIO3".RR'(X'$G;Z+0VEKL1"-KMR9O^IJCHM/,)G'@]=FXC23*YZAIM MSS> FU!>,P+8$\$&S9,1;O7@!+OZFT:$PJ12EX6,7I:"FE.D.,::NIQ)RYET MM\\D)]C\(V0H!"Q^$J>3[/PU,];E3&TT@G3,::JD7C1$S)I3%AGEF5=MD^7S MJ!"&W(J/+<>!H'Z4, 1P(+R+'7/%>;,YYV-N9,//<> 2/@^W<"G=93--BFD[3-+WT!,G)_WI5J-.P3@(T))MR3C,(?5-I MI/D B"!;CMMK^>1YH7V@SER?E&L:?B_%?LA4ZKRA]^'M8//(V\UR ]XQ22AN MRJ]95.3VM6S-FJ&O"JGS>P&//MO+T\Q$%GFQ+Y#Z61<&6F2RO% ?P9E%\N-9 M.FHLPR=ZU4ZJNLN<(^QZP (Y64;:69.9X\XHJJY@>&*@%X!2P?>'XX/M&/K' M>@[^A'*4>JI-"&+^\R)H;#>'/E;X"L8NI(\*&L1B3"/GA6@97Y?- 0DVBK0 M+[9"2+9!,79E^-3;%%^6TV(Y+4[TM'@%[0W:,ZCCO:"1J6@EP*JZISH9<( MO&E?]40MKF5-&X55.SR8_WS4J)R*)A:%W):$,>AKQ+2'8NFY5DLC_14ZB/H MG>&91 *,F8@11NZ\IB_HO;:^-\U&QL#&R:!#CWIEY D$AJ6*[^EE-WJ8Q]U!I[$?I_/)72 M7,H8D+AUE:M9W?MJ64LM:7%W[LS887TS'U6HM6CFCGXEZX3K%,RKY(*>IN?6 M[B[JZSXGAX+MK:7\Y0QR>77P;:P4MTL&R7N[Q=?H#;&@F3 M2O;A;9 R8&H2&HEM P SN[LAEXS7Q,/VX:*2. -&_SS:8/LHQ4+[Y@\/+R]Q MUS\\OKQ<]LNR7^[R?GGM*@M*IVNU!5_:E9J]$P2V!F$33W=^M/=IO8"]9TUW MFI03Q7-76E4R13JP.)3C\\U??*S"ONRL96?=Y9WU]$/:XB7='/37.Q\/B5I( MJ$39YB#YVP5:PH%V\,B?0X8Z^*"'^(%YE+0TZI>8U4B'CJVBHI"(FRTXEW&(#=A_V/I M>FW"]5NH:+F<)PQ=3NW5;6 PGDN'&VT4V4U!$\ 4LIV/H) 5X12^[R/@[&(,8O?0?Q'"J9OKHI*& M"K[(T+;E>JB&G:1HF!BZO0+UJS4FR]&;I\K>C&]![B MOD$C"I*=H$3.#>FWESZ;K*<0C[9J2VZM;-RWQ2&@?H87S&;!25@M.VC907=X M!_T2-KNYD\FR'6A"&UI4R9"T#'JGF./?P6GPE=*=I0J_&I&$!3R:S4:/3OW^ MZ C;TNL4;92C7';1LHON\BYRJ?+FV:\,= _0W64M^' ^ MPJI&&Y-0NUL74:9:)$O2WU9ZJ>PU-5">PU%K&=UAKQ=#Z#U*U:U MB@6#R8O3<)^\K%NC(LY !.),F^(FO!$::('@KBK\=YPHF.."79RT9:/=Y8WF MLWU^.Z!PVY;1&PD)AP9@>IN%SH[J=0:J^ZTST@0DBY-]E"^I1AHI@\)>>LW]1 MU_"5I('N:F7Z[@Z??#AF;(Q8))?>M(];C9X'PF0>@J;;6E3A'3!X WP+QK8Y)R,R4@&WV/N[)/66UK?Y/FD* MY4M.QX*TDK(-5>H;(,M!>Z&.4NVIYX02S;/+,1SEUF;I/7JBI 44'!6N8YKE MGM *[9F>^<1P3>.]2PM\4&/F@G"9+O[[EPO$Y9-8D/\/B3A^-B73VV0<[TYK M]<AKF_A!$U0<,'%)H%:CYBL[4=M74F3H) MV;K,1<498/&QVHG*-"F#1B?OWL)%SFIW+RAV+41\H-IIU+/E33C M'UA7EWHA%&:75863.[OJ/.R>7[GKFK701GP,F=&R_C]N_<_HY; C&TC_8&T- M.Q8$XAJ+EONUCHBYHK=MLW73[AM>Q'2Y)H_G?1+>%Q#L*-AK:RB8$V9S*)L5 MY_NAVP:/(^ZO,-^R$ZGLLD;DFS"3KT,H9->-[),^VQEO(_F%@181O?D@@NC& M85D7\;"P^FC4!YS2N[.LNK;.KS-A'J,1T8$21SY-I 4L M]+/ENETD;5INK!![QSC7EQWU+^PHU??K1$L8"^U\@] LKX2:F?Z^*:\&#F&P M=T!LAQ'3!%>]&5@KMA]67+>"8?OISP_,!@?.+Y[_D/"!%/#X,,$0 MFZR8CGH\;#'O8GBZ'M,8@XTB(U,@.:AB1)G[!;TU[!!'X*(<#7C@.Q"7 Z'+ MZ\I?B+Y'=@_A73OL^P"9N^9PN&36)+,@3 K8T0CW?<6SF(G>\X-+?\&VH-74 MH7#'"$3833;!H!24N@*?TX ISI);ITH*AONS:8T?_]%CNY4?U>7D_3RD6>#+!&R)^LU.8JM)\ < MX[Y3_@(6#EK A.A4%D(:R^GY"YAW:,CQY$??>&G\F8*AGR28U)$ &1BZG!4I M*'?Z^C(I1G3_:<1IYZV*PT(I9QV-4-DR@.2:C48+3U_9 Y_.6+T^4/W!-BUK=!NMUK@ M#V>8W/X=JIVP;;DW9W2 88LHGVT=!PUUTPNFVA %6$XT-S =K<1/FT%(B]3X M+Y[1:5J\&6V,;3-43)!@.A89)-,G#.H?OIV0_GU'CD7MPPY.15=9NPLSWX'2 MB0AJ2%H^W%FT"6:.2,?B6S<)_MOPHSA"RRN 1@U8TZ4$\78D;UIN1S8GL(* M7G+=,[GN^TNN^U_.=?^>B[&?MJS:@CF/R(34PZZ0))U8+$1"G53\,I]78XLG M68R+Y!5HQ@.;>HOI],[C46_$'ZJ*:YX=*A9Y"CK38,5,H00Z3: MB(/:]5S)61*PQC! @2B\,W8SF^:M0-NJ$N&BY@I]DXY$SUFR+PL1R]+..<]E MA,LU;2XI:,<3X2+A9D=GN#K&6V'[+RW;YA$UR#R+TVHOJU[KNFK@MPH5&0>Q M-UO:"2#,IVNP6HLX^4RKV6E=G7QZ4P"CG0$<>94KIE6Q0+1]^)3OR(=0TF(9 MG**^+MNF9MCK>"]J)E,K W[S-5ZH0'Y;ETY677>F441Y;E!-?IAR,8L4"&0I M&@A_]X>/:;O0F\KJGZBBX]64:#P'KHYB@-IRM9WK58DBR6R4/B%; M!Z#8[*,PR31?E^DP3!L(Z5?Z!2#/Y&-*20CA"' $BNN\LSB!$\0;?8#P^")B M>X(G3UA3W90M[;(8!*7@G%JU^8ENS;]/(]HDQ_-@];$E MW7':VZ JI#+0"1(M1!4$AZY;1GSPAJVBFO/47*MR,[E6'.V"J^CPI77&LAZ. MW8.[>/9@VY*6(=I]/1.6A/(=7N) I#A4B0-"IEPZ&>VM6?@=K56P-;D'Y&&U4J"5 MYG9.J(IHB#J@F@-OS"%%+;I;;\G2P)5^R966+?Q9^!HW37*@#=[QB+'4A&15 MMP4]63 >*H(!XT,^( M2^DKE2@,6BW)@%_59"^-(@Q0>7H\=C='SP][J['#%1GWCC8RLKY2>$+"?#$J MGT=JQ7"M?,KQ0M?HHNRET1RUP$%"%2[-<+2Q+=0:\80\OJ1GOKRT!:"&1-8$ M*P8Q'"+AM%8"HN?+44/8X3C<9&6%U']_V(LIX:MW$H4"V[2&\= KV:>A'K=!3,JN M?+->#^U%\@/BS;T#$ZGTG"]+X %A,GBSTRGE-BS>H=#)0V7I10VF@ )! M.S^U:QC3:WOF>AX:-81D3+5(E7GJ)WP@VN6+;W&J9H#A];1[75PLS8+ [;$? MF_N4'ATZH"(RW:_N6S',/PTKQ,QVRIT#SH4Z+PZ.ORYYUFW3:TNVS+Z M#D;!^1/NPHM-_WPX9YV@WW1[+C'QYSZW:4:Q0\.L&XC'&/1(NW"/>NA^' ($ M6&+OD0:!01 ,*(A89/P\V3QYI9NJ0,,CG64#\\4D=)* \ M[WW92<#0%86%PSF=AO5&8%CR.3UP]+OX<-:2(SW2 J1[Y'!BT:H)/Y_'0PX_ M"URNLQ:D-]XY9P5 !-N^Z9)=_NNR[0>5615F_50AT^2K;!O YGK80'IA=%F1 MK[V"RO<-/>IBHS[YP/%P%?'K Z%TH[K<"4^7%9G.GKYZ<2\-UO(Z1/>,2@NT M2']@B#HMZW7RLU8)?M$5>?;#S[_<$PCPNF!,E!>=E--(%-Z[+:US!_11BCZ/ M'%;DKZS51&-="_U04QA:6JM1LD@5*H$*/(38GVQ0$%1;=F^[]XM[ABDKTX;0 M;%8(JEX5CLHI>:5G M/[UX]?3I/?/['9^I1=P 7\P)3[@"#6]#IST:A0^VZUR7P0\ *];(F+?)W\KS M'\L M7GA_ X.1>HK^FS=<<-A:AJA:+S>T10RNBSB%@^E0=.@%J-V*>"40P%C M<6Q/TLX<]87@A"[.T.]CDH,IE583[M[=#$<#"TF2K0[)RZ%'-8YSZSN /\43 MXF_\,\Q/:=["VJQ6!Y\H\8E4\8^0R6?OJ-.T/+L8R :8M\6L+9QQW);[T-!8 MKS.,D3DO J=7;LP+!S??2^)N)UD)FA/+N5C>_UC216NFHZR+.[+8OZL=-G,S M%)-1G*TN^(2+.)AYBT,5;PW\.#MPC(RG^U:-E.GWY9XY7Q87ZE]TH8*HFJ=* MD0K.-\_3A!RD_9:30U=7X!1QB:)_#*@F"=Z@[L!(I")KR0IG,1P-W]Q.2XD^ MWRE,F,'-3#,9KK6 ?#6G1UHU=(J/(=I8%N;F\]ZCY=;YUPBWH&3C:0WM43CG M5"_=FKS$XDJPCSY%=Y"D7FK;UNM!6XY*4F6&39%HQVU*WK/AJYS$D;^ *F= ME0\64.5I$ BKY<,957.$5!9C('G/]K:BY:X:+%5G+)[R+*..:A10;&"''?VV+?59J MGPT*$E)8TFXZJV8@< 13, %F$8L=J-Y%O1LW&#N9-#QH8 $T3X7 MZJ?HUN'MP4L(]4-L=G(ET.=8GV.'I>;+XNO -)],Z6O!$_VGN6[1]:SOK*%?'PX3>/GSST__>XK(\R5A\YH3\O834]TJ/+!U_[_WLROZWOHAO^GZ&O?G3Q M^/X^_>?@-3==77UU^_3NAK_ZE8#0@"@,NA*^:0U;UK@5+<0@2N7O8%5J] MD8OG7*ZC'IT5%_D\.^&K922.ROJ^4+[<2*YJS=&XM3**SL>PR2 [ M=4Q49UGWR[J_^^M>0=)=N-+-]&L'A,\F&^S$E<_2L#TBG0#%;=9]JO B0%#9M4DV,\ MPYQLQAV)_Y?8;HGM%OMTU\9.E8R97+3KE5K1COI8,T^X/RMA"0ZZ9*=H5/YC M52D,5E@7C=E$T<72X<74'"S8X87V/$Z9.X!-O]*IY2V.P++13G*C>1=:FXCM M6-=%?GX4?[@IBCP\_)U8:^0R''.JEQVS[)A3WS&BR.H[.8X'H0%DDYQLHWN( M&V)FO>1E0RP;XJYO"//5LARLRQVHV$LE6?:I2-L0/_S\B^LG0X/1;:&AE0?I MOT _+)B;#YV19\8H\G+HP4@@Q_#K?LC+HOML(*I/>;(%K_>)F^QO2CXC9,6 M:89* 05J[,P1#R8..FUX%RH]A>/VZK)-80<5$P$5J2.? 6N&T)57A9$NR[9N MFQ7 M(ZEIM$UE0H].6AJG"@BJ,GEIY$^R=(^*8J%;SM1:HXPF: MW5_"/JSGO@]KL;@G:G%ETPM'PY$6.S*E#Y5J>?X\Y UJ3OF&>HS<,K\ MX>%7%U\G](Z5)<'^\.#)Q3?N-T:WSR1GB32U/R_6W*J9/+R?)N2>WN?OT3\N MF>YU+X='M;1LG^K:OG4)<;^@4W=QG'ZR"C7'XTG[>&GG1;&7@ZPOA;-J5X # M4&CMZDC*T+[*!=A--90YUUB],(S=P\Y\CB%8$EB2MHX]HBO60\OG/[T&C1/P M#,*D7*+)LJIDG;H]RF_!4O&Y<"*T1<$\2QD"^F^3L_OWPJ?SP4M(U\4*3^6U M.2LA6]N(E2_LV62M>E21I4U9^RAL@W-'#J3TSA[<$]/ E!.J1R^6),8JB0UA M-D'Z7=WLRG6J*,8Y/"MR&C>E)*_#-FDM>I\]O*>FBQ,4 T@;Z^9:>4*T MASCH7\[+5OJR^^8&#!*KMLEHJSE%&^_L73,45'7VP'U-#N>6Z4*T48E]Q8!_ MN[M%]YJ=,2'>"'CRS$IS>3YPB4%+S1W=DK$OF3;=Z1T)DP6_JV/WY*%"=:'H M162$QZ0'-W;(=Z[E4J;0*++Z3G"Z?+.;.K\ M\&E::2&R_I1@V&:TJ1='[!0/JS>LPLG&&V(;\$NM>*&M_&%K:=4*[TY791?+71OIP;-LW1[YJYV'R(XOUE4/G^(Z>X_BGY M?[+=_KOD67.1_/E/V=/DS'WR7II\G[T#$><+H>.3/9_2C^N+Y$S^=H\?ZON+ MY/LV&^H+=W7]C/[^'G-+&N-/FOS/ .5/+>Q>.-L&3WR7_K<6^(S^>B]9$SI M#78F)LU4FJ:<&;T?W[\\>WMO1.P]R-'NPOW_0G._F/,@WG^Y47+<8$S38-RL MWY"6))EME%Q5T40K-*DX0TBAUX5RI_@*;NRZL6'T&Q_*HN75$=HXL]Z29 B>H* M.;%7=%X6RE1B)%?:O(S>99>+@LX'Q23@U\&%(-^J.?!B\ MRRF$(0N-Q R-Q,.%1F+1YOKLRZJL-VTFHH @4XCH&$)S$V?*"XU6C&TBC:,& M2]-8S&9M[H$6Y".K4QN:=7*26ZW+ZG"5K(N43J1\ M54]S%^/\A%G&,)\1Y"P0L;">*Z_Q-;NK$BS,^[(N4G!A4QP9_:UPOB-4H)E\ MQUYTE75E-ZIZAM3-RIDW^Z .HA!4$N=2@"&9RV9 USX]&":JG4@C61 I.R#:U0S C'9/D.Q/&<$P:L"47XY- MBYGBO9.3=>:2'R+68#.K&2>KQGFI,[-CN&&V_L< DB7-(?SUW6ODL^]%@7D? MDESZ5QOJ\A]#D 3OE-T,AXP:Y0W9/N04PI2]"=E+8H?SVC,?$1-,5^^U+*!2 M3MD!NEKRO(/IRU]E$([Q=='@_4N2\3FR06)I !%J;5C+ M%((S# !Y]3Q@$;?:@U9J7(KKBGXI"R,O-[I6Q)%P(%)Z-@T\^ "DRY9=B.\Q M\<]BQ;?@$HA2]D@;8='W-(T.P$?R<&MZ*Q5 MKR!X!M"AMBCM90#DR I;D[& 4A:%9?*+_#OW K1JN&:VI[=_5T+RC)[^R>67 M@?,BKH*Y-S27V5X44(6X'9DO*>]Q67LYAD_N& ;.&J2X*.J2>7V%O'W;'Y8* MSBD>MX ;D %A*@[)[;+I I'E3(:7=CUJ^6;_R,DO>L[>^.!$.L*"];'7]9%P M>Z?8V;:0P *U[M5*747V!"59DA9,*7@\W1'?ZFR&W=A5Z71"Z:P77(:J9Q7 M)C>F8Q>X!B5L'CW][".>A#%:5O<]@5Q5L<05K)Z554!P>/':"TOC#U@)5X M% 4+WC58_UIF$8=;D'P7! MTR!=F=39KCA2PI2U[1^4'Z%J1 ^FT\":5G93!;0YMVQ"EIOL!2I#*[WQ$GRE MSUBX5X1K1'/,GDIV14?SSCL?C'HC1[$Y%(53X^,MUAA&97+MT27Z;=GF;%&X M[O3RV.[SP"9'71XTMAD83C4 1(X]U>\(P2E8SUE=0#(*>_#J#IS3H _C:>F; M30X?^"V0(^SE#[N]&UKZZWYQ2'YK"_!YXN]7; E^RXZ*)2OP.4DQN/0R ;^J M\F^>W/]&] WRY->+UQ=Z#L2N02W"(!)1!I\*I;>ZT*#T0> ]&4K-*BR\DLZ-\C4LL&']4>J%M;R[.7K7^]9D$W_5F/L MOLS88Q%PC8XWMF)LZ0K:&<%:I4[Q E][=&F#9.]%9\W3H>,N_2Q-GF5U MEN._6[H7<"&2,OE3@>0)Q:X_ :OQYP9YCO_.:)FDR>N]U>"",^W/-'ATY$6# M?_^)&_JY<:2+Z!5Q'8$"T=/+)DY>(E4C]IJ9+_E#^K=GC4L9)V\0;Q_"*7S@ MI_!CINKUKY]Y0EXC1:&?"]>4^1ISI^&:U80SAG1WKO1I(M,,C1)5XE7A)'UH MFEBP+SP578HE]2*FR/DK&8/ZW5K/X'-V5[0T,IHVDPM[X [[%>)KE.L2\MXB M6P87R,3.1D F/?1#7V4$F75-03=XNZ"&PHI&FNZ" !P]JDF@"0I?M?""C)VX M"IY;*LS">'HI4VS/PU;?6&31)?MB.*=_NR MQ=SW-T51)R_)QX2Q)T/_F(?\KZ ND-\\NL]@[S6.]E?4Q-J;V$Z M]96]D"_RC1XMTZL$(HMXPEUV2,-09(UV^A0VIE)DMAB$\*U$TR-4TN)T:=U) M;*.?+0K51(Q:D7/RUP^B7S2)BM3$LW:R!5AV&)S]^OK5FY?W\*A05BIKZPK@ MN5+U4OX^RY:2I40"FUZCVT(I'&]1;MQG&/DH)AWIV+SL;"[$"&L> DF+F]J= MGZ*'JO^NLYWJETC*0J*K1K+QVTQ2T+5.=BMK7:8.\RPA7E8C^XR'%*613#,M MMYR<=(/-P!7.N;]JHKT;*FZ5&IW^'%%EHEEIOQ.)"6ZKE _3AW;8W_*SK3.] M)U\_3*NLA[;5D;''TC2YZ_QTN$?<=A[3W[1R91V-]99FA59?P7KUUV367'.Y MQ7LYZ4C$SPOKPL*SLR66S9J)"[R;(=(:;(_RB M)^G+6.VP$%F679%A[T?GRBWY%6W"<3=FUF7UZL9I&$4_M-S0I0D='BY8ATRO M=@H[:('KSL!U'RUPW06N^]F7%9LV1&4-NT_L%QQ/0 ?6YT(\-F?L;C-4JMB) MXGFYAJ?B2S5ILFUNH-9*MI11>S?*^6 V<>T\$K.<^$B?O2W"@H\RG2$S7\Q8 MXEL>+I7JNKNX/BNVTWIK,J(W!8\.O!49H;SXQY QP3%8# N)2.'N\,7DRZ-V MH8]Z*KX=S\T->GI7!5@_DKHH?ZL/^!"C,8IV/O%8SK6> =! MPX8V)+O/ZO^3BU!>64QXW50:>!Q&Z2>W()F"YC]?XSGX@%)N=1)K[/=L^C\%3_%SV-:7)J_A.QZ29UM+]_ZE M01&4?.D%]7&*Y@-0-V8*D*,SZN$TI+32[78R]6M,/5CY@:E8#4&'H2Z$8P7: MX%=D'=HRU\JK1$T^(.M/+ZO,M:B[X>5LT?TY[K; M*\G+Z#M<]M:4>6,)\Z8^1QH)-7E.46>]2U#0"PGV$D:L+EH-FN!\<$9;D'V] M*W_/-S5G%"+N5I7B[)3[P"SOM">VT()&AA92#NY^=L3%R6NEDY",3$?'>B%Y M./TRN?_PT9/'KB?YN?!;'+]:1Z%>GK6GD2M9K/+["LJRP)_)9EN* MW7=MDC]M;_Q:]V7%F>*#KW*'1?-6"3)%K,=2Y-764MW0JFTW:N" M8'*FO[R7*H2>[-?/37M%P_%3656H!5"'\6N9,8 8A9:#[.I?*NE'E1;6;A:+KZAF8N M:#6BYQBZ"]LR"!=%U+OVIXD85PSMMLAR"N7H5V+B7],3_G<#&L-P?&[8&1?" M&H#A'0&3+Z&BM[^RQTJM8E[K*7S>;>7VR,2,0GTY""3C,YE3B,:V!DNF[M\-BR&8PZ7[;F0 M0LWZ+-G259,*9!=:0L<2"S?T.H.><2#/1T]4TGXBIT(5O^V:,5=6)\:I U=+ MV6UY<=KE8WL4;O8WY=^'#!B3GXMWY;I)Q3]C#7)>]V4M!!>Q11E=<%703-4" M<0RL)6\3;D%PO=LP+WPCKFQ"1WEEAE!X/9\^^^O3Y+5QC)SQS_=0(P5^Y5P3 M*T,O#Y4'[=]!,1.\IPK]= 2B(<-4QQ(7T@JY?GO>>%!+,#)1SZ)ZX2A$T*#[ MT>$64F_]6]=U6:\1EDL _O"[4%4.\W]^W53#;C(M#):HRBQ@2X_;*F^WZZ4\ MAHZO>Q5,0"^TK&+N_9\&IT??9;OB$ZSW+?933&84I4CJGKXD]_UWVTZL/D,' MX8P.#VA>;'H*+HB13S1RKP#%!HT<\P3*8'<68\5KV[$&C3!9LM_/V(/A?SZU MO].FE]^X36ML$.Y:;$*DQFCV8WKG*$NFF^,B^=6AUT:WM;MN2R29 [PU.K3^ M,<@^XK5OG$S@^D27&J):K,>@:G@/:)^\;MJ1HZ*ZX\S%MA!<<&US5B6LFW-,HI9K#BR=>7:[CSD;R*>3OAOWI&%7%4)#7'%"#ALO!&11,F,*K:0-\1QH+,4Q M(2,.W(GCK^165*Z:)@,'98%EE^U(VT&796:>YAUR.@$^N?@3+ MP0$;6/?(M;S$KF/@ZI:=H,8X?J3O/WA\F9!#4.4W9$:LUT;Z?^,^UV^^U(GL MBA!-P7TZLO5NYS547#7:U-JRE]YTAV!EMYP,2\V(#>OI17\*76372+O-=59= MJZU^]>S[IV3 R#GQ&XJW0Y^]%3^G _TL2'OY1&!2I(W!!2U\MM!^E_V]8;Y> M]X+N$?U3H0A;<#^-O[#VX0]U=IV5E219@6C>H#E[516IJS%U,!I\:N^D1%58 M;IGMA/2J9)3\9<^OTC.^/<<(,^60_3XNW'QH/K! M;[:P$35=X6FG+<;BMF=MF]57ZIS<1,6IAAME8#GT$(V=)S-"P )6ZI-KN4AR M S>,&Y$7 2ZDDT+WOA_E,-V8>'N7&NTFO*#.U792%Z#BSS_T6YKXNDA>OH,7 M"M8->N-_BIE=%1N$Y^8&BE=RK6C'P-R/:F>^4-86DRQJ?";1V>5K4_XD#,XD M?SL/<+>0X#7]3T9>+)GI%[3AC!YBT"LM: MTU'1[3!DR#7+':0517GT%6X:Y+9MQEI:3,(N4G(2P$_A73US[CQ"\?&"4/R7 M$8K+.3>+97!$V3N.,N,Z518YMQ/31/YH-DX;T7/.9*F-%X/"8U@#S>8):W51 MNU/RS/WJWH7_<^K.NV?H .GH3'KFN*E?U&NMS7%7 \QY%VMV\[<0'VPZ M=K4=W, B>-A?ICF:T]V&@ MC!F:'TCR,4SL%(PQ>DRT;H#L@&-ODJ*9F7)[)&'UKO8^3C":J:NJ62$K%-K^ M,'BXF$ZO/HUFH0&8HZ7C4]$(F*Z:T:DMB6)%HX#^>X7CXHQL%/WW7M1MX(0W MT-KCM3(X?;*!=%B.R8FNOBOHC",7Z,?&LOH-2[XXIV1*\&Z=8J!_-ULEL HYI -^&0<$PCCV1N7)?$QJ<7\ P2;.GM MT>BG"<##0=.J9OXZ\<4-_R0T';0_)$6R(LO4KIHZ4S' VSY+PX9ILP7W\'+--=Z"LB:@ 8B_18S'1Z0%8E@K0Q96?V?W$%5#V_'6W0WW!0DG=91%BZT3;JV@H/NC<,#)LN(E MQJY!8/A!U29W;BQ[Z2./+_6!J>VGL M%:6::TZENI^!*+;*0$R!O]'XOLVNY&,]>>Y7S+K1P?-SO:EPR?D3PA6A5!%< M251Z<>_C-5ILN ;Y798CZ46^]K6<\(K%UC]03*"7:7:-W,OIQ0C?6 !_2(T% M%:5*EBR3JB7WFL;SP#!IWWD^_K.[:L&,9DB!"7DIS_M$O]@Y=VA5%K[1J[,=(PZKZ#YCEDSCX%XOQ(<87._656_O/W-IGS2]=_.0H^'7P MFT[]B1*JL/@HJ2L\-8:8%M11)( MHVIO>]'B9O70U!E?^7".EKCK)B332$,3+9_RUW*_/WOU,\XE#[V "4LGMI0I M!RH02W&VA4.CIB[$[H$;F?]8= +1>/3=,_R8O$@3_<<+/(S]^X5]2EH^.:.@ M?-0%H :X*JJJ(0,VYZ[FQMT* RVEF,B+.P(2H@/6V!]C#D1XCB"X- 3! 5 M+=5&IP)0DQ?VY)[PT<;%P2:0+ (&$8^M;D&HT,[H0N9[Q"DC29ACM[.>W8S) M(*4>D&^%IMNY',\#-,R?! #B#A>3JHSHQETF1^%%@7D4.X= BX>/L"9KD4. M-NO/T:8<'QPE9__S^I=[/D$5D8UJ1S!G\ZI2H>3..^ UJ8Z#/2T[$(:7;(=^ MNU&D([RA';*0&:\7[]=$'H;>4+P,NIPKNUWXA1@NZ<#[>^^H*K\6F#ZSRA82 M(]YRH&/R /$4N(^ACU(J0 ^FJZ_EPW M.=WVNBC)OV-6/,])SS-4JF>#A[P:2D$!&31LZ;,^U7-+6 >8\\N,5KC@Y3#S M"=I;#YG0Q4U'[8.PL\%-XKLX*I.$9>I_<)UPJ(*C#HXJB0@JH)A=\!C^\ =98H1%O3&G(UTG[NF'L5G!#/4R@%@ Y%X4%B1GO7@@3&F' MNA>/6I'K,Z2\;.@IU^(P.4\AU;7$D6+DRY#?HC25V#T9K=%<.!&#=3C4WF>! MA%X_-OKQ>IB?3 F]S34S'%J8!5X=]_XNO'94-MXKX8-,UL9B?T_1_LZ%8#JU M/GK\V>4^7F7]]B;[?$(42]3X6^-\&T7 3S8TES)W9*P_YD#DC\H)Y?5%/9F MH(!P3I@=A9TQ39QC!ME)Y/!!1G>&Y]T7+IZJZ+C)G0J>/-9%\G3Z2;9I1PSZ M^&@P.T=6.TW*B^(B]0P)S"$9W]6Q%+1%$-VR=^2.(-P_C&)?2& ]>?H-%N MQV! 9>R\ M!SY+9ER3247=CIVA&_C" @Q4-PXA,Y;335%=P_>K^VTGQUVSZ=$GS!\6:6V? M@@8EDXZ+J^'2X1IQ20626@XW$#X85!-,L\B M95L /8X,;2-7HY5>BE (8Q3S^WVA@K9U#2)=][71QUVSYQ+:G+)Q?;'Q%A-I MHLZ;06^1;G-#9ZR=TK]6(WL'A3W!"3$[[W0_C@,&M=YAO!$\KNV1^44EGB=%H6^J,OHAC)]A@ZZ+"7<&9QZ^IFJ#88 MDAWC3SYYQN4;+@T MY>E&1DVD)KI.89,OJ-L9U.U7"^IVX07][,N*?55ZDKX0UX6M->P-F9"BFE:6 MF66\Y;0^?Z')A?U*RA*:T']?VF-ZWO"IX*LU9B)9 909^R,#K@3P$[=8 '&, MIXS-*115/;&%.X+\>1 XN70"F/V?W%1X1_F,\&^P\13I>AP&;MC,O3 ZKH_6 MO%__YM=E<9/*P0*N>YPR5TWD)5M6FX^8L/]O?&YU"WSS4U6*N%/8Q3+*J.GB M#X_2".)8L&U"NM:M.E%W;X8*@.RKFO_ +E7&)8ZPM$:3%]4]4D?I?\/?Y[Z8 MLI>\*Z/@ 9JNA6$_NBF U-RU':8J53U 8QK>(1//K6G39%)W#"^=\GJS9&,( MV;&2+5JW^\^X@+IZ/%D*F+. M1AFP-!@8-HQ^OJIC MMGYK'F95!AEFE4&)'MBT.'PF(UCJ88%YPUX^Z1T-6?9]4-N M> ?A'7)_ZA4>\N;8O9GS1?M-: 0V0X4PH5NWY3XDE@S02/!+HI[LHU^2MB?Z MB.\Z=PJU@OA@]D1.:<9(7^/:9^?"P#!ABU;0GG5DVD:)J=!MB72ZX*PH6QB< M.@8.%1)'";,/F#LL"KHNU">)/ DH,.RU;SF\ME"Y22102C;^_I-+FL1#R)3# MI7])N,F=,<#J^N49/*99-CS\:\\ MRRR-1NX$DMK790<7@(R;L!9*0Z2FZ<'&AWY[&Q/U*&BFKPO5:G3>'.T,LC9# MI@B&<,ATXIE "BCM'2R+BF>%)27WD]HN)EF#[:#OJ>H<96\7LHV/V>2_AA^8@_$$ =K MY7>_/$+CV+0ANX,'9LU!X?[G]2\7O*Y". &;@A%D;)\=C"_+E2X6C^]$/8 W MX0+6W(7K754+SV4IE_J/F1O+#UE M??'B6D5DY+R4JXNP!OJ3F]JZK >M4WS(Z*2 M1.,9&V0WN'$8"UP _$JL(V8;.8+XQ(E>3[&I@"&MJY7/ ME^"YXVGDYB(=L6G-AB:GO8+ 7+,WD#!,+^+1'RN+*RXK6N_LG!GR'!YH";XO:,T%ZJPJ4AE'T+%0S$6NC_LO6X#(^+ MHX\YJX)#4];.#D+M^G^<7AE^V[3E%5/HL^TFLV.^MMU)NV0 7]7G'Y'E8P) MTDS@7L-ZD5ZGMUMET%B//\'9C]G[P5>)\ZQ2EN,'EO!B)@(W=A?MJ37).^>$ M2;6AL)74N^:BZ:QIB2]HB['3SIYPC,O+YKTP3P,YTUOT5^VCFK0F>VR*!\0% MG<<"@5ZL_BE:_;F\[7,MC3Z+:KK+^'[:POPYA@#B> C"L3#+&H&I9LKCJ>$^ MZ3^.F2)_?%2AD%1R$3LY"N@21.T8"C[Q^!TF8Q1L<12?$C^+:)Z+' MR ?7-)BMNL*UEXZA">FHP.?PH8+ALL)]WMR EB! ML^ MCB'4CH]F[]$2(] ##OU^3-(0?3WL/3777HZB<7C,FJOP.3 /4G+V\P : M= U*76W3"4/X,Y71&9."01#@(ZP>/:TF RFDO7*D]3;B8XS'9AH?29G8GV?O MZT^2IEA3SQRC\$+RKO$ W63OZ?;AL.O8.CJ%PVH!Y0'D+*.^S+ZLC M%DZXE#63T@Q];-[$S;[=OH6%$&?J5$OG-N,UPL)8,J[LHL23/NXACCJ0J4SN M/[A,($ %W)J4L39S%3GYX@QCP\<5KF!9N20U5[6Z2)X/[G@29>VUJ__,7,V7 M;SC=2[%+(4'G7&<(N3)TT+26"V#/HXM>RPYK^NRVJ02SV-$J[Q39PR^PKIKU MV\2P6*,!.G)G)R_#:4-\4$B'9FZ.0[0IS,N3G*;&HKN6D M%N;>5II!+4GGX531@=@5Q=LNZ#ARB+; X3E66;J').YC#^9()5#._K];HF@\7%Q+F;@W);UF+@6/8K;%;-+% M$2 (5S&]HZ2!/;KN]DX,+)19#]Q0BEK4]"/L;DI&(Z>WRGI-!4NNC5<;ZT/, M=) <*2=Y_V^"OY@\-[V0_6Z>U8*;POP+^9+SQZ4WQD7A M-IO?JC-+@<4[:O=]_FHW YZ>?G/S. M-.!Z8D4L;YKXTKZF[0F'8?;+[*IN$/%C&X,G Z)@H-6HE2BC;-N"A3M6W"C' M9E!Z@RVTQ?TD,0[SJFNT9.9^8&=+181>#\09P(=;YOD[/R'DZXMG"Y MANCM/;O&=_11^JRK[]>-S^JSR1,4(+F,$+3#._,WY/)*R1XFSYG H\]0(T"I M(BG>"2.3NY*C"W-E@XX!-F?E];U$U9)F4$0J3\5)%6YF02S+KM\FJ)-Z@K&] M+!INB&=*&DMZ<(I'E@DW?@N=E(-$\74SF5P ,(;:2E)QRL*W(.OS!>R:,8\F M8_^\:&?J]$YO,B\K&W5ZVHEA./NE\^3S6?-G-BUO&)*YX*I_'U,=3&RO\I&< M(F;V*$D6C?BBM-;J*J?,V=. 2W=7'/OLI",-'1X!W*:LKT$<=94Y/$9 (NM[ M=XX&/09#5DB/L!3-=2='D?6+YS\$K,*=1LLBUQD_DD\%1\BF;;DJ>P]Q,L,[ M_]6 H&YSX-B];3,VUB,Z7\_ QX7IIBXI5)8(7'53#20)SYY!3]H-KG$,_\H_ M1--.^O_ M4#K*A0GMN"B=Z3?:Q A_)J5TQ4S(*:X7HZM)UL[(UH&P\ MV>/O?-A 90;$9>SU>*)GNP;"O(#T#1C@(:O+G4;"JK0.F(5PKC%2"ZQK6_'D MQ-?M'9(2DV8-:QX$QZ_812C-B4HX7\)!.WG\.]AK23SBE02'&E7()FOUH>+E M1?35H9]6"D#MU!V*2 M6I0#R#9Y(-;LNF?TD/9-)*$J8\H+4$'6LD9^D3CC>\C3)F* M*+8<+2XAG )3&XCB>B!C'19$.$1M)6*F5R'K-GNZ:5GZ"JX.=_DH$#" U8X] M$0R1ZQ>>^;P%A'S&SSS>+7X$&( G9VU,M9SR396WQCU[A.05BR'&THN5NWJ] M#;1\;'68#)4K2G405V<%(??=( J55FWA>^MAQ16MG*U66 G,P2/>8#4OE?,"F/D%YZK8Q@]#!VKW 3D^,BG M"\QW;_DRR]60<;(UZ#SP#14\ K;\N50R.LOHF5)KHL 5QQ^(CX.@8U^QCBXJ=&%;8'#AW@1XT& 4 U"(_4I@2--7RB MO)YP8%E:_AA ?5UEY>^K8;8 ;FJ@C50-6HR-LY:SV]G'X19.I%'5430WRP_-&H1+BNST*7C*"U!K M!JCU9 %J+4"MS[ZLXH1AE$T<.XTN@('L?*;T4NI-PQMG35[OY*B#@>-!&:2& M#G@@_H-BL8IIQ)])+PXRPFR]33)>X GAJ4??A<-;;+QG*( ,) HEM:F>"SKT M>93D3"6_:%WNV5%?T6FQ*1?FV!-=O[-,/D'3[+]!Z7.I.=TM8CNF/IQ6N858 M14%!*=(4!7/:LN=9M-=9)X0FCMTK2LIH",AA%USP@^GV*$COV]'DY>6U#92. M+<;0I@\.6Y4=OMU4Q;L/F;J_DT=9;@[G> JL GR/ED_6]M_Q!)W3N.ZZ;T&[ MB^_.3B>9U_.;,N^WWSZ\>/CPX9>G,K\V5F7-P\)#]E$7N&7PPC%Y_/7]RR>/ M[C]Y\.C1P\>7WWS);L2[!Y(#GTJV&5U2$6'A)7- M[[P]HO?6_UV6]K*T[\;8??''_WG]RRC](?4E:W^.2(1"+_$HTU :4$V 5*2^ MDD8!T>C5DIX+O5.GH.;WDQ3 K O?HV9]'WZ2:^X'25(F10J2C]P1+46"L-M? M>=F6';GLR#N](UV]89P10_079?>RJPQ$M^]/\5F3?&K18_1I094\^<[^VVPV MY_P0!LMQ-&',9L"I^ZEG:/=8]M>RO^[T_HHBDK:H,B4R"550&33+@*YE.2_+ M^4XOYXB].^RB-QGA$!W4>>7$\U@'1U%)MY#2'^4L^D ^>BZP>_(;)G#Q/"ZC MIYE(<3M=J_';O/KYZ?D4A+]LVF73WN%-.R*S\-6"P.<;1V)*Y11UN,H7P^[M M&A>9$)H:,C1LO[[T!YX*Z*[B=YS,]1, ML*>2*C'8(R.[0>^;F4RN W[:0[C6SZI\BW8F%.:S04"P_FG>\S".S<,]C'!3 M22_,T"Y[?]G[=WKOKYNV+92FDMQ0/N"T2)BQ&,N'VH)87GQJ"C9EP0>RW<[! M4=@MD-MUPL+*3]%A;S'^$Q0)M>PH^FRA@G32H\BLI\*BOCJ,+ !_@VP;^0S) M==E460BF$%)RPU0I3'%RZ67[+MOW3F_?&3(0WK?:(-\?L%?I0-+-D5TQB\@Z M,_5SQU\5;EXYO' 9A[O44FOF-JQO&8[WEC1'P6!4V4VGIL19CN_X%\N>6O;4 M'=Y31PFY?1YFO*X=J>Z>47@!<7> W!=RF<_+Y!U$OC-TWA='=MH"0_C I?!R M:.?K-JHH\8&H7O:AM&\5?_J?U[_8BF':827D81I(R?8JEA!;8[ M*&BIG6:_SCVSJW/1OR8%K31L7:49R*[XGS$7/TO9596OCH%KI5PKR?&FK%FY MTF5Q7(H%#RU S,?C&9%!\BV/*? M0SMA++;U*%$Q!^?9#+F])-]PU--W5T-7UDZNBA8*+^:#I/L<*>M0OZWQ_'0G MV@L[UT)XF#Z"K^<.=0C@BQ#G'"2,?X,JTQKH08:+@PG$%&.89HB: 0SB!V43XRE8-\I-WG>Q/*&K37%[:K+?'CIZYLPI@Q@%'+[,218: MKG0RS6-M#/\4<86[< &:/JKY8F,O#8#*IAIHY;7:90.]'VP,KQ.*:&OI]?@, M+#NKMLF<+X Q#K8Z']*!'L2^N2F"7ONY1MR;@NW']$@)CI,C@#;6X'(R5QF# M:@MA>PF>"1GSB42%V_Y"^&8K4S=I3(7399+HZA9\W.*_W[VQ^^*/$);ML8.$ MY!)K.].0U'ZA8G7/&A*H?MF7*N=[:MHGV^H!!B*5UV:N%U+S8H)5#NIIE RQK>UG; M=WEMK^GER:BW$66GEA5 8'0F5CNV! M.].,=N>['+]9NAP_ILMQ,:Z+28CF7,H"V<*6*7.D][-3Z]DW M/7ZW'7I-7P4YR<6-6%;Z75[I\ LZ)0PI!L?K*[*YMTE646N6@ZB MKJ(VFOYE.2_+^2XO9[;MPCHIHB%2NYHFN(_M1Q7395_W(#*AT?T]J+FRT6[7[SC]YJ5Y9="ZJ>MV[^% M*LD,.@@+J=Z-#G$V6N1&4?)-MJJ:Y*<"+G56': /\OK0D9&T ORO%Z\OV)X/ M3.OA]4RDI+KFQJ Z_R_N"VJ;NES3K;"/%,.1R@=!F*BTH4/5M]FFK'K3O^8R MJ5XJN,P:D!*%\ BQR&U/VPD2AE8*BQ7EX3,SI3@*5=R,OF)Q(^'#3N@AF&0= MW[LN\R&K/N!.X-NT_J8 G88[/FN8$04-#K\40JOKDJ6X,$WZ(3E[]LLO;^ZE MPN!MLNW;\%ZAC,RJ,"UZU>G&(+(42#OL!47$FEV \C#!*KWD:(PAVUI(Q,6W M.=2TG(1->ZB9"Z,()G;;.%;1OJE$ VQ+2]1N@(&=O3Z]BEXUZ[IF+1RO//TB MY&ZL>_J6--*F4./E!;)\!PA4STKRQF7M8"$>I0N\.=GLO2<9>,^\\GN5G5.O M*P3:Q-EJ6R03$(M30/0WCH2S/)9,%HRN$3R/_.(9G9YMF5\5)MU#"V.3M9&[ M#[Y;56_P&W9AVCI5@[PMJ^)]MK6[W5!Y=CCEJD>'I:=OB]8:*/0][BX+H$I' M4;@"7)?-]5HP>,GC!P^P]-'4X64_$:#Z@T/!-<; G2D<$:@YT(,:FW<':ES0 M> 2?S(M>(#E9K2,!(&*,0(O AJIHQ%:;!HTF]RIU; 3X)PAD*;,E>E02;.DR&!4!A3 MGJLH"@P%/RX>@'YZ4'8N.Z MR_+"]15+D[(*?8$E,40"=LVFOX%[,>QSG%RIO4>XLR+H8,-2-SO:RIA3XZ\= M;5LH[JAZ[0UV67E5,@VDH\3A701^-'LZ-$"3?6BQ9YEFAV&W-_I"X8(V#1FR M&>OM^;!WTC%Z9%\7TBO*-]0?#>Y \L4^#:SR<'J)L^VAI![-]%LS%FF MFT+]*GS8=NRQC]/2H&? $+HS68=*P,WE,(*ZO%4&Y78#PH/GY6X&>LB>YT;D"D:!REN_5Q1E%KVSUT_1 M"YB%5 6DFC6BCVB>AFM4/$BQ'&Z^%Q?HTV/2QC-#0NTY:5AN8*BE'0/S9MCK M><@ T%!; E1;W%-$0T9M@TJ<*U2X$>BG&W3MIHQT:D$ZHFX*4,Z7P> MZO7V@Z9YR>Z\+[OS$W==<=#^8YL-0BCP= 5K]9?LYO.)&7Z>IUW"FT^5,E3_ M2O)"19T*O6#%X?-K V6&6,4>-;)R:@6/! H M""L*0>=4$:B\MT6Y6PT45.2<5J*0ORI$-80A%BF>X6?FZD!F2OY5YEZ!;>Z- M5*VU2\XR.^/HQ(.W8@I]]*M'#WA$GETDP!]]_5UR_^&#R^P\^7IUMKEW3R*J M?4L.9;E';DSO,CM8\C(\8G*DPU\L6_(@NUYR>2PR5G8T8-RU7U3-S9(N.-'] M],;E6'5-/*6#\_S/Y?HMGE&2XSW3-V?:*.,J%9W^3?45A4CP2 \@MAN:R(S! M'EML,U2BDIR23TUFL>PS8[%@"3W>%OOL8**%Z&4AKVZH"\O6@2W^]UG_S?EQGW5:WX]L22D<6&NR'EM6_N N--K@"1]KB1H6,\2&-].FS MY!)V19HHU0S8^.&#YZZ%GJM\2C836 CU,/>TY7%G;08TB\'20[-&([O%+'C) M*K,K^*I9%FQ\3O8P'787-.J!,D=\V=2;+Q9RLC$-GVR0O]NKB\TPEWHOG-,6 M+N(NJ4 (K1VZ^JZ6_\(>T",IB,ZQ.;7GBQML)UPIMV_N@&-M0Y%P87=PTK\^ MOQ6"GE\T@C[[LF+/1?,8H$!PZLTL.J=B C[*T;(WG2"[ M?6\*OLQZ0*,54@/\]Y!?^>Q(5_1]%>76<&"P-:-3?\X,BN$KZ^NF0AH]5!#E M_DP5G:Q98E[X*6JF[/28F*K('(?&M:+6+U#LUA]FSJ*9\Z$P+6D^@UR=JGA' M)[FJ&)7 M;SIR+2866GN5N>\&"^W(S( MQ#F!7N]P^(F8/:#)?::Q3H:]I'U;R)3R0E9R!.=W^?7BS]A1EVYPKZGCD;W7 MY3B%TW.)6*<#]R<4!J06!.@RP#T?X.2*+]8WJH%;UC49.\!D$*VPNABG9%E? M]LJ,J 5MOEQ0[B1I+W4;Y_9#R!1K%B_S=H55X,U(]'@4F5'TUF8W=6KT-&TAP*3C-Q2EIYK9-/'J?W_^__9''90J/7;8&)Y\H;7# 5Z%>Q&7W:;PZ=N M]Y@51IF6X(RM6UIA-2?'KWP('O'+*!$E-JCEFK!AGD-^O;?DG)1?^)5^XFKV M:_-7SG[ZZ?6]Y"6">MY=+X1XBQ[J3T7-!OML;CG?G0/GY8L_W6/&'QTL^B+Y MJ]/YBL^&Z#1*)J8HFF%,ZOO-2"IU?R"8_NF]/WJZP$4Z-G&H-[.7?KXZG.._ M %*4BJ)5"7DQB$I?Q;V?97\(:R7&E1+6 G"B@IBN<^1<67+%MC@TFF7G$L3^ MR6\]KQ<3=Z+NV9M@9L5A'SOGR=F/R'O2=FD0-8Z]^O?EQ#AS/A>Y:'VA:6\/EQR8XR)UTV@$:PEB*%O_/_Q]Z; M-L=M7=W"?P65FSPE58&,J,&VK+JW2J9D6WDL6U=4[/?Y= OL/LV&A08Z&$@Q MO_[=:P]G0*,I65;LIHT/B442P\$9]KCVVM+N'*F!Z9N \'C"3!>:7ME]A3)VE.$^"N#3P3ACP:#Z-MBDKS&>'WC'<#\&'K M6OQXV932H9Y9D8HP^G#_^T=ARQY&H_D'B]TSS&H+O YD"1*2EQRT#R!IV%QX M5Q=!SOXUE%E?;!!+[OK*G3/6W,?E,:^MA6V5?^_+JD4.3^XEGQ&9,>Z?!;WH9XVAH/$4? MM1M3JONIV'W*O-AT%H&R;!Y/L@']5@A$&"#()^,UC:=Y' ;;6?0L]^X:,'7U MKN_(BC6- 6%-6\T[)&^GN:BTAZ$<0O$98X>G6 J;)"\*DI4\CW9"1AW6Z%0D M#=E"UF]7;,YZ]I;JV:>U+.-;DK\3,4?$!Q30NA28+. MVB@^9,=WM%YX)R1EN;JV[J&1GF0!SR2VVYA#E_%"[$R]%85X[?^FCW-!R@K@ MH*EK+7#PI,%+5Y5*LIL@'*0Z:OPE3'4X1A-PB=%-7ZUI5TO[,P _5G]!M&/@ M T/I[8514.5,^^^H?G\_3@1K])OD^>G*S8=F^F<)\_&6_"M/B/Q*MFF7G0UU MMP8"GTWY^*>[+$+()%FHEW=* H"I"*4JY1[L.@0-;*VG0!%\1B&)-E*!*+=^ M84[CV7 NKF?V3W)FGY6=[(!7K=,"/['67['^HP_Z85N2:9N]5J--2N.L[(_/ MW"LK/,2?3FD'&4B81B,",/EBXSKGXAC [\E"T6$KL+ZHZX$E@ID(7.'2U';2 M8]@ !QI7,)*\F<%(\KY&D6"5I$_%C69B&LRS?BO^A.9/55S<9V\B0,+Z&7-.5>L8>_RWN/DA$K0TY=GXO!*LPHD MR:JFX\BW>"D_D%,13ON5.^](NI"S$SCQD;%C@!A_TZBLJN"U2GGRDP.4AB)' MV6 UI;U?,YNGMU1YO*C]F0JGS&P'X(SCQ%FS(OTNIM-DTZ&D=HZO O_MT5NS M/KAJ(T:NV0LT?R=H9BW@\1%WX_9/'@^H(VR5BDP?0?8!C]HY% ;FTW"QV.UC M.29C".YF[/?OV'() )1M2K*5V^41*\IK"#/8TF& (6C2L;QY$L\;?[&5HHQ\ M\H#'F&AU,KK6PA.AJ#*T(XB8Z"^&'&;BLI=,E0@O8S_ :]TJ"1BH"(N ML2E'8:R0=C6VPB#;8T"MB?(I=SM2 @$0TSK2!7AA1QN"^[MRKG/O_DOG==D. M F+>UWH+590J';7,33R9VR#+9KS>!%[O9,;KS7B]3[ZM2)(OK!XBJ)/(G!IU MZ>S$SL5%%^4JL6\3Y!2;EFGH,J[Q3:7DRG$--9(LTNM$LBS,'\!X/):*L-!# MEGE*!4=U5II3Y"RO(FY$C26*-JJ#U(9IK-%83WA5-9M_MW1OOUDSSET*ZX(E MH)#\7'D\V/M#KH24^Z74ZO;MP)HT-=5&_;!$IS9P*K8::D\K^,:==\ '$O:O MX&SB*O$(!K6)6N9,V@+1@[CHGRU8*8V"/\.MIN1(LW$2EXE(.7!5BOEC )\& M <0\!HG1=3\/2T6DQ5G\=IR)0;T0Z9M CE+4L%[I?70[AR\&:9;"V2DZZCQL M7!QL+7J)3Z[ZW >C8)UU-/,?H88\3\RRY'J$6L&KDMTAX[D^&O=*BX1!4SNA MT VL_!^TRN1ETRV-(=4@@^"!+UG(^2<8!0):8G 0BHFM)B#)'DC7[5EE*=9P MW%^&!XL]2F9^K0V_N!8%[C]-+T)/ JLQ5 1W;%4'QQ<.U8UR"? ^\5C!E(:X MH@L&,BH8<(+9B2<%D7><;DTFCSNWAIUK7X5EJ16_F*[XCG6;^$E#%U,B1/4_ M"1@8B?L(I*5,&ZP18-LG'ADO;O@KG7%1>LT M;Q<"GD4$G9>04 > LZ0X0PYZZOQ$*WI'-ML*'Z+P( MM&=H&?UL'0@C.1OOL;26[-PQ Y%MNBC\K@/*<5+8+Q]B''@7DKV&Y\"> MC6 M4$83/VX@1QIN_&7JLKXDO23C4>YH@AK 3 MQ$?I;2A+9D6$1^EDW0KKY(]L=W\:+H97B*@L)#5P1@H91WBFBSBTM?[H,"2L M!1(#K91W*Y6E=0/PE@,(LX1_1_*7G, QZB*6.G&<^\ZK%R_NQMZ,Z*4CXS2* MKCW.OA_()D6I@86Y;@XVQ8_E+'RN>E"_A/--6OY.,A:Z5W[L=.]*8;I62ZWD M&SR64ZG#CI)/\PY8^$)D"'0BTJ\Y@YR?-)FB2)=$*=&RE?,/6N+ H]1Q=9B4 MZ ]LW#B+F/(,1=U\(UR56)WB*:M1JM(8^8YNQ/XT882S:%%1 J+#H VA<]L^[B$Q(.1\EQ21SZBR?VWX": M-Z+7+K=8M?W7&KJW3G=R"B.5&@N1!D!B:H/(3,KNN&>[C3F4WBF0+888YFP# M1C.CM(Q:OY8!3BG %J:UN.1_6E=IQ9OP9 "Y@)]IWFVO""V=HFL09>1@D)FC M 8W)H$HG$0.0;X)PZ M[DJ(<=9)@8T( /$JA3)!$, >8(DMYRL_?2(PGA(C4G.=Q:)(-[6U(T?X0FL* M+ S?#:4Q%<@#$GBHW$TSPZ>&2TH'!.W1@[< ]T=P6Q9-IR$W_S*_TU;.)7QV M*:I4WEO:"J%4EBQTIFF5/WF #.\5%R%C6_9"X#RHD+06OC$XFNGFP)+(B".> M2^@[03?H^O@!Y=P#.T@4]7-=/699+)4_,UL.VH&8/6C&E9:6K).W88[CVA" M+7%O[2YHASHE0J/M_[:B35.,<:\(Z9C]GKH7)D(# R M.08GFS,4,3Q 2 G1A>\:C4H2+72S!VYHV-S@LQN8'L,[D:CYIGW2O>6-$"3I MS=*=NWM%C)%(VP^MA'4A,!H)W^&YGC,W1?2%+>4UVX1#!P59N4+8%.V 1UA_ ME@5=K]B\\Z&E<\AA9W*K6Y56NO=!L]FQ:WL3PD(ZU=1&$$9&?>"'901H=-^+UXG65T/E2DLQ7"-USDCX$"U$$2H+B0 M0#MC9WR42+C'HD"\*JBT]$A'@VC.9MCXPL5@C(SQBO%K\CCKRE^JP MI6T'<2!O*]M)@R7>=9XU5N2GIS3%9.&D0XI>NUXDFLQUCFA)L6RVO?#+.H8T MZ?0;N:> 4B2_*\ NH>9E)T&V]Y8YJCPPOEG0DK33V730?B;AY=E]^]4HDIQM M\SUNE!$F>7;I<$B:)9NJ#+FH5D=)E/VBJ(U(/]<3M&61I)U")LSX7/"-O,03 M?V;R!6P[.=@XX$,E<76/@J#+E55LGY>TSTDB"R<8%:%R(JQ03>$ZV+R[F"KXL?[4TDV=NB8(65FNU( M1D,PX;"$K?P\%JF/ M0>$U%6.&/[XQ ./X3]%F"VF5 M6)1'EV95V:M+$G&1!YR7@:K<.X;W&SDW-+3AA_!- 77D#2%CO3>S57+5P=X( M(6%YSULGB0P2P)C,H?;E.NI!@XNWOWT+CJT&I/)]R KAF$A1H5- MW*;XN6FC@EU?8:2T,STPQ2'PG9[]![JAZ%URM3B=<5)D+*)&WFH-4?T60:!:\B5L4]40X9BIU-+>)R\*B:6"+F(,905_]6&(ST1^EOH;V 3EC ML@8A^.0=,M1TL:@H)T&CP:*&54%JS[$/-'N*< M)ZGJ!&<1E+;H>V,IDCQ53% $,@GDE8P'T M(XR#$2D!=1#[O)Y=D(-^5S>DA^0@F/<_Y>TS,LS>'E) /B+LK=RNJ!=I&G[V MKG]A"7%BJW(-OAZQ-RT@]2B&TQ8[=[Y^N]T;=A=I .;2 M"!97>'7K4))LO%):2L9^2Y?D'# E(JK8 \=GD8$6/6V_/RY4 M2L,B%:F^F9(..NV4.-1].[@]F+0()::E-[320\V+ E?6<4P3^%+>U5'9CRT" MQ(U%J6/):WY="%77'9J+<8-$TQ) !^9:]J;9;[_*ZGMSO$']?I\T,HVN/H_F MW.P)\-9BRHNN=UM>U;?.;:>>-AE'<4SHJEEJX_B>FII"64;#QAV#"WVC/D^4 M\N8TE,CB!XD.=)P/A3,850^Q>;2;RQ 8(RP<&CH\<9($.\Z>1V&:( %C\E;9 M2)QT#:;O.)35M%,)IEGW?WR/+*_64G$Z:;Q)Y,QQX[X&TEBPX4J3H=Y/\%!\ MZB="J:Q# M?1^6NNG=O5 %;1Q_#P6F!3](=:\H'<]1$OY*I!##2 ?L)8XUR. MJ17%=D5,4RS+L26E+=>5MR44 :)Q[>OH&/J3(5ZD+TI$A%#3V%9HG@1NY7*U M:6A&UE(_SQ,5Y2#H5[%D=%S@F2:;=Y]:+)=)*$Z+7*7L&XE;DN:=1[ 8M5 Z M.=SO\SK.FA@)5#YF8>/(HE2.B^;'#*72W:+&Y(4RK$YS*A@5FX8>ZQ2 M/OZ M[T&CC!BHN>N:?(06;XJIPS*#6UW'@<6-@R=;=IMX1L?Y_0T\R"U*-IMS=('F M'6J69[*UY6@P1,)#R--RD!A3.,NFCR7$WT:$Z1:93(#SA R8/6M/.3\T8E@PTPP^JJ:(/QPK]<:RT@ M>6'TKXF*%5J12Q!50%FV#8?BN:K;K%EFM@;LPX#P'3>UU'.N[9#X*[@@7>K1 M?:L?0_G1,=$F"O2]])&N5G:C 2O<4WA<>Z.<10S$U2]]#^UGB86#%8185 M=GW8,U#0653_LM,KD\=I(9A.17/5H.QD;/#^A?%WPV=,(#G M$;5!\'X8U-'U1SY?SGPG;.)/K1FW!TQ>R:6W+4?8(/BZ-!]*9^O;;\^.('*Q M"?UGY (,JR)N/YV<%T88>9J\_I6-^$NPT C@Y\T:*RK[])6:8,"5*L]1[DD" M,5'^XW/1:FGZ%*?=<;:X9ONE1>!:Z!,8UK=M2F51VL-OF7M)(S27@\* $(B. MMUS0YF4L-W(U=VI762H=-5^0+XO10D EM/#0%,(XM4Q73@Y@W!V6-?U,-WQ; M;86?S/8'C>VF(9D%C/:2=F@=2L_47H3WP"<;6R/R4_PNZ?7DJ/A-# &E!)U* MO:"MIN*'GSG0<3FU=J?2-%8!S95GQ4+E9FX:,O>&P@@&/];'V1Y]G)LA;9)9 M#-/WYH_\1W@@;X(!02RKE?28E0AO4)S$B*Q%LR0-K2K!1XP$B@FRXUK^.=(5 M>< ,,LB1K0C%0E4-@C'0V^O(QLFAC+MF<\401AHM=S=:^4GPE_DQ!L^IA:$6 M/I+%D08NL.B9-%_/@_!AXVXT9#Q&FK6[MFU:38GDOLY6C+]/QG*\7/C+5AQ%KO.20P0P[?-V'"S M==G-,G5ZD"1CQ44,@M"F_>#!/\&/%5U0+.DC-9XGI0 +;;0AS99P?$=>I+TN MM9QB3S!"F)!EU [;4#W%IA-9R>9I"HA?CE8:[(A\WB2Z!$(IX34*9]#P4A*9 ML@"4U=J^WW5-=1QS)4W,9![/(P*;B1X+&S@:&!"_6' =E3B:2#<-S>>//*@ M61SJ*/R:<"YIK>]R!_8LM.#@(F$&SRCZ,&O16ZI%O]Y3[1-6?@QPF(P2CN$+ M^SJ*:'' G3C_DA8#:7W=;AT0H'!Z#@/8T"ZW^FZ)4%EH7IY?S!#QV;HV"??5AJ/XT")-(J4JB3KA'FZGY>C%#X)_T;=(9/F3M9BA@1ISUS7//; MS703A[8)/CH:T<$HA\G]ANRFAEL5E%(_JI/W*TE Y>G?M*$0B%;6C M:H6NBBSQM7,:\DX99(T$*?<,2,%B,L[8N#XO#NX+2]]LQ=_*W3=UD&TSS#/Z MZ^AC@MA>,VV8B.U<20+;"T2S^?# 8_?GW1__TL-\ Z>:WDM2 2R0DBOSM>@3KN*TW6Y5'Q9E*] M=7*"\K#K;D?1^ >RYV[L'\+"-@"ENUO2;X+-/K\?0%=^$(FEOF MPCK8\/P%HP!.0%.Y,='-Z%,00ZXL6;\L.Y31GU>,N^HDZ<9/BVH0I(]P-(&: MF*-3IA/L9_39:*]X^)_FQJ1"K]G:Q^JKUD:3RDZ&<+Q@/\2K;'/BOR3FPI<) MN).2:>C,NF6XEWZ;S%5DL>S,]5T939S5@]\S6L0 4TSWB-]0.\?'2H^9#4I\ MO=E:^L-(\']ZK0I9C$RYYT?2[B?9&0O%[,ZK5V=W<^Z<$J0A>O0P@Q?:TC@3 MJ%Z>JJWN]Y2F^JY#HT;_IW#B>2NJQ(%!T#K.7HSM"=_?:Z?@7--[VO:+18"_ MFQ/Q.%[H7P"@1IW]L.@;KB1^S%7 )_*-"L%W@BV)"#:88<=:W_R/H_^[<_H_ MV5UM*.1[CBD417F$QL>-268@Z*:^O\G^>O_1Y\>/N:XY*L%>97]]>/SYY\S, M*H[T_T@G'GD!$W6L<.^#XY,'Q_P5C&Y=_@Q 7Q@)!Y]24GKW(TJN>& MH-C26M&+%EJ0\9/ G2Z+KD_JR!EFRZ?#6SJ1* TF+68K,FEWEKL< 4AD<,*^ M%ZH032M'90.D/3MEH[$FJ:(5\"E<&FXM#A4"Y&OB "875QRYP+H/]\X"^Y8* M[+1W'>O#U8PN952^SE,T MKS3MF"ZI1I&S*JZ%<.J!ORYFB&S"*R 35^!TZ/2QZ: F7^)9^U7=TE;V>C2\ M)38,P^O&7_'>UZ6>NZ7 (627#@0PJ$=DIYNM4:;A+T3?B\B?6KH\,;+[G3FS M2EC-;**&:+/E_HH,//6;D7G :8N63&?I(?8)6=>56!=6![9G!S.?)1O $W*X MX"5#W>"&"_C8X;B2]L6,0C%_()W,/?%,GB=\7(_J.]Z;;:".9%1)/3K/6 = M$Z/5"5N4,:#)BSWP-)G5HA92L OV0=MH$VA$APO,I:B,^7,7:A!P5I1YQM3) MTCX+$;C0)\))KSVU@]@BQFU MA6J\*TE; CW-OS<)(F,+4M@^&/M(\#18=*AXM][)\FW8=)STEY OGDD+$M:TB;AI"CP-?214DJ5^HUD4W.%"':)\__KPM%?@32 = MFSTX^5OP=LI:-Y21K28V?QZU"<2TQI@V>P2^@$G5>5MQ>A^927*\NHLBBA,]X@G?D-TY M??U4>L\8O3Z;.8'#<9G1%78U*ZZZ5CCAR%#[-G;;- J' #B]W7((\!8PL^Z MY/%2Y0D+CX0%(HDO+>FRSQ[]S>SN2&XF+8Q.O9U_Y,U\%**X(UD2MQR%[37G MP$4Q5TW:*[J+.G*7)K3O'RSBYN!A@ ]G&."OA@'."NS#D13E11^D2NC[#K87ERUU1CU3EAOT80&HY*G MYH+D." AO&8[ 6Z?AT=S<&:G3S_$DR'Y[_"-2[9MN9&FV3+@)MK YEPYNF83^E:>ERD)]$I!?"]L%\]3 M^Y'%+M:EH4O<4W^*=_ X"7Q2F->C5%^$LI$NSL)"PA$7M(\8MA& ZRDPVDN. MS)^RL2E\,_X1M17MMU(X"=N8.0J,/@>//C4AM$R8Q+_SA>S;7I)%"@(+,Q M.#U(03^:,V3O$#YY5A87=0-+YK5&&;YAJ6<(G)=G1\]>?W/W.#/4#FP>_MLX M)EQ&Z;@(&%'L9E:7\DYN3NPV!HM01$74X&4UM+7@89:#+]0FZTK)+4JI0.;V MQ%P_">,3@58-+-BTQ,%>M! PA)PO_9;Q'6??";6?W6>(0[Q1[%45Z%5QSH$@ MM_2((,QI?[WEHPP5%6*OY8 ZLVKE\W2\UH7^WB0B4?6HRCU$X(MR5%*!/;29,X MZY^ T+9]AS;80@0,F64F"!A].(BJ6QYI8(3T)\ MFKK9X&N5&T7 *W*$;H4B MG07IWFJ 2.29I$MAQ'D*NOOGU[S=X5PN2S0U8RXAV_MB>;4%A\!%0BLT11O" MC%XIDE![\^W(-'B0S-C,22'9TP6+N*?__8+Y(E*Y'M@G_)!A=U9]6ZS*JA=V M,FT)$F/C.A/<.D"> "$47YHH]V2JK5 LCJO#C9=_C,:M%2?/ V?)A9FP\1UG MWY1H@>['RZ?=V))6Y3M%$7N6HU7HZ-G*X]3HD9F\08C$(H3)OPK?'R>!L!1] MCWXV43\^;1)CW36UFWD8\H3L\.DYY3)A>FOZTZHT>,'!AHEOEP'\SYI[$)U) M?P&EUWJ-+;J9+=Y#6_*/$]2GBG& D(D:$Z.!WW6@FXC;.UE/)Z.&$9ZR"*)S M0XNYW283TC]*66F0&=^X=E$&4TYY@@S"R"88UU[CP(.XD$W2:( M"2< V+CD M,&I0;3$2(#COMC"\F/$U=H&@B,I MW"I/VJ5X!)%'AC<0$V ;5C60.V1&7J#\Y1:DVO? MZ 5KA99=G(/6W0%8?ZO]O;B^PUSDW0EQ5>>NH"OR:97!.\!)>3W: #1"!#^Y M-XT?T^=!.7J[S"Z:0K@PE2%HU&N;-VZN.@1_LW2T$J((]ZXTH-7> ;L+'Z]% M,OG6)87U]R:E5S1--QZ,='QE)*Z/HV'56P6%[,:PE?;*O*VQTF3K(G"?I;MT M(49[H*$*!,H, 945C)KPM49))2!(8T1@[*ANG153>47?I9\?^K8ES5X2[@03 M+G(PXY/KX58XK3L?,POZCP>:C'H$JD$Z%6B=.LFCJ@U@.^6$+N,M A'O;#= M K).VMK7<%LYBA*BJH7Q5*8%]S'E1F5LM;S?Z#V&Y5PZ-OSHRP842.B-<5-U MV?03GS8-I$EZ$B5UGKJGN[@=7T -;TOT*=3\4Q:!4-@75ZBO1^D$?SH/8/68 M,S&QE2/TS*AE<"2Z,G/!A>DY$31ROA,F:&B5NG$_QGT[PW_,4D4F M_L'X--$AH,HCU59$6+729^BT-TC2&DS)5H].&4%!O_YAZ(&&0WRK0 W23K=/1EEA814(,EZG 8SZATQ]:NF]MK*#Q%HBH(.5CT15FSY2UT8]58 MEZ?5(+K 0]+MJCDB<7OE7^NB>HV?Z2S#T-1>:W'/,9)J5>78]*#]9KV47:5V MZWZQF50I&\<0MW-?8I_:X2PZZ?ZR_T$"0/.BUH:'@[81$M <9H]T84\KW!_+ MT>V+=\H$)\BTT(ZHI6QH ;%!<82VIHF;0*52-7V(QC]-B6595L%.]\U ,M64ULT@832\ERBT>: MV^,!60:14<(RST5=8WY6SFG7BF7RO-$L10+>A]LE$\J-G%UV1[XIXB^@IP < M>C=J7YLJ0?=N 0Y*+#@]K6[J(^D9/+I.S<"G:(N#^B(2K@LRMEXA]RK+<3)> MCL^/[N?>,:%GOV1A?.(!]PCE-"T=CRKT &:\WZ8<-CR@!8H^>ABJI33B5C.6 M.Y;%H&8H_7)I'.J,AL7G O*G3L^FN=25?GCOWM]\D[0MU 'M<<',6UT;J#P] M.V>AZ$X.1@TM%HG/7JRUHI*MW?%WW-42O;')!$ M;W2TO:Q@K@@YZ$)R6_4: MFQ];76WH^_9>.XS#B9&G%KHOJ9TE[5E$<1MY,].QP6X./1-N@]::89L3L,U' M,VQSAFW^9Q(T%K++)P)-%GJ9:#LK@;5F"Z70E5;P-RF\8 756H*9XXZMA M>4%ZCT'C317, NB7*1=-!)N$$3BBXFL.U)'I$M1CT+1XZM\8>;XJ.RA$P,MS M7_^>UFY!SSTE8Z52<^J!E$!JIQ&H*>X:TJ=A.7K]T@_!8E+DKRCY"VD4::EE M+^$7WK_WX,1*I:/PZ>E4_UN46Q1O71T5&)'>=[X+6):P%;361=E>_*W\#Z>MLZR M9!I>Z)#\7<*=;7L)>7J%S^7/REA QAX^(7T$QQ%9\*'E):T73><]&@@YB*L5 MP&1L!4]-2@1-F.@^P_;6@WO:!S%YI17AWC^^_^AO/B"W*ENR%\D,6-ETR_[" M5SSXV^A3QY=Q:3*[G8*#12X/G;;'.T9;CFCD=AS6-D]^I>3Z/G9[91TM0UC= MI6&X2;??;$2RDNG1-,.OD?1;16?T_KXSBDCG4DIDHE/).5# DJ^W8GM%/1A" M7"6*CB@Y2\2/HB=*JHC*6TGS,#Z\M:>BSI>9(T/>5-;SU!/NY\./5//+,F-0GXMF@T[ MHI.5::/OS'GHY"FC0Q7'_9"K8D_>9G\KI#80+GHO]$9!:8.9SS,V%7&U(8W^C+2IQAF$X^G>]!1+9+8R#(;+ MGM-F/^/JX==,0O5,9^N-KW,[U;;0=YZC-?A++(FH3/I9?A1HAD19.+,7+Y_B MP+B&KO.QA5U5+ND[V3T\CW'3G-IM2;&C60OGP2*.. Z++I"@O5:/"><"\A471:/SX"P=U M3B;]M?03PV?[Q]-B]^LJPM=).:>0U423;!@Y*%,CQM"\VRZ/F&((PZ;L9%>6 M6M5#(F];M)HI2#?6?\NM;$_;%N+) O%(:,4V?>8UCLT=3KFQ?&0G6+UN+!50 M#Q3IPQ2=$]7R1E6\GI\CQ4X"E'K4\8%8T#X EZ).@LD1/$]8/5F>5840 &? MF=;J%-*%*B10=F93:;G>>$.,# +F"H)C @UNUM;>R42=*6)@]6A3WR?Y7496 MT:E^BS[(3OD+F1>#B/N)("Y0R6<';&1+,4&XK SAZ!N=H?^>?+X\Y.[ M/!JOC[.']SY[%!YR_X$\1:;I'Z2B MZ;;K&NV^:?-L&MU#%\4V>XZ4#EO)&/&=;U]G)Y]]_MG=F\:^=R@^8OC87O]B M9?Y@;B+]',=>*\]I\FE%G=,,O+ES&%<4007XH)30/$!@?.CWU*NWM++MDATL M^$@7&J7^]2LI9C@=WU1%&&Q&G.?<.)R2T\'C9=M4&/%VRE-V"N+$!!?;/G84 M3^Z+Q!JU*H9P84".)_3S= *6^6.F.:8XZ2-V6/FM=("QZCY-/FJ#]Z6E/TE1 M@QHQI^63_E]1'[&HZ2:[N7B"O#@3=XT=L[A^W\22VO+D2T-&:@1"GZ!V#%P' M17<*?#3*RM:1Q[!J%@/OP(@O:,*@X;2D^-JYTB"::Q4%73T'KM<4%H95>(LG MYF-&I@C[23XEHT<8HNI!#&*N&+8S6E$#).$<,3;CV#(JZO>/U ML!K*VKUA[ MM"[(".LIJ:A[%/6/!"IX,35Y5M:A@V MG!.N?-LA@WW4TVV@9V?K=CE;$Z33QATQHAH.J*E@@9H#=G[MO33#(L5RU?!F MO2!).(:A62 &W?7+4Z )?,M*E",I-346 M^1@!:R4^9P/4!H?)H"(L'/4]U(]D.N_?R]B4#YYI'/_$P^+>-?$D!\EBH+0) M8*<,>^2A1B;0_2\LR?>*GB?=#+_"?ZR[,(9K6=7G_K-^8($"9PKBZ((N8AA> M*/:N]R9K0Z]=I7#?];V $&O0!=A\DC)I]KD2-T)W-UUK^]2)[SQ]:C8L=B_GEX_,@HZ610P>SH8JWLFF MAR%7C*"RJ%S4E)C)SC5<0$];=D*K1V< H,HP.TNX&*H%^?D79%$S7&:#)+$P M?_/6N2Q!EG/!<"([EFRC&VNCL9F7K\EL:CP1ECD81KR&7-(VHD#QS;009$!=%DQ9?'[E@]Y'=Z6.^R MD!&GF"U&,5>7BG$J.Q2^K9OMUG!+([S"GQ0V.'11(0>FRBV MZNM5=J3I#J@S:CT:(9"9V\QZ@"G7*"#27. 3893WF0\A5Y.\0WN1CO/B(S%G MTL-7Z%FRRP\>\(08T![%FY5F4T(/5RX0OK=G>[U@=-%OQ'\\:SD+(P^T>>*#7%8"3R^SAPX>OGP"TYV7E4JX8M$VPO4/!YF?"31U$8&]IYAP7"N;IVW*A>V-/WFH>\)NF[5&[(";^ MGW3R.G0?S=M92Q:\8U&8FR=)!,!NS9PW/7K.:MEVYX@Q7_@1!9*M,Z MM%>8B[1^59&"4" (I1760M,J6N:G.M;4KZ1"F0J["1M*BN:"!O51*T\NLP I MNKBOYS1E6C 9:+3G-?QX9*5O%F764T =8%G(]QDN!L0*G]>79=NHPY9G9RCG MK.0T?\.N'+OO=YZ??7,7Z36<;OR@_[X;FEL%7U&]K2MW+B*ESV*CYA=-VG]H M@M9]O^V^_/O?R_J23#^XHLW0=ZY7B^V8C,"_NWABCKC,M3JB:3FZ\-/B]^;@/6KD.]0V(+BQA$S@[VA:X"E[I\'U%5V)':J) M/MJ(3Z4>1AX[TW!\$G*+-^#%ECC-J^(Z>[4NJZ9KMNLR.-JSD/[%"2M1B1MM M&"/<-& OMV3,.?S27J9>NZ2! 8N!XY7AR^TH>6=8?&&K"N):.[2GX/YMJZ+K MC_ ER'%[^<8T\*U;M$/9^R:%G.!QU4)2JA).6X"? "5U'=^B4;&VZ!-U2S6K%=J D5M#^6I,21U"IV156TVD?1ZAX71;?.SIMZZ'P1?%\J MS#2D3@4=R*&=>"@ %_"&UQ< P,+^DU'0\5CJSK>+X^1\= MO4XR'MR>BY[0NC60_Y>&#N*>=HNWPHCMY(GR0O5GG'1DT=_-0:$_A!)]%1V! MES[BEW/^F=;[603T9GAB?:&7S,+KTV!" M U59B050 Q]6ME# D+P;KKK;N. M5PS3 &0RF@Z9<4 >'- MFW)YQ..;?O.KHNM@4^][<_=6VHRGVU@%O.]&",R2D8;PJ^NQXVKF6,#+,NR3D,IY(4^(5 ;(#*=*RMZ=]- M9T2XYT,)H"B-BW?>&$MTI8,4)U]02\:D06:V1IM&YSW9GS[K'0855+]WC?N" MG-P>WB@7U0O_7"&59?&CO3U;B>^*]J=\=;=UC"M3IB&//&[J(T5OVL'U\<_9 MH/T56[?KR9J](!3/?J-L&F%_\#36X)WCN'E2'7WE/)U0,#>']M)=*[D+[=?H["!JKZ:# M!&Y\N15PP1#^ DZV[9W&?*)D)(TB"1!ILM38'02[8@,I[73(44O#.W,<-\UQ<%:SO"TP[HZ#/ )]R%]>S=/AT09F%\;YSAF-H-=DF8'_,^Z7C M" L#YQ";00+%!S]6#D4#R&8YJ3J!>8;_1F'9I9I8#YYPV4-3LVR2SD-EQ"'$ MQP]?)VA4AD4V0DG-*"B[YVI"QBG@-#SLLM0N33BHL96X: >&13&G).H)+*O' MY006":(9,BUY)0QOCEUXLF1;=%19VDX5V#$2BI%RO?8-"=C]9XS;57$M_0C' M"\!Z7LH^V%KF3_$Y*1C5W =%*L+"7@+#'0U!*_%4NYJE,'8-HD5.XAVZFL%5 MH.7$Z,"^8X [UM_H',,O8!(EDK@%6G:CI)&F!T'L92.5>KQ79O7]L28[B-+) M39'B6$2>.,< !.>%P8)5_2VU%P]XEF*C4DH.,RE+].+4!7%:>G':J3CE_;)T M*\YS2(D^_+Q4G7Z9G=S-R*[L>!M=T1]K+?NB X$#M2P[N)_*$FB%A%)$=/^N M0E;IR/G#=8T(6LM]A-EC[/IA:16@Q?*R60 3:^T>7&"_'=%S62F.$D+?+"=Z_.LXXF4H*!2OEJ!8P9D.^L:M?R"I?5S17A MR]2&0" 17+#1L0YKJT.JBBM#E%X8?P:_%!!5;F)"+UN7YZ!"K*_)^&LXJRC= M[, ?4 OI N@PFM:$"!,1,E=A>QM"=3,N=0*7^OF,2_W5N-0_LMKYN&VU-"?X MFH76D6\W+]D1!/!Z4 MHB+0::'/'U(Q5TJ@LP)( E6DY"]WG8 P(G+?JY'W)^^70<4X\S.Z_Q]DT2.- M30]MVKHL//*/$Y#TN;0.1^B*QJ:-%$JK;QA5_\*;O2"3ZM^*40TS[8FJN1+6 M!FL''M?QZH#.PTD2")'YS@)%3$JR3(, X '@]@?,F"&WYEI.W/'K7_]7L=D^ M>69IW@AFSS4^[&!W?;%:\5RE34962D>&&02S:.B8@C[&%@SHM4N%ET1Y1!_2 M%8BNA6Z27-.K(2UEZN "<$0?\841)=JR !TVB">Q9-SH9.T6;V$/HD3<;__> M=;U8?8MBXP* =^>#9'K\]59BY=FQQ+H5*BGM-WI9+!;:+,+WDJ3%X%B&0L/# M_;XXG?O0U)=DC!J79+H1(HYL_Q71FU#&L(@^Y#A[%H@VN?YT1/0IT&@+[!16 M9A_Z[,7<*T<8L$H$*Y<8[RD)F-J0),^70K&M9Q5_"NB_.:]4A\8B0IVN]CM$ M1BW"J]"N2.&5=7,5O2HD/,_)!:@E+\25X0BS"/!71&DL2Z ]%PN4^K-L8/*L M!L.X&$IT3JG3\C8D?S;X!S\N%(TH)$*8R5HCMF&&7 915=S^5#E,&;P84[4U MOG_&OR/PGJAO3>H&<*,_[4=R9B-!Q2%KIK.@[=2]3P'X"Q) ML#UKC_-I*^3QHY,'#Y5G<@#2JG+;-7)RVM^./N#.9Y\]OIO=?W!R] 5][:W M(\TR8A2>\W5'LXSX%#*"#3&0FA1]6EH&SPFT(,BP%["+SSG2 MR1J9[_=\?]=1(X$5%S]YKN SB1B4"KXVNIOL%+%:QFQE=\Z>G]Y53@![]W+) M#9%(BAQ:>=O5U=5N0=NM*%;;01S%JUUV#(^P0#L7>\F6$5)-6B,?$T*$WNY3 M-A_]/2=(E2>&D_/8#=%FH(<<8,4BEK1SB^.+YO)V+.2L2F^?*HW/WM-S]'&' MP(NX]=@<:P^GY$^?<&O4*W-$![Y%UE DI1F)R51L8?X7"&4(Z%>(3E.;6(D2 MA ".N24]J'^IIOQN,>R7HX73 <@LZ'S]Z^.AO6.:_]\L]%YTH 4>+ T] MAG2#;0<[JN\;BKU+=HF]C>9BG^BVT_8+\I#W_K"B^WNRIZ/3/;G+YHWQ&VZ, MWSP/9]GL\>(C^$E__]]_N?^7>2/\B27$TXM90!S2OC@8 3$O_KSX?ZC%GYC[ M@]D,OQU<\&-VRZM&.J+Y.Z8J/\D8F/^W^R;W\_H.'^?V')_$Z?M2>N9T2 MX#"6?!)!?E.\9UIZS&O\Z:3\KXMWOD_.SRLUK]2\4O-*S2LUK]2\4G\ U^$P MUN[3>0:?QH^\G>?PS%)Q/V+Q&\QK]F:6@;X^:9Z?KTJUVH8$,2CM=%V5K:+2OFJ)=SLF$/\L6 M^;XX!T/:T_7&3:[ZO)I_'*$\K]2\4K=EI0Y'0C[\;):+\VF;5VI>J4-8J<.1 MB^)1?.V[LJM'\9]U'6:_\A"6_A_-NLZ^.\Z^:FGX;C.'VOZH\G9>HWF-#GF- M#DY.)^V>:7FE3J$E3HNV59N3BG\>=;]'ZZHCWZHRLO2M=EK,)B]G_UD7LY;*G#G-9K7Z)#7Z'#$ MXL-[LQ2<3]B\1O,:_9FEH#@%;]#&B5YZJ7FE;LM*'8Z@?'1_EHOS:9M7:EZI0UBIPY&+XD+\ M((TTZXO;E%KX4Q L'\Y..>O=IU'UH,3O]%?\)?T>US:I8_ M?;//_5/VX?-C)\'/QD&U./WM>IQ\W.ZZ_\5HYM;>+]\6%TX$PA%WCOZRJ*Z* MZ^[)7[*_SQLK:1&J_5U_[[UVR'),+L:80G.5/<3*_:2[?D M%KA#FWF60B4CW$]46&0;MSEWS%6(.\_!58@?0EO=KJP7+ON^N90+[]\[>2BW M=H'F$+_;4[;X>BO::K[]\_SEYVQSK6GQM:HR73(I)NH[F]SE9ML\E^ M*MKSH;W(7M'M0Y?3N+9M>8DVONY?0]G3566[R;.KM6M=UM'=5P7:_T9?5=;9 M:_EJ>C\_\V71+M88[_VL;\)/#X]I?LJFQ2_1%SV/AJ?32,_JW"777;9-17-? M]-EW0]_4Y;OL3K&@$;5TU?EU=OHZ^XJ^^F[.$\F-YK.ENZ3IS1;R>;F,Y1]% MK?-Q<@\OCB;HY'Z>;9JNSVC":+!?WFM&JZ@>8J'2Z-M:QIC-^ZHNK7[Q_VF=OVMNSW/L/ _S'4#C\\/L[. M:!F*JFMHJ>C>9NAHZ&M7+;.M]M#JI*?\U\V[;[GC<\";E#2GR4M\579]/%,GC;MMFFY:38&9F>+$F>JHXU%LR(KRZ_,7OR(UW5;QP;J=J!1=+0E MHLOVOCS^?MY#/ '=S#C(] MP$^'BX$TE9[@]E@?,Z'5286^+%C_W\.CQUKLE,9(JK5R;V\O07\#?*C=[A^]6*Y(C$)[_&*IK_0!O!F#\2&%&'Y!'GQ=F M:-\ 21]]\>Z+G(:Q.&8=0'[[4).@$C6XK8I^1:M%FA(Z#A_-0N4I&3D53(#' M]&K:'1?KR%"X?\\K^QM>^V-#GU=PH""\, S$7@AYM:!=SK(S&9W,9].^74%# M=TTUZ"-XA,_()@EFGPTRC'O'EJ(99!O@LFAA$F25*^CUW;K<1F8!K6>Q6-!I MX,0Q!K"2+\KI3XMJ6/*O2;%]_0.^\2>ZPK6KH6+I7\C(Z.T/\%H,+,?%5ZZJ M;IRLFG=H;4\E9?36]6](F.M\V7/O/=;GDN7ZO&@KU$_1B-=E!]WNL'IA;R0? M&[Z0IIN^A R5#I]"@]G2;\OSLF+UTF?/VYK.T7\5F^V3[']H(BZR[[Y[)0,X M>?SXTQ4+&EC#RZXQ)%5YWQ6D*FG>BP]1 M>#^MR;2B+2(Z+X_O:%!26-?==759U&5QP&KO=@GH*;VWGQQP=IH_GF-Q0OG= M2+;C;5@1SA^B/NQ-P:TLLGHP?]N[EC]L2!B3] IB&U(33XS%MS@2+++I>XH+ MMV$'G]S2C?S6RVXYSDOXRAAQ#Q&7D?XA807_!D(LZZ[)ZMW(I5LZYIN"S/SN MRRD!^IV[*&0NGKGM0&=_/$T[KN+)8_&X9:;^ZW^]>_"Y>W+SH\UT=]-/]QJ' MG=#T7?[YO%HU%N69N@V_X UQ@.,$+PFOC)8Z+%6\OC!'S ES8??TN&!!^F^D MGK,SF?RPWK7KH8*QY&$5]T401#\EX[4IF!S$USA\=.?W\I)?]MHH4''O"PX M1..(9SY,+[WRE+:6[R\9%]>.(US_>/XF5Z"8YIJLE,27W0^2(_E MV;/BLJ0I"F[>=\75 6NW6R6#IY3;/F:KV:O[:'ZPO6Y=2@*A"NT'$I1RW"PL MHT^9]NIBN?/%E$RWEP@PE"3*>S5E>&48]+>D 7'ZOJF:];HA M%R%[):K?#9SN[[QW\4B]B\?)CM@5MZD<_6]Z]K!XJ_Y$]O+LIZFKOFN&LKLL M23A[N?H[PRH.4*[?+@$TZ;76R5\CO%O6JH-?4C87N]#'[,G)/ M-\6_F_J8K$$O4^O,522E8,PM.(C$806<]475#$NV' <.Z7@;4A)V].P;7* O M8Y'UO*9E>OE"36#_H7I280H30GG7*HSJC-W/JB*W4 MRKTC(^_;HFJR.X4Z1-D5R4D@9S1)'@_X67F!+:^AJ=."_MU< M^)DK6.BE-: ].Q2"&BQ+B MQT_H^Y^_6ZR+^L+M?.C)CK>B7XI'_TS[J>,/PS?TM.G?D7>6/6\OFKK9E(LD M-!>Y'B-7Y"3=TT%/T7;R*1]52LGO^+GT#8O'.,[8 '&2DLR*K7Q@6SHR)/;Z M ;^WT7_P>*/',][HEN*-;I>JG#)$;F8ZF$.HOXXT8J\=LE,9.($D^OQ#HJCV MHJL=9Q/ZEW/X9*V0R; H(J]38!GB3)T5E>K_Z.^D+6MQCOKLZ3G6@]3'MB1' MZ5UV!VK4M=4U#(;6,?RCY3]RSO&H61UQ%#4 3';"=9)F/'DTUGZ?3VI>^\;] MJ<: =,"87_H(\-]_^BGYZC[["IYD38;)XFU9=X(),13*%#!D BREIL[)(U'5 MYIW&+WKIWI6+!N\[VY3]NC-DQI3OK1 1,FE2-$SG7Q[BFF$@QV1C?1# ",G? M"WK3MZ3V:7*Z:/F^ 5;HO.CID3J^*2C/)IE;/S%/JP7-XW?%.4*J#9D #$SK MAG-:DQ*&!V\_\OW[LLN>?I.MFL70"8K'73M.%B*"OQS(QLFS'UT]=,6'OQT3 M_[Q?EQC#G7]PJO ?-^"0CI-]E$!>)GSP-V0&\V9Y7F6O"IKB/1E 6HUN7535 M-.PE>>19,]#1;>LHFCK'3?^3<=.]1;6S2OL5QR-B62R3M@=8P^9X' 2\H7R\WWB_L(\?IBY%^,M3)]%!^ M-%0C>)3D0(];KV 6$XF2R =_ LHF[BH>!ANP9&,!X$,4)+>N,K@D]_[_/1U]$K M66%]R^[E(@I6[UVQX_&."9)]7Q3V9=%UQ6)-JJBG,3W=T-)U_92 _PIP8W<= MW3X[N!\I11[0YC]QWFVM'6\LM' MNFZS21N._\[9ES0:IV@;L5Y,YQAEPLHT@N& 5NRGT9>0UPL?=-/0_ZV&BOSA MI>L6;7DNF1B\&_?XUW; 2).-<>YHH,?D ))?*V.E=ZV;@5SO<[H%F8\2Q1WU MST,M=[!9L_=YL#WT_KKIY1E528,8MO@K5W*Y=^N"+#%\BKU22SXV!;#=J,6B M9W=X..:0J]74%3W.TOFU]R_XE63,#17/'9+=,,GB>W/Z^W;HM7JF)6>@'ERN M@&1^*]_>B5E,[CPFG7_<-!@&?-ZLI/6@7W[Y2>3,;Z/:#T/,3'FVKWF97SO: MV$A,-MD/J"ZT2C>LPHMZ25ME1QPMR\L; @S+LMM6Q?67J\J]^Q!A]#-VX^J: M9H=,3UHWW$=#)3?G"<_J$>R%[LOSHG.X=[0&G\FJTB_(L^O77SXX?O#@P=]N MB\"RN2IKGA:>LE_T@!LF+YZ31Y^?W/OBXIT/^?=_N\VP]C[F2W%UK90CNW=-6H!6HZ&U%"38:>KFS3YO]D/>[*=-C9"J M)'.-P4.='ZG/1'+CHO()3('YC>\JLHJVE ,9 _Y0T#_'S^)(,UU7;DJ8\P'[ MMZ#Y;S9T;N:C,A^5 SXJ([U YCN.0EES@@I8PPT KIMF60(=67:J,N9=/>_J M ]_5",*Q2<.>:-DNCY#$O+-SHY'&&L^HVY>*3GL;/_A.'\=Y\&/^TAQ'1:PDA6\Q[[T;.L[J@,U-4 M"/C3W4<;U!?3AQ9@,9+CV)&M!9 &3+">.97B@'%XETBH(3]%/\YZ>]_1MV].;K0,# MK'&W5=?S_IWW[Z'.W:[I$O:M,C8)J?'B&BXNVR\>';,L^@)P&?*&Z68&NL1^ M\,B))I.?+)O>,:!GY8#LO2 KINMSI9ICV 13WLI[ Q<=W=(U6V2GP4;DR'>_ M/D=-3T^S*('?.KT:IY 64:[+W*(1WHSY),XG\5#G;NI]7)M-H(T5/RU@! $U= YHW M[_1YIQ_P3O^Z&A;]4'@*.>S=QE,J*"A]WL/S'C[@/?RJZ9EKO$KRMB"$$'HL MP\YQHQ7.0',9<>FT F:-MCA<\ (FKR/LL&5P027 &3G24?6LDCO.YV,^'[?B M?)!!4UYH#5)P32W=Y9-;=!"*,5 M>G_4SBVCYD'SEIZW]*'-'<#9<&,;CDIRV:];D;#N.\-6>^1TCJ9KB[4TF<'8 MMQ*LO(",EUOC:.4^?.]&:G-D3 M +#TZ7SV5!"[7-(^8IEK_8;FSFMT I@P68OIC>5.[O8P.AZSCUT_\=J?0WZ2UB&5CWZHX!/ MQ?H=*,U=5*!]EE?@F\@7+:HH%(YDJISM0.*G-O-JZ(= [I(JQB"L+4@2Q4$XJ>]K5^CY7:.C M>Q(GBHS))C VU$S?8#VNEJP%?$/-'O0T7:1I\&"!'(]513><;TB%L:+0SZ.9 MF-$TL[%XJ'/WE__SPI>FA!"C-'OHA/&AW)P/;2<-"5O&&L"(\@61W+!]([4H M21/"UG&[BHTK@,C_M-'Z^13,I^ _?@J*)8A3G7>6M.(JTA.L\]2=,!VP*LH* M^UU*N*J5DJB)>P$-I1?(X6(MT@V+M3U]5AOS@;D-!V8"SF]&H.^75UQU6L 5 MP@OT[Z)E.S"HBEP0THJ?EBI'14M;4==EV38+>+IKMM5W2MP70B:TZF/PC!%KK]F*Z9B'UB834 M5:T=6LF2PPY 7X>FSL[Z9O%V#JG-O5]7@:CD"@4:= M3P :I1@CRL:W2V,"(E"*,UM*-YRC RG':\,]/ADX;_YY\Q_JW,4!*[$LT:MMJ'INVGU%;AO^Z][1F\FP]X-Y\-Y_2I MDIYLG="U[F8D@Z^/[DO9=C@G<9WV'F[&'!J*I_2T-AP&;;G$0C4N^U9QYR3D M+@VH0Q.XJ!JFWM/K.P/P+-QRSO_/!^NP#]9N?PBF/);L)9^,M^X:H;.NJ6M7 MI2!D"<^U6W02I_U/]BC.P;SAYPU_J'-GJ9.QY@C@%XTZ% ORG;K28]]#N\)9 MH,_[^X#W]PWX%-A/-+Q6.0MR^<4Y.F>VU_K3IJE)WE<%?8EKS<@QZFT 6^;= M/^_^0YV['6ZP-OMY6%Y(U(WA]]C16MVU0!P9\,9BL:"A2XJP(8=A#B[/F_R@ M-_GST&LSW=;/S[ZQ3/@OB??^)KVM?[>([\.*TU]"2@^V8@)T:XZ?1PWI?8U/=IW.6+_Z5R/:#X]BR$299<]K6L M%X[ MX?Y/<5DA3$&'H9?0OW^Z%2#53>_";ZV=->S?OJ(_\PDY63QYZ=/+\IO'3[KL M6=DM!B[TX?N?UEH,0=_WM7_UJ045^9K70NK%P"1?0RM/7#Y)\A?P*'D"0JK$ M6LFNRLJ%*3U[?BK-L:6:R3<>MS5!F4;<$IRG76>:;'MTZY9V))6R$H?WT#8Z MSIX&GHU0+S74FJ]A3AD\@[;;HNQ T_>V;JYJG,!!X.[VN,70ME+@NW2.FW2? MHR>*]?[..=535!TYWO0BI]ZU_!%5P9H+39J"OUAQF9;LJ,[F +C@-M_I >ZG M/I0OCP+!/@*L?<7/73P"IAJ4<@#\Q$$RM_1[!Q _H?39!]B1ARX=JLK<\2WJ M)/X?JV@]F)3;P9=*WY]+I6_EQCK<7.X$DG'9CN']\^Q^ M5*;\)Y>MBTM &29[QTM2YLII__BDZ]U4SROO^/$91^R_V;+ M??>$VX[CO=/2(=?M0T?<%SJ@[;79IS?MO(X^ESE0ZC[:M#?NQ)W71_?1UO_K MR8.3X\<9C;WB$-Q?3^Z?'#^RGWE ?_WLB^,'_C?VKFM7D+O@:O"*/G,+QPV' M'YSD&7FS\O_WY##!4I>.&=:G@PQ:?O?$;5<8+;WRP>?WC[_P[Z0#L2BZ=<[_ MGP%%=%E44N]!S^W)V.,>&_@CAP?7Y(DQ&%R&0WM$-!9;P81N$M'LUFR M/_37S^Y_=GS/WGF#!@SIP[(%;K.>Z%F)N$9+PF(Y5LCECF2D#>2O);\/GC>(ZK%QI;&(M1K,Z>8DTT9/ MH9T):6GEL2(4[#R1#'"+0KL5EARRA8_"#J5KV5LM ;' 263AR:^)=N2ZZ'Q+ M]KC#^WDKKULT),Y[EC8O IMF;ISZGB.+3XSZK%+.+H:#MA!R"%:0B%F\A4_< MA=DZSD;9%Y,K?J(GI^D73!%'%Z3Y?'T=I)(:-TMZ2]5LK9I&5%(>VSVIH'(U MJZY!JN]IDB3AB9\2ZTGH%^U;M@TN(VG"HG-5-5?=!SGV\R&<-%;,_H"DWM.= MA]4NZ?^%Z%M=9BBQ/*9^"S1WGMN'%=3(KO%;6/:MH:(" 9$1>G[HA]8,IP[SKWN0-A"M%>'4;D+Q!%##BL/K-A8(@605[I& M^,BSYZ<12V*N)E'3A@6M=(I33;:>K>7BNL6 _9D, *0 M'+?=SB,A3Z88Z%S+/0_'G3::40E4DI%%(LZ&C@)&?EJ M> VD'I:L:3F7."P64>UU"6N;52GG36D^1+"WCM2U\!$NN!G**F5#- 0U7>6; M/"ME;S?'Z0YN[WVTZ8NV.+7ERAD^CW1GV HH9E9?9NO=/LNEJ_-'CVC+Y04I MV'^2WJTRLB?)*_/1+5\3AU2OJTH),173;].("KWRE&:0]&Q=%CX MW<$I->: MBNPHT:*B]^0I:YH>U^ZQ#:OBG*V&)1MC3F9(.1@O9!DCD,JES>OCH7R(!IK\\^6I>GS?EST-1%WGVDGR!16/FA%/% MSP8:;2S^8$$U>.>@&7J),RTC R8RPAD!D715:LGM?WKZ_=-% #79Z4 M#G L6'J)E^&K_7>B_,/OFI&O8*XT/9J&_*^!ED46(XJ?DH2D/]"&*7E&.Y1< MD?4IHXE=A]&6C2>V7].AO%A/+H@=$QJ+S/!QEKVDR?"K:]\:/Z^QU>"@2'/E M$(N6]'PG9ME-(M>6UX>#0BA3;.$0+9#8Z]0G27(-WY-.2=5(DV;_/6+IKEVU MS3;2,L@)G^TU"F"Q>]9%53FFYA3;TF]X]A6P4?%9"EA8%"2K:&&!#L,V*G%. MBA*!$Q98=!HJ.D2M@2C"\.GL?4M3=8E=!N.8(V,U>2(#O-3>C1R!B402'T > MGX>.>R=#8]GC2WR0V?CC^(*NP )W\:$_SKYNX)$5Z%WM,UHTB*$>#X.5L3YA MITJ*G?W)$R^\CG*\]/#;4](]H'Y0Q_Z(C3]=Y2 J_.R&%4^"4D67>G@==M'/ M@C1AMY3.UK]U]/IM<*E6;;%QHY"TAL$9'=2Z *_A2=)T32U@F=9QV($7U)]0 M?T!R(:=D5)+\;2DH%]]DUDOM.)07$',2/-JK@D <@KY=I-9W@F:Q!W M'7$X\YT[&BH2!A()C!O0:4PBBBYX/,ZD8N7UG7IWB#$4P>6WKS:BZ],??GSQ M[.CD<888D-N4B]'F7,IH;Y*=R0F/OX0>LG#M.>_8\^OP*E(6[.?X"KN^6:#> MSB',@JN]M&*9#"S7,EH^>Y\)!:R+J*IPC4F(:96MD*>Z0QZF&"G$2(:*PSY[%%)1^?4%[2X]?=/>F>*MJ\G*H M$%+QPH(GA":2?K&Q686N747<3,>&U1L'MWT9&$] P CB$7A?:>X!$]34:3#0 M+H^C\JI9:.+.7>U6R #0DK.1R;]5:B:(CK6 MY6I' .,6/J"Q%*(EX]]!TE37DOY*Q%(Y\;KW3$GN-<<(AO!>1RM/8C1C1-ZX MJE4B>IGV#$'K]XD0D7_&!,KP8\,ZAYP#G+W_][FR;T2K6:XMI!8H%4!8!0UM'2C/V9\_N-WT\?EDVS+13F$7 M"@HMMR!1M#'\UH()6*R0L2BZ:\EK%&T=?APZ^INE=Y!NKLB,/(>AX:40_QXR MC7ZJ. &0B]96*(QF-64+YJ($?-4_)Q_.W4511R>@_'=PL=0_(WW$W_#/FI/, M9SW7&=$7DJ#_0G+-_!!UFWDRI K//]/<0#@M:]*%V@#8]Q7@A]V_)[EDRV;' M#Q## ^F7MF26.' %=4@8A!P!DKN7134P)"3"TR0J@!9_6:KD#\DVGJR.)T23 M(';=FO2(IKU9CY*RIDG/]QQLV02RV/K)32OW\>]@KN&)*] 4:1>LD/.@!5^R M%=\YL=C*?N"G;DA%PIAB?F:+=I R=8PSR#GENZB M=4[$A_U7*WVYZU6NUI+050J)3B[''A? MM=,$Q-Q0_?/NOXV[O[YTM?AJC)@L!.*L2&?9[++3!:,_ M[_1YI]_*G>X-\CI" 4T FCW$..IR/6_O>7L?\/8>I5C4FY74H?9GXV9N')+J M$-ABT6^(=!^7,N=UYZSD:9OY^!YDV//YG,SGY!:<$VXA'5 0'/"_+,HJ:E>] M@#.+AM22AW3_&J1$*FZXF[3:983)MKA. Z[9!9[#S1&S8NC7C32&F$_(?$(. M^H08/H(>V75V-._T;VB8V^R5P!OPVQ^B3A)==N>;5S]T=_.L<^ZM\=E) M817(J%$&%"J?%-&JF3> ,#5@>CY<"^'=E>0S\&=Z;K;A"O'Y$,V'Z- /D50% MDEYQ4F+GB_2!!'9MG[0_ 8Y,VTMS.VK.2,2ED['^@%J:M_^\_0]X^S,NH/ 0 MXZNBK1FEB\D0O+-FUOSYX$I;0:Y)F:V *W<.1702CO>=@H/!5QU\V=[#N6SO M5Y?MS6"KW=D+#)7 XCBM:%8LE8!) M*EW,#B"& MDX\T"$'/;K82Q//T$X"2N\6ZIN^_*)T'JP(;R[7+:;Q#,/V:Z^2_&S >).2M M\R0?0 !]3:XC%V W<_KTQ-H.L6^.!@IIEF3F&RNXP=#""_#>L MA#X0M-#!B/3;!9G]*>5X!2U.3 ( A'9562 \(8&1VIHJQD B&K*?"J9@&@+7 M.I2Q,!:>7QD![ .NL E8S!E?>W!;[Z/K93]P@W53-$.\A_83,N6APD7H+982 M%T@>6]'\.2ZAV?A@A3$3641\ZJ1KW M(P_$4#>P>0O(XB%CP/"A#T8BV MR?Q"O!#D\C#D9A5Q<%OO8QO'9R^9)4S80!7$7G3>^8\HS$"7>%R 0 M""A^= Y:#+TWK1?KMJG+!6U@)"E78J"K_FB$S %E$B3/VF)55EK'[VLS61&P M6%<"L:BLE]\N0C>IQ*:C<-& _F__D1AW0MAM:I=;1SM12&AN$*J0N-K"JQ\E M3+H>/]1"]Z'@EU:R#2#B$/[J^7"0TP7ZMV> 40D_+C"<(P'TR(; 8 MU.ZB$$KGN&CW8XR+X^S4W-;97 #EG #K$K_6?$C M*?#L1;TXSN[(#W?Y]J]!NE"70Q<:\++@[XP()O[NL128JB&/OQ>ES9 -?#-] MPT5;&+'"VA45*!BON]Z*V\NZ;BX%9>E?I!]JM HC^A>O!K7C2=G*TMCE"5[9 M*OKBKY F_KBZ$-S[5EQO*>!JS19%=,5Z/:)Q04OYT"#?-FTKF'E> $$T?X) M%&=./*#*-@_-@B.GL7;*)CW8!@'7\3BOJ'I8O(%$T_,.> E!0:'P^"BSG)MEX%(-[X*>)OK"GF M\-OA">-/%GX[=/:,V;&W%I+K0[89#%,(8Q*\O9 ;[]U=$91T4,5E MQN@$P9#4+H&:_#_4?WR#QNJR5215+R;767 MG"1^QVQ*]-6/_Q8:CD6CCYB\=JKB\^SYT)+$Y8-Q2EJ^8(?#M]T,]:#-*OY6 MXUW:DL^!X]=(G?5E45VJ\?RJA<%,#RW;Q5#VV5=-T2ZSIUWG-NC<[QV]1Q\X>FG='EIC=M\*NG!)6*8?;0@J.K'I_Y4.!/R,M'C5>\U\2!I^T MF8&&U.D[=Y$)P-O#+80@*1X"QU21GY>(+KUE&X)RO2T]-Y MQC__%^:PEAVN+-%L 55-?2&]2U3C%& NV/C@#+O#GJ!.J")*Z7"BP'')!DW( MJ3U2*38O"Z9_Z+AD[RJ(P#V*]+U2NF6&0/;F MR:!#Y"5D(9HV4LR2G?;DW.3;XWPK,WD]T.Q,J XZ MBZ(SZCV?]>#4 W0"3..B'2TKR]; )/'!'YVJ!_.?/(N6* RSD#L9A#)6;< V MJ*THHXXTYL:PM /1N/]J7YD0 ^>,@^.#1IOZ"=XR4BZX$><@)IDI#YT(5;@] MW-]G+_^%AO$ \'K MA<$K%YTX7"N:#! "(AH)35((;[HAIMCI0?E'V17D:XJRJIW M"3>@R[1H#G*>>CBSI3!M7@P1> 1\YXPT*C_5KD !"HK"&5/B& M!58NFVK82+(2W&4U!TWYA1NM'/[0$V,T<"$:63&1K5N@XU+4Z&4%CEE0X%XT MS;*;9M/DV;7#9C?'Z[,NVHWU/ 4HAD,+TA_%!^-HPTDZ+TR!4, M:O&2*(]W4=PS*ZL=S""T58X[1Z2R =\I"D.B-WG@+&:Q$%I L'\_-2X3^MY: MFQX:U(6-S/>_A0 ]DHBM,>-*&PQ:HURC-2R3T#@PDA;2P3BTO[!.&H9+-MK9 M_#88=3.<DQ%*L3Q:1><-C"1DEI<3HO4/*:]CK4*B32\QY.W,N&WWN55?6GL19@Z$^W M9\*TBDHHV">*0ZY]@RJ: D;AP= W_%& $5.-6R:Q@O*8B4&@)IUP9B(N+!E M#" !8G(]-FZ?1EGF8GFG5#'KV$; MM/,4OX7SO MG@O,@L3 ;+OL?%VN]JT8'5.LBA,'+/=@MLH[K-ZWA WCG3%UKN+^;-S"@39@ MVLNL\^>(=P+RU&8)VYJ7[=YL;SGFNRZ:QY9 CK%RQ/,(.ITM\LQ%K)J(C?F>5>H5LN 3%D4W-E;!%%HT &A/[21):Z-+"OZ ML9:LK/6<93<3THRRQ3B\.#>FL#2Y<>1SFJF&LQ)X>!SYC:_E4$4;C+I@: M"WOKKL<>C'=:60F0()3.)N:M5CCTW3ZO420F#Q>"/@ )EN%(QQ3X910C,HI\ MR'GN;3#9H@(@'>[ZE[:H2-\F8CDF:W[?2T>M1$. "QB$U8=W'$A;%T2Q/[^C MTF!DU!,G3!U9S4=3ZV$K?( MZ,MI-B,"41@U8/:=F2@B=I5&7&SAY@S)+=6=:0D;G0;K[M.MRU7?R?%%#":$ MWC3,BY19LX%=VD 7Y-ZN_H6-0W(1R+Y%$)Y]437G0+5J'Y#:]1PIYOLJ;B@2 M2T^ZE3.I-=H+T89>N,+W7 $V[<3*=I6,BMO@':!31#W"9/@-'>IEVBTE?%J M?S"Z'K9Y=('TM5C:@WW+H]S_ABU+4__DD[1L+&1J+""HN!&\)PKQ+,PUU%53 ML,+'/B&MVV5<$$CG\)_'9\<90$AJ_6O3%:D#B9JF'&?/WM_Z)4HD3S: V6GH M4K0B]MD &C=TD191<5L7TGHH)_PE75M"&Z.;M1?6ZXPVU-HAH/RT*XO=UKBA M_4SN.]_&37+QISSZD-'HXL;?TXUHU-^38*CRYP0/12F3C6NSLTY: %P[-!J7)TG2NR+>DM#A,#-G9$??P 9"XU..<-O30 M(I-.G<*XY[B47XWD,6>!:N/M&PWP/P ZG;& OS<6,);E-X!BDLC#+T#'O%@E M/O+-#_:]U$*(/4._SQ!WRF$.OP\",0FO2.M=;@!8M&4#R\O#'1(0Q.(:@$4! MO?5 GAR) M#5_DFS:L#"$>J.VA6D&="U8K2NEK00?M8+SCRC$[FVP.6#Z0A M.QVY@@#D^@4KGJO-(K!Z[F2C Y#.D@H-$*G%>E0#T'N>&X\EU^9V'SX:?BE7 M@@@<@)^8@M2XR&"70I5-,H$'T*3:>F@:7F/CY)2@KS,OK-ET; JN F=EN@3%&*:]XYO"FKM)#$1.Z6@(N=J4 MB6TWL>KJA+UO("@]\\PQ$8Y^]%9.JL6 >V9? M L$6F_@PTU8K#ZOJF@<\,O%1(_EVRN20GZOF:MELK=*=BZX*M8,#4+46@!2_O>$*.Y !.FDZH]E9N1 M[HM*!H#!HGDCJ7UE@4,&;96C.@+TTQ&]+/*]==!(B^ P\@,$<"V$VC1<"\?G MS$05Q^;[XIT/R"IZ'+_F#,G44)(GVYAC2R^J>"!GA=;9$,6Y_.*\+<\1>F;+ M K_8-+6#0\_E;+@/KQV5KI\[\9I' ),;+(!(C0GZ0L+%0I2%<(*K?<6_!>UI MH[YR7=-E=U[^?]_?S2U7$Y%WC2P4QKS(/KE.*F5IP/V5TUIVGLLE+'=R+^_\ M\^R9< G0.U)05$(J8CCKL-#:\[U?#YTD ,P.DN;J=,.J[.-R)S&5;TF!D%#E&I?9J8^-/(CG;;4C T#)83"($ .D'X!'>B M&1C MPF>E@*[Q!F/"Y?=#6A.*,GCK* $39 UL#E;V9*T8QDU+#K0$K3&F:10W,#/W)FI7_MUY<'W; MPUL0679R*Y%T^ZM4.(F';;$8-UY/?+)QJNYR@: MRJ0E?EM'D;]N/?06@X!.]IB^32@B4^><9]O49#ZJQ[6,951B)Y'(V,C0A(!" MY/5#$-.V"5.S8!B/UKUSTAK 738@3HB%SU(>AF' MF"Z482)9[,NR'=* PS.:VX)']0.]HB4-;CH7@2>B\2@.%.P4H03@2918\L N/O3GG(Y:P&[#VW%$ MK31!J<@,;4L&%IW3YMKQ/E((IL!.6(&$*MUS8'UHFX9>0+NH75N8)U%R#01; MVEV%[><4*"P$PXEM&ZLX@?Z$AZU+B673ST?-:B7 O0H7Q1&XIC,X.C^^=OE\"[ M&LC(L0W"4(AM7Q6URCC\]LDH21GM#MULY->"DO[1R;T[;^_"(8A+O=KLUFEX]!:X_/C($_;7J&O?%M0*SQ(1+^F]M@9,]&SGL* M9;BO=TWO8U &51$X=,XZJ8^(D&FJE(M M&Q7&83RB/=ZZ74Q3>AU]%:=3/.6C)N!JQ\4:3"J4W% WT/^+A41T NCSG'QT M 5HUW([Z"NQ*;*SLS#H7#'#$@04.)YPD(W@QE$MN6I5(6WC.7%//CZ//[TK0 MQ<+\T2/O SJF8R_=.(,K(1JQBC2HQN$3$D#_=D$C=L7*(5W#6R^L+DV1K"J_ MVR=@/2Z3WM4@,=F]U18G@A478JRN]_E;MJMPB:9H&,7 KTR^79- C$YM%FH2 M@13,(->6JHIQS:1/Z5MXT_5(T#"/U?=-CQ?S;V0N%QR):EV]5%DK=B,^ +") M3N G2*+):DY,N2_OB&)%:H2]I\!DK_=J);RI!ZNBGWDJPX2EG4&'-DX^IZ5& M0%T PK"?9Q2T--JZ/ZC1[G] M[^3W0YRDP*U DAVJSF(*\-YXLD?\L;XD(Z:822J%U>F2-3=TOW\:.(6ZD9/N MIWQWGC]\EG\/93];:;?42@LA"I'10G7L>1KOI&3X >LG157,G<[ZVBRCNW'= M3I&)F$8XRGN\$&^AR*1&^^2"?+CC3>AE^4L._4CH@H,# M;=*V 79)W$Y/SA=]%8):5K'/<3PDXV1ME24DO'2GUHC&QG6 3+96] H-#'FV M:UFIJ?UTM78RDX/WU[RQMP>P'7&?3J;0HEB(=@'Q\^B+B%("-#:E!+''\#W_ MI:$7AR^Q___9>_L>N8UC:_RK#()KP &X>_5BQXX-!)#EZ,8/XMC73G-5J)5NS"H$']XFU,QRR65U=+Z?.>2-IN"I( M9?.]/+Z4Q,%4 NMW"[SWGF?*WWPV18:7F(WT9C4S9TF8DPV"I!& :;I@W4IO M'^Q8W,T!9P*];7$AAI/%O]Z'$*6:5&#H@190CABI29+I3JBM_0VAE(JK?A.T$QD.%U3V, M.DS* +F-%TSG@DCB@,N=8^:L(:IP\["9U&:J(4LSIHY9V[G#PG508T5(OY@ M%+,0%I4CCMF 8R4]<0)H4-NJ2:M'T0CT: 3K-:JX,X>N#8HL/*)S:5HW)I^0 MJ4!5V&%+8MN+413=RQNHB;*P+EJM.DD[@)C,A/P(PD>4=&:P?R&?>S]3R&B$ MP$0#WB(X";'A-7KPK*:G[(3&+P%Z>C_HD;7L:%<"+ I5#X,=969#LDF9,XOJ M]/.L>88A9YY&)1!/9"U*0FX)OL M?6WR'_+C7N5::+S0=FK*:Q;_FVV.&'A?5?J3H,"<45*FSG&5KA-1JU"S:5O' M]SI3/HGITUN\0;XW6^6?P1ZN7A(P*!A;O#5#5?G&)#R6\.)U?TZJ\?/PLZEF M\\3/Q+45?),(P1:=8RS,C+0X9@@%0FB M4\>I=K/SZ<&V;$$KW?,8&D.1;Y2#3 B7"Q M7V#/Q0D&ALA^$/A4S<@8'[=V:DY-VM(@6'-FCI#I@+ZHN&&&B!;LW<7_);Y!K9OZ;";2:H>^7< M897O),NR/29U$E$W6SKHWOV"8BB@RY2<,RI((8U1]LB31KK/7SFUU$#S.1+[ M4&*8Z#2=(.";OZ^I^1@Z&\.D'N]Q7*F@S].T!$]4GW!*=ASD#JAP_.PI?ZQM>.Q.S(TFNLW,;_T/T&F[Q!O-CISJO-X+C&R5 M1/KW3?ZZ%Q[S;RY7W[3Y4(\RD/\E<:)\]:W>ZL\6^_3WOH@>_%/^Z!_C8XD& M%E=8_7W0=).,4\4Y*(+U#3RAG6\&/C[_FP#>N[:IRXU/4GO*,WQF]$,48PA/ MFL6GH7,;7I?VH,R\ED':J$O0PW#CF>9!U*.Q->J9-R1 8D53,DN;8:F+SZR" MA<1005["GXQ(G8F/\M:%1]XC71PQB$0/!9?TYL^L;6&M,$VR @XP+E4D=X,D MKE3;^05E1L(:"KAQ0I!ADI'YS"P*\:"Q$7\Y:XU9P]6)@!!DXG'&@23 MKOZU&5]2+S,^%!'+=1$SII\;719<'=)DH_S7_6M@8@^DB%8YK4.,*%,61O,Q MQ(29W -F('FX,0(+]?,EC7[PJ&.X ?\D_@Z29FET_\P'/][F5H+*7_JJS?=Q M=W[OBIXMGW[_^?^]I#++WLW%'+0T7YU9 ;LHK_4NQ&.39]9#@;C;JOSXU;9R MK^]R(- ,:;D%[SOU'/ ]?RCE;?\UW/Z%?Z9]]Q5QC=!W9P^)O?^'F[+H=U\] MO7SZ].DG#^74T+4J:RP+ENRM+G#+XMDU^?R+QX^^_.SQET\^^^SIYX_^_ F@ M,MZI/WD2P#+FI:9W=:YK]X>_I%ITZC_J?$\=\TU#I#I^OWX=S=<_H_S?Q8P7 M,SZ/M?O#7]9MDX/\..8/OW9_^(NZSY3EU5!(4>TN;S<[@94FA2,#:LC&;%2FL,05 MI;7.%1L1^Q.T4,V8_VF);I9-] V45H5W@U[GGV1TJTQZW0CQ;)KNF5(:;*F M"4LE,;M\JS!E:4C-HRCBA*CB*>QH;H*E6*K,B\-;'-[4+I4[T6\;U[=*DD?)HQPV! M$3/+Q Q1N4^'L;>[UV+36.(5HUE RE.>P;ALS5QB ^SYD5+94O, M[-;@OZ!_ ..I3 5]$QF\.9*@;[[F%CR3B_K?%QV^X* #2\O1[T7OH67S&."$.@\4J5'S'EMBG'F)F0TH99SJB1]%'5;ZB0\18XCV'"W4*[W+U MG1W.LP&-1:_$L;Q6V(;[1'>>!>5G/D^'&,\F]CP:$)F1>"K%SF71OZ!!-18_ MV,KTX^Q/%&[O]P.7AM<^=F/FW#*PT^#*GABYB ?V0/X^W^"2US1SUMW,!Z3;$9_NM569 PL1Y*@7 )S+4B.T9J&D--FY'L/9YZABZ$ MQHO PB'70QI"ZEI".B)C6+@)?9[-KBEEUFM/.;M*\7#4\->7/WT+#B@B>6AZ M,X"4ZTK$JTVN0;SC)6]F%K?-B+/1L6*PSD&-UI=< B\NHZ>M^I!(10AO.97U M6)%D\KC^D[\Z86)!YD5[EM@'N[C:-*33$IVXOS8F1^F]8[2"/RM:O1R&JTS3*V@IOWS+L?'9&?._2 MR(:RMDUD%#+$JR[R)\3LXH9UQ)PD2&21.;[DF&B+$T%O^64-RB1./SI$8IK" M\6$%&W1^@V#V.$K34O&$4DV_)2@M+8H6/TQ\L97^)^V4?;,&<:>KW&%'D@Z< MF&7@7Q?>R7 +F0KK$O7@8?S7R]5+W1RZ&;A4-/#(:Q68I,(_[OQ+Q/WY"'SS MJE-!CPUD[!M4^-RU#T+!1-LV76 N4:X!\A:0'=8,CM=!8N,F[G0[ J0\8$96 MR4CDZO:ES_J8A01E'8TT!SE@R;@UW X>(7+5T@\28V[+SDL>5F^-L^K[W)N9 MT)6;@U^Z'BH*KF3TM\CW)"."TS?\-KCXV3/*BH=+^=MFTJG$7^62^/A=3XE0 M;#K88YG?6L9U U:3R_TSME L(=ZOLO,FZ5^[!' 5O=G]4$LB;V0!HMR1XPS<:PG&T07!%=&I8_W+8\'NTCSHJBH4XW%H3S:&JZ:PX[ MRJ_,W8B:C@J0T+773IFMAXT(^)@O"D^;3)4[L"D.ATXN5I3^)0[0:"6WD*-M MNH+^&=W-ON$I!98<\??6EYV[7+U@E,U=9=INS*%IE&>.:RIPB&T*9RC7++F$ MZ0],1'JUF*KK[>IJZ2?6:<;"E)'@3AF!(._&4F\@G(N54V36]D2/D74QJS>'LYH-?Y'=@*93^)M]B#RP&'&C;@G)TX6@)-3"G0&4[5(EWI,BV MV3,'G_JXR0FQ=_Z1BU1)&UOUHME>A*VJ&U34'C4 GW$ F13MJ!"")YA;U?&2 M&KD=9?'1G[9\>&Q+L 'M8\8EQUZCE;YJ];.I$.,V/6.>I75&R?? -*2\Y&KU M2T[P0&>*_KS,%'WDHAX?PJQLAC;*Q;1W@M209PI9Q]2['P[G$&/O/%13D!;-JK>JX%,0O\KV;[AE#,= M(VE$C=3;_)T8Y381N),?)?4.K@:,,CC3GQ..X.0-4#1';2-IIYEN>! 5R^*! MQ8TE*M II%I7+#;N4&-$I\Y'M=UJ$'9:'J\Z$;O[<)S>.5B'KUHB#U930W'? M;V/*%#20YFJBQLU4C@1]'VLH) 5#B(X4X/+MA>TVAYZ"(Y:&LN9Z!T<7(ES' MIS2"CBV% 3D4O'OM[]-M\X6J?*@W-/">$QJ >*U6/1$QL9Z(UF9#_C/AE2,. ME$UYB/HD9M&8O#'8J[B3BOBHPV0R&*,R.OP-2.\K8R_%V30JUC M41AG,TN^VDQ.25\:,5+V-\V%/TM]BN)C-^A*)+F:%AADP=.<4C5L!$A#,K T-%RJ(>(0#O258XB.\GUZ%FKK;^3'-DB>0UZT'6J\-W! M*)-XHW9'LYU&LX/UJTA1SN @%^[3TH]!;/CL&KE)(R]KM_%V.*;E&#\J. MM_?Y+!.*)TL8;X^/ ]R''J>2) V M>ACDJ_P\U,N@O& U%2@RR7.VTKQ0LFL1"EQ!_Z]!/P'?#UXG^(5@H&6[&?;P M03CKII8&(_(.DX91#RT<,3=]37;(D*(#)6&$KT@.?'M,6,924D71?Z=UR;1 MHRUEVC==FDO1"5>VL\=;$">14GF0@<"!DYQ!\= )#+WVSTIQ;^1?F=L<.TV] M;S(7D]3ZW%$9.:4I[>$ZZ1+ M[U+]/YWU!Y=@;9;IZV?B/"F^D(]:0YG8[6M&LU!1@Y:#(ANG D)!$F>\2#., MX'.I;;K:J2E/.Q"HJ?#1*XMD5&^MD8Z%A:;@G43F-@O-2-NE"V?R1K7BJ;KA MV#>"H5 VI3]?O'O-V>"(*=9?EYR:=B]+W2G"'1NN9UCYXW L:Y@$R;)@T?+G MD;:2BDSD)K T_1[M&6DK*"RE!I^&=G%APW^O33^_I,3C DH7(U/.O*+YE0J] MLP)R^E+G?>_28#L[@[DW2LL[NV_=QJ$6_?1QMGKRZ,GCC'51BM5GGWVVHDF[ M"Z)_CW&,CYWW(.C0X4SR8!23_E:H8ZR(?YA":BMTTQA M43*J2E=!?391_ACA/!4&E@0\,VP 8QBH@&BX2%KXB*@$U(JBLW!)L+\.**^; M_0(Q,P:>LK,/6=)(6IQ/-'+("==_3)F,(@5=B*])*7P6%\??HM5&B5C*D+S( M2*01;M&.7JJI!V MUQU:Q)FQA1!QHP$V>[GZ-G8X5*!Z!I,^/K;UQ)4%X@A% M)Y0G;YX.A;>],X!X:\/8[W_*O\MQ=$3QOZ9-M]S!1,A3>>*TK2!OQEC@+?(X MG-/IP9B$B$$7"9($-*?7F[<>#"(B)PSL**PVU^S]6[#Z8UAH-CEUXB1=*&OO M0YK>/'FX/@%^.JG0_:8>_R.K^#^L@.!GG9#>N7TSFI(.VU8\2(24,Q1WZOHH MB2"IK7X)",[/8.ZM:[=V%13H4B9[>>,6UPD(=3<9OI\QK)J*[7&DVZN0(ZN]QG$UDX:-I'IQ_D(*M(,_MPP=FR4OE9@ MPRU#TAC*'/D!9[FYD!V8^CHB11G51B+=:WH*UH0#($"U?B VM+8"'70'!FG! M!\%O(3FU +1_]SDG8EEFJQ)KP^O7U@:/!G2[!6Q*Q%?O&MY^,Q=F1!1CK042 ME$FX55)8@>^V;/A!Z4]4=J>7RT1&4@=-T5,W,DWF*GHF36])@_/O"> ]N=8! M^AETL-GF [>'MFWN8_^!Y\G-;Z3^5JZ\$CC1Y&573O)+W.6TC(D_L M\^W63-\E+^7DL^.08-U,J>3:!,C'TTWO3E1UN>HK>^JVHR7S 70OO0I5#Z7J M"C5?JZ-]<]'7/PAGOH32=ZBMP6DD69WJZWI+VT"HRXBOYB%OCM[5D.EO4*-# M0HE^F)&=6)&IFZ1-A7B7J/OL;.M^6_*%="BI?K9R?IV*N9IS@O8> M91&LMKM'I3L,D7(6+2DTU^TE'*6><(".3+@NN1@_J@L'WZ:HN,X%ZN4O>$Q[BBYX@H M_[6"P/DYI300Z!-,,W6K< U!J02M-V"I NZ*)H R&@<*Q"OA%GV,ZT#-T*&Z M ^3!:CCXIS;(AH./DW?4U/%W@^O'_K5(MN<").(Y\Y8ZZ2VC& T*4?HCW)]A MZ$ W[*GDTEF@5O<6[XF1;Y+?W2V,(@.1.X$.<<%94V)#0K!# $N+8*3? 9B5 MCS,S\,N3]>BQ[W"R!@-.&ZR">CO!FL';N!OU>OQ!&FDS^#*UN](5-P#->'*? MY-<@?(3L&[1V1/(R/CGC#EGVL^^B3M2N/"A3BZ!<]9-T9^]X5P\A(/BX ]GW MDQ'\0\;7 '>M+_8$E VC;!:5)'P=#*@9UTUF)K-HJZ<-Y1-@XCJQ0@/2^>"$ M-$O.]6&A#TGF/CH: E*-CO;0?H_-7FVICZJ%2)"0'55 Q_F#Y1\-#MQZ]9PZ MUTU;D]#RL^APS07EI&=H%[?"J;B+Z^ .*'?R!VY]VZ:R>\=GD_WN7T/^"GWY MLBJV)89HMU6# ;=Z@%J(_;(__@ ]$VWZ,&MJD&\*&"7P[[6P OAUP-3#@!%_ MP#U\!(+PGQ'+6AN;"$M&C-9**5C$4PW!1HTRK? MR-QAP')JS3"Y0IAZ,*$+_^ZS^F@@=0A<1@ *B5,XF$B/W?!8)WV;J"0+'UC$ MQU(5O74-NELD"]D,5SM&"%U'R\.\@?_(D:$$6<0E,J3%VXS,!$2$+3&TY&U[ MM%VU<)L^[M&^F7 GU5TN]$F"_$0J$ ;5>7VPKO)W,$GL83F;>W"5W1HVV2S" M;&3 0!C]$=HW=DR!=WTZ>)Z*M=_5#>!!W^ +QA2+QGBR% R8H*0-/1P#HFXQ MIP<1JWW,.?;[B2-&P[_,L+;S/W"A>#.E$-?62\S(,0(Q9R,V61 0! OR1I+@9XEN4O=)I97#K! M%YB"7BB"RNL?[-?'[\1@('!".,(ZCR[=W!;6<]A@,90^R](SE%RC>Q M^D"%UG/S1/[_XSK--5,M[_T;+23.0A$K944.4Q],OQU(:*S#FU T!-V(Q%&/ M5Q5+A]'.0+V,#J.4$='RD1D- 2@)*.+>E[\E"HVK-)F-Z0B.+5;.R=7*!S=C M^MC9=Y2-*F3AM2[1R4<1G1"(A;X?)G_9=CL3A"2*5DAD*',3EOMNC"DT\M\2 MEKA-V44J='B\;D_ E99YUF\ !@>R(^*VF:)\B1?.SNSN#]?3EQQ,S1^$Q%+$ MO7#A=V-.5?:?Q@2[V K*33<\$)9Q0A@IR<)OF4B$T2+-T'-;/8_S"P0DI910 M6@ODJ@-7.*UF<)\G]H+L&25=O8D06CABNOHAU@'"M#$0AM51<:EQ?0 C\ =O M@\ @TY'MT77BYPT:BD9WE:)/:(NTE26GBOZ YS!:@\RM#?0RC]$/;5$HV]*;[X 7'\7 %981DC?0E* M,6?&\-D5 RGKS=9M)0$;&^"0N%UC*AQDKGX": A'#Q-\JY >9_X3+A3L/41LF_I;9%7'>E?4C MKHY9**58B0L1E Q:')DPC'%U!5Q7\K_]V3A7G^%G\?_#%&NZB$$R%SY]WU-/ M0 PXASX7\GRC9DE#)G-4$V6LB%4($@G@0R=MZZZ$)+5=757-&D@FGP=N5CM' MC2UJ;LKLPK0[N9Q=#Q2D^G@!J2X@U?=N5C-8!1_9&/('3DX3=HE9X*;P.M)A MM2=J_7Y&3WMVKT9\Y1C7Q9UD*Z%_UM5X7]&#,7,._ ?(I6%9%X[W([E MV MO(LXKIN]$[)D2F_?:55K"B8\A%?XNH)KB["YEIX',QQ#C<72\/F9ANC?. M_;)09 G@U$P'4"M(EDY&,X4P>-P,/9:\^L<>:SWDTM54>8:3!@QAPD-FMGQ>>L-FTYJ+9TTZ;0G=2R+6F(? -X V9] M>M,/RKU;5E%[SPG!UZZYP; .+BP24MT(+'O+C5+=EJZ=-%?L;6=ONAL4A]_P M1"DHEAAB;W0MF!&Y4KT'^AO^P+4!YF7-;E_M+) PT$EIO@W(+E\^2Y[2/ L3 M5H=2-VAP6VZ?XF)YUPX=8VF7PRG NQS@D;F"9["J 0ZBA_RS=%P,4Q M:\(NK#"*6/,/A7Y,,^5;)[QM+)0X\<^_I[!N&AY:I9O(<;_%6Y^><(&;C?XC MQH+T\0FG1,0KZ3:R6)&%Z/.]5>3CD(*^\'1N,1F7B=C)5Q35#X%-?GJ5")Z/ M ]LF4XLYWO2K1+64HR-0>0_,6S,R_5%)\VHH"U3VQ #%6I8PY.P,]?Z("N\\ MVIXZ[#+[@ ;LG%,:%[:#&J6M'J!T[5VJE4#:Y-V.IEI(<./.1I_,A4PH"6[= M$Y>K9QM_%M*-JNRN>1Z,4]9.GUL8KFF I-OQ6"0?723D1.(,!U8@1*U=A61- M@\$ -KFW,+N>;]K](\&S1/$J]!7V,@G*RP3%:)TCCD/$,Z3\>AX352R=LUOH M+S)9>,!6F.<8LT_JO*W>+CQ$%" 4Q8'Y>S; &>+BH=M0/HJ^^>K,LNRBO-:[ MD&U-VU<]1U&2[N[Q*[]\K^_B-7X=NK[<'B_HQ9 #HN]YS^6MXVOXAHN2*&&_ MHA86?7?6D^S]/]R41;_[ZNGETZ=//WDHKD77JJRQ+%BRM[K +8MGU^3S+QX_ M^O*SQU\^^>RSIY\_^O,GJ)J_?O+HR9-0-SD)PDP& M(2:U>N%*EZ9$'$75,1#:OMYXAR;9=^<_;XA'5HG GP,M#506!*B[/KV&$)^ MF9PJ535>OG%-K'IUT6WR*,RDWTV:I8(>=O6.ZGF"RBX+2P(Q^AQ@QE(AE1[GLD^7?7K6^Q0$203DX[9LN5]3MW3/J@$5 MP=0DU1?69M:+%:@ H=*@_\2'5T2^ZRX(^$+*@'BGV/;[LCN6W7'6N\/4A5E_ M2M!+<5*$#C>5J.@CYB"@2^AD2XXDOW_XCT1JP:D_GR^"S09?EM*+]>9D6\Z2 M9;><]VX)Y#($NE$HJ!XP# ;CT:8(3,HBHN_V^2SZ\[IM-CC2QJ#YYDL$4? DC.9DS6 MFJ4"N@#M:%EJACT"D%17+(')LD_.?I^8,%YZY=G)(FL)&8[.Y>UFEUF=XVSE MPQ=7=ZS_$(8D@4N_)E5LV\&32I'AI$;/KRLC$Y%0S?,(O-^9_G_47:YRX8'@ MVH[%,4!;D,>0B46> MDFY.QU%1%C%0FEA()QS,6 X1A=?,<2TU+(S,7<=Z\FPROVRL96.=]<;2QCM/ M>G70Z1M5JI:"TV+5#\RJ*W=%09<1*HU!%1!8-/>5 *]&,P=Q1 %_D/(41@7K MI+O(\$5%)4IYMBIY3HB1D&[U,F_7>>VZBQ]>5^ZX>K;@%)<==.8[2(('2"MXA,N4<7KZP[G>1+3H"X M"_R*E=LM@",M=>NJ_$9(,60_7+Y-0V*9T9RGBM@,^X$U.P4DIX2YG0N:HF-2 M(E:,3F;VP!Q1RPBES@B)*YL=6YQ40"]7"88YI5W;^V6"*H00K' :UH_:S_W&:\Y?!S&O'ZMK\ MR< UL)7>?EF%[\\MY'%&]?? T M_?&9J=,S&Z)<-O:=-[;?!30S:V>E)]O32-O&O3WBY\0L']E=.L._C=UAJN&$ MO9S7A%GB@(8KO>0_=)>PD8(2Q4QYHP [V=^&/F#NY^=_B+K7^ KVI,PD=B.* M 91I@Y($N+!!\K407G],&^?]T#_\PFP^S_;YO_W;_L6M5R]%F1JZ-:*#@^*. M:G[[X[)J!JJJUK7CKD1$WQJN6F\NHG(=U(Q(=!-*MC0U6^7'\<"MMV<')0,J M+RG78"L!522N8:-4+86RACO';Z)5D;.,5:I0%72H%OZ-<[/D>RN@22F^.K(- M__*27OL.Q7Y"_9"57C#+M8_6.^]-W1XT7#@1P.W"NJ\P9[75:#83#5)\612D M1"$46A]*'T$0)>Z91]YX"7I2H4RZU:95>-+M=R%]\RZY!D5:UT-5BV8F@6F9 M1U,Y/7438D,D:KD[DJO?4'TIRN6*>N[F2)WYCA3ML:?[WK]MTCL5K=P^_A.+ MU[(8*7V@@@[84 O)1Q=D:QGPF(A@@Q.#"3!:)YP9>=#[#*JK.%-74$XTEVJ#<\H*F>=.06]5SOFFU_ Z&!0\%<[2W' M"?^.5(G@=7)?M@#?< MY=Y+ 'Y7(NGG>5(54[[VO^KOOMN;PNF>V@,U-0#X%FB3E/406/CJL%2N&#.H M!)F/Z/P;X;8%:0,;>$$"JY&P+'V)]>G?SI-=.]BBRSVENR1W$:7K5Y$?AQDN5H MY3W^.'N>B:(7AL#\UNG\/W?;DI\58LQP>S'BI3L/O]Z=LK20B'4#Z46&5T)$ MLVNU) XS]T3=TQLE8F7Q1!.V+:^NF Y/]8%E:S)>PA !*#Z(%!O5#C84SW.J MR!Z]5%8[02EL(&)^XVQ&S%0]='+N">T@J:453SX,+?U&K]<-=\$U>/7.,T0% M;W37B0*T8>UU/F^G;-5?9<.7P:_$56Y[6@]/OO,$QP:%5RU:O M#TD?;270CPA3H_^MR]5/[@"8E2!DJZ:^HEG"Q#Z43I"H IGVL>];0$]%A_CD 2"[@6'*W] M\< GLUU5-F<]6*?LU*DZKQ F)MR8#R%'6F++&;$MOS?U''Y#="8E+Q\6E%?: MU/.;T%]L[#L&U/0BL@N%,]688WX40P2.(L)$5XBO/.>9C-.Z_8[?? _E/$G+ MG7\!YU_K-SN5V_POT&7]]H4N5P-_)L.94I"[ 4>%Y:F .I]5PV:?:CC>A0?& MGXW-30UL&@FW2$;J'S$T4P&%VR($#!)C^DL(QF2(4]WW=UH;-NR>CDM%@4G> M$N6PRK$L0KQ5I ?C[[ &FIU4Z'U,KO&2_QC3?$"CO',]GUGXH2 SK/"\S>_ MH_H0O-*IDLI2OSL[<[IW_8X)Y/28NMT^0G_0!=43K9N8[#(>=:G0F6&1(VV*SN>E MZ\$$\BAJ)-6'!,Z+_D[ JV0ZF<+JXJU9(*\/#HZK:EYO.1/9&=C+17PPESYNR MBUJ>=(N2&=E"(>;)\UB%9 TP#>#X9QIW,WY"+K-(,,BLCZFM4O MX%F,?\7J\FKO:9RA'9&#(SV1.2+ZG?!8K:T@Z?4V887);EK3)&$=]]]6$N*Y MMHHREIYNO4V$8"-Q$8')A, !_KI7D%QS5,&O#36)E!*)F!O>MR23P@GB_T-I MNDLP_ Q*;,*BURKO(9?$)L=23B[.77O_<9*QREQ9&8I'\C M_MK24=:A&^S1WHG>@@S#B*2K/Y[A_/G'+E4R%SIDG94:S\GLO>2XKVH5,TR"9!OX," M;?+F9??*\'N;'3&:B7FCU;Z@*Q/L=$/F;\4CHY0 CL8 MK*)/2= >+@A"#H"*O)0RJ-W1S:#IYY05I2-/LW$)[U%VW),[D3 MPEFC3)&>KC..#@&@]"AI=C:7&\*REYTJG+""7E@#%G;3>CR9;#CV5:_V M@FVPATZ!O(>"1IK+;L<]7+,F^ #IP5J\'+^#T) &[F/V909].^P9( ?T=5V' M&PEI3XD,"\:?=RKGMXO0@4':12.-8/^S%[F/:O?KJI0MFU#[ZS60-^B10U29 M+DC^>4,NKMS#B*J6XV2Z<%PPE@Q(D#P,UB#'QQ&%CR)0ZQ#_ MM=GZU,0'8 IAYIFU4O/>]3%R+(TZ4K'+Y&I(8/",#S>)3*(IV#,,6Q#2,DD? MEMVQ[(ZSWAT,6*1!'!*:>6"J4C?*8L:+&9^U&>>KHC3,=S&_C>-,0.-J M@R!DO8ME+Y9]UI9M:TC[IG8]29SF-WE;\*03VL-4^<4PH' ::?5WL>[%NL_: MNK602HP15441>-GOBM;;-Q.=5OF:3&;<[?)?VS>"2?.N'*TDBN<7>U_L_:SM MG1!43&@$"A8PRRTVN]CL.=NL>[W+Z?DYM";8@X!W*F=@.QI9;_(#(5QL7VG1 MKWG'P:G/EL&I=QZ<6CK?LT J"J_\641]:\:<*N/(M,4=]GH&>''9!T(!4,@+ M@"E< /,;Q#Q#,R*V^SW1BR> SP3]!^RR00\SD- G^:>H#"P&EQGUK7?J 0(+ M(\4\)ML*MIS!T,FM,V$%\]13!E)_$;%&',&@SXR7535@G1EE&9&59&^RC+ ,A< 0[?\M;Q1K5 MF-4X]'&1F%&!(=%O0#](X?S0\C0 EG=7KLL[ !I^2<>3#SFO/+^8CO-=(0^A M7VE[$6%KJ+0OB/95Y_J^%#_"N-?;')6]/Q MJ$Q0'&I^O-:976P]"N6!&)O$3Z2MAIO? >V=PN? !WCJ!IG4"4C\0\411/?0<1QP7@BJ,*LD&YP*& M%7-+@2:=EPWL+@\0*E-],T009F?S7I0-H/(J9F LRA8I[E;H)>@7A%>K<.N MT*JO0$3FC[^9W[/'7HC!,9 %7M[HND&985D[?DCI1>5D,#\1?M[?L:O]\CAR MN#-7-60@Z@70'J6;0!_)YS09^]E,MQP!R.A?B&U#I2]3(:F,MZ.@T_2D\ ZP M:7N>G,.>-6)5]&]7;;XW(Y._Q8C+@O7_T"&JW8^S!DN[D!#T-TW["L>'[!;& M5?-A+D0X8=P5R&3G7F'V,,>$I#\8E2'Z.+O9=S@=$8'LUV3+2HO&NAHXW,IK M,G'9VPTAGVE',Y?:9),[@)MKVLX^I,N[$&_LFAL'FBB-E3%RAX Q8#YI^Y+@ M&@Y/NRY^*?!//9.9=38DT:5*QUJQ@VIQ&MO\NFFC8P$$/43&].6(*8\^:,[[ M&#]B4?L6]IJ>W.HL B>QGM[6B[Y?MF!A,RJ"$9Q^[:??,L ?_G7UX-+#>PYO MGN'SS0WA\FDT&#.=3G2_DK'"OMF\VGEG ]"YO.[".VSP$RD+G?AU'0H03LQ2 M"-+TA*E*?V=*VZ?.T6]*X6%3:/V(Q(*Q].8VPNAO2QLX+-8;5RJU]-6GEO. M/^%O)?PY607ZZA]/S7CXJ+!&APN'2YC*E_+_S$@VL1@1.0&9V"KH#NJ, $*# M\>ZA&Z!F0^)(8(?^(X,,Z!?.Q\OX9E'2<('?$Y>K9W<\KIOZ5GZM)1[]&.+1 M'PU3)C%'@JM4YNXG[ /,OQ6XM#3_)']Q8#/T9JJ#0L3_X/.P3L1LA M,*.7G M=G08)^=Q]FD^!8[L*=>F8<44U0<9NH?6PQ)@G9WEWF_#_]7[MJ+$(4,J%7!* MP?)0J:$SQB5V1^>_MR@I.0DD>,1'#8J]G'+ MY0;,[QX:OU^@-$+_PWQ3#E">R1*Z4"5D#:P6BK '&X<0\LC1Z9]1:#?PH;&8 M; @Y[8-O!>RI$H*7JY>L\Y'K)EWY Y8J/*Y5IOAC0IO+SB"<09246E:8PC'- M@6FV!+H4TDM0DA8JS57"34^L-(ZO:"DS4HX,&7:CV)1)4Q=W9F M8;+VS"NDGT3M$!P*,@ NKT:]T4Q5RHXKA2(.E2_5&JD(95X&EY1N\7PQD.0= MVMT6"";3FX8-:$O5QIVJRM"WGCQZ\IBBB/9*:<1WY9;'8VDT<-CCW6.A,(GH M1)2) ES_BYB]W+(D#OWBQK5KU#"]VP]BYLW0HZLCPZ%MX\.RAO 1G8QOXKI7 M5;.FB+^% Z J!Z5 _!4RBB)94_]5C';Y=2])C&?C\EILG[_/#BD<-YF9N$9K#M"0%D^F%;-G&=9N<0*AT?_\-ST#E M_=7.?YQ9KPSCL$@0T/?,CFW#P$2/;#F[QAH4P;DY;>7IT,W,5^(;FM^EO>)(O$>>' MK8"N29T* &XA0Y 9^E#>ET:"M8WB'7NX]WO^HFYH6F/ ]5H="3^:X M\D_JF/LB7!Q]/K#:]T''H)"JM*8R.J%/'_99?-&PCDFD#H/6AOGQ]-;MO WW M %7@0(@XPOUQ3XGB'/X9<&/(KR?YN%2TQN02HQ73AI@\1PPLC58NZ.\NF/[. ML N$-O$*R(RQKUY+T\N'8OZDY)+=^-?UJ3FV"VOH0RH61ID?5PHC'VB\?/= M.M"Q1>.W^;940;OE##D[N[LG$X8R+5)^C=P2!7DX%!!-'DG&"K7-X+[_68-2 M\&6/; QV)+(O>[=?2[[_/S_^P';S'3COX#F_U=#W'YRV=*M/O_OV']T?+\VG M_7]'E ?J9%Q^:(EIR&@ [$E?$=5;T74CA7,E,@N\NDV4K:JY0J_<.A%(@EH< MRYYLM]ZZ\8_QH8V.$#_=^&[[XX'NI)(9C3 6*B6TC;_>5=,>+];'"_W?(IZ: MM)<.KB\A#[(NBT)*?:(P5$H#1A1_B= 3NKP0*Z73;T\YFT]CK52 R@X$,E?P M-;7E-9*0YJ9>#HH'B@W]?,&&+J3ZO\%<#KM:Y#MAI'\9>K;R.3 M&I5GJF/BOU ;"1K+WE>JJPR>T7@W(U0R G<*7J5V-T+1)5A/;1QFD5A:0 M3.'T)P"(Z"!2D,,Q-A2@0_B$=GV\7J8*/!.+IVMQ8&/Q)-+N)R0SU.V("!F_ MHC #TF7T?RD@+B!!?NM,++/WZ7(B3T<*YCZV($(PR3B<5!V%G S@CRB6M"JY M$D[$>>'&J3ZMJ3GR_\F2!7[KT:)EZ>HX^\TT-MJVCA'%>I<(D:0XJQGUR"', M>:DDLFN=BD=9\416?A260G-#4'W_TR.ZBS\_6A7^" [ "I;U'/&7,_%:>#R\ M:^-W-KNFZ=)GRBM_.[7HR4EKRC)8&\::3J"/NC+/0B,*5+6_-4O, .H'?AP*5;['=+I>+L[/?> MU6Z4&E31P,A.C.9,7$7SXV;.)*IS Z(@I2V1S&9S93QS0AX^6^[(@K[\=D8+ M (4W;W:GKL\R"N\7SOAS>G:<^&4ZP"16UW8R\[-3"-XEH'=A&1807-N7$+;5 M:22='K,BQ+%5S-"ZYI#T@&?O\9^7+R\G=YA[&Z$EFPB[@WH(Q8-Y&XK2+U[^]8X;D6&640@'ML^_V+M\3[=%%Y/8QSRD M:.C.W=KEXL'O76M&PI"*W]?MP ADV8"N>'.TQ/8FE10 ,:120+N#,I$- MMNO6%9A)PNF%E) T/>1W057(&!*K4(?PO^(!5"U[HZ92 +(L4+8N@0,Q6,;J M<^2]%(?]$U-'UO\7,-1=F)/:^[>P8\6LAO1%W);^OUR>W3L-_R/49$*$1LH& M<#C)&9X?PCOC+TCL\4SWIN'B>B0(A7[\K5 RO!V:J%WI[<6*OV!W)U7 MGOW:OP8=.I2D".]V\.[/VRFZUNI4HH;9) EB+SUT/$1LBUL$^"FN_6)B$/>[ M_C+&LL#?,+/D>"^5!#*FA6W; M0T$[.6>Q0FKF%WYE;=HX9CQFO0KCL?T[(/"=I .\)BQ&A5,P;#)S(E&CAJL7 MT*9HG3$QZ.'P" PR" .[3S%CF 1F2)0\DWG\;'H>O(]#[X=T+9.D*: ;UKEN M37E&I$A ,J#J*#,W5B"2;5 D+#%7;C>]/QU$@&OT+L6HZ%\GXW<(F]41%VBU M]>ZTEE9Z#9W2^XWWQ^2F(_A4!S?NL2VFTB,:\<*1B*7JL: !!_WW/7+9)(H. M=FTN-GW9EZL?E0G+ZF)H0AP>5?4XR!7NCAU40^S-M?'A$X=@1%2.?OT8ISNS M3N$712%]B1Q6BIM'T.E[>^!5-> "4B(J>*(S148& 5Z M[+9QGJ64=78&1*F'P&C$:%=<)Q,[00X1!F"]EY>]5'9K"@QJ"IO M.0-_BQ)\:N;TO^88FB;HVIK0,98LG7X[%5F .YA/K9 #:6G*2.7PC-#. M2L2.]+TO5V9[EU$)K2+@K+<9'SKU8<")FG6&9/XUG3X4#9 2%\VY@M"5@EY_ M<_3%3HQ\H'[C@HY8>GM!Z)G/X5^'XHIA5 WT;]EF M&L.D@\A%X*A;Y'U"0G57K9,O4+:^(X 6UNK&6_*)VV$*'6\".@LO M,[]YG<08Z!MN_ 5BU4],6.3&S#?C#*X*86;!5&^UKY"_#"S&/K6VWXR>YYE< MC@?,P0FRIGZBV5*-[I&I_(#(9Y\ MLTZ!OX4&(GMW100/E0]D:*PU6_V*66%(U@EE@[_;RKO5UC1*S'GG+TOD@D(N M+3*:1->10(V3(R)H),\.SA00'^^:-(WFODS2L]8\DRZ\]DGA5O3V.'M6^ =' M>?[&_3TMD?_YF?4[<1O1;#C&E$Z:,\5"/G9ZDU7?RZ@%&FZJWX%T*'"#4M6. MZMY5N9K#3(C'0Q EDS5@D+ADV90+GFO718(IN->7J^^;UC774Q3.'5]H/F/M<73: M@MH2BS7O_)>@VTJ<" (6I%7W0;@WE.:&H9GS/]/Q:+>]>!:XMFSY3HN<]!UE M$R)&05))WDLIF!G"2Z5VP \Q[YS_)N!KE7.DI%52S9C,(8Z?Q@^!XC#B);4 MX)],E]O62)G(288X>:?$Q(VWD/RH9K>C._._9CS,*&<"E*OR01V+IO5@P.)/ MUM[M36T/SB@FCI+*T"7>Y%C&_*G":A.R??_0\#EOG8U]%)G'?V14_/L\]/D& MQ3\SUEPHRYE MOCG&3G,<_,: 5+YO*!7 #?MX']R4!,W@=C,5XCJ-[H2:EP_@+,[=VF%:4_V6 M/D)8=0G)I-ZMT:#8F@\Y?O7Q<5>(9)-V?9616-]'\A@I#O<^WFS>?OF>FL[% M:P6RRJ]&SNR$',]GEY\_^?*T',^?YCW9^U7C\??P](M%C:=-U^2+SY\\_N++ M/WWVYR=/O_CLBR>??R1R/&K]PN)&RAC2;F$(94501P,2#)]#[ZZINAANW4EO M:C'PQ*X40[.QSV(<A12(S:?\<5)5CDX4&F;UG]-XNV0F8/0JP%FB5*Y;UR91HI5[ M*O>'IE-N$BJ9U?Z;2$U<#;PRA;K+?ESVXSGO1Y@\RB Z=5 A<0M3!WXU.-JB M4"Q-Z3+:0QDA32F+"UL$\ B;[0G#$O'VH;9)R:'/:/H;Y^J8 2X[9=DIY[Q3 MBA+< G4?2+D.8'G9.$U'"'2$S#L05<7R1F3&3='N\5HRR".%*P[G,*&S;(QE M8YS_QD!HEA\QCE#N_9'2<:O7'Q?TC2RE:L0G>8)-)CB\76TOH"8H5.\\!L&L M=TM^OVR$\]\(_CG]5J!&14NT0NM -T^9 L/,?89#_RLB6-*JN$($@O8/002X MG+P8_V+\YVS\#*-"6,/(*TH->-R" 2CE?E]>M4:$@] 7/ ).+:I AN$WQ[6D M[GX?73NPG.28'5OVP+('SGD/\%@!Y@"4S$5 2M)4G)];$O 2M64)=A7Z("$S MIOVRF/YB^F=L^ICI P(TMJDICPU9W/]_/OHBC7H'1L"PH?BW>L(<:]?$_/#EB1VVC#+<"[4UHH%0:I)&1*NC MCA$\)4DS'?U[(FKQ(&GD\I;$Q* C'=61-X2^Z!6-(CQIR^C V9G1_?S(,VSW M;]T&/&JKIX\SD26[(6*\@@G5IDQ",R;UZ3]^^/L?1X;E+_U?GSWZ\^6CE?_Y M2B/1_WKR^.GE%_I/F<+ZP>0!% ^!?L2 BRSRNNEM^!_J B4%QIE]\ MH%\NO MKYU_'TR>P2"Q)X\>?ZD(4NZ^!O\@D%%W=T^_N21XOKDQM9##_R<\ACZ6_[RT2<*K-++"=!< ME@7G!3\'ATN B-&]7ZYNLXN\ZIK;C.,-KH3-PF_&U"@^OWQ\RB1^&%O &W]A M]KT]?73)V,8W?S]9W,O5/X%S?^GD&'SZY1-\\^F73Q4Z^9U29_TD&/_G#>,J M'__YRS^!WC3?.PRM?DH?I[_^D8EC#H*)%THI^J6K!L>E47MF8$YF^(@+4CYV M4 ;,5U>8ZVF9T^IS_]X%R+,^^G.Y&O#\]%@J-!VN2S5"DG';M9,Z$IKL9488&71(+9I-)$S% M8/O=Y5!+?V2J%&T?FR28(-U)[6?_E-/ M8G;@/W%J^8ME:GF96G[O9O7VGFRC(&:5A]6PP!\(MYUB="P%J=)5.U3" 4;H M>97LXS.>T#R4W\V0KAJGQM&%S+AYJW=='X@BTX1"/"88,LK:4&6-0I.)?I"D_!%]RB3D@.#BXPID@ M"Z3C?_@[0<#-K('_MW 8R31BS[!W![$ OB$^.73$$3.=\<#(N$H5T!Q[*-VN M*8H[-A*V2L=.&08-V_[TY)'7*&8 *TC>_HM&)_J8YA!@,".P2',@D20[UZL" MS2)W,3]*J"><(4"AYHS$GCQI8@[P["UMGOAC>#WGWJ9:77SY63)-WZL\A%&C MPQBC>=W^_[&H+E[I6"]:J8-"P*-S@7%&,$H>*+M?Y9",TPPK(OM#?MR+BN6) MX%IG1?/7[B,9,GS _OP]#=SM>$0WRC"R?8>)UM',^=YY?ZI#RM'>QL14WKKS M6NR/J6=#FU/"^%3@.OT^E5-+W0@\6=/F8 N/PS";'&IV07&N<.M>+T&30KU] M,/+ -+V+#_'FT=-)[VM\?,Q23RV5IW/;!?!_ADC_3/]%U_ZA2 CFH MJ?36UT>K?4#0ZZK2S9W[-#B9#],_ C$M.XIC@)VK<*V!/HX=E*T^M7-IJS]] M_LGHA#I4K@"=VG9T,5.8IWLKBY(J]MT?,QO@J%E5]:/?4O.^(=UI>QUE_R'V/D_Y\AB\:K3A7NK/<<0VAS#PI%Q M7QM](B*NK3N2L?5WE&Y*_@O5@^-%90.=V,3!FR2#Q/X/:8GQ*U53Y*%#IH*/ MD0<%$?05QX&,.AT"QWN[5Q4[5.+ SBBX>/+3(F0]Y/1PC@IV>]=>X19HI*2I MRD)=1H5-9);$9Q;^ X/\&9Y<9YLAN.+JPN9Z$LUW3'#-W$4:XEG?3)/1+GR8 M/+>L(3^FX8 1(J0@*=S%[F[D3.^/3'$9B20-%9 <-/%ODK6-_P!*3?W?5;.Q MPD!O,K""ZM>4_?'+=IQ]SX2FU+7 ATCI:!8Y9'^/Y<%_>)U7"A*?'/-W>^S1/@B; M"WDSWFOAMKGWV6."T-9K,%9(8K.O)M:HXU;0MFI,XN*?%&7#G<*=OJ9M,.(MHQU(>\ M-%DYCFHG7!-KHM\E?#[3#16B;NH7@"H(,X4F>:R;R*V:W*K0M :.4]! (/B" M'@R'?&B@& NSVI1W6%^\2>ZCK7NMK+S!3&ZH9;/9N(J[@TFY!$]AJE_8 +03 M8QD%% ;F(_)(B&((S]WO('*T[M]$;72"R'@I*CRXHL(?_O(3:"E^(K(Z;O[^ MCT7__Q10-Q\P>5[>[/LC+24/G.2!!](!$:J<;FBOG<]=A9Z.17.[@=-2\E4O MOGV&1)>\ 7.AO 3R*S@S^D#AF,!-V0?''XZ'O(^\P#Q);LV0C4O1>$?52M*S M)2IP' \L+:>_4[(D%D695!WR;L@'/[7PT;,M3PEJ&!J@>BCL?TE-+?I2I^Q! MKUP2'H' !PDW'T]%F]_@ LFS!=H@?U]5,2;Q'CG2I2)U=AOM_KD3F>0NAV&S M&ML@]C^QD10@04V-NF#FI3=LQK3_\OF3T']Y\>WS9Y>G_J"S\_]V7=@[./,Y M<,;O#]L)(FVQ%!/G9U$$4 MXP4J.T3I=&62[VX9&**4 :&O%E2TJ,GR"CJ*C01 A$$A9BLA+-BYO,)XM&4H MX&H0R=Y(NZ]G? U'DKF_YM;;B _"I=5"(''^IP/:3OZ?Y!X!NE(JM-S\:QLJ MCP\B*%KV].D]+2<@@F/L+)6,]"E%2^?(IR45@YVPFI'10OFT\@;8T!U1 MB]*A4.@7P]]U>MMZDVAD5J)Z47:SMT$;:'(/0>&1,W')DNP1&D];".5=^62L MRM<8&\J46B0(5$))RY_V1&!^0YM5/[H*JH/XCW:DFB6;E.\9#C-D[*@X%9!# M86UE[X/*/366;WE96=3:N.924,-:]165&M[T+O,>"X6Y$%IRK#FT/>TU(SJ> MKTD/U:Q)Y]5?XDX_\/86L/BEA^J7HN=AL 4<5!>/5PI"(O6C$*GKF9ZO=L.> M&V-$X.P?;RB.0)G>4'4 )0W]9$%@@PH%F-A3N-UR$?YJX-X2.>>(?1W2=Z?B MBKDG@;N%$"8:18+Y4')E2*#F?3]9G^:;7^#8/10,#&S B7W1'L "'^0_1M%&/8ZT!(E4MZFL%*N(X>;A5T20HS+U??N$T^0 J=DC_J@Y2M%7NCH?X8JY*G*Y&6D'PZJ,*=0<.# M*&"4WZUT^9&%20^K(_ \SB*4&DVZ MR0)BJ8RP8IV7*O@Y&]?]]N0/5M"3P!9TQN+\3.UJ?3048V/"?QKA@"-5YK'$ M_J@F@K(SP^D-];_FFOGJ.N]HZ/Q7EF=0/+P$+0*#^>O+G[[E.(K+)=^#W$^+ MU/I?,_L!)>I:>**HM,W1 N-+].$C.(\.[$Z".#JPHYX 0$N='*EX)/'QK/P5 MVFSQ\5Y$#C9YBG"?>!+(J_KSGL"4 AP-$) M#@K@GR9+B0L$T0]$AMQHR%>T MR"3]Y/^;Z@ Z8X"%&.%?*:IY/?X,C='2U,&!-)?36[MJ&D$\A1L)$9!,YS K MQ=CS,*)F]I8T@LP+HOAPK!*K8;)&K;2^_IVYEB9&-E3?6UVYYLIO@1T1?I.& M+>WQUYF!8VEM #\-V_GQQY>C/D[KB)"82IER<'HS$=E>H(ZH5!%!$QQ;(43* M2?>,T7%-[31B,CN$^A]=^ G'MN:W7,W0I-Y*;4EI2%H][('735MCHC)!CJB4ZW ;[FL7G<:67H;N2#HHVP=WBWL)X(L6_0M MP=SM9OKYQW]\]]>7[).0:033HI#WP "RY]^_-& IVH"[&Q:;7#W_Z1DCD@CU M'J[VBTS R<[E\2>(YA3X!G^.[-]'T[54 T4]4GWKWWR*&6Y&0F'RO"1?5\?< M]4!X\9H\[F9'8M1)'FNA7+R9PVH@6R.P%.'G)6$)?WQ64$FY4DV$!P4W4;P; I!Q N[\2E#3C@UGUN-N1SPR,__/R&4^'F'$1JD.;Q M0<&&SI,@("FO8DS[R54 ROQVE(YB9@'H.7%:Y%1$91P#:" IZ)@]@(?3,H8> MZ@\5HQ\@Y^WHO*0.#=HZ_6X M-2H-<:I37KNH7.CO@7NO..V6W/H]2#5(%5& M"S?^='BVV328+J@XUQ+P$ (2R0J*?1HY63&*3ILP:J@ +#XS(?I M,\DA\>0MHB]NLX;9D9WU'";1 ?"4]J2)$U<_YGZO?,-Y4TM#&_BQW!N<>T4B M]Y6868NH1+FC1:)S$R1.V3=*QW=\/!])XH *C+4M!L3$7GQ9C#8/._]U;ZTU MN\]82XA/ VDQH\W&""UV 7@.\]R$D"5!8-Z"KMNTY5I<,V^_$(V2OS#!J+J] M+M9\Z#>/[#V!_))S8/8>,][CIXI_842==C"55\ Y$]::+I_[-U "6L8RHBBV M4-VQ+:3ZDV.8P;^-G@:JYU\0A88L3S83T.=P1KOF9K6'\X.?H^>3@FF'[,=_ M\,3QF(:^6@2D/K>C_(5FCL#50I>!FZY'YDJOAI OYH6E[RCYX4 N,L*T^W?. M.4]%4](RB[VE6N&&:Z+<]D$K3LY($57+(X,1'](\N6P]/RPUV,7)]QTM+=A[ MK)5OJKS<*,R(I%.$GM!B>Q99)N)$;$7C6 -11!O2O9 M/S+?3+V[ULZ'[LJVN*#4@PK)H9;5M)(^;)+?I/P.S3TJN;O7KJ6)W)N:.)60 MBG3@41B?];.>YD%LWP5T-P.Z^_,"NEM =[]%=E@?&5&@F>GTZ M@% ^!,&BN3VG=%0AIB::N9>(><#D$U?8P56 SVCCLMLT!P5HE5*,22J,&@JE M0)M(]Z82%87;8]XZ[0>OTF***I^JWUT\ZH#1?E;;(*T#@7-8'X2,)<( M9RB<;IF4@?N^X:#NALU&X'NHHBYHF[,SE7O#DNE5_[,&"2K8R7ETHA6,[]J' M?1RWA>Z8_!G59BJ1E#5++J\I'S6UY@O_AZ=>&RL 0&<0_ M)TNWXJWF/TC;+."Q\[6_1C;#IEGE-X0Y;3M9'.(&(S*AAF6R,RK9]:RGR,=( M6%,9H#,?9D P#:+9_CWCFD>G@BT6O>E5C/E?\U:1SP&2RD20K8+W(F9D3O#4 M=BPNJ6PZ)DVS9H.+!JOAA\T9QA+)&^'1S'W'.YF%$7+7+J2$H(;$U" 7R*8E M#0$L^V,4+C/ONF;#:5$HP0F,6LSM9UD 71M<*3WQ)?.15RA]:5Y:;B>%&<5= MK%\PB>5NXLT%?@Z^G+U4C**A*^TP;, @)V4GQ7HV,4G]!AY^J87\KA[]F^.* M\#'^/4HU(_ G3YW\;/$B98YD]\!V2-O)9[V M%Z>Q OW2LDE M0SSDVAFQR?#VV/ %.:8 MZ+WMCBY7WZ&<.M0\%G@OZ4'K8"F!%AIMF8ZPQY%.-+X]&8J4U.*O/S]? M?4_+K..D0X4L7MF2:+A5W1L>Q[T^$ @HJ8HJE+%SAY94LV[97_YW_;B=1>&(0;UJFQ M=0'M[,]F_R'S-]]("CF&]YR:J3E/+H4!;.+G<=><7>1E&\LX$W4?%3@,F2QB M\LT.7Z?#6FE\DS)1Y''/K[V1&P"B<"(O!GE_105]>3J:/5\F-(4<(TPDIXJ/ M#?7HT0J)V&)3E9NCE,O\Y4,$.5-6HU-(4LWU,9:0.GGWL4$M!AXG3]E\I2($ M9T<.%NS:0YHK1@!-.D7S%J?X^SNS315O;CEX/;E\E9SE#8U,H E&BD7:=OJ' MOR8R:RA9N,K9$U\35.WFD\NW[U?'.2C#EAJ=37CQ%O5^,:TCLQ6""&98=3/[ MO5)!SB0/O>=9M6!.+,1N"V!"#Z +TK36/%92V4N+:^,:9%.;&J0A3TM?S>A( M>]O@?4:(:V;%N'ZGZ$"6W>JTH"H3A(,,MX3HXI8:?,*:8-J0_M1NAT-OVC]* M6Z#<\=.:K6&E#[&0K3%B%_'Q#[YZJ;J&X$>#I9E+A]'5AY#B++W(.[ ' Y-L M.>>IV'CQJMR\HMO.Q@4V_P_^I'""X19QM..U9LN0,J U]_>;(B\M MRS,@"+A%:V=,3TT .*)SG1Z,;S(9JD%W^K>8&XKDAF%WB4%*V^P;G9 EVAL& MOZ^E[:0'[*NR9GGR>%! [81%,E+Z)?A+@_-P$=>(W6.Q(-Q(RGQ:UB&6)0$' M'>O I*0NI#"SH&;62,BG-X164];8:F![):+=0/%=?X:%O:'7\SPP; M-@E]5_)BT93P$8]K^0OQ.2E@P]3L@?#^)0A^M0*@9*#9BB+$V'H-[*%)#3]. MS]%D&,4IB7W(>B5O.S$S@0%E05&=0J.HJIZ-F[3!62['X\,$/W[^: $_+J+- M[]VLN#<)EU*$@<[W7%,VN+(7(69[AA_^N__A<8ZJ=9<7<@Z_:!J?1'[;#DS< MO'K>='M_GFZX;<1=5"YC=?,.'S7BLJ,^D:%FIN2T#0G+Z-!Z$%G$$O7--$JV M5BY6H[PMW9J*-]6KZ[*IPING=)Z+H;H1,/IP%"-*D H3Q%14'0?GDN7C,Y%E M@J/RL1XI8+?^K*XERAS%/0?B3NI1?2WR?0Z>S2UMN8QBIK;L&BG8NM<^".C" MF+YE\1F NYJ%+( _(^_FQ_8R&W&!^A,Z51P8J2!!4A+0[>IC;6)PY@Z B.4B MP )WUOBU7*Z^;UI'/Y!AL5G_3O0=N6? 71&)L[2 !,BT=@H.PYJJ/8+IBQH3 M5/"H!.CG+>0"(=9>Q*YIN.5AL&I\S*?5>Y*D#@QG,YO>;$#P3W2TMY(QJ"NK M,1"-?:YV-];"$R9.VSZ(R@"F>J8<+YUALF!C92)4+5LI?VG\/!$@*<\G?WM4 MZ>)Y7'^=(Y:&RR]R T'9&&NU:RN#]WOJ?N5W9$:W)ALY-5I,?5170 M,Y*I?XWJ>'?/18%?G9G#+\IKO0LQ)3(9M=:B[ Y^7W]%ZO9WL50F*3G204<5 M&WS/[Q:_N%_#'B_\,^V[KV@LFKX[:[W^?+SP"]KOOGIZ^?3ITT\>BCGK6I4U ME@5+]E87N&7Q[)I\_L7C1U]^]OC+)Y]]]O3S1W_^!(GG:V)%"ZFG>:GI79WK MVOWA+PH[48T< \S)K%97IJ<6]6R^CM;L'UG^[V+5BU6?Q]K]X2]5OFY:"<"H MB Q>+2+'^:VZV*#-"2\J,%)*KR8\&+"9VW"VJR-E9+%9!>3/6N3;1WQ M5J]>.7?P?G#'@TM9]$-"GQ=AG&)MHHM-!P>]F9.9!VN]F;,$9ST.1->)#%HH(EA(C_$T< MU$I#I- X3W2,QUIK*U<"I2%2Y+$ M;&71:/9;JL2$,ZP+45<"4OC]H@;(#0I"M!4AR$%84HB<%4#K6RZ(BNCSM]FT#E!$)R<[/D MDH.@%33G\"IH$%1N-(NO@G7C=RZQ)/"*5=8)0\4\I4I)GRC>B8!%11,URJUA M06HA\:''#JUCXJCP[_Q;1R-3+MQ6)HP*DF-UQ&2D1X 1G>-;8* >5BGQZY*7+K4K+7_DK]:ZXP_4S MEM>R9,36JV (20!<3: 1N\6W8'?,'T- ]>&@88/<80$&9^+B(_\ M6A[G81+P83;YW.>0-:#LT XQ+TCHI4RWE.FF=LFLPH8WK'![$FT%=9@P#78^ M?.BV3$$5L\MGRA$DV0DQ=YHPFB@4^J-,Z%"1RD<'37$,Y%>)X&R63A_*R(]& MRFAU^C_FD%EHN,_#HTZ&BYE2FVN2\Y;DN7)7^/>0Q'/*2<\E[J+AP-+3@A3K+%A:5QM&SHL][0R!O++NAPV@T;2@8\]Y P@B63P:/\7W?ZE+FW MR/N<"Q;^G\.WI$_%67]RI67[+-OGK+>/ @JXXL>2+JX(L]=RJP"5D,THJY1+R?8![#0-L% @)9J F[+ M"HT^$]!Q=WDV(%N0>>^CM9&PI372YA>X@1+-,$,^E5Y>1VVSJ!JY=AM2#@$4 M@T8YO#E0(>>:>%U*ZL+^-!4+G6H;TST?."Q;%C;Y(4^/VIQ!UHQ M?QEB:39PEX3N>[::GBS5^%7;7Y J_?J(IV'2NRLF X^ $P6P1!) (W'0>;> MIUU:9DL@L 0",^2Q8QY&O[5REM"L7-^#)'RHA3XV_$O9>Z= >W?/"#=RQSVB M";]=PZ>4\++^=9!=F($JF[8VM"-DQ E\FI$R<\D;ESUSUGNF=8>\;$DXUM\N M'U7T'T38"CG9#=1A:9ZO_+?DEN@/+X:]&/99&[8$S$RR&P+NC%M!5!\?.B#@ M.=+N&^)3[G9#7S0WM4@STYC4,JF]F/JYF[K/^DL&W+%XU;\&US&WZ2Q\?C)B M$O6YF^$N M>T;X]EDSMFI=7AQ9C%SF5KZF+RQ6OUC]&5M]T'SP)MU!6;.IETKSNZ[J=R,) M#YIKHUDA)P-TF\W0,B$^BH5GRHC_D8WT/"P9"12A1:%T +1Z53B?K!1S_0)A MR,["!/.IXRM.%#M%+0_@N*GY MA;Y"ZWCP;'4UY#@(#?R"<:[^JC@BIR.Z,U%I,TQ5)AKSR^!*R*!3T?MCN.+' MNFU<]=2,JBJYCG^--ZD4%M,]:B6]V^9F7AW^G3?B(DWQ8;TY:9@(58I,_]OW M'.7?AY+L9'4H#PBS3 4A2C?RI_.B:.FKR6#R-FB#6EU,5A!>/>O0+V(E>?4( MV$KL%G@HM>U/>X=;MKN9'+U)1\2ITP6H('YP.]#,AKV>;*Z[^)NP%J[>T=]% M+I1F4*SGV;%4,8?Z%&IX3^A,E YA1O4FZ=9F YSNSW>WC M&\>7BI%";O1!'+7+CIY' N@>DJ$*8X-ALZ+]'HUUS$>B'[>[$"=3-%V"7C6I M+FVZ.9..^M+47;+4)4N=LADV5#2+42R&?C%S,OBM[ HR)&N=R$T3XM-]RUP,#\V3)Z+H@" M']RBJ=A29-LKE""9CY6/;*=]N[19PZV]DO$#Y#&]QP.)92R%R*>+20L2/G4K M,SZY3LFC;PLX!B8>6^D#=YD@;F>P.-P:HKMW[=(L?*!6_I*&PDX 4?!^)043 MU8_0_2;J4P:X7*Y^P,!KTF+6;PE)H^%+_?'[,65\=\LMV&O=0O(SUPFGC63Z M_4F3GP>@F52^F^&;]_!-$"Y?N P*OOQX,23,P2B$]G-C(9TI2/?L2L M3,9+V[LR!YZ]R,"$%LXE3HV\,2L M.S 8JU7K678'VPX'7%!E"0(JRJA$N82_$W\P"LGQ/G_E6..UV0Q,^!"DM0(I MJ[)?,/I;<$5Y,D/.2$S;]"2:HP(&?D-@( MK%5*R$R[S!5D?B3':A*M\X;7\K!7?0FN!TW_NLV#,^ HLL2KKPJO,JEIRLYDQ--N[7C9+;2%"ZCO239LM#\L0' MMMY5FUTO'JL+6U\I592/)74>PK$<_-Q_8U31O6(ALW!588WYM[P;9@,2#:-D MN)AR/P3MXF+*UGL XC_7Y0XVN(Y$0_041J5HRA3S,"+ Y4@],0*4>N;@9KI9 MM\S@4K^/+E2O1PX<-N!97TW.+/'745(1&QK?I&.[+WLH%-W!8WL#KF7*PQXK MK*$G25D^[\RIVM-T74FZC_P1.LB#IX>[]* H]-Q-'?,*E!N]T\B9L5G<* MT1ZZ2$UW%T2M#3=Q,F=E%IH5,3O M81-;FYLY=9Z.3E!PI;FJFCU-[3W)=](#ENL<_D]^"U.I?;[>X8/'H9>;>M?Y MQJ4H\2[),M?NI6X%;UR2?9)EC4GOFOJJ(:-(9*%F2#*58B\EQ-,Z_(TSA/S@ M"HRDA-Z3>+>\E\H[W9'ZEFQ<1V1K2X.HE$V1)?9DE#_(=;+-_D>5+!Z&.=\O MO/KK-:(4(J4,)\9))4W MK(=4,)6SYPPG9T<+GHUV)WY5*3P-G::5BXQDZ87W_SZ:W*RD"3=/E(M,B/4V M_!]XJE"+V]'7Y&UZ'EF?DP@._^_+G\PM6#2#I$QTY;ZC!O!$"-H>O^.P5ELJ MP;F$%^N\:15=4LL)!9PHT>.=D\,H6&:8HC+52L]6_QIR%NGLO!'P^Z]RRKOQ M#;^7\BO\3W\0M_D5+U&W*P\'P6:,=.,39EE>Z$Q(1+NH#BU+@G\XO7!"Z#K[ MYKEPHA/4W@P&>%41K$_?X6E^5*)='?I0#(@_G1<^C"T['R>DFJ23&[6/*=&W M&>N6>--_ZR'DR,M@T%X36N>4"=LG8/45SM(9RN:9LMXRY[O ^!88 MW]0NI\3,$^[FA:EYV2#_R1O$EDVHGD+ULJ%E;1)EE0&(:DMT%)P=2$*WV/9B MVV=LVQO_\-ZKJR2U-E*8P?8T0?GBLQ>[/FN[9MA"ANXFARDIE;ZM0"W&O!CS M61OS/*,^\N:%4__\7MAB[._FN;?4H[[B@-K?L?*WO=-1KV(E/P>(B7:)DA42J)(20!O1PPOM]!RG;:.G?-*VFO^7[9E;\#D M3(40)J%H7(E!SPS4O')UC#+]7P9WN7HQM-1C)[EM9EIXY7@ZO:GIJQ&*I"!_ M(=&O@'>6D5C\N\#C6,.;):99;WKC!+U$TT5O5GA.YXI4Y[E)5:,/ II/\&43 MW0HAYP1B($#A_C50DZ<'[BG(6GS4DT ?]3:S1 ZB-)^B'FOL&M(Q\&9AH:." M+F1 MB,LM1(^T#"/A>VE0$/:X3YF,*,D A6-(Q=L MK_HIFNI1N#\K'?$&KY1#A:8F*[0LI65O.!;L[(=" :G##^ -OC#0-.PI2*U_ MZL)[%/^B_?]]*8+QGS]YHCB<%]\^UQ&,,)&H4R&Z]/EJ-_B7I6S]8$(\9H2J MO''D$CKSR<+U?I/3/$@M&AWS3X_ES4OZ3[@V#$ZP:L3J[S0D0>.20*4>N2H: M!C>'^E5-M=+;0/'Q3:0=X=&-8#PI_9?MZ!L=#9>4;#U;U+4@1S^!-N-6@,,T M3L[:T"EOJ0#5_WWY4R9CX^HR=?[%7RGB8M.Z9Z&+L-["/I M&$"VNFZJH>Z%<808A?3.J5=#.\4^!,\8)"U('DBG!F04(1$EB=%FNAE!CO'B M_1.N!V+P%*"*+9HGXH,A,H@!94JGI2H4J,[R%!OY"!*50%\6Z MGYX!B_,YDTE7/=P!HWL80ZKWPTD^D!'5]R,_[TBNZEQI1"%<>PLG0T3U4&R4?D/)(W_&>)E#V0W7P_+_B+$W:ZL!?$ M4.(4-=L9F:''!4L'-ZJ2-T50[_] ^>T M&=NP5>GDU+,_.":>#=DY-9\)F3'_KE(PY-WV"E'>>J'V8GTY5ZB M9]!)K+V1A>%A65 ?7OKK^:4PLS(TX\P$'NER@DC.1GLV@ 5;7*Y&>3BR0UE*T>1!Y/N^'=4]JPXV$[XR^2-N MJ"2Z(,)6;GJV)Q\%>@=;!-;*$$WBK2>AYN7J^X0?B)X%#Q^N1[D;Y068+Y3Q M]D-3$;TE!WD;5W!X)X/H/L&A_.DJ;Q'PF\0"6=:)/0UF%G-L)@.]?!3*YH\_ M\\HY'CT+IM@9*AY8>@_N&AETBUG(!*8]17+?#;BMPV$M'U5Y &_/E "SV6C7 M)\8.@7T(=2EHOVXV88"/?EJY->8'/$^@LP(.8'5J-A2:;RE!XYWFU9<3[81* MGPX&GAPU9=\!WQ?&S_M($L*%"HVX+(/DB, BN$0,7BJ+0>&8=Y8VI\*JY0O" MX9 DI.*W@HY@FUY9:%_TS]YV42>EC!Q"DUQU++M7] 0[YZUW%TBLXBD^^YPA MKD1MQ\?$U$81.<)M64O1AL-)9M4-ARU,=1V*M"K5F[#/\ $W/3UQOJ5>?K-K MB%+%WYN-996[*3Q\*N MR?=KK0&9^6W+G)F*LJ8M69*T9!]ODON13YE^MDR9?J ITX_Z=$K+D'(PQ %_ M93*^JI-#Q,S]A\,D<*J,3YM00#D]96\RL\O5C^);)Q=V;=M(ATRZ>I9D\$'4 M[Y8(:6;EOG7*^B1:9SZ*;[D!)*$SI0"(V9GU$.-AX1"V))JS<.O<* M5+#CU8WS#%+Z/*,ZTIA^#Q7#I.7(SG^/YNVR4E"M*()C).*^Z02H?4&=*'0"Y-N9BL5:&\ZE,Q(:>S(]/VA\J+LBN(V M0F8@;+O.!.ZQ6\D7#/U&.G>Y@R''FH0&Y;>XN1#YWL7O ]Z\ D"*=$XL:[ M'N_]BHA Z5=5J:YN4^4EN:(K_Z8[H&[H7K4OD';_ .+Q]U42F9E4_;"%65:L$'AC?%&!^H6R)=P,E W MPUNZC^:Q;"C/Q9ZE[64&Y-$I-%/L!2FI[T-P>A\S"\/\!LAY:44 M@/5]7ML8L]OLW-YIXUSI:DU+XIY\> +145Z\[N[$>#O_@Y6ER,MB*B AL-^7 M524M?2)R\FF,(N9N8])+4*4S4 0"16VE&IHRWH60*;ZH;+Q&1@%,5C-MONCS M$T%\D;=%H'Y^ _0T2AI(+-$%FK\)H9]&$JB7$N9+_]-R/$Z69H2NLL_(QL/1 M'"4>;FRN!(48UGC+#*2[7"5N-_3"$OY[[C1/W"M6Y#KG@C,%"A,>06JU2%? MNV#JN_I[X'HQW7KR( _B%%]].]RQ M<)8267.K(_*JLWNK2D7[I/#5!-U[ AEI?M4(RNP5-%6](QKT%DSD75CKOAI7 M#MA?I.W;KV<8M6*EP/!GI=/_*2(S5&*^#AC&J$8U02M_+=P!)Z@%+)% 4B(" ML<"HNN'__NO@W9P@!JAK3-!7Q8I]/3TN)W-4H=#6OHE6?SIA%6A^=S[N\O]M M+GZ@F+ /T,T6Y2Z9V9HL"-*?F48X4+VB0QD.JDS)O9VWQ.;HEOK-@W6"S^;& M=&9E06;3>9C$G.\:#0 IV(=9DNL/JV68IGJ0T3&NQ?\/H$[QOS6F4C,K'4'<&(K*Q4@5 MGZ-Y!Y8VFFFR<5H&O]DZT?Z=QY/8*(V;LEF4K]%_B&UC[>*&IK*W6O28T*=C M]XYT=YS%B9.52G#^-C :TXZSP3:%?H;2G_&]V+%)[Y VK8^4:*ZG'4.81@-8 M0=NGROW"&DVEV'I8*Z"1CY: +6;4Z>-'JYNF1=^OH& =& Z+^()V.#<>BLO5 M.W5!WE?70Y\,M?+K*+7S83H<>)9[]#@BU$"?AX47O9$EE?@(\)SX7'\[:'UR MY" _.XT= H2!@XCL#MT0KJ6$B2:==D@FFNZG.+0$&P\YV/AEKB=G"FV0-IM0 MM:MT47V5BV+>WEOIP:F"L^2$0;>%3 =;>@DHSLZ.[E^"HGPD5UF>TS(]J.&W M(L.G%?Y);3X5.S'5(2ISCJ>L_2_MRG5I'7UB:Y.CG_49J88E5$:=2!\ZP:SS MT<_UBD2!Y7+USTX0S'(M5=6A81W2WIKY>J)YV*VX6.5_4\7RFNWV N%+4,OS MM^;/C]VQHWI,S4<'W2X?A.'S>]M>AN&(>X"A^8T6*>8B8 MZTO8XH21/NBOQD+/9M>4'+'U/L'LL?63J19ZO?P!_+0W^^4\>*A0X,\7*/ B M.//>S6I.H7,L]MO<_1 AI(">(5&[MQNY_=IX2NCV)FBE_Y^]=^&1VTC6!?]* M8?;,P@:HOGKZB3N 1K9G-!B/M);G#!:+A< J9E738I$U?'2KYM??_.*1&4FR M6E);MJM]>'&N1]U=12:3$9'Q^.(+;_Y"$$%U'@N,JG1AT,W5.])( MX!T.TOC 0OMS+D'P>[2%25W!-&LE,,5(E1W'ZTS'CL8VOMC;_+L!]RP^V0RI M#K=OHI@!^0N<^#P#O#T/3N5-9D62 7UX%I2H;]"0IXS M]3QRH=RO =?C&=W/I45;^F]/U0:*?.\/TB*3&+PYC/S6T0Q7:"N2,!>KIY4, M\Z02!=IAJ0^,#-"V);@%4'WT/KER:M*]:Q?>$KS3L)73H"P"V@U[@J5;V5$' M&E]6$RB"@ V@!].SS&$A@<=F;NNW[1>74V-^D>+NR?VMRGW).;,L $-R"%7G MC:_?AFO$'2SF+#2T*\^>9O-2'S/G4<0_IBPGQO_&A]'J9Q8QZJ> [!D<>NPW MRV0\:OQKW37M3J:(N+?^AE12)@'C#">XD<@&U"9S*NG,3<[-O;LVWU-K\1Q7 M5J2 8GJY,'U5T@G2ZVX2$4!DM?Y2D(/2N]$[ZO D^=M+V[IB9>(O>?9Q4Q%; M;>5V,8-:-_6],;T=5_DXR%2TV69 QK/26U#<-&B&6ID)#/E)@G? !9*7'?1, M84)4L^.4+/HM8]5^4AZ,*<5IX;#ET=%>(J\HSRK#C7B/65,I\XC%QNRCZ9C5 M-&1F!7!8 WY%P (6$:(>*"P^FO=I)N5X)QR'W[.G_G%R8G]WN[*K D8D0=VA M2M1)'Y*WMMZ])OH1[TMO40+I1?R(M \')KO+TO-DKG22)P#>[(@K@-6RL867 M3-N@"'L9^Z#2N<54^9B_$QCJ9##VDI(\.SF^G?I_1P0DY3X,0LY\0"6BC&.K M6Q4M9*(0[$3/9*3DISQKZAVUIAD'*D61,"T?,TL&-Q+25'9TO$2,)=?:)F1U M68)5YI:+D"L/]':6@*'1NIUQ.IFJH-G.'#K:D2@K#;E)$GZ!TK+T1V85\D9G MNNL4RH9*+T P;\MNS(G$XZ=A!21EJ]%IA,0JDVU@"(F:GB@FGZACM6Q M3M]FRJ:P>F7L!1^P\]/")6#\RKX8I7P^M"5-3Y-MI5SPW,Y^;4ET4WR1))Z^ M7ND 0C,]4_9=*-'MT93,A4A.2T!B5D(1MIB].VKVIFQ2H1!M';F8<=)/!IVQ MCA=G^8*,F%S)V 2MG54OZWN*YY1QGBM_ /*4LDAM'ZW--,E.;GA-E5C,0_:TIF MO4+"CQL'UFV3%S-$Z.K+K%X/_X/%B]8\OI'5Z 9'/(Y7JQXG0TRQF2REYKM+;"O>+)&$ MR/D04J/MX/^8OZ&LHWU.]0>4BC% 0:T,QM!&D!R:*2-O-CDBQ\ZL?_[+YEK1 M]^,W$/S:L'B<2TT;ODZ)6OT0V#=A]\15(4M?F.RN! NK/Y>%&TL4(S2#@G-A MH]24,[]P/'DJ/W"2M#LIIN+,:Q09-4$BOA:CQ^2T7PZ4NWF@$$%$L%1D9E%; MBMFTV 7+;YZE\42T'AK7:%X$V9[&QKI9"""IGCOR3U4"WY6N>P]O=3*Q,XYT M.961"^YW]&!?&<,7.PJ9$OFD2Z?)$---J"3*IY>;2_@0EGP]6QX7SUD<6&M/ MWQXT)M'S1!EDB56Z\G:*^X@E,,^+_$!&S7CA)@!)6QR9FCA6 SD/D7XF^N3, MT"MW)EXEN6? :5O?(!0Y HT2]18QN:2:YKAQ 141G'E)CEK>%KKIYK)TG!?N M_)%*-+UVG-&=L%@+"FP&!?;9@@);4&"_>''CF3;]]HRLDB@H=JC3.+0#]5FD M!QE*D_NRXV2/;2OYD4Y.>]G K>%=34[E'$,O)9=+J?(+X@?N;/'.,BK/4MG4 M'%=HRT$2M6TJJ0=O_5G>^H.=O7W.W_I3F8=!\5"JDIM?]-?ZE(G;"X\3PPN5 M:;SUW[I8?,8IVJ/SV\R[;C*N0RZ6>IG MO_%,-FK,4J88YL(11R&5O5EU-;G1E]\_[;)Q'D0&P9 B0@_RS1%3&W*O&<>F MENQ'?SS@1E5@>"D$NC\>4IQ%1@$MC(SL14Q]9"$>1"(7TT*[8:^/&8V"HC_$ M&D3[8*DM.6X+_5!^-51I2O='733=)W!]2YA+1?5MY+>C*\E>U<>P^&L:[D"^ MF??NFLD=U!\C9VV;7S6M\'?PRKS-8 *-T??86IKU^U6%CV# FT:ZX_N-J95D M]!MW"M+L#;*<]:Y)Z2#L-=-+36*7:?$K/"7ER>SVC=["[+-F6N;UD??>?CH? M'Q?21CCSM@@<&X&QQ-PS3IQO68IMHQQS[9O$%>7:C=>+<==.]:2E0RH7'EA 42P_ST6-SG-0<6W"X:1X*C M"]==4?Y2&E/X[4E3,3$6]&7'NPM&^Y7F# MPE.+!-/[2/]+PYW)'_$QS([3.7,JI@QTG62DJ NYI2>:,6:N.WC#C+5*P$N0 M MH83JG5@$N^_U-?K+Z3:!?MVD+@SX:6EIVNFFLD+*.3NW UGH>OAI%75/5E M""<9P,0:C;B,+1"HL\3'! @S$SMM/=6+6^!=<-?">O'8 MCB[TF!MJ@YAA(M2FG%!C96/GMS_\H^4TWC[\/[#AR&K85YJNJISW;L__"FR25O6"LH2X(Q M&)^.E L8NB05R[[OKIS<\NNHE/[-R7\7Y5R4\SSV[@]_,KYBQ%)0\,"!ZLSD MLJ2AAXA3M-$HY/OB=+%0_,1YB8YCVRE9URM0_D$]C;][$KG\S%#LE3_ M,&K4![[RD<[OSZ)NB[J=M;H9K\K'=\! Q49"FG.@8Q"!JQ6","OV2N*-1(G+ MVPUF&._RNOR/:8AX]L,+\?Y&2@0-D=%1?/G8L^_W:C03!>@[2LG4;M?8 !KK MOR(FYQ1-34!:U)<E&M1KK-6+IH#$-*;&*.Q0R+ILY58;2%S%WFU39+ M*K"6*O+$'"#JQ'.NESJT+F\ >'A=E*I13V0-#8(ITH-Y-[C;(RA-J$WTPD1,?A?^W*.6BE#\O MO:0JF>_=- OD]:EO_)KL29B ) 4"P11OU7Q#]]S!%[OR.*ET8W44JZ-$LZ:= M3Y1AF/+N'E1;Z/&_7C1RT<@[HY$Q^Y-!VCM35R%*.Y=FA7CL&I5,BE"'GRVM MW'SI_\6CV5F4H)9. M9"J53#'I, B%0$-(T_H/H10:9B&>&IE.#>D;4'P(^='I\?-TK9"$(L>8>U@C MVBHI,$M?D/2MZZAN@4K%*4U3%*:I"KJ13^>8 M_#LS[M;P]$E]U7\4O&O*<9;V)R>(D&U"Y;FHT*)"9ZQ"ALO@%(4!581 .MB5 MW/U"XR.YX\P<:$.-$X4P3%Y[ %WPVN)W=N,=57](+GJPZ,$9ZP'S6LIT\!U7 M,U&7K)HUSI=A[4\.K>YO0!K;C: 'VIK][,5_/__FWH,O5^#>4*S3UNLE;^D;D>BHC7TZ: MF6''/%!4,UG)OX<2?YR;#$'7B@XDMO"-&S^;(7#E 8#L&7M+X1?KA21XGU2X M8K;@T]3D5'T>T3X&?UMI*:*'?0T$]CPR].)#8 MB[=HQ!M4"I+DUR]7EE[.NF1DT8Q&W$!C?69L"(N8O^?&39C_N/G> +=+BK:; MMHC%[]$8<$%OSX8G[TW9;J])DQ!L67TR8 *X&G)UE*2K33JU(K\V ^.\"D?" M=!AMC8GP721M5@*)4\* 4@8&,K8@+Y?32TIXSY]*(5K\B;PG$#': $ [U6PSI>ZE21%[?R(*(2)!%E=Y MUS7>'$.>(<'2\*=#U#LE+:91*;PY8),2?*38H3 T;[?E664XV(2R;:DTBW6FJ3&FY=2UL.4>3H=TCMRY"*0 M8S"9$CD59%Z2O(R(=!GQ_$_ES>_TT-),4:)6B[[9"7+,>T:>%J[= MV7[+@W>*[L69]Y0 +8B&$[%=$$%D,Y$797;0E S,66E)6?.8PYD8ZN/PEH"2 MG9.22%4_Q@\&&N@@H-P;=T6#+Q-,+4NF#C=AD?U]GZ/CHLOO]E3]EQ-SJ+T3 M_M[>=F!B:N#>J.?)L?I MQ>I']O9TGLADA6),:2%:L&#UCO9$&[)F";1B@P@_ @_H&PJ*;/R"8 SK@D:8 M(JW8.B43$\XO.X:#NL7$<,GD"1G4/&'K8KI&&A(]^+7&!"]'[OKX99"Q2)P!?C]#[3\ *S7TE%R:#E6A:"(98K\=6O*7 M9 &1#!7'@?\_[9/SSQ\7WUV6W/DJ3S$='3A!)VL+'T\G4><#?(#_O'AUH1WS M"#)!@]E):X LE?.*Y!-H@;X1BZW^=[^JF*W&"^N=T MM7+#JMY@NO%B,'\7!O,;.TYR:[$"8>;&V-6*9RY-6=YCQC?U<,Z1@.:M0=R/ MAR=(K9&&^= R>!1/<@/UX>:'@7A/B;4V'?D9^]H-RI\**S3S4J&5$0X1/4%! M6_HH:0>N6Z37 O"RT/X -I554Z/Y-[I!J'\VA((VTU'IMC#RCF>ICSL5A"T7 MU+*8 A^C,1UJ,LHO*2 M\2P["Z;I82>X:$BQ1@WCG9R,C %LEP".G* M=FE?=I&-\S W>E[6V0YTU!K7*QN%]H92:)U3.M&_$&84DJ/C0\+<8.I& MP?(=F8BRQ"GOJUW=C;KC7O,+DL%%)6)&EVB>L@(/CHW@#\'6M=+]&5Y, OR MXNX]^-I5:6P>)A%CPC <$1TZ'+QC FXQ]Y_8$O+,N3>UF*0UBQF&SDC0>>+F M3#T:-HIN*2E9W)<5('C@V+Z-Q&":'::4!?OET8B%+[![!2MD#:IRDV.R)35! M)%]:_*NST^C;CS,TJ$S55<,B@E-ZY\'N ,:>ROSV] M$C&3I.326K>M!N1:I.0-[*1_MJ-W(!,N'0GAN"H^F^DH.YM'I+?4H-U^$UU&-3LECI%+)[Z$?_J2H29#+6.+ MD=VX$W[#8F=F$$KO\@F2/FOR7L&?SS5/Y/,C'0+-2(V6R$X=[$+^$+H5D3[A M0%X?S85F%"(0C;X;T3&"=X]TU"H.%OSHR:I VIX&']925?C&?X&P2P\?9BMO M1+Y@% L!",WBNLL!M=AK_UH=C$>E1@-U)PF)9SK6QZT#!!B\Y%ZE[=!6-+P9 M6'?21N'M ^/*Y+N&&W33WD](I7'Q>I% MN.<7?,_L?6X*P%/3RJQT78":9.^,[+RWWO%./4H9)7+GL.W!".FCQ&6R&TGPG/PKF>3S+F^U8O5 MGX/\^I?_MZ&R2PJG5T>'$\U(QQ12RBKX;8#_&Y:1W 4,*IK[Y_-T\[4$R_=4 M"B_X#\77E'[ X^-&U(+;79I-S5AD6!G]^H9#H8>H[. #Q-M]Q7VLF($.6*%V M+G1Z')GU(=1]][+^=5E6+KR;F*P8OQM&I6'>14/CY%(,AB M;'3(YE#S9J>5F)-QF!&Y$+<$BHV;6M@XH#&]S1S&\8>3_]FXM-54(IG^I-,KD9GQ?36Q!=-O;F:R.6G<1+Y;'KJ,0P+%R0E2CPZ1Q'WS M*[D+#LX" YR! 7ZYP 7&.!'%RO8)8$7$X$W?!8]3UVG9-ID(AE"94X/)I. M2=.)4PC@E'E_WERE9FK>X"DRZ9=)"/W.[-;=2NB^\*^4&!/@9U0-"DDV)R*' MH:05.!-#W172+\U@HQ)PH;TT),<81'R&]*])?N"OSU\^M3'AUJ$=H,HH@2,+ M(:R'UX KZDM!J.*\?X*3W/2X1V""P7ND#"ZH.H/RIA#6V?O]A5\+$ 9,T*6[3E@ MQ ^2&*.ZSY*//3N%O)T=^XVG?SAA UX^=?G]+>7SY]37;@[P6G!9L"Q MBE^(IOM(,.?P#0G-SG$+I>K*K))'&*@I#_?2E"7K^21'2+GU,D-1']WK4Z1^ MQ *!.4 M1-M#0Y4E-'L&+E$?]1!.=/SEB"6F8(KNJ9/)$5*[-G"&!F1^2# KFKZI9> < M]P/.W(90R'BL?&:1TJ(?#?*U0FGG'BF2H'8&*D%FZVXX!HLEFFX>),"K0K,G&,'-M5HLES2Y*S^" 3:P="U35UNH/#C M1&=>-(%R+"^\%2P)A%)>P0A>'KO01>#O#/Y"Z^!._:04":3"CBDB_DB)5SK[,FJ:V+VIR1]7DO\O&\#:Q MTJ2 1>L9;LJK4CI8VA+GLS_FG/\O&V0QMRA^2(+L/RYX GYSVMH=.\'\$,(* M4!IB-$KMO6;0.CKE.S K#:U@;_-K+^5>\O8YU3MC7VNX0>"40@$554#.8C:K MJYE')59HG"[>(<610CE0_E- M6VH47LE;CO 2L0M!17@,RM'ZS7GE N_0<60 M:]>XDZFFO&_@RV$BW9FE9!0;1_^ (MNU<_6*@"72C<$I4ERB&#C[1T<['H.V MF6^$+>U,%P>"!2X[[;Q(.NE@:]WF3>6M7RVH/V+ *CN8+'1GD%Z+3W*Q>O'L M!\F,2UXZ-GB4A,F*+1;>_2?^I6;:O*-/FG)"S41 JT]>Z6]_&"KW:>;7XS_/ M/2^2']CEZ"F*%IW3F%Q\]FX@O_02Y2W.".L%]W[9U/=L> 8(,$!#[9G; ETC MT4B+0?57G :!$GF%L8&UP/O%^X4:4*4*UPT=]MX2[QMXH.221FD(GN6D8X6E M7[GZ_)==CQI@T#Y)MA-[)!]MK5<>JE]L&N_J,291!)8\R.A 06'M0$(^ %9, MU\%RP/SR\$ZI M!1']68#4Y$YL3Y ?\8@G%)(**;.>26X^2.'B=).4!/DYH! MGP'1ZU6[9?&%\?OKJZ \3%U!Y++!;N3>4/3&8K^O(^?%6R;UX@M9=AA1>CY[#P# MQ)BB85S.AX81@RS1A3RY?]^>/^$4A)-VL?HGDZHQAPXO0Q%0;#0R^C&>^ENJ M)5(DQ@&]Z8YB/Q*?YW-X-@2+^Q4S2(M:WU&U_HY9:+($]:%XB(R<@[+S[D[! MY5C&N[<#!G:4*(WG/1^O?"B$I+P<4A&DYMZ6!)>([()$Y-PT0!D$^"=<'NM$ MD(,FHNW> E"G@ CR:.IR/^P-;D9]+'*);!;%W"8]H*7FH/XA#=,&MQ8>$$X1 MO,2CZ]E=XXW@VC0B.?R;^P7#SF@-8\H2Q-5^2D"P20F19BCF,O/A#",D0$5) MV_,B[3_[$ MI_0P\36();7(_ #1/) XU%A> 3)JX#"G-$WG+-'=HTI6\A/YX M$+\,VP \=G7D$/ M."A[R2@D_;/7Z=GK%R@X$E86NCPE(VK&V%#\Q6>07,UPV-UTX;_>G+?-*>'2 M(XJJ)>&128(2F,R HS55'%;.0NGG>3@*4<$?X+68$Y"2BK1C4#W\'F ,'[ -YZ8H?'RU\Y_H5L^\B/JUU&4> W&V,% L1NEPOYB02CEN MQRK;4%=+4T_>$NJ@0\T\S7UPU5U2*EN9B\&X"G03!W3V@_D:E[MDD.6)VT+> MM"^#32.?)^Q"PH#FM1!=:*8:SQBS=?0GLQ>(?F '.LK2LT?KVCWNLVZ;O" 6 M.4K=?VHQ0$UA9C31JKC\Q.FGLN34X234%)^HI'A,O1M[/^:+OXFT,)V)H%O%8N/4 MBO40VO9]'M,?TE89(H*8D#HT/9OZ6$_U&Q.LFK;-[<'A48/V/&\#QV6DX\.D M&;]>-D/=#+E%,'L.),/&P9HV>5(V&N^ZI8PO$LK'65VY6=$KUW7H: CX1Y]3J5'.*,7E>OHMUY&_T? MK:I.2&QW;4X\]AKYA@,JDO+N ?D6;@D.^&/E-IRAO(I4/[WP([?;AZDR5WJN MOOSA::8;X2_P#V^?& D/?+C_13PRQ%S[+S""=NK>C#+%]R MFX05*%Y;CQS9E;N@K@LZ<[IQG]U?T)D+.O.CBU48)9NQ7Q:-#MDDIBF K\H) MP\3V4O+$WYML2_>&OB$X&_;TQ2L5EY: *<_V!BVS('^%^ MQN,>6T?IT@@%1G9(D7.A0;H]G)2K%!L7^Q!B?C.6KRQ.9S;^,L48-N;[_*>F M->![5N+'M 7CZ-86^PE*@"2J$"K:!6WS MLDT45D=>D(;LAVJ72XI+=C(VNE#73]P+(& H_+ELZ'_#XK5#NR,,PHF=2Q.X MTM#%V[V/+=@^]O5QT]I1P@(@7']M3'&:"T/)7M%:N@12$,:6G.U MTXD0;VBW$SP0K\Q_71=-O'/LN-.8F[X=$H)'$W::5BOE']KZ;]!+0>3H*+P' M2:J/'%Q\-VFWD=:SY]#'L:A=\WCT#3+PPK2/NEC MX/J#*:1LL*&O1-">A#XO;Q">;N0 MJ3Z:L> 746E:B/$9?&2K1GC[,'"J.6A0DG+K"6&NL^+! ,2O$6G)MV(34 6- MI'N:74'RA!(48=Y[W\@$AG+/+8&);@IDXVJH8 G7H7WV>5":,;9_!K^1"GWJ MGTAERL>QA,UI>=9"1-N%]Q!W/33'AH'9O*T*R3\AER>2ER9,OI9$7$!JB&7C M!'Y2;KY8?6L )-$"FLE5(DBCJN\XAXA\\A2*LA26;LU6(LR>7A'\J7FLE=394KX@**9;OQGKJ3[FZ\Q&4),C]#I'6)13=&(2DW)$1 MEA:F>B2639>HSR[E(3( *2W:S66GR4//R%+3SLN.'/K!M13?C79:J:"$ TJ+ M!#ZJ&L'#./.NYQOYD4TG=4K+GHO-T4W\P.VG_28'AT;FS)+SPD?>P@00+0]D MC\]9FO.(XH79QK[]3&:A=?]VT;SIC&V8-EQ=818Y_(\.9 M\/7YY Z#E3/IME3"DR"ML6LSJ: &*X:OD4;?@T8?M;W)-EN)'54OM7+C,^CF MAP@X[J0NBS"GY:2:]\%[(Y=4+] _ MPOXV^VN"5\51X/I(X6/ACC'*;U?/?S1+CFR(_24\D)62J5'+BA>Z';6MC!QW M7.9RV..,;]NF%9/.-24>D([=OO("$P:D6UI">P#&VX6H@%! =!XCSKS8=="[Q$[,1UG6-CZME<%Q1%PTR>( =FY@W\N5R'6O,H5 CH'NA3(;-2 MK:4$Q &.B>7I"377NJG'N'#+/A$REWS"S8 TE\[WJ.3!: M:.^8,A1J9UF_,HHSU*9*%]9#NR'VNOOJS(QP45[I*D0:(74J\$79':K\^-6V M73QZ].B/=T4C=*]*JAG=HRW[H O-'3^Y_ M^4>"!+Q]>/_APP *,"\U7=6Y[AWS)J53SL9$MC.N:VR\HV%A _EJ2#1)+V)H M3!QE3P(?8V2U^SHJAM\]^>^B((N"G,?>_>%/*5-I\*\6N5WD]JSE=@K),!UH MY,^QJ5X/)UI:OH9GM0CY(N1G+.2,*+K, V20>=!O\$@2UP7=E?5F7.:1?H2+ M4\*_1*KOW][(0VV1C,^XV0A9ZO:-Z[4!);;7M"V*.@D%D+%8?IN]H(.]N$U' MKF(09 <8Q0DZ-9X3:?F6R?AEJS?EYLV:\\S>KFSO%?YFNBJAVL?BK@RFZ,8. M0"&SZ=N2@M(SBS?/)NEW]@CX!PL"?D' _Q((^,MR7?:K?'6-/LV6*]@T2A!L M!9DP$8 >?CB'++:V"R0&\EI;,4ILCAY8_ M-1F';A$*$35A$^*Y3OEBJ \#$HA>5E*4AC6$!AK&8I*6 [F8%@:N POC:TB7:"'K^61HX_34SZ3@6+@GD1 JW]HN2#"MUPN/UXJV\>/Z7 MR1,&Y!QZQU!EQ>[$T6;!3Y\&AH ML9/5Y7$VX1=PW)BRSD>4-!60+I-;^NNUK#&ML07PU@BU1=@!:IH@\(09A%(J M)#NB3H;(YZ!30>-\VE"PYKYPF+SJBA\>I7L)6@;ML R44AL+IQ*:>EM@U\[T ME(=^S(U'Z+(RE-=1S,\B(HR[B"Q#J+5 ?>L@\Y+F5VU* J3*A5;KF^:MSM',CM!DDLR-T>TEXP;7; /!I0A<@Z5O, M4>J=96)1BF":/B^H[/A+0F=T=!CG5( +Y(XUANU,&<,D7!$JK0%-(-?VQ.3)&"!$O!1SA-ABAYESJ0& 23C+K5 <5)V_I!A MA"';0[/(YV.N:6)5)<])P7&!D3BJW;QYCKQJ@VC>!MC.3_X176&KV MTPRZ7TZ'LS$#'VY/__"G'\B1_B%24Q-\E:AX'#M$+RD*[X^_H=E?WNW'._G) M_S?,_&PKS/L^R/M>SOFS$X+;G_-(!V+N)0X?CB>9JX&A?A0[^W *_PMY,..W M.=,V&CF1]PKVUM:'&?FQ\'5)T_VS)L*U5\3U9+X?SNI9A& ZA\)-(YAVHA5 M914);Z'EE?./O+9,K]R*0?EZ/G "#C_3,I'9QE&Y,1& M'B#<2I*$KB\)ESE_S^SFSR/=P SVMCO!/NB8!2 ^>";SQ]U6N!I3=(J$ MY.&.U%Q>7.7^]SNW=.O>EHXC]IRPV,^@\*1/PXL!-\!*<\7F$ED T(CB*U?^ M:6F(+Y(4M9(K2 N']C)LRG8S[*^H&3;T::@(HMFD3);"U&;A-L@;6GD+6;8D MWNIDYI3UX K7+RY;CQ MG11L=)9/-G&^.$UC![E%SQST-$'/-*^/%/] PTA:\=+,2%:[+Z$XHP?4*+&# MHYR+@?2B4^:&:\?A@+:2AL(@/RUS\W1,[T.E^*#Z^YSZ<495>&IU-=G$\8.* M6QG:U_R"D;<35HF^ 9=P;]_?S*[3/??3L>_FL^C83/14R*,)#I;1/.=[3("C MJ<# B")%.%.@5(F"#A:GU'K7Q$+3-=O^F@9@A>-5W7UC%)EQ($Q. MT$%@;'-#?(L8-@N\-AO$!C194=JVP8C"J)7P#453(HC +70 @/]D7M!H"+_A M_F%BZ!WK[%AC7#WB;AM=DW82#PG5S9E-WRS5!YGX'1?E4C/X^2+._(MOJ_TZ"G MH4X!0T)7$L8^H4#(*)7K60(.<;C$?YE'"L8H17VC8%29)5X@Q-I1X&_U4PEY[I0\@@I!NN^F*N<4+J.K\5JRZ'J/?UQ- 1)U(W9!JVB M WXP4$&D!7\,*1P8YKPPL8MEAS!LTR>.= RZ4N:O8W@A(3(*A@V29IF2Q-\C M6X[L>0Q3**^9L&%)0B%6;*;6[ ;C]6&[JH$\!:,)Y#'@'OCV&=DW,Q[MD!]Y M$J6@"P-H0G/C#5'.58, TN=>J6(GE>I*4(=7B:G>DNUB5Y3<2)>=N%R@(]P# M$I@S/D]> 3^FYFAI M%UF#T^=%DF"Y\?"(MU&=M((:7K%JA8PK#9?\**>.2GQ3WPL[_O[YH\XN* A7 M[7A#?OYQ1DDVA>SK^H3;C*8K4FY1.A2CF@6E9#YKRA^.JKF=/U:26N7 0ZC: M9#G4QA[S3YP,HIZ*ABG1(S4$ M K]<$,YXHYK/N/"0:V+Y#I:2VS8D@8=$$X^?30#1"OD*;(]Q9,*[(5%"%KA@ MHL[.$?DX'MV<9;AAG&9@8[2G7I:RD6JV\53^%HCSCYEJ6%S;W[K3V7HJHUG+J4=AL.#2:'\A=<,98M],CGRGN- ,6;"($=$.EDEP +-I*/IGQ$YB13#%%2,6U-(!QK"2A9:&+_,RG:Y>= M_CJXP-'RCQB7*9LI)0NTRGAQX:/BIA5$KX=/B-%G.YEQR[Y27,28:X"Z"/F> MDG',J84P5%#"N*&.4O]T]O%1Y5TVY&,#9?(@J(D;-A(FBJ$#VM$^#V,:H7NR M4,+)92YCO&1#WC[QNPK=9O3VT_TDX!0/P<-L8NO VGIJK-J* &*I(B.Y$(7[ MC<$W&4L=&M":,8CD+IRNBS6<#?0W>0TW'H2U*!W'0B1I&R62*2* L:10;*1_ M-.B5B8[IFQA^+IX]7>$R+T;HMDD,>D(AQJ,7"R%NYA@XL#2GB34Q-71X\Q!: MJ)/53&XTV%"8=X,ZCN.PD9T_79?42$5)_$/U8TLU9+\B)6S6F1Q2C8$?+CHI M&RK$C9@@+"NF&=3[LC-31(I1K0=1+J94@\S#FX)09V7T8%)JC8VCS= 3$ G# MD6LO8)B$C0<:E75Y,#!N),FKVLMDW&!FLX/9>9XOZ7ZQB/U$W,+L36 M67^8F*A-1CZ'D&PT/$$Z4L!O$TZ/]WR\^-;[)KOYT;+W>;:36(5K;7S1Z*N2 M256P6'^N;!A/XG_^34'8M65:#J9/:69O\9VA.Q'%T +,3OY$8! M HR0NO@4=UP>.XH(['0\/I6\@'7B-(=/X0>'U&/;U%[.QE]*]"H:)*&0'X_: MT85O%#C46=H0RM7%.;?PRVG#&Z222Y!]OO 08,G0IBY4(P@-2-2+O(G^T0D5T?&+2H)@8W1C> MI 0L2ZYMR;7]G.JYF6"44I.08(W]4[69,^H [&OBHIANBG&8H)(=)LI[%1 ? MWY JD&_#<%7\JFMHZIA$V#-Y!HL*Y:/?IBQH9",YYOZ5Q4C:5BWGG^Q:A[9I MP[;_\I)$/#M5N9V%^=XX[RDMC\U D2./H %$5IB5QY_$Y!V>HKC+=^8P6.V) M+06]@%S-8L9 M,GXAKG=O"7:;.O9:M(7F2?"B=;:Q?AI=9**A6A*OD<1']TX6QTT+3RO0E'G_ M'_Q&7"-W-=UE>F9/7DG1D/$]4V,Z<<)H MK_%^Z83NV8U9*"OO+/#QT0)\7("/'UVL0@R4?8COU=K\TJ6P5(TK6C&3=-(J MAC,DA8*ES5PX[\HISQX/1D2EQ2H M[+%/#HOF(LB3#U ^4Q4TM4#B"TW *VW&1' C&5?LK'Z:$X7LWO4TWOC#\'V& MQ51@.3+D=_)=?PMY$]3)Y-@1ZAG,AY4&S!FR6'U/4]TM;._KU:5A0VBI$L1@ M+&R(4^IJE %]1LK?K)" VG-M&,GOYU,$<:L8^4)Y/Q3X=H2 MB#I1#/>!QM5@I1++NIC2NVI*868,$-!*S+LE-()786"LN$HAD_AB?X447Q88 M4;0HILK6.2[M*;36)G _&/TK!"=<>OE@=",[);>&-P8RN!M C@QH-)<69*B, MN"6[ZC>.TKAS!&]&$BYAP\85X,H 5GWCCJ9F M%::(4T@Z%I,]N+VI"A]Y:LRZTKYH(V=S&>5ZR23_KHS*\6S,IU0"2RQ?<. M+SV3F?D=6 LBY4?*$2! 3MXNXE.+?@9$M(-.@T?WG_P@"$*?W?YY?'>JSV, M^U-O8OUU_0>N2.Z?>C'^)/G IO^4YET+I)!\?*]%#$00F?N M^2S8H?/KZ7NO1VKURJ+4:IA?L MA%V#T%X4!IZ**QP4[H-^)RC0"HQ28*WJJBF0*(A:LX M EF9P^K8M87CH<"U);GR-\NEN!+$N=#T#)S[ODWT6S* M &\Z?=DR'33B9"C#+(I-Y7?-[W3>2#@ZERZT$P]\) MK^0ST%F6@OV" 1=4&(Q*5;Y!:"P-,XZC[#>@?(RQPZ7PN$5;VJG5G8*.#7>: M7S4W4<+V&5KZ5C/#'VDMH?(KO+DPP#]Y/Z$#F-H,FS$+B_A[P5RK3)A;:06' MOI2/'%*=G7C;P%" _+VRQ+,Y.B^7]:)N:,6'ASA&(4Z90;=B51Y2JEW<]?Z:IL M*F9BY7X07(I^JA7NA64DM,Y&BFTN*])%F"Z+D=+P4VA*]MH%%H03ZI#O&X2O M 1F&0(.(*WCV%,^I[,9:0Y237+3U(45//1M=2LM\@NZ%,^#-H4\VO4G>B%(= M!'I-D_%SQ4S"CY]MW9)35'#!E0,Z)M4\DC\EC4;\# 1ZI^%E4\+*U@R B3L3 MUYLL-Z7,(RQ%Q6&(U##7U*7"T_N8$T0Q8N:9+U8OJ/>%>":H2(GQ9N5,E[O? MZGP5J6[C MQ).X]&S<250T:)J(4G,3%Y"LTB]9GR5[SXI/4=(D.':P,+MM:#?.%H-N,:3G M;@=["X9O!L/W>,'P+1B^7Z_]@OMR#353&(UJ_80VVMP/("M4O+9-<:W=.[B9 M+;/AXAV?G?C=SJH]&XW64/=F,DICGJU2A2\4;CF5&@FX"R;=F,STN:'+9XJ. M$]>*AY ;[VMK&^,B%)\+%<$SY_P\<2OGN7,*'U+'5:FV"],O!0?6/2!$*=H"-TWQ& MGI#4C_YBGJ)\X@8HYG! [I_\79HF,\ZN]C0HFR:_.V%MT0% '![&00],*E<= M1QE8)]BG\;R?@#U<2R%14L0A=+4O*.XMUP_+^B=Z^UV.?+8:6$.#)^G6*/N$DPLIF3JM 9.@(>T3[/=HIY* M1'YT)\6[A;AD U:<0DNF8=G_]__U]N']!U]^;2;KQ&PBAX.@&.%WK58B3%&= M L84[LR#16PY7<=_ED["](1H,1U(0AWE-Q S)N/,%%673'O- LB.FHM,VI]A M65*-M&=Z!YROTCB,"G6)F*&"*,3K2343I:X]K!/^HFW4QW@$S+1PS7L<<5#-^@TJY?V;GC.IT!N(P5T(N!;79+IQ"ON4 M:>J%9J6V^5739B/T)9\51)MCX1%"9\6IH'G)E-.5.GY)!UA?RWJ#"01&V_G@ M31(#"A#5T,K_X MOM'I4"86:,M]LC]-,BA&^PZV2NW ABFOCAU[:?!L.G(6_8-M7'FEM$RZ CZ1 M:AI[3QV,(UQR8EEFB^@ GC80QV8#T&J)J4="06M?N'V(8*?UTM4QP@JH?X33 M+[ +3:>OT-NO8>-T_S3I$SAMM\UHADZ+F&<2C'(]C.;L M)&E?VA%S_,4T4GAC<5V4JZL)P-O=O!GQ"(V]ON/NX!%-<3=T5(XC!CI*BRGG M\>G;I-/S*F(!HRPCNZGV./$2OR.2O=8\8YIGHZOM\\#.&X$[)V:;-FV_;:JR M(0"4K91'1HS0>U$B81HG:4J!=U)2G;$G4R%[/R!(BJ.F#&OB?QRJ'&+]"[/B M-LN@\/,\#S].S@.Y=U$R=GDW7_MW[!=.>L6_*KZ.0W12;W:+53,W!;RK%D MS&U!'BP[@[0U;YPB?C.%=?%EM\^PXE+>7&D>\2'?4#3D0Y,DR:215T.&7 M;1PS7$6_:#SE:R:8G%V?5O64XW>T 5A^6';#]5N!=(Z-'FU266L$RM=/YIA' MV4S72M\@4MZ(U3VQFV%7=-/]UUKV!)N:61NC)3\AI\C%<9V5LB1735GPW:D7 MER<2RDXDF\,6./*>MI+'"3(5!X:FAT&0H?=O%R81T6*P0L!-R6#U8BK4W"-, M&2W_L X A76Y&YI!>.=P2>R,0H43.A0,52; ,6NC/U[0[:PQH-LX:IIC7+=F M2Z:(.HOBYM4$8H,X8T(1CQ$?('#I\%GY:CTMG<=TXE C/-F4!TX FKDR#($/ M#92A!I_.P7VFS#^\X>]GW]@!#_9-B64$QMCUWG?TAT*A<; RHR>0Z>V<0;)] M&N17\P6\5/A71'&09: ^L<#P!,7,:H4P5:SI++DI[T34THYE9O9NRK#*A!>K M2'A<2&)X?ZA*"\\/KC3)!/@#IKM [:T!R3Y*&; L MK5%2.>D]GK;:L.X*C!A)G*K!A MCDPMQ *<8;( 5!: RB\/X;Z)N$%J MK$I7@Z'%8J#(!3?P2F)*6'JRST]*;F=\?J1Y:^!VQ&D2.^^UF2-'7% ([>5P M,RZ)IQ&HLZ"YY!N_0>E2&KEF>DXTT3[M)4B==&8;V9>:L JS>,:\^?XT]UZ# MMZ7):,FOSNS +,HK786(%$1'I1; DRH_?K6MW-OWD=B?AJXOMT=@3*"[]#VO M-=[W_IKD\EX)9O"O $;&=V>EV'LP]Z[+HK_\ZM'%HT>/_GA7Q%KWJJQI6VC+ M/N@"-VR>W9,GGS^X_\7C!U\\?/SXT9/[7_Z13JRW#^\_?!C.+/-2TU6=Z]X) M.^&DUD39IQN]:HZ @7'H2R*?"7^+H!\?J\3O!E1/!(-$Q-BH/VT2.*N9,1?W M/_$:PO!0B9:Y LN@]*^CVOEW(_]=U&]1O_/8NS_\Z9JQ=828X..8(^NYR069 M-(N&LO3:N3IE'N"LL65>Z,9*)TV?Q.YE6^KY@*T+PYQA>2,"#_)U[1=PK8! M_!AQI&E>?E&^1?G^)RD?TW[,M%:3!A)J0(XQ.?$"]5O4UD5G%ITY:YTQ_N+L MO#,[$SNO>M?6S%8PYL\L!E80E\Q:LQ]"DKH9^J0]]QTQZ:(]B_:2;A".WT-1T=BSPO\GS&\BRF>W/9 )4-"SYA MUH9WT@(@:0$)H5AYFCV#&%T3A"SN!,2C^_? ^;3T1B&%3([4; [LXI0^+?"8 M]Y[_\XMV^BU@SG,5EX]*"G4#6>1\[EI8[L?\-OTED10V@PQT:-IJX3L]/]FY M+1)O0L#9>S_DT$^G.LW&QPB/78M1U!2U&^+LFZ)WE%K>30.-;C_^.N?00&>) M9@C-R!&"#[R2_B'4OV/: #O$)(;JVH3#3#VZU CLNUMV<)'FZ<9]5U9$?1/( M[87D*G;3!*E3U!9:XJK*".RY( M4A?^TBFQ?C!%9":P4TPL'Z%'!H)L$H.,C0#"*#P0]=1LF1.)Q]U[44"_96SF M,>7B"&!LT/G78N&);;0I3;,&X!9M9YW,8\& I[YMN-0@$,4Y >%^(?,2CH%? M@AJO9'JI=@\:@_QN-D@K;'&2#$Z#A*$KRI_;LZ#(*5+O%B-[1XWL]S@]-Z&Y ME&37U<)*Z,7/GKY>:KPEVO-4/Q'LB4V^&=T?G8J1$4 3 3L&/+Z*[*3&O,%X M9:;E&O,ZY.^BVQ)8Z4?%1R'.J.DHH#!Q<,0\_4X"U:C2:6$U')-8CE35$ EMHW(E# 5",A][Z#_(_0^T!1>KEX;@QO)W?^@E3[W3#V'@ ME@F.TD!.>8PYXLJ%@*'PG!)PHCNZ(5MNEI05X2,FA8&;SL@HDE('[5RK:PFEDW!33Y*OD47M7$"_#=8[6 MFSCJRUCZ9';WWN5HE*=F_61RF'TQ?7,7S/S2(#K3(/K9TB"Z-(A^=+&Z]:&1 MMTQB&V*R0 JK'7MV5-2I'$!HRK.$;W.K"$0Q$@3$YH+%<;VCHB>.JT:UY+C" M8QJJKFF5E8EH'Q%T,^$$NVL)3W4;Q@#!VZID8NF(*6=,=S3BQ]BG2Z%,EG4X ME2W-3+G6HY\9:A@QXWVSC>"8S:]U)'S3!FH0)L51-]?,I(L/%)MB71&\@;&_ M&N:YS4_DIJ(07YG86&1 #3V2V:4\$OJ,6:$H,)71>.3^F$PAF#R@O6-JYVS2 M>GMHNC(ACJ9IX$1T/1I7\X$5DE]C MCOS,\YW]K)'_[T W&I_!"G"[VP)$2@ M3'S&_+*OP"_[&]8\EO?[D0I%/P96568+-GRWD4?X,N^XK4IY >R43U#H4SQ= MN?!WS'H#T5'7.W>HCIP'*_PKJ8ZC>=4IO[#_!^$4Z\V(6U7"4#]X[UP=:9F8F)KIFRF1O^H]=_EB*>[\YS<;/%O9+OP OQA.9 MMQ_;5@/<9^:="LH0/7!BV%8&<_I&/7B/',1]6W94LL"L)QY7B\[&8R/'-;DT M365@]@N/Q@(66\!B4[G,.8XETQ[9(\VDZ/0$$B\WDV%';2E^[MKUUS *1-TL MEQQ_*203[>%!8U#$&R,.U"+P*0M%#&%H9C2&<@1VQ#N1R\2+*F5 7E9#&]V[1!O# MV-?QMQ=-6S3MO#5M<]-YXMW$)I2UN ZJJ&,L6[RP5I!'9V,X!A<%7!3PO!4PMH=UESX> MFTTV2)F\:RH#XI*8DZ-HD&*C_SV&;/0K8*6'EH.'37Y !82\K;+? M+X1*BSJ=O3K9-/-J;[25,/>A6JI-D#1:+TK MDGRG$#J5C?NKH(7W9^7YO]D3]T[6/K MA:-E48KS5@K3HD##GFONKP#91&&Z'!8Y7N3XK.78$-B1.:[]WRKOWW=5'"&N M%*I!YFG4]CC6MM:>VHS*/6L$$K#M4%'7E8]0?O(?T6*CN&&,AV3$(-5N?5?1L/YQ@FT*,[F"?%D2$SR;6A%F)YM?I*1 MPA'***-'5T/="D"*-(0G)8+N=_(> M_PO@IC)AHK MR?]O,ZRZ2Q)A_+5%LX[0HT'Y(H@1XH=$DTX8DBIWX+\WRDM$ M0X22E/XL".Y0^QU#"[O^DO4FK[K&X/A/0$9F\"&<\5+?C_$J 9/2M 9(N264 MYU$VAG2=2&5PF W2W*U;>1=4:&G#GFG#_GQIPU[:L'^!6B];ORV2CFL'C-N< M-9JW.S3)'%]1'K5-3GBY69"KYC)QA?FJ.QJ'16,>4 /#\,N)W MHN7BX\)>M8HC? ^#_U>'Z!\TRX7K,P M]QK*S%)&^]-E^E\H<\.F;#?#'F<;93@28J9X@N^'+H9$A+.5!97CUP['4C,X MQGQHNS(%7R18=$)FREO9H/79>Z-8FO=0B4"6O 7>22KP<%N*SIUDDW4W8OWE M\'N7M7Z>=&TT$-Z@3HQE* 2):W>9,,,OG:1M^ M(3G/=[JDRWE[=JIP^ZY[??D2SFPCIC"^?>['JP9DKBD3"T2@3L=.IF2U[L!D M>C@NWZ56%$B(OLPK0V9480;MR'FDFKNJ&O)%Y=*AWRJLCO#!_B4DJLBI.R3+ MF^MZ1TR94XX*C?MROH?59*N"\@@SD\8^V";,4@;%U\&*RT3/5?G&58'6@S8$ MAY>29: QC"D0$BCN>-7V]3TFJXUWJQ0 M_[HJNU*.?'5$0D90*B5Z#N/O" +XVYQKO:U9(NKCCVR3EL/X-S3E+PBUCX+H M(:_2HA.S>832#$BN4^Z\@VN1(A5QAJS$> !9&F66<6_!L-G1S>;)8AEELOW[7FH606)=-0V*; SN/"-,&?_[@3$"$ MM]O!G>Q)D1YFC^X_RAY]^>"FWDJ,WEOQ&W#%O5Q.E:!I(77S7U]>?/$ FLH7 M8S*/AT\^S[YX>#]$D$Z1UR#:".<&GW<[>B14WN8?J[&T:*,]_V.@M3);GC[& MC3L+1YRGY(9 MT[R 5,@"!CV"1SXE$O'6(5&125UR6I*G4G:,O*--&\*P"&97B+ND_(-,4DYH M+M?U7:Q^)GK'Z#JGEM_G^4,T_ MAA0DXV"7PE4Y51B5GS_7,(@:Z(EK2?OGZ?[ZCJ:?TLD84$WVL1C>D[;Y6FZS MPGG!%7E+EDGORFL//")B@V&7:>-*2G/ZM>[+8:]9TTFFHF,'&E?AD:W!_:+< M2== B3[;..RGRP@%0U!"*B6VO.&@5,V'HZ[O3,JZ_+9D5D39 MD>>=MUZD+U9/;9Z71,E_%Z=N&RO20;:,M(A3N,9U$R&;?PV+-_>[\.:^XQ2: MB0-!)T_YOBE[H''&BK(:-,LYT3T:PD(LJ;8,MQ0'[HYPW7)B$@M3E""T.I[T M2 )?0S1V;.ODT*%$,@R4)(.CP4<.[GT$RU#O0GZMS 8&B1NX+[TMK;HFTVJR MS%*RGLF<0[V8_YE\2UR66G^4J"Q6,GA\YM4V*0 MV4)A ]B3R/<@<>8"@VS,1B=3660>E_SPN,.A$7PE,O#B')NWW8:G@Q_!-]V3 M.R0U:5JO'17M_CW@:#;F1TZ[,)Y2"-L[5Y=-RZ^BZ>;-2'KTZ0N9?[?^(7.6 M/AJE07?=SHAOX=9TN$X7BN=I73%L7$I;/2N$R1O0_' \AO6\70[5NPJL^F(! M5BW JE_<,_G&AUK7,/S^?W2T!?*Z GVGT 39;HES85*8L=.U/7ENG"\H:ZU@ M:U?1^DAC"LPDJ7RU=^T.:%O4YQU%\Z[E,*]YRXR]"!7"N"DY=-9'/:*Y]6*2 M-5[\OSL@KK>S@B]^OOPQ[9X1:^,/6-?OG4)%7'P\( XYBK+#N%=OBK,;\A5$ M&A#R%2.:OA'KKYM\D;&6]NILBI5=>PFM+(4Q\5[2E]'$?Y3;]!P5HE/6,] MU;![OX"EB7S1B;/6B0,@B'P>S4@U4A]!:?"9>J!R6BKZB%B1.\#!=95OYIIU M#D=1?TFC$>9*S.1 VC+SHF.+CIVUCK5(E**@-/ASZ%X0?Y%[=)H@/O3NV-Y] MY.3%HAJ+:IRU:N1#?^FUX3\N*9M I+GLO_EZ7>7UF]7FTFW>\*\*D-^ZK6O; M4!BBP^M$R,)IDH&'8I5 'W-<>_^I9]!>Y_=&T6_B M9W6KP/.9?+.3>8M]_@;#&"D4805)@->+CBPZ"? VNG@)%G3@?T M33)V!>T4A,WG]C'&%_C] !4#%?L(Y;@^CB#-8.:IA[3C+00="]7GSVWNJH\Q M':@NZH=G QL]T?&O!"Q%K_E2^"0<=VL0O--KAC88@[V#: /G&EBDD[;4VIKM M+-&.[$1BWM%NN$%*;H>U75;.A"Z$U3#J"7O5RM:!0JD9O-]70 M0<"C2Y)0H5%PBN-GH.&H,@5\X$KR6&'2OBY6M/%G0G^4::';7#:-]*<'-O.X MGG!WZG6+'5SA9,ABFR).DOVA:H[.?<3VI@63> *21Y#(PG:3 &=E882!FQ@2=[I\!K&%#!= M4SEI5IUJV2)\HIO(1DC]G$VSE$E>4T-I;UR<*W=95YM_=/ =['' M8[;ZY"%?42Z#!L>VE[.PRC$]8+L"B-TK*/5$;LMB\*K6^C4,*&]?\_()*[F] M2<.$KUWU#'L2M3*U!Y\\2M?4EN2Y'886I1/J/)UJ!N%ZT1B,KIQ%JI(WF(7;EO6W.?\2@3UP8,G8<_\ MCF1P2KAC"+]Z1@>"__NS2WCC;0 Q3 ^$3YHV4T+.Z=>*QK]G .^HH>>GP;]' M,!P'#C,]@;RMYBB7CR(E-/Q&?VWN^.E*R-TV.9CW#0<$\Z?C^_YNV"=[/V:. M #US=W!U1W03-%45"_224,A&@3 &]&$"SPTJ>(]5T!2NA7 J/QPJ/HVP[YVH M&&U6[!AZNNFUY>W;M^)A^M_="9]L.5IFN)F2OD!2RH(\//U<5L_*Q8K1=9T\"NQB,>VJO5/; M(3"T+00]$;JMB2!X'B.=/C# W<>2R'D3^DZ97/W5>R4T+^!VY[PTHR!8TB<< MF7^)6!)G47W%.,?CJ$YC-_4:[X+>+/V>,_V>7R[]GDN_YT<7J_>)(4\ZS($& M^)\UD?>2FTZ_?+KW<>(F#WP IY(WPA79"!N T!W!BGE'!4 R&]GH!)91=';* M\UUJ87Y\H/26"AYR?_G2B-PA$L8W3&TAR/:'C@G$Q,8)":2>QL*G'= MVJ@=BQZG%.$D>$6CG".-DOOP%.,H 6*YKV.7:ASO: JZFC6=NS#]+;TR,XU* M,*RDHMM2YFF=WK%;8[$91A)T1N1UTU9%/-DG_-9H[P->JALZ(AP3 MMF'+:^<=:B\_CBFY9%ZL_P81/841HSD('NDXVV!87T\+X.0^-5QT0IB516$& M>SD/UD&@F.]J&7P!ME!_^Q4G5S;'=)RIC#F5^9M*T0BJJ3B_RGA3,I\$,ZA0 M]MH,WN'9*RDHSZDM>.ZF/QG#T@@S.0",L!9&JP"(V H@0A@RM1-1^< (2RF? M]P^UW8Y8ORQ_NJ'/T&=VFFEL*5#!! 3OY?SSU3=R:GNWH"4.=!JSV#9X!;0E M?N^!?N.)H?WET)EE^X]ZH>W(1=R6=R/L6 Z']QA_A3K3I;\D4>E# HF,KY:( M@MCA+">+R_3(E#>P4=$>8Q&W.)F0ZUTY'G?M[G(G@P6 M"I=5 M;O5C6^YVF0GA$IEE6RXR-1["-AKD),(Y58><#?^,(/][\*^ 6%.B2">#JNS3 M,"86)=0B'0TZBEGIY'AN],IUC*+&X*) K3(QW;@#>#WS'D8 M?=7$=LK[///2:4CW=>3=!'=![UJ:%\S#B0)LLAY-/XE^5O#)#//J70RV%RLX MW;AG,C%'JWY370W,:!2IT42BWM7"H1'S<".;=5GRA$HU2*=%E*9.;N"Y\\&, MT7>$E,F)T\FK>4,CC#;B(N-#"=!(W/\\C@#*:YID%RP)><=YE;<\C9M&$9;$ MGNX--X_4(>T0XEU],)0*RUK(W(GC5OABA:N7"H. ZG))%#Q2;)28-18%T;!. MKRWO_++B"DSD K0EZ2?734%CLM>:8QRT8@#$/!7WV(A#I#AG?20!,]#=**O7 M#3BV2L? JPVX@QT=)C1RR4/.&UTB(_F-#T)*"=:].>%!5.'< MFKZU;&RN$SO-1G@KN0)K,^'^<=BC$QF5=)9 M+*"E_\4D*ETTO!3 Q061!$FG3560&)P*OWL!$H8WVE*;Q:&I2B)X$G;G"K(> MQTL +N6?S^MCI[7W\ GS)./L\UVP\TO@]4ZD.1_<<"0 A.!QU '8$+J0N=V, M\_B6.UP2^63=Y:/VS]9#19K=^)?S8CJ::2->\P@SRK/S<(6DW6R*BDKQ<=O5 M@R\?/>;IVE(P^V2,HON4J_:F+#9[B[Q=Y]ZAOO?B;>5-]5,)TP@!VQ3%O>]: MD,/\"['-J[YUWL/Z ;.&.,OQS'O6P]YOT,NVZ05"8*\P#Y;2.W_[C,^\4<#( M6Q[=+QG\[ HNQ/I3P;5&<>V1'](KHH RLVON)U M[+J_#$L(Q^J_-";S :=__^U[?#FBM&E.NQVR++(J"RK8\]H#:TQN0 =\&^+K MX2!D/WF5KIZ'8D/I.$]5$C[/!,XHJ@[M)@2\,8.&=\,-"*1S[+#>*$C_R+LB M__=*TO6O",RR^I[# 6YE4Y@TJ(^?QAE+[&C8A4=7>X^1GYH]E@;/B'/GK#N[ M,13RZI/(,RL!@#A#',+"336O.RTTB2/<12^9^Z;X2JZFKS"BOZ8Q8"3[]@VM MP]79%Q_"Z.]D]NHU)G!6CM^DZ"&B)LPL;0M,\:!.CJ[#/[UV^\. " WB$->T M3XM>F-?6LO%! R4?*'S2+JYOG\7*2'R+>((N$SOQOL]$!1%^D@CW2>RB?PP, M4MU#0F3):$,D*VKV3R" (NO&WTB?.LNHMS]7;/'<=%[:(_%/%GGG]MO,39LY8.4MB%#AE;L@5\0@N62V*Q9DW64;%B[%2Q,35( M^Y $N%C]I<1L1K2LUTG^.1Q>9OPXM[C(9&HZJK$$=J8G#KTWP,CI.:G8FL6Q MQR%V/$RKQ/5+OZMY&VZAC5C;W!(=AIT(&Q&&D9B-N+'F<6(&ZSO9X<_6WMZM M[,)SWE_3ORC3-Y#HC&=E=-0#M#(X;^'0EW$XWK$G+(,61H)[$-"&,N\R%'=E MX'MUE/O0'>S-R6/(PKB0;9L/-'.-O#=R8]234*^(H*,XH2O*N=4H]D68)T.G M(W=#W_"$=LSX+ N:!BM)V^#FQ>48!VW)E)R=6MPZ4\)VETC(-S2R-P2-W@[N M'-4]*N0X2!@J!3#[H''> Y_P!+(QM,$CN\-I@*W]8(_O/SZ=E[AXOX_%>VNX M,^.SO[_JCV+T$WI/<[BII=?7PN9.KAZ'!,)])CH7,7\04^).^[(":+]17,'DP,,]S MN83M5&W8;'!ZNRX<6>^]KU0X2/-T%@\GP;\66!J:4#F?P>5Z3I2RX-+<6M#" M7/'@7R0!$M<\_+\10O8 :#!^/R8W1CG$^/B$5@L.5]OX0!17&+EGN&E;DD&F M -EM+J72'Z_[IFZN*U?L&$DX$"N03I+D-,^X5*\'ST?119Q##%GRR^2:7/2" M2A><-SF,"#4A!YX]5K>G#KUP>3EY/TQ6<9J!T(S(!U"MV\B2/NS4-YD8[1)9 MNXA/N/8A6BVH3;ZPGJQ24[O-X9J=G##+E52>YP7L!PL'<8/$Z:F:6M8^#J!* M:D&0-KI$(>T3X&4 C@AY)5Y?T !!C#"YOI'PN/91^B[D]99"W._"57Z1I#VA MW; PR#^1^I3KP>35! W$>3W67V_-D[(P3X:7R^3$;0-SE45!KI16J?3?O!*E MH-9L)**.8A+S_773OO'QEE@"+\ITPE&$.UV-'3TBHZY M3GP&KJBP>=8%-B:JJ4R@N[889E;0J3X//G3M_ -9U49;PH:!,9(@ MH?-0=5V+BMM\@[W(M5DXO$7C$[5YW6T=IY_BKT%^2.YA?"O7+E1KU(L2+#^Y M4$3C%5R]8G7I\H)\#:VEZ?L9N7#H6QQ" X3@+0._XZ2<)&_@1/=@ %\N1^KO MX4C]%ZL)]RR[4>4:_;Q&!L)<(Q,;S:%7,L2H[7#H1QA9&?QNR6,9^\&QR-(;8#QG8LF1F+D;=<8C5J-? MF#W&PQ9E@1ZUX$O,?)^WG0 NWFJD[ZA>Q48X@2V7VP!;?A[QQQQU$L-A2<(1 M=R^Y(K,%$/Z&H$4!@X,&AS3#Q-EF"] SX6/ 4_F]TF"=&A=-@"K)$UX4FD!F M]H@"54=OAOBY:5E'BMFY1HU@O3 .4=BMT47BUB)_L>>\/)HRZYW,2>1W3TCT M*V!7Y26AQ(5&&_&2=@WU:<36%2W(=XQ>N'+>$^/7R1239G.O75Q>B.FO2@>. MR]KM".;, R$3:<],XH%%MO!_(B1Y7AV[_FZX#8NQGF[<=VQ\)QK(0#*9T@G> M^M 73*V X=0VB+:ADY+NN U$,9-#>SUN*&J% HCC2$-KRS?39+=9WU(#4R'+^]2+?'FW=E:?*)LL6(@Y1":(]+(/1F30I\(+]!V]KZ_"TS#/U[@#S07\(!29)SC_D[Z=RINT1%(_D P_;T MM$2-A"[8IYJ-S=PC;NVL-G+RY;\!]WFU DM;5;#;W:E,RTY/>-7'U1]5EV7<_". MGH-/O;0(EMVD8M:N=MNR#Z^;(QA4@RH&.&:KGQK0QP$](>DM:T_5X=-ZCE\. MU9U(;FYUM37-%J:I>N1TUJN_#5XY'MY_>)_!2C7GJOUE&'O^ZK__O/I[DW.V M3;#^Q]737>O8CR:=NPM2NT \9R">#Q:(Y\+5^='%BHY.]=^ZL:M&T;(+!SL: M/RA$3,/=W-]WE^^UBX)\E:ZID&R('F'(YDM]15CV9*(#L2LRS>+%*@6=;F?" M%N$K;/3G<1@2\@U@NE!'4%WRD.&91!"9%!:L4PW_*SOA?9'5GHEXZ ^@2';W MFNV6[J=^R<@!&J7F9^(.'_Z/D3WP ME/QJ6]0$*':B7ZS;TLO@47[RD;##Z!>"\H4(0C#0/&DD5.71AN]:[OQ"NX_7 M=2C44A@X.\GZ661#H^[4?UZ\HBY6XDU[QM*T>AD:W@ $8[,8*.""!]SQET/" MG-LT7;W+=T)N)\(8LQ+1>49:2!H)F\#;1E#Y$G0 2AKM3[M#PW30#.T/['#Z M0Z@A)+W@<5&VHRL U-9-\T:_@>"Z"Z4 BQM+TKQY'RGU^,^5(!;+HLQ;(J&0 M+:8#W.QS@K^+J%K:O1^14QC\'GT3:(5B-]T+:AW P^L;>LKYN6>\@HRO431[ MI-0W8;]I4&%,#=YH*213/6"/5B1&J)IP\\+PFK?0ZD LS4NC%D9ZO- T^FX3 M:UZ531>Q Q"RKU08^Y_&E[0X"._9Z0(#L&=:?A!6%SNV-I0*%)@X9<<526, MM4&E03<3PP 8# >H]$G,0*QA37.^B]MP=O)VRUE4-!T6AU/(,R=H]]X9? "A MG!' !>QY.C(B.A%,M^6*1!"Y:1N]B9_0P?:7IT]??AH 6,0SY! 5=R%[;VD% MI&4O:@*=;#["W!],T&M:MF.^7/#:FHV>>SX!N#/Z"ZOUT9_>8^8ZHP63;[#6 MMFVCK* E0V67E'+4%M" N*HM&P#F^/ 9/XR!5K#:PIMH&)H7'8U-V6Z&/3HK MN @1B*7"$WC3_)-V6T&XBND-3ZE$G1)EN&[L&_/DN/G MAV@\7L3C)_09_9AVS_,!'K>(6V,N:?M*/M3]>^8!?&KF\C4(J^A9\[:EUR- M1N2.I(+P'K&/*['E"Q;C/N(V[X\+?%1ZIRZX(?C)98233Y3X%EY![XN(JP@]=$6(8_QYIDAN"T-=MM M"UM,-!>^V"59&_@Z92'R((AR?^KLJ7"QQ\N Y76HL9<*WV6^!9'+#20X. M["I5">IK08<(7B)OKHZJB)=)D9LRI.;D A'4\ 2M&;%$M8LN[;".&0+!.HQ M(@K/0U.(-MZT>2%6M%1SKSWW[ZB^A;YT ?7L*E:?33MB, M-0&L5?O[+7,,SE-F;NVDH7S>*4B!)P@!:4\V38L%QK:D4$HYN7KO/PF8A>8R MNI92+!'%'H)D.B4R)0/:D$MG#B0CFOX>T$S:PD>_BU8EB-@=\B1/PFE?BAOVF-KDH[885'(E?(Y<,R'<% M\1I:#MC>\VYYF[\7,B70?*(_60]QW-"@94:G!?Q&H4=*=HQ.6/\"NYXWUW\ M)_0,5!21(JKF ._HR2?/HPA5SQ5*1L!WK4DM*-IG.WD M:!P4?A/QI>3,0CS)IE5 +_NUYIS((6K=ONRV4BJ!?=/E7ZR>QE%WJ%U)3RLQ MB(G(H Z3T/*?O%K&6YD*,S1%_#)I4 HBIM.EJ+GH)KD2U,P6&30O.@/O!B;Q MY?O< &68*"+,=_X";:$6ZJ M#'X%(6/],Z=OW^"U,#W->=>77$8.1]:NY]Z@G/PI8*H#[!A%2:%<3_>3WTU4 MY4",:Q8!?IG>.^%WPL=93JSIQB7VAAUOI6QD,F)G>=W,"1;5/J?9.*@6C$X> M4;(1.Z?_]@M_VL#3#;@#M(:[R UEP6P(8#H4&[4;Y=FV^ MIV:!,K16FU5FLD3#\\"L2/_2I#!J>U3Z7;M4?_@/&HDP!%VM/UDFNQE-0*8C MZ6VO34C2H1KUZ =2&HTXZ4F(YZ&>7CUL]>B@L+WIG%HD(D&MWG0;'Q+=N%S\ M(SYTWC&/P48+V9*1/TIVJ98TA2'-"^_ZQ>SL%8-@!/I0T:BTGO#5M,:JQI^( M3U[]Y9X*U_B4^A!G*G %H]? W6*4Q3=F=].CV\ *7\.1]+LHG+:70G3R,?IWR?GVK-0#HB &8K MHM/.0T^&3EOTUQF0H!RH*B><)!2*_%C^-.1UGJV^=V_+32.CXLTG*!_4T:@S MP."&LBH":=WC+[+'CSY?=?\>"$2$] PYZ*@(-GX%_"0^4"D%DN6?_K,[<20O$OR.%(F78'Z[C^]GCQ\\2L1' M!3;FZ4%B@P]0KK%JF!K?R\,K_YQ_:SJ7K9Z!J+AIZS(7H$ ^T0/*,H8I5RI/ MGX^E74AUD(7I7-YN+I72,9DS*,@/B47])4O*[!,O?R"@SYAWJ*I6>2>@066; M2)51*#N9T4GGQG&+@V0K0&N$NBA2]7<#ZK:HP+O9OWHEZPXX#D(T*VU$S1#+ M.$R.DM_,I6"&>YH60Z87D>1Z[<67#6J86F$;=LDHHR=X[02,[ JI[^Q=NRFE M"!8 .,3'03DMFFQSYLS>T8-\])K&2KRFPH+#P776CN2CB]7?:0S&.?N2+^-> M+O[DG31%WXUK%+%];B,U04H0PICP6!:C/U-FUC$17 KPYERU%AIBTC=+VQU. MX;U/$?BD]''F<6$[J798.'8@G,U MTYBF3.@NXA#(BAI%D#8'O<:.27\^=&3P+!QK'AG?"+G*MFJN[X:+< ZGP^/7 M>)VONWSK^N/KR)M^UF?$XXO5]X#.O?$WZTY(1_=D[X\<631X]^[SG2CZ>Q[*J?.>[W/PT+6KET)WQ=!,[O.(DW;O0 2VP.+3 M31,)?A[':"R^T>T.]1>C+I'(3U\!%5SH\)^;1N[&UK+NN/>O,S2,O?@^='7Y M@&R#\=:'GD;''Y M6;IT'F['PU^W%/WK//2YV(^_*A!OJZ==3?\GI ;4:FHC\, M:HS_/'CT8'49=YUY-DZ3M$I?GO1#:!NA7J#L0K, 8 MI&#/ND%2Y#TC]N5L3X7I&^3_G-_+EVB;."XZ>>M:&25+:["+4+-HWC*:^)"7 M,JQ&>D+,:#O^G+#J'/*C] ]1&WR#A*]CVFGATT>ZEY*FA;RT@(;?Y ?T\:E. MTU!U9CW3'+# ECNE'N);1S"S, +Q.%RY.M/9UYA:4%([[8JK@#2PL75)SGHR M2S>S)#QF_'&@QZ%K\M@Y<7O %U?R%,:0*$YH@$Y0PF53 C;N=6[%L%D^YBQL MEF4&,KG]0]M0RY",!6 ;H[UR\\\J8^-\O-=Z5^W*O^$ERKESEI!\DM5+TU/U M%W_9R\4BWIZZ9-N &X&F2URB(5]F:\B\1XU;,/BV"*$+(@TA'DOF93[X0MD3 M[$!WKI61D%(D$RLENEQ65">;'[&K/) Q8\&_W:X>?/GH$8%D MO"?BO^JMNGL+'A4UJ?[-$*NP2SMSS?(PT7RZ0.J'X44M18>/(FT[*"ZWS/*@ M8HP VV,09TED+6S]_?E8AP/4!N7/I%MN,BH1DF)?5X$-HYDAXC5 M(*>V,GK27O,$&QHOB0AO^A04&01:K"LW[E_%BZ;:W+CZL9X6G%7HG M9R7#5J _%&\RLNR>^/Y2X?_-BT6W+$,^7LJ0/SL?^-N>V.7>&XMV\[__X/_Q M\+-'GS^X_^#)D]9_O\'OUTKY-W= MP-^@8CVIW[;3^NW_](W]K67REX=_NS7[:'@_?QW[ SI"=S/7[^M<>'Y? M;\_9!'\.K-L'<1:?LTW\,#[E\S><2];X?4A0TSQR5$'-W?T?]MZ].6XDQQ?] M*HS>]E[[!E53#[U*/GLB/';WC/=TCWW:[IT[?W6PR"P5QRRRADE*KOGT%T ^ MF*R')%=)I609$;O3LD0F,P'D#T@ "7Q3DP=TFMGFF523CPKR4<%HI^P>_ 7; M4)-C\JTJ<:X\P?,-NPD&I^@DW=W%*Y8[!5E6Y3#M"-I,3(;)3F5$T< M2U2?9$7Q17DT[<3(*5F*:6;ZGIH[I%B02X8K=>;IFNI4UR%K8KY.32Y=9-JI MR^74F]9S3+J0+7FE<9U&I MJJ_=427^MU1^"7[6U5YM$ WIX)2V-[0PE\FV>W$KIQR\[8 R<7K FF;2.F+1 M:B'+T:M'PR&33Z(/8E0H=9Y6*XA$44<0DA0K=>I_5[-2B& )OY;4FKIL6D#? M"07Z@B%V5OT-XY/XR8\@A\'[]V&@]'MXD-X$1HA#MW8"(9G:)*IR(@8Z?L;F M!(/^R?^Q<31<=D#!V;7H41_O(6:F735%>']ZBZ/\2F43,(%.5::<4H,X:S;=_9C .[^#*%$:"%2CF- 3W]=SCLZ_JPPW6F!"W;'AU#_!4'KP3# >4 M<#N740Y5)72JF881IST+I8@ 6%@39B:RA5L1'&1#M;+ *+DIQQ]1-ASVU"BQ M;#D8 2*_QI++OU$>&$73Q%\4I<@,+K&];2,9%76L>[V M3IEJB?/AUMKL]^98NS3'1:DR196X;NZ6J[DOZI)24RP(%_F)+G2NAL'!87;8 MU4T9?%@=":B3B6!T!D)MBI''E2GZ E"(87BIZ$!E7-&?I&PE.S?LGX&A[3P MVT=@-=N_4R=-;(FYR 1LA!,L.5X5=3S#]$*1JYZ 6)8;R'Q;G-Q&V-NH5-WH MT"&I^K+.TT;K1#CU!<@)U:VA9^CP7&'?(K =*[1D0SU13'N@"N.S J]?8#?R M!;R.>0T$^V;B%"O_/<]2;'!D,A1G+I\-W9M(/2P_2^>J11XM'-B$E^>![E2X M)XK+0JJQL20XU:XW\])E3J@YC131'->;V5?F6&@>"-9^5Z_^%NOXEZKERK3Y MLLZ5Z$[K.0;-#3E.)!P9IJ905?HX*^K$@='0M&8".W$!DI)2[G!1.EB#57F* M/%7-#6Y4XP!$-DSO-SWKL&DDUNK7V1L&MA1J%0O*A*+=IK>52I.-:J H%0LW M,J?N!7P18F&Z$&2Z.R?!!=7TEJI#IRI^-85)4"5].B/E,\P;,:=!E1'TX?,; M4P>\9T#7F)^Z0K5(5($._ X=M"62@[KW8N\C5>D"KQ1$<+XN2J&N-)SU@77] MOB9**_&%,&2!O:-AU"EU3" -8FE&93H(N? DAX^'NF+V/^O<*9F-)BP QG5> M**@A)4#]J^DLGUUC!?,95C-'\#&E.Z@R-NJ :KD0*VTXL R_;BMF.F'KI_%2 MV52M3BR# LN.4_%P5;@C5%.E#&FLX26(#7BL=4#?U/":8>L 7;K)ML_ !S2M ML*WIO!OY/0PJVR\NJ!)QJ*[F(L+&,]B@3%#RFSX% 3#DJB&,\@PTJ(+Z"L0B M@X\&TNF[9CUAV%U/5P:+=8U^XR4AF5/N$M5>1)^8TK)1P*;./YYCZP5.YK+_ MPK@>T$;()6ZA6/412:N5.OD*-^U-2SDK;G.U(C(&@[*8U+)J@$OI^_?(+)BC MD+;]KNYUBYF_UI:C/]C>@]9(I:*5XA93[9;S!JZ:VKJ8KXH;I'0YJLAW:6B3SMF8+94"UQ$DN@! )PNU"S1%HCP M"@G![36U8P:.QZH\O;J%-4L7#>T==+.V4@PP[7@3?G[WAK1++6U7M%DAZ6I% MJ(E)_1!F"%7:3&&8Z"A,O"O3&ZK]F!0+$BG:-) MKAICV2Q9 S_*&ZY\/:8/$S7KA#U7S+6ZM#O4X%)(U5W!- '3&O85$BXR-2CM MP[I$)AA*H/)5!VP'HVC'5JD4N@D[#ZZX3 M[KE4XY1R0SN_;Y%()THC<1Q(3=;,&3/]:09'#MT8DC:K ZK.@:)E8&EDH_O; M#9H3NLKH1A4)4ZGM%L2)%>A<=VPE88Q-PXVFV.+J"16C&W!R2H1)9P;+A'JT M3R(I-LB(IH)3<331$E;C>O[M=-G(\/8G4!-.>BU;JKDK9AJ F';I5%4MOR[P MCV\__,_[=R>#,: B[&Z4I%GD^-Z G"@B* M ON1#7H>!MO%,X$:FS8$E5G7D!76I[NYJK",=]-((0?H=C!0' MK51+)W.*2\IB4=15:&^G(#QFIB/?'7XG8RU9J\SJ_+DJS*JDTMIY"JTL?@.P M8H-S?9XKW%<1#@H8GFPNW-GT^_?O?H(UI&A,6&/+VEGF@I6UI+!E+G;3;7U& M7P!*]/?2%B@7QGR,\28[4(:^NNK1 ?.G@.-@+@P@T)\(NV0=8Q2-NCO1=J>2 MT*C>U-60$G9[;I!3#]X43<;HQC4YG73)9*VE)'D,B43DU03=4YMS7%2J*.]2 MQ2BB10KO@8X0ME*D$IJB_&(+GEN #QWK45_XU<%G>ZC#AL'"UK=LJ?JWO^O0 MYZ1,DVO">T<6$;RBQ9*(M8J?I'4V %M+?K3)8,G8QCO8?A0'=NH!&W%N3(*5 M[MUUA1Y@=1YG,.PH&/X=)2/+: ?)(E/5QHTS2/E3\ :VMOJ*\AILG7_K6JVF MPBO:2( O$D/9_Z1.GA5"(*!&E.NM;+'L]SQ5M;>4ATD5VEB[AJ::@:U_D\Y( M:#&FA #38'3>7,RGI\D$G=-HJEJJ;K&FW'3Z"$[M[;'MI='O3AM28Q+ /R^' MCHG[@-$?:E_9_=E4=*_6;:T [SFN-J13"3)8ML,XCW!*89LHXU$S1PU.DCHU MP#&>'&[Z70*A+FQMH+#G2:.6=7"C:CP:(51\M91X\U=K@)U( MJ+]C Z,T MJM$]5 >EZ>KR>4QR_ MG<4H;%2ZK,CX-[:5F9ILR:RID*!FJQPD,Z%.9SH92L^,-H]=GV/QB.(82P?H0_GYZ$48G)^_4&;9X(5Y7"\C-#W(=0_TM2$UU5=&'8QAU,%( MC3KHWSFA^W0L^M*I)7(1-1S=J$"4JO8[W'S^06U,! U; M*3*4VG X'H47%Q>FKA_&H=SJ%R_5"S:I?!".3H?A^?FY>8$BC532D$IBH%<> M!1U'7SBU0&Q-#_$5_=/20@U,3-7YN2U3K%-L'.R!]FU4A7&?MA!(?WUSXVL< M]!6>BB)=Y\+XTDWMC@V5-MZW '7C5'>>)O$#\%VW\;Z^Q@A?A;7H*M,7A"A/ MR4U?*6T>A.G'X=EI[S( VY1_!^Q-'?8 M@C>4HH@4QKBF4XZ3<>)QVGBVK[&ZJ:XV84>%@K=M"')8N?MJXGHER)F6FR2Q MY@*HOB%I MA/J,.,;KXL)IT+=N9B#I9QRFF MNI*^1_$(=64(EH86!KH/BVF%J2"KES#PQ(%MP:?+U6Q%-RD1!DHC)V%Q MT_6GN]$1#DE$XT+?CE?9)-=+F[14BLFR25MI>2Y).:4Y7:'7@9VM&&USH#2P MK_9?[8)W@/'X/CS^:3VU ;>8UH]_Q6@>P_%C69A1RUPS^\I:;4L%;-+E ,53 M5VY3H@:U26VXE7/E:2!L3/.\N%$5*U8OES9W4M81W/:?F1?P;J2K*N 4=7+@ M^D2:ZVX*>G $\J<03MRD1JH0B BM(WM?TTWJPR_A1=56QB]^K9VWIWM4JQX@ M.LDP :)FQ4+5KK:QM (,677"O7Y\ZW5"9="Z@W MYT+:_B"Y8W,KPY:NBFG5UY0*N0]R&?+V@;R_T$7A7VE)#&H[@]IZ)JJQ3"+* MS#Y!)U1. 0AEH+2K&*AM>:TN;1,I, R-5?Q#>[JFFO[_J@'A5#,MZ_)J&403 M<0TD%#G]-_UE$>A<&O +YQT03I3"D! M"G-E630I=.*+O6.!81CX+X8K;7^<*)D#UDJ3)&,B\P9ZPP LX[^]Z6')V )O MJS8N &6(Q2)=D-_N;-!_^>65NE9&YR2;T/#SNS=L>W4T\^^",_\X\^_1QPF_Y=W+\ (PUI%!&JJ &QIS M:9G0BM9UU-K=],*"$ M!-\\'>7S4"-0V0ISB0F+*RC[/'0O VK'0V+H[;JI0WLW1BTRH>O" M7](OXI:NF*:-J=S8R<8AK8HS4#A,EWYL?\6Y'T"LTHI7NS[8=-ZE;BW5,;*- MG.QET8_ZLN@S5A?;9-=SOL@CQ<#NOR$\@Z]E^$5UO4T5<])N0]-_:^7.KW4G MKMT3-NB?$(RNU5%I7^\)$H6MJE_WW[5SH)5DON$VG3M?'7NSZU%E/V\#C*PG M&.>/)"6E:ZF?4\%9'84R1W55[X9;E3;@!;'-S*J-,G3K2 MO"B1ZL.."S_$XBA9L51-UD0% BM35EB]C=7Y5/F$)L)B MX,'<-3'!YB8@H[=[VA0C[ 5OY@6^VS(;='ZF:D%+A9;S$S -X 6*Q)1@C=J\ MQV8^%)R17S3\T-U%?=&Y_5RE+ORJP[-V*F(K74O:2CL5)T"=.8#'391F&,Y7 MR3Q.O0N\+8A^O<8)2:D"RI.0"MF D3[K)\%-%,>FM[!RP:KK@CJBWWZ?JH]% M7Z@+)J5GYG2%UQ 65P$_*P-\4B*A"JV 3;[3ZC;,& MJWEAJVM]NWT5[$YPPCI-$!A%)&E1>Z)2^99V2@IQ/P!^8N*2^IX3PY]C92X; M981]2A%]\14&U9D"5 <1,X@P,T!?=VT^BY) MR=Y5$JO.)-I8;3_: I <$P7_W= VD-%45$N5F.9L2WV977\[7+WMI+Q+(%?R MB\* HBK@^U3=3&)?+>S(2A'5FR*[484;*2J@+DS@)UMKU^**IS-94*@4;^VK M?'A]<1[OGZ14UD4M'0*< +;^$LG*S?RG* $)H.6,H0I,@@+: M*O$FQNHVE5/^W5X?4_B)\IW&7S)=8L$Y-N !A3K9MI-8*%/30:XZI\J:9;VH MFC,6=NQV[XT8X%/\0U)=PZZR.>P3K&Y,P^@RQY9GH:DIH3&2$FEG8 !C?)R5 MY^X5%/Q@0@ >]W6UUY*J%ZF*AY43ZEE3N*V:.4YDO#+^ KIN MM=F]T=B%#LB;F-'NKN/0JH0[O-BAVE-H*RZ%:WC(1)2=8X@7[UH)\"4KS )!0=_JD*?>A'$A8 M$=.85(;(-L><,C_FHGE?!B\;56!F&2-N4YD\^]@K6Y;2/H3MXT)'PZJ:7YAJ M7E/U)]6&01<_!CP69:XBNDIFI.[K36T,:%&F6HJY'26U/4)2@$J""NT6$E'0 MAB\V2ZU%-P51E2Y(*O0DM1?PBUBZE,!WJ$H!UI%Z 1HD',:#@,<+9=XR#2B^Q)& MG3F72U%<0@U6R[:A3&74FX6LS,[M!*0\SL!_-( KTS+#*2H(YW,@;V6I:9?F M%)+6)W;G!O9['P,S3CZZ$YC13D*4_]8,R'E/3H0Y ,FU0P(M$$V:N2*H*L5& M@2M]]1J)JRUWLX%.K!SAHM,FSF/;%9B+\U9R0I4&J=JR4Z=[%4(WL02:*.J9 M51'8*L ][,U"CR8M2W)ZW\;16:0J3QY>QDH_Y+5S=ZANPY3CM3-U5%'&ZVIZ MT2;-25A'(*(B4ZFUA@BP[<.IQ/12BIV8%14,BX!CKR MNI2M^@J-I?HE)) M?CI>+<7*^J>";D&BZ8L*61>OQBD;YX)-8-RD?;"-&38&4R>MBE2&H5LI*EWQ M47Y)*?M]?8%KF&J-I"@Z)]_5 M0MOD)Y'V)KD&$9S%23&E[B1-:&=;Y5Q-TAX46GG[WJ$I943KZL< MN3YF)R>57-L+=,BMLZT7_!4.?+0!K:)0/1'H+E$3!5L1@_7#X1YLBI&QEU%^Z$,-&,];1%#K5 M>+U*)YWH<'EP]":?FK896@5&6\7&C8\J:KQ2^NLZT(#6N'/CRMKB*Y:S&JJ5 M[,_&]*Z%I(I;LE)7?-9TRC=1;K(D$UWU3'ERE*Y>4%]@X(TQ6L.5]#SMRV[D M6!M9"S*&D=O:<'+NHK2"A).ZHJ.FZ7>&O83R)8E%B4U&A,VONDG+6CIO"I ^ MLAWQGK-V;M%+HIGHD& M6D[PH,Z#,%CTA7K*V2R$4-NK1*V;O2L1:K$Q*)#4 M96-/2K3+="Q_Q>/KN /=\W8(QC60LG6['OWB=SLI;3Z28: !C]7@!QF&2@PV M2D&@:;ZUT;%8(1:5)D-[9A,;7$FU7A1U5FJ=,%8=7&!2HY293E>W:,%J2&I$ MF]*C&L>5W@GT_28=P]#%^+NVNC9HHS@X3,BH\:\):FUS'H3F40NTU ^G$+Q4]:IM M.$NUN#S1CKXFAN84T#9;-3K"J>XA4K,*-.?^[I#[^[8)[C7]IT$^=%-J_QL+,T/ORY?^3=FHG,7M&WOW+X?L'$$V ME40VI9#MK0QE>*GTIO4B'>1Z494BS149I]*7:HY24EM=IQ:&,;/UWW.5V:G^ MU60.8']I-4UC;M"=F[4AR4%G.M[K(^*FD46F7U W:-1UE=0<]2BVC!EH&1YT ML7F&RHI+8ZJ-H2.3*W/4K5I57-CL\^;&';R_=ME?FZ#JH^;:8P/I8\V/H?01H'1UQ[= M-#3U#Z, RUI0Q@M&+T("$5W!%\%XM6F,A@T#Q$UNP4/+S.L2:AO&;15-M]!! MC9VQ\"K"7%&K\$9)(6CZ/IC_>0/&J23T@B/(OS'! 3/FS=6^S0N"%RAE0M4< M#IV/8B#*)K?H1)6O5"Y6'E$.I%76FV-;%(;@?6IB ( M12_O^\"VM6,93RS]"L=,!;!83C1'58*NO0D5^*ZR5Q>9EEIM495-3%9XJ!R%NG&:';U1 M,"W6\<6B3H+9)KWPR=DS'VC/L 8[*J:W-=C*5>C5 \$:%#;)SQNT2QMCU0#? MT&?D]SS1J+S^63IK:(>2V_,,@7:!B5^D-4WC3F,FA[8)@;ET8Z_1KS3L=)&0 M5O;7>M*Z5V\K^]4+3"16@2E][63J7@UK;J,:VNC.2NNDQ.&JY4+7W:>3E*FZ M3^Y+O&IZLK3UD:T66CNK;:)7&]GM>6$E-=&6TE'?T0.%*XH.1(42-*W:M/I;706"?3^>LOFQ-*=A-)]1CY+E#8-7SZ>-=M=W/.G @I/+>;%<#[5%R\LFI089TX]9-#NE:VGS8U&MI M_&3VOE.X\FU413,1Z>3/QO]GYZ0_N'*_#K0^4E1ENYLTER4E-)JZR+;83?N# MS25KM]J.2A]9?QH3U"?.[6V3D=@40U]QI<9;6*;;I\ GR>=9+9UL0[*'I+V2 MAF6-=52UF*#EX=ZQPG/?MB\$T81Z!&-%H"S#IA:Z%K#I;BV=OKTW\.2\R7[L M1E$)SDKF#Y5[-;ED= MJYT&Z:K2),/\*%*.U%ZK5?FM.2BW5+_*C*58GIU.^SI!NP1TXP=1K0A4P0=* M"E-U^VR)E,>HW*8CELKY]$FB=+FDV ;*@++UW>=J0W< MVP.>H[K5< MKP.F+1JOQI=IZJU*MKKAC*HJ%P9T^5$TG47O/D";JA%4P5&K,5-=5Z=1ZWJZ M1C&OY*XJ5X1RW*?Q+$2W?4.3T&VK1C*L2.(LNK%%6D5/6LUTW"WEW(_7'&QM MN+MY2/-1UPZ;N_6F!FZ6?L&\UVF&THA_H(" *0L ^L?63,?A69N$FQ_TO5[ M6!W[QNG'.G?^)J2(RE@5V7O77!MB"N\&02UZNBV!;/_:M>.H<4##GYN;1\UY MT/JJ.[+:(S MG:K"2@V[9JFN[F.+&C@U':E,FBIH8.^9MK*K]>!TM=3\0=_BVGBH#QV;8OLL MC8"K9J@F> ^T"/7E-%4<5*TT'+W%.W-P*<$^7>T=!/F[.V]!<:E^7*G=&& M$(Z:*VT,4UUVN(/>C!"[5F>4J\6=58.7-8>UZ:D@G#8!VS5@PROK 1?1W!7P MT-2 W"8NZY>1]8?ODH/6V7B3=WJ]L\&=VG)F"OH\_/,M6HI-QW15^*I!B$B: M?'_']^+>M<*P/XOXXRG!OZAK!$3U-TYYY!N.)AX)U]L\CEH\WEM)8S'_.K=: M.A/7D:NW2G&-7G(\RDW)BM>W5N#UH9NGX2RHS##PL/&^-[56MO3_M2U&]+<:@70$4"UM1;VV5>EJM7=; M&GU;7& M(NY6N'@C5TO'M_K#.<=#5SL_A&WF6$N^;S5WU669?E*\^#83PM;] MVQY.WV&2#[4>PG7S(63[X0EP@BQ;;*RA\S%:JD)SKGVAW*1;6"&XU^D2WFE@ MZJ+C#Y.?.Z4X:>73H/C; IDV/\/DY=K+E"J>.9_C!3ZD@ZZ30DV-I,1+(@V MNH2*L$^.FTV#/0JHQ82^]=AT8FE:T] ';*,$XW4SQ=2:ZJN-P\S;DBR^)W1> M]CFAD\M,/GFT[[WI7/0^C['I29/,J7X1POL51RA]8_ZNG02,UW%'WY )0*JR;:*H=*?RCQJ"I5RDN%SB\\C M8X?.9&"8\(W/>\*$L9\WPH#>_XF8*,LOFL-6-SWHL9!&<[JD9Y)4TOF[%WP" M4_)O8-H&%^:$-$WQ_C>5Z\#218WD0A!"8=8UP1.V%6*/W\LA:HV$WRB \C?56YE\$NJDQX9>'R3DYT[ M(V^Z_4%=4K%M:(+)[$[%!5U;Z2,Z=Q9T9OV,EL8O!2SNC5-02!^%$Y.5JYKP MF6.LG$6EL-52/V%Q5AF\".@-Z0SAE(PP(<0&G-OM@8+?%SKW M!/TOF:@ M>AZZA=6_%*K+WD]?48KJ5,Y,_I#=:PR_OK%^-_@UK!9KK*8#7(:PFDJW?J?: MSHMHZ>:4;81CV)?_7<.)4L& +O%F,DE4R^]%,Y+NXE!1M(Z-OJ, DH^FO@$9 M]MK=]!D+Z3%^^,;QW39*F\/:QZ1*)6ZI55+@!:IW=9V M/8[@E)AE9+3H#($L*V[)7L)Y),:L@+'P4"K:R;Y4]K$IPX@0B&U PQ\<_GA4K*?[(Z8]R0=[>&&TW_FP;CH# MV_KQZ..KI31'7]L+II5'8IJ"!E2D4/7 >2=B,9^(,A@-0NJ#3 ?)J&S,S#L> M[G?"0CR(#.D1.B-$GZD1-NIKJFU)3@'4T"@CU2QLB0K: 4D:J][D^D[/>K!;A.7Z!>JGLY#B2L*)";,7X4,P.(QNE20:8LIMU@_!4XE51S3XV67O M]&S\ J7D3U6RY:%![W1X>>\SP_[Y?<_T>Z?C^S[6[UV,[__8J'^\$_KF^< / MY:H0& Q1@KK._GMPX!:D31E:5\KA^7]84">9_;3[D+4,:YGCE>ZVEAFR MDNF@DD'G 2N4;FTY5A0,8E[(ND<@UF<08Q#SA*8,8EV2=7] ;#!F$.L,B#W> MT7[8OPB'IWV@]9"$ZU@@SY^PF6ZT<+7;]MJ%/XI.FV74&Z91EUN?%153_I!& M%U/;=VIW ?49/UBBF=I^4IOQ@_'CN"2:J7VPP+-+13W&3J"CB85[WXSSW SR M^_3ZL=VS]! ^(MY6A_%<:SK[1%6_]\*/+/UW2;\_C+H\#4>#(>^AC@(3GQ2^ M4S'U!T$8ZCL"]:-Q>,Y0WUE@8JC_3L74'P1AJ.\(U ]&X<7905+M.K*'NN+% M6_&MLB_ON3JNJ8YE3BGAO;QZ[#+O2(#BX0F4/G'!1U/L($SHX.;P!^,&E^%P MO*.1\)3<7<]I]8FIQ[+7^#CI"88Q$SQ@ BN2?11)/QP-1_YQEQ4)*Y+NTI45 M21>9P(ID'T4">N32/^:R'CEHTN+PD1R=0W9TWL_EST4599RRV 6W)@=F?"%J M!X77'\09](?A>9_S4+JZ!_B\QV+:':(R5.\!U:?C<#PZXRW0T2W 2,UBVAVB M,E+O8U2?A?V+'5UGO 7\2?@[&ESW9VN\+23U<"RYN)1/KBXN[N"EDY&I[3NU MNX#^C!\LT4QM/ZG-^,'X<5P2S=3FXE+?RREVP46F?-E>[%GK#E$[*+S^8,_E M:7@^.DC/ ]X"' ;L $593!FIO43JLXNPSPD;G=T"C-0LIMTA*B/U'D@]O @' MYZ>\!3KG"N,*37YL(.,0DURIJ;L.,KX7_;TPH8.;PQ^LPP(;9SL>Z_AB=-?W M&I\*/<$P9H('3&!%LH]_,!R/+OQC+NL1UB/=I2OKD2XR@?7(7GKD8G#N'W-9 MCW"AIF/U=ZI"37'[,AM'>WSV;NY$9S8C.D+^#FX(?]!L?!J.QX<,?[+MP+DM M1T915AC=(C\KC#T4QODP'%\'K(% M)BL,'W,RAV>/Y*,\8Q_EO;S^2UE(B5>4IVG%Z9?^.RCWH+9/M/71-/B^!-D? M"+H(S_N';R'C$X..93?P^8]%MIND90#? \!?#D9A_QF2%'UBD=]6_BO6 4<" M5$Q:U@$^(LS+P45XN6N+J"/>#_YP:*,.>()TPZ/1$OZP[L-"E%&5YM>!^+H0 MN11RQY+XG$9X^&*T3'./(WM,9TX)8+1@*68Z>T%G1@M&B^Y+,=.9*WI]'P?3 MWX0441G/J)17(FY$5BSF0"KVW3WW7ONNG6X=)FT'!=D?.!J=AQ>G ]X.1[ = M^"3 (MM-TC*"[U-C^3*\/-OQ"@!O!Z^V R,XBVPW2A]G M&/JRN U[]]Q@G&#FQP;ZB\A%&67D#HN2>9JGLL*K4#?<*[(#GC%NS?*],*&# MF\,?D!N=AR/NS?*][C4^#GJ"8@R'.QZ$^!I&,OV V>V=(NBK#&Z17[6&/MHC/YI>#KB!F#? MT09CC?'LD,7D9XW158UQ-@S/^F<^\945QH%2,H]&O?BSFW[!5I#3LI@;-V21 M[^A^Y#3+CL33?**MC\K_^Q)D?Z#HY8!R60X?@_2)1WYK"^XI=BQ(Q:1E)> C MPKP<#"["TW,N)N4OBU@)' M2,6E9"?B(,"\O^N&HSSK 7PX=JK$D7\)^)@:_ M1\P2L@K2/"[F@BYC%]5,E/H789"+'5M^<)ZBQT$LGZCJHTGPO0BO/TAT.N:R M5UV5?SZ_L9AVAZ@,TWNE9>Q8S8+E_]GEGV&:Q;0[1&68WJVZ_F+ZKRX$%_QUA1QP1Z#!I.RC(_L#0RT%X,=A1CQ_Q=O"'09PD M<2PXQ:1E%> CPKP[( M&?QV%N77(DCS8!JE97 39;4(BFE0BD2(>33)1! 7.5$=?X8O3T4)?X25%/&7 MX']-RN!/&GK=_[V-RC+*JR!+HTF:I=62PRL^.Q@Y,N(+43LHO/Z V7_^Q]=A M?W#*FZ"KFX"/@2RFW2$J8_4^1[_QB.7?0[[LZ/1CG/<"DIBHC/-^X$BL0?GG)& MXO<'@LP$#YC FH@/-=_!;GN"S,:C43;^["=RB4[$M"@Q(;&X265:Y '\T]3Z MJZ*OW(/8;W\HQW9\(6H'A=[-C+[RCW@#^\>>);R<<:+O*' M@1\?V6O'N8Q'%W'RB0L^6@0<]O/=@AB,#]\)F"-^7FRT+E@#7:0K:Y$N,H&U M"">/\&YC5>(575F5=)$)K$KV:9VRXSUL5B*<@>@#Y?W927\359 5DG,,O?93 M[D3G-F(->\,S1*RDJ+'\9;\H?GE+JXWATR%YL][.V>^:$ M/PSE#!K66U[0WY\MP7KK&/76P;,X66^QWF*]Q7J+]1;KK?T24G=-*6&UY1T_ M[TQBA?]B[Q7Z<1L]7]Q)SL%P ST'WT)//<(S$'129,FWD5,]C#.Z2BN8; S3 M_$WG[Q./,Y/\;Y#'IG@^$CC#/N]4?W?VN\,LYSA;[6 RP&Y[S19(VUU'E[G\F\ M@X""&[*"ZZ:"&_:' U9O MG=MXC&^,;UXSQR-\.V1K/L8WQK<.D9GQK>OX]GQI, QN#&Y>DYG!K>O@]H+! MK4N[[GG+$[+[]1L9J9/'KIZS'B'OFV_65DSX UIC3&PF=F>)S9#"4L[$9F(S MI'2?\$QL)O9Q$ILAA:7\J(G]!/F(+AGU&#M=\7,YHS\#$1.T<4?T!$4;[CJ#]Z6EXT3_D=0:?>,/ Q$1EHG)W M]:Z ]6 P8OGWD"\;D\J?+'69(S7/Q.9/HKQ)8Q%$>1(4U4R4^\5L=HF'V(?>P)K8W-[P^][KS%I/8 Q9H('3&!=LH\NZ8>CX8['4]8E M1[+7F+1,VNZ1EG%_#]R_",?G%[P;CFYG\.>BBC*^_N.=-MHI:,Z-63N>3H?U#A.5BS,< ^#,X6.P:DN(MX,L6 M8*(R4;M!5 ;KO=Q AS3%?6*,WR??.Z-.\-\(#B_TXT9ZGO= [^XDZ"#X0:* M#HZ8HBMUWH(TCT%=9\++B% MA^&/0$F899# /."-*/AQ-.R-S/>;I],<1LYE@0=5/6V\_ 3/ _M.MSY?SU$\ MI'EG90K-H/8)FE92IO /I$8.9(MK"4R&949)L:B(*M-,B"H07X&]$C\;Q64A M)?PBE56:7S>O2&"@#&&:,^ 7#@%H$%V+0 J8+SP(!(A%J):R>;49_ *?O',% M*\M<602R 23OMIKA\T5=!I_A\0+^(:LHRY#O,%;/V6>\G1[C,M[*QKKL]5O[ MZN+B8-M*JBE*&$D6<1I5,-!M"O* PI !\<5FF0AQW*Q.4 SM1*S81XD+D"^ M@PO+X;H^[5C#;KA"N9G-FU@ -"@#XB2:PB*NHNPV6LK7/P1_VH/&FPR&Q]^/ M3V(P/Z=@Z1&> 8:^O9N8>AAGU#25?UO(*BBF@>Z$% 9_(1T%RG^:5@16ZA>_ MTJH-T=VU/>/D@Q4A("MO4UY/5%>%\6OCK "IKOJOZ?&3+%H6=74U3;^*Y/5M MFE0SF Y)CGX!%IA%"RFNI !P!50T(D!'%37V#ZO)33>I3"=IEE;+*_/^AA0G M];G3L][9V? %"LVF\X2>4^_\;'#O,X/QQ3W/C'L7Y_<\TN^=C4_O>0;,J>$>ZQMMXS&]D^D?_ GE?ZO9WZ/P,L'# M.M@?:1Y4LZ*649[(5ZS@/%%P]_5'8P7GJ8+# 6KM\YM/,8WQC>OF>,1OAVR M*#WC&^-;A\C,^-9U?'N^BV4,;@QN7I.9P:WKX+8Q=YC!S===]V2-*G8J'_3< M'/ [Z]6DE^EJ!0RO/<,@_3]2B7=: ZU=[@UR0PQ,3%0F*H.UUV!]>LGB[R%;GKC!Z$H C0,VSQRP MD=L*YW(NL6<::H_0\\.ON3 3/& "FQ5[M9 (1V<[>OR>DKOR?!TL*-SDG>#C[N!2>_!T?!J.QX=, M0[R?L>PRY#2CKA*5]0[K'3]8ZKG>.1^&XXNA5XQEO<-ZAXG*1&6GYF, _&@8 M]H>'!'B?>',T6X")RD3M!E$9K/=)'CMD2SZ?^.+WP??Y[C>-'BD"->((U/UL M_DM92(GEZ*9IQ5>9/%-&1QQD[S!I6=OODV\2GO'KR#@$X>.;#LP:9FT MW2,M@_@^96#.V!OC+W>>XP(0AU\.'GY12^![/]YHHZ.,+7>2J*S<=T87]3#. MZ2JM8+XQAE]Z7/:[XSO"=Z+Z(OY;K*?OE"N=%'4&_T<%_Y?#\QXGVW6#5SM& M<)A/SZ11XH?VH?Y>@) 5#M.YLXCC4^-Z%F2/!9GIO,4Y#?^-)IF@'S?2X[QW M?G[QXDZ"#(8;*#(X8O/B\TP$U::24$&:QR"*4B3!9!G\. +"!#!&EA9Y&!1E M<#9X$093^*&"$98B*@,!5$Z"=R(6\XDH@]$@#(;]X2"()(P]7T0E_+4JZ/E% MF<*;^%8O^#Q+I?U8+$2).S&Z!J+-838W:@ZC4>_,_=NB2/-* M/B+-U+?F,#R2YMHE!O:,:+(,% 4$^^+NE1R -^MXPIH%\!? MTINT2H'L..@,9 TF&@$VX9JD KGUSAT+&3/;$]7U@\HS($##\^+ GJ$SL# MN[I$-J(T3$$(8+/]JXY*4"XH%2B182#KQ0)$)YY%($Y)*LMZ@0(BC3 UTJ7% MJLBO"QST[8?_>?_N9# .8.6)F*=Q("1HM:@224@R=2L"$/1@&L7X>+./6U^, MX5-5&>$6"H,YRFA>(-XO@]L4IHL?A#_G@ZO@.0##6KX>J6( +NNRF'E\-%/10U#1/"Q-S*->O"_001[0]99 M%>*T9[ /<-YF)?-H2:.FN0(N_%/HK&AEAOA**8@2M.U@="F+.*5?T+(2D0%Q M:5I1(H GE3!D@>6II54P>(4H(/&3M+!:@A"*4O:"]_F=3#5K@#]DZ32%ST:P MIV$)0'UX):956'!>(26"C8&):@9R?#V#UW,0JZT$_55\3>.B%_Q]EF:"& _$ MBM,%KJN:117\#R!;>P:W@.+!3&0+P/,JO79(H"5C%F69R*\U0A%T"5IU+F!! MB+=(7'@>_QQ'L'?2:GEB!0H7G98@%K2!#,F71GX:R0GQWR"H,,.\0%;5P,Y8 M3_Q63Q2DPY7 IP"/JL%E*E$C6T7H:0I+NHL M 2H S6!),)!!>I"1EG; -VO@ED!]E19)@^1W(2D R_'BZ*3(DOU]:A^ GD!\ MV 0_?5V(7 JY0E@R63?E,D1U59@J/CA-&..J_YH>/\FB)0#3U33]*I+7MVE2 MS6!^Q W] JPXBQ927$D!FP]VC"$KF>=J[!]6$SIN4IE.T@SVQI5Y?T-:A_K< MZ5EO?'GY AFQZ;BCY]0[.[O_F6'__)YGQKV+P?">9\#6;8&UV<'>5\ MSD[O&Z??NQC?SXO3P?@1UG79&X[OH\^P=]D?M)YY@ARC'8_5!F*\.50WY_QC M\EXPF=<<<^=/X9C;J2-51YCCA^;_X7__ X[E,OAI[33_;!7_'M2;JGO\9LP[ M%C(SYG4=\][.(CAT,\)U:>L]LY'M$_D/[)"E+R@6'+G)6;YW;>(QOC&]>,\4UF!K>N@]LA;YHRN'GD>-VE"LYJT93G MYH#?R;!-TI;025M77*?>8QUUQ'6AGMOB8M(R:;TD+8,#2S"3EDG+X, 2S*1E MTOH%#GQ'GZLQ>U 1X8G*]>HQ]B[7.W!HY1D.^>.,^DU($97QC*Y\)N)&9,4" M+_MRZ5YOH(M389]T!QPRC-M!5>(/HT;GX<4I5WMD8&*B=HVH_H (HWU'T'YX M&5Z>'3)_U"?>,# Q4;M+5'] A-&^(VA_$5Z.V;1G7&*B,E$9J_W&ZN&.?=*/ M4OS]8#OXN!V8M$S:[I&607P/$#\%$#^_Y.UP/-N!2*.:=@H7/[PT&)/_6H]G=T*O(.\&4' M,%&9J-T@*F/U'E@]&+/X>\B6Y[M!,WRDZ,^0HS_WL_ES44594*Q5X>=K-)XI MICV"W6WGP[ W/$/G0U+4DTQTS*GGS\;9L9K"8=C(!LD^!LGH,ASL>J_W2?G+ M3D).$3H&TK)"8H7D$V-]5TC]T_!T=/C[IJR0O$)-)BV3MGND9>3?)T]A%)Z/ M#W\2\8E#1[8=F+1,VNZ1ED%\'Q#G^ZG^,N?.,!?\-X*S#OVXD9[GO?/SBQ=W M$G0PW$#1P1%3=%L3'1M:"M(\!@&6(@DFR^#'B]XX@*&RM,C#H"B#X<6+,)C" M#]5,!$L8*A! ["1X)V(QGX@R& W"8-@?#H)(!G$Q7T0E_+4JZ/E%F<*;^%8O M^ S_-I\*;N%A^"-0%F8=)+7 -Z+@Q]/>F?EZ\W":P\"YK#,*B4E1WJ2QD"$^ M/^J=VN=S4:V\,\<51A7^$5>_$*4L\EQD\"=929QP%)0"!PZ*J4.'F8B2&)A7 MA0%P!6@'?\KJ!&O;X12'6Z;H?*Z83B5,!P@*;_1[E_:-1#1OR*J(OYQ,Z).M MMS5K#%V0D@7(:P7,#>)Z7F=T'\P^5@KXA2(Z#1D4"QQ&!K=I-<-53U%R\E@X MI?GT9V^$)*("?9-4O003 W;V0W4##6=_NG&]51F!,%DQ:C,8OBU*X'\$ECV#">X&.^ ."AQ,8NC9KQSD-M3!Y( 6[)R> MOC@_KQ(&2P!>7N P2"O.$V_ '!0M,CD$1VC9@1(#U-O"RF0DIX M"9]P(738&VP<#[9M$1.NJ*4B-Z91G&: $YJM:4[(0E.L1#S+0;:NEX1#L).+ MLB)V7.L;K;"(*)<*'8.B+DV: TPT5%2Y> C0.,"T^?D$;\RFD]JEG'1!LN&2 M(M5-D=5S!8[3D@1>+9F!IZ/ L_T.]3;\.6M4-,'/8'Q(JV>X!0]2V,(E*6Z2 MQ[5=R"@0Z.7(W# MQ$_LNARM4&YF4SL7T;50+H>3: J+N(JRVV@I7_\0_&D/&F]R,3R^X1ETXJ3(DF\CG7H89W255C#9&*;Y 8"D#-[G ,,B>/F35HNO0GBM>C3L M>)RIKF()>8$VI1A'=568,#G."L#YJO^:'C_)HF515U?3]*M(7M^F236#Z9"< MZ!=@@5FTD.)*"M#F -.&X>3/5&/_L)IM?9/*=(( OKPR[V_(N5:?.SWKG0U> MH(1L8# M)[G!\-YQSL;W?>NR-[IWG"',I_W,$]1]VC$,8;#/&S?W9C7_W#$?)O-CD1F( MBG_YKQ_.?WB.^@";,NDZPAP_3)(?_O<_X'PL@Y_6CM5^EX'H'K\9\XZ%S(QY M7<>\M[,HOSY((4=&N,?:>L]L9/M$_@-[_>G+B8@+Y=.\@F^($M>SOTOA98*G M]9)\O]6LJ&64)_(5*SA/%-R0%5PW%1R&Q%B]=6[C,;XQOGG-'(_P;<>+?XQO MC&_'3F;&MZ[CVXZWUAG<&-R.G%=" MV=5S7I'ES?3-*HP)?T 3C8G-Q.XLL1E26,J9V$QLAI3N$YZ)S<0^3F(SI+"4 M'S6QGRM)<;7AQW/3WF\7V7L4#"'ITGZA*TX4Y#93OPCQ1C^W>?<&H#AA]TFW MPR&#S5PR<0]&G8XO>0,Q*C%1.T94?Q"$H;XC4'\V/.<-Q*C$1.T84?U!$(;Z MCD#]RR%;]3[RY9#74'WG"NL*)BI#_?Y0?\;B[R%;7AVVJSM'=)XNHJ,K$W.? M=L]TS1&G_G>8M*S,]U'F@_!BL*-"/^+MX ^#=CS '3%O.@Q53%K6 CZ"S,MA M>#G>L=;2$6\'?QC$6N"(H(I)RUK 1Y 9A(.+'0/VO!M\W U,6B9M]TC+&+Z/ M)7_*9KR_W'GJ&,VWA=@X.O/MY?:QQO)RM; M'ICUG__Q==@?G/(FZ/@F8*(R4;M!5(;K?0YOXQ'+OX=\X23JCJ,2$Y6AWB]( M8:3ONO@S49^XBCWCRQ[X\O^R(KB+45TIH,67+IYZH_Q22!D4>0#S3?/K.I6S M.1 *'?L@R/,@*Z*<[V%XIJ_WB%4^O#4*,\$#)G10M?@#;?MY_Y^2O^O]:GQB MZY'M-B:M!T#&3/" ":Q-]KLI>'9^X1]WNZ=+_.$I7RLY(AQDTG)*LH\@\SQZ MPR<&'=EN8-(>N@<(@\Z!XA_?%[NZ$@6Q N1248^Q4TA$$PO!PXSSW SR^Z#P MN:BB3+<7T=6I)#<8\4NC[Q2[;1^OA[WA&1ZODZ+&.RS=KM(+IQAA##OY65,%<1'F:7T_K;,>0\I%RSJLL"Z;QTR0),5V9KG[1 ME3&!99?IRG1E3c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

=+I(]&O3R&VA43_6%VB_PO-FX1&=5-" M-"7'K#Q+([CD1K;_Q_[!U_W%=1VK?S>Z'YY$RSFQ\*0\;8I-V4&5)\PAY2^3 M7BAI;.HE+O*8'U+^&F::RL(LCUV(-BL,#&@ VVH V$6JLW2Y>PN07-(GY&\A MN>2K2R[M-_6D*.'RF'QG%H+L1K0EU\3:@N:8[LH,H3]I!LDDDOE#0V]1(9>

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ʉ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�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end

F MJCS!7\ NT2T:>Z1P^5MUW&''>")DP*\[]M(R^/XY@5.VD71$Z_0:ZUD,+V)R MT_(\KWV8?UCU5IA@.76[@>@PBVZE;<]#G)-X#ZO^*UC4H#W9>-*?M4*V2-:M MR!NRO\?DL&RZ)2=A<9P;%. CZ:*>[$7HQ%27&^=>4/3ROV]R(7KL7ZS\M-<= M^(G=VFU3SR;75_A= _=CRXUO!XOLHL%;,16^[O> R^D>8=YB [FS$K\KO^#'>MR9""M]N)XHES7A%]N*.@)H;G7 M:S'"W+!$S9^[R_8618Y@TUH_J9Y$@9-%J-67SNP4Q-#3)]48>!<[QUD]-:'H M:-C/+LJBN-:2D'OP6 [F6[6L(:YMV24BIU,DNTAAE;(KM+NX64ZGIBW\2+XS MO'=)TG;&3EQ_6F!Z[&\_]S]U61DG1G=:5Y-I&OG"YZ@V'0LD4V,Y8J/%$^AE M%3 'YK AQ!4W^MR<;U!A97[2;\W2W.PG4FZA'T^!RSO12*.%2L<&]IJ46GN\ M"T\R.X8.))I#UTCWV=##EK9JOXWW,JN-;' PO5W%K6-\C88S4[PTKR15[L!1 M4TS]'&M#9">30*^]ML5RJJ!N98=7@QCSK&6'_C+WDZ%A_-#TA2"^K"3-N8"/ M M4C:4E9ZLX$SDB!U;V7U<1L'S_U=$I8.!E#0+<6^T_)D]<#NE/XB-CK@\3! MB.+;5[Q^:BG"S%C:U<-\1;19/*?L)3'1Y5UPB9 7@E%/EWL=&9/Q>+.IJ_ MW1G/.(1UMN7Y.7$VU]@K_Q!5;5PE%&&:J*DR&)"HZ"YT?S7_2N]XN1^^.E&+ MR@^&+&>F_I*6$X"\YM?Z TU;$_! K'B=KFBFXC=UCV@S:::R)K)R#F;AY4L\:JX5>[5 M_-8%:1FWDJ>@%R';DD&6?>)MZU[@O-N0);22HPB WSU8Y.E<;>&SX?,INP(%B_Q4854O. MMK=;X89Z&H&1C@%79#]8#W)K&I"Y> ]"&]/0_[QN9XP<>]L>#NKLFA'I-_AU M<;:+807IIV>>5 /Z/$/T@#:ZJ/]F#E^B [0A@,G*X\9'1'<>S -<'PAWJPDH0>J<^\TJ03KD5TH[G7[@V@AU:6<@ '7QQ+;;9EP!S!+ MWJH=#DMR03R:O)5]8FCW"QHR=C$\6.G /NJG5.! M'J37/+_0$@QT2!B\O^%V-\-TL^RC%U+O>'AEONW_INZ?V^63!/%)V@5EK=/] M;,2-QG;XG'CS39OA],>$Q4]QD)+DLG1[A6VCFG#:!ZUZWMWN)(_W4M]SA3T' MG&>),8[76ZHU8%Y?J0R9&A#*1/LX%8&JSLV6SQ@,]"= 3&D5;LK(&^,?]YPJV^%8EL8ZFW$1G*60[4"J:P@'T]:E87WXM63,\/P M'3@&T_ 7^R2[N2Q8HP161,T37/!(H,L65(AHR.PY:9#;KSW%O>@\KJ_[[&C8 M!5Q86*0:TO\Q>H+;UT(>7(2\_<0#&_>-267YRR)?L^%\*A\L^_^?_@_T@Y)?M7 M:9(YC:5U_,$H9_'I\*"148FGL"LYW*&]4^J3WK_GI;]?VP,P-1V34.#]%&%G*7%[B"JD)\D08/!C1&W9HP(\@/USYWT M0BTWQX+PP\XSBY!YB4HD3FC63'.&N$K=)!>RB&+;T3+N;D>J$$$8F@W0&=+: MKON]%6#PBRC\;+$(-0XC+W7V@]:*56X6*.QI&2$Y3P_5VVS2/"^_$*JO=_S= MC_\T@;INW<3Z*W[_N9'Q6:H>]>Q-C>%G+E M/B &W%<0H(^.[7"(O?F8K)#P M<\%"D7[-K0Y&X7$P,+7"<:,[47#ES\9Y?H/Q2>W/>KZ^MO3JWRAF!ML="8OU MX=>SG5^L3M1FCRR2_1L*T$7N =Z!JP/?HK]IU61I<.O\E-30T7B=&Z8QAA;$ M_J?RR41+0*&L'::7868.W5E7J7-\']6;;$ 'P4:;G8,$V'9?HC7P^!7BQ)9H MOZ#8%4?[3%(W>C;C#[SO>-E?H?!M877/X#W@)Y=-[X8L*^)S#,M&_:!G"9C% M?F*+,X,NTZ;"'$AB>L.B)+![15A6;4G4KUAD!=N*^;G])C)^6G,+CZAC=7R@ M,Y-5ASF*U/[XEXZ\?N;OEN,-_:D6ZQ)54/[ 3)-#\Z%?4'!J%M5\-K*@JI]U MZYV\#"L$Q0:/PNH-$P17&RPO]-/]<$_01F-P^_2.T*??<3F\9$^*Z1[PB8\D M=\[;6GL*U8?IX/98@Z8_Z*.HQ(Z/_1W@2#NY]5;BO>GDR@=,PYJ>!5LG0'.5?[68]#LJRL-?08Y]TC-,/ZK@.?#PXGR'8S6<'VW;P'R=IK7/1O'GR)T#F)_U]9NC,>T9!Q;>E3'P>3?1L%5U">E^E+D'!-.K3Z5M M5ZJNMM0T0+N.O!VR1L+%K^:+V2@)A3:_H7=B>N44C"4+U=A?]DMHQX$K)BO& M$ X,4Q!S^,);"0D]I6,=]3,+4]-,]MD8L/Q^O'G]MZ+0\F]5Q^\!*:&H&U+SE."E:Y+11N#9%.IUXD@#\&RZ M_;E:;K"M0#\0>0D>2>0'CQH 3TJ\?-G0OB;^'7[?7=C,WP-6P+>[DWLVZ)(Q M=]O(W;F59:>1_-R@*OK.?_]V:*KF'3GCO]GPQ0[LTRZ6 $'O\F.X/;H'!% + MM5^OH!""+TBQ(F'/_AY( GA%_HM[9W[ES>0>&Q5-GJ*,6T-L*E6W<#]2*J0P M]_/G9$>]LSEW*^1>AZ*8:/$>K]SO+J,"AFZ%5)YC($=*-"XWN07F66S)]U#G ME?,A+9A2L%RG1J;/<>&I0/B'!0^E8!D-N4Y-H/C*>=X1IN>C;^\T?>QVV1<- M8VZEC\,3CS1VXA2FM%H*\GE"%U'NQI+K-2%"B4/AZMQJA6,HAC4]!T%+/CR_ MQ)_VEM9Y1._\()\Z)-LY($9RJ>@BF!C)3"&%4_13"V^5]Y9H5D/8W0R$SE4< M']\.[JJK%QA0!Z'8LDZWJZM^IG&/ZZ2@,*9^WLE)F$@OO3 ;B==[,Z7E5:S9 M$2(IYZ:RL82I"%/UK#O+(^,=\ORQLP*=;15(?S2QN+=;0MXT'+89:$G!SH@H M7D*6++IUOD(T$K=%".AS1['E"5C]Z_XS2B,1W<[A5<0X]**BK5&==N.0!]^M MO5RP@5:RD<$^\F^*R-G@V![F_ /XQCN)_ M@FBQCRY7./5H'>A.Z@_G2;-XC,#J)?2$_!4V+*D":,$KE:A6\H"0 XL)J;&; MVZDL4!R^-53YW G^MD7CR5 3XRTR*>OTAX?^[/4\%:9'C\)%[N@/$_J_69MD ML=04*J1E 45N#Y$*H+H'8 /7%)!<;-*#(!*B6QLP/$W:5WA>V9JXJ+^_UU=J M?@,N4REZ#P@KM/+=T\- 8=\#9@HKN^DD[H[$ML"KKS,Z+E[5"U]C[R@L0)'G M#!D^<'A& ?%PP=C?=!'*]B%E\ M*<;=:-\1J1)@SW!B84JN#D M[6]3]@Y;X:J/"!:8E+N/@33_H7LUC3H:8D7-XWJGL=Q6OPF,!?8$"4N-XZ!X M%=*)=]>K^(CDS6YW-2YZ=Z1ITN,N/MR,*?^C _6("-U32MRUH6KL+4+NN>@; MI=.ITJ0#?2(VI&.&-->K,*%9;6 QB3W^ZX7S;((R#7V4?UY^^ ![XF%L M]R1FA6]E_43C]EZWG;<7ZK4=:J_LCX*)'*GFOY@$5O+#1KL&RQ^A-MY.'HX- M?=62*/^=@+;F=UGYM@*[!X55-Y7;.GT4@;");M04=GKF3G]7A/'KE:&)(OSM_8X)TTE0V?]KMJBINI+(L7=J1R40UU95S'O0E19 M'G]=Y:<'IX&\7 M>+CHL>-7&GU:)G93X_A,(GN7FZDD/]-T;T$ZOIF+YS(2*BR3"TPBI3IDM2V> M*55&KYLMHEZS7: 79,O\\Z>M_P-%?8Q0Q1$*JE'!$7A$=UI@#$W0GN#JVGO= M':F=']DC!?J:G[\MQ=?[%!GJ&]5<>^'@JTQ_G24I1[ZND?XP</8_SL6 MKC5UY\P9,GU9.FRZN6@ZV@!MRCO.OL"HM6S]'1L!RZF!?NO:$>00IL8=;#># M8\OXK!N5AC9FRCNF;P4,PST9@LK28S0-9(C8F<9T94?T+UE26R,%&E.W^[4S MJY,'-4W=PCH*8G<96I3*9E@%+OKSA>6%!$R=]: S)52B.82$./GQ 6Q_^^!/ M4;QT^QX-HS =,BV(3I_C!69V:JF#[ZG:S^[G2J1;!GYZ.MBQE;K/Z99J6P>" MHS?L LT;/!26OE%GV1WU3+Y.-,(ELY9#'>N^LJ7^)JRG*B3Q0\TS90DR,RYA MXE/ =Y=PE/^)WF%+/ EJ@13L;7GZU%O0A-SF8Q_!;"WA=6,ME?)3MT^M)P>( MPP#L//B"PM2/&-[Z!J<;ZV>H-\YV^0;$27P_..1EZ C\MSZZJN0E:"1M\M"& M'I@L%<;$?-K-ILI]C\=A67%B?R:NPP4UPTM?AG79C&IC$L?+6>Z9/I_T,/J8 ML+SF!DUEV.(\&K:Y^TYT<\1P=\$FV36I]R(W3VD];HW.:%>F\)@4W_ ?V9$= M/6B:=.*EXIDXUAN3H=YLNEV,[7M %$E Y;I:,:M.9+XL"CT46&$G HS/[3LZ M*ZEPDV_V%N0RTVA_K3Y_G+%!WQT+?*NC&KAJL!ME[[+='RL)*"?^DCKCCS5I MZD2\3YWXJI]43A9RI# M2\94A1W"UC#%55ZVV93PCC':58%5ZBMMXM'45.Q6@)WN9X4?PH3"?<,_*8-_ MQ??U41V-)?@!5%WF36).(FO961LSZL()7A9WO(TE \YS>$MJ* )]?C)_7?8. M-=#4+BNC,H_JX'2B=Q[JS!'M63OXM$O?K"KUFTYLF"N;@:W_9>!YU6;5)?.9 MG<)Q)5\@:V#HT\35T21=E.O#M?;J])FO&<4MUY'QXP'8SX)B!2IT.O\HD=-ECWN M.*%44'-CCKKX 6V.OOQ(B>D%H+=I]H7TVXQX2#V>!P\ZD1SP^3V20R6#VHB\ M34?FE4X$"71RHU2:^[VUV3"8OZ'--\=7[ID:\9N]22>D5/3DD?I$2SM#6.SE MLHY#4%["9\ 9,]1Y9^'9)RF]3P&/Y0\; 2F_G]+HV&W"BFE%0D$897I:D0[E MQYM65GU]>J/F *]>N?E6_8T1"; ;<]-Q*>:L_-9ZXQRSR":@HYZ.S^6B@ZYT M97,B40V&'1%\DY'FC$&W\(@T/G$J,4'=5=T>]V:E1VG+.\*4MTA.+"\;K^,9 MQ7H)7TND2U4SPZ=R!W_Q-8=W*\OJ0L4NI*[2DP21^)#' +>Q>+,WAG#USBM% M\A7YJG=B5F2LYQ*S4:2R:^T10,9COSF99_CW@'*URPM!:Y:9[DX3 UU)H1Z& M2T_//=2A,K! 7W\Z<#_X@G2?P]'D4S=EP7^ZS.11LX.\DTS:AM/7UH)!DD$F MZH-C-2XKX"'#EK''BI 6T16X7).ON-%#'D"?)/C*3=76DEB8K/I)%S'T2LX" MZ-M<-/KB>\JD7- ^*;J\2P(6NGIQ(&3SB\$4D5+U/<"^%ZZ=9S@%V!J[LR@< MZ)QG*EJ/Y4RGOIO;CV> X]P#J+V0S,)T:Y]0V$B;K0\CL>&)!>_!OV6%O1F1 MPQA=FO> T1IP:-9I7C(TD^6.ZP,1,=AW]@R,JE64D"4^<-S8[1BWHNV;S^^V MA#XQNH:8321YA\^V: 7*(D$&T%0OP:*RG'4\X/%;X"H3TE9N]J6Z;GQ@D4TU MX$A6:3=S>1/HM=L@+Q: MAC!*J?!_3& &AZ%'CZ=ADO[;!7=4V:\U5.1MT$3S"X9).Y1Y5>2>T=3%90L@ MV"&=%D.JC3C8D[7:B-K9_FCUQ<7,>J\H T60F)4VH0,Z\7 M>4QZ#_#<> G4!"?;%%YE9E""5IOKZ Q5?%"S3ZXY.G@89 Q] YOI.CMI>R1& MLQB]C7C?!J =KAQF=0J \QAQU_Q\F=FX?MY&,"2,?\/ZR:";YN^ M!S\+\ZVQ]T;V &'[%\03T9H[QQ%]"/[X\1;P]_WJ,BQ3*B-F)D*7@]B_-24X MH\"A0MUB3T7Y49\VA#,5)ASB?N?[)S]*+C,W2T"/U[_0RRR=+K!5P7;@U"OR M>*.Q85RPA24'Q-C+9!V%05>TL5@_X.NAM3@V8;L+JCD<04"PE3GP_E4FF+?\ MG1LGU^PO?/=+O\":0O/S?)7SD"CMF55G7A<7BMO?S6V=NYR?U"]A)'=K)BNG M%0%81D_"$Y+&Y^,H$;O7B3.$ M-E -P+.R4C#\&GHW;BR"J Z!.;R^ Q9?#M%OAW MV8Q"I =5F?T&9)+!KC%.CE !D'D/2';N)#%I9NE%[@)8ADWZWJX7D MJ)XS9;AQLD<%'\TBV>T=!/'0STWW@;:1%3M:]$)9CG;\1XA.FZ/R*,8Y*8^: MA5]0R05)%\->LLBV1+JMQ0;W@[P9+M%6G"!PF#Q"I6H0-*^R4_%AN\@8_MVF M-H/]R;.JYAA3U14?+Z_1FSU=CQC7 S7JJEB1.4-F^]1[@%V%G5Q4-TOM"HJR MTM]E@@G%A:?BE.^-JJ79K?L4MTQ3Y>3!##:$G!C.N _C.KP^QI,7D:5(41=O MM:U99I]6R^-JS?C$[_/NY2'>$\5G3[%W=&C57NR7B4]Q@\U!799P4XGXD3]5 M=S9BY/$KG:[0:T<@XM)PH\?/G5*0TT_.R^>M XT03^=RC2"4N"(Q=W[E*_[W M#1#.-P^J@R/U ^_/!0.UA+9ALFM+Q-49Y)>B*"IU^!3X]+.-^DROIOK0/P_)B<4>&1!!?//4!G/1)PE$JI^8_?I):R^+>3+#" :W@J3@;5 M;[;;K_N^U]807:_&M)6JWRI+?H!##_A$=,:1RH6;,%+1>T!E-4I@[;MW'TFU M@3S")/3.[D?:BEJ8K"HI<8AGB#Q? +O:%XM[@-3@/2! &#Y]#[#1.G@$+*N& MDM-+O/-<:L[L4(L EK/5P\/SPI*AWW>'/5;^" '/CX$GW_^VT* )>QD:"XZ M;^>J5J1^O&4JHN\"G[-MC^C> X)R4$FYU[WCT'25U(@[5X8U$[TK8R8:YE0B M\Y_49C_$H"D(6 OZ]^*3^M]=^!R9[D57KUA QW-'0 ?!=\#<%U@"I /@,'L M!OI3D8KR]XW&%EHM2&-P&&AO?"!.-&W?X.S/H[=TN?5YIC$@U^ZJ,CD$[6-8 MW8^L W=AAJOA;A%OU!YPQN8,"L?#/3A$RGX,<#Y-MDG%L^Q[Q--Z("]?+WV[ M3-O3//=$Q,QP_\JN,?!/101F.W&VV673QPZDBV9E5PQ_S(P7)QRR7U'I?N @ M);Z7I\[X&CWK)75*6\ M\'N =&"UW?2D8CPX";R7TYV4O9 9K!"@Y7G*\&JS(S MA4\/P(,PLS('%!D;+"N""#@?#S7.(]K3K ]MD>K-X&;HR((5F76TT;OR%I;< M YIZH%:W$7518M[UG4>3NO5(5PYWF-"G3B:=6J2QKA92_/36O3XY$'H/F"G* M6JN(7'%>[$4=0$_S_O0%SK!<7Z%B5[RT:H!74UJ3!A-SL"+#>\#*N''R=><2 M^<@+-^[L[F^,96\+OJ)T5)'8!46_'#X2W2K62B0PU$3MNNP+/9V:O-N]!R NH&N4$E'GH;%QT#9M-!:EV7TT:N"WJ%NU5S:I^HB9'\L("F&7I0^Y4Z$]X"^M^ F M.XY:I 1PW9SHEJ4@>$9#CC3\7UPF/TN3]U[>]7%ON1@$B69%SO[?'2@Y*4MPXZ*7SX==DM4^AMH=4VEOXN'-UA M6L5ZEO+ON6Q#*&\OV&'Z9\_LC?^+JEO6T!35!OX!XRQCESO.7X<7GX\4M%7L MC$ O4M.WY.C\9B?;*";-E$Z78I(^UVY$.])_.@/AS^9"_HN'O_WK4,HJH$*\ M0Q]72N.7QI/CZ:0 ;W??8=9H/SI;! _^'=*?Y"A=+8#_,3]P M*4W.5K+B5,=P]@<$K.$"[Q0A8\1QMTHXBJ<<(I"U#/'YJ(E:AK/9>P"=0!D% MU[AV;+&]&#]#;AIHNKQ7+@Z%@03]"1L/A R+=9GD@GL9-E11LJM2*77T?1R Q[P$Q OO"K/ . M!!! $Q%#[->1.A012\QO#4EQ%4\PJ-C1J M8J"I"S!;4=FO>UZXH'ALV*L=XU\IW.>LZ^M?K>ON 9D__IZNKV/?;8N%NCT^ M>&FQ__OK;-T #K\"G*?"^D@W&UP!/65,OQITNMD/C]5PPX>9UA?U.]I?&(&& M(DZ, 0",,>M6GPUO)P/_OIG8D:Z4Q<7$?55?X/P1#%43J!U0LB#*!^V[!X2Q MXGVC_(;)R[==S+HW=BYTZMG((QI%,=>P'HG$*%/L4#[-O18_D_,U6^!20-:. MCC&) '=NP<[R_ZC6?%.\CO;QMG6L':.6@<^F*H7$S(K1BM\#4XPVXU13![C8C M;Y\*SVAROM^'8),?P7]\S]!H-H)V_[W.IFX(R*DAMWC';*]"!=ZY7?U?[+UE M4!Q1M"[: 1(22$(($)S!@H80W!D(P2VX$]PEN 08",$=0G &=PGN[J[!78.[ MC[S)>:_JWCIUZ[X?[]:[/^[YL6IF=ZW:W;W7WFM_W^K5JP7AIO9GA0F=R>RI M*4_'_B2B_&KB?ASHSO35?06GOW+#8714.\HBPJ(E0@35A$M^7GPYX<8*=:!3 M'$2+ +WB)8,"9BWXSQ\3W3!AIYT@]?PI[P=(=N545E8?#+7SBC$X=U3D3/' M"FM$466O4/>IDB!93\RR-U]W*F74G_85$4^/,W" M_8$6=-.>_< ]AO!:!VOVF!+GT*>$*,Z(R;- -U >$8T.RH2=@JY0K2">5@^^ MZH<$"$H^A[CRJB#0LG[7^L/X8 SGLPB/J(>=?WJE[]!+*M"\>[C*CGR10%1P MVTF%IM?+=N.%)'9TO(CLXV2^CSNY%\U*DH(*$_V5!OQD%)*H8:B^',/[9/1I MFMPHSG65TWNJC_AR;+O'5"_J]I?YI#A"HG+G\PQ.'[7IV)0U)$"^3-D\_\F+ M<&<:OGQUG #[Y!,YW'XG6DQ#X>)%V(/ZE9D%%6\9X08T6")N/:@J4+[.;;51 M!(<*'(S0]>%:JNAEWHT*]FR8\;)T'%PO/0)/;';T\S[,P9SD\>A-##1UB-]^ M%%DD>N13$^!59:U/IR-K,] PPXF]BIK4)'_?OW^2ELL1%X(5_T47>EKZY3N" M(D'I[,MU6#)$S4XJ> M2Y!4\+_[]8K_DO]S1=VG-&?1ZCJ/N /S5M?E2ZZ%BLXQ-)>3[BL/-_\E1_7O M3V..@$1C;9QE_#=[_1\/,9J?QBOE#13GSA499,AN' M5$U3K2I=,M78^481CD MG05K$+!GHX<0XT:*D:S>\Y0'VH;I$GNRZ&N;'D"0O N3:RO]_:VL=X%PMD?N M/JZB@]"4'CS99$Z:3T"M4L)CDU*C6GXH>23V8X(!>H_N\YU##W21TST*]+I? M=)%27$]Q8WJQZE)]_?]ZSK;,OBUU=QW3;9G:C5]A#F,N*%.* _%)O*B.$HML ML2[!($E*D+7&%L=7)0GX3^E_K_0A?:FKQR1;^3OS085**/^(=M0L1 M;)ENFVT&#U9X]9I/:(2,01)]F!+Q\:?,;EK?1=XN=PZD%N>OE92QI5.%-.\8 M069PN@UTE;/5V;^%N7>B=E89IX5S'+UY5\CA3FF'8A],)=_SGN&17!(" U:P MA*(V\70XN:P*6=%/MDY()M'?0*:CAB=CCJ1#@:\6%8CB<[JX&\E;THMLHB,) M!F 15XC(A],F",5*V&0PA1C9^F0 ;C'X'EA&L%[QK&V+H8]XA$'?4^51JZHD M0AO: [F_3%?UV!"%NN0;1>2,H\N)(($AT[[)N'[0Q0P818AOZNA/XP,X<^D6T Y_"FU<-L8AD #T+!\[3=133Q8)0!X5<+N-,C#W M:;MB5_:W3/?)ABAN,*[:_PF2WH;]1 (R^=43_BP.^0C=+N(NJY\O=VF<9">GQ15:HGJV@3WQAQI\BH[@2FI5 M&%U-8_B%LA8+2:0JV4E#GJ"DR\J_1]R^8L1M3("C_X<"6$'XMSG#&^>/"(O$Z#@F4:E%XI75";Y_F7&A>?0*?DO!] MAN=$=&P8KHPC7D.N"C>[?U/43N)D8[6S>_9"XRF,;D(8MD6/B"=P7B^Z?;>? MC+J5ML74-(<%WT4K^/6;*Y=<<&41&)W3.NHT:8'5VS'_#SWPMB*4CZ]?4OCT'684GYK MB -=A3VI=)Y"UX/,/'\>#EY^-N,6G.- ;X1=:D9SA>=S_UHQ(S$&16^F (=K MF9E%R7.5@06O N:9Y)'>Q9K.Y7S6C,UO2\6-T1]7_I*( MDXL9&R*%MMGU/90 '4<=^\R-4RY$+LQL@H8Q?HRTBEW=FT5U]?EO_V"Q9K-L M-%_T?*"%O*IN4(UBE[6,^?FRN"(%>HMO(5E?_O%]T3,C )TVO;->LI:_+7Q* M4^+.X=I:S2XR42!G+(^X'W2:\[S78<62]Y+S22]ZQ3 MSPI&OSLLJ"&;2,!=PUEX8_A"3[".9^':D$:FN1^[P1D%=@&(XP9(C/5AIB]=*0O$9YB-TX MA"JIA^\.?=]#S:X$1UA+.,%4P]C"0:-/"]DOUTIP$JWD5^8;]J<[#6?E"QWK MTLY)!$B@FD;,=LMXQWB*9J$I\5#YB5GH'V.SAQZ:#K!VR.6BBM-U0E7P*'@[ M,]P.MC^E!,'^/26;V=F3<]PVY=R T%)(-O[JZ1\(S@3G:B1;)SE'O>IRSSYZ M,]Z''>O4A%GJ2:HM,LOL;*#"'X[91^FIBK>GKH&V.5(3T3H.)&PC :W(I"*U MJS\0#9+T.G."XCU,A5/=2M+"W8M8CEKU?GT!-=Z9JYK%"T/^/J:]OU*4:5T& M:YX:&?.XLYL@(_PWN? + &2*I&)I. MD,!SK+SD5"OOF$NA1Z4T#!'N@NU+OVPNDM/%.;04+0YQKEU:VBG]#FH@"M8Y MBB\MK5]WLESWQGFLV0F"2^6*=.'W;;-B&X)E^^ /$4P.OET!.J:7:MG1!]XRJ1J8HW^E@2DK^PKSYB[_(J MEGNW[*EPQLR'Y @%(^K#8\FBX1E^M3^##*QD)@4W93+]>EH1Z,H/+MUY\,XQ MT@KF"T]O#KVWOX)G#MB75I?T)=^9L9'E4Z+/WJE]LW]>VK+B%LD'M;),RFO3S9X#_W4S7D$?I M;>#Q*/; N_4*]./G"<8'1QJ0=;+>N&\F=9@\>'<=%5/1#O?*^A9U%5:.5OSB MG1V<^V^<73"X^4'EMW\:8^(N]FXA'2!V,XF*\A';0EV=,"1 96.$:;>4M$J\ M.TX1;V4KJ39=5CJE^$O );E;H:?7M5;3X:I'LV7\)/;LQ&9E>3M-59&L'ZOJ M4<12:'.C;?N?UUMWW\03 VK/+K;B_/9&Z)DLF1]/#%O5U7G6!5TV56S3P O5 M.HXW,RE6_E1PYQ:5-2>;?$3; 0Y'.@./O1U"21W\+*SZUU6Y;7,M&38H!PTBA!U-Z MYQ_/HX7 ]U<)Q5^6]&0S=!=U"B.UZHJ:4WQLG(67]_44>N$US/!&S^7<[B^- M\:MHX 12ARN$\U *R\=5V7%M ?ID'3XQ69*8^+6'R>^A55/WHO@QKB=ZR:1) M+&O56J9UP?*./)L6QYB%.S4V9:_O!YD+JK;[&X@1:L.K>R8'3E8\_+8](RW3 M3%C=WT>9*0 M V7Y]3#+Z!R2$@/;SN//?4(7^T+%#963ES=3MK)S[=V=/V+3W FHQB^S(%L@ M>Q0GG&T8C4Q7=SRW&%^V5'=]/5Q.]KQD^^7R[1@Z.?^,[9A_3LP:]P4U=?_P M/CO[L_Y>@W9,WHU+487RFC M)8RI+/]Q(UXTYNUT[*V*BK76V )XDR#I>Y$;^ME.4]2M)&>&L(X'(7Q> M*AO%9'F])QS;I$?(_KJ:>7VN_BH1+LM>@'&?JG)]H='V^]VL@%GSEP=WSB#1 MJ%M[>PW$HEFDLR(-T^-\C$(D\%OGUD6VXHHOAY^@5UC/S %Q:8 BD'SCCNP! MDT8W"D+@R00D(,H%#E.^EWKW. %:KPM#*/&ADY\I0G#T.9C)#2K$&GATHG[> M3[:FE482:JE<_<"2SU-5$<>^KG^0GR[GFO?=VSW^_F$MW !]EBNAH"2_R['Z MCH/42+-^EY?/^%9)?]Y!7R?RE"WJ&0('! M0(ZB_[L$4A@O[KL(>S*"' MCP=_P"?)BD?8Y2<92,!W_,D(0:C]\=W=.*2=X<%E%78%NND!;)4TH;:-X/-I M'VSIZZ'RNR,D$!D*+&7]1LRZ( &A,?@YPX/>*NP&')WQ8I 9Y\A-"^7!%=>E MKYN@=X<0)F YZW?K+.K.A!;/O?8HN?L7 M8N_W$-VX![H%$L#ZTR)@2R?HW8DY/U$HG5S+=5/V MC%L.QVA7D@GXE$:W;;%L$:%O"B.)&ZWWJ1J&K)F5_TQ)D]B3VI%$C?7(AX=8 MG[R&5)GE+?M"NB@Z%23P;@GQ!,H0&5YMW<5?/AUJ6%^G,CR!-^AN M1S-M%TL^$M&K"SAWMJ@1AIZ6@%FJ;E!H/-_#IS)_QZ(2W61?W1^AC7<@_J6O@WT!=GY2* L-E3DO6(&;,_C$I1&Q^@@@O7L&O9WZP84_Y8H M ],)?C(9#OHR&8WEMB[R5/)!(BG*%;:O --@=BG72Y/8(?4X,@JD8R)1FB7S MX:IA8B]:B!+#^K,N3O\^7];OY&ZB!M*4W%'UA_7-RO'QSL[,!F]6OY3"4QM? MCEX'M75H-V&C5_)WW3Y\*^QWAIC#F/JKHS7W)8W5X:T-A-;BM5=WWKN* 9?X M&3C'.(,-06>TJW//^ ,((ZC">-<,S+^"@O%')%Y\D:R-O-R/E5G\WO_C-"?\ M\J^DE?4SY@5YNDM]DV9G[9WOMF_=MEP,T,=Q!G\>DVN AQ)5G+?WSI!15774A=NOS\M*;/+_M'O]VOKB):B@9Q-C0P_U6XE1_9# M*)1)6[_/I?Y^HOX^60ZUO,K%'2A\&X1&Z.2)LO&[V9T>@I" \_@N6QM-'B-J M)D5Y@)1>SF.>'JE$>4'/"HB;UGI[_BQYK&5%@_D/K<-/W4CBVZ^"0;.H<^K%?65Z MVY#C^J'9N+0\",;F :E_]LF4BJ)L"><,QKS+K"M@'U,UJOEP53:U21CZ>*?J M39#]^[\E"$L1(5.AJ'$(_QIZM6M/"F5JG#S+L[CIW W9=:')10DW#," HF7$ MF_"T2@+1>_KV>Z-M^KK<))J0I\-EWZ[^XS4(SL#&"5F'W>>:QKHDMDM1E!OO M\39^+OVS_*\:Y3\Y'3._J;.F9\X51#O-J<[<*&6_^7JW M=V-52Z3BR[E )9UG40IOV.^!K!!EUF#_WQ6>GL\X!-^*>R]G)_PZ%[M'M #+ MEF$MF3%8+8_@<:4E_#'G.<,35AN5MY2?YJ\Y6_B30P\AV<)"C]&^O8[TWY,I ME6>):(6IF K0N*(+B/)>94A'U%^3794(="IOZV"PDLW4W@CR.T5RDYT=?6[J M\,P3+,;]@_.<:3,S3=R1N#X=D_Q %^>G415=E$$M /JYME-#&,WPJT/1%4CV MIK<2[2@9Z5/Z3Y4=2B%(@((#TJ2;VO3)I+/6X9*T;5SE4_U,J>G\V(>5["R$^RJK\:\ CO!SJ<&/X= M"?!7F%*7)X.B/X>;$QI_'ZE@SUN8GPP\AGS*I=BVK=IB])LT/3WR^5\FC+W,?)"#"5[W*.'GL - M#Z(]-;Y[Y8N3N_''4 ;A&>#76X[(^CYPZ0N[[W2=:8//;GC!@\5;D3\0SDTI MEJ21.$KIU8_,<$D7F&0#'H^-[+6C]NFI%=X\-!L,TD<++P5B5,\=(AT4M&@_ M8C6A\1M<9F [+'21_-[]_"7.3*)!N$2EP"LBACM)1P&$VFM%=O/7//3T M!S)Q@ZG9N'Y1VD",K4@X'SVE'0T1ACE(6R*4-_Q0]8/&PB,AH=M[9>\L@UPW M\^]\:-$R#\L#&&TK_6OC:&$.'+%^\5)DKQ2_*%H)=\^K+?&0G>V%JGS=#<22 M)-+]RC:%3YR6\])UR[Q.]RKCJ6E ED'IDLFW:??BUW6)DH/XCWP?2];Z$H?* MJ:98NHYC:.8L*A_E4/M2]] Q*3.RR3T]DZ?.[:%; *+P)YGTJG]\IGZG;)3+ M+-^>\?1,2EPZ]"-#/6Z,M#)NJ B[Q:O$O!A%ZF1+WR5EW![>*7G@76E\0$5L M<=3TK&-$=,3ATS(2\>&G*UL0Z&@3,]VJH=U*1?EY04RIT,B5;3_IM-FOC&K; MF8.C'D7--(O<(DO7A98?O]PL&^DOUPK)GPIGS++1I11:JMS-U\<:9+%]LR1R MC<$4Y90\P85O[S3)R*DH6Y T="_I[[N-UHY80CR)D$"QK(HM(1GL&-X2Z!/8 M^ (DDSP?L7S0>Q/9Y-H'?4]P4.,TL!O;%W<+<%7(R@]E_+3Y5UI*]']%IJ_N M37BOES!BDO6B+/"W%PH!4!^VG>1!^*V_"BY#9NFG-9RA^W'P"5TFZ$KYM(8+ MZ#X1"2P3R'V<5!('U%H$U#1=B+F49X:.WE0L27OP"V;38QB76]5 ;C#'IUVA MYT^K[T$[UIJ'3M.W(>K=!7I:2S<\16\O3'?=A2"!$C$C)VF:U!4 MT_<#HAI>'LK=UK8K&X_]L6'JV*G;->C4$&X9V'GH7%U+ [] <%F'@#2EU: MRSA9N_?*MG7D!LV@ZR&NANL0D8?IK V%+>7[4M#VQ^T0_S YI^O<^TY+J4K MS#)HAF3E02Y]VCNSJ2@96CB.^+P5\N-U?SB\T/=&3OGI8? &''-:'0DL<,QP M90P'E3#?*=_'XVR_E$H4%B]\J#LU7O;-Q]8,OK,W )^RZ>B;2)8V@MJ5\6Q7 M9L /6ZKPCT'G"*H!/"+-+5C=J[IZ!\EKYZ!X][&)8N,WWD?_R(4X?8*1XALE MG%L@%PX5JWHIE02:GR7WY23GWG+:WMW3;C.?&D#!/%XD<))L/\]YB 3Z6H53 M49C?7.F"L$I"<H4^0KQE^JBZ>LCXG"HD8+7 M4#3DH+"4P9!*PFO"QNH-IXT>H6*-N@TN%AJ.<6C%#IWP;8EQOC9>C)-KFW0$ MY]YO:!/$%7Q46):N:CT\TK(';6U+(YU& J\1+D'PE+&A0EV+R0>V-[)2C+<1:C,-"CB0_IYE%'\ M0EX[<%<5=+Z%!&Y.U>EJ^.HGN-Z8,%)W=TRG!R:K$YP8T[0W[_. KG9!YP1S MKF5B[?Z$L^"K/51K]KK@U^XGUUMBI=E195ZM'7#5!^(=OER!3SH9']!?:TPUW MPF_VUJX^1$)/2!2-$L02;]T;SFHJZ(_]8<7+!YT(,@9[DKZXB6=PYF4FP]_[ M7N+?IL*D^7HEF(F<".2Y0FM MF.L[)"O(""2KY/(G?-:H6)[<2,(F-I#FCE_*K-B+4?[*GXJC;69DFTV4/?P# M,O39YV>@!2:L&L[PR*&'*"\E&/,,.IAR7>RPW,:$(1W*I@0O6YU DS"\_;P M65BA'QT#$Q-K;0=\ (PZ] K%\I5]5!^]%U VRGJP^7(QJ#@85=N#! 1-8 6_ M7V^$JTK<@^\VWX+LHA#N+6_0;)2-DX..SC;A8N.LV2BFRRKNFX(?#UK\C__2 MUW_;=L.4#!JX&9\6M*X^0_5M>S>ED&G'GPD*SNIP-&*35AAL+&9HIVG!#^0. M_4K,.4!&U;=YF?&XAP!G(>$/^*1"<@$S"[)JY,M57=["NJ[M$I*W(DX63DOY M1M!@I[8# XV?Y'\8(LHO@%YZ>?Y&>"#B!]W#CK6C7,&#C6F2Q_0/J^.S+!NL M+19"B8B:'+GMAE_$6;7!F5T?:!%F*=R0K0V9X M=J7TQC2,KSB7E*<>O5349IS^C(:EKF>&5Q<(0UR';5/Z)B;7?I(GF_ M0B[>E"T&%VLW^T,_Q>V)SE1Q?W+-L:%Z5+7ERLPE7.'CJE2]K-[';_&1LV/R M%1+#3Q365A, 'R[NQ,8NRZC\DF=D+/%XX+>J5^@@%9TSRZ]]#.FV-X2@BQE] MATMRS'4-CE[I/O(#::-\(1*)#QTJ_O(\B]/#-:>]J394-4WQ\\IB5"9WTK0& M"#*LY>:I2^P#D\ M64JQF(L/N^0*.%Q2(Z\C346O#.5Y7+M*AVD.*$O>*N>D M+25-D*AF)2NIFVAHT_V:E7:QH0UU/\6-">Y]@HD9F5C"//+FV%M;8"@D+Y69 M$4S)XNOY7./3^R/([OXJ E%^.PDOFA5<6D0"JZ@92%(P4TCH/!!/PJYN/5:! M>1V1$6_D\4.9[4Y=+A,LM\EE<46@;UEB'M['W,5$P0U-SOW1.U[^4S-C[WY$2_EPQ NW M^D>\A;6;&KQUNA/J2KKO;E[+WE5P<==0+VK^6&,C0BNR8*)P.%%RKY3[$N8% M'V=G&FZD&#G%$[.V?7*A'8-5LY2N^RFR(#_N;O>\W(B<.>)6 R?N=$Q,U_A# ME;?C(:3452S7[(8[M!+K/Q7@_"_Y+_G_12JY\H1-*UW?1IVC%NULB9Y#A9/U M,>F]FJ03?QLV?:U2\N];M"(=,#A ^MT/E6])>;'H,W&AOH.6>5:N;ZLU>] ) MOHS=Y. ]3/TN"_N8L_9([8U5M&R,3)?\2Y]XM>QE]O!3_NE863FQ&QWB(7,8 M8R:WC81CQG3-<]"^RBP!W7%7G%95%JN(D)/\J*>30J\B9_V12#?Z3$*HU60Z M \9C480+P=A]'HS)P+W 3GCM?OR[SM,^+,5\+H:"/B:G/5F\)Q%2?'G]GUB> M!N,DUADH&NYIN2GEE.5LR613)=QZ%]N)K]1SA?;X_V2\.%=LJR\*(9#EKGNB MV3DH:E!/7XX"*M7&AG4%)3_"JR<8#43LA.-+^I.(@?1IJ:\-E%;*5A\2CRWG M +.,F4/W/7'T7/S0__X!.Y.5)(E7F\Q6/A+0 ,%=%>%/-;2*H+<)0[<0_BTS M<%,8HHD>$:!:RU;8X,VOS*/R\2JS<8HR5"&P+DC$NQCMW^\R2%2,3$%X7RCA MQL$/Y@A148WS9=8^A72?KU&9^Q#".FEQ=>T="N\_P#06 C7&.SQ6SO\@ 7( MQBQPG>2 MV69)-%\>WSC>2R#SAK>=U$]EU%'1*L=Y[S@ST"144T7K9PF34=?\3TE>(P1=OHLY"19% Y2SMWREM MRRDKY;X<,<&O#4EH QV!*A=HJ:_/PLO;M!=/ZX)2-*;MW[,>D1"]HCS7I)1: MSHXX?<*SNR,DC>\45,79%^'%&IYF-^WMAK.G^(7HUK31>@847H]PR?/"RS.G M)FK3#FG&S*V#_8Z,-'0DR#[3"#)]2-Y)A1RM0WI+WC=E\Y&Z1 CN3NZ!>QOD M93]63)65;<:))&M2)4I4BD5!F8G[!XZ:MRXWT5/_D'J#NV8/L#IRAEHMPOM) M225>/AOEZZO+S$[DPQ&//!\533QA2854L4,/E -#6@\KH-G^NA)1:Q&$^M7? M$FU, I2N;>,UZ'T=V:X0+A8P^BF^Q3<;?RJ(GS%3IUIVI[FK5XJRU.$2J%J';"I%KVL(5/W2E[V$8U6OM_"3AY*<>3 M(/7--J873)>+LI5'0?G2#!?E-UPG>M#M%5GGED!+8DY'&3WBUS,=:SI:T M#_M&4-HERB4<"1S^._L*0<[B3#U7Q=DEWV(YX>4JAB02,,TWWL R1]!QGR"N M,\ MJB]=R#42"&\+DYARNOP).>Q-7*$[ M5DAK!3=#MD /+-B;0M\0VNZ&/F'.D**)?VHA^#\T: 4=(-&@+HZH&[N@*VWP MNM!!6]?L)KGK$#'"/3L).SY-"S]^&(=<)V8TH @._+NEZ=5;Q1(QKP6)LK;K M 1S$F&(2)C-_W&2*;OVM7VXMCZ95EQ!B&.?D#.>2/2I89]K_)8RP])5 MOJEAS3U2N_3H('FR)&F6_'LH0\[G_Y5A477"L)]U0>9]9BKW,T>&M_5(H$<( M//W9]T+T9OIRIZF@X3OX1ORK_PGK3%,!>'.!]>:Q1;< IS*)_A]*]19B<1@D M7M0<"5!^D[L'[5A]&ZN'ZOK$/X;"_(Y:H=,SXW.[A6>O0[_(B,[\Q*KZD#9' MT$41_RSII\EO]%4"EO:[A#TMS\1P;+_*R[4=EU_EUG]9F0?)_D2X MC @1S[]0IK[8'265:\5$U,?)7@>"/ =O(8M-:B/:]SJRA;7+M-+/*>Q_JN(Q MONOZKFCC4P,UW0@+83FFV/F#WTGV"^<E.__%BP6X[4*R M"[/2]+#P[QJUE%["F!Z6:=R>=])H,J?0%EQCWYS(YEDMRW?GVKT7@F82Q,(: M3$(%.R\_.4$7?M&4# L7B(,6:HF00%0\Z+.XBT"BW]A?QJ>81?ZW2J-D01^X M9-%1O-L!X9RM4B'$BN+@K<59'T20@"?1XGX-J::6]$TI%5@M.PV3*I#U<$RV M0!'V5"5@N6+/ ???6Z S_!+)GG,BD#4NW''G0/#Y2]]_I9L.)D;]HS-W.SWE M0?!KQDZI,6D41VP/,,X="[(K'TEK#::%@ >62"UHS6E-+C=J\41/+R>)-B)I M*+>*P#0UPB;OE=P8$9RH2PE Q\P$^>7&=2Y\_'Y8F4'>G0@:_'FKWD6D93<% MGZ^ ,^R*]G?W4&4Z]U=/#CVOZB?%O"EO LGHJK0,6/6$!-K.GA9U8]7QP+Z] M5LD[PZ<;G1(H9@XRN0I"*D*>5Z(V;_U''S1C(O?JT#Z6 M>?IZ$.U;3W*7'3V(NH"86BBMKR/3Y+]W&Z^_'97J'7_ZX0:'N3VV?V&RU?1ZI)/U9,LY((\^LSL-_^!V#_J MJ:(8Q@6Y?Q$)O?AC'6$X/275(W#'6B\$35J((MCO?GZ0 5E40N!#.E6*T$?; MD$ ,^/Y/]Z1?7"CK5NOZ-ZZEHZ"0J_=!W>!;)( $M!,0K[T_[2*8:)" ]RQ! M^$MWZKCO\F0KLL>@*KW1N=M()( (9(7YQ"%>,[?=$ZU>>J0$?86BHV)DS9YV979=P:P*X&T_4$$1[=4( M&4)**/;8!0DL7D#&?>QAG@D/K@I!W;%(K! M^3#T9$?KC&CP.E4#^!23J\\DVK)]\T!2X!"E$C*+ZX>I5[\+3\@KRW3;U1YZ MDLLY(7.+$&7K](9''&A;J2NA"$!]SA_59KB[^JA M)E\5,;GV7!U+9F(:+Q<>NQ\GD"ZNZFL]6]!QC]?2BORJ:'6%\U+7H]'SNX1( M#QVGS80X 7LPL;(1KP:*-U5^/?!X Y\0P3YM,M M1(W(JPE)61I.@*N"CW%VK-ZI3N(L=R$!W?:"_8%76&PC#/CU&1@T^?CUN8)8 M1G,'"H\B.*_$!D^2+B+GB0Y$4LA#=1U$)FORMI8M0XZVFR!*"HB^/U%ZR@.0 MY6KZNQ;FC*9#'GS5L,R5F(<1$YS[;2OH=#+XMQF"Q1$U91KPC5$8B5/O\:IA M8C8!TZVG<'F1E9UW*NNYMLKZ$!V8[/)46NMR MH7ENPC4<+N'M8^5^NA+-BQC4 !_] @]/.)/$LPM 1Y/-0GPN@X5+F$4%!7)/ M"<6J!Z["03LO=&RQ5O[41KP?)S,/3H Q.E'M&Z0T&<[LX%Y%*UTWZ4,F,Y! M6S&"J\T>32;=M*:$]%FO^@>.6S_U-PM;QC8&H,_YH>^9.1(?3,MAL XD 'E, MU5)SQ ^ZD08/-E;8>T):;AF+;L*XXMO2&#J/L2/J#R39L3E2'USJ_YJ"CSMH M(&]S>,Z@38\/($WFK$@ 3\](4[<_LW*3DN+G6=X212Z\(1N%L?APG8]NG.'2 MK;]*P)?OE.]N)(__WOLA 0]<2,JL+F>20!QJ<:DD2!MXH@ZBH="U5G^Q%4=$#,?E75) M':Q1DQ()6.U%G&R?(HIUS$;LJKKRC&&U!,I4A\BE5Q9?H($68%N6W]Z61#[J21#2[3IU1W3&:"%!+' M?:P9."[5X69-8Q8;\X1$^ MW%^"/'E.$=2OO?62VM)H%R3"+#[+YUO^;@YZ2JM&&E7KB02N]JN;RLOMY,I,;+?HB39X86XD?%VNUIT"TH-'A(("6CNBJ"V M6HX!?,X7SLPB_RYT8])ER:N;U.<,>.[MS2A?75SEW:ZW^RSVR4E^J:,B&?KG M7];,?/+9G:U6I&[JG^F4-^1VOY'QK#%5OW&;Z#(DNZZJ:BFQ?'0^]#1J@2<5 MND[EH'51%;"QX+H-@ZRY".@4\QW9FJ3-Q8O&/H4Q,STDS2(:"A$NQ25Z GL: MP T*BWTDB'.'0**D9N_4)QKFCL9]7S("N[D,>R)%: )^#_Y7H&'E-E'$+<)9 M$5&"H_YE]Q/40[(D#/8778/X^Y9G]Y^?[8_!QV=WH7_TE0V1@-SBG;K*95_I M1^+L]5:N.<4B7CCX?KJ-L*QUZ'1,[>HGK1@"8TW5\]EBFZ#'*!P>R-!&X-Z%'1#@'0\ MDA'0F!G#:;/"VYWG7O)_#('?#Y^_;#&%WX,4W.E6#].?3E BME-1WHF3\4A:CEWNQE^W?J^*>%3S_V\LL_Y?\GRG=LWTG+#A-.-LZ+E'EX7TV*Y&2 M>VKDP_M>[TR;PJ$9.>FF%-5#D&:?[]GU#W^\Y5@SNMBAVI9)WO*?Q#FG.&Q^ MCE:G.YH7%KS@3N)Y'Q+M.1WBF)Y7U2/U4S.73MMCD[ZP<(-: CO]$4%Z5YQ& M:=M,(3FQY'FNX7*M3>:ZJJ=JZDNFIZ1O4^_75.='S$9_7I*G6]#L8'+ZEPH( M;L18*%SR*,FN)"];8&81UHB"WQ/"XU18:\U+UAOR M^K1Y5HEQWQ&L],D-J^FU!"84!';;H9TI8QLXT)JD_S795'X\&^OM6^Q:S%"G M_G-'XBYE4:CMT:?O6 MXDWB1+TA]*5_6D PU?DU1E+^#6F^Z3I*J[8>/U%YYOF6P*U^BY]"M*!^TJ MW_I+5?YY.^_TU$Q?K?ZM:)GG0:5-J+GP,C-;&C!C+.C1=5%$ MN/*VI39M9?ZU^VO*X=S@=])"3\<47K)-5LUV>*I(E..-5"0XIO6U;L'Q;["KRNIGS7">,[L: M7C@*=H2'NQ)OTL.LA;SD/5[\8##1<<)7:BK^5O%(D>Q1I!3Q;KB&X KA'P?_ MDA/,"M&^'2::=5M%8NM;HLN! (O?>FG+O]H^$MJC11VNOL[&O2YV_$9FSJGY?NPCR:'_;6&77MRT1GH* M*UY!OX54']^3Z(Z- /JM.EK7+26#'?.L"!=X89>^O:B^/1(@4(Y)X7WI388$ M M!VNS-,2VC0VTYP;O_I?>,N=YYE>:="H L0\E' G#.L;SKE/GQDGWLDX%J& M<[1"J39DV2* >2 -+R]CI-QC-W%=XI\5_#WKIFRQ&_]F>9.NU=R'ZZ&-%H_, M= !8YW>8+2\5XGKP;9)[VE?!Y#33?'NP4 0_8H)XX?: 3F/VL3PFRYR._.&6 MWMK2JVEA\PHWN^9Y/:4?S[(%135]I2ZYZ*]K"A$XD\W5[GF[@GL)_HA'2& V MGS5,-SR%]+>05Y4>%K>D3)Q,7P'$4@NZ!HIG73Q4/&7=UD?M;<\<'_WZOBYR MD#C" Q?TVLWW[M<$=S>%@^RF!H[+?6 PNC4Q0JC':#UEDC@ M-,ER,XX-I$8=ALFW)W"Y.:<4P8L$7)O7O& M&3 KM3/75(7'2Y";/V]> M.HTWIPDUE5)53:4TSF*T,OX6>K^)!%J+1#=TJ-V;HA#W^)I\D4M[C=9NBOWJ MGS1\")-X2/L-=9]0>-Y]^WEIF)YQS17<2E5SY B]^:."*29L<,YRQFSW%1R, M\$DBNLGPZM^CB>O44):(V>=^>6YNL<0N,JHXY3^FP'3O_DTR35;\VH.0]RUW M#%2!.2A*X72.N4ZQ9O [(<99JO_JTDQ:Q')D&F:,>>73JK1@!; V>C*]E!=] MWBN($R'X<#9M($+" MHXYBQ[F08/8<.Y'VE8;V@K9* R20_@JR2ET=\2D^/%>ZSE&0IVY7-O!($3'@ MC_!>!P>@2_N2A5E<'/6 +7&_O6%_)3Z-(F@ND%+9=V82/X[[$J@'ILIP9.)9 MY"Q0S/>QP$#<0TV*995%,3/.+\W\K^>+8C0O \9?"P>F($*5HN<[:NX,?QNV M5J?+09=SSJ$/@7G]Q16%MGDY$=1[U_O''[9PFH5ZM$+=#13?,ZCA\6'AH&6< MYR#6<\ZW$'LC;T2'AZ V7XX1U=XU3C<0[?SMMAN=\YSSQ8?\\]Q!_Z0$G[F@ M6WG611K$@1IY..0'0C5%,3,['I.#%5X)/J[;EK'+,A!]X=_+IO6@V$*4'8/) MP0%>?S.5_3/%8S>4.^FM2;M]4RJ@2%.J.^F?41IX"IGX*KPVNJ& M928NU'\>;_FWZ_-\FIFBS5"/@4W.Q&*97OFE=/O;:YGBA=(A)$!QH!;QE&A! MQH4[\=ED'/Z^#&#':(>+G=:?3VE.PY?=(DN-Z15(+F3Y:,R*9\;3^ZI$8F6. M,^V9"!:NZ=>T- T!RP]RZ5ZGJ]*&RZ9O@6;)1%OO@+=!O 5QXM4A M,GU8!;04SPZ=%/Z^PYW7#L'U&:% MP.Q0K1_;<*=5 NQ0_!C>;E>C.%Q6^Q3 M4UOR7?907>?D8=0B@;/3&K\R7GZZ2L@<>+#.=NQ>9I:GK)93WH!B'Q(ORT2K MCP[:2X!>'1 BOC.7'NE"_40(Z_Z?9@DY\S,[%TG#%[;NU@CA'23P59WK/_[N M(H$RX[OIBC06?"4IP_])WB)FB)?%;G>C]A:D@!XU2JB%JB&VX5?7KB[#"^_^ M,M-P$F[L%N9\*<';[;>5IDB@2O?F]ASR$ZJ.+P S(A#WDH.A?@%-RH8X5"6SV'C4&)DE M7EMCI+?6_)U>VLT]#98^45Y8&/%P_'5]5AW;T%E0$,7U37(:4GGUN)[M+E@M M9I;WK:;!YFKR\$3LP#I#[!HQ-\-V1K_9;/J- M?%_+QAS]M8QQ-2[S+^"TI?*W*C"S[2/"1CF)OQ\SIYWWJ@=FB!?8#_T0$J./ MMGSBQVMV"I^$N5D[Y37I$JVZ#/$P$S/7QZ0W8-_-\G@[73=!>>S&8O! QP6@ MR>@IFR W(OQ)CQR0MG[+;486/-"GSV?U<@A44-SH%ORKLY/998K%U-EVC*-, M*_!P#0DPY1J!-_0*0->$=U.7:1+7'6^Y70\HS90/C5;#*3!K+6-'",X$Q=YQ M)F)SO,$HN/-)524Q:WQG9Y?W#2,MW\@UGDC_FX-*;4.A2+JQ99:@UXJQA/MN M :W#9ZW]QK3\%%I7O^Y*C\DW07ST^;Q[(J5;.DC@1XY'&.,DI8!4.\.'KP)G MF@E3?1YN;X>Y>S&<8K.C<6KL!C;D%5S=3:>H[+DD# MO>EXCW; W24--JZA2ISZ*D )YL$6T^-"HDG*J89AT@HY MN]!665+SP?OK\A!RF8N??5P^&7H1T5E5$W5["84/3A(DE:1JRR...#'?3TG2 M6A.,5+LQM#E+L6O\M1)JA'C3XY(^MM\F"ISDS+)>R6W>)C_R->?>993L5 MPZZ_*,$9/PAH,V3E_*16M,_2W.8/>SGH'([4RHZK#W")HP68:]E]R9O]XHYBF7_RWV2"TB3I MJLM$32-"4[]_=5 QB',=WR?4G>!A6!%A($K/,">BV-H-=;1.%EOJ0Z-Y$R<@ MC6'RW1$G7V9S436B=H?AEBH0TV'\3,:E\!D*P(ARECS$IBFR-B&>K7@7#3N' M09TD%TN#I'[5XY7(>6*"462K<"D]9A"R]J2HYX*CH'X:#6(MJ)S;1/ YMO(8 M%];BL%IJ,&>=X&D[E(+[K8 F?.!)5B>C]!'MM[8?%WU6I;OZ[\Q,0\6:+_Q& M-!JTRC^_[4V?8N!#^S3*I&M?.*:>FC>==3A[!;?0;FKE_WGB4)"REZ_R@U_% M3( -OG3I>JQH%U^MW M3>)WT*&0GS^ 1[Z>QA1_N#-FDR.S69:T'1>3?%_4D:90Y!-S-G#1\;H1.ZW. MCMU?P*IYG&W%2ZO=-S2 '[E<2F79)D0BY2F:'\ZU-J \T7Z:0&^J3 MJ!DHP3>&/Y%O90NC])8N-69VYM>;S[6&E-'^.A#:J):"N&MUO&=;#:TJL4+; M&3%:C3;1YX!J]Y(H9'D>@=)DGX0Y[?ASE$W )SZE=5?SM-6T?Q9,&90']CPX5Y)RXWY9#H)=@M(^'##"DM3)(#U]70#0C#=<'+Q^?%F2?[-Q>VTN?:7$Z>KHJ'U>AR=$(Z_1%-!02QL MOSQT9@7',2)*66^*JZ=2VJ_I_EP$)3*"^O1FW19E.P@;>RE,0ZPG<>X1U_-WY..T,TMNBT:O1[NL[<:EPNO%'O_ M:&[?\1EYGQ%3?%2('?4TI)H+XT%O3HQ,FN1G).57A2?/WGUEE[XNG6/93./I M(%-^[]! ]&$L'W]Q@B+-;):'#2-$"J/$-$J(]T2F/PAC>_B&>6"S*8/A]K.Y46\BR6R=&3#>*45 MLN4M[S)#\G^Q]Y5!<75=ETUP"00"P6D")+A+\(8DN#3N 8)+<-=&@H3@#L'= MFF"-:P(T[N[N[MH,SUM34]^?^::FZIN:J9KWQZI;=?K'/?>><_9:>]_=>W>U M7(Q^;#51D17[3"M [U8(;O2XT]@9+QB26N\RJ$ER]" V#L"W4J$@MQ18V7@" M7);65:O4*A4?DA ICMG!=.F2]:@ 79]Y?Y"^T)X!BRX4QYS\B('K.PW#L-AT M4<=('([Y-) M*1MZ'XIUUBZG7R_KS!/X'B![(4@'Z=PTWSFA%9H[P:D,Y\";8;^-[J/2ZDJ? M #V\\-*L]<=5-3M<6Y*[9U;>H2G9$X0-W?#OUXB7".2C]Y=M/4$489^XGAD%K& M%M,01",KP*JK)]ZS^PG05R5]*_@$2--HIJCV*L4;JZILP/B7$T%C]:KW(G&V M3#OSS@J48.;M"3K]//N[/"OS#EM]_\W9);:Y"$KIK5F1M_MV1Z+ $R K ._! MI5ANC>Q&$7UUL-9;/._T"< JZ5YF]^:/Z4V++[H0#/^?\D/["/(_>#^^H0.8 M7P]737-#'YX ).7MVXCW"G>O986^)X;>F<#Q?:;:J_)BOO)68U MCA2WE\6+-_%RT-:1P[SPR(U+E)&M]1#>AEKM'G;U(@OC;5BGG4R4*3RP3T1L M7-.1N7V1F.@(T-@+X_+#U+%BB" MMR'Z>E0Z)/A'!03_T^@"S6VN;2?7EGD=C/[QZ_FS;7&F6#^G/>/-&H1YNJQH M? [=+Y[1L^L^,3;$JY6ZA#I^X,KH'UZ7287K_CB#DYI1._3RJIM^\D**^,O, MS":UK08C_:624&8S4Z3QN![Y%_CHZ6S?9>YC;@GX$_0M_-[E4>+-B**F)[F: MLH1XQ7]81:08Z(=%@RL%I[$G0$D4HC'[>1V#[*SIN=9'05##7D2V3Q[X$4.= M-?Q=@X>%;SPN(S"?\U7OM;4CV]=G+Z,*E& $^J2KL[ MU%"]#>M/ EK05P(0"76__3?$O(YI+_Z)NM!&I>/=TY0+D0ZOT9R%-R9RQFP@ MI]V1]9]*M%RX*O_DN'D77O*CR1ZY4'8QV)WU>,UC(Y*.HX+EL,:%W!V^&HPZM?!D_Q=1*U/^L5<>%'9V7 AO;(@H(BH99>(A$3 M<;UFN#LA1]WK@9E7%6#1E#*3VX*<.BE)JAKJ39E+S8?)S&6$OHSY^WL&F:_U M6;T@141" VJ P@M^^("(=>8X46L'@6&B7D1K,O_NC4;HQ(,?K9&X_E)"Y5"9 MQ1/ C$T0JW_*^8NDM5*C23'A+]VXA1.Q/0YW6M&M?+)VQ*5&H'Z3]6Y.(J&< M"Z@IFL\MJM!*X@LIN\TZP^$S__YP29N6#?U8/O(]Z;9BON'6XVJ]C8BZZI39 M\IK*-%DN$-]]P H3KX8#>:N;.P&^K[NN2?DAS'ZR6_3D83=H=.BCRWE2TPA= MA+KX["LSA[U]Y5,X,^OE^??\)_X!SNI#J NN49RAFV:(H;]P[ M=,#?H:Z>M.34O6])=P;JW9"P(23.W^UQ?05*JH227A*E+H[3;I'LBWD5> @3 M.%P:#V^+X7#'(AU&*K ;* J9^-]>Y_5TKZ"AX8E$<&)H;O4ST-V%_U.S0%S= MJ28JV5X +CH!3 A%.>]&RJ=W>H4W@(9)S__(@%16N9X \"2"@V5Q,/Z&PODI M(WU PX1/@.3 2"Z/7H3S6%;$@&8(XP"ODRKP?-VOTMJI.&V M*&W$3S91Y7NU:=RIK_KE<4D?FG5.0(RY*PK M5XM@:EX?M98L]TR%A("F]/!,0<,/5F$/=:4[NL!TG9-SF]84$>/A#0F+*\[@ M;4EKR<%J6Y%(9L%RK0_+!MU5YO(?V$8EB-YG_U7'NRD%+?PJ5 M[3\E.#KYIZ)W@D+:=?G6.$+8\ E@KXGCJ>GPO&VIWFP_AM72?&0,"50A MLV5$TC]_U(,$*@(:@BSB=;-_G7#3JG4'/E]3H/!&]U>'HUPUL+Z"+TC:44\_HZR%-R6VB5X M?[KQ@C=I'9@'8H3=G(V>?<,5>9;)TSWZL2- ;Y%'1,4C#W>A5YA5$9POVZ]?X MJD2#.)VJ8''R'TQ3E/.PX:A.-X[,:NT_YC^(WKQ/YCLL)'$3O7ZL97S0QY5\DH]B?6 M9KCXH>2,2)L@5$((M3^\2 GM'@9,P)-'U,0^TU\C@D@O3.9E%7QV#7&:Q_=\ M;W>$BWYT-!+=B0#/ 7/BRQ+S8S)+&/B8K"M$I\Y%(UVA2OJ@(@7C<86TWPN7 MB=%;+C_K>_Y8[U9K^ZN+:]$);?^6*PG$;1Y?X/WV69E<"T2Q.D)?+E\H"JN0 M?E_1QG9 IVS+'OD57_!ML$4ULMX^,1RCXR _ .HD[%@2'S1,MC#XW:09T$6%#Y:5$,5+>P4S-]^ MP0NW'MN6FKC=>^GB,$RK6*(;);L&VQZ**C&NM>3*;H"TAWR8_DOQ4PMR@?_% M8E>OT%_LWN;9DRG\UX"!5;=NNO(,L_5?@]-KT*,3<*A2P>;& I*O")D!#F6' M[S+DA'WZSSZK"X/6D=^<)H2]'IM!^J>)ZZZP4:<[6R]D-QYTAUENO-:+#M<( M#$1$9FT_KG^1BOQ%15PMQL'W!W3:EU0IYVSF_1:P=^=/&T,"W]9OT93Y'$V5@%H7]92+H!K$T2XJ^^QRU]T"0BC@]R<8#;"!#4D'?AESE2]-! MP9=.I(1_['^0%%NZ!Z'^M\0Q.O>A-?X"7M-*-4=&5+:7])Z?>,JZ>2+D%J@? MK7Q>J[>.=9::6\618MSWZ)(4V7 ^!A5_N%?&FYB$HFWKU)WCQF/J(4[LQ8>A M**UY=8)#U1XV3E97$+J9I3>T,#[' N"@!%%* M@\[E%ND\VCXAZ?9;[@D\Q00%M)J[]KD"ZVKQ-PZQEYY8K>6OU"T=,C**5%BV%IE.=\8B2RI[/=MZR[ 2E M-;/.$R!*VS*+HZUV-?A=7<.9+K9_2X6#TB>/G"ZF7B)H(_\&_MNUBDL@WE\7 M1S/MCY6]0M.\$MX,/VLPU_]LU]U,. U73A0I67Y0/1&<_WGJ3FS607:!X355 M&&PJ[?+&@U29R%$[$E N)3,&JA8>H\.A@_?E HSJ6+MMV*4>N>![3.,V5DZ* MG.&'Q,Z>F),7JT\ ]@I?W)=?4%YA;)"=WNNJ_"#G.SA"3ORM#[ZTOLC.HOR/ MG4 +,A#Q>V'&H2:B\%LE-,>TS2@5)[WN6LB:,:CJ-R+PBR!>$E&_M?">*@+Y M@JB$BWD!;PE/+/<62SK'DIR$SA/W"?!H-547C+9DRAB]W!693!1[QL,90^*4 M#L>8ES,\07J0>6#L.A=54^AG_4;[<; "P.7.#XP0ZT,CQ>M;"/.2UH,3QM7% M)8J:';SIYF@*F7AT4%#A,^1TP7&-=91&M.F4:J,./!(CI+Z(A9^:I>,I6MM: MZ]+'Y"<*9Y1U0:!?=]9%6:? ^7E&-3)@7^*$0;3T@ .9-$(KGT/EJG?^'62E@T M##K8JJUT5W=%D^H,P2")W(^4@MI:OC&C+?3@B]/MH/SYOE>*08Z]S^>&U[&0 M!-HATQJT$;P0W:I2FN$0%M]%QBBJ<[JKW/?+A1_^R(TH**.2Q>U*"KPLDZ-@ MR>_&H16M+[N'?L06"K1C>&\H-E.YL>$G-CS6A,Q%%=A&) -3X""E__ FM_^M M273C0V':"R\J\+[LX4'8IB1.DFOM-= \<95 R5ZM>%WX''[+RY9./3&Z41.3 MRLN_6./GB+1[,YG.MS6V=&46IP++\/J[!:\($I(4ZQ8\79Z92L^H-/<-GTK" M'RBR[\)U4#AW18D1LZR.6W#:5;O$V*S$WR23= H"K-,[1L&#Z1$OK'.)W2DE MS/?TJ6%C#[G.IMBTASB5B=@CII4C)I%@Z+N!Q6B>Q$)1MJ.I[C\>+":+SB2W M5HIJ.,:_Y;=O)R/8S"?*FT/&CZ"]'S'5\-"5$,^PS )VZP;N13[ M: /$.@6H*T0XA_BOH;IX^+J+>YID-HVROKT)EC+D,B0D%!N7%Y>%_+3V:[$=@^ M:9T,$RB(G9=+G3.L-/;DXCZ:43P"7]=>'>NDED-][-PL[:PM[1PH)S)4;ZL2 MJ-W: 1LV*&E/ )T.,/[BNW.=62TM<9YKJL^H,1.'Y*UN*R9?AG?2\BI* [DC6M*V!A_CD5@NQ]N2M<.5 GQ2:JYKK="H.:#JSL7 MRR_SY'Q/A&F=JTKBFF,",,0P2>$MW\C#MS.L\72FS&NF>/J=$]:"-0;*PLC= MADJ0ANV2+[:CO=1:/M#D2X]'<;^M/-FWTNCEVALGP;:)YOF6WT?A]FWE3&## MCUE3ZJ33\\OQG(%2XOKUBU=5R'#:C,+Q2]Z([#W-6&M-3 \'[A3\C1]O5NE^ MJ/JB8W%AD%""/7<>SF6LF-2-581[R7S5:-/"IURV0@J6EGZ6AC[T?LP)OR#7 MJG@$@V2_IHV_C]GX$4/1/8"!BR:;J>/*TR@0-'KHO)^"VAKH1?/9&Q9W*/0) ML(#OWRLB&K)4QU.?VU+MQ:K8\^=KC X_9>^?("3IC0OX]J!C:GH-]NH'6+JM M>>9PO;6;J1G+?90>!)^T0P23)&_<*/JF9X&'@-:G0&&T%Y.M=-,&QQ3.!$;R M4; [(/K5!FD?GM.&XDE45%6,'?H.FN,E8!C-N[WNW?,HWN"0SA)$P^KP$PD] MUI94E3QS+_-0$ CS+-$E"%'TH<&.MUOF_5/,U)S9?D0]J8 M-DGK% M].> H9=,*S8TJ\VSK[A[JDI?>=P/!CB-F!.5YL4J;CC5'AI7U3;"8HEBEWLM MHA8L*M2BC$!D,>5B4KO7"DXZ+VNN=.0=]!AD9IM[>I?#TQ4%NQI3M=V;+&,\=00Q)#^/ MUN]_0VC&&==4I5XMO%99DD5.3'&TK?KP,.P<"=AVL?* MAQ)51!7[=5MV4=*C3UOY^4,1LOZ,F;S3R!. J5\,$WA4APBP5AE/"9DFB@4? M4U]'LY\389A8S9.2N!I":-410DXK\SB0$4G0(VJ)P2JO[KK_< !/[?!#6R?D MM#N?=61JH//&GJA9RJI>8*D3F).Z :-N.VE@\[MOF\/E$@UN8@\6@_P!?X/L M%R+\K'\F1#VP"56AZ]ZB@9!EA2)U:7?[E7]*2W*>L9\5ES [_+0(N4>^58.A M^?\_T*?UW_C_$-JI.X-^5S'6BM6P['3>QQ1(.O^1/.*-2DCVOY)S+O&;L M#4\ +"O1.9ZT,*Q)5A503#5,B6<9QS,,R[_R=%'00#,,Z>^+_^Y,*N894)D M9=A0@2,J,=UBWN[U OZ="J.ML](AZ:>A]?&3DMBW$53$*= MFMXW1_-VOGETXUMCYKH",:N8T6[&V_Y3QWB?#&:[Y%I_((5?B/[P:"5B$^!! M%XE].%P@"?J3YD9X&=%/9FT;MG))B?3 ''%RV2TL>QK7-6$KFDPT(>6(21! M"?NS&NR9X:0C^.5/C569XVBMJ-\30#$A4+0EKZ:;M^U['0ZZ0$Z*F8$2 G)S'*YN8?!4\_10* M!!'OXTWH+8:OHZ@1GCB"-\6EA+4N_NMW-B3U88FRF8?^E*$UQ?6&9-^ V(A+ MT\8?%A'[S,'!!DP6A"'?L$/MD>]L*9V4LNUNI">O =BRR2+@?BJ,AP@)B#?/ MH(C1;*.VL1'>M1?R;@I,]_5Y0.=;A+?UW!$;E)ZR%1%M#4QT)^B:%#D M;H8^ :JD]JQSIP@IV52\B$!%Y0YMD^5>G"61G6H+OWTL*1>P*4:#PSD41@SJ>M($]GRII&SUMD/0$PO]ZE_L#\IKVTF!*R9J5+ M'ARV;'M%)^2H" F=X)45^",C^+JOQ_W.#P*EX^EAC49V(MM^EN++X7'P;:5% MO&43>XQBJ!YL<(5BS:" "]5LOU'A*HH*K;3(=[Q"GM+;!FCS9HM9XA MOH+XKG&Q+PB9_GT;PW].20SQ9/Z%Z#S5,28;*)QV9 3V1>_ZNPNFG ZMBVI"*H_S2/5O\@D18W MA%MVH$H-(-U=M]IX&P.!EH$31_XRR">%^.O\W3(P.R=<$)1:13S7FBPRMUCB MW5^Q1,>\'/Y)W,<]I?"XB=6H0M+R1+ZO-#'3O ,\K9S([['99F/5HXWPVE'W:P"0(9[QVQ6=A/<;_H84!0$^Z;G'1S9_W)\VD4F"O MV?_V"2 K@2JUL#TNPJC([2/D\]H6Q@-W Z8>[L0T;\DR! W32+%3:+4!C M "2H>OCV;OQC93L@LXC"AU,1*=!>X#C2X<93U77S*@,3N(C(B$>B2 *9I9! M"!+HL(:G"L;M6 8:\YO 1/7F #0Z4WM[='K:L%_J]74PV/F1B72NY&WZ+_\, MP6D!A[5T:EK)V'Z79B)F.U)A_,AFK+%TTHF;UT:.[GI0^[V@B=G/5.AGX3YMQR3$=I!AF4UT,B*WR=_JAZU'D_"K9[14R]/1C MR'VI9"TGV; M4DIH5?-G4F5->L:BS0L"O36D/BY,YH0Q*03\5];OJ89M+F;K1]V9+/?56"7^ MCCKP&K@XT_*-1]J _/W2%2+H\LQS1O6._.7+BML*=4\ 5VAHVIAJQ#MJYD5( MB<%U26+*$X#Z.\G.AOI^VZ78$Z"&*3+I>23-4PAKCIQ$?:&FYE1>QYW7[..H MLL@ /J?VN\],'RCA)(25>N+<1&$6BTE%&BAA@,2P@#/SNNI$K3])RF?!NZF9 M!V1%_.=ETD\ E]TO;_-F6HHE/H]8R:3U%^)04%3C0@3)EC75A^-,Q(Y;0BYS M=KS+TCC1 R08S"A)HK*+C(F9,!HC>>S=\6O%J6 ,61_I+ F"(CXR;*"2$!:F M;:?JR +D'<)QR"Q^$.=9\,,7*=&M? B1\&99$2-U5)]]'2-*[B7%KG(/$F>4 M;++_I/EO1N+]GBK,\6/^12ZYV#B%W'1LB@[2\=3]2W[\O,%H2=4!:_G_/8SZ MD=$B"VU,-327Z@*)9_GTJ"W(#/; +!S]O=XMBORA_B=2IN=8$D)D^J2(QTCB MJ@ )M$]\2Z9915G>IU"LF\6RZU@B\"Z;&DE!,+U@K+./F&+K?3>(Z5=7M<+5 M%]$9Z37RGS61AGCJ/>N79P<_T0<I[\P>S% M$$ 6N9LH'&]1<7N[,V1XPX=$JNS:E0P8Z$V+5L2XV)<6)K>*OZ%%\/WOW 6I!HU#%F* GU :MJ4@9]PA)1#D&9B9>#?3+!L\U?O2^?[:^5J MY+S2(ZKMWL8;0YV=Q^4U^6+[\2./J?W^A MY%3GKXN>85G@UT3F,R@))SQ7AKT@)7T"2 -EUWG'T*)*D)=Y9Z6> $#:73WS M4- &7O$C^+PXQIY/& LT]OM9PLP!']$:,R8'W"E0FR:D\IM!=R]=*$M);5T^ M?65V^FMX>TXU+W5>QJV[1'8_#91 P'!RLW/"&/^SW JD50/"OK8H:#OU&BHP MN3BF5KQWB_B M?3;KWD(6 MS;ALH/C0"FPZ+X-AJ]!!Z*0C23PW(A>94G*B5.[G_9HU6$>K)+JGP/MM[. /\J]PB_RYP0C)[KZ7% OR8N# M+H=##7%+WBV,V5)' K!O4DTG4K_?F50N6%\=VQ("&3C>-9V(..DM RX( XOY MLP3DB$>Z[$!)* C/KXH/QK$")>NDW8QXP%4I$4M"2UU#"^)'CT3.A[VC(&"H M1//83C][0IIT;[CYZ567BA^D"^3Q!/B2BX"A%N1ZF'#:.)Z6._FYT^^*"RWL MO WLJL/ZC'%$9\!Q@!U,R041A#<*EJ=X2OQ5L',TGO/HF-V%VS+&6$V?%.,O M2ONM!_'OSI4NZ VZL*<(1]!>]%.,HZ0XWX1HF9L)AF_^*K7=0/!L3_-*U7)0 M?C0F?UG6U!@EVU_H'Q? 2&0BFQ6MR%PV+O4 =N;=190Y($[+M=%Q/':_N*:0 MB+X;5?=$(GU44)F](YU8I+I9=A_W)'/R69?10UL+ZYMJJ(W&S?>#*D]HB-;. MU#HA%GE0&6U.;$T>LV_I#K-\0F):[T=FG=%X\,P1]&1L4.2696>-AP8Q=K&B%PWS[O+?"TUUHS M8-D.?O^F>MXP;F^RA:I-J >%&2>,GVG;V)<*QI*;FU,ZJ]\%L=O^Z-@PY[YC MU47]/[X5_79UL%W:P*I49V^;9+BTLI OR71^K5=;QET,/OI[B[6GF76GR5E\ M7JSPO&@@J$4=MPDQ_>/;UIJ9?/R \J;H*[BL"_S!&W3?G=.E]!-H&?X;I:Y" MA>F]S^RPZJY\H6L6E@[-$Z!+#OKAD.?4^[WT[[A,+L]S,ZS73GZ* M@NNI8R>#L,(9,VOF7MNOYY+"FX9J-B@N!YZ!R[Q$\"#;X;K%K;#$T7!"<2.?OU9LW&FXX/=9B*6TQT&V;VZ+U(00 M&X,/BV.GB(NV1ZMB]?B$Y'B"F84%:VZ=<;I)Z-3RD'3NT&&WR% XQM^WPR\G M?'DU[S4U[)H*VT7Z*Q'Q(CJHZNR>BWN.]WML4R_1@M\I%;FB;$2V.1L5^91^ M\0V8=-CY_@304;@[Q_$XP7V09#P7TF*)#.31%*G6A=Q"D!]G)B"RHOVEG-MJ MT3XOHC:8/F[-=Y!_D;)W:J4S,0#_>N:&$:E];?!JA*!"]R?GP7JN#QFS4:CU MGR:E!B""@?<@I6]'$T,9\&0[8Y(X6% MWI%1"9+Q<60-Z:I!"Q->*18MK6U?F^UU0= O#MKN_82K937S>\<4_00=%_(70H K^-Z=Q\YN$J/!T M+UG@^:N0$P&$.NDI52S_O;Y/PO,T9:-UYE]@!'/OGJF$4J]_DT7S07H"@/(Y M&O1N?LD=LD"70W52O<%?'S@7Z\: B!:]LYP]V@< I>5G"]!WY+TW_GI9WF"; M!S[-P4LQ$/0#@D#O<9#IX%$V' '+>2,ZT_Y@T=[-9[Y%EKT?CS%\(('M0>&V/W0]KP]4TE M/%EHD=;NM(/P74#/J.[7>$EI >H O'*GL)'A8F#2C8;(]@]GJ)!RXI\'T !1 MWJ)8Z2L#B7ZB\SCO'//$Z"U436"*=95><*Q%*.T]DO5YQ_E*AQ$&AKJV.T M"B2$#Q-YX*\?'/Q+"N]_NK,?(*9KLA+Z#Q?33"YX=B%3((-FST=+G:$!S=8B MPYS$I#!3_+J[GM;"6[((J3MYY(4G %-,R''.71TBP++X6;QP/ ':VQ( 5K/G M@I?[VD).(EG;0,M08P0*L_XP0O3UX^K#_KOZ>I@ _$X-=$<6YA]^UK>R_MMS MZ&;([09=2K0N.O/!H=2S;VM.R29]W'X]H^&B#"^"'XQLB57?WA(*60_^X4PV M^RS)7\;9A4(5,;>4GP"1J6MD'6XT,9I MJT[2JN2@&HI3Q+Y:9_&WJ$*;)\#Z$NA:ZJR8,?H)4!3U. HN8OG/6G3]&__& M_RDP199S%R@<(#U*Z)>D)@_]$FD@RYJ[;K /2CZB=E4V6^] MJ*S,A5&;\*A/RJ,^C1O)_\AK4D0\Y6)V[;SS_6)E)^D>DVR4BD!2.JT M )RKBZ+5^NF4F0Y+1#4KE;J:I""@OU.#*P2_],+C MC!-^&HX;DI&F+MI9.%%G7NI1I]IO[F657\M45CO&^>XGTD@X7OS586J(\F1! MPYB^3/:/F.#/M>,!G&FV2'\R6K=/2UT%]=@+FH;.JA=*;N\S75>:?= \ACA3 M<]DRJF=ZOWH)UUE3F[BQJ*U[0)@&\UTO83>UJ1< MO&3:^O)BP2_6XR=V_2RS](R=?1$N>NT19HZZQ(B1"C&-.GGH?EP >%M&\NC M,5:&3L*'\'HNE-C3-G;JEX'WDE73)0D ^79[1!U]E"=@9VWJCU0TTED!"<"S MDOXW\ME5>RR(L\9<)(K(8\,&G'XL>8A9P)6" M6;\,9Q)QYG5!_XP?_4$4LW=W4*Y [LI:U75_R^2$>_[94YLJTC^*W1%/LR<6 M3>?6F2H*2@F+>H>>&$@!U$,$Q-U\X]\[4J_WBE#TR.NG8?GLG>M7/TS5>FDL M$W08G%K%I\/ 5T2.<(6L&H/L&J-MFYIXUU0&DLW4;T5#+ M%#/,.HAS+@W6D=B4&@N<2@[^(#M;\02((FD#;EE3AA!!"REF"BMI+[,<%LQ* M/EAJ4KM@9O:G;O4,UH,.GR7$/MOK 5BJL,_.C&]P \_6S/TKJ]Q*WE>Q./,9 M8AV]#Q$JJNYJC\D?U83,!WH$AKS4MY5&9!)Z2/@?('>7^L.;7GZ< :O!(A,: M+L8#4"]/TCZ*$]C7+9\ 3E;C]QHV3&$<*5*:749I M>J5?1&'& 5'55LWO.QY8+DX7%(Y\&+R+MN#;FGQ?9WZN[G N+6,2^"<^8"$PSIUK$'!1RY8Z;KJ(P/\D6HPOGI#/."!F+1OMH M>*9&( B)D4MO(!G6QW9Y NRK,'2TW[KOB8BT,$CV=J])>B*)84GU!MQ+\M.Y M4-6@HD2T>#[D!CY:HF$L- =O$'@^0NXFRDCH!\]Q5R)!=Q> ='3^[2*19W&! MR0*6W"X2@*]^P@%^!(]$G>;S=Z#8Z-\'6R"5R"!%2@\Y>CT!,KOC_@X6TQ-+YMVFBG9=KS_+GALR)4OXXGP*7*"Q]B M2M$K0'8\UR%UU46WX",#TF ]E:*4"CD(46(!<$23@=,"'AD6(YH!F =.3X"] MK$N4M.O>#8AP&$ ^H:=[/".E'?0CRWMP/ R \@II.T $ M',(B:L0Y3.UR!]$1\U6"Q\W3E_O&LP^(GMH^\ *J11?+P$['8DC*<1E2;>?# MGAQB?]F(*[$[LFBO]*426Q=T?^N(<5FB4OYNS1Q3)"F^LZN"!/9LG=J$W;[;? M?IR;IZJ;LLH7!A.6D)4I$L+LQM-FSGB/8(MQ]OIJQ[IF9Y M>Q0Y[_:Y#CUR8>:VQ ^R&] <(]AM=*Y=-D_LGES=W4PF+'K@U#,( M%Z;,^IO3ZV*:+V[G6,6 ]T8SP%X2"0Z1'36VGBVW@?(E%^T(A"$!Y-1L?W/>IO\[X)(3O/9YY98 M?G3B=2W9,Q;\,@,\[WV6KQ[8P*23\GGY;?E_(L+UB2 VGU+8V/"#+!21\$TB MA_$EZ]M=:0RVX*_ 8ZSL H?\"M#Y:*GDAAFPN[JF(X+U]@F06'BG,3+SIWPS M?RU]+KG%\M),@OE>QA:KV2JJVAC%*:*3DR>Q]OSG,I^NRP]-7Y):.5OJ]9,N M@UT)@.8$__B6J!]$<*<7Y41*MHN:GZF=0T2F1_4)1=PJXPP!B2+9\7"*.%$!@]EXVDC>->*K(/M0%M, MTKN=?;D6"Z;0ZLY[C'4Z8Z:F>[EQ!91WR3('RRU57BI\+;O0]9$D.:N2_A5S M]UTXLQ-G4HZ=Q'*L77]+'1RSB2NZJTX?50[(DI*0D+)Q(MJL<7MSADD3;:JE M%O^O4&6\\G#^>Z$1U!]M$^RKZF7^-0V-":%?A5X #J-T*MD?O'ZOJN^^49M$9V".50"B[\6(0_:/=A0Y0^=]EYAB M[&Z[V5 =;"G\8.O2V]VUEI-Y^S!PPE$4=OU(H*6:UJ[9X\.!OT2 M=D>97$83YT5'E>PJ.&VW?))R%]L&>Q, M(C:SV( G?L^,FRHGY4S MU)>I"Q20U:+@=#CTWDUZ3+!$$@LY+?WTQUS+M?(H&F(,E9:T#1FK/_21'H$! MX;?3YK;DG0#-$)X5,=7G+TOVM@T1./ZXZB62\-JYN4T\"@L6'ET5(+0[W\F M4)F9._6IJTZF8MBR/9\ -'@)2+=I=T@ZJC*;XG3)0UVL47I8MW;=2^_;3M'J M[*>=^']0E-D?W1I3!?@QN&=V$>MH^ M3',Q7>#,4@(08BKS6N+\./=G(HRV%_-:20PD0"?%/PUSWLRGS9ZXY5/7G;^L MJ_#SZ.-M.^\A$3ZD%#]8K.F^D9*8:E$$,*^-:="OQ-Q,UWL3G]I<7HQ;)#D* MG]+IF[#!WP':YR_RN"=^#Q_#*TI@9@^()P!5@H[_OVKEF+JGU][8WCP!QFEU M)G^N_8W"6=I&>*0Z+.!E\CX+9N./,KW6P:";G3+YT[#%2_)7]W#S!Z8U@*9+ET,8HH/E^VJGAP_<+T,B;L&4' /W[$11M&?KY67(*N M65=9*(OBWT8X9:+Z_'B-^4\.'NS-#?:U4U9B= QM3E:? %:036W?UH+DZ!4G MN4P=6PX)P>@NTGVP!KR%PRR#"PW"A*88T4'5W63#ZK#V^(YSU/@)0+;VBK(P MC;*@J87R@_NRHFHO-A 1P)0X/-)7L'.-=M\=F]"8JIC0;LNPKS6WS;?I8_*B M-D3G[S1)&2 R1UP!F7_^5^FL'.S7)PJ':F:[+YTQ#R65#9.3DH)NR7IJYR!,M-.QD3DB4C8KZ_&+P82K_:ZY&QCYH]!#>4Y MYQ+6]6M,O^/Z'2&X3":\#8F\)&RYB^07*P&<89WU#>^!#)7D]W%A.^].%L(Z MFH_I/--P(63?+5Q?97+MKC=YAPOQSP)7'YGT9!7A$X%*Y00:/_(2P+O7U7[C(W-9F"5@.U]Y[OY\ 7X;/H31F?>/G0IE7$5)AWFE-/I9, MG3PNA:YY<)X]L4^KS7R%Y7R@S55BT G6 8N>E#%!)( 2?>J9T'",AZ=T1>QD M$;+,^?X]=>&>K/)U&-\L;N%3<8,"SZ)HDO7BUZY6:8+MO&]Y9ZQTD#M0XWDU M5<.]?+B5WBP6#X#%0KG ,/GG8P92OAV16^#[3>$T_TQ Y>%(3X I0@+.N/'; ML3N'0/F/N*#.,$QXH7Y\+IT]EV5>N O M0O YFF(?S.:@>OI@TZ81_7@&Y^& M5P@#4/B/ _7"T,#E/JBDUX^"RO "L<.XX9L1I-[G"9O%"9_?N.9OBX:T>BFG M>1E7HOF]>A8[4R*6'MN_"YXM");\=L7P-_S 6Y65N&Z'BRP4 1PI\64!'L-' M< %$]J,/(IUA)9+SF>\R=Y\%GMUN&,80J"@/.1+ICF+T+#+/>,D/Y[1CN()Z M[$02#5R\_U LZ"=.=RV0^[MN70R=_SA3<2V2_T#$229#$90(8@E3G@[W>F7Q MRAC%(=8+7^I38-2VE.HR57UN82V>4RI D5C$_3I_NUS\X7EBZXBM:0R!X<2C%3VU\&P80#+\2X>!_V-D6X>Z&/&KEB@@@XGW&PWW1 M_)!&8G$GA<\X'TJ'V'FL'R5E7#Y'9# G<64C@QA![+MA%\\L20JF#N!"KRLJ MQX4 ]'0:?#XH-\&4?"6T,5\TAQ)_LO\-[X<-7T1D@+WR#0F4=YC]-]=H/)'$S"O M)/0;Y 1@@JO /+<=!EJ/VD2#/_B"@#]7^J^#-"* M/("D*X\T<]ODU,>^0JY%YB"AW[.ZMCK?.'X_-%/*C-E%6)\3\UG%@04B!;HY MI,&[*+I[G$+$[Z(?JSYV(^(G2)L4P5@6AM;:3X#?X.L@$[V3(D]\8:EG:\[Z M;39J^>VSIZ[Q/L=56[Z3@@UX9FC-F51FR[)>CW6/$BC4J@AYK:]^F@F/\B@& MOOQK0QSS5=C))XN39;B:'RXF:C?6 G HZ8>C9"2<;T>9G N[E67*)1KT1^WJ M**:&R=,R-Y&U4MUDEKG[/@$.E3]9LNOE=DLZ'>$11>"%L=.>REG[&W,W0]^J MB.K5BB/,*AC*!EE\8*N4ILWBJR(?U&-Y(HZ^XO:$,!5F(Y\2U>F_//F[=A51 ML",("8%IF=7R[2E]P4LG9P%3.PK>3S?JZGURLR;J:O[)PE7D["* 4Q@M7F1A M&3OZO^B']V_\&_\G0*3S!/B%^018X#4K-3C]ZO $T!L^*ZA[/0.'@1KAL(]_ MX\#/MEU#-)[_ME2Q$/A1)"?5%?%8ZU7)Y1%E.&?;G 76DT/)Y. M:4'5P[;U*^!U$#>,!9W8 7@5]#9IR4WWNUYZF>SV.91$.91%]Z0$53VM&BG> M*:RQVI[0A2;[%^LE31/RMBT:+?W9AB92B=4'D-W,7%=^8R_]0.50V5[SJRR M!P7"9=V) J_S3E/(0\@PLV8NNP?)NQ?+/\U5^%)9G?#S;*)) MA-%W\B;,."X9QGJV#S+PQ,Z@;1([^3?H:>JJQ7).PJXG^XE5! ,(M=?G_NW* M9R>XJW'SAI?EB7U'8K2J'F8R!LEE50SH(AZVR8=[0FH#J-TEQ2T9U!VXVV;# MIPYQ8:56=!>L?_FR";%1:EU#C%!IR*L4'<9Q I=;3+&G9,K)UL;.%JA[V7$O MX?>]]1H)$Z-<9C('6B;5MV%JZX7H>Q)B5[%@.@#@1O M2&FCG"6U/--G=5>AY;(FB_VM&>F0)_Z$.H2-,]]#]Z\MX$6>O56Q4C(TKOU%'0!C@1U+\_9X]J_:K=WI;,X.YP3 *PG!7/] <5+*"0A3;*50 MXI_783K6.%&%/(Q](Y12S^X5#B/>)SD%I^_&!Q;(Z<*)#]9,*V9C*Y!Q/H0D M+"YU,,8Q-LH())OG5*6E^/737N"MZN"G;T[6SSN[P/JAQ(B_0'I\K.;B+R)4 M*C=U@#>_ %(4#:E[1$65(.BW'\L'3 MBMV2D6Z4GCDE]+)O^Q06P\++7O&8X2,J992OEPL 5_(RT0J]1'/YI6Q?#DT^ M3=MPN3K^0N5&F?>6/@O=7P\4[Y.CV)R(L " M&F(,>/VN#?<&#MQ>BB\_TL*A0DRTHQT5(:T /,5,?R!.AM=3/[W,I?=3 MNT#/$'&2%: MIMMXX?&L_D8P%Z/@@%,I^2+^2]H8!$^[P1(30-?:F"(NZN\S M,2L 7M<#%!71&(F1L$I.! ,?)1CI(G4#=]Q\XP$?T-/;GP!>;3>J;@3@OJ:H M5B?9+'-^E*A/X2H']N ^AX43CP<+@# .CO]\K01_@.*85F1ZR*["L)$:^SV= M_ZUR/?-/Q&!?765TT5KM#\Z,.HJ.8L<(#K- U[ M[QC(8D 1X %,YR#T;MX(.IY_"/L4,8-B3GFC+Z2TS+A2LEVHG-F=1-I]E"G^ M_%!YR&[&="; CYRWYK>J4:1*'A3F(A F\T7;%A])3D747^'XD2& ];/U*3\< MQW:;EX=QF6>,&"O&R.@ \[OQGWYH6T EZ>%5F28[>GI@3 % ZX#\YRMX>$9; M,*.8S4(%?2P_P@!1@L3?P01=P.66Q+4GIOTM//+"YW"^RB% #+YGB8;TCL/1 M70#AC(HCA>T_XCG&,,P:ZQO@1^6.LDXO_#JR=>*[=Y.XH2 E'$7%=ILQ8EE/ M)3.)SE31]^0R"W7XHZ QR7[FIDS:.BT__X[4.<^+/*)]_XBLBZO\;Q0$@/8] M1^D[([_76Z8=]"(8(L74IN0C'.BNKK'NG%Z?A^ZMZ?KZV5'\CG/PG"?%*W8,,*M!F>4U)A-.RK30.187BT MHT$.&K6>&\HU#GO3KS[G/NHN<,4A#E7K1^W>1VRE:J>T+U!9XAET3COVF4*W MPJGX1")_KOZ-.A"1?25N 4.GP^V(D49(-L['):^+ADEM*-B#L-E?_MW_&82E M0XJ!#N+$P3O[+9[LNRI:QMPO.\?M8>N*,;^NB3@+?MBUPD9;+)Q__000GKY5 M#QM8&*T1J*."$XFH5X&:OAYKE&C7N&+]5S;;++4"GKUL^*?I\4/)H&;K$R * M.^IN:[G/3]BG]0A#H'Q:!G3*4/=@'1YW#.QN8J78E@X\+35B(Y-]2>@7O/TH M?C?EF\I9*/O?V'NOJ"BB]UNPR)(%04%"HX!$D9RA082FR1DD)R5):'(0&D1 MR4$0$&DD9P1!JVN5=55I_KL M;^]]ZJMSZG>X,,D_/#!9:$6[G1XT[AV?JL>=T/YG7EJ48HA&?J2/XR_^!9SY M!(3:J0;M-[9'JL5F9B^+YU>('ZYW_#R\.BLY2B.CNFY_U1@4V"PD1]:85E:Z MF48C]321)@/78=ENV@T\YJRAY)N*!<(4"^&]DO!+GEQ@WUR*)$V*EM8CDZLT M% NP7&F.NV)JGD@V8('!YYJW5<@;@]AFQ\MTV@6!"$%!\A^220EZYU/I<+*% M^1Z:,L%7:5J4P[[KH5#EX2MAG(AXA4F4!QJ[EB"B%X>*#^HO;50,FIJ$[+2#5G^I4SE^R?9[,5 M91A>TZB!5O$AE^'">M+'QR%Q>0KK9K(\9OI>=")]$T8^"LYOQ3#AD=/]/I:P& )RW-KWLN3\(PJ-R50)Z$X^8%A_(JQ\M?1G][WMI6 M"7@F!@G*UI18B2Q<9#*DHZ/,H,1V;W?=Q3F6Z4H^?O.V'296VMIG?\ZQ:IQ& MG/F?@:=*L?\:V"O^T_J?,E/#'WCT-L^F&T&.]E@@\/+E1F!7T<97W_F+3@Z+ MKV^YU5G1ZLOH]R TCF- YVW"^5EI^F74+0??C$[/W5TJX^Z)>,$G[J)ID4_P M>F(YL'R5I__;-R>)ZT\C_G6:-$M$8 'C=W>9 MTV)/>V?+^O-%W/F/3QR3_A-(<,L[__%=IGN:>4J."FKMVUR? JNV-IV^SDS" M.YX7,WJ#AQL:!;XEGY5;_)'V5=7% B%PR;1WIF**K03P\JD[KY[IA@6VGS7P M38U<<5K5Z")6(K" O,CH] N/8BGB_U2%GJ()+&?D5\N3L$ ;O$R!<_G_H3P4 MAQR)\EV SXAB]$\H"J&36[)5#R)O3M"_=V;4=T@1HS.]C]8E/T9,-=OC*:B_ M[ Q)-U-^GVL=(_'[F<#TM\+?*[[%5"&BKYI+)EL(X;TS N#3?VU!UDU5VE_7 MYYHM5JQQUDS">U _Q8OPYEWC;J#,4^8%S7>9X?<-R8=@$F,53IR Z4?1&M(O M_ [JRN:03>_FW[_PU,S3\WD9P$Q>"@B7X&2^3D5+&1"O1Q^;-(QU?[/:JVG] M;H6DIZMX6=L]:(^ZYRI\KBW_IJ<,0.Z\?DPN#3*6\RL0RQ.VU<*-*Y..!9-8 M'ZF#HTD JST50DUAT/@7RG=:A!FAS$RA2][@_E\V%H*VES&$Q.#V MW@P\P>A_'T]-V$Y$<=2'KS[!3(4LMC9D4$XC.#H^6_=*=E5:SKL1!J*=1L(F MUS$F0U@ 3@ZR1R"6^^YZ:R;)/IH_M4LP/-58CE-0(V,;C79.<*MANU%+6O<:SR C^;N\ M;(\JY&M=L.C_:A+9VS=^YOKTWY:^NY(X$X%+2[3Y^O!MX/CW1K>RD$@S:1Y3 M:AK6G:6APER[9\.(;I_>$0L1<&$H MER@]]%([X8RV!OTC1_$D\&=BTWW*/(^I,CJ506U' 0WU%SHV+".\X >0]+K; MO>M)//UQCS Q\H/*2E!_SJ3S] 4KB;HTIYM[3/B_0&XK[*M=^0",KM0EJ ++PD#/U6=)#LQMNDI%F7"^&Z$3F8'"&% MICAK!6%2QCHH 0L\EH1=^X<>JLXRQ@T'/RC:0_PA$6IC+;!6I&.=8?X.-Y;D MN@Z7W K!V?;K/0Q5\=L6.@?U)\7*6O70$Y71]8++">6R\(CH-C!$6& *&A_X M:U@^KQ>9*8G,PXLM.,DBP 1=Y3*^+\ [&L$"YM&VQTE[7<"*G33%TA? 32JH M=4388Z:B;@=5R)@!>)QGW24JR5&C )0\Q/"S=3>0BB04D?\42N+?03-E.B0B.,RT9 M ;8W,X8HUO&Z/<7N'+6E+U^RTTDXU__,V"G!!Z?04^@N4S?_M>@ MP2E-"18 *:!']A3P=&8^/YJ-[)X20"/\N@48W .L?SN/#!8L&!CD"UGY9[E; MPVX>#Y$57CUN2CT7.:V-&7[O488%9OXA;J@JL@O67\,OXT#?W^^L6UPSG3>= MW[YKO:$JVT4)/ ,]X+?/CFR;W7]/N>*LV?4HV.@/'0O%B93S*V8LL&IA9.\M MN)-.F_QE_X$J&7>LM5E1O,2<%*6\*;A=BK;F"N8D.OIXRS ^83+8.PY-V,SH M691TKSQ[3)&6_?_3%0[^._X[_E?"8!*\ 8)A5DM$3+2P0/Q[+'#PV DF$ZT* M/W^9W,5>AQXM(C&(\XC[06GL0%CP=TCY]S\T3O[3!,+4OV5"-L\$"1W!/Y7A M$2#ME]:PM]YK4CIV;!L>AID=BB.TKW.X_>CRU=/IU$4TV)7.GB;'*/F'RCUV M8*W9^)1E*;'.Y.CQS'"SG;6(B>!-\U_5>AI<4D8\A+9Z0Z.OL^W)NA\)%W?) M9+K!B]2BHL7ZR6RC RMMJNOU$]6DS.]7A[K&98/'FWQ+@A]+'I"<'O"\T*AN M31-KFE%1"UHMSX$=TE&_!D+I"S#C# M2_^3Z.]H9DM6K$11]9_X3O[ X5T]NT$2V(QL!@PB7S:0U/?[?IE;/UJN_M-] MF2M0K",/PYO$G>6^W^^+GJQ:?_3<,>WB"E+5Z1TBT/+%@8..06"VED>,WSZZR M08',>]RI>#'I'3D5NW[IHF)+:7&ZE*_Z*<](880H?9#PCUM[E1M08D(_L";F M6?V';'[3TM#ME(%-_X$ 9E0*YQV_3G.OC,39GG$*U;^)93JV9X+8Q%.0YSL7X@6B;VSZ# MQZJ=X-.\UB(K*VG<2O<,2",\-F?;=9;ZG;7L;(F(KCK++"0VXR[O5VL06%]* M6:,G6<4<(R5P^ZTY,ESPYL+?X?;4Z),96(A3$K6XK2ME#1/-C:((W=";3 MPR 2?ZA!%YHG1=P\25&OX8O@_A A<@([T'DL#U32P(/R+.5FBI408NUAY0*? M!?67ZJM+8>2/0J?T7VR0/;MX ^1[2R,E/ M\>M_BQD88"P9-@>#G=>@O5?1:V],S4=<80[W?_,]=6VAPGDUA5J*Q]Z M3*"E2GUOO:ATY+ZOA7;3)//:&&D)+=TIP/#R=&:IQA#2]*WSV;!:5 5GT8"= MN#1N8%O/^BL==VBU0!'7^:&[70W,9)=[L"PQLR> ?1+/_A]$FT9=7?&3U-0U1M*V[_YM?5V/5 ML5+G(Q7K.RIT#RX;O("U^-"X"X^^O?_4>>'5LT?AM&\#:*Z<@U5EEK->C.=! M@3<-U>C9^G%^= 8CM:8+)\[^]X%N2OE$P: TFD%.O&B;:(&-(!IF^5F!_0RM M91[FG,GC_W0 2RD.EMC%B()F(-'CE#*KYVH<%^%3MVZ_3H.I6VB*A1B@"G$R M5G^Z+V"8ES?&0Y-B"0-CU;DDQ)]?9P3I!5.F$KQCQ&7XD85/3QSRO6"B=:*& MC]"=\-Y*IAQ-B'?H92 _SH]?];!$_]@(&B#K]Z-W85\NC>4_X."19J[%1U?V M,L9"M^$CFRHR[AZQ=?NH;0!?H&]^Q*7@6F*6"@!L$K&IT4$6LWASQKJM#O(,AN*#OMPU[&8; MA[AO10#Q& MA,/D)&P!./&.BO*Y>2JR]BRW/[2MHY:NVV-?CD3CGUWA/XEY>5-&/A^[GZS" M60\0IAL;%Z@BT9B(#-#:".L)#9!K!U"6^X/:9I*O<;;1![LWS_N!.UI%X2A M%(L%'.9V=6>0UO#O 6/X&Z+CFFPATQGNX. 5QN/Y'>.&J<>_DF[;>1R_KOA] M[0C@JAZR,:NJ,ZOB%:C$]Q< 33=+FCL'G\%WL,!T.8,2_!=*MR$BD8\W%P^A M9( \*=^5OXV0"0%-?_%^ZM_X_5F*CX-W#SHZZ-54P_#H[.\4Q+]&RADL4&&L M3S;USK@2+!3773X=^.,/%M VIN6=D[JC+N7_8;V-_Y=(2--Z\PGP>?:SXKVF M*]Z_6EP=RRR>CE'F&@=Z; M#8-P2>",>E?R)VHG?.N^X!OMJYGOORN$O%(15U2%&MG0OB1P#. /GB^3Z_L. M7 IW%AO%U@I@O+:VL "X2TWL[V$Z<.8]_>X1QIP&S1538<0);AE9-?>X^'4( MO4B1P!^5S/V>IU M]M7BXAN>IOO^%17C)::S@7D;S^STDD650W-L M?A0/K-[RWWO.IR:KH9#0,Q[,YRAE.WY Z%X&T@HP^&/\IKB[T7C##;S9:$#^ MA^O-#RB)BVTX(]F),FT91;V+M<)%P-A)[$_0<6'R#2V5:W;-Q+[Y%F22_M'A MO0)KN?,;G;I?ZC(5X_WDZUCX/H!> M:D72U!J*^LSII5"KPQA=(K\EDN?:,)XFS.4/-A.OV>=]YJC-=,A.=3%(^RR. MLJ?NMCGU*1_^]JL'^1KQU_M2\I4H<8!47B.\C*OY@NO]+^]]JC@' M4YL,I$BQ4, WX$,]$T8&'OM6Z 0N$9=8B[)+^M=IP M(9VO/7;2AXZ]!N]L?K3LX_HD?4/]VF:]:QOZ7LOK._N&SC'"8W8N8OZF>35V MT6Q+AF\WSM3(TZ 225 W*7JL-^EL:^]GNNO9JZG5V:TM+;*-O AU]79[4D5D%MFN,PY8* MX1W@@H] 3\("6<\U_3"%@8[DC-8,(S?7X!OH9!"H]Y&;34JB5PHZEQS7,[IV M=Y813V3 ]ROF%5IA&>7(7NEYJ;A,@ 4&3?)?=MY=4/JVE*',2J)':;3G_=.] MD[NO!O\9*"3PE'U\^^N_!@@]IEP&3,PXJ^C(PN4HR:/U!&/'(Y%6QZ;N2#1] MS[KA Q,(<*W&A5.F:$>N3WDDMJF*+D[% GIG.#\4M1Z7V$! M;J!94>=Q7CW19W$L\#9N7]7UH@>%/THPQUUPD5Q[^0USG7.K,G_;@[G.(O74 MER^_;,(N+R7:^4 MVGDU7):!=#XI9E*"[YM#@S#VT@JV:%I]K43H3N0-Z:IAB.M[28Y)$38!4V7< M7 A^R#(XSTV6/ D>Y?G3#3[^H+8YD%ZNS.;9*486<53HZ-1Z=0/OR,Z2OQI3 MI %\RNUZ8FH[)M9;:2<,WC;G\#7GUR0-C_(P?M5.TG_T-C6S9_AF7,K(85[[ MTRRZ>>]!?Q)H=QES+7+(=?0;7U&^S/2=>7!W >B[]'O^4$RH(>AR!][1R&Y M[;S03Z)M4+EBKM=Z.H0%#M/U([7@4RW@19%#Q%'I)Q!]$D%-?R4:GS MB-G;/0RZX$HO0-F'9^F?+T>"$.,G6Q;_)P6!F2Z9KT*WPYN1&-JP"HO];ZVW M%XA5U3OEW#'24N&'!=X77&GO/UF0.>@)B7K=@ZI,PEP)'_X:AMRD@0^3S*_O M=NP? )_0-&&!%ET4YUT2>&.#!>15.^"+FD<%^UR7E &5*R^G33W(TK" VT18 M-3)7$)3]^++[ZHVE_ZXA(A$>QHT2GNA!_7E!.6-WI7,1?\!\O%8K6DLD]Q.7 M&+K\9)6RL!0+_%RTP\C<]?56.Q3/$A98-=Y!TD^ZQDJ^^0I*^<])[?(I9!?] MX2NJ&)J[)N+G^G)6-APZ@=&WX%7(K$OE'5@GX,N_S"]D&7:"-\R7,!3@CI"C M957&P*I+S"UH%5(=X7891W!+.PL^WA>;&1!>M?-*BG*HG+_\S_G JR8[%J?G M=S?0?T%X8YF#G*HYRY-IGU/T]^-O+E_$O*]"44,JL(^^SZJ;>4 M0A]"5-O/4PC=R7T1D\RX9=\ M_WRC9-.)@Y"* T_&J,:DMK(]77U^$F1=$3 ?[S9_>XE;71S^%5.NNWL>]#]- M=WQ_BFC+$+RO?ZI7F6:QZ_"#GY%QAIG"Q0-S7-Z.T;/Y!T^&1SL>8>=Z+LC-?""/ M44H(7[CUT!#4F<+/7L\1:GK" \G6Y#?KW8JB SIJ]K4,Y91PY8(%( M Z7S% 5$?[E?DUB4:5-7JNH7@+-2>F%;LUFEJ>30^ M8G6$$5,](K:4-)1#&?(CXJN(B-WN\E:'5X$,VX"DH+"#H'#8HBF7-UL*"X5? MF701DW_ M'>B>])OG,4G>\80A,6&4^'@/>3RT5H24_W%$/,ZXD>.M*W-WIX: ML$'1R>0Q?R3,>-S.VJ+(5+B0_I=$E81E"U]_EY M%_!"QD&H1T:S*(&L[=/8KVH"[!#:#2-Q690 M[:0#&E>RS4)R-[$R?EUX6> TYB^6=@G78C0 ;&$]4N$P/G!80$4H4:>?#22@[FZ3F)O8M(V4F#8_]8;%'M>9M--&M HT/,FEB0AAP"X@-U%01ZA:X M\]H!HW-D>@+SI=&+A#@*,L7X]],(^Z[6W>EX2/6#-HRP@P!8T'>L= MSA(2O>$ASUIPR@0F$1KV]QXAH@&H"?'< ORMX]Z%[,W%*1[NC'_0_'DQ? ^U MC5N>1UP_[K)*H)\7,DH-JTYFY3BM>")+TH*_A9G$66C% N;-L1M/:N)E56BO M&V-J1DIV7-WUYKF['E/O;^Z3!)!E%E2H86IJN&-) ZBX57)JROU6CM[579\[ MR6,!7":XI-O1>WA/J4E< 18H;Z9QF#8\VGTD.FKJ_#N$S JOW"@IDU\,%AEO MMKWE]_1AEZV:R^O[/^AWVH$IW:Y;J/CBM7-1GFGKW\[,I<:=6D3:YY48:AE1 MZ.:'8Q?]3V1Z@4L\Q?^XDW-'58OC?A7J49W@K&1,K7%S^'"X/RU-?-!,\T_' M4B_E%7P&<8-$VVMC[H",@ZD&75W!+Q]A@9<%+%@ "O[/DSNZQUIND(KFMXZ@ MXWT?S#H68#5VBTW^YB_$-'IN"/I1.CHX/_\QRH3[CVTE*UC7_,FQ C2SLT=L M/#55T:O*=Y:KTT41/"*RBV%Y8T'=P2!=X3&SY5AY'(QW=-N)!)V<$F&"G?Q; M\5_S!YU*XZD?+566F)8UIWSWX"W[7ER9Z2:$YJXV]IJP8)#'#W]C71H"98EM M"K!N^7 5!#UF_S%RW'?'ZS5^F,1O05QJ1/CF"T%$MLG#::75,I>K-;^,4=)C MUIZ<'=3>":$##]!.Q87[6&!][L5_7H3F)OW?ON;Y?\?_/Z.D$ OT2JYCZM-K MM,Q^)([;XK''AUSKFGS^9V7,-!9B3#4?SCAM]KFMRZ4]7,Y)R5W>U''^:<9D MNQP='NTSSB[UH2]*UJ$:+!?B^&0']&$$J5[N:;,$B4G%%A 9:2>38U M$[Y5UO7I[X#<:Z/.J;P0GJ7XJ^61J8<%!-3K5>WB:]/N&=*Y"O-3$)V5+FU] M2A_M>UQR[<,H!O0*14\W$%,_4S)IT2!2NC&0[9UZY5I=K*B*GO>]W,CX75JV1>Y/(U%D@??/8U0G?H+0( M2$C[_@0/$=\.R]A8R0"]A*)X(&KAZK>H@5@?\J\ =>!5Z6?6N/W2X)U!S5X; M@ARX#O'.-OSQ[,_/V3Z\B2]QK0R'EBB9(/GCTMU=TWF:S>7 ]P4:5RBLY+/#^3HS;<1TZ4K3)^=> M+(Z&E1,GR'5<:N]I+R9QZK.$S- D/OW,^GR4OR]_0"S-_249BRF7S/76QY#& M,I5;?39IRF35AS<3[Q?_,'Z>]C,NSS:[&V>3?J'OE\V]!<%IBK68:E\6QC:<]GD[S62%0?98JZ"5B"K MOGP5L4HMOXV*&MW*.B$^C??=&Z'397V)JPU4AC8\BZ8U]O\N*A^"1/D=_0L* M^EHD^/G%,O3[APX\%1<)%'SN]&,B%FAP=/QPBI%AQP+>\4O=TH$\HN9\RWO& MVF>E>XB4?U.LQ/>-HDV2SQ)Z,-*.4WJ_)$YG;G^)G8F\TV73-:@>.3^AO("7 MZ8O8:8@WLDYIGF7!%J;*X48,(B)6D]F(WO1M'B(SNN:P1KI/J+@[DOUTH*_Y M<5A:>?GP#:6O0'] M VT::4COMFM[E-!+)LPX#ZW]_F[S,/,DC2U=$*]VJ--&QM?T'.,[JH:3V>8F M,0SFKBGL0SKX< JB [V#BMC:-FL;(]$_;4PE^C9@<@/TV&! M1U8:2[GABS-':"Y@/:'ZP0BCUI-[! +Q@#1U1RP%\78!O4Q0AA; 2J(:4$'X M95-SJ)V>!@AE;]$:U!P]E1\.>L-X_)U,T!L5$7J"T+S3">;QA.ZP)(15 MW'@PHS@]Y2K8*U?N=Z+'D80K)@0S]R?:.+XU$O MU\8&OR<#'BDCR_Q6I\2B,!GC MN!E, ]5'1*S7WGF]C,<]'*/C8;!3H%W3#5[&SY#)K[&L@ 6F\R3,Z\Y9CN"= M)[D;"8FYF1&98$E36)CN1('5822@-/!D)&]CUA1G:DG+!4QX 8^D'OS' #X%,;=0HI3.QOJA*!2)V+5O8\/)\.JY MLU1[9_FXY%WN#*2S<:> OKB/%TP^?5Z'5,-V13(602UP@-Y9L+&L"9P=<:L@5^86RZ$HX#D1'J MRR6*K0<\S^^DL+%N[*9*R.*G+((-G!'6W^YP8S7@[WR*"UKH:FS;ET. MO,SG5>#Q;L&-?H_UVW?V^$PR$;D1UR13I9H4LC;UFDKDUZ$8VEK=YT.L5>RU MXG4JXZ6%P^P6A67&*4Y =B37P__U:GYMT]9D!^%OO_=?>NQT ;"@Y\?4U3V: MM1SWX+YM1X$EB6(N_CK0!@=CB(0=^[==>ZH 7;K,]YG5?HG,6YF5<2J^<@2X M]93# 1,?*J73,]C%.6IPW''HSXN"A@WI)9[EWR.0YA FV821*S\IZHCTU9:[ M?T]1.7XR2[<+$(88>LZ&6KR2V?U91LZ! :_=C!*I&6ZUE2OH1LZ;3@/?5=O? M$G\6.OF%!7QGK.'3<64P8_^P>G&ZA2I0Q:!#%O=([XC_PCAXXR'B\''GMSP7 M>RQP0JIY.21*,*BCDUG]40>7M.+J'-YY/44N3>5TE]#,YJ])1ANP0)P="OQ= M^R>H[L[!E_=,.AE;O(51%*OVGX".J_N;:0'YM@SD[D^5C@B>A7YT&/R5$" MPR:3(<']/YK,0[T*T79$95Y: K?2$(XOM,.[.+'?W&E6KNT(R^?_[BZ__8@% M'/\$W;D$7L=GIJKI75U#+7%>,J4EC+W?DE-=F"".'_:TTCR?2/MPD?U+V#+8 M@-2%U,7)9TR*:5O,SS5]-2[+?DDT.-YY@A$A^UT;WK=YE[$U1,M# X3IE33A MCE\2?+A ]X6VIV_"%EQ9A?QLNV4OB!DB*KL$0??E>4T^OF@J7TG;%3(6>+D& M5#57CZW0-7UJDVOI"*L),>4/YV^CQ>?<]I\N[M9T5\X]?0+E5]HD8OYR(\3II\FO;=R2L.M)'5]=S616*,OW1/Z7/"K* M6AINW'[9$=:C+_*@^6BC+3>*$@ M>=2^;[M5B_B,N5Z-Q*6JQGST?,/TJ7#C*!;Q%+$P*)3XVG8CD1\J>^8!J7N= MT+FVR.>4$MST^?2CTIO5OL.SLO5.RW/"G_!5JI\.JU_8KC\6Z2_W, EUO>OC MA]I KLUUO..,?32M7B<&C&M#U5YN17))CA*DM:XO:HZ7^)10_Y^+7)DTLXD: MC\.GS.XP/(+IK9%9OLD(F'+FTS,ZZ)0LNH6\A,\:IQ\H#RI0$);73QLGM%1EAD"IZ,W*Z#38K$.O6KW6U_PV60&\BJJ<_G;\R43,EVH@GY'Q2CP;/A^AA\G' M:=N4H\6K1N7(-;9D417ONMYM[M=*ZA51U36L@OPW9<[S5ZT0UF_QLM6G^;/" MT;)=K@E80"U,>$=4_#\5U+I8X%W$EU.+A_8]&(MLD '-\5H,8S2Z!73[ MSP VSDMI)CN#04[(Y;GYPS1^,]; M#U=*7UQ!JA$W!.W7VEC@WD'BW?Z4FXK!2X\/4N";F'D,)E*[;,?V[N]'UZ+1 M%L?E< S5$"LFI!*C%+HZQ($)V;G"4PS>#J_(S_PZW8.9*U/[FE*5 ?%X<">E M5F:XWPOEM"[]!(6 US7B.OWU.#R]RR.FS"+.LR!F[;3N\[JJMJ[5+:R,AQP' M,SSDK?$A3].]M$ I/8*Z:/QA:M0+3.PWE08ZGY7 M:O#'GE]XD^?E3;ZL*KSU%FWZ1NKIA+L,TV(/3X@^W_ ?JKYN>%SJ[YH2>B^Q MH9 Y>#H9/^PY.WT60:DFS=[^ZA!HOPAW<+.#N[)MR-G NR874O8ZEY)%@?'# M*VM!/$KMI>*'#5NS&A>C2&>4_%K)9U:H\+R)JPA>M^K#!$A ^9)*2(@ &8&X MQ$[DHLKW<]7C)T5&Z^6R;'MRW!>? D( G)D MD93.ZW$/EM)4+)2BZ+N#AB50119=F.=++\T[5@2 :TL[VOF"S@J*;OZ$Q<*S M![KK5_#5[5""#^YTE@=?QO;M+U $?;*;E'A[_E.8O ";,ERVSWB%7-71T1C] MN6F7M*S9[1,H>W:_[1<"!_;X1DM/>ID2E?IB\7ISSFFNO+?L+]:ABF^UJK_\ M7[5+HBE)PH V5!&/1$')@3@+/SN2 '!TR'GXYR9C:JX@W\.V8!*!-/R?'@;C ME.E]V?R,3#*T%7\92*#SZ7V-<@IODTE_(%5K,@PZ@'B#J9DS@]E)@$\'L0"K MJ2/E$O@6,5T=(O@8$; 49?@]=3ZUO[,O40Y6APQ#52H[/*)G3ZZU8?BRSKJ< MQQWO,LV=,>GJWJN\%@TA*EZ.TY$^;#L]O"J^>%@BMHR?>< M*^NE@2=P-/Z4HM&PQN5;B[""6W!H#IOM@'#4V77J9_52SP MT5^[KX%C&[A3_AW2\$AOHM8:GMBN[P#HY_O]^JCW/70+ =,_6'\P22"C]0-X M%*MKJ;CP[:3N3%-QJ6U@P"B@/#((03Z=9_@(P!BGOM.\NQ MBLRS*)PAD"?L9IQY(61;$:!GQ6,)\,+H4)L:PGC(R.&E$4M-)G$5'%BS/G2.M8!O[#R#B(%7)D!'CG M\@$+1!K@D1I<1HE+F8@?6>OE)^)#T.[ ,UY$DTFSN&@ MU!WMT@$V8LG0FC96MXU0M4=R)TKJ@!&=.*KA E6491F[=)YYL_D!K^% (#0T M:70M623 T, V4Y1$3OR?R@'>,>/$9F"8I[VM38;-M?8$!_VP1)<=D_4H[>!Q MN"4L#=B)1DO&ME1?G=/ENE?VQ[9EXN%-5&@69@_Z*&(B8L%Y'"YNXL5];D-/ M*RYCN=)CUG8NJA8D$Q-8I0CVNMC*_WVXX ,=)(S4#S'72WO2ESZ7^O-;,KOP M=[T9$F/4VK_\%=Y1\P[IM^;]WE:Y5V"; NC2RU[;9^/L@YH)(C[EB6(>3W*8 M5[8-WMLE]SVY2MRGXT_7@K#,5.]6YLZ9_7$%OC/!-JEEW\_0WC%6M8AK M0A^SE3@JS,L*.?"(P1R#* JS%V-GFW.:.7L O?K\U-?&P$SA]9=='$=CY*GWE1B 9*$]T(7FQ;_@(]@[^D3!%RH1Y MVY79V1M$6;.'[*^'6_51<9%&PZZF$_9ZRJQT3">0$'ZKW Q8]_A!]E6FI>;MOMX_WM.2TY.BLV M!.\]8][7BI2^[?%!6!TSY=!:DZGYRL9._3I^%WX%6]TZ<'D^@E$0&4&I?,Z= MJ=X/KK3/ '(D[HSFS?DHRB0FY\HKJ[MS2S65)L[MH\$4Z&#%CL!!.6+U$A7M MC3A4UD2?3+5M]_AT/>.XJKAS:*.VY;>KUZ"CI#F/[COR'S6NDR''N2KN]V>X M;L<"+;;E;R:WORKLS+M>G4>AVU'%QK8LO%2%VS0D@5#Y_]TKXOQW_/\SE!WL MLRB\#T"5NV0 >AXU@'92&9]Y)0.@.OOA;U:%*SB7=^(\YR M(9(]Q3ANFG@BB:/:91BIU9&WJ&VC_V2RPYY#9DCIS_KA8WOUZ"]'?J4#W1V/ M&WF.G)Y=J'T@,#7(IZ4/\3E5=E27'"JH5YYT']*T]ZF=;G FU;P/N8B@>TMG M8672_[Y28F?"(RVFK'ANEX7/K9C_406@[_4VH(M],Y8EQ]N2K$[Z_'SG6A]Q MG__Q/PEZB39D7(,$.,Q.ETX7C_NKI F;"26PM?GJ6 MRN2.;@3V5?,#^(W31 *G)SW5+ZZWBE\_[U23?R0OA^>3F@O/;$U6+68;FZV" M>.X>GGSHIZQ17:BI&1R@^^BA2".P^KKE[NX0[SKY;_0Q)B#W0]R%J@GI]N+R MWMK#)*(&M6Q7/FR<**]5N]BD69NE3+BY>0]+^D>C[5/6/URZ*-6*!N\W?!WD M8,"/=T;#,##UT[._SS=.TG&;HGE6[/(E;]*97[^.-;[A133UE^?,[^C93#ZW M^1UOJFS$R6MLXMZL.9Y<_H@!7W0L68!&\*D7>5(?%GB:@MEH=TEC?=Y&MZ_U M>G%>'9-'4L*4\^X5&:7N]11#$5M3$]>C)Y)DTPF&;W6\E0[2&>7K(_CVJBG. MQVIYC R4]EQC* M63VB'W"7<4CI2\NUOG<-.?_QCM+=[X&4WJTA6%I)ZB_K?*;F&B46,&X@IN0Y M+QZA%EYRD7UG_:GQ@8@[^L.Z9D3M0/K(E,@3![*J;KS!2!5<8N*#P*#0]*E0 MW'MM=VD/.?7:-?>[R?NX)QUWDNS*^HN7?_K07QZRL7];"\;__+X*B5ZK@LYM M)O9T\ /V/B-Y.X;[%39PP=/*X$_,N_7<1!YU%[2N-FKJ,96V6$)T?"A9NC-K&:TJE5IFT7,J B@1=IEHWQN#P$-4H-UT->N.G@A. MU,<;79/4YDCO)C.SN!O[>R@]_3'])VL7L(5BL5/0>#E)-FY^E7ASW#+KF0A5 MP1PL@!@+.(:4#35TSXS"<\#OJ^[:B.9Y6^6UBHG#P0+YJ6ARJH5Z%&]7_)8< M_"_16;%Q^MJ<&F-B2.79&:KX+/3+I>:>?D5'M0IQ]W9O-RRS1F>V0RH)+P%A M_"Y40/Q<%U7T5"*,\I;U6K?+5HC7[#-OCUJUQ:#.K.@MYST9+4MJ7Q"R^>VK M+ANJC)C<"@N%R,9<:N'>*FC;82QXI,QHH%3%HW47BC^>&(T%>"@RX@-Y!"&+ MTOW7SF4A$2PVS,$30>;M/>-*-$9OJS9/%R@/HL<)^W&;R&SHQ"^[R=_ >@2/ M)R[#O\+6D5]#$SZ#;R:-R,W=!2EE3A$G7+F$+J]]O-IU425"K(W#\/TL\*!N M;1%C[TYU3#@%I2GB1E0 MW8H]7M[=I)ON_\MA3/3=^M6T1<0#$Y=M?!@_W%^ M9O^ZD 6:CL(I2*IFM(S]BQ3^"*RFOE\4##"P[E_!3=JP^6!#%#?\15,0/1^' MBL ",]EM#AL9Y6Z:SI,+>).P&0+_*3R8P,:@Q-YMSL1I06!^$'R*%$;PMS^?*8?_\2Y^9LA*Z-M*-P\>SN#X1O>@<^:V%$S"2[!@ M^: :88X%PB7'>LTV?9E\?%#%G]+E!+9,Q.HI*&?R7LRQZ]:;D\42#2ZORCT2 M8SRW#L1!!W(-1!#1]YXQ3K'ZO+BT7H_'8[0[R8^J;Y>&Q#E(@/)X<'PK\9Y$ MWB0LSZ>_S(%U;&36,^U^G7^&!3*U;28&Z0H8:EVOK2.8B-(Y<6>M-7#6RR5M MCH2CFVQ:?Q9W'QB =^]C@69!+! #LO_F\I#7/X3;$E.-\\9TG85"R@X4)UP_ M'[Z/'A?0QXQ)<1(2VAQLP\LX,]^!SAP4F->);D;Q;T.D&3,A2WVLQWF\'J.6 MS#YDD_<7B6U]0P0:J)*M0J/M$,=%5<5^*Y0-'A_ '<$T\0,CXCLI64>:.!EG MO7O0>.(@H9 V"=2PI =$@Z%(>CV2CO%%[+=_#2U1WJGHJ07-Z VW/?//U7[# M+8-$F^8!QT\H+YRKV^ E"2:U=U13\5+:]'AAZD_:PR8)3,,&O*K@7*35].## MK1>Q[NT88C1RN_A-O=NL=B?>H7%./,^S&E:)SYHUJJ+!-YS9"5;_JPRHYQ4: M\_@("TP\P^C[%SFN2RK.GG\:)4H&B&BJ??+RG\@53"B*^^OB0&B.N+(S.7': M=,.$== .P+$F3=>-;H^:%FZD%\N."B=.1[4PXOJ>HAZ12FL>K! B%XO &&-$ MNHUD][XP1W'>Y9<8;\3);*!3Q 2#F,._-Z R84'ZQNFE6/B:$='MV\I\1H/N M.ZO&,H:YSF]K<)#2LL_%-\03'99%#!?.DK4'8@&SN!/:(/@YI5YIW,%AZU[M M&6VI*'])70Y>#50[TK>,3&U?52/SQ#<_?./E:,C/=\,:[AX[^J-BH2FV\AQF,;'FKP< 6?Z_ V'%Z)JE4X-%27Q.NE/\H_LP& MN>1*4LAFII/U],W(/S=XO@G2$@NDE&!$XH*$"A8HC8;>&1N;,#"\G^\.DD>) M4,_6T7A-QFG]E,?_[0$ER[9X!E7Z*Y 0.M)L^":=DE06='FZ:;W44%/25+#NLJM8+R#Y1)E0W=\#BDW03.BPQF*P^= M8 ]CG)QLN!5Y+5T'B$7/>]>*VPE+*TD=V'!>&Z5)QO\M&?"S>YA&>Q:?]]$] M9O CDHCC-&M7U(H4_8,D>B-VMDP[:>'7O3?A(MX+[7(WW(S)[53$1,SEWOC MSUO,0KO!_E+1YVPSY@)=?@4QYX',6W=I[$/'OZM(HE?5"0]^#,L/PZ+'3;X^ ML#.=/B2L9_]Z\<'A?ON;B[Q$1:*1(%D--_$1Q\ RU$TN,W-+@US2$$,*8,G< MMKY@B1&)6+.=0!XKCONV^E8^M)Q-UC$<7/T(\O@<(G^:R#$ ML23PP=MN&3"H;GGJ^,)SYU3)D:"AUH_,2?A=/XZXJ[&GKB*_S8,($C?8[ QT M&(HJ8^_<9Q!1M>*S_U51/Q+9#][:#?;91NGXO- MG'&W>$@O'P6LO=SQWY)"H,?FG%F#U 'Y?7S0%PKD7,'X9D/BM8%3P!\YXL$L M9U!"N;G/_O-^M,(<.+QS:6Z-)TJ!MJK*I 31'/PG*<2@-%'Q]S/[CSI2#VV) M@C7SC/,3,L^GE8/?=Z18W:[/Y^$=4I9!A7G'J>^U7_Y'>.[V%3@%1+T1)%IR M7^[J$<%=M#\>=M9YL9C2O2(H,^2T8"\Z\TAI37$P>OXS48N ELF5"ZF[=Q^K M'2ORW8J_9X'G0^$G@'*6)VA5_1O:*=#1WM+3D]$2-OTC->B\I;HAY"$7U^27 MML [@PJ5\3>D6GO;$VIWZ8$:\A%MW1L9KW.E^2#-) I'WB46P;_)Y&,U*Z5^ MDCVWQW=4;8(N(6U/O94MA_BQ8I1J PP$%W;#.]6UXQ"/'63'U+% 5F2#NE8$ M!F+V8HX>'E]$'ZAY^.9FHJ@(4Z5PP'7635-WD0VE7I3W)M&DEST+EZ^NAW\A M0\H4XCCX3["F/8N6%/>4H=,][L+%497+:09H\L,84G&6DI=!W,Q$IEIX'D// MA=C0!Y"*/*D\0+)D*6ZQS*CX,F+#F.ZA\^EM15:1\+RJG[2ZC]M125\=WQ;3 MA\A(LBW>6_UF#HR"6!D64*?$A.H04>7,YR*H_B[8!A9^;RZQZ_9.4+7*%VTK MVX)>^JY[O;5G \=)GM>+U*^U8\+R[H0 Q;8UB>U7D)"\05ZX 7XBJ;&ZRP& M339(VLRH&)5!?^/I2,H,_7CW.<;B=]_Y5?W*?6^F\U>Q@/3\::DFA7!L8LZK M_O<]I F=9.?EH7U?&QX#T:";MW!)4\0U\F:.'(GQPU2W MBET2(36>S%R1Z]:%'6S=_\P1O1Z30=D=_!RUO$CS?GG16)DWD\QJL0X)&W:T MHHF(J<9A9ABS[X3_>GW1,-6\E']!E?O!=EB50KP$[&QQ( )HAF,!NY.\]O]\ M%G>?0XY$GK187&]-&I$:R9921(X5KK&4D=E![1;^<11_7K,053BWO 1*-A2S MM-D49BB?-[HC2)/)(+U&SC0_>]SD3-Q2=>/]1]'Y]'IL?S#:W5'*M M7=EL>%)\HX@R7M 9<$HVFG=8$ABR^*KA\-6)OSO@,5!6^7FE8E.I^]RB/SNB M,XJL$=4!NU3R-XCXRWYN#!15MLZBBD3%;FD]_KG[EX%LDJ;L<;^F+'V&;M9F M3QU60N.:J@,C-0_+ '7KQN=4'NF5VIV@9.J"/*CR_\B ^![Q3^ _BGMEY77- M&%\&'H&-8PCUW+A3_C3W5L0*[\7"-]/*Y651B(.X+:>RR5CAOI'B]?-R%7 S MUXU!_%/;MXE?UGW,@1'F9)JOU(JN(OUL/*X/?098?^ZT SC#DG8S(NJSG]45 MS1*GG+5_VU^6[>#=HSV:A>M'I93$X1:D._VY<8LIXI?6C@Y>I&%UMVR. MF7Y-)WKNJQ5>ZK(/RY&V$1MXR?9*03;;G>UW7@X<'-A[,>;%_4G-JTD/%6U'S M38:HJ*TP>TK_P&!)F?YU[FRNNT"BT%E9*R^NLC;"_,S/YC=PHR5%AV?2?7IA MQTT7UH8$[!!_=&+T-UD'JGR>9_!+,]Z77,]S20WE,F#X8DY3F.5O IX>0CQT;B"\7A?O(Q%<-2W_GGY F3:1/GF!JR+RUNMEP3"BZ M4A\>V)/2U[X _]TZH;N^U6C39&@TD(([2_:S!H01P-W'_:Q"#IL"_6V6&D8J M.X1.0+?;X^A$T/466 @C OO>0+T:5,"O5#7ZFJKFS8#PNMMEVTB!3#-W Y-? M'E7O6"')4#)IZ R)QKUAV$2-%Q:PC:JV.06OJUXH5V)*R3P+]J7CZZ6'K?N9 M7KNP.M6OV8?[/ T9L9#?BYNNV:^\R(+B;;A@]@S*%9N+N\>58&Q%U&'TUZDK M!I*^W]15H2_"FG;(W.^E!9N>9KI1R%W[%7XI%V%X*$*7FTF?':GPH!57OMT< M@2G.NG$>'O^Y*_04"U"XN_L "21( M9G""2W!W)TB P0GN.KB[#C,GO_?>?]VJ>\ZY]SU5I\ZG]\/35;V[N[I[[]V] MGV>OM=<"R/C?7CU,:3I\Q"%F>27\:(:ID\+8;)(1%.17-&SA;A8O>$TJZ2=U M:BWT\>1GEOW"W%6-X->C!+_T&\Z+E"TAM*R@1YW3!0OJBU'@:9SJ(N>-[;:A MHHU'IL+NL".&\E,C[/I4H]N&,M>'6*/YHA'=9RA$C+4(CV8O.OO6;E4W!_I' MP\,)-8S;C(EW'F 61V83EQ66BYF52JVP?#&>NY-9_3B=-.1N\;%V$&AEP\BP MZT;*Q^;/5Z[&R[4@^#W=STB D02C%<26)33*F"C&TI'?EC MK3U[E;X+M;E MN!4X+]0?\(@[5/15\8*#(8O5^K4<:KQ;#SBL%9=Q,94K:O5=LH\)=@>GM397S_H5<.+D#2H@O0MORD.Q#]:=C M5N5>5$ BQ6[1)<&3B$;]C%*V)<<2(4GR!PR2U\"X_,S,/X)E)+/B% U3 _R- MKC]1$-6-._!QON!>DCS?A<3FN": OV6"(96NHPYAG$O3VB4THR<](:'-7%U= MY\/!'-VP4O(6; M*0P$&*6RSP4W9+..UFCE.VMR[7(774:)6SH,*9FXCG"N. MIOU&FUQ&8[YWI5W$;:RXM;Y'B!G[@BR&'T?'["?+LT_&-:AH?PFXEJ31')75 M'PL.VT#Z0QNS&[);U+W^ M\]2*:V6YI=]>+"PM.JD/PC=^]EV^9O%J@:[G/ M9O.Q^)RVIVJPF:"B#+4H):[=668JR,NO?8L$Z O,@)*$WU^?!"?.4/,6/=7 M2\ZP!]8,J+JG.XFK3[5.@'/*GNUYP@\/;W=&6!8NXU ^A@;E^E4 I1 %PA>(C_WYI=]C_X M#_X7@-YG=9#L![3[%OC[-'39?[:"EI2DC_=(*2^_?$31+U)]L*R,N517!PFP M:!Z"K @-W-R4T ?.G'B4%5D;<6NYO.7Q(8"*JO$/% :_LE$0$.!SUSQ5RW=B M"R6P3-!*3= E5JTF?A/V>\M$M;/!,U0"@/.Y0,K)F7T#BRNKZ%!SUCUI84:% MHA@F*E>;Z4P4D\/B[I.![5B>_6[QG:YO_0T;,,)HESY+V]=>==HU8,GKE5KBS/S/)$!?, M^ CEW^B>5J>(H'U#]36I3PIUX"E%/7'I;X 9GEXQW-=O*BG7";>+[>BIRUWH)W3Z!;Z[=&TJ4>;A#>1. K/[K]UTWL#''30:/W>0LAW>A[DOTP]"+F;Z9XMC8O>,YQEI!Z8J5$* MM9598.$\ZD+4U_?GV$CXSUHWI]>?K"/]A6H""P28T7E)\AO6?Y-W?GIY)>T\4I*2R/OOHF"S6?/B@ M/6R1Z6SUKL/*B>RW8+,\OFO7DCQT7_)80.,K:(<.>0JS3-9+3EK=> M$BS?CS4 +_LDF1Z<7$E0N#.VU_UDUR"73Z NS17^ M7U%M;!P:W0_("+?S6:K8(K_H]C]'I_*XJB!C0HN:;AG;T>RH7S.T]6EZ.9Z)I9%OL/H6(H+.=-&MVSBF,R^C M=*AYA,I8*9U?5JBU3[7$+UG5UP[D.^NXME 5*&3 *(.3#*3/Q;J8]G9S+!=ALC-I X:T7%L!0T>)LB;UR,"_!B^SU1) M]K4IX<9\<5&2WC&FM*3T$"'T>*-=6C !MM?@9MOG*X+$'!G+OP=;RF42J[VU^A, KP N8#9_R MQ1XN3U6ZW8(3-=0E/I_E13$!3J5%T"Z01V)2BFS&8H^+J[!WA2=CYIYV[HKFR\>JUT5?\M6(IZLI1AV,)'0<0K1RPC M.&E*E\NZFV\/2F)#?XG1&O6VQ?/F=7V.4*AX4J8!41$GKGV$ ^5@<5Z43.B_ M.W>KS<>5R;$'^F?JUKG,'GB!W?JO,*O%:(/[07;,TEPX%)KAO)KAG)23V4H$ M&]?Y:'V"FM*":FBS&T?Q MO&8GSF>_)#/@%TB \ EHN_HA:J,>P8=.\?<&B1YW:A'\P<\<;-?^66(3FC;8 M?&K0^A[^&?*XDXYZ7SBY$Q^+;T1A*!=4FAGW-'/ZY(4(JUAQLZ.]*?4&'E2! M#HNN".OY.,?B42ET7=(M! MMN7+OHN0T3UYW-HGSJ8YC8XT\1C6C;)9OS/?#1>3V(V9DA#_>E'0W>\*8LG2 M$KY9TH//2<"&Z\J'0.!G).!Z_ZOF#':8S*33 E1F8 #NH5L= M] J=^B1-B'9>J& YEZ.H6*64@U>N "V6-+0;KBQ)OVHO')ZN:LJ^\863@9,> MW;S!559-=C8^G*1" Y-9C)R[*V1BB"4,,?&P,(;K\ M4=)2!@-FE%$"[+86'4(.;N9?5IVWLMO*Z0BQA+/2&>97M6NIF#GP$M%AC_E@ M;O?/GZ> &K3G\$OO6I,R;XC-E M-\X(LUK>;=2FX1B+L.>8G0ILQ"(7?T"^P=;IK=2GP84MQE0.W97*#CX^[/VT MN@!($C?/YST'_M^:J:7VL6_O! 'OY)="Y] (CC!]?F$C >7_F @X MHRT&K09O*XEV3:9/Z$,W(FFE?3@&5$< @FA1*;\1M.W3[Z43SR)0!$A5)&\& MH"K3[M^.;@RI#N\G:I=F0,)%TD2$PS7YM(,QW^>/',+.;:G/OHX(!U\^I!U7 M^*9VKE32]_UM(H+\K+_=6E/C(85RHF:]2[JQ"@IOD #2&W:4$7V51ZV%>-*?%TV] M.05.@UB"..FGCQ K#M7B?^1HOYJS\E-2V5K)"#@/M2SG9Z='S>NR^,)+%-'@ M:)[UIQ MUS#N=%%E%SAJ1NH+.9/OSX9PE54Z]N,QY]S@RDP2EL:$8M^P^[&, MT.0R[T]7 Z:X#JZH=B8-$M [^T^"(QF$MLD\X.Q)6F_2;]H+ PDHA,!+)6#M M/)>^&Z##%B'XJT_G?<,?LJC5Y+ OB*"%]BGAQ.+:43R1Y)A5,_]13&[[X=;+M"S5G); GA5B +!.Z2.L; MPUGNT&XA"* (UIYG[KXIL[;=J4\/\M7_3'$3]GI$74X(3=0&W :/,< S2T@ M9.$L)W%_Q_,!U=*=RNF8'J+%.R%":J MB63\MOOU%@H/9X?",9& "O6@S[U=,0Y$=V)B2(#"_@YYBMV>)&'TV_A%8 I) MYAPIIA"T@;,Y%KI)HOVE24['!ZXN83_U;*Y8\OVW6_(2?3 MW$MAW; P+W/.#TW[$C&G=[+7?4F4V!OIAE/:Z>)3O'YQJR(F-/2B/_R;-:D@L-)=\H>^PKN:,9D\DL M6ZIZOWIL:6AFD6!Y)W[-IU=KWB.FU(][VG=F8!H%*)E-9G&Z#*C"VK>@9F.X MUC_S)Q) 1;!9;I3>6%CTQ7QEXTG00K !\[K,1\=?.[FP]?OT(&'OGIDJMQ+: ME(AL)2>/AB\+]MZL!<5+P4X3^]GRMH9CEB$G<6;V;9M7HCD4E#'>Q<>W[JJ% MK (BCOS3YAGM8#_0!FG4O%ZF='Z3GW2+(<+[5P'OOO2J;]JCOWV :T3 ,YW&UB?4S1C6;ZS%\EE M&6Y=;OI14DV%>W8993+1,9^K\2:%34F9%4T9LAQ,6.*8/ISA#S(8F>+FW7,% M?0E^U\0[8G%R<]3/1"Q^A\YW9<.I[+AHK3/4*BO7;SX)6QE4\(\T=";#N!\C-2/2C]F-P M31$FC%1'(TR@IU(W&D?6GXP+PD^#X=^@I=#BFOB.BIL/2KQEW]'*QPH0,JJ*-;W#F8F/LI*49C.6]P MCK^6)Z4Y-LN2'"BL3+)N''1NK/Z&%U_SA5R2YC-TTR%@$/)8[\>%!'BJCXAK M9AF_434ZKFX$5%M\^ZJ>094IH[HK.<'VLNPI:LT](XP.+AK9M/Y;;]EH5-CXN3L%>HD M*H,'W*%P5LYMP2GJ;UL1,ZB&LLS+-J8HZI>O.L$L+5-P':,!#E,=IV;-,.*Y M&%UW.O7%1)F?.64WO^2RI&+/*<$58NWT2N8D+J^?@=A.Z+<=']"RQ/KL%:U$ M&UGQ?N0WJTU68=*3?[L:YVNJ5J_64C":V+;JA+!']8B MN%MRO9.X3]Q'2:Z6\(RSP&+;D&;WZLFA<)$)2E(>E!B(N'&YCKP/&NBKFRIL ME$>?JK^GJ=SN_X/!A0BR%U.FU3./V'SK6_D.K[99K)L^].29"WZ?E?U1-$=Z MRXWUD>E#)J3/CM#*TH)_ZSYU^ J,;&J5S")EL1TA^*Z])DB)OL&)[CC,*]^ MHKR"0M')@4)Y^]O%3VHF(;2S0?BHVJRHME/!RCAZ6L" 13S?^R24)F8:<#XL M[GK4,R='2/"VM(6?%4N(0I?>JF\G]R_S>_\>_E36O/SEC/5KM;GS>_(,\D@< MT+I,AGQ6WRS*':V<> @28& ;Q3/YMW$#KXL2$DZO?V*>467,D'Z?YQ17!W>! MF; RP[*'0U6%*"7ADO!B\2]@X<^+(61#'_@)0L&_&HRTCL1U!(]C8!4?,/GD MT OZV"GW8\+]+G&?>)& !6GQI5.!V;C@0R3@%RA)?#X()G^$U8&W4SJ.!%"_ M1]PCO)Q%K?^OG?'S[%V-)E(-KHL'CZ=G?SL^82@2\(58$0FHSLN>*"M1R4[R M^$1,[!)2[[%\\ (DDWOTN7G\JP0U7C=XU8SZ=K#RY>]UW"A3;! 4OO;P-<0MR-[&0@!6"!T>CC]E_ M&;;:_R0B_7_P'_R? K!6?XYKS,W[KY><0^CI<50ALZ3F<,;V6='AM](E1 - MZM9>]$&2E7@XS^&EP/H83Y>A.A>^:#G!^ VM!^OBHDC>=17GE,LR'M<4"VO% M\"N7H?IZWUF)2R?Z#.PH6':O#C?_=//@S;[Q2<:FLO *5(H$6,!L&X9GKVM5 MRI17)XR#VU\044:B7XD?@_82U<7BL6^7:FUZAC?^4]V[M].?&4%O)45]8)3V MNV :[QFVPDA&/Z[MS>= M\RB,F9HMKMI9PW8A+AOP0TV5QF$;6RW)R;JKS3$BX#MI](14/8H -^-7&50& M=38TTX/SI6[-RK2V*69Q\@Q66F\FZW9;([@:%E9"MGZ,BWKM&[!1:>LP,ZV? M@3%WM3B(Y*0HFW">D["'22MP!!!2.8A%Z+X B"D$1*GS9PPWW4J88I"+^;M! M+J,\C.GZ*[85L^3O<>]/%8ER,:ZX&3*PFTZ^JZ5MWE>I47>+8!WS=+#FQ(LY] MR>_.8ON54(NBP>@+MMI+C66;6_.ZJLK)/C+ZA YY"5Q&-$8J6(7PSKU9KQF$ MYGL)HCI+?.]T[IHP_>8YGYU90/,7I=]GB6?:5W:5*1 MZAQJ*F?9*0Y4)+#'_!@DH"OT.F_<[!=7B%XJ&?[G+E)1)(!ED9_SMRM_V*JS M%$X.Q6M@<:6+7!O8R5O+5.=CQP^WJ8A^(!W+5,?(5H5#)MO'R$WZ%M2&-AW> M.JS3MZHGU6[P0_UTL,BTW&QZK7D=+&>PN'UFEQ$CG6T?.V#+$7O=;5 \Q*>T M;O&I!18O&T>/]J3G:"/>G$N3F$IY-3%0>OCU^0!58?$JJA.]BXFT&&X*:N&J M6O4#C._M6M)3-EF_OR:>.V" F25P.#CL&$SQS-!C>,S9K? MS8?.!?HA&B;O0,HI2K6<8Q;8AJYZ_9C;",*7!RJ;RX:4JS:K.I&11B&R +?I MV7SWVF5R/Y5@8SCX9Y$""F&5[(,!7CYJ1??I5-HWKZZ=PFD9QB8A9UC<5%1$ M&ADW1[ND@]T[?9\/;_R"-O0NAL-ENBV2GB3WU:&;F<):W#3-MF&GW%C-+P_G MQ'SW,R;*/JT9#M7*%D72?(R-/3_ED'6$-+_8V@*[15785:P8&9=SW_EM?$O$ ML'XLD#_ 6#[SZX:J3!.:'W=&LCGG\O36I7M]W[)3, 7DO.;*V,U6Z8_U_:G M3W<[EG*TK0_O?HD?&I.5M:[C<#:]C.]&QC*5T9KKE"PX"XI;^\, MNW5#B^3&591>CEU["1TZ]JMV>(X%*56[>32X/\VW2#Y-)^IYEGZ8" O6O/-\ M&_@YR?YD\E3OHM5&))&LOI5Y-#GMH.ES&@I3&$9UMD%3C-\L@ISH5DA&WPJR MC2I-*H0FM-2]/[58R3[Z8Q;6U/A' U@7D3%V;@%AZQR$;#+ +O,V+#36>M.L M^F);Y3/>J];7C;]99;I];,@]P"WE>@V4 MM$=;6G_2F.;+(63'&MM:M>L^5VB=XE<&GVQ]N._5]]Y39]*C-;]J:WS.[>H[ MKA3%022,Q;?"O;,8\*/RLZ1S;D&"!2!GEU+61#A(S$ZEI>#;Q_X;6GQKM5W! MH9@LMWT]G=;DV#GFPLQWOGV#>GHT3U,VF(Q9RQYS:::SGD0-R3.>)5^(' _P M8LO:!&D"5_Z*=PK_S>AP<(28AT+BIIC, M@-4>W5#TIB.30PY)^99A_#&Y"+ MQ2, R#/F;(26LT97X>R7N.W8;9M]H$N$I#.LPY[5RHZH!'?8L56V"_!^L@Q; MW!0\T9[N=R<(:X=TK%'*NDGW6>0AIJ?.LYL,+;("9Z" -VM_/M]-1_LXC@QQ MF+'E)*-*#Z"5B-Z<&CGZF!#RXQLH.XFJU0J3M,^:9J"!<6E@],L!,]]VS^J] M+^QM&>0^!1IVNV2/:#9;-"V+^5NL1H.A6N_9Y=6:.!MWL/@'7')D[)-XH, \7-PS:A":$/T^F),1$: M8I*5*I.PWY/S !-#%U$Z[E;X G8S>FB8))IX.J3" (2^;VT=9[#)SX3WQ10# M!5,0:@29S>RS=!D45;<92>;M&L3N,K4AA>^OAZ&@XP7,LOTBKDTVW,>.1_.5 M#RS-;(^ T<_($O2=9<8;KD@DC)6XO>Z5H-]ZL10A>)W#*W 6Q R,=CGW]ZET M].4>,%9VNQGNN7 &!@:VU67X>_$:^PJO;KU[[XR?S/L!=LK?M_AV))3>B^#>8:H\0<0R7A#UK!S]/'SU1^!/1#\'>!7O/:*\I* M:59=I RY8^3T^WIK.&L^X90"EF^WN@)0):G'2D6B#"D-:L@JVLZSN7 O*EN; M[U6&?U OZ,V9^V=7O*$4S],^!%X#OZN7-8(.((\S&!/+==($&KS_=G"N*M!8 M]C\Y2);NM:.J@I *AXD8([G'P/#N0)F!:._NI)4N*#F,^$?.$5@YK L)I2> MC Z[9TQ]-%3,/6G,TX -%8()!2:\HWN I,,OXG" 7A\42 MQ,!I-#]!B0&\G7>/[9QC*8P$7-VE^ZSGEY:23M5C3R M1Z$<^^/WHE@Q>\7W+^SBYPT'^F$!.>:!L$'XH3@E*5O\_J:W=SQW;A!KX=0) M?;1*(UB&Y9 $6^R54M6?YOG!CK.==!O[*?P@ID_KD8,6:DB F9U3_G<5H?=I M]-0_"/62H84\!@^M(#N[^$7#M8[T :Z=O*W0Y6#>WM"?DX@^R@,F/*RD]MP0 M?QOJJ=7""]8/$2G/\N;+;[B5&7C@OT*XD\68BPJXM-YA2>A_FRJGH;3:S\C8R:/M!K+:H FC!OK5)*/ M0HXVW%RS!_N%&R^6SV0*[RJH@@"%*M>#O:--U)<-$W U)H%HB U4)@/$;W,( M$%[4[1O,G;.=WZMFEG.ZNCI@G$ 5ZN*) \S'Y%E\?"CO1:\KT]2CP<7;94_T^S9QE0(WN0=9KI7<0>.W\TT2]5DBSZFQ2I=W*+B_G#!.XN?L]CQ#_$7%7JO_<]!OZY M'.ML+M=$1@*JN]:!!L(<;G&A)(I(?M*V6K MIFA-;T8PP[[T/4_P^$@M&@JV-PEGES^J#-]N3E7+89-X-?7N1J$LK4X("9!1]2])DR,Y4)"PL_O&E!?SAPLP")@R M.)A796,I\M1;@1:/"@:M!QUR=6ZQ@S*\($B 9 5SG_R!E8XS5RN'HI\#@0O# M9_OB0<&\B<5['RDK&LJFS**+4EW\5'.FBH:Z%GE2 #C#AV"^4I&G8:9^8N!^ MU32!9>$4/+VK7!6.KU *(F=3]GC5WD.>+F_&\+HM8=LE][J ]CG.M[*X[D6> MJ+'FM!U#[Y"?[*5-J:F?/!+F<14F/EW;(?80VASLK'7:#*LQKTB[=N(3-/_G47=.OP[=P$N/&*ZA)WQ_YM'6_$WMI9 M?&CA@?@E$O#= 18U=/:C/[686A\)**EPGDEL$K:H[F'E7@;U^5DA 2:3(%J# MH@(KPTO8H:J#/.Z^AGI^MA_BY[WF?N1M]@$P2?S',PMCAV.GDH;LF\"Q4@EN M7/\E>@J-BC/K[6O5GMB(RXD?^LDXI!D6G\WG<)232"!CS/),7>C9"3 MHJA$=Y12Y:/N@E:B*&;[+P1DS+8H0GG)40"IR;)5$.YD.562R6ELIP()T7&+ M;W!>^3Y-=(4$$M#$>%W,KL+PY3$J6^%Q\7/ $$A3@P=\9K:R:>HWIH>(J&\W M\YP=W4!PA^M#-J)&SIA7JFJN7L&_V_J."<1?2D;*J,;*416!62QV-)?7S@IK MO"J,5Y2]2"!#:M]^5E>6">J(SPS[ZNRMFGQ2L+BX*7W'[[37?FXL!2H+7F,N MM<2WDR+3;FJWN-<>&IWB0+5+'II0P/HN>8];8/BH\;?FA4"GG^6>[Q6+SV9? MCGUZO+%]- #]4[B0\]R0A+34?<>95 WE#^:A)GFB65@\$K"&D;?F3)+-H80$ M--NBA$NR-O)Q8!U<\=I:_*89+WQ(""3%'$X!9]/F-+1Y17UZ7)]"I;=NP:Y& MB:'N5&AA?D30;0Q'W0:]992EH\A+2+@ R< M"HKK?;3,MGF2GS>1RPL!#1+&((^U_SQHHI%T1LC6(S,OBGG46+;Q%'OAA?-[ MLR@C&\L8PDYZ)7'ZB<3 Q:3JAR%FE!)I'<-#'[6AWA)2=+0PYLT#;I3[:M " M+PJ?Q5TB3";8[?+%])L22G+$/=_7S=^\B\R*MG_%&@N\)I>1 $6UJS:RO(B& M(@*E[G"V=7$[\*4=7T'X?-:DH;=?:&]TF"_%G+9$S[_AVO7"1U8 'W(C_R0M M%GS:(.MV:8*R]_D^^ZR$N&A#^T]6 ;LI$M#;#+D)]Z _Z7Q<^Z.K6$&AAWL+ MO> ;!>-WS",!"K/DI,/NPN+U]=KQ:!5F=]W?SD:[D0 [8*9SJ-'M][$U[ ', MXX S>F[6G M]<A99/-6:Z<^%*CX)/LPHJW@\I?J,PVNXVWK)%D1Q(;B2!OP:CJ_]3Q!)2NK^:2FM!979SHQM M2>;?FB5ZO\ZD@5N3Q.U>J<72;%TV^8) ;C?O^]T=LO8%5-690[L"WJ323;32]-J*A)GRHDS_9Z'>, O,#N/]?/Q5C"J=#8M *[\P#PUM24.<0:@4A'1&?_A,:\]'YV&NKX5 M"*UP7U11TF@>4ZH:>)@=3 S52Z-AM\I2V17%@4_)I?(HYAY"?_'()K%A5A,H#L8T6&#=7/ MJ+ B4]'&_>Q/_;FG6B%,!7D_\)F>%L3:^Q%)?-4P\>O7D&7([=+]],WO*%6S MO"VI0VUGP*/A@PMPK (Z6V:$>U6$!( >IBOZU;]1YE/]!" ^M*S%4/ABREP_ MNH/>5<9QNLM*?7YXL8/@.7%$B@T,!OJ/2X!)"(<63(+ MYC>A?H@TRH9[*QP$DW]_F.7*\(23 V%&B;@[@5;M5KO"W\> IZFL?-,MGN)Q MD">#IV?"J<28^P;\?I^\_^ _^]X-P='7?:?/YSV9BJ@]YB2_KO/T. MIW5ETP;_6+[6)]+ NJ1 %?LQP['55"K[:A/WE>%?VM"9FI%]4DP-T\>[DU)I M1<]/85(-+$$D3?M>:$=]'$9)6-XL\W6-_N'#O SHKGA]ZVQZ,*HPF-&.(&RH M&2X8G:"YG0?>&%R]1W.(M]>IU9?'4[V-J?FY'%N^O:%$RDE8YZPQGX7V*Q)I]]H2M2->#-'GR6L180PW^<*KV^PI/G>#]LF0:.P:'3(2[M5 M$>[$GUB0^U!L._7YTES#[R\I]%EL_?C;T'D_+FVSOBT@TD#(4HHZN2\J/W55 M@7LKOO/XC;&GS\MM& U5>E"94(4R,Y^Y&1F1#OT.&J5=0N'=0+\]T:^P=XO; M$9C&1804:0VE7-BC,:&911T*2H4SY5J@Y.=GOG@.NGECJ7RO!W!QEY^,&\W:V4;G=%5W= M%!8_QU!+D3NDK_'SK\1U=F+&99:+%PEK0//5[ZF%']_7+8B\46U=D5T:.6+5>BRV]-4Q(/S==E7':533_#F!=OR M@!;BNGI/3&(=,I1M5TSJ*#\_SNNKUB&PFSM^OV?7:1MET]B^*#'X =CJCW\_ MZUT(JJND[6C4K.:?TYQ"OX;6D,*568W(M]OX3)B)B)LS/R\_H_6^@HA]O9MI M,Q++=\0)5E6*2JE17Q[+$%@L5+_5'MS-6:<^ M+R5*[6QPDD.E,ZME8/U<3^'\4+UTQW2JP_TX2O@!S M7WU:JVX*5TE$@UN255NJZ)\R=W"I!&VH(",#U3R,,/'!J3^=#6@[;=WQ6ND1 MN^4M"CI,2-037LK$PC#%)\OG;'1('?Z'9CS54-% M^%(;8I)42L;#Q^3%K!#T(P/3J8Q@57T+F^=-QOK)?5"?NMMF02S=#X8O=&&[ MMK%9[O[K5)FMN 9[MM=%YI4>%TU1KP47__)_?N@(.N[[T6?5F$* ,"!+"2^" M^]'H.V5%\5=R;7([=/^G]:"RLM-1RC:-:J/M_-;SF%1U"_N2=DOLUYKT]*<6 MA2#AM""IWGYO0T4LRQ C4;.5#YFAU>3D3QUU\ =AYGD.#W,DH*]_;00QUG") ML;']YA9B/7:2*7A31"G5)Q)5F>KL:[W<>_X;3U#L[/-Y9524SLN,Z]F238;D M9:D\AF]G],/Q[I P?7?<:K2UV;P@0P-%V^&]0;[>,/,)/T?<(9GE +.O)NV; MK?;"4W^?;\I@=IXQ=6,288'7EU@,(5DDI]FM,LG0\A&NV&[7$2C9.&=H3O>5 M(V?"ATLRD4+RZ7E-]5#9;=2.31ND.T^ M_C7%ZGKEY%G7C^FW&W@H;32[A[% EB9I@#H9_P^\XIH0U*6!);@^)O ']5^E M^O\R6>I<'1&-3SD>+HFY RL\Z<6@C<)D.]=2C;V_Q+>^(0$)+_;P(,SR)EC4 M7!1!H'$^-F/9N#$]3P:T?J P*JS)N?/)_T.''+1)".')3*GB"Q,3-_Q#%F)H48I"ZI[!>XI)-%7'R^CX*= "XL MK@8)I_>/VY0;&:L2.X^Z]$.EW=KY$_'L#\I/\$9J@XT* M5;@*-3@%##R?J?P[M%50A[O^H;[+5!)[_\," 4B,8!]?=:FPW;ZCONQ[L>5HGOP<4GMWK'PF+2C^:]%>_\0.V M2?_1CU/7",I2/9G8DG\:X@BWYA&_2BT1C90]T_![C02X1X?_6)Y(\TEX?\MT M8878R.$C3Y"Q6U7*7N'UXP:Y_B'[3M "JV"*4CTA$RT!MMJ24BZ5UF)X:D(V M'76"1CLZ)C0N>ONTD]Q_A[D-P,O4\VRZ?3_#0IMM"+*MJ2^/LF]'[6F\RFAZVY*%V&X1 T!9TD;] M6%CC?+*SK__BA!S(A)Z1H?%Q57END2";9_CBJ48&BMB'E_ WW:INR_E#DC5Y MG,T&#Y4Q9Q,<0)X(K3;#QZ*+G)<>U%=:I5[VCD^I,CR3I>L/U$/Q&*0%@_G= M5\ D9O0;WBZE- 'USWL@%F?6>)E0G?*B@N%65&A:W68-"?C]HIR(LIE?8-\7\$+NKH+3NO4^L#>$&V?Y7[ M^';G/V%NBZ%?88@'"T0S[OE/!/[=7Q9(_?1W>SB+F*0<>QL)T,D^B2IPR7_;OM3$,Q8^X-T/2[+?^N2 0*&G_DZ_5M0GS1!^&IB6*Z!D2=&51 M8\X5M5)TWO4D1S%_8_Z_/3WQKHHY6G$+5/RUB(TQ)Q-0CZL>YB,$!W8*ISCI MIG&?O!'6>8V8HY"S$M[E:/);Z-D(2*>$% H'2GBEXOC34_^9DZYD$O[U39"! M!<2RBZ (7.P;%-U\)P@_S)L-00*^1,N8( &,%X2LYEF[RB\@QPYA &JZJP?M MDD[8JA'(<\87$Z[,@8@"*F1M;4Y:[$64AP4$!B6S>UYD "C MH*?#??)A!D5E/()Z] MYCC&HJK6D$44.RC.P"6YY5:E NL4I(84ISJJMGPWX#=ZE%BE9 MU]6$D6)U6TK@ %](?/H?O/C_$/EBS':O .JQ.^=/89!=S>+-LET!#^J;KX@P MEB$PYF19[COOIK__.UO@$O7 G'#PZ28HT]-@%^X/15Q[0)_T'A(>9NMO>)*W M/%V9;8]UY))&?8^0@-Z(M]1]@IB(>_O]-EUVV&\DX/4P'W6?VQ/PX>H-.WAV MV<\.T$42@^VQ)U8ZA@3XEZO,FH"^YL"9 \?]!R;>W&==:VI[/"5Y_6V( ^7K ME.(#_EI#(X.WO4ZNG-CVRV _A$P(+WL_NR:%JXC6!)<&K&CTZ9DLH)>)"Y*2 M4QBQ>'I]>I4C9UV\&+T86CB([7%*GJ;>OWIW.*Y08;LXI+^FE!\3%2)NGPL!DOZFVF^LEA:. <-*N MW7Y6!W2:#--]-:ED ?IS@5ZE+7F54P)]_9C0U;[1)A\<'">$2.(+62A:>I^O M %2H28/7YN^U- W=GG3>OYE1T%E[>!SZM.B-!/0TO;IJ IWE>I$L=.$9>X # M(ZA'M(<\08?$3QL*. GQ1E6G2$#(*\66/Q/2A ]^7?]?>I9VS^''.5L>NZ[\ M*QJCU&I@NRLG<+S "[/ />M=*OW,U;0=?WS\,571UF;:JFU"NX3K;E MCF*""Z(>+;1NIU^8$@G(H3QT&.G>"M8>$^]@L>=:;$@K\5ND\WDM@9TCH&3Z M^3Y&9SS]3B?"L?9B@^21+#>/6=B=XDV_OV9!"MY $ $2P*),"MK4Q8*J,>'G MN/VQ( A/$<4+SM?Q+G-Q\-I^"Q-4C^>OH4 "PG6I2"<7?)ZRE(LPV9X\INYU M:HJ(*M%9O;/5A#A$Y$RJ MG_.Z)1+P:2@>]G&2'4^T,819\'%AI)_]UQ+"_^ _^#\*3?T> M5+WU%P O:=X>!H;KJWSN+4M75N[-:\M86S]71=D9B/]!66:_VC?+^=-;J?J^]# M"3 &QGY-VC3'#O$MM%>ZAN.GB/>%(KR&EO0<2JK*=5O'4I^RZ;G+B>:X*Z:P M*=OD[CTR@@D7I*R<9VLPHMZ12Y(G4KF=7I?R]$P-\QV5T95DQ)C;M;6PYTV_AU7@U:A^72,L/;G-Z ?B&A71K\ M,=P*_11U/;RV\B\RP>[%="RL#)E@L0SSQ(F _S:G)B8(T8!YF6RA-,J68YQK4@ _@O)/5 EJXDIUCAZ5KXVJ:"C]VW91U[1 MP.EK>JJ5TOJ3UZN.S4:TPQ8T;G.4^VE&\BX%2])X/0P6MF@DE,TYKYY[D=)I MHPKV@#OLHCVQ+@%.O1?/86?%A:K"=#QW,T1O95"Z& #,3(6O;=1=N!5237XE M(F"\.##;XW?WF13-VF8=O$ MO%J-(3.O=\]1UJ#B7B2J*3I[J2%KIS&_S5/>K7%10$RW+' MA57(5XF)3FQ9-=Q[PG&3 TZ'UH]I20T-?16CWW 9=%V=4@:"54GW)+"YLC31 M+?$-I8?W'R'*V7_4P@S!9_"3$OY,KI'&7)F3L:*3ZALHM;H\[\7*JF+!_""# M N[I29)O] P>$A"($/$;%R2,\V)NBE\]4_E#0[>Z(VWZH@:T19JRE MXVJX"'U6[T!ARQG5P87P&Z]@=G'/.>EX<:$O[>!B0UCN0, Y0$ 'YL_" AI= M7Y#N-9,:X7 DT*!=6?.F46SYVU M5.\>I6(HRW_MQNF4YG^I.!)#/;6"%F'"658L^P<8S1,6!X 11L'V/3DS^:N. MXZ*J\P\EA'S[2\[DCY5%U__(/ZMEA*-\1F M\^XAY% 9A2._Z(@;>Q>3,:W4 M?^:Q,VU,#="_VCQX@P0(EE^+Q!E.O\CG)?BO=?^$!$UX'X9JQPD<[QXG\Y'&=%$&F/\L8,]N;;"NB!%JB %0C#/YVY,1C@2D#5#PTQB1($/ M_DHQ]W;#\J+=IJI?"]7T>^LM#JB_=;++:]$!/+ETM/;FA';K^5$^&J6@E M'=1-##P;2"ZY1_V@*YO/_\0R_\ !I)/VB/=P1/2"#%;.'HDFNQ!',<"JZ]+D MGJ*6$AW'ULX-[=+1[%7_T-_R9$M:BN\(0DB\25[J*#8^6\'&0,][*P- MA8C^N,Z#^#]3PR'84*9D[@G%PHFS%K\B!A)CH-WH#QG*WN$7T4XEC/&'P)^R_SGCW:AB MPR[B+U<]U,[^;^R]=5#4T?LO_D9215 $:9:2!FGI!966[D9 NDM"6!"1$%A: MZ>[N$@%ID"ZEN[O9O.OGSOW_>V?NG3OS^WUWYLSLV7/.<_IY7J]GS_N\A9 = M')Z:-8G8D4!!M+((>;A:T30@I4S*'QZH[7MR!"T0QQWZ.].QLPV"7]O[BQ[W M3G9[,;OC:^I9;.!XC(BH]L2D9RDY*\ZL2UXWG>=W45&'%># &;**5VRX./PA7W^8#W=DE)ANID[PD(*0*&E@P\:R0&E_Z[5' M&>'&X1_,&*.!:-;YAD T@#'3/U7XO"QX=B*M%.(97#K=E":MX 3YV M=FZ7>_./:7@O_AW"C@JN14L?-#-HS=%I;DD&FJ>&YW[%'>IPF8'L+&/?3OU< M*4$#8_6L*%Q=J?&5)=+[HX&[F.(=US%Y:$ J#K+B^4A>X\0&A+SFZ.WZW0X4 M*0K/]DV,:V0;5R#SBKW@)*!;BGS4Y#1XIQ=\LEHX6-;U:.[O"M8O%XE+,ZT[ M3>$JJF&.[V/' Y2HLU$1)%NU<:R]7OLE1D=U? HI,<%P$@G(2F_90Q[C>R&5 M[+4>;ND OTCN (\,LNA#UAT^(61.)Q\UW89A?BXH6<,&KAPK)O-BS/Z_QM^1 M_;3)JMV"23$ 7\_8X96XJXEI05:V2A!GR"[5&%D[@"]*P[P%F-Z6].P#74_8 M$16]0-Y;1 ,+LB5YP")AD)P::14;#I3+J\"\17T_'C+.H0:'U4^5="#O819_ MQU>5QEDGGJUX(2P3<=$^^8:WSCD\Q<_X?]]7IQ;M% MK^&+-CNBO$KFZR2X_HX?]_%]_8+R*IJO2=YY*TSEP#&5%?X$;O#RO$++0!=R MKJXWW]N1I&B=&$!]@&2__ -[.0?3:@,5\-+[+GTOJ,5_U\T'+T,)C2@6W:9X M.>UY&W+_7?KAU%\XOUO$+X]AC7F0\C_"&]-7I2^*]Q]'"=4.=+X/Q\\J4(8* M;R0URD7I$1'$;.&XTV&AGL'\ CAFU'F2NJMPR!TK'ACU M54O2 W&(A[1/'ZW.#?589R;9LI1?E+$>)XRD4YX;CBG.^M4P1R%B/$&5*\UW;[*6. MSOR[&=DJ9+7"%>7VW>]CYGQF:)P-.RW^CK8+:5FH9%E@S;&ZY'Z)"&[0>BOE M5H*1"D$R> 6SNP/T:,5&X_==R",*/BL<2@W3O%W DKB^O+RJG)%X>%^Z6[,9 MMP5>IBT49D9D]U*WYDU=VZ^A*9&N'28)[<28AW)-#I29)F"3%L4'&7WBNA+^ M9WHV#BE5YJDNCTW2BJ_#ZVS=)45ZS6X=@WF$[A,S2_M%?NN%C5VS1GC">X)9 M;#?D"'S&[A7]KFP4J\)?YJMK#7@%4]SFMQQ)!7.'PRR:G(^/YD==$]B?$]QK M 1/NX_>YCP5PM.=^F6>2&Q"A=<#,X6=WHING@5YOJ&;1P-D1.3SD3CLQ,NN^U_R7?V7_*O.4_7?PEB9T,B^I$=NQR=Q>1(J["9$56." &A*13T8/RZJB"E(;M.P#G(6I#&>>]4\AI)(#.6.65>L9'CEQ&V1JG(K91G:V7FB@6PR M9/KZD.$J'0W(EM[$3!@?&Q"/BF'WSY:E?4&=(0YZRD)Z1O,+R*FE;EHF1IY] M^S%74'%']6I'PV?15-:!B@;WW"1B[*?T>G7#0W\LYH1R-^I?P\U?AKTN84_O M9O)O0T=\[*312=+,\K.$C$98MZ5OY\_2#2?D4MSR2&)]VY V2BD MOVGWI2TMCW=*ZC>UGW?/&*-9KZW<7'#=6&Z-NV>R8&26RSW]2OIS-4[<*,%A MP/W2#\FSR89"L(7YW+)?FZ65[MZK=/9FX.4:YTI6(X<%Y8Q7?ZUC%*K/VK<.)V7(+OO>$.[P]N51AX.Z40&E: #!3%4H]V*3;MD8@E )Z& 2EN+W>7%?YYDF M;X@-^3G["\]B\F/G1ZX'.R8)U#MLU5^2X)$&CSW*=.L\,G0)\),Q.^*<.*Y[ M;+OY[NC)WF4*V=;V\5[KRG(6W"\!#406#P_U)+?]<+Q^J?D$#>1H#'3/,\V\ MQ B6=.C9:OT1\&H=-]*#5$XR9DKYXIZ,Q [^)Y^C&,QV4[9IJR$Q7?B^S?-7 MCD=*W6PM"2NMT$['U9)^8ZJ/GZXSY7- M3VVM0+>IAEGY07-\5?N-'UJ/XNK;%,FHW\0V?.;/U^1CEM[Z9G#GRE"]9T%?&CF- M$\VI3O2R"(ZJK=,5L:0@,VL:QP1\5SUB.*$8 MK;2BQ?<9KF5N"61O7%:IS2(DWU=1_)S#_SYAA<<\SIAV+H$!'B \:4*JNC.MN7=/DSU [ MA;JI<#YE%^5DS*YO:P?M:?IJ0,8HX$@U/\?JRH&U(%P9EG'\?0XXOZP48-"8JX603[5[$NDC(KHD#Q[J+)$.%"_U M*7:)C$ED9H42/+>*+J9YGBI _R(3^.[]X:):6-$R.YGS;FY.+, MTMRLSY4+YAQA>=E4PMI45&&CN$X](DTV45[S!,2]M2SN;E]Q5;/^R M&3^]S#+;A^?-)_/@_+=KMG^"OOMMWA%S(=3J)CT)_CJ+ Y"'OWG?L4H/]2MN M%3,>N\Y0\A6ZW^1B!D8:6WG^!2V!3-7:[7#V4AMPF@2\0*^36C*W(4]47Q@^ M:U9YN6.;6+I9>XK%O!&GUM*]7_Q]_LV33WSCAR-BVB0^B_.)N#P,T31WP:I8 MB](4.P5Z<3]&=+>M#SKF1"NR/12O!#?#("^8A[,22YLWHNBFHW&>2MTQ$?[I M4Y0D &XNL<^+)X9IDD4ED?9]DV&$O,N)Y9S02,'H32^UE#O+YLVKFQND?:>S M_22;?=]9KX8-JB: *8UVZ]'$Z_QJ*QNNL5G8>T6BV0/_FK-Q[%N MZ31^YFB 2[VBKF\XS17I38QW..'([/P:Q+B(#2F0X^%EXIC+%ISSEF_KSC>D.W&-GRCN#[%VR CL/EO5O#!XNET);( M.0I*RR<3M>F'<*"R=?,.A&\'-6D;O._G9@M"[7FDDWXDR-1ELG'RZ1-!- MML18D1$H/3,FW\SD[PA# Y65$;JB>-.QNCSL==@;EM+9D]F0CF] P M=<1Q%TAM1VN1W 4\]):_W(,A\+6Y!W1+QJ]":?:B;:QH4##R'#]Y6958)F%L M;4ZDW!I-L*J](A\2.6E>?QL4U M/X%9E)GNRQFB1SQ<:3/0_IS"_)_49&VIO^[:DT-B$^'%#8G&3GOH"EV'T M/)Z^#I9W-"G=VR@:OGU@K+B4__;+\9Q24\2]@)&8WQE-3R[W#&$I[=.79#^F MIKO*I#'6CC<^8:O9;4E.L=^UU+Z96%;W8?U0O>W[+T]J;>&)L.D37S,T(=X45FK]"%Q)[$<+#_9 MFJ-?!4^1W:>[>AHY,C Y]R1FAWLQ?5K8@/SEUX7?A& R$-(OD3B1RLJ*)X_# M\N0-](X$_*MTG0>KE^F!ADPVOB&-:4_ /*1HRZ5\& +;>Z><,93BV^5%6P?M7?(_I/D.GIV09+C5DU8?T4BLR/@\2GH.$^M:H M2ECI?O[*0:W47*8'6 C]6G+@^X/1A9IP%\YM7$I)UGWHD_S['4QTQSU0^JUQ8JWGB@%ZW&L?V3!H^04 M%T=SJ&;;?-=K\B8N?> G(F#BXFB5$#?&],#5?WKL86B(O?%*V!V.@Y[#FR@?3SB!19*> M?OOB2-MOWL:3]MC[8_3>:("QX;)LX1'_^$) J^\B8T"S MRH2S/AIT=/3RQQ$:"$Q#-[[!;5CXL4I[_Z?>"(]ATUKJ +D275B_?ZCXM:YOE5 M/H^F.EI7)+P[PBZ@*/^A^M]:W5S9\X;S45F=[KD03),,4X/.XN8U:F MK6RW_HY#>X''&D6D('$JNBNZNETT&BZ/^/ABF^UOOO ]U= (X%XGD5J%MT1M MJMXVQ&VT)GZ^UQ?<]$Q@Z^"9D\0W N4([=S"V:7SN,[193Q%R;T;$H=?DXJ6 M,]R$JT&Q^7&QW4PMINT0I2:W0D,9!C7V?! ?+M\G4NS, (_@ Q7_1\+TF9[A M40?-/*NN_/*7Y3G!.2]MIUTVC6N$&"M7'186BQO#C8T7**^)>?.B"VI&)>NT MF&L&7..9LF3-';+@=+&0K34P@\'\;V]A8>OMT2U-SRU*(@*AJFMMT[BTCB($ MR3,!$XUY#8-6O%*A"I+Y6US"#2)\Z=75V22?(X._&;]X%Z.*FGM5Q\UU=%JJEZ;RD5#S&J0 -N*(!#N!<#SYRE:TYP,>$M6^'JTY40)J8&TQ$ MUUP4:5X4*2WR[W+;7H#MWR'.2$!#E?13HM;C,]URD?:O!SJRAC5H /KG9SW6 M3-,R2&D-3SZ\@1A.0(S$1ZHFGZXCK\L&M !SQ8_XG@[L1QS&13SOSSQ#V4N0 5F6?\K!OX9F-0@ MF1+J-,'\44'@0)\NL,3Z[/LJ(0WNVOU^4V*A<9R/68E3CO!#I^VB &PVL:L<3+Z?#)O'0@$)_ MP+02Z#S8AL=2!:K!E4R/N0U![9GX6JD'&H]P,&\?%D>GCR>A4_5FZOT4K M(S-J+Y\##2RRGA8RBAN\/7W-KEGPQ55>R!)E$8L&6C$,[M&;9RK#21):=?^N MN@8O09!X"502:$ #=&9L2LC ? HJ6@)-">X)!O#>+XS<(XC%?4,3RKUW._LA ML@O#-%,O,T.#0;'E[Y\KF"N\&Y"Z.I1[U"L(8QKQ4&RPM)^3:VRVQMM+9'_/ M:DL=?GE%1E=0,#]O>#>^Y"+ZX"G=X@5L5GY'&B<63U$"X%0U,+UAW%^@*RF M#.#UHWY""IS&HKOW] W?H8&(1\G$RIF0D]3Y9L+1#G8FVK+>K+XQ5= ]ON6' MW*J*-"VXM&;;G?C8Q=3!H4[P'ONJPTW[])EM)()>:5H$^(_)%<%,(X(' I8B&@E(EG>75"55?>,10NYYH MK1B->-F>RHU0NF/STH2>Z-17B#F >(>..(7)C+):Q:S\QO'*(0?XLQFL,#30 MH^V6?$&^)1G %G?F*N@I^,<6!T=/-@6YGF>OB9[S9N.& &-#.GLTOUVCQ0*+Q^Y&WLUL]]N6!8:KL MS?7G5^^>OA&(KE!B5%=\7,R:<'Y54J$M3Z\3Q0C#[3M']JSV,J>@T+WG\1++2")3AX*&?220Z7H6LHH%LS#3H MMX\65'^I.51#&#,=6 MR9[(J5""(D9>C[$2(?N$(KQO#>(D2[W9&DJE!K^"X^W"/P4(G7R7X"KA('1V M_NQ'5<"34?QJ2R6MF99*(-:A.$8HXAZT?SF-^_=C7@-K;0N!3PY4B3G9/T6FYM^D8K M3JWH@=N7'KU>[:HS1[)$Q+XZ&IB3Z=\P;$A$ ^>/H<@SQ(&<1T;^QS=9QY$7 M:(!6Y,FB\ZHCTY70[OT;\EW.42GZG9N?:6H70L06R=LN002/]Z/$?,&SM3_I M,^;GL=/+.?^],V[V%M+[I1RR%XORBMLXEGBS477<#PHJ\2?]R51ZJ_Y](AT- M3&E"E"[],#6$*N$%&=$:SV7K<$GOJ!)WJ9-V MD*_X'"U=H($B;Q/]HY1(-?/)\5EL_4>(Y M;R3Q-%Z2WR'E3'YD'4(L!]DI%D$#P56W>O*V;^+ZNJ/[6:/,B3$VR2.0@0'A MN[8+=QX#G8!.G[K3D>(LXU)B8*M3AED1?R9%PT)KZ@6:MO3MV MIA=C3I_02RTH &'L0HE[#X:$2:#Q#="T:4<2WR M4?QED\HADA50F,K[JFOP+L;U4.Y#2)2_=9"\GQ@1PJT/3+5]==\M@&WC1$]! MS#('A@'Z<\;+1?DK8P',C<T MJ_WX>(/6K#;HE.K#-5X>0N_A+99LK[5V76-C=?1&DTKI42Q&_1:#IPDXN-W(^+P W2CAV!?Y!J0@$5J$&X9ZD\,D6BYCMZG&$!P MG)XN#=/QK+".O[C5A#XRI@M<8%W-0[ UZX]%TXE?=./PK.#K)%,D2>_@JR^F6QV3P';@I:QSPJ1)5A; MXX&,C9 ULDF]A,<(8PTT0+ =E9T1$?>G&@U0\3R38_\!!1U8HH&?H8(KO\3& M0,AK3G\XMARE4PV9:9%/)RQS>FNBWMB5$<&,EYECY5&DT70B ;F98;W.Z$#< M*.U]DYU4>_,:#=P;NRK1DYL*7J<8FV@N<*WYI?CL&UO+,!KH[SZ)C3KWN;[. M_2LX+!XLP84R-\G.Z(>J9G"VHP:JQQZ_:!>'C>H_DZ5'_AA(W-RQ0U:9_YUB=MZQN4\!&S;G M817JQ(3K[Z^5O,PP 3 UZ*L*+O'>?+G3##/,5+!*);!'L\LQ:%+,@#C]',F^L\/[)DJ8EM1O\\[)Q M9%>O,B5_9(DW>-(HY@-$1@]7IPW4X=PN?TX:5 %:3BA:!@WH<9Y!46\>L7FB M ;6O:$#:;W_\T23T.NR<; L-/-EI.Z,I*Q(:[K*QVN12$&CODSN'O/7.R3XV MN-7ICWR*PB%&GCLDG_[5O:W?)9)?<,:#K+[0KH<0C5E^K%LX>-EXS@:6<*H_ MYYL3(LOZ MU$=.P[ M2O-Y\TC MPVT,N5VOWZH)*=ZJ[KEX@(A(OV&]%[Z1["7ED,C10Q:U@<&61I0TY+$ L>QE M$>]Y^@#Q@/RH5,:>L$A965S IZ68MTH*Q[[%JWSE%UQQI5;A _UF:IV1J7/B M!3L-R] MUQ2R6!KD -&OLC])?!)!CRDCL.>_QLL6_D:,=8'#!!O/7R21!'\:3O?L5:GG M@26@@6=V5DGO0O,M0S42WG+%]DTJ[8?_J./KQ%Z<$P\H6[0OK;:M+H]SP:T\ MQM+WD21U-3O]!1]/ZO=G"CQ_0_7QDYS.Q>/LQ05WA=4 AP='RHF>"\U]VE: MSTT^E7G\[O)2F\D2WG+T"TYRI(?I5P12L629DLP7YEF\ M%S_4KJ_^M/Z^/9-D[D&@F5#3G0TRR,>L^,#0OD/MK%":V?QW-R5SI22'HV5- M&6/WJZDPX\SI_,W-*5=W@ITY4JR1WV&HIRRM;W3/U^GC^^EQ=Z+\9SUB$TC: M[^\9GBG3&%8,#PD_B^6H>XSU*"%XC/7AU'*-97.D41&//O\Q/=D@@_*]%;5O M5W0-^1]$YZV3JKF(B!UUIH-AJ6%JO#^%-[PG6)?H 5_0%-1O\H),[E64!FN) M(L430WO7_;14-JE.]2 9Y#'R;LS8J;_1PPA+043(7.1=\RF'R#+[HH6V4\\J MYSU5LU*7T>BYA%;!74K_%<>3=1?//:NKLN'P^9O+P#+6+Q#$MNW M;T=^QAG.;J]P55H,NK#5!JE*$K N9!4X&?1N%(,%#JWBWZ5.I MI,2LU_K/_:$>@Z7G=!RZ0B:CJAP:FI;:>(.2I63N%Z?\6$6JO>KT)[-IH&-+ MWW!6^X1(*Z\:H62J\ZUOU(1!GOMN(6-K:M8Q*F%(?:[Q(#%40"N$H\RVC]9I M0R-\443T>/$EZ/:TS 4GI7GI/+^ MF6]>_(/-.KU*%!#*SGQ39/&)PXBCFZ!0F/W035U[YP5AX^PX\KB.;@4//B1WXB!8=ZNQ!/!H#4]\ARNELA7 M['^ZLB.SZ0._-&D?RTKE"84O]3K,D\S&/?WKIAC#(A]!_E7^^.&+74[*40,U M.&,CXBWQ7Z>T2<= >XM5?>G?YX^>0+L=-*X]^0_=;CD6EHJ.GP0?;=/(5I'N_LKIA MG]GELCH[GN;4/B]G<"ZRH63*@E2\5Y'P=EU4X7GU9K-F(_@VR^_/IR=.CC78 MG=2N>ED]LT1Y0B,9TU_I,F\T6O#=JS<.4NOMA;OUZZ?3G%H^KC;]YG4E(J:5 MEYH)K 4W.">_10,6QBZ2"DRL9P54O:/@S:>NTI=>0C*>YCXK7?$'\3QY163D MI3FT]SL3B3Z#3&=^96'[I$-^2Z*!$PQEH+I**!]M&8WS!I/E4RUF7+95NZ63 M=&RH*"G;6"2.L4C=/^-% ]\=BW:[$79A7:CGH(N'61>@#=,69',GB6?;;V)I MXJL"% :!%3WL4/UW\7V5 W@;XN.1B8&J!%D1;\!^@[BJ; M.C.?3#LU>,T(L1GB1J@EQ@1:6_!-5?=ZKRQ,$-]YM5ZMX=].H@$7::)'#7-( M>$F2XK"B<'?Z=&YM7YLC9"MZ# G//K@.6NUU)T:Z";UDV?V7TF$-VK'C$\C-XI,(SW[A-Q:<&)M6;<4O#5_ M@$(V<$1K$+S#'3=W)Y##T6L&/;'[LVT'W$1T_(+>*@@NVHR92[Y509%5S99! M!![VUVST&Y_)6%NW3BNZ_%#TR+J(+!(ZKA(UDUB2ZFKX@"="R0I*$3K*ZZ'2 M )V=$T.NG%"D'0NM!FC@6S 4MKVRIFC!T:]#[_S"T\=LW@MK6N6.2F+IE3OC M?8'DW1Q%EO;?!WZJOLW0L]"%@Q=' 8Z-)2$,@0S7S B#M)Y3 O&U&!0I8RJ>PV[3[YQ)0)#(E6H$3KA">-U)*4U1Y!155K MTAJCI*[@MH'L&OQT?^PQ-% 9&Z,(@E#N104VT+-OFDOA%[/"YL@W1*X=_&@[ MM9+:PQ)0L#G; .FQ.424'N490;BCDS,449T"B@H.DCFYS+DG'FJV(G*E"RHP M.1U$(H?00#7Q 8:\ELI__27'JX]JL.P>:=*) [=3@N+PZI-[7J^+1=;9_7-H MFY8;0LI="JP\N?_CUU;_+_NU=RB;8OU*4#K/^H%4G(MVW+7J PU:$M,M-9P?6EC/9$V& :Y&6+#<@H1EI.R+RSZ_M M"-DX?U&A2VL_\@T1*'N5_63VI<8E6==@?WB#L7<'%,,HR)::7 IH+6$M_NU8KJ#T!N:$GZ-(&7M/&RU)BMQ/3O"<: M=@QBC2ZLS6F-%!X:>PP^B9QJI:Y@,=-^!]/#=UF-IEE@4L8)76#.XH7-_-)E M=-T6?Q*8=7%%CD20!K2#=[9?P _U&)?OCZ.!G64U.,S^V:GN%S&9%TBDD.G4 M -1RVYL%28SX\>_PYP.90*R!9BCTNM?-IBM56.2+&2:[P.H1B.*\ UT?(': MMN'7!(Q.'2EV0++H#G?$PPP_+-2-S3-AR%JO:U'7O)3'EC(:@*CPWKY6H&5, M0Z%2 V>\R6LNQ%<:,>K !Z.>U!8S%%>IDW0A2/#[U/';G]9_#6R:=5),R1@,W MEU.0-8K)<^)O+T&7TQ-'>N;7Q"VSRE9U0Y/#R,S1_NX/P^1U!,Y@+4_$MIF+JJ;H;9_#)6=X!">I[ M@ Y$X62=WU>1M-:HW*WZO7ZUZ,WFS)2?FL'3"[+MCM.8O1U48,?)7;X4S53$ M$BHA"W9L+UD59]IU(\EYE'4Y >:3^0&^F(#PF=I@].MR1ESOX!'JQV36([N> MK-L[S+CW0>W;B/]([10@JR^7.[X72@[$-0E&JDWKI8(>V:&:P#>W$YB"HUG( M@W+,;K&4KS<)/01Y3$G-+UK+[NVSO:Q Y+D_Q3\>TRVO@SD00<<90=9HYI" M ^U>F.F*IIOP!E4'C"G#'2 !$#[EZSY:6N)USM_]7R[/$'IF_U/\+*9<%1QA M>_VUVA]_\;*%YVU52X8B+/+# LW&MMGDC]\^+FHTQVV@ZS\8Y?U+U+*/N>T: M>9W7:'J96OPS#:#%!?]D_DE^/_1ZH M#JQ-1R_9:WQ@#6C8R3J-U ?=^;;_FX]T"4Y+- #6Z[A!3!R1FU^_:-DU<_@( M>214N0+J-J:ZE>O&5(N9\1+\SX+GD(WM&Q0:2)7,/:3KO1'[6_5>O=-IT_S, M6"_JN]0W9S%H ^O&; 7D%WFAXF#F?W+ZW3Y5],8M:',J8O+,7YWT:&V(C.84 M7UP\M4\:]R*,::JU1,$J$OJ52O+V3NW\_!>,!+X/DSOM,-=(I#;Z%EL7OS:@ MPBS^KR$O&R(J_/HQL[R98PR9"V5(K0GHOBJ:8H2'':@=RO+**N+$+RARM47Y M/&=4?4CL8;QOUTHR5.?[]/X'-ZI&/:FE ^_KL_@10H/EBEH%6$+PU()40V)= M7VV*2LQ#@.EM0LB^BAJ'?Y*D24J]H;(:=ZWI4C7%R^?W]Z#V[:G#D;?+AN]R MSS<3$W5&/?8#DPKQ ,HC%6>2&99^G6&*/H.Q<9TWKXY)O5@:+&5HWLG;$PAX MF:C/QY'B^+8O3+;,Q5NWON09??]^7MDO@/.U0?!&.T]GDD>L_9,/SWH>T2E0 MC#7X"FWN:/2YUQK1D#UG9?U@T1XZTY>:QKTI9>#>:Q8W9E;@U?A!T=<^@942 MQ'LIV>O>I)6?3:I>^F.]Z5*$CIKVI"OV"_:X;K/H<,:O&]FUS;L6/RJOQ,X, M)88#>I17F8%EAB8(M@O.\&-]-\^Z:%;@6]3#VI^1, XQO&R Y^V9*IXQGKP_ M' ]2['^G/F04UHWR;#%2@DX>])Q=6/;<,$F20AB,P$091K(S%WWWK$ 5 MYCYW%^O#O3JL-&Z79"\L-L[H0DZ;GZS]00Z#9MN&U@+)+]:*_;:4[Q'/MI46 MU!"[YD:RA[/E1@+_)P([L9*AW)XTF27('[F!V'^GWN?#C 8P"EDLQ3Z%K6] N\J(5$6UH29!U#MXQ>6[(["T:M;I;0$A0Z?1-9 M_HX&/'?NIK\7'.F\(\BCE%3V$AJR[X;T!.#Z#@4M^ON&P?3TB9UG!DT1:("T MON"PL;=#D&5^2KH@LMPA MZH6+VD6JQZY'']QJC@\)MKM\M=_:.TI3VN?',_Q[\^H#CP:N.H\,3,B'?E]\<&RFL]T8 MWT0EF1X8UM5&250P$"I0JS>J.#A-K8,YG&&Z+&6^[UU*I(_NU7*9AUIVB4>; M"!8PAW*3'>NXD!DF(7N3%I#:;"@O$(*YR26+4]D5LO -P8FI3'D)#=A4-UE2 M4'^EH7,70.R=V]?-R_+0-[P/_B!U_VA,PA\ZU"K*F-$">D7Q*(K\IUS.8+BY46\Z^0 MXD^H0Y3Z)AL*VT..S.RC*=_SA8\]_R)P<&SWHL$FE5A*18Z%G5J@OY/O5)4O M<[,8$5!\[9(Z:^8ZH^!^P7J;ZF&D1J@FL!]?$^4R3_.Q)X #7).&!BY+A!S" MWZ;?V;&K=X2M&6OZQ!BEY'X.#C-O#[ W&GGEU9ZAJ99D7(P0J33VI.4T7NU= MWRNUFX?=9;A-8&S45X,VT0/X=CYJ8*I_>:8R!KQ7@^$RZS%Y'AC[%5Y!(:$T MP)7/%=Q(M*4/7O,-!H M'JH'@[%\M\"G8AA.R!CWYHL(O5Y-^^YR>W+S,/E^.$?[%6 M# KU[TX=*W#Y.],S,[UB4$[ HQU1 -5RLB$M6QY6/?1SQ;E(V?_;971 MFE*;!^E>F"W$1?RK)*WHA#/02V)@2+]4$5X_=4=;W#AI_FTPU.APDL<:YXH^ MNF,T7]@0:V=P%4. M#LYZ.U<3$N)9F7+P[J!K,GK]&T)<_*^$>*[\L[.0()$!BK$.&>W0+R%_]0.% M!HB?V 7QK'G_UGXF+?\HN%-T)V,1'JD,)=GK8WE6H[+M1&VP M#<4(IN=%!> MDDV6J)59C[9+#>R[L$0.*TVC>GHMORP./WV2+B5]XMYX/B/'USU[(I-,;-X!,J(BCY<^>5.>2[\IKR^=7 S4O0^=15 M@9,%GMS#9Y-^M'\KC00*=ZL\FUP@0A4-!V^X_WS\BQ\H+;F793W3M:&! \^% MA+HO,\X9]MW^L&'1M7!WFP*T;?H,/_JP$YZ[MRS"I6F.C]W=H#*7E?N"5GN% M\1!F=^T*50&[NG)AV*S']0PKL@#-?PD*NCE1:S\JY21XJ/)#A?ZNI9N2EBHJHK:I_SPLGI._>Y[ MH9:HLQKH)26BY=B>X94S^U\RCLO$5,<]V9ABO\42#"ZQ0Y%2/Y+'2>NE/2>A:1< #_8_I&A=G,SM] G!^R M/)@6[2;7!>2.4KI*O4M-]"KFPN/B[F)>D^08H)G+;!3[E>@U F@<7!;R4>>B M@69PDJWL+^("F^I52"O^GJ$&-!9K3[-/ <]-YP5X[F4Q/>I3)=M.A?8/-& L M_Q&ZR:&A9M%*G/D:N@X:T'M2+$.]_^VMNM707W!$Y3+=!SO)SK&3UB#O!\RS(.)DBQT M<&8\0:+K7XEVM/)\H,:1UW_,%+X]*^^B2<)*I,,:Z/>[?.[4765_?HM'']U. MJ[;/.4V*93 =:40EL^A%JF'PW\\"_'?XOQ;(DGSIE0MU?VTZTU4$[QDV1 0. M/T+$' R':KN\2T"?1 D>O=MV^W& _%ZOF3?DOJYAUIN$#N%LYR91F3%HT,!K LG MT2[\FC+Z32N:2+EO3)%,A&\?;VY$P;7,O3)T=7!LOIBNPK0[85H:;ZR2 )L* MK$WMZ0VNR.(6GD70:Q0DR:C+=N[##O0REKVVS^F8[^;OFB\C?X'^/$)61G)@\+)4GBKO?D?J< M;ZSA5R^YJP',YJ][0*B,9/MQC>N%/7]#0]E1;R+Q)Y]-I8UD#!A\!UDNJ^XG M?<*EGMM/!92&M^G(9V,7&$(]6)\'/ A3_::>83W+8M1"3FV._>PL2T=U!UG( M#+-HF/">8J2Y+!.W^_G+<+\O2%(JB3#2N\;:F5EDA^*R#"!$^H@(95$0M 'X MB^=^?I/4//W-,G3GBO/\OWVE+LW/!@Y2/PTQ?YG!L8N*[ZWC"?"WY'& MXQ?;V&?G%Q5]V,^VC/CK(UD3-B K#?4LIZ(E&.:XL-W=\"?0!"0IWG MDSF?O.)(RR/51H(S\N/U]I+'5CD#YU_3*+%$]'66\'!_#N&,V@ ;*JGP MBSI7FG>]HR%G\;1LB658]0@"!D]^H0HKOOO@!VM*!"H'_(Y;3J,FAZ1)BKOI MWM>WC;I+N;PLKJ@O(<( M31]ETDC!8J83WA%O]1I5A,V)^^8JTM4\ZN%C?!,_<$O]*FB4,H9O>N,37XA) MVN61CG6(#VL[\R&)+"?%A$[&69! Y@RUJDUBYA(>^^CGSK/'B[R6,'6!S MJQ5EJF3%/S&*1X;]#-)",)[7;]16T -Y MN46A 8X:KC%/U[]/KLW,*J1\FD9_$#J!,D1X1$L<)[@'9GC9I8NN\_/%]>U( MISH%K]?+E%D$WN(I7)DLQRMRM TJAO:+3Q,B[2CWGP4V)+ _Z8W4R:DTKV+0D@6XPJ9YN]*NXGSHYV1,F#9&4OHKDH!B2AI$$]LJ#&*8+P@8=?Y;MD$*; F?F87 M_?!MXP-U8=[GXE#3/]?Y-P2'QJCQQH&>7IE#+-*';2;9)U$HG,"LS>D7Z\J/ MST-K(I*YWO^V6H(Q"5???/Z>INN);&ZI M25^*'7 0PO[9#/=]D "-QU "DC.]>>:HTDL\@@E'GA/*3DKB3QCH.=>NT/F" M<%68[_MW&TD^4RE.VH@B7?6BAP6;<#HZ3M[>J3(VS2+/UK\_PQ2$PA_BQHCB MMZR"NH5P#)$_HB\B]&@0?[#OYB2\]/,>,D0Z_3#_OD!S>71HG]1[Z4 8Q:@> MS\F(31,Y%)B_BN0S7#U+8LEJTKW37\"-J1!Z42ZWPM01M40V9)A.%_(!"#2> MO*-*0 /#%%T@SW14PT@5]-CBBTA?I\:K5:P_%@4)?88#*K\HW9J+^Y:S0_O- MM"*ON/SZ7W%YO>R[1\1WRN/#CWD^_YC9Z%^]ED5_?DJ'"(M&/(%1^^\ I:K$8]B9KS5BR*<(BM?]W\TPE?0OH?)A2:W#7#75R MH*MG,EG GSQW/,[.R%C-55Q\KGG_C=7(!CJG+1NV!2>]\4\-;! :!(2\-.4E_BM M7S(HU$M8BK6YL>;+"\E/I5&$UQ(8X+_^FY3F'1MSTYZE_>-TZNO4S%0)WFPT M4 &^F<'OID]/480U.HRB@34>#-;*W$0)<=&Q=C0'Q+:U#% \.C!]GS+A^6'E M-.I>\X7 25S6*/163L$DUU22GS.<"E71HF?UUZE++O!Z4J:_\D'64-P/^9*^ M>/&[TKAT<1)>8IK W*]X&3%_;M]%6&X3U@QVFG8DR;\(*VQJ\L62/Y])PQ/: MP=XSECY+FD/1N_0NA^V!_LO:R-_UL5%B=B$=" M54+<"]'1"4_C/;! L\WB8V3+^DN#CO&Q-1FEDC5ZW%\7";12"FH60MBU*-I=#EOLDX@^D2]4*' MTD[O6C$'C^=D1T+ "+O8XC*JW\]1PY5:F8)6. XV&9 Z1K,7JB!!:".U@9<3 MUN_"V/8]][TLSJ:[WR4MC/BW3OV9WR#7X+61M7X@/+E3TL]M3.F,:)BQI6&* MG,/I,5&*3[1C:2F3>"5[DP;V3( M0R]=ZBLQEP:Q\_$VN[.5"]"FRA1O9P/H9PRE5IW?F4P.^:N=\NHW-D7LF=3B M7<0-,!-?W&G&WM_[Y.X1 Q&[6"M.>HWC-UP[T!65Z2;N=G4UMJ?Y\&M"*-5E M&#*.#QQ;KJLGO/*C_@H-,/YLHA6T\5&@Y+ZS:7<'/UXCN;5X14ZAU22QL6L? MO[14*7PP=@3_C0;4*BQ](GA62"+*D6=0=YN>="JY+I@4EC/N]N?.1EW<9@-)#L_LL* M^+-SA"RY^>23NQ!CDT>Z\6(7L^6& =R0Q\+&+0NUOX+.KE_ CQ+Y8-JE6Z,L&$76&[@(1B_C$!](B M6KW"&=)$I/6?,B:#'["O_^>F(#*+L:_-:&"Y=+WLP.WE#X?4G8:1%N0C9GZC.'@_&O"9:0>AC*#V91ZH&HP$ M(4MY<[KWK/$BI>;V&Y&O)$NF$X,L>59E=NV):U]/V6TLEX_+ MK"PIN;.8@] MHBQGOQS$_E\,W$,#-H9HP!7E.55H2%>3-5HY;GL/>JV3A;@ _SLAJ/+M/U], M>Y_SLJ$!RW_W&#.A@0 M2(TC>"S M!0S9UC8()MA_HL<)<.Q_)?^)3)W*[P6L,_X3?X&)8VJVR_I7$NJG,*LO,5#:QX%"[_,R4+TUI,-]' #L;4K.C\1]([.S1P,8(& M3EK-#I5!=]LK-S.V$]*4W;(UH/,1S!B :PX[FO_]J/E4FA12R]7_Q@6^#STL M4P_